PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PODOLSKY, DK				PODOLSKY, DK			INFLAMMATORY BOWEL-DISEASE .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DISTAL ULCERATIVE-COLITIS; 5-AMINOSALICYLIC ACID ENEMAS; COOPERATIVE CROHN DISEASE; TOTAL PARENTERAL-NUTRITION; POUCH-ANAL ANASTOMOSIS; LONG-TERM; DOUBLE-BLIND; COLORECTAL-CANCER; CONTROLLED TRIAL; ELEMENTAL DIET		MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	PODOLSKY, DK (corresponding author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034422, P30DK043351] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34422, P30 DK43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER DJ, 1990, AM J GASTROENTEROL, V85, P717; ANDRE C, 1981, GUT, V22, P571, DOI 10.1136/gut.22.7.571; AXELSSON C, 1977, SCAND J GASTROENTERO, V12, P89, DOI 10.1080/00365521.1977.12031117; AZADKHAN AK, 1977, LANCET, V2, P892; BANSKY G, 1987, DIS COLON RECTUM, V30, P288, DOI 10.1007/BF02556177; BARBER GB, 1985, AM J GASTROENTEROL, V80, P612; BECK IT, 1987, DIGEST DIS SCI, V32, pS26, DOI 10.1007/BF01312461; BENGOA JM, 1985, HEPATOLOGY, V5, P79, DOI 10.1002/hep.1840050117; BERNSTEIN LH, 1980, GASTROENTEROLOGY, V79, P357; BLACKSTONE MO, 1981, GASTROENTEROLOGY, V80, P366; BRANDT LJ, 1982, GASTROENTEROLOGY, V83, P383; BROSTROM O, 1986, GUT, V27, P1408, DOI 10.1136/gut.27.12.1408; BROWN JP, 1983, J MED CHEM, V26, P1300, DOI 10.1021/jm00363a015; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; BUXTONTHOMAS MS, 1984, GUT, V25, P1372, DOI 10.1136/gut.25.12.1372; CAMPIERI M, 1987, DIGEST DIS SCI, V32, pS67, DOI 10.1007/BF01312467; CAMPIERI M, 1981, LANCET, V2, P270; COLLIER PE, 1985, CANCER, V55, P516, DOI 10.1002/1097-0142(19850201)55:3<516::AID-CNCR2820550308>3.0.CO;2-K; DANZI JT, 1988, ARCH INTERN MED, V148, P297, DOI 10.1001/archinte.148.2.297; DARIENZO A, 1990, AM J GASTROENTEROL, V85, P1079; DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DICKINSON RJ, 1980, LANCET, V2, P620; DICKINSON RJ, 1980, GASTROENTEROLOGY, V79, P1199; DORDAL E, 1967, GASTROENTEROLOGY, V52, P239; DOZOIS RR, 1989, ANN SURG, V210, P268, DOI 10.1097/00000658-198909000-00002; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; ELSON CO, 1980, DIGEST DIS SCI, V25, P42, DOI 10.1007/BF01312731; FAWAZ KA, 1976, GASTROENTEROLOGY, V71, P372; FONKALSRUD EW, 1982, AM J SURG, V144, P81, DOI 10.1016/0002-9610(82)90606-7; FRIEDMAN LS, 1986, AM J GASTROENTEROL, V81, P412; FUKUSHIMA T, 1982, AM J GASTROENTEROL, V77, P238; GIAFFER MH, 1990, LANCET, V335, P816, DOI 10.1016/0140-6736(90)90936-Y; GOLDBERG HI, 1979, GASTROENTEROLOGY, V77, P925; GOLDMAN P, 1975, NEW ENGL J MED, V293, P20, DOI 10.1056/NEJM197507032930105; GOMES P, 1986, GUT, V27, P92, DOI 10.1136/gut.27.1.92; GRAVALLESE EM, 1988, AM J GASTROENTEROL, V83, P703; GREENFIELD C, 1983, GUT, V24, P713, DOI 10.1136/gut.24.8.713; GREENSTEIN AJ, 1987, ANN SURG, V205, P72, DOI 10.1097/00000658-198701000-00013; GREENSTEIN AJ, 1985, AM J GASTROENTEROL, V80, P682; GREENSTEIN AJ, 1976, MEDICINE, V55, P401, DOI 10.1097/00005792-197609000-00004; GREENSTEIN AJ, 1981, CANCER, V48, P2742, DOI 10.1002/1097-0142(19811215)48:12<2742::AID-CNCR2820481231>3.0.CO;2-P; GREENSTEIN AJ, 1988, GUT, V29, P588, DOI 10.1136/gut.29.5.588; GUARINO J, 1987, AM J GASTROENTEROL, V82, P732; GYDE S, 1990, GUT, V31, P1089, DOI 10.1136/gut.31.10.1089; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; GYDE SN, 1984, GUT, V25, P228, DOI 10.1136/gut.25.3.228; HABER GB, 1987, DIGEST DIS SCI, V32, pS16, DOI 10.1007/BF01312460; HALSTED CH, 1981, NEW ENGL J MED, V305, P1513, DOI 10.1056/NEJM198112173052506; HAMILTON SR, 1985, SURG GYNECOL OBSTET, V160, P57; HAWKER PC, 1982, GUT, V23, P188, DOI 10.1136/gut.23.3.188; HAWTHORNE AB, 1989, DRUGS, V38, P267, DOI 10.2165/00003495-198938020-00007; HILL RB, 1979, GASTROENTEROLOGY, V77, P938; JONES FA, 1969, LANCET, V2, P795; JONES HW, 1988, GUT, V29, P325, DOI 10.1136/gut.29.3.325; JONES VA, 1987, DIGEST DIS SCI, V32, pS100, DOI 10.1007/BF01312473; JONES VA, 1985, LANCET, V2, P177; KESHAVARZIAN A, 1985, DIGEST DIS SCI, V30, P1156, DOI 10.1007/BF01314050; KHAN AKA, 1980, GUT, V21, P232; KLEIN M, 1974, GASTROENTEROLOGY, V66, P916; KLOTZ U, 1980, NEW ENGL J MED, V303, P1499, DOI 10.1056/NEJM198012253032602; KOZAREK RA, 1989, ANN INTERN MED, V110, P353, DOI 10.7326/0003-4819-110-5-353; KUMANA CR, 1982, LANCET, V1, P579; LAMONT JT, 1980, LANCET, V1, P381; LAURITSEN K, 1988, GUT, V29, P974, DOI 10.1136/gut.29.7.974; LAURITSEN K, 1984, GUT, V25, P1271, DOI 10.1136/gut.25.11.1271; LAURSEN LS, 1990, LANCET, V335, P683; LAVERY IC, 1982, ANN SURG, V195, P508, DOI 10.1097/00000658-198204000-00021; LAYDEN T, 1976, GASTROENTEROLOGY, V70, P1017; LEDDIN DJ, 1987, DIGEST DIS SCI, V32, P377, DOI 10.1007/BF01296291; LEE ECG, 1984, GUT, V25, P217, DOI 10.1136/gut.25.3.217; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LENNARDJONES JE, 1983, GUT, V24, P177, DOI 10.1136/gut.24.3.177; LEVITT MD, 1991, GUT, V32, P126, DOI 10.1136/gut.32.2.126; LICHTIGER S, 1990, LANCET, V336, P16, DOI 10.1016/0140-6736(90)91521-B; LINDOR KD, 1990, AM J MED, V89, P73, DOI 10.1016/0002-9343(90)90101-I; LOGAN ECM, 1986, GUT, V27, P868, DOI 10.1136/gut.27.7.868; MALATJALIAN DA, 1987, DIGEST DIS SCI, V32, pS5, DOI 10.1007/BF01312459; MANNING AP, 1987, GUT, V28, P1489, DOI 10.1136/gut.28.11.1489; MARATKA Z, 1985, GUT, V26, P43, DOI 10.1136/gut.26.1.43; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; MCINTYRE PB, 1985, GUT, V26, P822, DOI 10.1136/gut.26.8.822; MCINTYRE PB, 1986, GUT, V27, P481, DOI 10.1136/gut.27.5.481; MEYERS S, 1980, GASTROENTEROLOGY, V78, P1; MEYERS S, 1983, GASTROENTEROLOGY, V85, P351; MIRMADJLESSI SH, 1986, CANCER-AM CANCER SOC, V58, P1569, DOI 10.1002/1097-0142(19861001)58:7<1569::AID-CNCR2820580731>3.0.CO;2-U; MIRMADJLESSI SH, 1985, AM J GASTROENTEROL, V80, P615; MISTILIS SP, 1965, ANN INTERN MED, V63, P17, DOI 10.7326/0003-4819-63-1-17; MIYACHI Y, 1987, GUT, V28, P190, DOI 10.1136/gut.28.2.190; MORAIN CO, 1984, GUT, V25, P1078; MORTENSEN N, 1988, GUT, V29, P561, DOI 10.1136/gut.29.5.561; NELSON RL, 1990, DIS COLON RECTUM, V33, P451, DOI 10.1007/BF02052137; NIELSEN OH, 1987, DIGEST DIS SCI, V32, P577, DOI 10.1007/BF01296156; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; OAKLEY JR, 1985, AM J SURG, V149, P23, DOI 10.1016/S0002-9610(85)80004-0; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; OLSSON R, 1991, GASTROENTEROLOGY, V100, P1319; PEMBERTON JH, 1987, ANN SURG, V206, P504, DOI 10.1097/00000658-198710000-00011; PEPPERCORN MA, 1990, ANN INTERN MED, V112, P50, DOI 10.7326/0003-4819-112-1-50; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RACHMILEWITZ D, 1989, BMJ-BRIT MED J, V298, P82, DOI 10.1136/bmj.298.6666.82; RANKIN GB, 1979, GASTROENTEROLOGY, V77, P714; RAOUF AH, 1991, GUT, V32, P702, DOI 10.1136/gut.32.6.702; RIJK MCM, 1991, ANN INTERN MED, V114, P445, DOI 10.7326/0003-4819-114-6-445; RITCHIE JK, 1981, GUT, V22, P752, DOI 10.1136/gut.22.9.752; RUDDELL WSJ, 1980, GUT, V21, P885, DOI 10.1136/gut.21.10.885; SAVERYMUTTU SH, 1985, GUT, V26, P955, DOI 10.1136/gut.26.9.955; SAVERYMUTTU SH, 1983, GUT, V24, P293, DOI 10.1136/gut.24.4.293; SAVERYMUTTU SH, 1986, GUT, V27, P809, DOI 10.1136/gut.27.7.809; SAVERYMUTTU SH, 1983, BRIT MED J, V287, P1751, DOI 10.1136/bmj.287.6407.1751; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SCHWARTZ AG, 1982, NEW ENGL J MED, V306, P409, DOI 10.1056/NEJM198202183060708; SEGAL AW, 1981, LANCET, V2, P230, DOI 10.1016/S0140-6736(81)90477-3; SEIDMAN EG, 1987, DIGEST DIS SCI, V32, pS82, DOI 10.1007/BF01312470; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P870; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P887; SNINSKY CA, 1991, ANN INTERN MED, V115, P350, DOI 10.7326/0003-4819-115-5-350; STEINBERG DM, 1975, GASTROENTEROLOGY, V68, P33; STROBEL CT, 1979, GASTROENTEROLOGY, V77, P272; SUGITA A, 1991, GUT, V32, P167, DOI 10.1136/gut.32.2.167; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SURAWICZ CM, 1981, GASTROENTEROLOGY, V81, P66; TAFFET SL, 1983, DIGEST DIS SCI, V28, P833, DOI 10.1007/BF01296907; TAFFET SL, 1982, AM J MED, V73, P520, DOI 10.1016/0002-9343(82)90330-8; TEAHON K, 1990, GUT, V31, P1133, DOI 10.1136/gut.31.10.1133; TELANDER RL, 1980, MAYO CLIN PROC, V55, P420; THEODOR E, 1981, AM J GASTROENTEROL, V76, P262; THORNTON JR, 1980, GUT, V21, P247, DOI 10.1136/gut.21.3.247; TOOVEY S, 1981, GUT, V22, P445, DOI 10.1136/gut.22.6.445; TRNKA YM, 1982, ANN SURG, V196, P345, DOI 10.1097/00000658-198209000-00014; VANHEES PAM, 1981, GUT, V22, P404, DOI 10.1136/gut.22.5.404; WHITTAKER JS, 1987, DIGEST DIS SCI, V32, pS89, DOI 10.1007/BF01312471; WILLIAMS JA, 1971, GUT, V12, P739, DOI 10.1136/gut.12.9.739; WILLOUGHBY JM, 1971, LANCET, V2, P944; YARDLEY JH, 1974, CANCER, V34, P835, DOI 10.1002/1097-0142(197409)34:3+<835::AID-CNCR2820340709>3.0.CO;2-T; ZUCCARO G, 1989, DIGEST DIS SCI, V34, P1505, DOI 10.1007/BF01537101; 1987, DIGEST DIS SCI, V32, P1370; 1987, DIGEST DIS SCI, V32, P598	139	308	316	2	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					1008	1016		10.1056/NEJM199110033251406	http://dx.doi.org/10.1056/NEJM199110033251406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886623				2022-12-28	WOS:A1991GH44700006
J	RICHMOND, M				RICHMOND, M			A FUTURE FOR BRITISH SCIENCE	NATURE			English	Editorial Material											RICHMOND, M (corresponding author), SERC,POLARIS HOUSE,N STAR AVE,SWINDON SN2 1ET,ENGLAND.								0	4	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					379	382		10.1038/353379a0	http://dx.doi.org/10.1038/353379a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896079				2022-12-28	WOS:A1991GH60600025
J	CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC				CORRALDEBRINSKI, M; STEPIEN, G; SHOFFNER, JM; LOTT, MT; KANTER, K; WALLACE, DC			HYPOXEMIA IS ASSOCIATED WITH MITOCHONDRIAL-DNA DAMAGE AND GENE INDUCTION - IMPLICATIONS FOR CARDIAC DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OXIDATIVE-PHOSPHORYLATION; MYOCARDIAL ISCHEMIA; PARKINSONS-DISEASE; FREE-RADICALS; REPERFUSION; MUTATIONS; DELETION; INCREASE; SEQUENCE; NUCLEAR	Objective. - Oxidative phosphorylation (OXPHOS) deficiency due to hypoxemia or other causes was hypothesized to increase oxygen radical generation, damage mitochondrial DNA (mtDNA), and reduce adenosine triphosphate synthesis, resulting in compensatory OXPHOS gene induction. Therefore, we investigated the levels of mtDNA damage and OXPHOS transcripts in normal and ischemic hearts, and then in other forms of heart disease. Design. - DNA was extracted from the heart and the levels of the common 4977 base pair mtDNA deletion were quantitated as an index for mtDNA damage. Total RNA was extracted from hearts and analyzed for OXPHOS transcript levels. Results. - In control hearts, the 4977 base pair mtDNA deletion appeared at age 40 years and reached a maximum deletion of 0.0035%. Much higher levels were found in ischemic hearts (0.02% to 0.85%), as well as in three of 10 cases with other types of heart disease (0.017% to 0.16%). The OXPHOS transcripts were increased in all diseased hearts. Conclusion. - Ischemic hearts have increased mtDNA damage and OXPHOS gene expression, suggesting that mtDNA damage is associated with OXPHOS deficiency. Oxidative phosphorylation defects may also play a role in some other forms of cardiac disease.	EMORY UNIV, SCH MED,DEPT GENET & MOLEC MED, 3031 ROLLINS RES CTR,1510 CLIFTON RD, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT PEDIAT, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT SURG, ATLANTA, GA 30322 USA; CTR COCHIN GENET MOLEC, PARIS, FRANCE; UNIV PARIS 11, CNRS, F-91405 ORSAY, FRANCE	Emory University; Emory University; Emory University; Emory University; Emory University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Lott, Marie/0000-0003-2035-479X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001336, R01NS021328] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45572] Funding Source: Medline; NINDS NIH HHS [NS21328, NS01336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARROYO CM, 1987, FREE RADICAL BIO MED, V3, P313, DOI 10.1016/S0891-5849(87)80037-0; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HATTORI K, 1991, AM HEART J, V121, P1735, DOI 10.1016/0002-8703(91)90020-I; IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B; KOTAKA K, 1982, J MOL CELL CARDIOL, V14, P223, DOI 10.1016/0022-2828(82)90191-2; LOCHNER A, 1981, J MOL CELL CARDIOL, V13, P991, DOI 10.1016/0022-2828(81)90474-0; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; OTANI H, 1984, CIRC RES, V55, P168, DOI 10.1161/01.RES.55.2.168; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; Sambrook J, 1989, MOL CLONING LABORATO; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; SHOFFNER JM, 1990, ADV HUM GENET, V19, P267; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; SHOFFNER JM, IN PRESS ANN NEUROL; TORRONI A, 1990, J BIOL CHEM, V265, P20589; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0	30	302	308	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1812	1816		10.1001/jama.266.13.1812	http://dx.doi.org/10.1001/jama.266.13.1812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890710				2022-12-28	WOS:A1991GG55100034
J	STEINBERG, AD; GOURLEY, MF; KLINMAN, DM; TSOKOS, GC; SCOTT, DE; KRIEG, AM				STEINBERG, AD; GOURLEY, MF; KLINMAN, DM; TSOKOS, GC; SCOTT, DE; KRIEG, AM			SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS ERYTHEMATOSUS, SYSTEMIC; AUTOANTIBODIES; LYMPHOCYTES-T; BETA-LYMPHOCYTES; HEMATOPOIETIC STEM CELLS	T-CELL SUBSETS; HISTOCOMPATIBILITY COMPLEX GENES; FRAGMENT-LENGTH-POLYMORPHISM; RECOMBINANT INBRED LINES; HEAT-SHOCK PROTEINS; B-CELLS; AUTOIMMUNE-DISEASE; GROWTH-FACTOR; PERIPHERAL-BLOOD; MURINE LUPUS	Although the cause of systemic lupus erythematosus remains unknown, pathogenic mechanisms are becoming clearer. Both genetic and environmental factors have been implicated in the induction and in the perpetuation of lupus. Implicated environmental triggers include ultraviolet light, chemicals (hydrazines, hair dyes, drugs), some foods, and possibly infectious agents. Lupus is mediated by the immune system. Patients have excess numbers of antibody-forming cells, including those that produce antibodies reactive with self-antigens. Patients also have an increased number of activated T cells, some of which help B cells to produce autoantibodies. A loss of tolerance is a critical immune abnormality in lupus; many of the activated helper T cells may result from a failure in normal tolerance mechanisms. A hematopoietic stem-cell defect could give rise to both B- and T-cell abnormalities. Such a stem-cell abnormality might lead to both a loss of self-tolerance and polyclonal B-cell activation. Antigen-driven, T-cell-dependent expansion of B-cell clones would then give rise to pathogenic autoantibodies, including anti-DNA. We believe that lupus is a syndrome: Patients differ regarding specific inciting factors and immune defects. Some patients have genetically conditioned abnormalities, similar to those found in mice with lupus; others have a combination of genetic and acquired defects. We hope that insights into pathogenesis lead to improved and more individualized therapy.			STEINBERG, AD (corresponding author), NIH, BLDG 10, ROOM 9N218, BETHESDA, MD 20892 USA.		Krieg, Art/R-6166-2019; tsokos, george C/O-3360-2013; Krieg, Arthur M/K-8109-2019	tsokos, george C/0000-0001-9589-2360; 				AGNELLO V, 1972, J IMMUNOL, V108, P837; ANSEL JC, 1985, J INVEST DERMATOL, V85, P181, DOI 10.1111/1523-1747.ep12276652; ARNETT FC, 1989, J AUTOIMMUN, V2, P403, DOI 10.1016/0896-8411(89)90169-8; ARNETT FC, 1988, AM J MED, V85, P38, DOI 10.1016/0002-9343(88)90381-6; BELL DA, 1980, ARTHRITIS RHEUM, V23, P1268, DOI 10.1002/art.1780231107; BLAESE RM, 1980, AM J MED, V69, P345, DOI 10.1016/0002-9343(80)90003-0; BUDMAN DR, 1977, ARTHRITIS RHEUM, V20, P829, DOI 10.1002/art.1780200312; CHANG BL, 1990, J IMMUNOL, V145, P94; COMPTON LJ, 1984, J IMMUNOL, V133, P213; DATTA SK, 1989, CLIN IMMUNOL IMMUNOP, V51, P141, DOI 10.1016/0090-1229(89)90015-9; DELFRAISSY JF, 1986, EUR J IMMUNOL, V16, P1251, DOI 10.1002/eji.1830161011; DIGHIERO G, 1985, J IMMUNOL, V134, P765; DUNCKLEY H, 1988, IMMUNOGENETICS, V27, P392, DOI 10.1007/BF00395137; ENGLEMAN EG, 1981, ARTHRITIS RHEUM, V24, P1396, DOI 10.1002/art.1780241110; FLESCHER E, 1990, EUR J IMMUNOL, V20, P2425, DOI 10.1002/eji.1830201110; FRANK MB, 1990, J CLIN INVEST, V85, P33, DOI 10.1172/JCI114430; FRENITITULAER LWJ, 1989, AM J EPIDEMIOL, V130, P404, DOI 10.1093/oxfordjournals.aje.a115348; FRONEK Z, 1990, ARTHRITIS RHEUM, V33, P1542, DOI 10.1002/art.1780331012; FUJISAKU A, 1990, J CLIN INVEST, V86, P606, DOI 10.1172/JCI114751; GAHRING LC, 1990, J IMMUNOL, V145, P1318; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GOLBUS J, 1988, CLIN IMMUNOL IMMUNOP, V46, P129, DOI 10.1016/0090-1229(88)90013-X; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GUILBERT B, 1982, J IMMUNOL, V128, P2779; HARLEY JB, 1989, ARTHRITIS RHEUM, V32, P826; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HIRATA F, 1981, P NATL ACAD SCI-BIOL, V78, P3190, DOI 10.1073/pnas.78.5.3190; HIROHATA S, 1990, ARTHRITIS RHEUM, V33, P644, DOI 10.1002/art.1780330506; HOCHBERG MC, 1990, RHEUM DIS CLIN N AM, V16, P617; HONDA M, 1982, J CLIN INVEST, V69, P940, DOI 10.1172/JCI110533; ISHIGATSUBO Y, 1989, AUTOIMMUNITY, V5, P71, DOI 10.3109/08916938909029144; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; Kastner D L, 1988, Concepts Immunopathol, V6, P22; KASTNER DL, 1989, J IMMUNOL, V143, P2761; KEEN CL, 1990, ANN NY ACAD SCI, V587, P208, DOI 10.1111/j.1749-6632.1990.tb00148.x; KEMP ME, 1987, ARTHRITIS RHEUM, V30, P1015, DOI 10.1002/art.1780300908; KIM T, 1987, CLIN EXP IMMUNOL, V70, P562; KITANI A, 1989, CLIN EXP IMMUNOL, V77, P31; KLINMAN DK, 1991, IN PRESS ARTHRITIS R; KLINMAN DM, 1990, J IMMUNOL, V144, P4520; KLINMAN DM, 1988, J CLIN INVEST, V82, P652, DOI 10.1172/JCI113644; KLINMAN DM, 1990, J IMMUNOL, V144, P506; KLINMAN DM, 1987, J EXP MED, V165, P1755, DOI 10.1084/jem.165.6.1755; KLINMAN DM, 1990, J CLIN INVEST, V86, P1249, DOI 10.1172/JCI114831; KOTZIN BL, 1989, J IMMUNOL, V143, P89; KRIEG AM, 1990, J AUTOIMMUN, V3, P137, DOI 10.1016/0896-8411(90)90137-H; KRIEG AM, 1989, J IMMUNOL, V143, P2448; KRIEG AM, 1990, J CLIN INVEST, V86, P809, DOI 10.1172/JCI114778; KRIEG AM, 1991, J IMMUNOL, V146, P3002; KUMAGAI S, 1982, J IMMUNOL, V128, P258; KUMAGAI S, 1981, J CLIN INVEST, V67, P605, DOI 10.1172/JCI110074; LANE JR, 1991, IN PRESS J IMMUNOL; LASKIN CA, 1981, J IMMUNOL, V127, P1743; LASKIN CA, 1982, J EXP MED, V155, P1025, DOI 10.1084/jem.155.4.1025; LINKERISRAELI M, 1983, J IMMUNOL, V130, P2651; LINKERISRAELI M, 1990, ARTHRITIS RHEUM, V33, P1216; LINKERISRAELI M, 1989, ANN NY ACAD SCI, V557, P567; LYDYARD PM, 1990, IMMUNOL TODAY, V11, P228, DOI 10.1016/0167-5699(90)90091-M; MCGRATH H JR, 1990, Arthritis and Rheumatism, V33, pS165; MILLER ML, 1984, J IMMUNOL, V133, P1325; MILLER ML, 1988, MUCOSAL IMMUNITY INF, P119; MINOTA S, 1988, J EXP MED, V168, P1475, DOI 10.1084/jem.168.4.1475; MONESTIER M, 1986, J CLIN INVEST, V78, P753, DOI 10.1172/JCI112637; MORIMOTO C, 1984, J CLIN INVEST, V73, P689, DOI 10.1172/JCI111261; MORIMOTO C, 1982, J IMMUNOL, V129, P1960; MORIMOTO C, 1980, J CLIN INVEST, V66, P1171, DOI 10.1172/JCI109948; MORIMOTO C, 1987, J CLIN INVEST, V79, P762, DOI 10.1172/JCI112882; MORIUCHI J, 1991, ARTHRITIS RHEUM, V34, P224, DOI 10.1002/art.1780340216; MORTON JI, 1974, P NATL ACAD SCI USA, V71, P2162, DOI 10.1073/pnas.71.6.2162; MORTON RO, 1976, J RHEUMATOL, V3, P186; NAGAI H, 1984, CLIN EXP RHEUMATOL, V2, P131; Nelson JL, 1987, HORMONES IMMUNITY, P93; OLSEN ML, 1989, IMMUNOGENETICS, V30, P27, DOI 10.1007/BF02421466; PELTON BK, 1987, CLIN EXP IMMUNOL, V67, P159; PINCUS T, 1978, ARTHRITIS RHEUM, V21, P873, DOI 10.1002/art.1780210801; PRICKETT JD, 1981, J CLIN INVEST, V68, P556, DOI 10.1172/JCI110288; QUERY CC, 1987, CELL, V51, P211, DOI 10.1016/0092-8674(87)90148-6; RAJAGOPALAN S, 1990, P NATL ACAD SCI USA, V87, P7020, DOI 10.1073/pnas.87.18.7020; RAVECHE ES, 1985, J IMMUNOL, V134, P865; RAVECHE ES, 1981, J EXP MED, V153, P1187, DOI 10.1084/jem.153.5.1187; REIDENBERG MM, 1983, AM J MED, V75, P1037, DOI 10.1016/0002-9343(83)90885-9; REINERSTEN JL, 1982, J RHEUMATOL, V9, P253; REINERTSEN JL, 1978, NEW ENGL J MED, V299, P515, DOI 10.1056/NEJM197809072991004; RONNBLOM LE, 1990, J INTERN MED, V227, P207; SAKANE T, 1979, J CLIN INVEST, V64, P1260, DOI 10.1172/JCI109581; SAKANE T, 1989, AM J MED, V86, P385, DOI 10.1016/0002-9343(89)90334-3; SANO H, 1985, J CLIN INVEST, V76, P1314, DOI 10.1172/JCI112105; SANO H, 1983, J IMMUNOL, V130, P187; SCHUR PH, 1985, ARTHRITIS RHEUM, V28, P828, DOI 10.1002/art.1780280716; SCHWARZ T, 1989, J PHOTOCH PHOTOBIO B, V4, P1, DOI 10.1016/1011-1344(89)80097-1; SCRIBNER CL, 1988, CLIN IMMUNOL IMMUNOP, V49, P133, DOI 10.1016/0090-1229(88)90102-X; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SHARPE NG, 1989, J AUTOIMMUN, V2, P701, DOI 10.1016/S0896-8411(89)80008-3; SHEFNER R, 1991, J EXP MED, V173, P287, DOI 10.1084/jem.173.2.287; SHIVAKUMAR S, 1989, J IMMUNOL, V143, P103; SIERAKOWSKI S, 1989, J CLIN IMMUNOL, V9, P469, DOI 10.1007/BF00918016; SMATHERS PA, 1982, J IMMUNOL, V128, P1414; SMITH HR, 1983, CLIN EXP IMMUNOL, V51, P579; SMOLEN JS, 1982, AM J MED, V72, P783, DOI 10.1016/0002-9343(82)90544-7; SMOLEN JS, 1987, ANN RHEUM DIS, V46, P457, DOI 10.1136/ard.46.6.457; SOLINGER AM, 1988, RHEUM DIS CLIN N AM, V14, P187; STAPLES PJ, 1970, J EXP MED, V131, P1223, DOI 10.1084/jem.131.6.1223; Steinberg A D, 1989, J Immunol, V143, P3858; STEINBERG AD, 1990, IMMUNOL REV, V118, P129, DOI 10.1111/j.1600-065X.1990.tb00815.x; STEINBERG BJ, 1982, J CLIN INVEST, V70, P587, DOI 10.1172/JCI110651; STEINBERG EB, 1983, J IMMUNOL, V131, P2789; STERN RS, 1986, JAMA-J AM MED ASSOC, V255, P3120, DOI 10.1001/jama.255.22.3120; TALAL N, 1990, J CLIN INVEST, V85, P1866, DOI 10.1172/JCI114647; TANAKA Y, 1988, J IMMUNOL, V141, P3043; TEBIB JG, 1990, J CLIN INVEST, V86, P1961, DOI 10.1172/JCI114930; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; TSOKOS GC, 1983, J IMMUNOL, V131, P1797; TSOKOS GC, 1984, PROG ALLERGY, V35, P93; UEDA Y, 1989, J IMMUNOL, V143, P3988; UETRECHT J, 1990, CRIT REV TOXICOL, V20, P213, DOI 10.3109/10408449009089863; UMLAND S, 1989, MOL IMMUNOL, V26, P649, DOI 10.1016/0161-5890(89)90047-3; WARRINGTON RJ, 1990, J CLIN IMMUNOL, V10, P52, DOI 10.1007/BF00917498; WILLIAMS GW, 1978, ANN INTERN MED, V88, P729, DOI 10.7326/0003-4819-88-6-729; WINFIELD JB, 1989, ARTHRITIS RHEUM, V32, P1497, DOI 10.1002/anr.1780321202; [No title captured]	120	103	105	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					548	559		10.7326/0003-4819-115-7-548	http://dx.doi.org/10.7326/0003-4819-115-7-548			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883125				2022-12-28	WOS:A1991GG28300008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA MEDICAL BULLETIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FDA MED B; FDA DRUG B	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-28	WOS:A1991GE45800006
J	BARRETTCONNOR, E				BARRETTCONNOR, E			POSTMENOPAUSAL ESTROGEN AND PREVENTION BIAS	ANNALS OF INTERNAL MEDICINE			English	Note						ESTROGEN REPLACEMENT THERAPY; PREVENTIVE HEALTH SERVICES; HEALTH BEHAVIOR; LIPOPROTEINS, HDL CHOLESTEROL; BIAS (EPIDEMIOLOGY)	REPLACEMENT THERAPY; BREAST-CANCER; WOMEN; RISK	A mailed health survey questionnaire was returned by 1008 of 1057 (95%) previously studied older women from Rancho Bernardo, a socioeconomiclaly upper-middle-class California community where replacement estrogen use was known to be common. Women currently using estrogen had significantly healthier behaviors and more preventive services by physicians (recent cholesterol check, rectal examination, papanicolaou smear, and mammogram) than nonusers. These differences may explain some of the benefits and risks currently attributed to hormone replacement therapy.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40207] Funding Source: Medline; NIA NIH HHS [AGO 7181] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; HORWITZ RI, 1990, LANCET, V336, P542, DOI 10.1016/0140-6736(90)92095-Y; TIKKANEN MJ, 1978, LANCET, V2, P490; 1980, NEW ENGL J MED, V303, P1038	10	347	351	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					455	456		10.7326/0003-4819-115-6-455	http://dx.doi.org/10.7326/0003-4819-115-6-455			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872493				2022-12-28	WOS:A1991GE81000007
J	BURNS, CR				BURNS, CR			THE UNIVERSITY-OF-TEXAS MEDICAL BRANCH AT GALVESTON - ORIGINS AND BEGINNINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BURNS, CR (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG,ROOM 2208,GALVESTON,TX 77550, USA.							BOWMAN IA, 1986, TEX MED, V82, P51; DOWELL G, 1867, GALV MED J, V2, P736; DOWELL G, 1870, GALV MED J, V5, P183; HEGARTY ML, 1967, SERVING GLADNESS ORI, P233; LUDMERER K, 1985, LEARNING HEAL DEV AM, P81; McComb David, 1986, GALVESTON HIST; PAINE JFY, 1892, T TEX STATE MED ASS, P235; PAINE JFY, 1901, T TEX STATE MED ASS, P210; RICHARDSON RN, 1981, LONE STAR STATE, P181; SMITH A, 1901, U MED, V6, P1; THOMPSON TC, 1903, HIST ED TEXAS, P222; WOOLDRIDGE AP, 1913, ALCALDE, V2, P26; 1881, J SENATE TEXAS, P100; 1879, AAMC P, V4; 1892, DANIELS TEX MED J, V8, P243; 1880, AACA P, V2; 1892, DANIELS TEX MED J, V8, P230; TEXAS MED COLLEGE HO; 1900, U REC, V2, P383; 1881, TEX MED SURG REC, V1, P213; 1876, TEX MED J, V5, P41; 1888, GENERAL LAWS STATE T, P19	22	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1400	1403		10.1001/jama.266.10.1400	http://dx.doi.org/10.1001/jama.266.10.1400			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880871				2022-12-28	WOS:A1991GD80700036
J	ANNAS, GJ				ANNAS, GJ			FETAL PROTECTION AND EMPLOYMENT DISCRIMINATION - THE JOHNSON-CONTROLS CASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1988, JUDGING MED, P53; BECKER ME, 1990, JAMA-J AM MED ASSOC, V264, P2113, DOI 10.1001/jama.264.16.2113; FUCHS VR, 1986, SCIENCE, V232, P459, DOI 10.1126/science.232.4749.459; 1987, PATIENT CHOICE MATER	4	16	16	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					740	743		10.1056/NEJM199109053251020	http://dx.doi.org/10.1056/NEJM199109053251020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GD497	1870647	Green Published			2022-12-28	WOS:A1991GD49700029
J	VINER, S; SZALAI, JP; HOFFSTEIN, V				VINER, S; SZALAI, JP; HOFFSTEIN, V			ARE HISTORY AND PHYSICAL-EXAMINATION A GOOD SCREENING-TEST FOR SLEEP-APNEA	ANNALS OF INTERNAL MEDICINE			English	Article							SNORERS	Objective: To determine whether presenting clinical history, pharyngeal examination, and the overall subjective impression of the clinician could serve as a sensitive screening test for sleep apnea. Design: Blinded comparison of history and physical examination with results of nocturnal polysomnography. Setting: Sleep clinic of a tertiary referral center. Patients: A total of 410 patients referred for suspected sleep apnea syndrome. Most patients reported snoring. Measurements: All patients were asked standard questions and given an examination relevant to the diagnosis of the sleep apnea syndrome, and all had full nocturnal polysomnography. Patients with more than ten episodes of apnea or hypopnea per hour of sleep were classified as having sleep apnea. Stepwise linear logistic regression was used to develop two predictive models of sleep apnea: one based on the presence of characteristic clinical features, age, sex, and body mass index; and one based on subjective clinical impression. Results: The prevalence of sleep apnea in our patients was 46%. Only age, body mass index, male sex, and snoring were found to be predictors of sleep apnea. The logistic rule discriminated between patients with and without sleep apnea (receiver operating characteristic [ROC] area, 0.77 [95% Cl, 0.73 to 0.82]). For patients with a predicted probability of apnea of less than 20%, the clinical model had 94% sensitivity and 28% specificity. Subjective impression alone identified correctly only 52% of patients with sleep apnea and had a specificity of 70%. Conclusions: In patients with a high predicted probability of the sleep apnea syndrome, subjective impression alone or any combination of clinical features cannot serve as a reliable screening test. However, in patients with a low predicted probability of sleep apnea, the model based on clinical data was sufficiently sensitive to permit about a 30% reduction in the number of unnecessary sleep studies.	ST MICHAELS HOSP, 30 BOND ST, TORONTO M5B 1W8, ONTARIO, CANADA; SUNNYBROOK HLTH SCI CTR, DEPT RES DESIGN BIOSTAT, TORONTO M4N 3M5, ONTARIO, CANADA; CALGARY GEN HOSP, BOW VALLY CTR, CALGARY T2E 0A1, ALBERTA, CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Calgary								[Anonymous], 1989, AM REV RESPIR DIS, V139, P559; BRADLEY TD, 1986, NEW ENGL J MED, V315, P1327, DOI 10.1056/NEJM198611203152105; CARSKADON MA, 1981, J GERONTOL, V36, P420, DOI 10.1093/geronj/36.4.420; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HAPONIK EF, 1984, AM J MED, V77, P671, DOI 10.1016/0002-9343(84)90361-9; HOFFSTEIN V, 1988, LANCET, V2, P992; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; IXON WJ, 1988, BMDP STATISTICAL SOF, P941; JEONG DU, 1989, CLIN EXP HYPERTENS A, V11, P1301, DOI 10.3109/10641968909038171; KALES A, 1985, J CHRON DIS, V38, P419, DOI 10.1016/0021-9681(85)90137-7; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; SWETS JA, 1989, EVALUATION DIAGNOSTI; 1990, SAS P200 SAS I INC T, P175	16	210	220	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					356	359		10.7326/0003-4819-115-5-356	http://dx.doi.org/10.7326/0003-4819-115-5-356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863025				2022-12-28	WOS:A1991GC06500004
J	LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D				LEWIS, C; KRAMER, T; ROBINSON, S; HILVERT, D			MEDIUM EFFECTS IN ANTIBODY-CATALYZED REACTIONS	SCIENCE			English	Article							HISTIDINE-DECARBOXYLASE; 6-NITROBENZISOXAZOLE-3-CARBOXYLATE; BINDING; ESTER	Catalytic antibody technology has been used to explore the contribution of medium effects to the overall rate of an enzyme-catalyzed reaction. An antibody generated against a derivative of 2-acetamido-1,5-napthalenedisulfonate efficiently catalyzes the decarboxylation of 5-nitro-3-carboxybenzisoxazole. This unimolecular reaction is not susceptible to general acid-base catalysis but is highly sensitive to microenvironment; thus, it provides a simple chemical model for biologically important decarboxylations. The 10(4)-fold rate acceleration observed for the antibody reflects the kinetic advantage of the low-dielectric environment of the binding pocket acting to destabilize the substrate by desolvation and to stabilize the charge-delocalized transition state through dispersion interactions. These results are pertinent to an understanding of solvent effects in enzymic reactions in general and suggest approaches for developing antibody catalysts for numerous other reactions that involve large changes in charge distribution as the reaction coordinate is traversed.	Scripps Res Inst, RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM38273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELL KWY, 1986, TETRAHEDRON LETT, V27, P1085, DOI 10.1016/S0040-4039(86)80055-7; ALSTON TA, 1987, BIOCHEMISTRY-US, V26, P4082, DOI 10.1021/bi00387a051; Azzi A, 1974, Methods Enzymol, V32, P234; BUNTON CA, 1975, J ORG CHEM, V40, P1321, DOI 10.1021/jo00897a031; BUNTON CA, 1973, J AM CHEM SOC, V95, P3262, DOI 10.1021/ja00791a032; CROSBY J, 1970, J AM CHEM SOC, V92, P2891, DOI 10.1021/ja00712a048; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HILVERT D, 1990, BIOMIMETIC POLYMERS, P95; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P645; KEMP DS, 1978, TETRAHEDRON LETT, V8, P741; KLOTZ IM, 1946, J AM CHEM SOC, V68, P1486, DOI 10.1021/ja01212a030; KUNITAKE T, 1980, J AM CHEM SOC, V102, P7877, DOI 10.1021/ja00547a009; OLEARY MH, 1981, BIOCHEMISTRY-US, V20, P2743, DOI 10.1021/bi00513a007; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; SCHMIDTCHEN FP, 1986, J CHEM SOC PERK T 2, P135, DOI 10.1039/p29860000135; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SELIGER HH, 1978, METHOD ENZYMOL, V57, P560; SHAH SC, 1978, J AM CHEM SOC, V100, P1426, DOI 10.1021/ja00473a017; SMID J, 1975, J AM CHEM SOC, V97, P5932, DOI 10.1021/ja00853a058; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SUH J, 1976, J AM CHEM SOC, V98, P7060, DOI 10.1021/ja00438a054; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; Williams J W, 1979, Methods Enzymol, V63, P437	27	75	76	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1019	1022		10.1126/science.1887215	http://dx.doi.org/10.1126/science.1887215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887215				2022-12-28	WOS:A1991GC98200042
J	GREENMAN, RL; SCHEIN, RMH; MARTIN, MA; WENZEL, RP; MACINTYRE, NR; EMMANUEL, G; CHMEL, H; KOHLER, RB; MCCARTHY, M; PLOUFFE, J; RUSSELL, JA				GREENMAN, RL; SCHEIN, RMH; MARTIN, MA; WENZEL, RP; MACINTYRE, NR; EMMANUEL, G; CHMEL, H; KOHLER, RB; MCCARTHY, M; PLOUFFE, J; RUSSELL, JA			A CONTROLLED CLINICAL-TRIAL OF E5 MURINE MONOCLONAL IGM ANTIBODY TO ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; HIGH-DOSE CORTICOSTEROIDS; LIPID-A ANTIBODY; SEPTIC SHOCK; ESCHERICHIA-COLI; BACTERIAL SEPSIS; BACTEREMIA; MORTALITY; FAILURE; DISEASE	Objective.-To assess the efficacy of adjunctive monoclonal antibody antiendotoxin immunotherapy in patients with gram-negative sepsis. Design.-Double-blind, randomized, placebo-controlled trial. Setting.-Thirty-three university-affiliated centers, including Veterans Affairs, community, and municipal hospitals. Patients.-Hospitalized adults with signs of gram-negative infection and a systemic septic response. Intervention.-Patients were assigned to receive either 2 mg/kg of a murine monoclonal antibody directed against gram-negative endotoxin (E5) or placebo. A second infusion was administered 24 hours later. Main Outcome Measures.-Mortality over the 30-day study period, resolution of organ failures, and safety Results.-Four hundred eighty-six patients were enrolled. Three hundred sixteen had confirmed gram-negative sepsis (54% bacteremic, 46% nonbacteremic). The survival difference was not statistically significant for all patients. Among patients with gram-negative sepsis who were not in shock at study entry (n = 137), E5 treatment resulted in significantly greater survival (relative risk, 2.3; P=.01). Resolution of individual organ failures was more frequent among these patients, occurring in 19 (54%) of 35 patients in the E5 group vs eight (30%) of 27 in the placebo group (P =.05). Four reversible allergic reactions occurred among 247 patients (1.6%) receiving E5. No other toxicity was identified. Conclusions.-Treatment with E5 antiendotoxin antibody appears safe. It reduces mortality and enhances the resolution of organ failure among patients with gram-negative sepsis who are not in shock when treated.	UNIV MIAMI, SCH MED, MIAMI, FL 33152 USA; UNIV IOWA, COLL MED, DEPT MED, IOWA CITY, IA 52242 USA; DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27706 USA; BAY PINES VET AFFAIRS MED CTR, DEPT INTERNAL MED, TAMPA, FL USA; UNIV S FLORIDA, COLL MED, TAMPA, FL 33612 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT SURG, INDIANAPOLIS, IN 46202 USA; OHIO STATE UNIV, COLL MED, DEPT MED, COLUMBUS, OH 43210 USA	University of Miami; University of Iowa; Duke University; State University System of Florida; University of South Florida; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Ohio State University	GREENMAN, RL (corresponding author), VET AFFAIRS MED CTR, DEPT MED, MED SERV 111, 1201 NW 16TH ST, MIAMI, FL 33125 USA.							BAUMGARTNER JD, 1985, LANCET, V2, P59; Bermudez LE, 1989, REV INFECT DIS    S7, V11, pS1564; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRAUDE AI, 1977, J INFECT DIS, V136, pS167, DOI 10.1093/infdis/136.Supplement.S167; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CHERNOW B, 1986, CIRC SHOCK, V18, P141; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COX DR, 1972, J R STAT SOC B, V34, P187; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; FISHER CJ, 1990, CRIT CARE MED, V18, P1311, DOI 10.1097/00003246-199012000-00001; GREENBERG RN, 1989, 29TH INT C ANT AG CH; HARKONEN S, 1988, ANTIMICROB AGENTS CH, V32, P710, DOI 10.1128/AAC.32.5.710; Hinshaw LPP, 1987, NEW ENGL J MED, V317, P659; JACOBS RF, 1989, CRIT CARE CLIN, V5, P9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAYES JT, 1988, TRANSPLANTATION, V45, P349; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MCCABE WR, 1972, NEW ENGL J MED, V287, P261, DOI 10.1056/NEJM197208102870601; MCGOWAN JE, 1975, J INFECT DIS, V132, P316, DOI 10.1093/infdis/132.3.316; Miller RG., 1981, SIMULTANEOUS STATIST, P8; NASTANSON C, 1990, AM J PHYSIOL, V259, P1440; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SCANNON PJ, 1989, SCHRIFTENREIHE INTEN, V71, P140; SHENEP JL, 1984, J INFECT DIS, V150, P380, DOI 10.1093/infdis/150.3.380; SHENEP JL, 1988, J INFECT DIS, V157, P565, DOI 10.1093/infdis/157.3.565; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TENG NNH, 1985, P NATL ACAD SCI USA, V82, P1790, DOI 10.1073/pnas.82.6.1790; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WOOD DM, 1990, 1ST C INT END SOC; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1988, J INFECT DIS, V158, P286, DOI 10.1093/infdis/158.2.286; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	42	598	622	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1097	1102		10.1001/jama.266.8.1097	http://dx.doi.org/10.1001/jama.266.8.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865542				2022-12-28	WOS:A1991GB97500032
J	THOMPSON, CC; BROWN, TA; MCKNIGHT, SL				THOMPSON, CC; BROWN, TA; MCKNIGHT, SL			CONVERGENCE OF ETS-RELATED AND NOTCH-RELATED STRUCTURAL MOTIFS IN A HETEROMERIC DNA-BINDING COMPLEX	SCIENCE			English	Article							CELL-CYCLE CONTROL; IMMUNOGLOBULIN ENHANCER-BINDING; NF-KAPPA-B; TRANSCRIPTION FACTOR; CONTROL PROTEINS; RNA-POLYMERASE; REL ONCOGENE; GENE; DROSOPHILA; SEQUENCE	Analysis of the heteromeric DNA binding protein GABP has revealed the interaction of two distinct peptide sequence motifs normally associated with proteins located in different cellular compartments. The alpha-subunit of GABP contains an 85-amino acid segment related to the Ets family of DNA binding proteins. The ETS domain of GABP-alpha facilitates weak binding to DNA and, together with an adjacent segment of 37 amino acids, mediates stable interaction with GABP-beta. The beta-subunit of GABP contains four imperfect repeats of a sequence present in several transmembrane proteins including the product of the Notch gene of Drosophila melanogaster. These amino-terminal repeats of GABP-beta mediate stable interaction with GABP-alpha and, when complexed with GABP-alpha, directly contact DNA. These observations provide evidence for a distinct biochemical role for the 33-amino acid repeats, and suggest that they may serve as a module for the generation of specific dimerization interfaces.			THOMPSON, CC (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210, USA.							ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BAUERLE PA, 1988, CELL, V53, P211; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROWN TB, UNPUB; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HASKILL S, 1991, CELL, V65; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON C, UNPUB; TRIEZENBERG SL, 1989, GENE DEV, V3, P1372; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	37	435	440	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					762	768		10.1126/science.1876833	http://dx.doi.org/10.1126/science.1876833			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876833				2022-12-28	WOS:A1991GB29500029
J	POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C				POUNGVARIN, N; VIRIYAVEJAKUL, A; KOMONTRI, C			SIRIRAJ STROKE SCORE AND VALIDATION-STUDY TO DISTINGUISH SUPRATENTORIAL INTRACEREBRAL HEMORRHAGE FROM INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGE	Objectives - To develop a simple, reliable, and safe diagnostic tool for acute stroke syndromes in a setting where computerised brain scanning was not readily available and to validate its accuracy with regard to pathological types of stroke. Design - 13 clinical variables that potentially might differentiate supratentorial cerebral haemorrhage from infarction were recorded and tested by multivariate analysis in a prospective study of 174 patients with acute stroke. In developing the Siriraj stroke score stepwise discriminant analysis of the variables was followed by a linear discriminant equation to differentiate between supratentorial haemorrhage and infarction. The score obtained was validated against scores in 206 other patients with stroke, computerised brain scans being used for definitive diagnosis. Setting - Siriraj Hospital Medical School, Mahidol University, Bangkok. Subjects - Prospective study: 174 consecutive patients with acute supratentorial stroke syndrome (not subarachnoid haemorrhage) admitted to Siriraj Hospital during 1984-5; validation study: 206 patients admitted to Siriraj Hospital or another hospital for supratentorial intracerebral haemorrhage or infarction. Results - The Siriraj stroke score was developed and calculated as (2.5 x level of consciousness) + (2 x vomiting) + (2 x headache) + (0.1 x diastolic blood pressure) - (3 x atheroma markers) - 12. A score above 1 indicates supratentorial intracerebral haemorrhage, while a score below -1 indicates infarction. The score between 1 and -1 represents an equivocal result needing a computerised brain scan or probability curve to verify the diagnosis. In the validation study of the Siriraj stroke score the diagnostic sensitivities of the score for cerebral haemorrhage and cerebral infarction were 89.3% and 93.2% respectively, with an overall predictive accuracy of 90.3%. Conclusion - The Siriraj stroke score is widely accepted and applied in hospitals throughout Thailand as a simple and reliable bedside method for diagnosing acute stroke.	MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,CLIN EPIDEMIOL UNIT,BANGKOK 10700,THAILAND	Mahidol University	POUNGVARIN, N (corresponding author), MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT MED,DIV NEUROL,BANGKOK 10700,THAILAND.							ALLAN CMC, 1983, Q J MED, V42, P515; ALLAN CMC, 1984, THESIS U CAMBRIDGE C; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; Kurtzke J.F., 1985, CEREBROVASCULAR SURV, P1; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; SCHAAFSMA S, 1968, J NEUROL SCI, V7, P83, DOI 10.1016/0022-510X(68)90005-1; VANARBIN M, 1981, STROKE, V12, P288; VIRIYAVEJAKUL A, 1990, CLIN NEUROPHARMACOL, V13, pS26, DOI 10.1097/00002826-199013003-00003; VIRIYAVEJAKUL A, 1976, SIRIRAJ HOSP GAZETTE, V28, P1648; VIRIYAVEJAKUL A, 1982, SIRIRAJ HOSPITAL GAZ, V34, P501	11	95	98	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1565	1567		10.1136/bmj.302.6792.1565	http://dx.doi.org/10.1136/bmj.302.6792.1565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855041	Bronze, Green Published			2022-12-28	WOS:A1991FU54900023
J	KRITCHEVSKY, SB; SIMMONS, BP				KRITCHEVSKY, SB; SIMMONS, BP			CONTINUOUS QUALITY IMPROVEMENT - CONCEPTS AND APPLICATIONS FOR PHYSICIAN CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL MORTALITY; HEALTH-CARE; ASSURANCE; EPIDEMIOLOGY; SURVEILLANCE; MANAGEMENT; INFECTIONS	There has been a growing interest by health care leaders in the continuous quality improvement method of quality management. This method uses measurements of quality "indicators" to initiate and drive organizational changes in a never-ending cycle of continuous improvement. Many discussions of the continuous quality improvement method have emphasized the organizational and attitudinal changes necessary to fully implement the model while deemphasizing the uses of measures of quality to guide improvement. In this article, we emphasize the concepts behind the measurement of quality that underlie the continuous quality improvement model and give examples of how these concepts can be immediately applied to guide improvement in the quality of physician care.	METHODIST HLTH SYST,MEMPHIS,TN		KRITCHEVSKY, SB (corresponding author), UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,877 MADISON AVE,MEMPHIS,TN 38163, USA.							Batalden PB, 1989, PROVIDING QUALITY CA, P133; Berwick D. M, 1990, CURING HLTH CARE NEW; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BERWICK DM, 1987, HLTH CARE FINANC REV, V9, pS49; BRENNAN TA, 1990, ANN INTERN MED, V112, P221, DOI 10.7326/0003-4819-112-3-221; BUEHLER JW, 1985, NEW ENGL J MED, V313, P211, DOI 10.1056/NEJM198507253130402; Crosby P., 1979, QUALITY IS FREE; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; Deming EW., 1986, OUT CRISIS; DONABEDIAN A, 1988, INQUIRY-J HEALTH CAR, V25, P173; DONABEDIAN A, 1985, METHODS FINDINGS QUA; DONABEDIAN A, 1980, DEFINITION QUALITY A; DUBOIS RW, 1989, PROVIDING QUALITY CA, P107; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; Feigenbaum A.V., 1983, TOTAL QUALITY CONTRO, V3rd; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; FLETCHER RH, 1990, ANN INTERN MED, V113, P645, DOI 10.7326/0003-4819-113-9-645; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; HANNAN EL, 1989, AM J PUBLIC HEALTH, V79, P430, DOI 10.2105/AJPH.79.4.430; Iezzoni LI, 1989, PROVIDING QUALITY CA, P70; JAMESON EM, 1936, GYNECOLOGY OBSTETRIC; Jarvis W R, 1984, MMWR CDC Surveill Summ, V33, p9SS; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Juran J. M, 1964, MANAGERIAL BREAKTHRO; KAISER AB, 1986, NEW ENGL J MED, V315, P1129; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; LOHR KN, 1990, NEW ENGL J MED, V322, P707, DOI 10.1056/NEJM199003083221031; LOHR KN, 1988, INQUIRY-J HEALTH CAR, V25, P37; LYNCH P, 1985, AM J INFECT CONTROL, V13, P161, DOI 10.1016/0196-6553(85)90103-8; McLaughlin C P, 1990, Health Care Manage Rev, V15, P7; MOODY BL, 1988, ARCH INTERN MED, V148, P2241, DOI 10.1001/archinte.148.10.2241; NASH DB, 1989, PROVIDING QUALITY CA, P5; OLEARY DS, 1988, JAMA-J AM MED ASSOC, V260, P1760, DOI 10.1001/jama.260.12.1760; ROTHMAN KJ, 1985, NEW ENGL J MED, V313, P258, DOI 10.1056/NEJM198507253130409; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; SHAININ D, 1988, JURANS QUALITY CONTR; Shewhart WA, 1925, J AM STAT ASSOC, V20, P546, DOI 10.2307/2277170; Shewhart WA., 1931, EC CONTROL QUALITY M; SOLOMON SL, 1984, NEW ENGL J MED, V310, P166, DOI 10.1056/NEJM198401193100305; STRUNIN L, 1976, ANAESTHESIA PHARM SP, P46; TURNBULL KW, 1980, CAN ANAESTH SOC J, V27, P159, DOI 10.1007/BF03007780; Wadsworth HM, 2002, MODERN METHODS QUALI; 1989, HOSPITAL STATISTICS; 1989, QRB, V15, P330; 1989, AGENDA CHANGE UPDATE, V3, P5; 1958, STATISTICAL QUALITY	49	178	180	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1817	1823		10.1001/jama.266.13.1817	http://dx.doi.org/10.1001/jama.266.13.1817			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890711				2022-12-28	WOS:A1991GG55100035
J	WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF				WRIGHT, JG; MCGEER, AJ; CHYATTE, D; RANSOHOFF, DF			MECHANISMS OF GLOVE TEARS AND SHARP INJURIES AMONG SURGICAL PERSONNEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NEEDLESTICK INJURIES; HIV-INFECTION; RISK; SURGERY; OPERATIONS; BLOOD; CONTAMINATION; EXPOSURE	Objective. - The development of strategies to prevent exposure to blood for operating room personnel has been hampered by a lack of knowledge about the specific mechanisms of exposure. The purpose of this study was to classify the mechanisms of glove tears and sharp injuries in the operating room. Design. - During a 3-month period, a nurse interviewed operating room personnel immediately after a glove tear or sharp injury had occurred. Setting. - Yale-New Haven (Conn) Hospital is a tertiary care teaching hospital. Results. - There were 249 glove tears and 70 sharp injuries. Visible skin contact with the patient's blood occurred in 156 glove tears (63%). The mechanisms causing the tear could be identified in only 81 (33%). For 230 glove tears (92%), personnel were wearing single gloves. Of 70 sharp injuries, 47 (67%) were caused by needles and usually occurred during suturing. The following three mechanisms accounted for 40 sharp injuries (57%): (1) hands injured while stationary and holding an instrument, 11 (16%) - a position of risk not previously identified; (2) hands injured while retracting tissue, 12 (17%); and (3) injuries caused by sharp instruments not being used, 17 (24%). Instrument passage caused only four sharp injuries (6%). Conclusions. - The majority of glove tears have an unknown mechanism, and alteration in the manufacture or number of gloves worn may be helpful in reducing cutaneous blood exposures. The identification of specific mechanisms of sharp injuries should lead to effective strategies to prevent exposure to the human immunodeficiency virus and other blood-borne pathogens in the operating room.	YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & INFECT CONTROL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University; Yale University			mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ADLER MW, 1987, BRIT MED J, V295, P1297, DOI 10.1136/bmj.295.6609.1297; BECKER CE, 1989, ANN INTERN MED, V110, P653, DOI 10.7326/0003-4819-110-8-653; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; COHN GM, 1990, AM J OBSTET GYNECOL, V162, P715, DOI 10.1016/0002-9378(90)90992-G; GERBERDING JL, 1991, JAMA-J AM MED ASSOC, V265, P1572, DOI 10.1001/jama.265.12.1572; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HEALD AE, 1990, J GEN INTERN MED, V5, P389, DOI 10.1007/BF02599422; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LAFFERTY K, 1987, BRIT MED J, V295, P392, DOI 10.1136/bmj.295.6594.392-a; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; MCGEER A, 1990, J INFECT DIS, V162, P961, DOI 10.1093/infdis/162.4.961; MCKINNEY WP, 1990, INFECT CONT HOSP EP, V11, P243; MCLEOD GG, 1989, J BONE JOINT SURG BR, V71, P489, DOI 10.1302/0301-620X.71B3.2722946; MCNICHOLAS TA, 1989, BRIT J UROL, V63, P565, DOI 10.1111/j.1464-410X.1989.tb05246.x; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; ROSENBERG J, 1989, STATE ART REV OCCU S, V4, P3; STOCK SR, 1990, CAN MED ASSS J, V143, P256; 1991, UNIVERSAL PRECAUTION, P237; 1989, RECOMMENDATIONS PREV; 1986, MMWR, V35, P221; 1991, HLTH POLICY BIOMED R, V34, P5	23	54	57	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1668	1671		10.1001/jama.266.12.1668	http://dx.doi.org/10.1001/jama.266.12.1668			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886190				2022-12-28	WOS:A1991GF41900033
J	BART, KJ				BART, KJ			THE MEASLES EPIDEMIC - THE PROBLEMS, BARRIERS, AND RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; CHILDREN	The nation has experienced a marked increase in measles cases during 1989 and 1990. Almost one half of all cases have occurred in unvaccinated preschool children, mostly minorities. The principal cause for the epidemic is failure to provide vaccine to vulnerable children on schedule. Major reasons for the low vaccine coverage exist within the health care system itself, which creates barriers to obtaining immunization and fails to take advantage of many opportunities to provide vaccines to children. Ideally, immunizations should be given as part of a comprehensive child health care program. However, immunization cannot await the development of such an ideal system. Essential changes can and should be made now. Specific recommendations include improved availability of immunization; improved management of immunization services; improved capacity to measure childhood immunization status; implementation of the two-dose measles vaccine strategy; and laboratory, epidemiologic, and operational studies to further define the determinants of decreased vaccine coverage and to develop new combinations of vaccines that can be administered earlier in life. The measles epidemic may be a warning flag of problems with our system of primary health care.			BART, KJ (corresponding author), NATL VACCINE PROGRAM OFF,PARKLAWN BLDG,ROOM 13A-53,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; ESTRADA AL, 1990, AM J PUBLIC HEALTH, V80, P27, DOI 10.2105/AJPH.80.Suppl.27; FREIMUTH VS, 1990, PUBLIC HEALTH REP, V105, P232; HUTCHINS SS, 1989, PEDIATRICS, V83, P369; LEWIS T, 1988, AM J DIS CHILD, V142, P283, DOI 10.1001/archpedi.1988.02150030053018; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; ORENSTEIN WA, 1990, PEDIATR CLIN N AM, V37, P709; SCHULTE JM, 1991, PEDIATRICS, V87, P204; WOOD DL, 1990, PEDIATRICS, V86, P666; 1989, RES B PROFILE EMPLOY; 1991, MMWR, V40, P369; 1990, MMWR, V39, P317; 1989, PEDIATRICS, V84, P1110; 1990, ADV DATA, V188; 1989, MMWR, V38, P1; 1991, MMWR, V40, P36	16	156	156	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1547	1552						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880887				2022-12-28	WOS:A1991GE45800036
J	FARR, BM; SLOMAN, AJ; FISCH, MJ				FARR, BM; SLOMAN, AJ; FISCH, MJ			PREDICTING DEATH IN PATIENTS HOSPITALIZED FOR COMMUNITY-ACQUIRED PNEUMONIA	ANNALS OF INTERNAL MEDICINE			English	Article						PNEUMONIA; TRIAGE; PROGNOSTIC FACTORS; HYPOTENSION; TACHYPNEA PNEUMONIA	INTENSIVE-CARE UNIT; PNEUMOCOCCAL BACTEREMIA; LOBAR PNEUMONIA; MORTALITY; DISEASE; FAILURE; INFECTIONS; ETIOLOGY; FEATURES; SURVIVAL	Objective: To validate a previously reported discriminant rule for predicting mortality in adult patients with primary community-acquired pneumonia and to determine which factors available at hospital admission predict a fatal outcome among such patients. Design: Historical cohort study. Setting: University hospital. Patients: Adults admitted to the hospital for community-acquired pneumonia. Measurements: Using stepwise logistic regression, we analyzed prognostic factors (data available at admission and recorded in the medical record) that showed a univariate association with mortality. The predictive values of three discriminant rules were measured to validate the results of a previous study. Main Results: Of 245 patients, 20 (8.2%) died. Of 42 prognostic factors identified in previous studies, 8 were associated with mortality, but only a respiratory rate of 30/min or more, a diastolic blood pressure of 60 mm Hg or less, and a blood urea nitrogen of more than 7 mmol/L remained predictive in the multivariate analysis. A discriminant rule composed of these three variables was 70% sensitive and 84% specific in predicting mortality, yielding an overall accuracy of 82%. Conclusion: Tachypnea, diastolic hypotension, and an elevated blood urea nitrogen were independently associated with death from pneumonia in our study, confirming the value of a previously reported discriminant rule from the British Thoracic Society. This rule may be useful in triage decisions because it identifies high-risk patients who may benefit from special medical attention.			FARR, BM (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, BOX 473, CHARLOTTESVILLE, VA 22908 USA.							ALLEN SC, 1984, THORAX, V39, P612, DOI 10.1136/thx.39.8.612; ANDREWS BE, 1987, Q J MED, V62, P195; ANDREWS J, 1984, GERONTOLOGY, V30, P290, DOI 10.1159/000212648; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BANKS RA, 1984, BRIT J DIS CHEST, V78, P352; BENSON H, 1970, J CLIN INVEST, V49, P791, DOI 10.1172/JCI106292; BILLE J, 1980, PNEUMONIA PNEUMONOCO; BISNO AL, 1971, AM J MED SCI, V261, P251, DOI 10.1097/00000441-197105000-00004; BURNS MW, 1976, MED J AUSTRALIA, V2, P787, DOI 10.5694/j.1326-5377.1976.tb115356.x; CALDER MA, 1970, LANCET, V1, P5; CROFTON J, 1981, RESPIRATORY DISEASES, P190; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; EBRIGHT JR, 1980, J AM GERIATR SOC, V28, P220, DOI 10.1111/j.1532-5415.1980.tb00523.x; ESPOSITO AL, 1984, ARCH INTERN MED, V144, P945, DOI 10.1001/archinte.144.5.945; FEDULLO AJ, 1985, J GERONTOL, V40, P29, DOI 10.1093/geronj/40.1.29; FEKETY RF, 1971, AM REV RESPIR DIS, V104, P499; FELDMAN C, 1989, S AFR MED J, V76, P593; FINE MJ, 1990, AM J MED, V88, pN1; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P61; GOLD MI, 1974, CHEST, V65, P388, DOI 10.1378/chest.65.4.388; GRANSDEN WR, 1985, BRIT MED J, V290, P505, DOI 10.1136/bmj.290.6467.505; HOLLAND WW, 1960, BMJ-BRIT MED J, V1, P1917, DOI 10.1136/bmj.1.5190.1917; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; MACFARLANE JT, 1982, LANCET, V2, P255; MACFARLANE JT, 1983, THORAX, V38, P231; MARRIE TJ, 1985, J AM GERIATR SOC, V33, P671, DOI 10.1111/j.1532-5415.1985.tb01775.x; MARRIE TJ, 1988, CLIN INVEST MED, V11, P10; MCNABB WR, 1984, J ROY SOC MED, V77, P550, DOI 10.1177/014107688407700705; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526, DOI 10.1093/oxfordjournals.aje.a120763; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; POTGIETER PD, 1985, CRIT CARE MED, V13, P798, DOI 10.1097/00003246-198510000-00005; ROBERTSON L, 1958, LANCET, V2, P233; ROGERS RM, 1972, CHEST, V62, P94, DOI 10.1378/chest.62.1.94; SPENCER RC, 1976, J CLIN PATHOL, V29, P187, DOI 10.1136/jcp.29.3.187; STARCZEWSKI AR, 1988, AGE AGEING, V17, P181, DOI 10.1093/ageing/17.3.181; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; VALENTI WM, 1978, AM REV RESPIR DIS, V117, P233; WHITE RJ, 1981, THORAX, V36, P566, DOI 10.1136/thx.36.8.566; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; [No title captured]; 1989, VITAL HLTH STATIS 13, V99	47	225	227	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					428	436		10.7326/0003-4819-115-6-428	http://dx.doi.org/10.7326/0003-4819-115-6-428			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872491				2022-12-28	WOS:A1991GE81000003
J	SUNDELL, CL; SINGER, RH				SUNDELL, CL; SINGER, RH			REQUIREMENT OF MICROFILAMENTS IN SORTING OF ACTIN MESSENGER-RNA	SCIENCE			English	Article							LABEL INSITU HYBRIDIZATION; CYTOSKELETAL FRAMEWORK; ULTRASTRUCTURAL VISUALIZATION; PROTEIN-SYNTHESIS; HELA-CELLS; LOCALIZATION; ASSOCIATION; SEQUENCES; PATTERN; EMBRYOS	Specific messenger RNAs (mRNAs) can be sequestered within distinct cellular locations, but little is known about how this is accomplished. The participation of the Three major cellular filaments in the localization of actin mRNA was studied in chicken embryo fibroblasts. Movement of actin mRNA to the cell periphery and maintenance of that regionalization required intact microfilaments (composed of actin) but not microtubules or intermediate filaments. The results presented here suggest that actin-binding proteins may participate in mRNA sorting.	UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [HD18066] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018066] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABERCROM.M, 1971, EXP CELL RES, V67, P359, DOI 10.1016/0014-4827(71)90420-4; ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; BRODEUR RD, 1987, CELL MOTIL CYTOSKEL, V7, P129, DOI 10.1002/cm.970070205; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHENG H, 1989, J MOL BIOL, V210, P541, DOI 10.1016/0022-2836(89)90130-7; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; HOOCK TC, 1991, J CELL BIOL, V112, P653, DOI 10.1083/jcb.112.4.653; ISAACS W, 1987, P NATL ACAD SCI USA, V84, P408; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LENK R, 1979, CELL, V16, P289, DOI 10.1016/0092-8674(79)90006-0; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MOON RT, 1983, DEV BIOL, V95, P447, DOI 10.1016/0012-1606(83)90046-5; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SHEETZ MP, 1983, NATURE, V303, P31, DOI 10.1038/303031a0; SINGER RH, 1989, J CELL BIOL, V108, P2343, DOI 10.1083/jcb.108.6.2343; SUNDELL CL, 1990, J CELL BIOL, V111, P2397, DOI 10.1083/jcb.111.6.2397; TANEJA KL, UNPUB; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; VANVENROOIJ WJ, 1981, EXP CELL RES, V135, P79, DOI 10.1016/0014-4827(81)90301-3; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	29	233	235	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1275	1277		10.1126/science.1891715	http://dx.doi.org/10.1126/science.1891715			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891715				2022-12-28	WOS:A1991GE68900039
J	LEE, JS				LEE, JS			PREDNISONE IN THE PREVENTION OF EARLY RELAPSE AFTER TREATMENT OF ACUTE ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LEE, JS (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.							CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9	3	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					585	585						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857395				2022-12-28	WOS:A1991GB44700022
J	SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI				SARAGOVI, HU; FITZPATRICK, D; RAKTABUTR, A; NAKANISHI, H; KAHN, M; GREENE, MI			DESIGN AND SYNTHESIS OF A MIMETIC FROM AN ANTIBODY COMPLEMENTARITY-DETERMINING REGION	SCIENCE			English	Article							SEQUENCE; ANTIGEN	A technique for producing non-peptide compounds (mimetics) of designed specificities was developed that permitted the synthesis of a conformationally restricted molecule that mimicked the binding and functional properties of monoclonal antibody (MAb) 87.92.6, which recognizes the reovirus type 3 cellular receptor. Binding of either MAb 87.92.6, peptide analogs, or 87.1-mimetic to the cellular receptor inhibited cellular proliferation. The mimetic was a synthetic beta-loop structure that mimics the second complementarity-determining region of the MAb. These studies may lead to strategies for the synthetic design of antibody complementarity regions, ligands, and other pharmacologically active agents that are water soluble, resistant to proteolysis, and nonimmunogenic.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV ILLINOIS, DEPT CHEM, CHICAGO, IL 60680 USA	University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CHEN SH, UNPUB; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; FULLER WD, 1990, J AM CHEM SOC, V112, P7414, DOI 10.1021/ja00176a063; HOFFMAN RV, 1990, TETRAHEDRON LETT, V31, P2953, DOI 10.1016/S0040-4039(00)88996-0; KAHN M, UNPUB; KANG CY, 1988, SCIENCE, V240, P1034, DOI 10.1126/science.3368787; Kieber-Emmons T, 1987, Int Rev Immunol, V2, P339, DOI 10.3109/08830188709044761; NEPOM J T, 1982, Survey of Immunologic Research, V1, P255; NOVOTNY J, 1986, J MOL BIOL, V189, P715, DOI 10.1016/0022-2836(86)90502-4; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SARAGOVI HU, UNPUB; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; TAUB R, 1989, J BIOL CHEM, V264, P259; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537	16	153	204	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					792	795		10.1126/science.1876837	http://dx.doi.org/10.1126/science.1876837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876837				2022-12-28	WOS:A1991GB29500039
J	POTTS, WK; MANNING, CJ; WAKELAND, EK				POTTS, WK; MANNING, CJ; WAKELAND, EK			MATING PATTERNS IN SEMINATURAL POPULATIONS OF MICE INFLUENCED BY MHC GENOTYPE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MUS-MUSCULUS; HOUSE MOUSE; POLYMORPHISM; LOCI; OVERDOMINANT; PREFERENCES; RECOGNITION; SELECTION; HUMANS	BECAUSE of the central role of major histocompatibility complex (MHC) genes in immune recognition 1-3, it is often assumed that parasite-driven selection maintains the unprecedented genetic diversity of these genes 4-7. But associations between MHC genotype and specific infectious diseases have been difficult to identify 8,9 with a few exceptions such as Marek's disease 10 and malaria 11. Alternatively, MHC-related reproductive mechanisms such as selective abortion 12-15 and mating preferences 16,17 could be responsible for the diversity. To determine both the nature and strength of selection operating on MHC genes by we have studied components of selection in seminatural populations of mice (Mus musculus domesticus). Here we assess MHC-related patterns of reproduction and early (preweaning) mortality by analysing 1,139 progeny born in nine populations, and 662 progeny from laboratory matings. Reproductive mechanisms, primarily mating preferences, result in 27% fewer MHC-homozygous offspring than expected from random mating. MHC genotype had no detectable influence on neonatal (preweaning) mortality. These mating preferences are strong enough to account for most of the MHC genetic diversity found in natural populations of Mus.	UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	POTTS, WK (corresponding author), UNIV FLORIDA,DEPT PATHOL & LAB MED,MOLEC GENET LAB,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRONSON FH, 1979, Q REV BIOL, V54, P265, DOI 10.1086/411295; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; DOHERTY PC, 1975, NATURE, V256, P50, DOI 10.1038/256050a0; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GILBERT AN, 1986, J COMP PSYCHOL, V100, P262, DOI 10.1037/0735-7036.100.3.262; HAMILTON M, 1978, J REPROD IMMUNOL, V19, P267; HILL AVS, 1991, NATURE, V352; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARLIN S, 1968, GENETICS, V59, P117; KLEIN J, 1986, NATURAL HIST MAJOR H; MCCONNELL TJ, 1988, NATURE, V332, P651, DOI 10.1038/332651a0; MELVOLD RW, 1990, TRANSGENIC MICE MUTA; NADEAU JH, 1981, GENET RES, V37, P17, DOI 10.1017/S0016672300019984; NEI M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P222; PALM J, 1974, CANCER RES, V34, P2061; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; PAZDERKA F, 1975, IMMUNOGENETICS, V2, P93, DOI 10.1007/BF01572279; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; ROY S, 1989, SCIENCE, V244, P572, DOI 10.1126/science.2470147; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; TAKAHATA N, 1990, GENETICS, V124, P967; THOMAS ML, 1985, AM J OBSTET GYNECOL, V151, P1053, DOI 10.1016/0002-9378(85)90379-5; TIWARI JL, 1985, HLA DISEASE ASS; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WEIR BS, 1973, GENET RES, V21, P247, DOI 10.1017/S0016672300013446; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; YOKOYAMA S, 1979, GENETICS, V91, P609	32	488	500	0	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					619	621		10.1038/352619a0	http://dx.doi.org/10.1038/352619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865924				2022-12-28	WOS:A1991GB21100055
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR PURGING USE IN AUTOLOGOUS BONE-MARROW TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-28	WOS:A1991GA07300008
J	VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M				VOJTEK, A; HAARER, B; FIELD, J; GERST, J; POLLARD, TD; BROWN, S; WIGLER, M			EVIDENCE FOR A FUNCTIONAL LINK BETWEEN PROFILIN AND CAP IN THE YEAST SACCHAROMYCES-CEREVISIAE	CELL			English	Article							ACTIN-BINDING PROTEINS; PHOSPHOLIPASE C-II; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; ACANTHAMOEBA PROFILIN; ADENYLATE-CYCLASE; A-431 CELLS; GENE	CAP is a component of the S. cerevisiae adenylyl cyclase complex. The N-terminal domain is required for cellular RAS responsiveness. Loss of the C-terminal domain is associated with morphological and nutritional defects. Here we report that cap- cells bud randomly and are defective in actin distribution. The morphological and nutritional defects associated with loss of the CAP C-terminal domain are suppressed by overexpression of PFY, the gene encoding profilin, an actin- and polyphosphoinositide-binding protein. The phenotype of cells lacking PFY resembles that of cells lacking the CAP C-terminal domain. Study of mutated yeast profilins and profilins from Acanthamoeba suggests that the ability of profilin to suppress cap- cells is dependent upon a property other than, or in addition to, its ability to bind actin. This property may be its ability to bind polyphosphoinositides. We propose that CAP and profilin provide a link between growth signals and remodeling of the cellular cytoskeleton.	UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA	University of Michigan System; University of Michigan; Johns Hopkins University	VOJTEK, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1991, IN PRESS CELL MOTIL; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Rose MD., 1990, METHODS YEAST GENETI; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WAHL M, 1988, J BIOL CHEM, V263, P7581; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254	35	179	180	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					497	505		10.1016/0092-8674(81)90013-1	http://dx.doi.org/10.1016/0092-8674(81)90013-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868547	Green Published			2022-12-28	WOS:A1991GA94100011
J	FARLEY, CT; TAYLOR, CR				FARLEY, CT; TAYLOR, CR			A MECHANICAL TRIGGER FOR THE TROT-GALLOP TRANSITION IN HORSES	SCIENCE			English	Article							FORCE PLATFORM; LOCOMOTION; GAITS; SPEED	It is widely thought that animals switch gaits at speeds that minimize energetic cost. Horses naturally switched from a trot to a gallop at a speed where galloping required more energy than trotting, and thus, the gait transition actually increased the energetic cost of running. However, by galloping at this speed, the peak forces on the muscles, tendons, and bones, and presumably the chance of injury, are reduced. When the horses carried weights, they switched from a trot to a gallop at a lower speed but at the same critical level of force. These findings suggest that the trot-gallop transition is triggered when musculoskeletal forces reach a critical level.			FARLEY, CT (corresponding author), HARVARD UNIV,MUSEUM COMPARAT ZOOL,CONCORD FIELD STN,OLD CAUSEWAY RD,BEDFORD,MA 01730, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018140] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR 18140] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1989, PHYSIOL REV, V69, P1199, DOI 10.1152/physrev.1989.69.4.1199; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1983, J BIOMECH, V16, P565, DOI 10.1016/0021-9290(83)90107-0; BIEWENER AA, 1988, J EXP BIOL, V137, P191; BIEWENER AA, 1986, J EXP BIOL, V123, P383; BIEWENER AA, 1988, J ZOOL, V214, P547, DOI 10.1111/j.1469-7998.1988.tb03759.x; CAVAGNA GA, 1977, AM J PHYSIOL, V233, pR243, DOI 10.1152/ajpregu.1977.233.5.R243; CURREY J, 1984, MECH ADAPTATIONS BON, P80; FEDAK MA, 1981, J APPL PHYSIOL, V51, P772, DOI 10.1152/jappl.1981.51.3.772; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; KRAM R, 1989, J APPL PHYSIOL, V67, P1692, DOI 10.1152/jappl.1989.67.4.1692; MARGARIA R, 1938, ATTI ACCAD NAZ LINCE, V6, P7; MCMAHON TA, 1985, J EXP BIOL, V115, P263; PENNYCUICK CJ, 1975, J EXP BIOL, V63, P775; RUBIN CT, 1982, J EXP BIOL, V101, P187; SEEHERMAN HJ, 1981, RESP PHYSIOL, V44, P11, DOI 10.1016/0034-5687(81)90074-8	16	214	214	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					306	308		10.1126/science.1857965	http://dx.doi.org/10.1126/science.1857965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857965				2022-12-28	WOS:A1991FX22400037
J	TILSED, JVT				TILSED, JVT			COST OF ROAD TRAFFIC ACCIDENTS TO AN ORTHOPEDIC DEPARTMENT	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,UXBRIDGE UB8 3NN,ENGLAND										0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					27	27		10.1136/bmj.303.6793.27	http://dx.doi.org/10.1136/bmj.303.6793.27			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859952	Green Published, Bronze			2022-12-28	WOS:A1991FW12800023
J	WERTHEIMER, MD				WERTHEIMER, MD			AGAINST MINIMALISM IN BREAST-CANCER FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											WERTHEIMER, MD (corresponding author), UNIV MASSACHUSETTS,DEPT SURG SURG ONCOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.							COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; DAVIDSON NE, 1980, DIAGNOSIS MANAGEMENT, V12, P348; DAVITA V, 1989, CANCER, V3, P1240; HENDERSON C, 1987, BREAST DISEASES, V10, P324; HORTON J, 1984, CANCER, V53, P790, DOI 10.1002/1097-0142(19840201)53:3+<790::AID-CNCR2820531330>3.0.CO;2-F; SCHAPIRA DV, 1990, JAMA-J AM MED ASSOC, V262, P380; SILVERBERG E, 1990, CANCER STATISTICS, V40, P18; SMITH IE, 1987, BREAST DISEASES, V10, P369; TANNOCK IF, 1990, NEW ENGL J MED, V323, P989, DOI 10.1056/NEJM199010043231410; TOMIN R, 1987, J CLIN ONCOL, V5, P62, DOI 10.1200/JCO.1987.5.1.62; TOMIN R, 1987, J CLIN ONCOL, V5, P369	11	39	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 16	1991	265	3					396	397		10.1001/jama.265.3.396	http://dx.doi.org/10.1001/jama.265.3.396			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER256	1898616				2022-12-28	WOS:A1991ER25600033
J	BOURNE, HR; SANDERS, DA; MCCORMICK, F				BOURNE, HR; SANDERS, DA; MCCORMICK, F			THE GTPASE SUPERFAMILY - CONSERVED STRUCTURE AND MOLECULAR MECHANISM	NATURE			English	Review							ELONGATION-FACTOR-TU; AMINO-ACID-SEQUENCE; NUCLEOTIDE-BINDING PROTEIN; ROD OUTER SEGMENTS; SIGNAL-RECOGNITION PARTICLE; HA-RAS P21; ESCHERICHIA-COLI; ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; ADP-RIBOSYLATION	GTPases are conserved molecular switches, built according to a common structural design. Rapidly accruing knowledge of individual GTPases - crystal structures, biochemical properties, or results of molecular genetic experiments - support and generate hypotheses relating structure to function in other members of the diverse family of GTPases.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94110 USA; CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BOURNE, HR (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94110 USA.							ABOOD ME, 1982, J BIOL CHEM, V257, P540; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P523, DOI 10.1093/oxfordjournals.jbchem.a130596; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOTSTEIN D, 1988, COLD SPRING HARB SYM, V53, P629, DOI 10.1101/SQB.1988.053.01.072; BOURNE HR, 1989, PROTEINS, V6, P222, DOI 10.1002/prot.340060304; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BUTTARELLI FR, 1989, MOL GEN GENET, V217, P97, DOI 10.1007/BF00330947; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CERIONE RA, 1985, NATURE, V318, P293, DOI 10.1038/318293a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DERETIC D, 1987, J BIOL CHEM, V262, P10839; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FRIEDRICH K, 1988, MOL GEN GENET, V214, P595, DOI 10.1007/BF00330501; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; HWANG YW, 1989, J BIOL CHEM, V264, P8304; JOHNSON DI, IN PRESS J CELL BIOL; JONES DT, 1987, J BIOL CHEM, V262, P14241; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURJAN J, 1990, PROTEINS, P571; KUSHIRO A, 1987, EUR J BIOCHEM, V170, P93, DOI 10.1111/j.1432-1033.1987.tb13671.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LAUFFER L, 1985, NATURE, V318, P334, DOI 10.1038/318334a0; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LECHNER K, 1987, MOL GEN GENET, V208, P523, DOI 10.1007/BF00328150; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MARCH PE, 1985, J BIOL CHEM, V260, P7206; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATSUI M, 1989, GENE, V76, P313, DOI 10.1016/0378-1119(89)90171-6; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MENG BY, 1989, MOL GEN GENET, V216, P25, DOI 10.1007/BF00332226; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIYAKE S, IN PRESS EMBO J; MONTANDON PE, 1983, NUCLEIC ACIDS RES, V11, P5877, DOI 10.1093/nar/11.17.5877; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; NAGATA S, 1983, P NATL ACAD SCI-BIOL, V80, P6192, DOI 10.1073/pnas.80.20.6192; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEUMANNSILBERBE.FS, 1984, CELL, V37; OHAMA T, 1987, J BACTERIOL, V169, P4770, DOI 10.1128/jb.169.10.4770-4777.1987; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PIZON V, 1988, ONCOGENE, V3, P201; POKALSKY AR, 1989, NUCLEIC ACIDS RES, V17, P4661, DOI 10.1093/nar/17.12.4661; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROMERO G, 1985, J BIOL CHEM, V260, P6167; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SAXE SA, 1988, DEV GENET, V9, P259, DOI 10.1002/dvg.1020090408; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHLICHTING I, 1989, P NATL ACAD SCI USA, V86, P7687, DOI 10.1073/pnas.86.20.7687; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIGAL IS, 1986, P NTN ACAD SCI US, V83, P52; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA K, 1989, J BIOL CHEM, V264, P15489; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WINSLOW JW, 1987, J BIOL CHEM, V262, P4501; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMASAKI K, 1989, BIOCHEM BIOPH RES CO, V162, P1054, DOI 10.1016/0006-291X(89)90780-8; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZENGEL JM, 1984, NUCLEIC ACIDS RES, V12, P2181, DOI 10.1093/nar/12.4.2181; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	150	2931	3017	3	189	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 10	1991	349	6305					117	127		10.1038/349117a0	http://dx.doi.org/10.1038/349117a0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1898771				2022-12-28	WOS:A1991ER41800047
J	CLARKE, RJ; MAYO, G; PRICE, P; FITZGERALD, GA				CLARKE, RJ; MAYO, G; PRICE, P; FITZGERALD, GA			SUPPRESSION OF THROMBOXANE-A2 BUT NOT OF SYSTEMIC PROSTACYCLIN BY CONTROLLED-RELEASE ASPIRIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE ASPIRIN; PREGNANCY-INDUCED HYPERTENSION; ACUTE MYOCARDIAL-INFARCTION; ANTI-INFLAMMATORY DRUGS; PROSTAGLANDIN ENDOPEROXIDES; CARDIOVASCULAR-DISEASE; PLATELET-AGGREGATION; ORAL ASPIRIN; INHIBITION; BIOSYNTHESIS	Background. The antithrombotic efficacy of aspirin is attributed to its inhibition of the enzyme prostaglandin G/H synthase, which is necessary for the formation of thromboxane A2 in platelets. Thromboxane A2 is a potent vasoconstrictor and platelet agonist. However, the formation of prostacyclin by vascular endothelium also requires prostaglandin G/H synthase, and prostacyclin exerts opposite effects on platelet function and vascular tone. We wanted to see whether controlled-release aspirin would affect the formation of thromboxane A2 but not prostacyclin by reducing the aspirin concentration that reaches the posthepatic circulation. Methods. A controlled-release formulation containing 75 mg of aspirin, designed to release 10 mg per hour, was developed to inhibit prostaglandin G/H synthase in platelets in the prehepatic circulation. The effects of the controlled-release preparation on plasma levels of aspirin and salicylate, serum levels of thromboxane B2, and urinary dinor metabolites of prostacyclin and thromboxane B2 (measured by gas chromatography-mass spectrometry) were compared with the effects of conventional immediate-release aspirin in normal volunteers. The release of prostacyclin was stimulated by intravenous bradykinin. Results. Steady-state inhibition of serum thromboxane B2 required two to four days and appeared slower with 75 mg of controlled-release aspirin than with the same amount of immediate-release aspirin. Maximal inhibition was achieved rapidly by adding a single loading dose of 162.5 mg of immediate-release aspirin to the regimen. Over a 28-day period, suppression of thromboxane A2 with this regimen was comparable to that with immediate-release aspirin taken either as 162.5 mg daily or as 325 mg on alternate days, despite the minimal systemic bioavailability of controlled-release aspirin. Bleeding time was prolonged to a similar degree with each of the three regimens. The five- to sixfold increase in the prostacyclin metabolite induced by bradykinin was depressed by pretreatment for four days with 75 mg of immediate-release aspirin, but not by 75 mg of controlled-release aspirin. Conclusions. Maximal inhibition of platelet thromboxane A2 production was sustained during long-term dosing with controlled-release aspirin, whereas basal prostacyclin biosynthesis fell only slightly and systemic synthesis of prostacyclin stimulated by bradykinin was preserved. Controlled-release aspirin may facilitate determination of the clinical importance of preserving prostacyclin during platelet inhibition in humans.	VANDERBILT UNIV,DIV CLIN PHARMACOL,RM 538,MED RES BLDG,NASHVILLE,TN 37232	Vanderbilt University			FitzGerald, Garret A/A-4222-2010		FOGARTY INTERNATIONAL CENTER [F05TW004262] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030400] Funding Source: NIH RePORTER; FIC NIH HHS [TWO 4262] Funding Source: Medline; NHLBI NIH HHS [HL 30400] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAENZIGER NL, 1979, CELL, V16, P967, DOI 10.1016/0092-8674(79)90111-9; BENIGNI A, 1989, NEW ENGL J MED, V321, P357, DOI 10.1056/NEJM198908103210604; BRADEN GA, 1991, CIRCULATION, V84, P679, DOI 10.1161/01.CIR.84.2.679; BURCH JW, 1978, J CLIN INVEST, V61, P314, DOI 10.1172/JCI108941; CANNON PJ, 1986, AM J MED, V81, P123, DOI 10.1016/0002-9343(86)90913-7; CERLETTI C, 1986, J CLIN INVEST, V78, P323, DOI 10.1172/JCI112569; Ciabattoni G, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P598; DECATERINA R, 1985, THROMB HAEMOSTASIS, V54, P528; DEMERS LM, 1980, P SOC EXP BIOL MED, V163, P24; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; FITZGERALD DJ, 1987, CIRCULATION, V75, P956, DOI 10.1161/01.CIR.75.5.956; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FITZGERALD GA, 1984, CLIN PHARMACOL THER, V35, P633, DOI 10.1038/clpt.1984.87; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; FITZGERALD GA, IN PRESS J PHARM EXP; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HANLEY SP, 1982, BRIT MED J, V285, P1299, DOI 10.1136/bmj.285.6351.1299; HEAVEY DJ, 1985, NATURE, V318, P186, DOI 10.1038/318186a0; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KNAPP HR, 1989, NEW ENGL J MED, V320, P1037, DOI 10.1056/NEJM198904203201603; LAWSON JA, 1985, ANAL BIOCHEM, V150, P463, DOI 10.1016/0003-2697(85)90536-6; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; LORENZ RL, 1989, AM J CARDIOL, V64, P1185, DOI 10.1016/0002-9149(89)90875-8; MIELKE CH, 1983, AM J MED, V74, P72, DOI 10.1016/0002-9343(83)90532-6; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; NOWAK J, 1989, J CLIN INVEST, V83, P380, DOI 10.1172/JCI113895; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; PATRONO C, 1986, AM J MED, V81, P71, DOI 10.1016/0002-9343(86)90909-5; PEDERSEN AK, 1985, J PHARM SCI, V74, P188, DOI 10.1002/jps.2600740217; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; REILLY IAG, 1988, DRUGS, V35, P154, DOI 10.2165/00003495-198835020-00005; RITTER JM, 1989, BRIT J CLIN PHARMACO, V28, P573, DOI 10.1111/j.1365-2125.1989.tb03544.x; ROWLAND M, 1972, J PHARM SCI-US, V61, P379, DOI 10.1002/jps.2600610312; SIEBERT DJ, 1983, CLIN PHARMACOL THER, V33, P367, DOI 10.1038/clpt.1983.47; Siegel S., 1988, NONPARAMETRIC STAT B; UZAN, 1991, LANCET, V337, P1427; VANE JR, 1990, NEW ENGL J MED, V323, P27; WALENGA RW, 1984, BIOCHEM BIOPH RES CO, V119, P982, DOI 10.1016/0006-291X(84)90870-2; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; 1990, LANCET, P827	43	269	279	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1137	1141		10.1056/NEJM199110173251605	http://dx.doi.org/10.1056/NEJM199110173251605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891022	Bronze			2022-12-28	WOS:A1991GK53800005
J	GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF				GARCHON, HJ; BEDOSSA, P; ELOY, L; BACH, JF			IDENTIFICATION AND MAPPING TO CHROMOSOME-1 OF A SUSCEPTIBILITY LOCUS FOR PERIINSULITIS IN NONOBESE DIABETIC MICE	NATURE			English	Article							MELLITUS; MOUSE; PANCREAS; INSULITIS; ISLETS; GENE; HLA	INSULIN-DEPENDENT diabetes mellitus (IDDM) is a polygenic disease caused by autoimmune destruction of insulin-producing beta-cells in the islets of Langerhans 1,2. Its onset is preceded by a long and variable period in which lymphoid cells infiltrate the pancreas but first remain outside the islets (peri-insulitis) before invading them (insulitis) 3-7. Among susceptibility loci, only the major histocompatibility complex (MHC) has been clearly assigned 8-12. Genetic study of the nonobese diabetic (NOD) mouse model for insulin-dependent diabetes mellitus has revealed genetic linkage of insulitis and of early onset diabetes with two non-MHC loci mapping to chromosome 3 and 11 respectively 13. Here we report a close association of periinsulitis with a third non-MHC locus mapping to chromosome 1. Successive stages in the progression of diabetic disease thus appear to be controlled by distinct genes or sets of genes.	HOP ANTOINE BECLERE, SERV ANAT PATHOL, F-92140 CLAMART, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	GARCHON, HJ (corresponding author), HOP NECKER ENFANTS MALAD, INSERM, U25, 161 RUE SEVRES, F-75743 PARIS 15, FRANCE.			Bedossa, Pierre/0000-0002-8487-7322				AITMAN TJ, IN PRESS MAMMALIAN G; ASAMOTO H, 1984, Journal of the Japan Diabetes Society, V27, P775; BEDOSSA P, 1989, EUR J IMMUNOL, V19, P1947, DOI 10.1002/eji.1830191028; CAHILL GF, 1981, NEW ENGL J MED, V304, P1454, DOI 10.1056/NEJM198106113042403; CORNALL RJ, IN PRESS GENOMICS; FOULIS AK, 1984, DIABETOLOGIA, V26, P456; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GEPTS W, 1981, AM J MED, V70, P105, DOI 10.1016/0002-9343(81)90417-4; GOILLOT E, 1991, CLIN IMMUNOL IMMUNOP, V59, P462, DOI 10.1016/0090-1229(91)90041-8; GORSUCH AN, 1981, LANCET, V2, P1363; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEARNE CM, IN PRESS MAMMALIAN G; KESSLER HS, 1968, AM J PATHOL, V52, P671; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LUDWIG H, 1977, GUT, V18, P311, DOI 10.1136/gut.18.4.311; MIYAGAWA J, 1986, VIRCHOWS ARCH B, V51, P215, DOI 10.1007/BF02899031; NADEAU JH, 1990, GENETIC VARIANTS STR, P506; OKAZAKI K, 1989, INT J PANCREATOL, V5, P359; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; SIGNORE A, 1989, DIABETOLOGIA, V32, P282, DOI 10.1007/BF00265543; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; WHALEY K, 1973, Q J MED, V42, P279; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639	25	139	140	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					260	262		10.1038/353260a0	http://dx.doi.org/10.1038/353260a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896073				2022-12-28	WOS:A1991GF67400060
J	CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P				CHALEPAKIS, G; FRITSCH, R; FICKENSCHER, H; DEUTSCH, U; GOULDING, M; GRUSS, P			THE MOLECULAR-BASIS OF THE UNDULATED PAX-1 MUTATION	CELL			English	Article							DEVELOPING EXCRETORY SYSTEM; PAIRED-BOX; HORMONE RECEPTORS; MAMMALIAN-CELLS; PROTO-ONCOGENE; AMINO-ACIDS; W-LOCUS; PROTEINS; DNA; GENES	The murine paired box gene Pax-1 has been associated with the mouse developmental mutant undulated (un), which exhibits malformations in the vertebral column. In un mice, a point mutation leading to a Gly-Ser exchange in a conserved part of the paired domain of Pax-1 is present. Here we show that Pax-1 encodes a DNA-binding protein with transcriptional activating properties. The DNA-binding specificity of the Pax-1 protein has been extensively analyzed in gel shift assays, and in conjunction with binding interference experiments, a DNA-binding core motif was defined. Comparison of the DNA-binding properties of wild-type and un Pax-1 proteins demonstrates that the Gly-Ser replacement at position 15 within the paired domain dramatically decreases the DNA-binding affinity of the un Pax-1 protein and alters its DNA-binding specificity. These results decipher the molecular basis of the un mutation.			CHALEPAKIS, G (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC CELL BIOL, W-3400 GOTTINGEN, GERMANY.		Fickenscher, Helmut/A-3004-2010; Fickenscher, Helmut/J-9655-2019	Fickenscher, Helmut/0000-0003-0043-1153; Deutsch, Urban/0000-0003-4265-6262				BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BASH PA, 1983, SCIENCE, V222, P1325, DOI 10.1126/science.222.4630.1325; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; Blandova ZK, 1975, MOUSE NEWS LETT, V52, P43; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRUNEBERG H, 1954, J GENET, V52, P441, DOI 10.1007/BF02981536; GRUNEBERG H, 1950, J GENET, V50, P142, DOI 10.1007/BF02986800; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Maxam A M, 1980, Methods Enzymol, V65, P499; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORNES HO, 1990, DEVELOPMENT, V109, P797; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PLACHOV D, 1990, DEVELOPMENT, V110, P643; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRACUSA LD, 1990, GENOMICS, V6, P491, DOI 10.1016/0888-7543(90)90479-E; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; TRUSS M, 1990, P NATL ACAD SCI USA, V87, P7180, DOI 10.1073/pnas.87.18.7180; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WALLACE ME, 1985, J HERED, V76, P271, DOI 10.1093/oxfordjournals.jhered.a110091; WALTHER C, 1991, IN PRESS GENOMICS; WRIGHT ME, 1947, HEREDITY, V1, P137, DOI 10.1038/hdy.1947.10	55	248	250	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					873	884		10.1016/0092-8674(91)90434-Z	http://dx.doi.org/10.1016/0092-8674(91)90434-Z			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889089				2022-12-28	WOS:A1991GE46000007
J	LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD				LAROSA, GJ; WEINHOLD, K; PROFY, AT; LANGLOIS, AJ; DREESMAN, GR; BOSWELL, RN; SHADDUCK, P; BOLOGNESI, DP; MATTHEWS, TJ; EMINI, EA; PUTNEY, SD			CONSERVED SEQUENCE AND STRUCTURAL ELEMENTS IN THE HIV-1 PRINCIPAL NEUTRALIZING DETERMINANT - FURTHER CLARIFICATIONS	SCIENCE			English	Article									BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; WILFORD HALL USAF MED CTR,DEPT MED,LACKLAND AFB,TX 78236; MERCK SHARP & DOHME LTD,W POINT,PA 19486; DUKE UNIV,SCH MED,DEPT SURG,DURHAM,NC 27710	United States Department of Defense; United States Air Force; Merck & Company; Duke University	LAROSA, GJ (corresponding author), REPLIGEN CORP,CAMBRIDGE,MA 02139, USA.		Shadduck MD DrHC, Phillip/AAZ-9781-2021	Shadduck MD DrHC, Phillip/0000-0002-7519-4319				LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685	1	19	20	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1146	1146		10.1126/science.1887238	http://dx.doi.org/10.1126/science.1887238			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1887238				2022-12-28	WOS:A1991GD80800035
J	FISHBEIN, DJ				FISHBEIN, DJ			DO-DNA - ALCOHOLISM IN THE SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHBEIN, DJ (corresponding author), UNIV MASSACHUSETTS,SCH MED,BOX 426,55 LAKE AVE N,WORCESTER,MA 01655, USA.							ADELMAN SA, IN PRESS IMPATIENT P; KIRN TF, 1987, JAMA-J AM MED ASSOC, V253, P883; KIRPICHENKO AA, 1989, PSYCHIATRY; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SMITH H, 1989, NEW RUSSIANS; 1987, DIAGNOSTIC STATISTIC, P173	6	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1211	1212		10.1001/jama.266.9.1211	http://dx.doi.org/10.1001/jama.266.9.1211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC858	1870239				2022-12-28	WOS:A1991GC85800013
J	ORENTLICHER, D				ORENTLICHER, D			HIV-INFECTED SURGEONS - BEHRINGER V MEDICAL-CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ORENTLICHER, D (corresponding author), AMER MED ASSOC,ETH & HLTH POLICY COUSEL,CHICAGO,IL 60610, USA.							BARAFF LJ, 1989, ANN EMERG MED, V18, P654, DOI 10.1016/S0196-0644(89)80522-0; Barnes M, 1990, Law Med Health Care, V18, P311; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; DICKEY NW, 1991, JAMA-J AM MED ASSOC, V265, P2338, DOI 10.1001/jama.1991.03460180043023; FRIEDLAND GH, 1990, NEW ENGL J MED, V322, P1000, DOI 10.1056/NEJM199004053221409; GERBERDING JL, 1986, NEW ENGL J MED, V315, P1562, DOI 10.1056/NEJM198612113152434; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GOSTIN L, 1991, ARCH INTERN MED, V151, P663, DOI 10.1001/archinte.151.4.663; JONSEN AR, 1991, ARCH INTERN MED, V151, P660, DOI 10.1001/archinte.151.4.660; KLEIN RS, 1991, AM J MED, V90, P141, DOI 10.1016/0002-9343(91)80152-C; RHAME FS, 1990, JAMA-J AM MED ASSOC, V264, P507, DOI 10.1001/jama.264.4.507; WONG ES, 1991, JAMA-J AM MED ASSOC, V265, P1123, DOI 10.1001/jama.265.9.1123; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1991, MMWR, V40, P1; 1991, AM ACAD ORTHOP SU S2, V39, P1; 1990, OBSTET GYNECOL, V75, P1043; 1985, MMWR, V34, P681; 1987, MMWR S2S, V36, pS3; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1991, PHYSICIAN CHARACTERI, P90; 1991, MMWR, V40, P377; 1989, CURRENT OPINIONS, P32	22	16	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1134	1137		10.1001/jama.266.8.1134	http://dx.doi.org/10.1001/jama.266.8.1134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865550				2022-12-28	WOS:A1991GB97500041
J	WAHLE, E				WAHLE, E			A NOVEL POLY(A)-BINDING PROTEIN ACTS AS A SPECIFICITY FACTOR IN THE 2ND PHASE OF MESSENGER-RNA POLYADENYLATION	CELL			English	Article							BINDING-PROTEIN; POLY(A) POLYMERASE; AAUAAA SEQUENCE; CLEAVAGE; NUCLEAR; SITE; RECOGNITION; INVITRO; DOMAIN; TAIL	Polyadenylation of mRNA precursors by poly(A) polymerase depends on a specificity factor, CPF, recognizing the polyadenylation signal AAUAAA. This paper describes an apparently novel poly(A)-binding protein that acts as a second specificity factor, mediating the recognition of the growing poly(A) tail. A transition from a slow initiation phase of polyadenylation to rapid elongation occurs when the growing tail is long enough to serve as a binding site for the poly(A)-binding protein. Elongation of an RNA carrying a tail of 10 or more adenylate residues can occur independently of CPF. A sharp decrease in the poly(A) chain growth rate after the addition of approximately 200 adenylate residues invites speculations about a role of the poly(A)-binding protein in poly(A) tail length control.			WAHLE, E (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P295, DOI 10.1128/MCB.10.1.295; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BIENROTH S, 1991, IN PRESS J BIOL CHEM, V266; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; CHRISTOFORI G, 1988, CELL, V54, P75; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; KELLY RC, 1976, J BIOL CHEM, V251, P7240; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SACHS AB, 1985, MOL CELL BIOL, V5, P1993, DOI 10.1128/MCB.5.8.1993; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sambrook J, 1989, MOL CLONING LABORATO; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHUMAN S, 1988, J BIOL CHEM, V263, P8405; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; WAHLE LE, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	42	244	245	3	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					759	768		10.1016/0092-8674(91)90119-J	http://dx.doi.org/10.1016/0092-8674(91)90119-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878970				2022-12-28	WOS:A1991GC74500014
J	LEE, I; HAINES, A				LEE, I; HAINES, A			HEALTH COSTS OF THE GULF WAR	BRITISH MEDICAL JOURNAL			English	Article									UNIV COLL & MIDDLESEX SCH MED,WHITTINGTON HOSP,LONDON N19 5NF,ENGLAND	University of London; University College London	LEE, I (corresponding author), MED EDUC TRUST,LONDON N19 4DJ,ENGLAND.			Haines, Andy/0000-0002-8053-4605				ARKIN W, 1991, IMPACT MODERN WARFAR; CLARK R, 1991, WAR REPORT      0223, P1; DOLYEL L, 1991, INDEPENDENT 0403MOFK, P9; DOYLE L, 1991, INDEPENDENT, V8, P10; DOYLE L, 1991, INDEPENDENT LON 1115, P13; HOSKINS E, 1991, GULF PEACE TEAM SPEC; JOFFE G, 1991, 5 OXF RES GRP REP, P21; RANDAL JC, 1991, INT HERALD TRIB 0211, P3; SEAMAN J, 1991, WHATS WRONG INT REL; SIVARD RL, 1990, WORLD MILITARY SOCIA, V22, P3; 1991, HARVARD STUDY TEAM R; 1991, REPORT SECRETARY GEN; 1990, 1990 NATIONAL SURVEY; 1991, CURRENT NEWS EA 0320, P16; 1991, KUWAIT 1991 HUMAN RI; 1991, MORTALITY MORBIDITY, V40, P443; 1991, UN SET UP BODY DISTR; 1991, STATE WORLDS CHILDRE; 1991, HOUSE COMMONS OFFICK, V194; 1991, 1 SIT REP	20	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					303	306		10.1136/bmj.303.6797.303	http://dx.doi.org/10.1136/bmj.303.6797.303			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1888936	Green Published, Bronze			2022-12-28	WOS:A1991FZ72100029
J	ROULD, MA; PERONA, JJ; STEITZ, TA				ROULD, MA; PERONA, JJ; STEITZ, TA			STRUCTURAL BASIS OF ANTICODON LOOP RECOGNITION BY GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 2.8-A RESOLUTION; TRANSLATION; REFINEMENT; ATP	The refined crystal structure of Escherichia coli glutaminyl transfer RNA synthetase complexed with transfer RNA(Gln) and ATP reveals that the structure of the anticodon loop of the enzyme-bound tRNA(Gln) differs extensively from that of the known crystal structures of uncomplexed tRNA molecules. The anticodon stem is extended by two non-Watson-Crick base pairs, leaving the three anticodon bases unpaired and splayed out to bind snugly into three separate complementary pockets in the protein. These interactions suggest that the entire anticodon loop provides essential sites for glutaminyl tRNA synthetase discrimination among tRNA molecules.	YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06511 USA; YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06511 USA	Yale University; Howard Hughes Medical Institute; Yale University	ROULD, MA (corresponding author), YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, POB 6666, NEW HAVEN, CT 06511 USA.		Steitz, Thomas A./C-6559-2009					BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FINZEL BC, 1990, CRYSTALLOGRAPHIC MOD, P175; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; NROMANLY J, 1989, A REV BIOCH, V58, P1029; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RAVEL JM, 1965, J BIOL CHEM, V240, P432; REDFIELD AG, 1986, STRUCTURE DYNAMICS R; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1986, J MOL BIOL, V192, P235, DOI 10.1016/0022-2836(86)90362-1; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391	26	349	353	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					213	218		10.1038/352213a0	http://dx.doi.org/10.1038/352213a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857417				2022-12-28	WOS:A1991FX18500054
J	BENSLEY, DC; BULL, AR; HAWARD, RA				BENSLEY, DC; BULL, AR; HAWARD, RA			CONSULTANTS INVOLVEMENT IN THE CONTRACTING PROCESS IN YORKSHIRE REGION	BRITISH MEDICAL JOURNAL			English	Article									YORKSHIRE HLTH,REG DEPT PUBL HLTH MED,HARROGATE HG1 5AH,ENGLAND										0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					95	95		10.1136/bmj.303.6794.95	http://dx.doi.org/10.1136/bmj.303.6794.95			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860011	Bronze, Green Published			2022-12-28	WOS:A1991FW58600022
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - MULTIPLE PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					111	115		10.1136/bmj.303.6794.111	http://dx.doi.org/10.1136/bmj.303.6794.111			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1859986	Bronze, Green Published			2022-12-28	WOS:A1991FW58600030
J	KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J				KENNEDY, DH; NAIR, G; ELLIOTT, L; DITTON, J			DRUG MISUSE AND SHARING OF NEEDLES IN SCOTTISH PRISONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,CTR HIV & AIDS RESOURCE,GLASGOW G12 8QQ,SCOTLAND; RUCHILL HOSP,DEPT INFECT & TROP MED,GLASGOW G20 9NB,SCOTLAND; UNIV GLASGOW,CRIMINOL RES UNIT,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow								CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; DOLAN KA, 1990, HOWARD J, V29, P177; HARDING TW, 1990, HIV AIDS EUORPEAN PR; Stimson GV, 1988, INJECTING EQUIPMENT; 1990, ANSWER AIDS NEWS S	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1507	1507		10.1136/bmj.302.6791.1507	http://dx.doi.org/10.1136/bmj.302.6791.1507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855021	Green Published, Bronze			2022-12-28	WOS:A1991FT50500024
J	ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R				ROBEY, EA; FOWLKES, BJ; GORDON, JW; KIOUSSIS, D; VONBOEHMER, H; RAMSDELL, F; AXEL, R			THYMIC SELECTION IN CD8 TRANSGENIC MICE SUPPORTS AN INSTRUCTIVE MODEL FOR COMMITMENT TO A CD4 OR CD8 LINEAGE	CELL			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; POSITIVE SELECTION; LYMPHOCYTES-T; GENE; MOLECULES; EXPRESSION; RECOGNITION; ACTIVATION; ENGAGEMENT	Immature thymocytes, which coexpress CD4 and CD8, give rise to mature CD4+CD8- and CD4-CD8+ T cells. Only those T cells that recognize self-MHC are selected to mature, a process known as positive selection. The specificity of the T cell antigen receptor (TCR) for class I or class II MHC influences the commitment to a CD4 or CD8 lineage. This may occur by a directed mechanism or by stochastic commitment followed by a selection step that allows only CD8+, class I-specific and CD4+, class II-specific cells to survive. We have generated a mouse line expressing a CD8 transgene under the control of the T cell-specific CD2 regulatory sequences. Although constitutive CD8 expression does not affect thymic selection of CD4+ cells, selection of a class I-specific TCR in the CD8 subset is substantially improved. This outcome is consistent with a model for positive selection in which selection occurs at a developmental stage in which both CD4 and CD8 are expressed, and positive selection by class I MHC generates an instructive signal that directs differentiation to a CD8 lineage.	COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; BASEL INST IMMUNOL, CH-4005 BASEL, SWITZERLAND	Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; MRC National Institute for Medical Research	ROBEY, EA (corresponding author), COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1986, P NATL ACAD SCI USA, V83, P8298, DOI 10.1073/pnas.83.21.8298; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GOTTLIEB PD, 1980, IMMUNOGENETICS, V10, P545, DOI 10.1007/BF01572589; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; JANEWAY CA, 1988, NATURE, V335, P208, DOI 10.1038/335208a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIAO NS, 1989, J EXP MED, V170, P135, DOI 10.1084/jem.170.1.135; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MAISSEN M, 1988, CELL, V55, P49; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; Robey E A, 1990, Semin Immunol, V2, P25; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTO T, 1989, J IMMUNOL, V143, P3379; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; YOUN HJ, 1988, IMMUNOGENETICS, V28, P353, DOI 10.1007/BF00364234; YOUN HJ, 1988, IMMUNOGENETICS, V28, P345, DOI 10.1007/BF00364233; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	41	217	218	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 11	1991	64	1					99	107		10.1016/0092-8674(91)90212-H	http://dx.doi.org/10.1016/0092-8674(91)90212-H			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898873				2022-12-28	WOS:A1991ET17500012
J	PIERCE, JA; SOBEL, BE				PIERCE, JA; SOBEL, BE			FRONTIERS IN SURGERY - A PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LUNG TRANSPLANTATION; ATRIAL-FIBRILLATION		WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL)	PIERCE, JA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV REPS & CRIT CARE,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; CAMERON A, 1988, AM J CARDIOL, V61, P714, DOI 10.1016/0002-9149(88)91053-3; COOPER JD, 1987, J THORAC CARDIOV SUR, V93, P173; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COX JL, 1991, J THORAC CARDIOV SUR, V101, P584; COX JL, 1991, JAMA-J AM MED ASSOC, V266, P1976, DOI 10.1001/jama.266.14.1976; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; COX JL, 1991, J THORAC CARDIOV SUR, V101, P402; COX JL, 1981, J THORAC CARDIOVASC, V82, P211; GOUAUX JL, 1947, AM HEART J, V34, P366, DOI 10.1016/0002-8703(47)90487-0; HOROWITZ LN, 1991, CURRENT MANAGEMENT A, P51; KAHAN BD, 1989, TRANSPLANT P, V21, P9; LANGENDORF R, 1965, CIRCULATION, V32, P69, DOI 10.1161/01.CIR.32.1.69; MORGAN E, 1983, J THORAC CARDIOV SUR, V85, P134; POGWIZD SM, 1987, CIRC RES, V61, P352, DOI 10.1161/01.RES.61.3.352; STEVENS PM, 1970, NEW ENGL J MED, V282, P245, DOI 10.1056/NEJM197001292820504; TRULOCK EP, 1991, JAMA-J AM MED ASSOC, V266, P1943, DOI 10.1001/jama.266.14.1943; WITKOWSKI FX, 1984, AM J PHYSIOL, V247, pH661, DOI 10.1152/ajpheart.1984.247.4.H661; 1991, CIRCULATION, V84, P527	20	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1990	1992		10.1001/jama.266.14.1990	http://dx.doi.org/10.1001/jama.266.14.1990			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895480				2022-12-28	WOS:A1991GH40600028
J	BONHOEFFER, T; GRINVALD, A				BONHOEFFER, T; GRINVALD, A			ISO-ORIENTATION DOMAINS IN CAT VISUAL-CORTEX ARE ARRANGED IN PINWHEEL-LIKE PATTERNS	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; ORGANIZATION; COLUMNS; GEOMETRY	THE mammalian cortex is organized in a columnar fashion: neurons lying below each other from the pia to the white matter usually share many functional properties. Across the cortical surface, cells with similar response properties are also clustered together, forming elongated bands or patches. Some response properties, such as orientation preference in the visual cortex, change gradually across the cortical surface forming 'orientation maps'. To determine the precise layout of iso-orientation domains, knowledge of responses not only to one but to many stimulus orientations is essential. Therefore, the exact depiction of orientation maps has been hampered by technical difficulties and remained controversial for almost thirty years. Here we use in vivo optical imaging based on intrinsic signals to gather information on the responses of a piece of cortex to gratings in many different orientations. This complete set of responses then provides detailed information on the structure of the orientation map in a large patch of cortex from area 18 of the cat. We find that cortical regions that respond best to one orientation form highly ordered patches rather than elongated bands. These iso-orientation patches are organized around 'orientation centres', producing pinwheel-like patterns in which the orientation preference of cells is changing continuously across the cortex. We have also analysed our data for fast changes in orientation preference and find that these 'fractures' are limited to the orientation centres. The pinwheels and orientation centres are such a prominent organizational feature that it should be important to understand their development as well as their function in the processing of visual information.	ROCKEFELLER UNIV,NEUROBIOL LAB,NEW YORK,NY 10021; IBM CORP,DIV RES,YORKTOWN HTS,NY 10598; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Rockefeller University; International Business Machines (IBM); Weizmann Institute of Science			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Batschelet E, 1981, CIRCULAR STAT BIOL; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GOTZ KG, 1987, BIOL CYBERN, V56, P107, DOI 10.1007/BF00317985; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1978, J COMP NEUROL, V177, P361, DOI 10.1002/cne.901770302; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8779, DOI 10.1073/pnas.83.22.8779; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; OBERMAYER K, 1990, P NATL ACAD SCI USA, V90, P8245; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; von Seelen W, 1970, Kybernetik, V7, P89	18	630	638	1	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					429	431		10.1038/353429a0	http://dx.doi.org/10.1038/353429a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896085				2022-12-28	WOS:A1991GH60600056
J	MORROW, RC				MORROW, RC			DR-DAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1987, JAMA-J AM MED ASSOC, V257, P536	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1507	1507						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880878				2022-12-28	WOS:A1991GE45800012
J	TUNICK, PA; PEREZ, JL; KRONZON, I				TUNICK, PA; PEREZ, JL; KRONZON, I			PROTRUDING ATHEROMAS IN THE THORACIC AORTA AND SYSTEMIC EMBOLIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						ATHEROSCLEROSIS; AORTA, THORACIC; ECHOCARDIOGRAPHY; CEREBROVASCULAR DISORDERS; CEREBRAL ISCHEMIA, TRANSIENT	TRANSESOPHAGEAL ECHOCARDIOGRAPHY; STROKE; ARCH	Objective: To determine whether protruding atheromas in the thoracic aorta are a risk factor for systemic embolization. Design: Case-control study. Setting: A referral hospital. Patients: A total of 122 patients with a history of stroke, transient ischemic attack, or peripheral emboli and an equal number of age- and sex-matched control patients. Measurements: Evaluation using transesophageal echocardiography was done in case patients to detect protruding atheromas in the thoracic aorta and in control patients for cardiac indications other than emboli. Main Results: Matched logistic regression showed that the presence of protruding atheromas was strongly related to the occurrence of embolic symptoms (odds ratio, 3.2; 95% Cl, 1.6 to 6.5; P < 0.001). Furthermore, atheromas with mobile components were present only in case patients. When known risk factors for stroke (hypertension and diabetes) were added to the model, the presence of protruding atheromas remained an independent risk factor for embolic symptoms (odds ratio, 3.8). Hypertension was also independently associated with embolic symptoms (odds ratio, 2.7), but diabetes was not (odds ratio, 1.0). Conclusion: Protruding atheromas in the thoracic aorta can be detected by transesophageal echocardiography and should be considered as a cause of strokes, transient ischemic attacks, and peripheral emboli.			TUNICK, PA (corresponding author), NYU MED CTR, 560 1ST AVE, SUITE 2-E, NEW YORK, NY 10016 USA.							CULLIFORD AT, 1986, ANN THORAC SURG, V41, P27, DOI 10.1016/S0003-4975(10)64492-X; DANIEL W G, 1989, European Heart Journal, V10, P204; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DIXON WJ, 1985, BMDP STATISTICAL SOF; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GUSSENHOVEN WJ, 1988, EUR HEART J SUPPL, V9, P1572; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; LE CT, 1988, COMPUT BIOMED RES, V21, P48, DOI 10.1016/0010-4809(88)90041-9; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; TUNICK PA, 1991, ANN INTERN MED, V114, P391, DOI 10.7326/0003-4819-114-5-391; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; WOLF PA, 1981, JAMA-J AM MED ASSOC, V245, P1442, DOI 10.1001/jama.245.14.1442; YOUNG W, 1960, AM J CARDIOL, V6, P300, DOI 10.1016/0002-9149(60)90319-2; ZENKER G, 1988, STROKE, V19, P345, DOI 10.1161/01.STR.19.3.345	16	266	270	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					423	427		10.7326/0003-4819-115-6-423	http://dx.doi.org/10.7326/0003-4819-115-6-423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872490				2022-12-28	WOS:A1991GE81000002
J	HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ				HAMMOND, KB; ABMAN, SH; SOKOL, RJ; ACCURSO, FJ			EFFICACY OF STATEWIDE NEONATAL SCREENING FOR CYSTIC-FIBROSIS BY ASSAY OF TRYPSINOGEN CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; PROGRAM; AGE	Background. To evaluate the feasibility and efficacy of measuring immunoreactive trypsinogen in blood to screen for cystic fibrosis, we performed this test in 279,399 newborns in Colorado from 1982 to 1987. Methods. Immunoreactive trypsinogen was measured in dried blood spots when the infants were 1 to 4 days old; if the level was elevated (greater-than-or-equal-to 140-mu-g per liter), the measurement was repeated (mean age, 38 days); if the level was again elevated, sweat testing was performed (mean age, 49 days). For the second test, two cutoff levels (120 and 80-mu-g per liter) were evaluated. Results. We found an incidence of cystic fibrosis of 1 in 3827 (0.26 per 1000), with 3.2 newborns per 1000 requiring repeat measurement. When adjusted for race and compliance with testing, the incidence among the white infants (1 in 2521) was close to the expected incidence. The false positive rate with the initial cutoff level (92.2 percent) was similar to the rate found in neonatal screening programs for other diseases. False negative results occurred because of laboratory error or changes in procedure (three infants) and trypsinogen concentrations lower than the initial cutoff level (three infants) or lower than the remeasurement cutoff level of 120-mu-g per liter (one infant). Sweat tests were negative in 168 infants with an elevated initial trypsinogen level but a level below 80-mu-g per liter on remeasurement, confirming the value of 80-mu-g per liter as an appropriate cutoff for repeat-test results. Overall, 95.2 percent of the infants with cystic fibrosis (95 percent confidence interval, 85 to 99 percent) who did not have meconium ileus could be identified with the use of a trypsinogen cutoff level of 140-mu-g per liter on initial testing and 80-mu-g per liter on repeat testing. Conclusions. Statewide screening for cystic fibrosis based on measurements of immunoreactive trypsinogen in dried blood spots is feasible and can be implemented with acceptable rates of repeat testing and false positive and false negative results.	UNIV COLORADO, SCH MED, DIV PERINATAL MED, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	HAMMOND, KB (corresponding author), UNIV COLORADO, SCH MED, DEPT PEDIAT, BOX C228, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000069] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00069] Funding Source: Medline; PHS HHS [MCJ-080508-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADRIAENSSENS K, 1981, LANCET, V1, P833; [Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; BURLINA A, 1980, SCAND J GASTROENTERO, V15, P35; CROSSLEY JR, 1981, CLIN CHIM ACTA, V113, P111, DOI 10.1016/0009-8981(81)90145-5; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Diem K., 1970, SCI TABLES, VSeventh; DIXON WJ, 1969, INTRO STATISTICAL AN, P249; DUHAMEL JF, 1984, CYSTIC FIBROSIS HORI, P208; GIBSON LE, 1973, CLIN PEDIATR, V12, P450, DOI 10.1177/000992287301200817; HAMMOND KB, 1984, LANCET, V1, P42; HAMMOND KB, 1986, GENETIC DISEASE SCRE, P81; HEELEY AF, 1982, ARCH DIS CHILD, V57, P18; KING DN, 1979, LANCET, V2, P1217; KRAMM ER, 1962, AM J PUBLIC HEALTH N, V52, P2041, DOI 10.2105/AJPH.52.12.2041; ORENSTEIN DM, 1977, AM J DIS CHILD, V131, P973, DOI 10.1001/archpedi.1977.02120220039005; REARDON MC, 1984, J PEDIATR-US, V105, P271, DOI 10.1016/S0022-3476(84)80128-6; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SHEPHERD RW, 1989, J PEDIATR GASTR NUTR, V9, P200, DOI 10.1097/00005176-198908000-00012; SHWACHMAN H., 1967, MOD PROBL PAEDIATR, V10, P158; SOKOL RJ, 1989, AM J CLIN NUTR, V50, P1064, DOI 10.1093/ajcn/50.5.1064; SORENSON JR, 1984, PEDIATRICS, V73, P183; STEINBERG AG, 1960, AM J HUM GENET, V12, P416; WATERS DL, 1990, NEW ENGL J MED, V322, P303, DOI 10.1056/NEJM199002013220505; WILCKEN B, 1985, LANCET, V2, P1319; WILCKEN B, 1983, J PEDIATR-US, V102, P383, DOI 10.1016/S0022-3476(83)80653-2; 1990, NEW ENGL J MED, V323, P70; 1985, SAS USERS GUIDE STAT	30	125	129	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					769	774		10.1056/NEJM199109123251104	http://dx.doi.org/10.1056/NEJM199109123251104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870650	Bronze			2022-12-28	WOS:A1991GE45600004
J	STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				STAMPFER, MJ; COLDITZ, GA; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			POSTMENOPAUSAL ESTROGEN THERAPY AND CARDIOVASCULAR-DISEASE - 10-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; PROSPECTIVE COHORT; WOMEN; REPRODUCIBILITY; QUESTIONNAIRE; MENOPAUSE; VALIDITY; CANCER; STROKE	Background. The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results. Methods. We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes. Results. After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taking estrogen was 0.56 (95 percent confidence interval, 0.40 to 0.80); the risk was significantly reduced among women with either natural or surgical menopause. We observed no effect of the duration of estrogen use independent of age. The findings were similar in analyese limited to women who had recently visited their physicians (relative risk, 0.45; 95 percent confidence interval, 0.31 to 0.66) and in a low-risk group that excluded women reporting current cigarette smoking, diabetes, hypertension, hypercholesterolemia, or a Quetelet index above the 90th percentile (relative risk, 0.53; 95 percent confidence interval, 0.31 to 0.91). The relative risk for current and former users of estrogen as compared with those who had never used it was 0.89 (95 percent confidence interval, 0.78 to 1.00) for total mortality and 0.72 (95 percent confidence interval, 0.55 to 0.95) for mortality from cardiovascular disease. The relative risk of stroke when current users were compared with those who had never used estrogen was 0.97 (95 percent confidence interval, 0.65 to 1.45), with no marked differences according to type of stroke. Conclusions. Current estrogen use is associated with a reduction in the incidence of coronary heart disease as well as in mortality from cardiovascular disease, but it is not associated with any change in the risk of stroke.	HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	STAMPFER, MJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILAR JC, 1985, NEW ENGL J MED, V313, P1080, DOI 10.1056/NEJM198510243131709; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BUSH TL, 1986, MENOPAUSE PHYSL PHAR, P187; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; EAKER ED, 1987, CORONARY HEART DISEA, P122; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; JUDD HL, 1980, AM J OBSTET GYNECOL, V136, P859, DOI 10.1016/0002-9378(80)91043-1; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MCFARLAND KF, 1989, AM HEART J, V117, P1209, DOI 10.1016/0002-8703(89)90398-0; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; ROTHMAN KJ, 1979, NIH791649 PHS PUBL; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; SULLIVAN JM, 1988, ANN INTERN MED, V108, P358, DOI 10.7326/0003-4819-108-3-358; Walker AE, 1981, STROKE S1, V12, P13; Weinstein M C, 1983, Obstet Gynecol Surv, V38, P445, DOI 10.1097/00006254-198308000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702; [No title captured]	31	1872	1903	0	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					756	762		10.1056/NEJM199109123251102	http://dx.doi.org/10.1056/NEJM199109123251102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870648				2022-12-28	WOS:A1991GE45600002
J	LOZOFF, B; JIMENEZ, E; WOLF, AW				LOZOFF, B; JIMENEZ, E; WOLF, AW			LONG-TERM DEVELOPMENTAL OUTCOME OF INFANTS WITH IRON-DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PSYCHOMOTOR DEVELOPMENT; PRESCHOOL-CHILDREN; DEVELOPMENT SCORES; ANEMIC INFANTS; THERAPY; ACHIEVEMENT; NUTRITION; BEHAVIOR	Background. Iron-deficiency anemia has been associated with lowered scores on tests of mental and motor development in infancy. However, the long-term developmental outcome of infants with iron deficiency is unknown, because developmental tests in infancy do not predict later intellectual functioning. Methods. This study is a follow-up evaluation of a group of Costa Rican children whose iron status and treatment were documented in infancy. Eighty-five percent (163) of the 191 children in the original group underwent comprehensive clinical, nutritional, and psychoeducational assessments at five years of age. The developmental test battery consisted of the Wechsler Preschool and Primary Scale of Intelligence, the Spanish version of the Woodcock-Johnson Psycho-Educational Battery, the Beery Developmental Test of Visual-Motor Integration, the Goodenough-Harris Draw-a-Man Test, and the Bruininks-Oseretsky Test of Motor Proficiency. Results. All the children had excellent hematologic status and growth at five years of age. However, children who had moderately severe iron-deficiency anemia as infants, with hemoglobin levels less-than-or-equal-to 100 g per liter, had lower scores on tests of mental and motor functioning at school entry than the rest of the children. Although these children also came from less socioeconomically advantaged homes, their test scores remained significantly lower than those of the other children after we controlled for a comprehensive set of background factors. For example, the mean (+/- SD) adjusted Woodcock-Johnson preschool cluster score for the children who had moderate anemia in infancy (n = 30) was 448.6 +/- 9.7, as compared with 452.9 +/- 9.2 for the rest of the children (n = 133) (P < 0.01); the adjusted visual-motor integration score was 5.9 +/- 2.1, as compared with 6.7 +/- 2.3 (P < 0.05). Conclusions. Children who have iron-deficiency anemia in infancy are at risk for long-lasting developmental disadvantage as compared with their peers with better iron status.	CASE WESTERN RESERVE UNIV,METROHEALTH MED CTR,RAINBOW BABIES & CHILDRENS HOSP,SCH MED,CLEVELAND,OH 44106; UNIV COSTA RICA,HOSP NACL NINOS,SAN JOSE,COSTA RICA	Case Western Reserve University; Case Western Reserve University Hospital; MetroHealth System; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Universidad Costa Rica	LOZOFF, B (corresponding author), CASE WESTERN RESERVE UNIV,METROHEALTH MED CTR,RAINBOW BABIES & CHILDRENS HOSP,SCH MED,CLEVELAND,OH 44106, USA.		Fahimifar, Sepideh/M-5303-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R22HD014122] Funding Source: NIH RePORTER; NICHD NIH HHS [R22 HD14122-10] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; BARRETT DE, 1986, THEORY RES BEHAVIORA, V3, P147; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BEERY KE, 1982, ADM SCORING TEACHING; Bruininks R.H., 2005, BRUININKS OSERETSKY; Caldwell B., 1984, HOME OBSERVATION MEA; CZAJKANARINS DM, 1978, AM J CLIN NUTR, V31, P955, DOI 10.1093/ajcn/31.6.955; DAVIS JM, 1987, NATURE, V329, P297, DOI 10.1038/329297a0; DeMaeyer E, 1985, World Health Stat Q, V38, P302; DEVIZIA B, 1985, J PEDIATR-US, V107, P75, DOI 10.1016/S0022-3476(85)80618-1; DOBBING J, 1987, EARLY NUTRITION LATE; DOMMERGUES JP, 1989, ARCH FR PEDIATR, V46, P487; Dunn L.M., 2007, PEABODY PICTURE VOCA; ESCALONA SK, 1982, PEDIATRICS, V70, P670; FLORENTINO RF, 1984, IRON NUTRITION INFAN, P31; GRINDULIS H, 1986, ARCH DIS CHILD, V61, P843, DOI 10.1136/adc.61.9.843; HARRISDB, 1963, CHILDRENS DRAWINGS M; JACOBSON SW, 1991, CHILD DEV, V62, P572, DOI 10.2307/1131132; JACOBSON SW, IN PRESS PEDIATRICS; Kenny D.A, 1979, CORRELATION CAUSALIT; LEVITSKY DA, 1979, MALNUTRITION ENV BEH; LOZOFF B, 1989, AM PSYCHOL, V44, P231, DOI 10.1037/0003-066X.44.2.231; LOZOFF B, 1987, PEDIATRICS, V79, P981; LOZOFF B, 1982, J PEDIATR-US, V100, P351, DOI 10.1016/S0022-3476(82)80428-9; LOZOFF B, 1990, BRAIN BEHAV IRON INF, P107; LOZOFF B, 1988, PEDIATRICS, V81, P683; MCCALL RB, 1979, HDB INFANT DEV, P707; MEJIA LA, 1988, AM J CLIN NUTR, V48, P595, DOI 10.1093/ajcn/48.3.595; OSKI FA, 1978, J PEDIATR-US, V92, P21, DOI 10.1016/S0022-3476(78)80063-8; OWEN GM, 1971, J PEDIATR-US, V79, P563, DOI 10.1016/S0022-3476(71)80301-3; PALTI H, 1983, HUM BIOL, V55, P183; PALTI H, 1985, EARLY HUM DEV, V10, P217, DOI 10.1016/0378-3782(85)90052-0; ROCHE AF, 1987, PEDIATRICS, V79, P706; SMITH M, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P3; WALTER T, 1983, J PEDIATR-US, V102, P519, DOI 10.1016/S0022-3476(83)80177-2; WALTER T, 1989, PEDIATRICS, V84, P7; WALTER T, 1990, PEDIATR RES, V28, P295, DOI 10.1203/00006450-199009000-00132; Wechsler, 2012, WPPSI 4 WECHSLER PRE; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; WOODCOCK RW, 1982, WOODCOCK SPANISH PSY; ZEE P, 1985, JAMA-J AM MED ASSOC, V253, P3269, DOI 10.1001/jama.253.22.3269; 1984, ASSESSMENT IRON NUTR; DHEW PHS781650	43	709	737	1	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					687	694		10.1056/NEJM199109053251004	http://dx.doi.org/10.1056/NEJM199109053251004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1870641				2022-12-28	WOS:A1991GD49700004
J	PRETTO, EA; SAFAR, P				PRETTO, EA; SAFAR, P			NATIONAL MEDICAL RESPONSE TO MASS DISASTERS IN THE UNITED-STATES - ARE WE PREPARED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCED LIFE SUPPORT; AID LSFA; SYSTEMS; EARTHQUAKE; CARE; MORTALITY; TRAUMA	Preparing for a resuscitation response to mass disasters, such as major earthquakes or industrial disasters, requires revisions of present local, regional, and national disaster plans. These should include the following: (1) life-supporting first aid and basic rescue capability of the lay public; (2) advanced trauma life support and advanced (heavy) rescue capability brought quickly to the scene from local and surrounding (regional) emergency medical services systems; and (3) trauma hospitals sending medical resuscitation teams to, and receiving casualties from, the disaster scene for resuscitative surgery and definitive care. Local and regional everyday emergency medical services systems would respond first. The armed forces should help, at least for transport and security. We propose that the National Disaster Medical System replace its civil defense model with an emergency medical services model, designed to mobilize rapid support for local emergency medical services systems from regional, state, and national resources. Coordination should be by one federal agency, such as the Federal Emergency Management Agency, which, however, needs to focus more on resuscitation through physician input.	UNIV PITTSBURGH, PRESBYTERIAN HOSP, SCH MED, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	PRETTO, EA (corresponding author), UNIV PITTSBURGH, INT RESUSCITAT RES CTR, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA.		Pretto, Ernesto A/I-4679-2015	Pretto, Ernesto A/0000-0003-4732-534X				ABRAMS J, 1991, PREHOSP DISASTER MED, V6, P257; ALEXANDER RH, 1984, J TRAUMA, V24, P486, DOI 10.1097/00005373-198406000-00005; BEARY JF, 1982, NEW ENGL J MED, V306, P738, DOI 10.1056/NEJM198203253061210; BIRCHER N, 1983, CRIT CARE MED, V11, P251, DOI 10.1097/00003246-198303000-00135; BISGARD JC, 1985, PREHOSP DISASTER MED, V1, P35; BOYD DR, 1973, J TRAUMA, V13, P275, DOI 10.1097/00005373-197304000-00001; BOZZAMARRUBINI M, 1985, PREHOSP DISASTER S1, V1, P414; COMFORT L, 1986, J LATIN AM STUD, V1, P12; Copper PR, 1987, HEAD INJURY, P1; Cowley R A, 1975, Md State Med J, V24, P37; COWLEY RA, 1986, PREHOSP DISASTER MED, V2, P1; DEBRUYCKER M, 1985, INT J EPIDEMIOL, V14, P113, DOI 10.1093/ije/14.1.113; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; KER RA, 1989, SCIENCE, V243, P170; Klain M, 1989, PREHOSP DISASTER MED, V4, P135; KVETAN V, 1991, CRIT CARE MED, V19, P854; Leaning J, 1991, JEMS, V16, P11; MAHONEY LE, 1987, ANN EMERG MED, V16, P354, DOI 10.1016/S0196-0644(87)80187-7; MAHONEY LE, 1987, ANN EMERG MED, V16, P1085, DOI 10.1016/S0196-0644(87)80764-3; MANNI C, 1985, PREHOSP DISASTER S1, V1, P412; MOLFESE A, 1987, PREHOSP DISASTER MED, V3, P96; MORITSUGU KP, 1986, ANN EMERG MED, V15, P1496, DOI 10.1016/S0196-0644(86)80951-9; NOJI EK, 1990, ANN EMERG MED, V19, P891, DOI 10.1016/S0196-0644(05)81563-X; Olson Robert A., 1990, EARTHQ SPECTRA, V6, P393, DOI DOI 10.1193/1.1585569; PRETTO E, 1991, PREHOSP DISASTER MED, V6, P245; Reardon JD, 1988, FED REG         0420, V53, P12994; RICCI EM, 1991, PREHOSP DISASTER MED, V6, P159; ROMO CR, 1986, PREHOSP DISASTER MED, V2, P4; ROTH PB, 1991, ANN EMERG MED, V20, P391, DOI 10.1016/S0196-0644(05)81661-0; SAFAR P, 1981, CRIT CARE MED, V9, P403; SAFAR P, 1986, PREHOSP DISASTER MED, V12, P34; SAFAR P, 1985, 4TH P WORLD C EM DIS; SAFAR P, 1988, MED DISASTERS, P36; Safar P, 1987, PREHOSP DISASTER MED, V3, P124; SAFAR P, 1986, PRINCIPLES PRACTICE, P2; Safar PBN, 1988, CARDIOPULMONARY CERE; SIEGELSON HJ, 1989, NEW ENGL J MED, V320, P941; SILVERSTEIN ME, 1985, PREHOSP DISASTER MED, V1, P39; STAR LD, 1980, AVIAT SPACE ENVIR MD, V51, P1262; Villazon-Sahagun A., 1986, PREHOSP DISASTER MED, V2, P15; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x; 1968, JAMA-J AM MED ASSOC, V204, P595; 1985, PREHOSP DISASTER MED, V1, P17; 1985, PREHOSP DISASTER MED, V1, P15; 1989, ADV TRAUMA LIFE SUPP	46	21	23	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1259	1262		10.1001/jama.266.9.1259	http://dx.doi.org/10.1001/jama.266.9.1259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870252				2022-12-28	WOS:A1991GC85800036
J	PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL				PIERETTI, M; ZHANG, FP; FU, YH; WARREN, ST; OOSTRA, BA; CASKEY, CT; NELSON, DL			ABSENCE OF EXPRESSION OF THE FMR-1 GENE IN FRAGILE-X SYNDROME	CELL			English	Article								We previously reported the isolation of a gene (FMR-1) expressed in brain at the fragile X locus. One exon of this gene lies within an EcoRI fragment that exhibits length variation in fragile X patients. This exon also contains the CGG repeat within the CpG island hypermethylated in fragile X patients. To study the involvement of the FMR-1 gene in the fragile X syndrome, its expression was studied in lymphoblastoid cell lines and leukocytes derived from patients and normal controls. FMR-1 mRNA was absent in the majority of male fragile X patients, suggesting a close involvement of this gene in development of the syndrome. Normal individuals and carriers all show expression. The methylation status of the BssHII site at the CpG island was also studied by Southern blot analysis of DNA from patients, carriers, and controls. The minority of fragile X affected males that show expression of FMR-1 demonstrated an associated incomplete methylation of the BssHII site.	ERASMUS UNIV,DEPT CELL BIOL,3000 DR ROTTERDAM,NETHERLANDS; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Erasmus University Rotterdam; Emory University; Emory University	PIERETTI, M (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HUMAN GENOME CTR,INST MOLEC GENET,HOUSTON,TX 77030, USA.		Warren, Stephen T/A-2498-2012		NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HIRST MC, 1991, GENOMICS, V10, P243, DOI 10.1016/0888-7543(91)90506-A; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; McKusick VA, 1990, MENDELIAN INHERITANC; NELSON DL, 1991, P NATL ACAD SCI USA, V88, P6157, DOI 10.1073/pnas.88.14.6157; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OOSTRA BA, 1990, GENOMICS, V6, P129, DOI 10.1016/0888-7543(90)90457-6; ROUSSEAU F, 1991, AM J HUM GENET, V48, P108; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WARREN ST, 1990, P NATL ACAD SCI USA, V87, P3856, DOI 10.1073/pnas.87.10.3856; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	15	1207	1226	1	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					817	822		10.1016/0092-8674(91)90125-I	http://dx.doi.org/10.1016/0092-8674(91)90125-I			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878973				2022-12-28	WOS:A1991GC74500020
J	GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM				GRONENBORN, AM; FILPULA, DR; ESSIG, NZ; ACHARI, A; WHITLOW, M; WINGFIELD, PT; CLORE, GM			A NOVEL, HIGHLY STABLE FOLD OF THE IMMUNOGLOBULIN BINDING DOMAIN OF STREPTOCOCCAL PROTEIN-G	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; STAPHYLOCOCCUS-AUREUS; MOLECULAR-DYNAMICS; SPECTROSCOPY; CRYSTALLOGRAPHY; RESOLUTION; PROGRAM; CRAMBIN	The high-resolution three-dimensional structure of a single immunoglobulin binding domain (BI, which comprises 56 residues including the NH2-terminal Met) of protein G from group G Streptococcus has been determined in solution by nuclear magnetic resonance spectroscopy on the basis of 1058 experimental restraints. The average atomic root-mean-square distribution about the mean coordinate positions is 0.27 angstrom (angstrom) for the backbone atoms, 0.65 angstrom for all atoms, and 0.39 angstrom for atoms excluding disordered surface side chains. The structure has no disulfide bridges and is composed of a four-stranded 13 sheet, on top of which lies a long helix. The central two strands (beta-1 and beta-4), comprising the NH2- and COOH-termini, are parallel, and the outer two strands (beta-2 and beta-3) are connected by the helix in a +3x crossover. This novel topology (-1, +3x, -1), coupled with an extensive hydrogen-bonding network and a tightly packed and buried hydrophobic core, is probably responsible for the extreme thermal stability of this small domain (reversible melting at 87-degrees-C).	GENEX CORP, GAITHERSBURG, MD 20877 USA; NIH, PROT EXPRESS LAB, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	GRONENBORN, AM (corresponding author), NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Wingfield, Paul/0000-0002-9515-4752; Gronenborn, Angela M/0000-0001-9072-3525				AKERSTROM B, 1986, J BIOL CHEM, V261, P240; BAX A, 1989, METHOD ENZYMOL, V176, P151; BJORCK L, 1984, J IMMUNOL, V133, P969; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1988, XPLOR MANUAL; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1987, PROTEIN ENG, V1, P275, DOI 10.1093/protein/1.4.275; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; CREIGHTON TE, 1986, METHOD ENZYMOL, V131, P157; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAHNESTOCK S, COMMUNICATION; FAHNESTOCK SR, 1987, TRENDS BIOTECHNOL, V5, P79, DOI 10.1016/S0167-7799(87)80016-1; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, P133; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HAVEL T, 1984, B MATH BIOL, V46, P673, DOI 10.1007/BF02459510; HAVEL TF, 1986, QUANTUM CHEM PROGRAM, V507; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; JAMES MNG, 1980, J MOL BIOL, V144, P43, DOI 10.1016/0022-2836(80)90214-4; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LANGONE JJ, 1982, ADV IMMUNOL, V32, P157; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Pfeil W., 1986, THERMODYNAMIC DATA B, P349; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SJOBRING U, 1991, J BIOL CHEM, V266, P399; SJOBRING U, 1989, J IMMUNOL, V143, P2948; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1989, ACCOUNTS CHEM RES, V22, P36, DOI 10.1021/ar00157a006; Wuthrich K., 1986, NMR PROTEINS NUCL AC	47	708	729	4	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					657	661		10.1126/science.1871600	http://dx.doi.org/10.1126/science.1871600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871600				2022-12-28	WOS:A1991GA30400037
J	LEHNER, PJ; POWELL, H				LEHNER, PJ; POWELL, H			GAS-GANGRENE - OVERWHELMING INFECTION RESPONSIVE TO SURGICAL AND MEDICAL-TREATMENT	BRITISH MEDICAL JOURNAL			English	Discussion							HUMAN SEPTIC SHOCK; CLOSTRIDIUM-PERFRINGENS; CHALLENGES; INJECTION				LEHNER, PJ (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0HS,ENGLAND.			Lehner, Paul Joseph/0000-0001-9383-1054				CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; EDWARDS JD, IN PRESS CRIT CARE M; GIBSON A, 1986, NEW ZEAL MED J, V99, P617; GULICK T, 1989, P NATL ACAD SCI USA, V86, P6753, DOI 10.1073/pnas.86.17.6753; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; ISPAHANI P, 1987, Q J MED, V63, P427; JACKSON DS, 1983, ANN ROY COLL SURG, V65, P281; KERSHAW CJ, 1988, POSTGRAD MED J, V64, P812, DOI 10.1136/pgmj.64.756.812; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; SHOEMAKER WC, 1990, INTENS CARE MED, V16, pS135, DOI 10.1007/BF01785243; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; STEVENS DL, 1988, J INFECT DIS, V157, P272, DOI 10.1093/infdis/157.2.272; SUDARSKY LA, 1987, ANN SURG, V206, P661; TUAZON CU, 1974, J INFECT DIS, V129, P327, DOI 10.1093/infdis/129.3.327; [No title captured]	16	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					240	242		10.1136/bmj.303.6796.240	http://dx.doi.org/10.1136/bmj.303.6796.240			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884064	Bronze, Green Published			2022-12-28	WOS:A1991FZ56300032
J	PALIARD, X; WEST, SG; LAFFERTY, JA; CLEMENTS, JR; KAPPLER, JW; MARRACK, P; KOTZIN, BL				PALIARD, X; WEST, SG; LAFFERTY, JA; CLEMENTS, JR; KAPPLER, JW; MARRACK, P; KOTZIN, BL			EVIDENCE FOR THE EFFECTS OF A SUPERANTIGEN IN RHEUMATOID-ARTHRITIS	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; STAPHYLOCOCCAL ENTEROTOXIN-B; FLUID LYMPHOCYTES-T; SYNOVIAL-FLUID; CLONAL DELETION; SELF-TOLERANCE; CELLS; ASSOCIATION; ANTIGENS; MICE	While studying the alpha-beta T cell receptor repertoire in rheumatoid arthritis (RA) patients, we found that the frequency of V-beta-14+ T cells was significantly higher in the synovial fluid of affected joints than in the peripheral blood. In fact, V-beta-14+ T cells were virtually undetectable in the peripheral blood of a majority of these RA patients. beta-chain sequences indicated that one or a few clones dominated the V-beta-14+ population in the synovial fluid of individual RA patients, whereas oligoclonality was less marked for other V-beta's and for V-beta-14 in other types of inflammatory arthritis. These results implicate V-beta-14-bearing T cells in the pathology of RA. They also suggest that the etiology of RA may involve initial activation of V-beta-14+ T cells by a V-beta-14-specific superantigen with subsequent recruitment of a few activated autoreactive V-beta-14+ T cell clones to the joints while the majority of other V-beta-14+ T cells disappear.	HOWARD HUGHES MED INST,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; FITZSIMONS ARMY MED CTR,DEPT MED,AURORA,CO 80045; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOPHYS,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT GENET,DENVER,CO 80262	Howard Hughes Medical Institute; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI017134, R37AI017134, R01AI017134, R01AI028495, P01AI022295] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28495, AI-17134, AI-22295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BURMESTER GR, 1981, ARTHRITIS RHEUM, V24, P1370, DOI 10.1002/art.1780241106; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DUBY AD, 1989, P NATL ACAD SCI USA, V86, P6206, DOI 10.1073/pnas.86.16.6206; DUQUESNOY RJ, 1984, HUM IMMUNOL, V10, P165, DOI 10.1016/0198-8859(84)90037-5; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FOX RI, 1982, J IMMUNOL, V128, P351; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GIBOFSKY A, 1978, J EXP MED, V148, P1728, DOI 10.1084/jem.148.6.1728; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HEMLER ME, 1986, J CLIN INVEST, V78, P696, DOI 10.1172/JCI112629; HERZOG C, 1987, LANCET, V2, P1461; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARSH J, 1979, ARTHRITIS RHEUM, V22, P1055, DOI 10.1002/art.1780221002; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KEYSTONE EC, 1988, ARTHRITIS RHEUM, V31, P155; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOTZIN BL, 1981, NEW ENGL J MED, V305, P969, DOI 10.1056/NEJM198110223051702; LEGRAND L, 1984, AM J HUM GENET, V36, P690; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MCMICHAEL AJ, 1977, ARTHRITIS RHEUM, V20, P1037, DOI 10.1002/art.1780200501; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; PALIARD X, UNPUB; PAULUS HE, 1977, ARTHRITIS RHEUM, V20, P1249, DOI 10.1002/art.1780200614; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; SCHIFF B, 1982, ANN RHEUM DIS, V41, P403, DOI 10.1136/ard.41.4.403; SIU G, 1986, J EXP MED, V164, P1600, DOI 10.1084/jem.164.5.1600; STAMENKOVIC I, 1988, P NATL ACAD SCI USA, V85, P1479; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359; TRENTHAM DE, 1987, NEW ENGL J MED, V2, P1461; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEICKERT K, 1989, EDITORIAL COMMENTS, P5; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YOCUM DE, 1988, ANN INTERN MED, V109, P863, DOI 10.7326/0003-4819-109-11-863	45	634	671	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					325	329		10.1126/science.1857971	http://dx.doi.org/10.1126/science.1857971			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857971				2022-12-28	WOS:A1991FX22400044
J	JONES, K; MOON, G				JONES, K; MOON, G			MULTILEVEL ASSESSMENT OF IMMUNIZATION UPTAKE AS A PERFORMANCE-MEASURE IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							INDICATORS	Objective-To provide a measure of general practitioners' performance regarding uptake of immunisation against pertussis, taking account of the impact of patient characteristics on levels of uptake. Design-Multilevel model of immunisation status against six measures of patient characteristics (level 1 predictor variables) with practice constraints as level 2 variables. Setting-126 practices in southern England. Subjects-2048 infants identified from infant surveillance and immunisation records. Main outcome measures-Top 10 practices with respect to uptake of pertussis immunisation according to a "null" model (model A) and according to a model that included six level 1 variables (model B); differences in ranking between the two models. Results-Practices with low numbers of infants requiring immunisation had imprecise and unstable uptake rates (range O%-100%). With the multilevel procedure, after controlling for patient characteristics, practices in suburban catchment areas comprised largely of mature or young professionals performed best. Most improved performances when patient characteristics were taken into account were in practices in areas with a stable population and local authority housing-one such practice improved its ranking by 47 places. Conclusions-Crude uptake rates are inadequate performance indicators. Alternative approaches suggest that praiseworthy efforts to raise immunisation rates in unpromising areas are unrewarded by simple target based assessments.	PORTSMOUTH POLYTECH,DEPT GEOG,PORTSMOUTH PO1 3HE,HANTS,ENGLAND	University of Portsmouth			Jones, Kelvyn/A-3939-2011; Moon, Graham/J-9664-2012; Jones, Kelvyn/ABE-8689-2020	Jones, Kelvyn/0000-0001-8398-2190; Moon, Graham/0000-0002-7256-8397; Jones, Kelvyn/0000-0001-8398-2190				AITKIN M, 1986, J ROY STAT SOC A STA, V149, P1, DOI 10.2307/2981882; ALLEN D, 1987, SOC POLICY ADMIN, V21, P70, DOI 10.1111/j.1467-9515.1987.tb00263.x; Bock Darrell R, 1989, MULTILEVEL ANAL ED D; CHISHOLM JW, 1990, BRIT MED J, V300, P853, DOI 10.1136/bmj.300.6728.853; GAZE H, 1990, HLTH SERVICE J, V100, P682; GLASMAN D, 1990, HLTH SERVICE J, V100, P232; Goldstein H., 1987, MULTILEVEL MODELS ED; James M, 1987, Health Trends, V19, P12; JONES K, 1990, AREA, V22, P264; JONES K, IN PRESS SOC SCI MED; JONES K, 1987, HLTH DISEASE SOC; Longford N., 1986, PROFESSIONAL STAT, V5, P28; LONGFORD NT, 1988, QUASILIKELIHOOD ADAP; LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; NEWLANDS M, 1988, PUBLIC HLTH, V102, P369; PECKHAM C, 1989, NATIONAL IMMUNISATIO; SKINNER PW, 1988, BRIT MED J, V297, P1256, DOI 10.1136/bmj.297.6658.1256; URQUHART AS, 1987, J ROY COLL GEN PRACT, V37, P148; WILTON J, 1990, BRIT MED J, V300, P851, DOI 10.1136/bmj.300.6728.851; 1989, GENERAL PRACTICE NAT; 1983, NHS MANAGEMENT INQUI; 1988, DISTRICT PROFILES CO; [No title captured]; 1989, CMND555	26	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					28	31		10.1136/bmj.303.6793.28	http://dx.doi.org/10.1136/bmj.303.6793.28			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859953	Green Published, Bronze			2022-12-28	WOS:A1991FW12800024
J	CROMBIE, IK				CROMBIE, IK			SUICIDE AMONG MEN IN THE HIGHLANDS OF SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article							TRENDS				CROMBIE, IK (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND.							ARMITAGE P, 1971, STATISTICAL METHODS; CROMBIE IK, 1989, BMJ-BRIT MED J, V298, P782, DOI 10.1136/bmj.298.6676.782; HAWTON K, 1987, BRIT J PSYCHIAT, V150, P145, DOI 10.1192/bjp.150.2.145; MCLOONE P, 1987, BMJ-BRIT MED J, V295, P629, DOI 10.1136/bmj.295.6599.629; Stengel E, 1973, SUICIDE ATTEMPTED SU	5	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					761	762		10.1136/bmj.302.6779.761	http://dx.doi.org/10.1136/bmj.302.6779.761			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FF229	1878024	Bronze, Green Published			2022-12-28	WOS:A1991FF22900024
J	GREEN, ED; WATERSTON, RH				GREEN, ED; WATERSTON, RH			THE HUMAN GENOME PROJECT - PROSPECTS AND IMPLICATIONS FOR CLINICAL MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YEAST ARTIFICIAL CHROMOSOMES; POLYMERASE CHAIN-REACTION; CYSTIC-FIBROSIS GENE; LINKAGE MAP; MOLECULAR-GENETICS; PHYSICAL MAP; DNA MARKERS; DIAGNOSIS; IDENTIFICATION; LOCUS	The recently initiated human genome project is a large international effort to elucidate the genetic architecture of the genomes of man and several model organisms. The initial phases of this endeavor involve the establishment of rough blueprints (maps) of the genetic landscape of these genomes, with the long-term goal of determining their precise nucleotide sequences and identifying the genes. The knowledge gained by these studies will provide a vital tool for the study of many biologic processes and will have a profound impact on clinical medicine.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	GREEN, ED (corresponding author), WASHINGTON UNIV, SCH MED, DEPT GENET, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040606] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00375, HG00136] Funding Source: Medline; NIGMS NIH HHS [GM40606] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONARAKIS SE, 1990, SOUTHERN MED J, V83, P876, DOI 10.1097/00007611-199008000-00006; ANTONARAKIS SE, 1989, NEW ENGL J MED, V320, P153, DOI 10.1056/NEJM198901193200305; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARKER D, 1987, P NATL ACAD SCI USA, V84, P8006, DOI 10.1073/pnas.84.22.8006; BARKER PE, 1990, AM J MED SCI, V299, P69, DOI 10.1097/00000441-199001000-00015; BRONSON SK, 1991, P NATL ACAD SCI USA, V88, P1676, DOI 10.1073/pnas.88.5.1676; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CANTOR CR, 1990, SCIENCE, V248, P49, DOI 10.1126/science.2181666; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3576; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DONISKELLER H, 1986, COLD SPRING HARB SYM, V51, P317, DOI 10.1101/SQB.1986.051.01.037; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; DULBECCO R, 1986, SCIENCE, V231, P1055, DOI 10.1126/science.3945817; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; FARRALL M, 1988, AM J HUM GENET, V43, P471; FRIEDMANN T, 1990, AM J HUM GENET, V46, P407; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GORDON J, 1989, GERIATRICS, V44, P89; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREEN ED, IN PRESS GENOMICS; GREEN P, 1989, CLIN CHEM, V35, pB33; GRODY WW, 1989, MODERN PATHOL, V2, P553; HIETER P, 1990, GENOME ANAL, V1, P83; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; IANNUZZI MC, 1990, AM J RESP CELL MOL, V2, P309, DOI 10.1165/ajrcmb/2.4.309; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KNOWLTON RG, 1985, NATURE, V318, P380, DOI 10.1038/318380a0; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KROGER M, 1991, NUCLEIC ACIDS RES, V19, P2023, DOI 10.1093/nar/19.suppl.2023; Kumar R., 1989, Technique, a Journal of Methods in Cell and Molecular Biology, V1, P133; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINK AJ, 1991, GENETICS, V127, P681; Little PFR, 1990, CURR OPIN CELL BIOL, V2, P478, DOI 10.1016/0955-0674(90)90131-W; LUBIN MB, 1990, CLIN PERINATOL, V17, P889, DOI 10.1016/S0095-5108(18)30551-7; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN JB, 1987, SCIENCE, V238, P765, DOI 10.1126/science.2890208; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1991, FASEB J, V5, P12, DOI 10.1096/fasebj.5.1.1991580; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; PHILLIPS JA, 1990, SOUTH MED J, V83, P868, DOI 10.1097/00007611-199008000-00005; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PORTEOUS DJ, 1990, THORAX, V45, P46; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERTS L, 1990, SCIENCE, V248, P1310, DOI 10.1126/science.2356467; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSE EA, 1991, FASEB J, V5, P46, DOI 10.1096/fasebj.5.1.1991584; ROSSITER BJF, 1991, FASEB J, V5, P21, DOI 10.1096/fasebj.5.1.1846832; SCHLESSINGER D, 1990, TRENDS GENET, V6, P248, DOI 10.1016/0168-9525(90)90207-M; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; SILVERMAN GA, 1990, P NATL ACAD SCI USA, V87, P9913, DOI 10.1073/pnas.87.24.9913; STEPHENS JC, 1990, SCIENCE, V250, P237, DOI 10.1126/science.2218527; TSUI LC, 1990, CYTOGENET CELL GENET, V55, P122, DOI 10.1159/000133003; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WADA M, 1990, AM J HUM GENET, V46, P95; WAINWRIGHT B, 1991, Current Biology, V1, P80, DOI 10.1016/0960-9822(91)90283-3; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WATSON JD, 1990, SCIENCE, V248, P44, DOI 10.1126/science.2181665; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WATSON JD, 1990, JAMA-J AM MED ASSOC, V263, P3322, DOI 10.1001/jama.263.24.3322; WEBER JL, 1990, GENOME ANAL, V1, P159; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; WHITE R, 1988, SCIENCE, V240, P1483, DOI 10.1126/science.3287625; WHITE R, 1985, NATURE, V313, P101, DOI 10.1038/313101a0; Wood WB, 1988, NEMATODE CAENORHABDI; WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	77	29	29	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1966	1975		10.1001/jama.266.14.1966	http://dx.doi.org/10.1001/jama.266.14.1966			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895475				2022-12-28	WOS:A1991GH40600023
J	TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM				TRULOCK, EP; COOPER, JD; KAISER, LR; PASQUE, MK; ETTINGER, NA; DRESLER, CM			THE WASHINGTON-UNIVERSITY BARNES-HOSPITAL EXPERIENCE WITH LUNG TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE; EMPHYSEMA; DISEASE	Objective. - To review our experience with lung transplantation, emphasizing recipient selection, choice of procedure, functional results, and outcome. Design. - Retrospective review of patients who received lung transplants at Barnes Hospital, St Louis, Mo, between July 1, 1988, and January 31, 1991. Setting. - Washington University School of Medicine, St Louis, Mo, and Barnes Hospital, a medical school and its affiliated referral hospital, respectively. Patients. - Sixty-nine lung transplant procedures were performed in 66 recipients. Patients with clinically and physiologically severe lung disease were selected according to predetermined guidelines. Underlying diseases in the recipients included chronic obstructive pulmonary disease, alpha-1-antitrypsin deficiency emphysema, cystic fibrosis, pulmonary fibrosis, primary pulmonary hypertension, Eisenmenger's syndrome associated with an atrial septal defect, bronchiectasis, eosinophilic granuloma, and lymphangiomyomatosis. Intervention. - Double-lung, bilateral sequential, and single-lung transplantations were performed. Eight patients underwenten bloc double-lung transplantations or a modification of this procedure with separate bronchial anastomoses. Thereafter, the bilateral sequential approach to replacement of both lungs was performed in 26 patients. Thirty-two patients underwent single-lung transplantations. Main Outcome Measures. - Pulmonary function tests, arterial blood gas levels, pulmonary artery pressure, pulmonary vascular resistance, and actuarial survival. Results. - Actuarial survival at 1 year for the 66 lung transplant recipients was 79%. Actuarial survival at 1 year was 82% for the bilateral lung transplant recipients and was 90% for the single-lung transplant recipients. In patients with either restrictive or obstructive lung disease, pulmonary function tests and arterial blood gas levels improved markedly after lung transplantation. In patients with primary pulmonary hypertension or Eisenmenger's syndrome, the pulmonary artery pressure decreased and the cardiac index increased into the normal range after single-lung transplantation. Conclusions. - In carefully selected patients with end-stage lung disease, single-lung and bilateral lung transplantations can significantly improve functional capacity, with promising early actuarial survival statistics after 1 year.	WASHINGTON UNIV, SCH MED, DIV CARDIOTHORAC SURG, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	TRULOCK, EP (corresponding author), WASHINGTON UNIV, SCH MED, DIV RESP & CRIT CARE, GEN THORAC SURG SECT, BOX 8052, ST LOUIS, MO 63110 USA.		Kaiser, Larry/L-7940-2019					[Anonymous], 1988, JAMA, V259, P2258; BATES DV, 1970, NEW ENGL J MED, V282, P277, DOI 10.1056/NEJM197001292820511; COOPER JD, 1986, NEW ENGL J MED, V314, P1140; COOPER JD, 1989, AM REV RESPIR DIS, V139, P303, DOI 10.1164/ajrccm/139.2.303; COOPER JD, 1987, J THORAC CARDIOV SUR, V93, P173; EGAN TM, 1991, CHEST, V99, P867, DOI 10.1378/chest.99.4.867; ETTINGER NA, 1991, AM REV RESPIR DIS, V143, P1386, DOI 10.1164/ajrccm/143.6.1386; GROSSMAN RF, 1990, NEW ENGL J MED, V322, P727, DOI 10.1056/NEJM199003153221104; HENES G, 1991, Journal of the American College of Cardiology, V17, p372A; LEVINE SM, 1990, CHEST, V98, P1107, DOI 10.1378/chest.98.5.1107; LIMA O, 1981, J THORAC CARDIOV SUR, V82, P211; LIMA O, 1982, J THORAC CARDIOV SUR, V83, P418; MAL H, 1989, AM REV RESPIR DIS, V140, P797, DOI 10.1164/ajrccm/140.3.797; MIYOSHI S, 1990, CHEST, V97, P1130, DOI 10.1378/chest.97.5.1130; MORGAN E, 1982, J THORAC CARDIOV SUR, V84, P204; PASQUE MK, 1990, ANN THORAC SURG, V49, P785, DOI 10.1016/0003-4975(90)90023-Y; PATTERSON GA, 1988, ANN THORAC SURG, V45, P626, DOI 10.1016/S0003-4975(10)64763-7; STEVENS PM, 1970, NEW ENGL J MED, V282, P245, DOI 10.1056/NEJM197001292820504; THEODORE J, 1990, NEW ENGL J MED, V322, P772, DOI 10.1056/NEJM199003153221110; TRULOCK EP, 1989, CHEST, V96, P738, DOI 10.1378/chest.96.4.738; Veith F J, 1974, Vasc Surg, V8, P273; VEITH FJ, 1973, ANN SURG, V178, P463, DOI 10.1097/00000658-197310000-00009; Wildevuur C R, 1970, Ann Thorac Surg, V9, P489	23	67	70	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1943	1946		10.1001/jama.266.14.1943	http://dx.doi.org/10.1001/jama.266.14.1943			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895470				2022-12-28	WOS:A1991GH40600018
J	MENNELLA, JA; BEAUCHAMP, GK				MENNELLA, JA; BEAUCHAMP, GK			THE TRANSFER OF ALCOHOL TO HUMAN-MILK - EFFECTS ON FLAVOR AND THE INFANTS BEHAVIOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY EXPERIENCE; LACTATING WOMEN; BREAST-MILK; MOTHERS	Background. The amount of alcohol ingested by a breast-fed infant is only a small fraction of that consumed by its mother, but even this small amount may have an effect on the infant. We investigated whether the ingestion of alcohol by a lactating woman altered the odor of her milk and whether exposure to a small amount of alcohol in the mother's milk had immediate effects on the behavior of the infant. Methods. Twelve lactating women and their infants were tested on two days separated by an interval of one week. On each testing day, the mother expressed a small quantity of breast milk and then drank either orange juice or orange juice containing a small quantity of ethanol (0.3 g per kilogram of body weight). Additional milk samples were obtained at fixed intervals after the ingestion of the beverage and analyzed to determine their ethanol content. The samples were also evaluated by a panel of adults of determine whether any difference in the odor of the milk was detectable after alcohol ingestion. The infants were weighed before and after nursing to assess the amount of milk they ingested, and their behavior during breast-feeding was monitored by videotape. Results. Short-term alcohol consumption by lactating women significantly and uniformly increased the perceived intensity of the odor of their milk as assessed by the panel; this increase in the intensity of the odor peaked 30 minutes to 1 hour after the alcohol was consumed and decreased thereafter. The alteration in the odor of the milk closely paralleled the changes in the concentration of ethanol in the milk (mean range, 0 to 6.9 mmol per liter [0 to 32 mg per deciliter]). The infants sucked more frequently during the first minute of feedings after their mothers had consumed alcohol (67.0 +/- 6.5 sucks, as compared with 58.4 +/- 5.9 sucks for feedings after the consumption of the nonalcoholic beverage; P < 0.05), but they consumed significantly less milk (120.4 +/- 9.5 ml vs. 156.4 +/- 8.2 ml, P < 0.001) during the testing sessions in which their mothers drank the alcoholic beverage. Conclusions. Although the mechanisms underlying this reduction in milk intake remain to be elucidated, this study shows that short-term alcohol consumption by nursing mothers has an immediate effect on the sensory characteristics (odor) or their milk and the feeding behavior of their infants.			MENNELLA, JA (corresponding author), MONELL CHEM SENSES CTR,3500 MARKET ST,PHILADELPHIA,PA 19104, USA.			Mennella, Julie/0000-0002-8855-0204	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000882] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07375] Funding Source: Medline; NIDCD NIH HHS [DC00882] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bernt E, 1974, METHOD ENZYMAT AN, V3, P1499; BLUME S, 1987, JAMA-J AM MED ASSOC, V258, P2126; BUTTE NF, 1988, AM J CLIN NUTR, V47, P815, DOI 10.1093/ajcn/47.5.815; CAMPBELL RG, 1976, ANIM PROD, V23, P417, DOI 10.1017/S0003356100031536; CAPRETTA PJ, 1975, NATURE, V254, P689, DOI 10.1038/254689a0; COBO E, 1969, AM J OBSTET GYNECOL, V105, P877, DOI 10.1016/0002-9378(69)90094-5; COBO E, 1973, AM J OBSTET GYNECOL, V115, P817, DOI 10.1016/0002-9378(73)90526-7; Fazzalari F.A., 1978, COMPILATION ODOR TAS; Fildes V.A., 1986, BREASTS BOTTLES BABI; FOMON SJ, 1987, AM J CLIN NUTR, V46, P171, DOI 10.1093/ajcn/46.1.171; GALEF BG, 1973, J COMP PHYSIOL PSYCH, V83, P374, DOI 10.1037/h0034665; GALEF BG, 1972, J COMP PHYSIOL PSYCH, V78, P213, DOI 10.1037/h0032186; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KESANIEMI YA, 1974, J OBSTET GYN BR COMM, V81, P84; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; LAWTON ME, 1985, AUST NZ J OBSTET GYN, V25, P71, DOI 10.1111/j.1479-828X.1985.tb00609.x; LEGUENNEC JC, 1987, PEDIATRICS, V79, P264; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; LITTLE RE, 1984, AM J EPIDEMIOL, V120, P794, DOI 10.1093/oxfordjournals.aje.a113949; MAINARDI M, 1989, BIOL BEHAV, V14, P185; MENNELLA JA, 1991, PEDIATRICS, V88, P737; NEVILLE MC, 1988, AM J CLIN NUTR, V48, P1375, DOI 10.1093/ajcn/48.6.1375; NICLOUX M, 1899, C R SOC BIOL, V51, P982; PHILLIPS DS, 1976, PHYSIOL PSYCHOL, V4, P473; PIKKARAINEN PH, 1967, PEDIATR RES, V1, P165, DOI 10.1203/00006450-196705000-00001; Siegel S., 1956, NONPARAMETRIC STAT B; SUBRAMANIAN MG, 1988, ALCOHOL, V5, P95, DOI 10.1016/0741-8329(88)90002-X; THIRY L, 1985, LANCET, V2, P891; WALTER M, 1975, B NEW YORK ACAD MED, V51, P870	30	206	207	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					981	985		10.1056/NEJM199110033251401	http://dx.doi.org/10.1056/NEJM199110033251401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886634	Bronze			2022-12-28	WOS:A1991GH44700001
J	MASON, J				MASON, J			THE INVISIBLE-OBSTACLE RACE	NATURE			English	Editorial Material									DEPT HIST & PHILOSOPHY SCI,CAMBRIDGE CB2 3RH,ENGLAND		MASON, J (corresponding author), OPEN UNIV,DEPT CHEM,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND.							BINDMAN LJ, 1990, J PHYSIOL-LONDON, V430, pP101; CARTER R, 1990, WOMEN ENG GOOD PLACE; Darwin C., 1871, P475; MCRAE S, 1991, WOMEN ENG SCI EMPLOY; ROMANES GJ, 1887, 19TH CENTURY, V421, P654; ROSSITER MW, 1982, WOMEN SCI AM; SHUPING Y, 1985, 17TH C INT UN HIST P; Sivard R., 1985, WOMEN WORLD SURVEY; SPURLING A, 1990, 1988 90 KING COLL RE; 1986, SURVEY WOMEN MEMBERS; 1982, GIRLS PHYSICS; 1982, WOMEN MINORITIES SCI; YB ROYAL SOC LONDON; 1989, ED EMPLOYMENT ATTITU; 1991, SCIENCE, V251, P628; 1989, PLAN ADV WOMEN SCH; 1990, WOMEN TOP; 1984, GIRLS MATH; 1984, GIRLS PHYSICS; 1990, CHILDCARE EUROPEAN C	20	7	7	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					205	206		10.1038/353205a0	http://dx.doi.org/10.1038/353205a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896068				2022-12-28	WOS:A1991GF67400025
J	REGILLO, CD; SHIELDS, CL; SHIELDS, JA; EAGLE, RC; LEHR, J				REGILLO, CD; SHIELDS, CL; SHIELDS, JA; EAGLE, RC; LEHR, J			OCULAR TUBERCULOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									THOMAS JEFFERSON UNIV,WILLS EYE HOSP,DEPT PATHOL,PHILADELPHIA,PA 19107; NEW YORK EYE & EAR INFIRM,NEW YORK,NY 10003	Jefferson University; New York Eye & Ear Infirmary of Mount Sinai	REGILLO, CD (corresponding author), THOMAS JEFFERSON UNIV,WILLS EYE HOSP,OCULAR ONCOL SERV,9TH & WALNUT ST,PHILADELPHIA,PA 19107, USA.							ABRAMS J, 1982, AM J OPHTHALMOL, V94, P511; KNOX DL, 1989, RETINA, P647; ROSEN PH, 1990, EYE, V4, P486, DOI 10.1038/eye.1990.63; SCHLAEGEL T F JR, 1977, International Ophthalmology Clinics, V17, P87	4	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1490	1490		10.1001/jama.266.11.1490	http://dx.doi.org/10.1001/jama.266.11.1490			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880877				2022-12-28	WOS:A1991GE45800009
J	UDVARHELYI, IS; JENNISON, K; PHILLIPS, RS; EPSTEIN, AM				UDVARHELYI, IS; JENNISON, K; PHILLIPS, RS; EPSTEIN, AM			COMPARISON OF THE QUALITY OF AMBULATORY CARE FOR FEE-FOR-SERVICE AND PREPAID PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						QUALITY OF HEALTH CARE; AMBULATORY CARE; FEES, MEDICAL; HEALTH MAINTENANCE ORGANIZATIONS; HYPERTENSION	HEALTH-MAINTENANCE ORGANIZATIONS; RANDOMIZED CONTROLLED TRIAL; FINANCIAL INCENTIVES; HOSPITAL SERVICES; COST; HYPERTENSION; PHYSICIANS; IMPACT; HMOS	Objective: To determine whether the quality of care for common ambulatory conditions is adversely affected when physicians are provided with incentives to limit the use of health services. Design: Retrospective cohort study over a 2-year period. Setting: Four group practices that cared for both fee-for-service patients and prepaid patients within a network model health maintenance organization (HMO). Patients: Equal numbers of prepaid (HMO) and fee-for-service patients were selected by randomly choosing medical records from each group practice: 246 patients with chronic uncomplicated hypertension and 250 women without chronic diseases who received preventive care. Main Outcome Measures: Adequate hypertension control was defined as a mean blood pressure of less than 150/90. Adequate preventive care was defined as the provision of blood pressure screening, colon cancer screening, breast cancer screening, and cervical cancer screening within guidelines recommended by the 1989 U.S. Preventive Services Task Force. Resource use was measured by the annual number of visits and tests. Main Results: The adjusted relative odds of HMO patients having controlled hypertension, compared with fee-for-service patients, were 1.82 (95% Cl, 1.02 to 3.27). The relative risks of HMO patients receiving preventive care within established guidelines were 1.19 (Cl, 0.93 to 1.51) for colon cancer screening, 1.78 (Cl, 1.11 to 2.84) for annual breast examinations, 1.75 (Cl, 1.08 to 2.84) for biannual mammography, and 1.35 (Cl, 1.13 to 1.60) for Papanicolaou smears every 3 years. Prepaid patients had visit rates that were 18% to 22% higher than those of fee-for-service patients. Conclusions: In the type of network model HMO we studied, the quality and quantity of ambulatory care for HMO patients was equal to or better than that for fee-for-service patients. In this setting, the incentives for physicians to limit resource use may be offset by lack of disincentives for HMO patients to seek care.	HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B,1ST FLOOR, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; HARVARD COMMUNITY HLTH PLAN, DEPT QUAL CARE MEASUREMENT, BROOKLINE, MA 02147 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health								[Anonymous], 1989, GUIDE CLIN PREVENTIV; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CLANCY CM, 1989, ARCH INTERN MED, V149, P917, DOI 10.1001/archinte.149.4.917; EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HORNBROOK MC, 1985, MED CARE, V23, P484, DOI 10.1097/00005650-198505000-00011; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LOGERFO JP, 1975, JAMA-J AM MED ASSOC, V233, P245, DOI 10.1001/jama.233.3.245; LUFT HS, 1982, MILBANK FUND Q, V60, P268, DOI 10.2307/3349769; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1978, MILBANK FUND Q, V56, P140, DOI 10.2307/3349516; LUFT HS, 1981, HLTH MAINTENANCE ORG; LUKE RD, 1980, MED CARE, V18, P219, DOI 10.1097/00005650-198002000-00008; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; SCITOVSKY AA, 1980, MED CARE, V18, P30, DOI 10.1097/00005650-198001000-00003; SCITOVSKY AA, 1981, SOC SCI MED-MED ECON, V15, P107, DOI 10.1016/0160-7995(81)90024-1; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; WARE JE, 1986, LANCET, V1, P1017; WOLINSKY FD, 1980, MILBANK FUND Q, V58, P537, DOI 10.2307/3349806; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; 1990, MARION MANAGED CARE; 1980, GUIDELINES CANCER RE, V30, P194; 1987, WORKING GUIDELINES E; 1990, CA, V40, P77; 1988, ANN INTERN MED, V148, P1023	31	73	73	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					394	400		10.7326/0003-4819-115-5-394	http://dx.doi.org/10.7326/0003-4819-115-5-394			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863030				2022-12-28	WOS:A1991GC06500011
J	SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV				SCHWARTZ, B; SCHUCHAT, A; OXTOBY, MJ; COCHI, SL; HIGHTOWER, A; BROOME, CV			INVASIVE GROUP-B STREPTOCOCCAL DISEASE IN ADULTS - A POPULATION-BASED STUDY IN METROPOLITAN ATLANTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BACTEREMIA; POLYSACCHARIDE; INFECTIONS; COMMUNITY; VACCINE; COUNTY; WOMEN	Objective.-To define the incidence and clinical spectrum of group B streptococcus infection in adults. To characterize groups at increased risk for infection. Design.-Retrospective population-based surveillance of group B streptococcus infections occurring in adults. Patients were identified by review of microbiology records at all surveillance area hospital laboratories. Demographic and clinical data were abstracted from patient medical records. Setting.-Metropolitan Atlanta, Ga, 1982 through 1983. Patients.-We identified 70 adult patients with invasive group B streptococcus infections; 14 infections occurred in pregnant women and 56 in nonpregnant adults. Results.-The annual incidence of group B streptococcus infection in men and nonpregnant women was 2.4 cases per 100 000 population. Incidence increased with age and was higher in blacks than in whites. The case-fatality rate was 32%. Group B streptococcus was most often isolated from blood (71%) and soft tissue (16%). Common clinical presentations included skin and soft-tissue infection (36%), bacteremia without focus (34%), pneumonia (11%), arthritis (9%), and endocarditis (9%). Compared with the general population's risk of infection, the risk of infection in persons with diabetes mellitus was increased 10.5-fold (95% confidence interval [Cl], 7.8 to 14.4); in persons with cancer, it was increased 16.4-fold (95% Cl, 11.5 to 23.3). Conclusions.-Group B streptococcus infections cause serious disease in adults as well as in neonates, providing an additional rationale for vaccine development. Determining the incidence of adult disease and groups at greatest risk will help in focusing prevention efforts.	CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV BACTERIAL & MYCOT DIS,STAT SERV ACTIV,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ANTHONY BF, 1975, J INFECT DIS, V132, P561, DOI 10.1093/infdis/132.5.561; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, NEW ENGL J MED, V322, P1857, DOI 10.1056/NEJM199006283222606; BAKER CJ, 1990, INFECT DIS, P742; BAYER AS, 1976, AM J MED, V61, P498, DOI 10.1016/0002-9343(76)90329-6; DWORZACK DL, 1979, AM J MED SCI, V277, P67, DOI 10.1097/00000441-197901000-00008; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; GALLAGHER PG, 1985, AM J MED, V78, P795, DOI 10.1016/0002-9343(85)90285-2; GIBBS RS, 1981, AM J OBSTET GYNECOL, V140, P405, DOI 10.1016/0002-9378(81)90034-X; HARRIS M, 1985, NIH851468 PUBL, V8, P3; LAGERGARD T, 1990, INFECT IMMUN, V58, P687, DOI 10.1128/IAI.58.3.687-694.1990; LEDGER WJ, 1975, AM J OBSTET GYNECOL, V121, P205, DOI 10.1016/0002-9378(75)90641-9; LERNER PI, 1977, MEDICINE, V56, P457, DOI 10.1097/00005792-197711000-00001; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; PAOLETTI LC, 1990, J BIOL CHEM, V265, P18278; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; VERGHESE A, 1986, REV INFECT DIS, V8, P912; 1981, J INFECTION, V3, P385; 1985, DISEASES IMPORTANCE, V1, P423	22	177	181	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1112	1114		10.1001/jama.266.8.1112	http://dx.doi.org/10.1001/jama.266.8.1112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865545				2022-12-28	WOS:A1991GB97500035
J	OSTEEN, A				OSTEEN, A			LICENSURE AND INTERNATIONAL MEDICAL GRADUATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											OSTEEN, A (corresponding author), AMER MED ASSOC,OFF PHYSICIAN CREDENTIALS & QUALICAT,CHICAGO,IL 60610, USA.							1988, JAMA-J AM MED ASSOC, V259, P1994; 1991, US MED LICENSURE STA	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					956	958						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870224				2022-12-28	WOS:A1991GB20500007
J	LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA				LANGE, C; JUGEL, A; WALTER, J; NOYERWEIDNER, M; TRAUTNER, TA			PSEUDO DOMAINS IN PHAGE-ENCODED DNA METHYLTRANSFERASES	NATURE			English	Article							TARGET-RECOGNIZING DOMAINS; BACILLUS-SUBTILIS PHAGES; SEQUENCE; ORGANIZATION; RESTRICTION; MOTIFS; SPR	5-Cytosine-DNA-methyltransferases, which are found in many organisms ranging from bacteriophages to mammals, transfer a methyl group from S-adenosylmethionine to the carbon-5 of a cytosine residue in specific DNA target sequences 1. Some phage-encoded methyltransferases methylate more than one sequence: these enzymes contain several independent target-recognizing domains each responsible for recognizing a different site. The amino-acid sequences of these multispecific methyltransferases reveal that some enzymes in addition carry domains that do not contribute to the enzymes' methylation potential, but strongly resemble previously identified target-recognizing domains. Here we show that introducing defined amino-acid alterations into these inactive domains endows these enzymes with additional methylation specificities. Gel retardation analysis demonstrates that these novel methylation specificities correlate with the acquisition of additional DNA-binding potential of the proteins.			LANGE, C (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.							BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BEHRENS B, 1987, EMBO J, V6, P1137, DOI 10.1002/j.1460-2075.1987.tb04869.x; BUHK HJ, 1984, GENE, V29, P51; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANGE C, 1991, GENE, V100, P213, DOI 10.1016/0378-1119(91)90369-M; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RATCLIFF SW, 1979, MOL GEN GENET, V168, P165, DOI 10.1007/BF00431442; RAZIN A, 1984, DNA METHYLATION BIOC; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRANBETCKE A, 1986, GENE, V42, P89, DOI 10.1016/0378-1119(86)90153-8; TRAUTNER TA, 1988, NUCLEIC ACIDS RES, V16, P6649, DOI 10.1093/nar/16.14.6649; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x	16	27	27	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					645	648		10.1038/352645a0	http://dx.doi.org/10.1038/352645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865925				2022-12-28	WOS:A1991GB21100064
J	SOOTHILL, PW; AJAYI, R; CAMPBELL, S; GIBBS, J; CHANDRAN, R; GIBB, D; NICOLAIDES, KH				SOOTHILL, PW; AJAYI, R; CAMPBELL, S; GIBBS, J; CHANDRAN, R; GIBB, D; NICOLAIDES, KH			EFFECT OF A FETAL SURVEILLANCE UNIT ON ADMISSION OF ANTENATAL PATIENTS TO HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To analyse the effect of a fetal surveillance unit, which undertakes a wide range of maternal and fetal tests on an outpatient or inpatient basis, on the number and length of antenatal hospital admissions. Design-A comparison of the number and length of antenatal admissions six months before and five months after the opening of the unit on 1 July 1990. Main outcome measures-Admission rate, antenatal bed occupancy, and interval from admission to discharge or delivery. Results-The antenatal bed occupancy rate fell by 22% from 174/100 deliveries during the six months before the unit was opened to 136/100 deliveries in the five months after it was opened. The difference in distribution of lengths of admission after the unit was opened from before was highly significant (Mann-Whitney test = 5.14, n = 752 and 679; p < 0.0001), and this was due to shorter intervals from admission to discharge and from admission to delivery. In contrast, the antenatal admission rate did not change significantly (50/100 deliveries v 49/100 deliveries). There was no significant change in the stillbirth rate (6/1294 births v 8/1372 births; difference between rates = 0.0012, 95% confidence interval -0.0043 to 0.0067). Conclusion-Obstetricians are more prepared to discharge antenatal patients from hospital and, similarly, admit patients for delivery rather than for assessment if the patients are reliably monitored on an outpatient basis. If this change in practice is sustained substantial financial and social benefits will result as well as improvements in organisation, audit, teaching, and research.			SOOTHILL, PW (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT OBSTET & GYNAECOL,FETAL SURVEILLANCE UNIT,LONDON SE5 8RX,ENGLAND.		Soothill, Peter/D-2814-2009	Nicolaides, Kypros/0000-0003-1266-0711				CAMPBELL S, 1983, LANCET, V1, P675; CROWTHER CA, 1989, BRIT J OBSTET GYNAEC, V96, P850, DOI 10.1111/j.1471-0528.1989.tb03327.x; DAWES GS, 1982, BRIT J OBSTET GYNAEC, V89, P276, DOI 10.1111/j.1471-0528.1982.tb04696.x; DEBONO M, 1990, J PERINAT MED, V18, P77, DOI 10.1515/jpme.1990.18.2.77; DRUZIN ML, 1989, CLIN PERINATOL, V16, P627, DOI 10.1016/S0095-5108(18)30625-0; MANNING FA, 1990, OBSTET GYN CLIN N AM, V17, P147; MEDDIS R, 1980, BRIT J MATH STAT PSY, V33, P84, DOI 10.1111/j.2044-8317.1980.tb00779.x; TRUDINGER B, 1988, SEMINARS PERINATOLOG, V11, P311	8	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					269	271		10.1136/bmj.303.6797.269	http://dx.doi.org/10.1136/bmj.303.6797.269			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888925	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100016
J	CROW, YJ; ALBERTI, KGMM; PARKIN, JM				CROW, YJ; ALBERTI, KGMM; PARKIN, JM			INSULIN-DEPENDENT DIABETES IN CHILDHOOD AND MATERIAL DEPRIVATION IN NORTHERN ENGLAND, 1977-86	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CLASS; MELLITUS; IDDM	Objective - To determine the incidence of insulin dependent diabetes in the Northern region of England in children less than 16 years old in the period 1977 to 1986 and to relate the incidence data to an index of deprivation. Design - Retrospective analysis of hospital case records identified from the regional health authority's computer; validation of the primary source with hospital clinic registers and community paediatric registers. Setting - Northern region, excluding South Cumbria District Health Authority (659 300 children under 16 in 1981). Patients - All children diagnosed with insulin dependent diabetes before the age of 16 and resident in the region at time of diagnosis. Main outcome measures - Incidence rates for the 10 year period and analysis of incidence rates within categories of deprivation. Results - 919 incident cases were identified. The validation procedure covered 54% of all cases identified and gave 95% completeness of ascertainment. The average annual incidence over the 10 year period was 14.8/100 000 for girls and 13.4/100 000 for boys. The annual incidence for the most and least deprived areas of the region was 18.7/100 000 (95% confidence interval 16.2 to 21.5) for boys and 7/100 000 (5.6 to 8.8) for girls. There was a highly significant trend (p < 0.001) of decreasing incidence with decreasing level of deprivation. Conclusions - In the north of England the incidence of childhood diabetes is related to material deprivation.			CROW, YJ (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,HUMAN DIABET & METAB RES CTR,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Crow, Yanick J/N-6120-2014	Crow, Yanick J/0000-0001-7211-7564				AKERBLOM HK, 1985, DIABETES CARE, V8, P10, DOI 10.2337/diacare.8.1.S10; ARMITAGE P, 1987, STATISTICAL METHODS, P372; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; HILL AB, 1984, SHORT TXB MED STATIS, P168; LAPORTE RE, 1981, AM J EPIDEMIOL, V114, P379, DOI 10.1093/oxfordjournals.aje.a113205; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P337; SIEMIATYCKI J, 1988, DIABETES, V37, P1096, DOI 10.2337/diabetes.37.8.1096; STEWARTBROWN S, 1983, BRIT MED J, V286, P1855, DOI 10.1136/bmj.286.6381.1855; Townsend PP., 1988, HLTH DEPRIVATION INE; WILSON RM, 1986, JAMA-J AM MED ASSOC, V256, P877, DOI 10.1001/jama.256.7.877; 1981, CENSUS 1981; 1990, DIABETES, V39, P858; 1987, BMJ, V295, P479	14	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					158	160		10.1136/bmj.303.6795.158	http://dx.doi.org/10.1136/bmj.303.6795.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878639	Green Published, Bronze			2022-12-28	WOS:A1991FX57800021
J	GOVES, JR; DAVIES, T; REILLY, T				GOVES, JR; DAVIES, T; REILLY, T			COMPUTERIZATION OF PRIMARY CARE IN WALES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To obtain information about the computerisation of general practice in Wales, and to enable more effective planning of educational provision for doctors and other primary health care workers. Design-Postal questionnaire sent to all general practices in Wales. Subjects-553 general practices, of which 401 (73% replied). Results -The level of computerisation varied from 11 (85%) of practices in Powys Family Health Services Authority to 22 (40%) in Mid Glamorgan. Less than half of practices had a computer in only two authorities. The commonest uses of the computer were for patient registration (208 practices), repeat prescribing (180), call and recall of patients (165), and partial clinical records (122). The main suppliers were VAMP (78 practices), AAH Meditel (46), and AMC (23). 102 of 226 practices with a computer had a terminal on each doctor's desk. Just 33 practices had full patient notes on computer and 51 had modems for electronic communication. Conclusion-Mechanisms to encourage greater and more sophisticated use of computers and information technology need to be explored.			GOVES, JR (corresponding author), UNIV COLL CARDIFF,DEPT POSTGRAD STUDIES,CARDIFF CF4 4XN,S GLAM,WALES.							GROVES JR, 1991, SURVEY GENERAL MED P; 1989, COMPUTING SURVEY 199	2	7	7	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					93	94		10.1136/bmj.303.6794.93	http://dx.doi.org/10.1136/bmj.303.6794.93			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860010	Green Published, Bronze			2022-12-28	WOS:A1991FW58600021
J	CRUMP, BJ; CUBBON, JE; DRUMMOND, MF; HAWKES, RA; MARCHMENT, MD				CRUMP, BJ; CUBBON, JE; DRUMMOND, MF; HAWKES, RA; MARCHMENT, MD			FUNDHOLDING IN GENERAL-PRACTICE AND FINANCIAL RISK	BRITISH MEDICAL JOURNAL			English	Article								Objective - To estimate the financial effect of random yearly variations in need for services on fundholding practices with various list sizes. Design - A simulation model was derived using historical data on general practitioner referrals for the 113 surgical procedures covered by the general practitioner fund, combined with data on the hospital prices for those procedures. Patients - Resident population of Central Birmingham Health Authority. Main outcome measures - Expected expenditure on the relevant surgical procedures for the whole district and for practices with list sizes of 9000, 12 000, 15 000, 18 000, 21 000, or 24 000 for each of 100 simulated years. Results - By using average hospital prices for the West Midlands region the mean (SD) annual expenditure for the 179 400 residents was 4 832 471 pounds (87 149 pounds); the random variation between the 5th and 95th most expensive years was 5.7% of the mean cost. For a practice with a list size of 9000 the values were 244 891 pounds (18 349 pounds), with a variation of 27.5%. With a list size of 24 000 the values were 652 762 pounds (32 512 pounds), with a variation of 15.3%. Conclusions - Random variations in need for inpatient services will have a significant financial impact on the practice fund. The problem will be particularly great for smaller practices. Additional measures are required to ensure that the scheme is not undermined and that the potential benefits are secured.	CENT BIRMINGHAM HLTH AUTHOR,DEPT PUBL HLTH MED,BIRMINGHAM B15 2TZ,ENGLAND; UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; SE STAFFORDSHIRE HLTH AUTHOR,COMMUNITY & MENTAL HLTH UNIT,BURTON TRENT,ENGLAND	University of York - UK								DRUMMOND M, 1990, BRIT MED J, V301, P1288, DOI 10.1136/bmj.301.6764.1288; HALL C, 1991, INDEPENDENT     0503, P2; SMITH R, 1989, BRIT MED J, V298, P1166; 1989, FUNDING GENERAL PRAC	4	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1582	1584		10.1136/bmj.302.6792.1582	http://dx.doi.org/10.1136/bmj.302.6792.1582			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855045	Bronze, Green Published			2022-12-28	WOS:A1991FU54900029
J	SWEET, JG				SWEET, JG			FARE WELL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	1991	265	12					1518	1518		10.1001/jama.265.12.1518	http://dx.doi.org/10.1001/jama.265.12.1518			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC604	1888351				2022-12-28	WOS:A1991FC60400007
J	AKHTAR, M; GARAN, H; LEHMANN, MH; TROUP, PJ				AKHTAR, M; GARAN, H; LEHMANN, MH; TROUP, PJ			SUDDEN CARDIAC DEATH - MANAGEMENT OF HIGH-RISK PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; MALIGNANT VENTRICULAR ARRHYTHMIAS; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; AUTOMATIC DEFIBRILLATOR; PROGRAMMED STIMULATION; CLINICAL-EXPERIENCE; ACUTE-ISCHEMIA; FOLLOW-UP; ARREST	Sudden cardiac death remains a leading cause of death in the United States, accounting for more than 350 000 deaths each year, and the survival rate of victims remains low. Most survivors face a significant risk for recurrence. The typical substrate is chronic-abnormal myocardium with fibrosis (often from previous myocardial infarction) and left ventricular dysfunction. Acute triggers for sudden cardiac death are primarily electrical, ischemic, metabolic, neurohormonal, and pharmacologic. In most electrocardiographically documented cases of sudden cardiac death, the trigger-substrate interaction appears to result in ventricular tachycardia and fibrillation. After initial resuscitation, survivors need a thorough cardiovascular evaluation, including definition of coronary anatomy, left ventricular function, and wall-motion abnormalities, as well as an electrophysiologic evaluation. An attempt must be made to determine what each survivor's correctable triggers are. Management should address all reversible triggers, such as acute ischemia and electrolyte abnormalities, and should include modifying or correcting the arrhythmogenic substrate. Empiric antiarrhythmic therapy offers no advantage in such modification. Pharmacologic therapy with antiarrhythmic drugs should be guided by an objective therapeutic endpoint, which is best accomplished through the use of programmed ventricular stimulation and serial electrophysiologic studies. Other therapeutic options include surgical suppression of ventricular tachycardia and implantation of a cardioverter defibrillator.	VET ADM MED CTR, MED SERV, MARTINEZ, CA 94553 USA; UNIV CALIF DAVIS, SCH MED, DEPT MED, DAVIS, CA 95616 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Davis								ANDERSON KP, 1984, J CARDIOVASC PHARM, V6, pS498; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BABA N, 1975, CIRCULATION, V52, P53; BACH S M JR, 1989, Journal of the American College of Cardiology, V13, p65A; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; BENDITT DG, 1983, J AM COLL CARDIOL, V2, P418, DOI 10.1016/S0735-1097(83)80267-8; BERGER MD, 1988, CIRCULATION, V78, P885, DOI 10.1161/01.CIR.78.4.885; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1987, AM J CARDIOL, V59, pE2, DOI 10.1016/0002-9149(87)90195-0; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; CECCHI F, 1989, J AM COLL CARDIOL, V13, P1283, DOI 10.1016/0735-1097(89)90302-1; COBB LA, 1975, CIRCULATION, V52, P223; COOPER DK, 1986, CLIN PROG ELECTROPHY, V4, P306; COOPER WD, 1984, EUR HEART J, V5, P464, DOI 10.1093/oxfordjournals.eurheartj.a061692; COX JL, 1989, CIRCULATION, V79, P163; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DIXON EG, 1987, CIRCULATION, V76, P1176, DOI 10.1161/01.CIR.76.5.1176; ELSHERIF N, 1975, CIRCULATION, V51, P1003, DOI 10.1161/01.CIR.51.6.1003; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; FRIEDMAN M, 1975, CIRCULATION, V52, P34; FRIEDMAN M, 1973, JAMA-J AM MED ASSOC, V225, P1319; FURUKAWA T, 1989, CIRCULATION, V80, P599, DOI 10.1161/01.CIR.80.3.599; GABRY MD, 1987, J AM COLL CARDIOL, V9, P1349, DOI 10.1016/S0735-1097(87)80477-1; GARAN H, 1988, J AM COLL CARDIOL, V11, P603, DOI 10.1016/0735-1097(88)91538-0; GEDDES LA, 1971, MED BIOL ENG, V9, P185, DOI 10.1007/BF02474814; GRABOYS TB, 1986, AM J CARDIOL, V58, P59, DOI 10.1016/0002-9149(86)90241-9; HARGROVE WC, 1989, CIRCULATION, V79, P178; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HORNING RJ, 1982, PROG BATTERIES SOLAR, V4, P97; HOROWITZ LN, 1988, PROGR CARDIOLOGY, P109; HOROWITZ LN, 1984, TACHYCARDIAS, P283; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JOSEPHSON ME, 1980, AM J CARDIOL, V46, P948, DOI 10.1016/0002-9149(80)90350-1; KAISER GA, 1975, SURGERY, V78, P749; KALBFLEISCH KR, 1989, AM J CARDIOL, V64, P199, DOI 10.1016/0002-9149(89)90457-8; KEHOE RF, 1987, J AM COLL CARDIOL, V9, pA108; KELLY P, 1990, J AM COLL CARDIOL, V15, P267, DOI 10.1016/S0735-1097(10)80046-4; KELLY PA, 1988, J AM COLL CARDIOL, V11, P1278, DOI 10.1016/0735-1097(88)90292-6; KEMPF FC, 1984, AM J CARDIOL, V53, P1577, DOI 10.1016/0002-9149(84)90582-4; Kleimbaum DG., 1982, EPIDEMIOLOGIC RES PR, P96; KULLER L, 1972, ARCH INTERN MED, V129, P714, DOI 10.1001/archinte.129.5.714; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; LAMPERT S, 1988, AM J CARDIOL, V61, P791, DOI 10.1016/0002-9149(88)91068-5; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LEHMANN MH, 1987, POSTGRAD MED, V82, P36, DOI 10.1080/00325481.1987.11700052; LIBERTHSON RR, 1974, CIRCULATION, V49, P790, DOI 10.1161/01.CIR.49.5.790; LIBERTHSON RR, 1979, CIRCULATION, V59, P748, DOI 10.1161/01.CIR.59.4.748; LIE JT, 1975, CIRCULATION, V52, P41; MANOLIS AS, 1989, AM HEART J, V118, P445, DOI 10.1016/0002-8703(89)90256-1; MIROWSKI M, 1970, ARCH INTERN MED, V126, P158, DOI 10.1001/archinte.126.1.158; MIROWSKI M, 1980, NEW ENGL J MED, V303, P322, DOI 10.1056/NEJM198008073030607; MORADY F, 1983, AM J CARDIOL, V51, P85, DOI 10.1016/S0002-9149(83)80016-2; MORADY F, 1984, J AM COLL CARDIOL, V4, P39, DOI 10.1016/S0735-1097(84)80316-2; MYERBURG RJ, 1989, AM J CARDIOL, V63, P1512, DOI 10.1016/0002-9149(89)90017-9; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; MYERBURG RJ, 1984, CIRCULATION, V70, P538, DOI 10.1161/01.CIR.70.4.538; MYERBURG RJ, 1989, J AM COLL CARDIOL, V14, P508, DOI 10.1016/0735-1097(89)90209-X; MYERBURG RJ, 1978, AM J CARDIOL, V41, P365, DOI 10.1016/0002-9149(78)90234-5; MYERBURG RJ, 1988, HEART DISEASE TXB CA, P742; NEWMAN D, 1989, Journal of the American College of Cardiology, V13, p65A; NEWMAN WP, 1981, LAB INVEST, V44, P496; NIAZI I, 1988, AM HEART J, V115, P830, DOI 10.1016/0002-8703(88)90886-1; NIAZI I, 1988, CIRCULATION S2, V78, P71; NORDREHAUG JE, 1985, CIRCULATION, V71, P645, DOI 10.1161/01.CIR.71.4.645; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PATTERSON E, 1982, AM J CARDIOL, V50, P1414, DOI 10.1016/0002-9149(82)90484-2; POLL DS, 1986, AM J CARDIOL, V58, P992, DOI 10.1016/S0002-9149(86)80025-X; PYCHA C, 1986, PSYCHOSOMATICS, V27, P841, DOI 10.1016/S0033-3182(86)72589-9; REICHENBACH DD, 1975, CIRCULATION, V52, P60; RITCHIE JL, 1985, AM J CARDIOL, V55, P645, DOI 10.1016/0002-9149(85)90129-8; RODEN DM, 1986, J AM COLL CARDIOL, V8, pA73, DOI 10.1016/S0735-1097(86)80032-8; ROY D, 1983, AM J CARDIOL, V52, P969, DOI 10.1016/0002-9149(83)90514-3; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; RUSKIN JN, 1983, NEW ENGL J MED, V309, P1302, DOI 10.1056/NEJM198311243092107; SAKSENA S, 1988, JAMA-J AM MED ASSOC, V259, P69, DOI 10.1001/jama.259.1.69; SCHUDER JC, 1970, CARDIOVASC RES, V4, P497, DOI 10.1093/cvr/4.4.497; SCHUDER JC, 1984, CARDIOVASC RES, V18, P419, DOI 10.1093/cvr/18.7.419; SCHUGER CD, 1988, PACE, V11, P1456, DOI 10.1111/j.1540-8159.1988.tb04995.x; SEBULSKY AM, 1989, RACE DEV IMPLANTABLE; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; SONG SL, 1989, PACE, V12, P1555, DOI 10.1111/j.1540-8159.1989.tb06163.x; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; THOMAS AC, 1988, PACE, V11, P2053, DOI 10.1111/j.1540-8159.1988.tb06349.x; TRESCH DD, 1981, CIRCULATION, V64, P1; TROUP P, 1989, PACE, V12, P688; TROUP PJ, 1989, 24TH P AAMI ANN M EX, P92; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; VELTRI E, 1989, INTERVENTIONAL CARDI; VISBISKY M, 1989, J POWER SOURCES, V26, P185, DOI 10.1016/0378-7753(89)80026-6; WARREN J, 1986, PACE, V9, P1079, DOI 10.1111/j.1540-8159.1986.tb06673.x; WEAVER WD, 1976, CIRCULATION, V54, P895, DOI 10.1161/01.CIR.54.6.895; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1984, CIRCULATION, V69, P766, DOI 10.1161/01.CIR.69.4.766; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; WIT AL, 1975, CIRCULATION, V52, P96; WOLF F, 1979, HEART DISEASE REHABI, P120; ZHEUTLIN T, 1984, CIRCULATION, V70, P399; ZIPES DP, 1984, NEW ENGL J MED, V311, P485, DOI 10.1056/NEJM198408233110801	98	46	47	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1991	114	6					499	512		10.7326/0003-4819-114-6-499	http://dx.doi.org/10.7326/0003-4819-114-6-499			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB640	1888350				2022-12-28	WOS:A1991FB64000011
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; KATO, I; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND GASTRIC-CARCINOMA AMONG JAPANESE-AMERICANS IN HAWAII	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; ANTIBODY PREVALENCE; ATROPHIC GASTRITIS; PEPTIC-ULCER; CANCER; POPULATIONS; DISEASE; ASSOCIATION; RISKS; MEN	Background. Helicobacter pylori are gram-negative spiral bacteria that are associated with chronic gastritis, a known precursor of gastric carcinoma. Persons at high risk for gastric carcinoma have been shown to have a high prevalence of H. pylori infection. Methods. We studied the relation of H. pylori infection and gastric carcinoma in a cohort of Japanese American men living in Hawaii. The 5908 men were enrolled and examined from 1967 to 1970. By 1989, 109 cases of pathologically confirmed gastric carcinoma had been identified. The stored serum of each patient with gastric carcinoma and of each matched control subject was tested for the presence of serum IgG antibody to H. pylori. Results. Ninety-four percent of the men with gastric carcinoma and 76 percent of the matched control subjects had a positive test for H. pylori antibodies, for an odds ratio of 6.0 (95 percent confidence interval, 2.1 to 17.3). As the level of antibody to H. pylori increased, there was a progressive increase in the risk of gastric carcinoma (P for trend = 0.0009). The association was strong even for men in whom the diagnosis was made 10 or more years after the serum sample was obtained (odds ratio, 10.5; 95 percent confidence interval, 2.5 to 44.8). Conclusions. Infection with H. pylori is strongly associated with an increased risk of gastric carcinoma. However, most persons infected with H. pylori will never have gastric carcinoma. Therefore, other factors that increase the risk of gastric carcinoma among persons infected with H. pylori need to be identified.	VANDERBILT UNIV,MED CTR,SCH MED,DIV INFECT DIS,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	NOMURA, A (corresponding author), KUAKINI MED CTR,JAPAN HAWAII CANC STUDY,347 N KUAKINI ST,HONOLULU,HI 96817, USA.		Perez, Guillermo Perez/AAJ-3761-2020	Perez Perez, Guillermo/0000-0002-0131-5798	NCI NIH HHS [R01-CA-33644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; [Anonymous], 1983, LANCET, V1, P1273; BEAHRS OH, 1978, MANUAL STAGING CANCE, P71; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1990, NEW ANTIBACTERIAL ST, P143; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; BUCK GE, 1986, J INFECT DIS, V153, P664, DOI 10.1093/infdis/153.4.664; CORREA P, 1983, CANCER SURV, V2, P437; CORREA P, 1990, CANCER-AM CANCER SOC, V66, P2569, DOI 10.1002/1097-0142(19901215)66:12<2569::AID-CNCR2820661220>3.0.CO;2-I; CORREA P, 1973, JNCI-J NATL CANCER I, V51, P1449, DOI 10.1093/jnci/51.5.1449; DOLL R, 1970, CANCER INCIDENCE 5 C, V2; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MAI EUH, 1991, J CLIN INVEST, V87, P894; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MEGRAUD F, 1989, J CLIN MICROBIOL, V27, P1870; MORRIS AJ, 1991, ANN INTERN MED, V114, P662, DOI 10.7326/0003-4819-114-8-662; MUIR CS, 1987, IARC SCI PUBLICATION, V88; Nomura A, 1982, CANCER EPIDEMIOL, P624; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, IN PRESS GASTROENTER; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; SIURALA M, 1985, SCAND J GASTROENTERO, V20, P69, DOI 10.3109/00365528509103939; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; STRICKLAND RG, 1973, AM J DIG DIS, V18, P426, DOI 10.1007/BF01071995; TALLEY NJ, IN PRESS J NATL CANC; TALLEY NJ, 1990, REV ESP ENFERM DIG S, V78, pS7; TAYLOR DN, IN PRESS EPIDEMIOL R; WALKER IR, 1971, GUT, V12, P906, DOI 10.1136/gut.12.11.906; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YOUNG JL, 1981, NCI MONOGRAPH, V57; 1991, CANCER FACTS FIGURES, P3	51	1638	1682	2	50	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1132	1136		10.1056/NEJM199110173251604	http://dx.doi.org/10.1056/NEJM199110173251604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891021	Bronze			2022-12-28	WOS:A1991GK53800004
J	TURELLI, M; HOFFMANN, AA				TURELLI, M; HOFFMANN, AA			RAPID SPREAD OF AN INHERITED INCOMPATIBILITY FACTOR IN CALIFORNIA DROSOPHILA	NATURE			English	Article							LONG-DISTANCE MIGRATION; CYTOPLASMIC INCOMPATIBILITY; UNIDIRECTIONAL INCOMPATIBILITY; REPRODUCTIVE INCOMPATIBILITY; NATURAL-POPULATIONS; MITOCHONDRIAL-DNA; GENE FLOW; SIMULANS; MELANOGASTER; POLYMORPHISM	IN Drosophila simulans in California, an inherited cytoplasmic incompatibility factor reduces egg hatch when infected males mate with uninfected females 1-7. The infection is spreading at a rate of more than 100 km per year; populations in which the infection was rare have become almost completely infected within three years. Analyses of the spread using estimates of selection in the field suggest dispersal distances far higher than those found by direct observation of flies. Hence, occasional long-distance dispersal, possibly coupled with local extinction and recolonization, may be important to the dynamics. Incompatibility factors that can readily spread through natural populations may be useful for population manipulation and important as a post-mating isolating mechanism.	UNIV CALIF DAVIS, CTR POPULAT BIOL, DAVIS, CA 95616 USA; LA TROBE UNIV, DEPT GENET & HUMAN VARIAT, BUNDOORA, VIC 1083, AUSTRALIA	University of California System; University of California Davis; La Trobe University	TURELLI, M (corresponding author), UNIV CALIF DAVIS, DEPT GENET, DAVIS, CA 95616 USA.		Hoffmann, Ary/R-2972-2019; Hoffmann, Ary/C-2961-2011	Hoffmann, Ary/0000-0001-9497-7645; 				BARTON NH, 1979, HEREDITY, V43, P341, DOI 10.1038/hdy.1979.87; BINNINGTON KC, 1989, J INVERTEBR PATHOL, V54, P344, DOI 10.1016/0022-2011(89)90118-3; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.2307/2406138; COYNE JA, 1987, AM NAT, V130, P70, DOI 10.1086/284698; COYNE JA, 1982, AM NAT, V119, P589, DOI 10.1086/283936; FINE PEM, 1978, J INVERTEBR PATHOL, V31, P10, DOI 10.1016/0022-2011(78)90102-7; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; FLEURIET A, 1988, EVOL BIOL, V23, P1; HALE LR, 1990, EVOLUTION, V44, P1383, DOI 10.1111/j.1558-5646.1990.tb05241.x; HOFFMANN AA, 1988, GENETICS, V119, P435; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOFFMANN AA, 1990, GENETICS, V126, P933; HOFFMANN AA, 1988, ENTOMOL EXP APPL, V48, P61, DOI 10.1007/BF00343386; JONES JS, 1981, GENETICS, V98, P157; JONES JS, 1987, AM NAT, V130, P83, DOI 10.1086/284699; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; LEU SJC, 1989, J INVERTEBR PATHOL, V54, P248, DOI 10.1016/0022-2011(89)90035-9; LOUIS C, 1989, J INVERTEBR PATHOL, V54, P39, DOI 10.1016/0022-2011(89)90137-7; Model Gressel J., 1986, PESTICIDE RESISTANCE, P54; Murray J. D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; NIGRO L, 1990, GENETICS, V125, P551; NODA H, 1984, ENTOMOL EXP APPL, V35, P263, DOI 10.1007/BF00369142; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; SKINNER SW, 1985, GENETICS, V109, P745; SLATKIN M, 1985, ANNU REV ECOL SYST, V16, P393, DOI 10.1146/annurev.ecolsys.16.1.393; STEVENS L, 1989, J INVERTEBR PATHOL, V53, P78, DOI 10.1016/0022-2011(89)90076-1; Subbarao S.K., 1982, P313; TURELLI M, 1986, DROS INFORM SERV, V63, P131	29	484	496	0	47	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 3	1991	353	6343					440	442		10.1038/353440a0	http://dx.doi.org/10.1038/353440a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896086				2022-12-28	WOS:A1991GH60600060
J	DUKE, RC; SPEIDEL, JJ				DUKE, RC; SPEIDEL, JJ			WOMENS REPRODUCTIVE HEALTH - A CHRONIC CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									POPULAT CRISIS COMM,1120 19TH ST NW,SUITE 550,WASHINGTON,DC 20036									ARAL SO, 1991, SCI AM, V2, P65; CONLY SR, 1991, FAMILY PLANNING CHIL; Gold RB, 1990, ABORTION WOMENS HLTH; GRANT JP, 1991, STATE WORLDS CHILDRE, P5; HAUB C, 1991, 1991 WORLD POPULATIO; HENSHAW SK, 1990, INDUCED ABORTION WOR; JACOBSON JL, 1991, 102 WORLDW I WORLDW; PETROSBARVAZIAN A, 1990, WORLD HLTH       NOV, P2; RINEHART MA, 1984, POPUL REP J, V12, P659; ROYSTON E, 1991, METHODOLOGICAL ISSUE, P23; STARRS A, 1987, PREVENTING TRAGEDY M, P13; 1986, MATERNAL MORTALITY R; 1990, 23 POP CRIS COMM BRI	13	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1846	1847						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890715				2022-12-28	WOS:A1991GG55100042
J	NUSSLEINVOLHARD, C				NUSSLEINVOLHARD, C			FROM EGG TO ORGANISM - STUDIES ON EMBRYONIC PATTERN-FORMATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BICOID PROTEIN; DROSOPHILA; POLARITY				NUSSLEINVOLHARD, C (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35-111,W-7400 TUBINGEN,GERMANY.							DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1848	1849		10.1001/jama.266.13.1848	http://dx.doi.org/10.1001/jama.266.13.1848			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890716				2022-12-28	WOS:A1991GG55100043
J	BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ				BAVINCK, JNB; VERMEER, BJ; VANDERWOUDE, FJ; VANDENBROUCKE, JP; SCHREUDER, GMT; THOROGOOD, J; PERSIJN, GG; CLAAS, FHJ			RELATION BETWEEN SKIN-CANCER AND HLA ANTIGENS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SURVIVAL; INFECTION; WARTS; DNA	Background. Recipients of renal allografts are at an increased risk for skin cancer. It is also known that recipients who are homozygous for HLA antigens are at an increased risk for certain cancers, as are those who are mismatched with their donors for these antigens. In a case-control study we assessed the relation between skin cancer in renal-transplant recipients and HLA homozygosity and mismatching. Methods. Of 764 patients who received renal transplants between 1966 and 1988, 66 had squamous-cell carcinoma or basal-cell carcinoma of the skin after transplantation. HLA homozygosity was assessed in all 66 recipients, and HLA mismatching in 39; the results were compared with those in 124 recipients without skin cancer. We also investigated the relation between skin cancer and the use of immunosuppressive drugs. In separate case-control analyses we investigated the influence of exposure to the sun and keratotic skin lesions on the risk of skin cancer. Results. The risk of squamous-cell carcinoma was increased in recipients mismatched for HLA-B antigens; the relative risks were 2.6 (95 percent confidence interval, 1.1 to 6.5) and 5.0 (95 percent confidence interval, 1.3 to 19.0) with mismatching for one and two antigens, respectively, as compared with no mismatching. Mismatching for HLA-A or HLA-DR antigens had no effect on the risk of squamous-cell carcinoma, and there was no association between mismatches at any of the HLA loci and the occurrence of basal-cell carcinoma. The total doses of azathioprine and prednisone were not associated with the occurrence of skin cancer or with HLA matching. Exposure to sunlight and keratotic ski in lesions were strongly associated with skin cancer but not with HLA mismatching. Homozygosity for HLA-DR was more frequent among the patients with squamous-cell carcinoma (relative risk, 2.5; 95 percent confidence interval, 0.95 to 4.6) and among patients with 100 or more keratotic skin lesions (relative risk, 4.8; 95 percent confidence interval, 1.5 to 15.1). Conclusions. HLA-B mismatching is significantly associated with the risk of squamous-cell carcinoma in renal-transplant recipients, as is HLA-DR homozygosity. An indirect effect on the level of immunosuppression does not appear to explain these findings, nor does exposure to sunlight or the number of keratotic skin lesions account for this observation.	LEIDEN UNIV HOSP, DEPT NEPHROL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT CLIN EPIDEMIOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT IMMUNOHEMATOL, 2333 AA LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, BLOOD BANK, 2333 AA LEIDEN, NETHERLANDS; EUROTRANSPLANT FDN, LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC	BAVINCK, JNB (corresponding author), LEIDEN UNIV HOSP, DEPT DERMATOL, RIJNSBURGERWEG 10, 2333 AA LEIDEN, NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BARR BBB, 1989, LANCET, V1, P124; BAVINCK JNB, 1990, NEW ENGL J MED, V323, P1350; BOYLE J, 1984, LANCET, V1, P702; CARPENTER CB, 1989, CONTEMP ISS NEPHROL, V19, P1; Dausset J., 1982, CANCER SURV, V1, P119; DYER PA, 1989, TRANSPLANTATION, V48, P131, DOI 10.1097/00007890-198907000-00030; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; FLIEDNER VEV, 1980, TISSUE ANTIGENS, V16, P399; GASSENMAIER A, 1986, ARCH DERMATOL RES, V278, P219, DOI 10.1007/BF00412927; GERKINS VR, 1974, JNCI-J NATL CANCER I, V52, P1909, DOI 10.1093/jnci/52.6.1909; GUPTA AK, 1986, ARCH DERMATOL, V122, P1288, DOI 10.1001/archderm.122.11.1288; HARDIE IR, 1980, SURGERY, V87, P177; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; Henny F C, 1986, Nephrol Dial Transplant, V1, P44; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KOOTTE AMM, 1988, NEPHROL DIAL TRANSPL, V3, P666, DOI 10.1093/oxfordjournals.ndt.a091725; LUTZNER MA, 1983, LANCET, V2, P422; OPELZ G, 1988, LANCET, V2, P61; PENN I, 1988, TRANSPLANT P, V20, P885; PERSIJN GG, 1982, NEW ENGL J MED, V307, P905, DOI 10.1056/NEJM198210073071501; RAY JG, 1979, NIH80545 DHEW PUBL; RUDLINGER R, 1986, BRIT J DERMATOL, V115, P681, DOI 10.1111/j.1365-2133.1986.tb06649.x; RUDLINGER R, 1989, LANCET, V1, P1132; SHEIL AGR, 1989, KIDNEY TRANSPLANTATI, P603; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; TING A, 1989, KIDNEY TRANSPLANTATI, P183; VANDERLEEST RJ, 1987, ARCH DERMATOL, V123, P354, DOI 10.1001/archderm.123.3.354; VANHOOFF PJ, 1980, P EUR DIAL TRANSPLAN, V17, P435; VANROOD JJ, 1985, TRANSPLANT P, V17, P681; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0	30	152	155	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					843	848		10.1056/NEJM199109193251203	http://dx.doi.org/10.1056/NEJM199109193251203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875968				2022-12-28	WOS:A1991GF61600003
J	ROGERS, DE; OSBORN, JE				ROGERS, DE; OSBORN, JE			ANOTHER APPROACH TO THE AIDS EPIDEMIC	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STAGE RENAL-DISEASE; HIV-INFECTION; TRANSMISSION; SURGEON		UNIV MICHIGAN,SCH PUBL HLTH,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	ROGERS, DE (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021, USA.							ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; [Anonymous], 1991, REPORT WORKING GROUP; ARMSTRONG FP, 1987, MIL MED, V152, P414; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; FRIEDLAND G, 1990, AIDS, V4, P639, DOI 10.1097/00002030-199007000-00005; HARDY LM, 1991, HIV SCREENING PREGNA; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; RELMAN AS, 1980, NEW ENGL J MED, V303, P996, DOI 10.1056/NEJM198010233031708; ROGERS DE, 1990, AIDS, V4, P695, DOI 10.1097/00002030-199007000-00016; SITTITRAI W, 1990, AIDS S1, V4, P5269; 1989, 1 NAT COMM ACQ IMM D; 1991, ESTIMATES RISK ENDEM; 1990, COMMUNICATION   0329; 1991, JAMA-J AM MED ASSOC, V265, P1872; 1990, 3 NAT COMM ACQ IMM D; 1991, 4 NAT COMM ACQ IMM D; 1991, FEB CDC OP M RISKS T; 1990, 2 NAT COMM ACQ IMM D	19	21	21	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					806	808		10.1056/NEJM199109123251111	http://dx.doi.org/10.1056/NEJM199109123251111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870656				2022-12-28	WOS:A1991GE45600011
J	WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; CUPPLES, LA; HEEREN, T; COFFMAN, GA; BECKER, CA; BARKER, TA; HAMILTON, SK; MCGUIRE, TG; KELLY, CA				WALSH, DC; HINGSON, RW; MERRIGAN, DM; LEVENSON, SM; CUPPLES, LA; HEEREN, T; COFFMAN, GA; BECKER, CA; BARKER, TA; HAMILTON, SK; MCGUIRE, TG; KELLY, CA			A RANDOMIZED TRIAL OF TREATMENT OPTIONS FOR ALCOHOL-ABUSING WORKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INPATIENT; CONSUMPTION; PROGRAMS; OUTCOMES; 6-MONTH	Background. Employee-assistance programs sponsored by companies or labor unions identify workers who abuse alcohol and refer them for care, often to inpatient rehabilitation programs. Yet the effectiveness of inpatient treatment, as compared with a variety of less intensive alternatives, has repeatedly been called into question. In this study, anchored in the work site, we compared the effectiveness of mandatory in-hospital treatment with that of required attendance at the meetings of a self-help group and a choice of treatment options. Methods. We randomly assigned a series of 227 workers newly identified as abusing alcohol to one of three rehabilitation regimens: compulsory inpatient treatment, compulsory attendance at Alcoholics Anonymous (AA) meetings, and a choice of options. Inpatient backup was provided if needed. The groups were compared in terms of 12 job-performance variables and 12 measures of drinking and drug use during a two-year follow-up period. Results. All three groups improved, and no significant differences were found among the groups in job-related outcome variables. On seven measures of drinking and drug use, however, we found significant differences at several follow-up assessments. The hospital group fared best and that assigned to AA the least well; those allowed to choose a program had intermediate outcomes. Additional inpatient treatment was required significantly more often (P < 0.0001) by the AA group (63 percent) and the choice group (38 percent) than by subjects assigned to initial treatment in the hospital (23 percent). The differences among the groups were especially pronounced for workers who had used cocaine within six months before study entry. The estimated costs of inpatient treatment for the AA and choice groups averaged only 10 percent less than the costs for the hospital groups because of their higher rates of additional treatment. Conclusions. Even for employed problem drinkers who are not abusing drugs and who have no serious medical problems, an initial referral to AA alone or a choice of programs, although less costly than inpatient care, involves more risk than compulsory inpatient treatment and should be accompanied by close monitoring for signs of incipient relapse.	HARVARD UNIV,SCH PUBL HLTH,DEPT SOCIAL & BEHAV SCI,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02115; BOSTON UNIV,CTR DATA COORDINATING,SCH PUBL HLTH,BOSTON,MA 02215; BOSTON UNIV,INST HLTH POLICY,BOSTON,MA 02215; BOSTON UNIV,DEPT ECON,BOSTON,MA 02215	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University; Boston University				Heeren, Timothy/0000-0001-5643-3559; Coffman, Gerald/0000-0002-0044-6219; Levenson, Suzette/0000-0002-1979-2373	NIAAA NIH HHS [R01 AA06461] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006461] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Armor D. J., 1976, ALCOHOLISM TREATMENT; CHAPMAN PLH, 1988, BRIT J ADDICT, V83, P67; EDWARDS G, 1977, J STUD ALCOHOL, V38, P1004, DOI 10.15288/jsa.1977.38.1004; EMRICK CD, 1975, J STUD ALCOHOL, V36, P88, DOI 10.15288/jsa.1975.36.88; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lawless J.F., 1982, STAT MODELS METHODS, P52; LONGABAUGH R, 1983, J STUD ALCOHOL, V44, P1049, DOI 10.15288/jsa.1983.44.1049; MCLACHLAN JFC, 1982, J STUD ALCOHOL, V43, P261, DOI 10.15288/jsa.1982.43.261; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; MILLER WR, 1986, AM PSYCHOL, V41, P794, DOI 10.1037/0003-066X.41.7.794; MILLER WR, 1989, HDB ALCOHOLISM TREAT, P261; MULFORD HA, 1977, J STUD ALCOHOL, V38, P2197, DOI 10.15288/jsa.1977.38.2197; OFARRELL TJ, 1987, ADV BEHAV RES THER, V9, P91, DOI 10.1016/0146-6402(87)90010-5; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Roman P M, 1988, Recent Dev Alcohol, V6, P131; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SMITH PF, 1990, AM J PUBLIC HEALTH, V80, P309, DOI 10.2105/AJPH.80.3.309; TRICE HM, 1984, J STUD ALCOHOL, V45, P393, DOI 10.15288/jsa.1984.45.393; WALSH DC, 1985, J OCCUP ENVIRON MED, V27, P745; WALSH DC, 1991, J STUD ALCOHOL, V52, P17, DOI 10.15288/jsa.1991.52.17; WALSH DC, 1982, MILBANK FUND Q, V60, P492, DOI 10.2307/3349803; WANBERG KW, 1974, INT J MENT HEALTH, V3, P160, DOI 10.1080/00207411.1974.11448664; WEEISNER CM, 1990, I MED BROADENING BAS, P579; WILSON GT, 1987, BRIT J ADDICT, V82, P343; 1983, HLTH TECHNOLOGY CASE; 1972, ANN INTERN MED, V7, P249; 1990, BROADENING BASE TREA; 1990, NATIONAL DRUG CONTRO; 1980, DIAGNOSTIC STATISTIC, P163; 1982, DIAGNOSTIC INTERVIEW; 1989, PREVENTION TREATMENT	32	202	203	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					775	782		10.1056/NEJM199109123251105	http://dx.doi.org/10.1056/NEJM199109123251105			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE456	1870651				2022-12-28	WOS:A1991GE45600005
J	JONES, KW; SHAPERO, MH; CHEVRETTE, M; FOURNIER, REK				JONES, KW; SHAPERO, MH; CHEVRETTE, M; FOURNIER, REK			SUBTRACTIVE HYBRIDIZATION CLONING OF A TISSUE-SPECIFIC EXTINGUISHER - TSE1 ENCODES A REGULATORY SUBUNIT OF PROTEIN KINASE-A	CELL			English	Article							HEPATOMA HYBRID-CELLS; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; DNA-BINDING PROTEINS; LIVER-SPECIFIC GENES; MICROCELL HYBRIDS; TRANS-REGULATION; MAMMALIAN-CELLS; MESSENGER-RNA; ALBUMIN GENE; HUMAN TESTIS	Tissue-specific extinguisher 1 (TSE1) is a trans-acting locus on human chromosome 17 that down-regulates expression of seven liver genes in hepatoma x fibroblast hybrids. To study the mechanism by which TSE1 functions, we used subtractive cDNA hybridization to clone transcripts encoded within a 2-4 Mb segment of chromosome 17 that includes TSE1. High resolution mapping within this region indicated that 8 of 9 different human cDNAs so obtained were distinct from TSE1. The remaining cDNA clone mapped concordantly with TSE1 in a panel of fragment-containing hybrids. DNA sequencing indicated that this cDNA encoded regulatory subunit RI-alpha of cAMP-dependent protein kinase, and RI-alpha mRNA levels correlated with TSE1 activity in various hybrid lines. Stable transfection of wild-type or cAMP-binding mutant RI-alpha alleles into hepatoma recipients produced an extinction phenotype indistinguishable from that encoded by human TSE1. We conclude that TSE1 encodes a regulatory subunit of protein kinase A whose activity differs in different cell types.			JONES, KW (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT MOLEC MED, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026449] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26449] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CHIN AC, 1987, P NATL ACAD SCI USA, V84, P1614, DOI 10.1073/pnas.84.6.1614; CHIN AC, 1989, MOL CELL BIOL, V9, P3736, DOI 10.1128/MCB.9.9.3736; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DAVIDSON RL, 1966, P NATL ACAD SCI USA, V56, P1437, DOI 10.1073/pnas.56.5.1437; DAVIS MM, 1984, P NATL ACAD SCI-BIOL, V81, P2194, DOI 10.1073/pnas.81.7.2194; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FAIN PR, 1991, IN PRESS CYTOGENET C; Favaloro J, 1980, Methods Enzymol, V65, P718; FORSTER AC, 1985, NUCLEIC ACIDS RES, V13, P745, DOI 10.1093/nar/13.3.745; Fournier R. E. K., 1982, TECHNIQUES SOMATIC C, P309; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GOURDEAU H, 1989, MOL CELL BIOL, V9, P1813, DOI 10.1128/MCB.9.5.1813; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; IP YT, 1990, MOL CELL BIOL, V10, P3782, DOI 10.1128/MCB.10.7.3782; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JUNKER S, 1989, EXP CELL RES, V180, P63, DOI 10.1016/0014-4827(89)90212-7; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KOZAK C, 1975, SOMAT CELL GENET, V1, P371, DOI 10.1007/BF01538668; LEACH RJ, 1989, GENOMICS, V5, P167, DOI 10.1016/0888-7543(89)90043-8; LEM J, 1988, P NATL ACAD SCI USA, V85, P7302, DOI 10.1073/pnas.85.19.7302; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T., 1982, MOL CLONING; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MENON AG, 1989, GENOMICS, V5, P245, DOI 10.1016/0888-7543(89)90053-0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PETERSON TC, 1985, MOL CELL BIOL, V5, P2491, DOI 10.1128/MCB.5.9.2491; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; RIEGNER DA, 1976, TISSUE CULTURE ASS M, V2, P273; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRAMBLER P, 1987, AM J HUM GENET, V41, P925; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZPIRER J, 1983, EXP CELL RES, V146, P224, DOI 10.1016/0014-4827(83)90343-9; THAYER MJ, 1989, MOL CELL BIOL, V9, P2837, DOI 10.1128/MCB.9.7.2837; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WEISS MC, 1975, SOMAT CELL GENET, V1, P27, DOI 10.1007/BF01538730; WEISS MC, 1971, P NATL ACAD SCI USA, V68, P3026, DOI 10.1073/pnas.68.12.3026; WILCOX AS, 1991, NUCLEIC ACIDS RES, V19, P1837, DOI 10.1093/nar/19.8.1837; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	65	136	137	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					861	872		10.1016/0092-8674(91)90433-Y	http://dx.doi.org/10.1016/0092-8674(91)90433-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889088				2022-12-28	WOS:A1991GE46000006
J	ISACOFF, EY; JAN, YN; JAN, LY				ISACOFF, EY; JAN, YN; JAN, LY			PUTATIVE RECEPTOR FOR THE CYTOPLASMIC INACTIVATION GATE IN THE SHAKER K+ CHANNEL	NATURE			English	Article							POTASSIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA MUSCLE; XENOPUS-OOCYTES; RAT-BRAIN; CLONING	INACTIVATION of ion channels is important in the control of membrane excitability. For example, delayed-rectifier K+ channels, which regulate action potential repolarization, are inactivated only slowly, whereas A-type K+ channels, which affect action potential duration and firing frequency, have both fast and slow inactivation 1. Fast inactivation of Na+ and K+ channels may result from the blocking of the permeation pathway by a positively charged cytoplasmic gate 2 such as the one encoded by the first 20 amino acids of the Shaker B (ShB) K+ channel 3,4. We report here that mutation of five highly conserved residues between the proposed membrane-spanning segments S4 and S5 (also termed H4) 5 of ShB affects the stability of the inactivated state and alters channel conductance. One such mutation stabilizes the inactivated state of ShB as well as the inactivated state induced in the delayed-rectifier type K+ channel drk1 (ref. 6) by the cytoplasmic application of the ShB N-terminal peptide. The S4-S5 loop, therefore, probably forms part of a receptor for the inactivation gate and lies near the channel's permeation pathway.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ISACOFF, EY (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.		isacoff, ehud/AAP-1459-2020	Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Isacoff, Ehud Y./0000-0003-4775-9359				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF E, 1990, COLD SPRING HARB SYM, V55, P9; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCORMACK T, 1990, P NATL ACAD SCI USA, V87, P5227, DOI 10.1073/pnas.87.13.5227; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; RIBERA AB, 1990, NEURON, V5, P691, DOI 10.1016/0896-6273(90)90223-3; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	30	309	314	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					86	90		10.1038/353086a0	http://dx.doi.org/10.1038/353086a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881453				2022-12-28	WOS:A1991GD80500066
J	JOLIN, LD; JOLLY, P; KRAKOWER, JY; BERAN, R				JOLIN, LD; JOLLY, P; KRAKOWER, JY; BERAN, R			UNITED-STATES MEDICAL-SCHOOL FINANCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									ASSOC AMER MED COLL,STUDENT & EDUC PROGRAMS SECT,WASHINGTON,DC 20036	Association of American Medical Colleges	JOLIN, LD (corresponding author), ASSOC AMER MED COLL,OPERAT STUDIES SECT,WASHINGTON,DC 20036, USA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					985	990		10.1001/jama.266.7.985	http://dx.doi.org/10.1001/jama.266.7.985			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870229				2022-12-28	WOS:A1991GB20500012
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INGREDIENT LABELING PROPOSAL PUBLISHED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28592	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-28	WOS:A1991GA07300007
J	BOWLING, A; JACOBSON, B; SOUTHGATE, L; FORMBY, J				BOWLING, A; JACOBSON, B; SOUTHGATE, L; FORMBY, J			GENERAL-PRACTITIONERS VIEWS ON QUALITY SPECIFICATIONS FOR OUTPATIENT REFERRALS AND CARE CONTRACTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To ascertain general practitioners' views about which quality specifications should be included in contracts for hospital care. Design-In depth interview study and postal survey. Setting-General practitioners in City and Hackney Health District. Subjects-Fourteen doctors were interviewed in depth; 77 of 131 doctors (59%) returned postal questionnaires. Main outcome measure-Rating of listed quality specifications. Results-The most popular items which doctors thought should be included in contracts by April 1991 related to the availability of patients' notes in outpatient clinics, respect shown to general practitioners in telephone communications with hospital doctors, supply of medicines after discharge, patient management plans for general practitioners, the earlier arrival of discharge slips, the type of hospital doctor to see new outpatients, and the unnecessary duplication of investigations. Conclusions-A high premium was attached by general practitioners to effective organisation, effective communication between primary and secondary sources of care, and effective communication with patients.	LONDON HOSP,COLL MED,LONDON E1 1BB,ENGLAND; CITY & HACKNEY HLTH AUTHOR,DEPT PUBL HLTH,NEEDS ASSESSMENT UNIT,LONDON,ENGLAND	University of London; Queen Mary University London	BOWLING, A (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON EC1A 7BE,ENGLAND.							[Anonymous], 1989, CM555; HOPKINS A, 1990, BRIT MED J, V300, P919, DOI 10.1136/bmj.300.6729.919; KLEIN R, 1991, BRIT MED J, V302, P1102, DOI 10.1136/bmj.302.6785.1102; 1990, NATIONAL HLTH SERVIC; 1989, 2 DEP HLTH WORK PAP	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					292	294		10.1136/bmj.303.6797.292	http://dx.doi.org/10.1136/bmj.303.6797.292			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888933	Green Published, Bronze			2022-12-28	WOS:A1991FZ72100025
J	EVE, R; HODGKIN, P				EVE, R; HODGKIN, P			IN PRAISE OF NON-FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT GEN PRACTICE,SHEFFIELD S10,ENGLAND	University of Sheffield	EVE, R (corresponding author), SHEFFIELD FAMILY HLTH SERV AUTHOR,SHEFFIELD S11 9BD,ENGLAND.							HICKS NR, 1991, BRIT MED J, V302, P991, DOI 10.1136/bmj.302.6783.991	1	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					167	168		10.1136/bmj.303.6795.167	http://dx.doi.org/10.1136/bmj.303.6795.167			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878643	Green Published, Bronze			2022-12-28	WOS:A1991FX57800025
J	QUE, L				QUE, L			OXYGEN ACTIVATION AT THE DIIRON CENTER OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Editorial Material							METHANE MONOOXYGENASE; HYDROGEN-PEROXIDE; IRON; COENZYME-B12; INTERMEDIATE; SPECTROSCOPY; MECHANISM; COBAMIDES; MOSSBAUER; PROTEIN				QUE, L (corresponding author), UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455, USA.							ANDERSON KK, 1991, NEW J CHEM, V15, P405; ASHLEY GW, 1986, J BIOL CHEM, V261, P3958; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, IN PRESS J AM CHEM S; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ERICSON A, 1988, J AM CHEM SOC, V110, P2330, DOI 10.1021/ja00215a070; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; LEISING RA, 1991, J AM CHEM SOC, V113, P3988, DOI 10.1021/ja00010a050; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; QUE L, 1990, PROG INORG CHEM, V38, P97; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; STENKAMP RE, 1984, J AM CHEM SOC, V106, P618, DOI 10.1021/ja00315a027; STENKAMP RE, 1985, P NATL ACAD SCI USA, V82, P713, DOI 10.1073/pnas.82.3.713; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TAMAO Y, 1973, BIOCHEMISTRY-US, V12, P24, DOI 10.1021/bi00725a005; WILLING A, 1988, EUR J BIOCHEM, V170, P603, DOI 10.1111/j.1432-1033.1988.tb13740.x	27	25	25	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					273	274		10.1126/science.1857963	http://dx.doi.org/10.1126/science.1857963			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857963				2022-12-28	WOS:A1991FX22400029
J	ARMSTRONG, P; KEEVIL, SF				ARMSTRONG, P; KEEVIL, SF			MAGNETIC-RESONANCE-IMAGING .2. CLINICAL USES	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE-SCLEROSIS; MR; PITUITARY; DISEASE; BRAIN; 1.5-T; SPINE; HEART				ARMSTRONG, P (corresponding author), ST BARTHOLOMEWS HOSP,ACAD DEPT RADIOL,LONDON EC1A 7BE,ENGLAND.							ARMSTRONG P, 1991, BRIT MED J, V303, P35, DOI 10.1136/bmj.303.6793.35; BARKOVICH AJ, 1988, RADIOL CLIN N AM, V26, P801; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; BRANTZAWADZKI M, 1988, RADIOLOGY, V166, P1; CHAKERES DW, 1989, RADIOL CLIN N AM, V27, P265; CHERRYMAN GR, 1990, CONTRAST MEDIA MRI P; CRUES JV, 1987, RADIOLOGY, V164, P445, DOI 10.1148/radiology.164.2.3602385; DIETEMANN J, 1990, DIAG INTERV RADIOL, V2, P5; EDWARDS MK, 1986, AM J NEURORADIOL, V7, P595; EHMAN RL, 1988, RADIOLOGY, V166, P313, DOI 10.1148/radiology.166.2.3275975; GLAZER GM, 1988, RADIOLOGY, V166, P303, DOI 10.1148/radiology.166.2.3275974; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HAUGHTON VM, 1988, RADIOLOGY, V166, P297, DOI 10.1148/radiology.166.2.3275973; HIGGINS CB, 1988, AM J ROENTGENOL, V151, P239, DOI 10.2214/ajr.151.2.239; HUEFTLE MG, 1988, RADIOLOGY, V167, P817, DOI 10.1148/radiology.167.3.2966418; HYMAN RA, 1988, RADIOL CLIN N AM, V26, P471; KIRKPATRICK JB, 1987, RADIOLOGY, V162, P509, DOI 10.1148/radiology.162.2.3797666; KUCHARCZYK W, 1986, RADIOLOGY, V161, P761, DOI 10.1148/radiology.161.3.3786729; MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089; PECK WW, 1989, AM J ROENTGENOL, V152, P145, DOI 10.2214/ajr.152.1.145; SCOTTI G, 1986, NEURORADIOLOGY, V28, P319, DOI 10.1007/BF00333437; STARK DD, 1987, RADIOLOGY, V165, P399, DOI 10.1148/radiology.165.2.3310094; SZE G, 1987, SEMIN ROENTGENOL, V22, P42, DOI 10.1016/0037-198X(87)90021-6; SZE G, 1988, RADIOL CLIN N AM, V26, P839; UHLENBROCK D, 1988, AM J NEURORADIOL, V9, P59	25	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					105	109		10.1136/bmj.303.6794.105	http://dx.doi.org/10.1136/bmj.303.6794.105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1859984	Bronze, Green Published			2022-12-28	WOS:A1991FW58600026
J	WIGHT, JP				WIGHT, JP			ETHICS, COMMERCE, AND KIDNEYS	BRITISH MEDICAL JOURNAL			English	Editorial Material							ORGAN				WIGHT, JP (corresponding author), NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							EVANS M, 1989, J MED ETHICS, V15, P17, DOI 10.1136/jme.15.1.17; HARVEY J, 1990, J MED ETHICS, V16, P117, DOI 10.1136/jme.16.3.117; MORRIS PJ, 1987, TRANSPLANT P, V19, P16; PERRY C, 1980, ETHICS, V91, P63, DOI 10.1086/292203; SELLS RA, 1989, TRANSPLANT P, V21, P1391	5	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					110	110		10.1136/bmj.303.6794.110	http://dx.doi.org/10.1136/bmj.303.6794.110			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FW586	1859985	Green Published, Bronze			2022-12-28	WOS:A1991FW58600028
J	CHANTELAU, E; LEE, DM; HEMMANN, DM; ZIPFEL, U; ECHTERHOFF, S				CHANTELAU, E; LEE, DM; HEMMANN, DM; ZIPFEL, U; ECHTERHOFF, S			WHAT MAKES INSULIN INJECTIONS PAINFUL	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUSSELDORF,MED DEPT NUTR & METAB DIS,W-4000 DUSSELDORF 1,GERMANY	Heinrich Heine University Dusseldorf								HODGE RH, 1980, JAMA-J AM MED ASSOC, V244, P266, DOI 10.1001/jama.244.3.266; KRALL LP, 1978, JOSLIN DIABETES MANU, P81; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; THOW J, 1990, BRIT MED J, V301, P3, DOI 10.1136/bmj.301.6742.3; WILLIAMS G, 1983, DIABETES, V32, P466, DOI 10.2337/diabetes.32.5.466	5	40	44	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					26	27		10.1136/bmj.303.6793.26	http://dx.doi.org/10.1136/bmj.303.6793.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859951	Green Published, Bronze			2022-12-28	WOS:A1991FW12800022
J	CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA				CUSICK, EL; KRUKOWSKI, ZH; MACINTOSH, CA; MATHESON, NA			RISK OF NEOPLASIA AND MALIGNANCY IN DOMINANT THYROID SWELLINGS	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DIAGNOSIS; NODULE	Objective - To determine the risk of neoplasia and malignancy in "dominant" thyroid swellings. Design - Prospective analysis during six years. Setting-Thyroid clinic serving the Grampian region. Patients-574 consecutive patients presenting with a discrete thyroid swelling, of whom 179 (31%) were classified clinically as having a dominant area of enlargement within a multinodular gland. Results-After clinical and cytological assessment 77 dominant swellings were excised. Of the excised swellings, 45 were non-neoplastic and 32 neoplastic, including 11 malignant lesions. The minimum incidence of neoplasia and malignancy in all 179 dominant swellings was therefore 18% and 6% respectively. Conclusion-Dominant thyroid swellings should be regarded with greater clinical suspicion than has been traditional.	UNIV ABERDEEN,DEPT SURG,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen								BEIERWALTES WH, 1983, ENDOCRINE SURGERY UP, P18; COLE WH, 1945, JAMA-J AM MED ASSOC, V127, P883, DOI 10.1001/jama.1945.02860140001001; COPE O, 1949, CLIN ENDOCRINOL META, V9, P1012; CUSICK EL, 1991, BRIT J SURG, V78, P94, DOI 10.1002/bjs.1800780129; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; HOFFMAN GL, 1972, ARCH SURG-CHICAGO, V105, P379; LENNQUIST S, 1987, SURG CLIN N AM, V67, P213; ROHER HD, 1987, SURG CLIN N AM, V67, P233; THOMAS CG, 1976, ANN SURG, V183, P463, DOI 10.1097/00000658-197605000-00002	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					20	22		10.1136/bmj.303.6793.20	http://dx.doi.org/10.1136/bmj.303.6793.20			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859949	Green Published, Bronze			2022-12-28	WOS:A1991FW12800020
J	DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ				DONE, DJ; JOHNSTONE, EC; FRITH, CD; GOLDING, J; SHEPHERD, PM; CROW, TJ			COMPLICATIONS OF PREGNANCY AND DELIVERY IN RELATION TO PSYCHOSIS IN ADULT LIFE - DATA FROM THE BRITISH PERINATAL-MORTALITY SURVEY SAMPLE	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC COMPLICATIONS; SCHIZOPHRENIC MOTHERS; EPIDEMIOLOGY; CHILDREN; ILLNESS; TWIN; RISK	Objective - To evaluate whether events occurring at or around the time of birth contribute to the onset of psychotic illness in adult life. Design - Pregnancy and birth complications as possible causes of adult mental illness were studied in the population sample of the British perinatal mortality survey. Subsequent psychiatric admissions were independently identified through the Mental Health Enquiry and records of regional and special health authorities. Logistic regression was used to compare data on perinatal deaths with those on survivors to determine factors independently associated with perinatal death, and this equation was then used to calculate the risk of perinatal death for each survivor. Subjects - 16 980 people born in a single week in 1958 (the British perinatal mortality survey sample), including 252 patients admitted to psychiatric care; case notes of 235 patients were supplied. Main outcome measures and results - Patients with a schizophrenic illness (whether defined by "broad" (n = 57) or "narrow" (n = 35) diagnostic criteria) did not have a greater mean risk of perinatal death than the population in general, but there was some evidence of increased liability (relative risk 2.43; 95% confidence interval 1.17 to 5.05) for those with affective psychosis (n = 32). Specific high risk variables for affective psychosis were decreased gestation time (273.9 v 281.2 days; mean difference 7.3 days, 95% confidence interval 3.1 to 11.5; p < 0.002) and prescription of vitamin K to the child in the first week of life (19% of patients v 5% of controls, p = 0.016). Conclusions - The findings give no support to theories that factors predicting perinatal mortality contribute significantly to causation of schizophrenic illness. Further investigation of decreased gestation length in relation to affective disorder is required.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,BRISTOL BS2 8BJ,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0BH,ENGLAND	Bristol Royal Hospital For Children; University of Bristol; City University London	DONE, DJ (corresponding author), CLIN RES CTR,DIV PSYCHIAT,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.		crow, timothy J/M-8327-2014; Frith, Chris D/A-2171-2009	crow, timothy J/0000-0002-5482-6655; Frith, Chris D/0000-0002-8665-0690; Golding, Jean/0000-0003-2826-3307				BERTELSEN A, 1977, BRIT J PSYCHIAT, V130, P330, DOI 10.1192/bjp.130.4.330; BUTLER N, 1971, BMJ, V1, P127; BUTLER NR, 1969, PERINATAL PROBLEMS; DALEN P, 1965, ACTA PSYCHIAT SCAND, V41, P527, DOI 10.1111/j.1600-0447.1965.tb06169.x; DER G, 1990, LANCET, V335, P513, DOI 10.1016/0140-6736(90)90745-Q; EAGLES JM, 1990, LANCET, V336, P1139; EATON WW, 1985, EPIDEMIOL REV, V7, P105, DOI 10.1093/oxfordjournals.epirev.a036278; Gottesman I.I., 1982, SCHIZOPHRENIA EPIGEN; Gottesman I. I., 1972, SCHIZOPHRENIA GENETI; HARE EH, 1987, BRIT MED BULL, V43, P514, DOI 10.1093/oxfordjournals.bmb.a072199; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; JOFFE M, 1985, J BIOSOC SCI, V17, P113, DOI 10.1017/S0021932000015522; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KETY SS, 1983, AM J PSYCHIAT, V140, P720; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS SW, 1989, PSYCHOL MED, V19, P5, DOI 10.1017/S0033291700010977; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; MCNEIL TF, 1973, BRIT J PSYCHIAT, V123, P341, DOI 10.1192/bjp.123.3.341; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MEDNICK SA, 1971, SOC BIOL, V18, P103; MEDNICK SA, 1978, NATURE SCHIZOPHRENIA, P442; MENDLEWICZ J, 1977, NATURE, V268, P327, DOI 10.1038/268327a0; MIRDAL GKM, 1974, ACTA PSYCHIAT SCAND, V50, P553; OLSON SC, 1989, BIOL PSYCHIAT, V25, pA93; OWEN MJ, 1988, PSYCHOL MED, V18, P331, DOI 10.1017/S003329170000787X; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; REDDY R, 1989, BIOL PSYCHIAT, V25, pA93; SHEPHERD PM, 1985, 1 CITY U SOC STAT RE; WEISSMAN MM, 1984, NEUROBIOLOGY MOOD DI, P60; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; WREDE G, 1980, ACTA PSYCHIAT SCAND, V62, P369, DOI 10.1111/j.1600-0447.1980.tb00623.x	34	193	193	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1576	1580		10.1136/bmj.302.6792.1576	http://dx.doi.org/10.1136/bmj.302.6792.1576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FU549	1855042	Green Published, Bronze, Green Submitted			2022-12-28	WOS:A1991FU54900026
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - MEDICAL PROBLEMS IN PREGNANCY .1.	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 25	1991	302	6787					1262	1266		10.1136/bmj.302.6787.1262	http://dx.doi.org/10.1136/bmj.302.6787.1262			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FP272	1863288	Green Published, Bronze			2022-12-28	WOS:A1991FP27200031
J	WATERS, MG; SERAFINI, T; ROTHMAN, JE				WATERS, MG; SERAFINI, T; ROTHMAN, JE			COATOMER - A CYTOSOLIC PROTEIN COMPLEX CONTAINING SUBUNITS OF NON-CLATHRIN-COATED GOLGI TRANSPORT VESICLES	NATURE			English	Article							BREFELDIN-A; ENDOPLASMIC-RETICULUM	GOLGI-derived coated vesicles contain a set of coat proteins of relative molecular mass 160,000 (M(r) 160K; alpha-COP), 110K (beta-COP), 98K (gamma-COP) and 61K (delta-COP), and several smaller subunits 1. We have now identified and purified a cytosolic complex containing the same four coat proteins as those of Golgi transport vesicles. We term this complex the Golgi coat promoter or 'coatomer'. The customer also contains polypeptides of M(r) 36K, 35K and 20K. It represents about 0.2% of soluble cytosolic protein. Gel filtration of unfractionated cytosol indicates that beta-COP resides exclusively in the coatomer complex. The complex seems to be a likely candidate for the unassembled precursor of Golgi coated vesicles, and its purification should help investigations of the role of coat proteins in membrane budding, for which it is necessary to use a refined cell-free system.			WATERS, MG (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	15	434	447	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					248	251		10.1038/349248a0	http://dx.doi.org/10.1038/349248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898986				2022-12-28	WOS:A1991ET51900059
J	FLANCE, IJ				FLANCE, IJ			SCAR CANCER OF THE LUNG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FLANCE, IJ (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							CHAUDHURI MR, 1973, INDIAN J MED RES, V61, P858; KUNG ITM, 1985, AM J SURG PATHOL, V9, P391; MADRI JA, 1984, HUM PATHOL, V15, P625, DOI 10.1016/S0046-8177(84)80286-5; MEYER EC, 1965, CANCER-AM CANCER SOC, V18, P322, DOI 10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J; MONTGOMERY GL, 1947, BRIT J SURG, V31, P292; ROSAI J, 1989, ACKERMANS SURGICAL P, V1, P297	6	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2003	2004		10.1001/jama.266.14.2003	http://dx.doi.org/10.1001/jama.266.14.2003			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895484				2022-12-28	WOS:A1991GH40600033
J	CUBELLI, R				CUBELLI, R			A SELECTIVE DEFICIT FOR WRITING VOWELS IN ACQUIRED DYSGRAPHIA	NATURE			English	Article							GRAPHEMIC BUFFER	BRAIN-DAMAGED patients with acquired writing disorders provide important information about the normal processes of spelling and writing 1,2. Current models indicate that to produce a letter string, its 'abstract' representation is computed and stored in a temporary orthographic buffer, from which it is converted to a verbal code (if the word is to be spelled aloud) or to a physical letter code (if the word is to be written). The stored graphemic representations specify the identity and order of the component letters 3 and their consonant/vowel status 4. Here I describe the spelling performance of two patients with a selective deficit in writing vowels. When writing words, the first patient omitted all vowels, leaving a blank space between consonants or consonant clusters, whereas the second produced errors that almost exclusively involved vowels. This pattern of performance supports the hypothesis that the consonant/vowel status of graphemes is differentially specified in the spelling process and may be selectively affected after brain damage.			CUBELLI, R (corresponding author), OSPED MAGGIORE BOLOGNA,DEPT REHABIL,I-40133 BOLOGNA,ITALY.							CARAMAZZA A, 1987, COGNITION, V26, P59, DOI 10.1016/0010-0277(87)90014-X; CARAMAZZA A, 1990, COGNITION, V37, P243, DOI 10.1016/0010-0277(90)90047-N; Ellis A.W., 1982, NORMALITY PATHOLOGY; HILLIS AE, 1989, BRAIN LANG, V36, P208, DOI 10.1016/0093-934X(89)90062-X; KATZ RB, 1991, CORTEX, V27, P111, DOI 10.1016/S0010-9452(13)80274-2; MARGOLIN DJ, 1984, Q J EXP PSYCHOL-A, V316, P459; Morton J., 1980, COGNITIVE PROCESS, P117; POSTERARO L, 1988, BRAIN LANG, V35, P274, DOI 10.1016/0093-934X(88)90112-5; Sartori G., 1984, LETTURA	9	70	70	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					258	260		10.1038/353258a0	http://dx.doi.org/10.1038/353258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GF674	1896072				2022-12-28	WOS:A1991GF67400059
J	BONE, RC				BONE, RC			THE PATHOGENESIS OF SEPSIS	ANNALS OF INTERNAL MEDICINE			English	Review						ENDOTOXINS; SEPTICEMIA; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR; ENDOTHELIUM, VASCULAR	TUMOR-NECROSIS-FACTOR; PLATELET-ACTIVATING FACTOR; RESPIRATORY-DISTRESS SYNDROME; KALLIKREIN-KININ SYSTEM; HUMAN-ENDOTHELIAL CELLS; CANINE ENDOTOXIN-SHOCK; ACUTE LUNG INJURY; SEPTIC SHOCK; FACTOR-ALPHA; PAF-ACETHER	Sepsis and its sequelae (sepsis syndrome and septic shock) are increasingly common and are still potentially lethal diagnoses. Many mediators of the pathogenesis of sepsis have recently been described. These include tumor necrosis factor-alpha (TNF-alpha), interleukins, platelet activating factor, leukotrienes, thromboxane A2, and activators of the complement cascade. Neutrophil and platelet activation may also play a role. other agents that may participate in the sepsis cascade include adhesion molecules, kinins, thrombin, myocardial depressant substance, beta-endorphin, and heat shock proteins. Endothelium-derived relaxing factor and endothelin-1 are released from the endothelium and seem to exert a regulatory effect, counterbalancing each other. A central mediator of sepsis does not seem to exist, although TNF-alpha has been commonly proposed for this role. Animal studies are difficult to extrapolate to the clinical setting because of cross-species differences and variations in experimental design. Rather than being caused by any single pathogenic mechanism, it is more likely that sepsis is related to the state of activation of the target cell, the nearby presence of other mediators, and the ability of the target cell to release other mediators. Also important is the downregulation or negative feedback of these mediators or the generation of natural inflammation inhibitors, such as interleukin-4 and interleukin-8. Endothelial damage in sepsis probably results from persistent and repetitive inflammatory insults. Eventually, these insults produce sufficient damage that downregulation can no longer occur; this leads to a state of metabolic anarchy in which the body can no longer control its own inflammatory response.			BONE, RC (corresponding author), RUSH MED COLL, 1753 W CONGRESS PKWY, CHICAGO, IL 60612 USA.							AASEN AO, 1983, ARCH SURG-CHICAGO, V118, P343; ADERKA D, 1985, LANCET, V2, P1190; BALK RA, 1988, CRIT CARE MED, V16, P1121, DOI 10.1097/00003246-198811000-00008; BALKWILL F, 1987, LANCET, V2, P1229; BENVENISTE J, 1985, CIRCULATION, V72, P713, DOI 10.1161/01.CIR.72.4.713; BERGER M, 1988, BLOOD, V71, P151; BERNSTEN A, 1989, CRIT CARE CLIN, V5, P49; BESSIN P, 1983, EUR J PHARMACOL, V86, P403, DOI 10.1016/0014-2999(83)90190-5; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; BONE RC, 1976, AM J MED, V61, P585, DOI 10.1016/0002-9343(76)90135-2; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BONNET F, 1985, CRIT CARE MED, V13, P972, DOI 10.1097/00003246-198511000-00039; BORM PJA, 1988, AM REV RESPIR DIS, V138, P1589, DOI 10.1164/ajrccm/138.6.1589; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BROUCKAERT PG, 1989, AGENTS ACTIONS, V26, P196, DOI 10.1007/BF02126607; BUTLER LD, 1989, CLIN IMMUNOL IMMUNOP, V53, P400, DOI 10.1016/0090-1229(89)90003-2; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CLARK RA, 1979, J CLIN INVEST, V64, P913, DOI 10.1172/JCI109557; CLARK RA, 1985, BLOOD, V65, P375; COTRAN RS, 1990, J AM SOC NEPHROL, V1, P225; CUNNION RE, 1989, CHEST, V95, P941, DOI 10.1378/chest.95.5.941; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DEBETS JMH, 1989, CRIT CARE MED, V17, P489, DOI 10.1097/00003246-198906000-00001; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; DINERMAN JL, 1990, J AM COLL CARDIOL, V16, P207, DOI 10.1016/0735-1097(90)90481-4; DUNN DL, 1987, WORLD J SURG, V11, P233, DOI 10.1007/BF01656407; EASTGATE JA, 1988, LANCET, V2, P706; EDEN E, 1986, J CLIN IMMUNOL, V6, P326, DOI 10.1007/BF00917334; EGIDO J, 1987, EUR J PHARMACOL, V138, P119, DOI 10.1016/0014-2999(87)90346-3; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FONG YM, 1988, JPEN-PARENTER ENTER, V12, pS72; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRANK MM, 1987, NEW ENGL J MED, V316, P1525, DOI 10.1056/NEJM198706113162407; GALLIN JI, 1980, J CLIN INVEST, V65, P298, DOI 10.1172/JCI109672; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRIFFITH TM, 1988, J AM COLL CARDIOL, V12, P797, DOI 10.1016/0735-1097(88)90324-5; HARRIS RL, 1987, ARCH INTERN MED, V147, P1895, DOI 10.1001/archinte.147.11.1895; HEFFNER JE, 1987, AM REV RESPIR DIS, V135, P482; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HOLT PG, 1986, CLIN EXP IMMUNOL, V63, P261; HUGHES GS, 1985, RES COMMUN CHEM PATH, V48, P121; IBBOTSON GC, 1989, PROSTAG OTH LIPID M, V37, P237, DOI 10.1016/0090-6980(89)90060-9; INARREA P, 1985, IMMUNOPHARMACOLOGY, V9, P45, DOI 10.1016/0162-3109(85)90046-3; JACOBS RF, 1989, CRIT CARE CLIN, V5, P9; JACOBS RF, 1986, AM REV RESPIR DIS, V134, P745; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KATORI M, 1989, BRIT J PHARMACOL, V98, P1383, DOI 10.1111/j.1476-5381.1989.tb12688.x; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; KUHWEIDE R, 1990, EUR J IMMUNOL, V20, P1019, DOI 10.1002/eji.1830200511; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; KUNKEL SL, 1990, HOSP PRACT, V25, P63; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LEFER AM, 1989, CRIT CARE CLIN, V5, P331; LEFER AM, 1984, BRIT J PHARMACOL, V83, P125, DOI 10.1111/j.1476-5381.1984.tb10126.x; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; LUNDBERG C, 1987, AM J PATHOL, V128, P471; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MARKS JD, 1990, AM REV RESPIR DIS, V141, P94, DOI 10.1164/ajrccm/141.1.94; MARSDEN PA, 1991, J AM SOC NEPHROL, V1, P931; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MASON JW, 1970, ANN INTERN MED, V73, P545, DOI 10.7326/0003-4819-73-4-545; MAURY CPJ, 1989, ARTHRITIS RHEUM, V32, P146, DOI 10.1002/anr.1780320206; MEHTA JL, 1989, AM J PHYSIOL, V257, pH1240, DOI 10.1152/ajpheart.1989.257.4.H1240; MERRILL GA, 1987, DIABETES, V36, P585, DOI 10.2337/diabetes.36.5.585; MICHALEK SM, 1980, J INFECT DIS, V141, P55, DOI 10.1093/infdis/141.1.55; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MILLAR AB, 1989, LANCET, V2, P712, DOI 10.1016/S0140-6736(89)90772-1; MIYAUCHI T, 1990, CIRCULATION, V81, P1874, DOI 10.1161/01.CIR.81.6.1874; MYERS AK, 1990, BRIT J PHARMACOL, V99, P499, DOI 10.1111/j.1476-5381.1990.tb12957.x; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; ODA M, 1990, AM REV RESPIR DIS, V141, P1469, DOI 10.1164/ajrccm/141.6.1469; OGNIBENE FP, 1988, J CRIT CARE, V3, P103, DOI 10.1016/0883-9441(88)90042-1; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PARRILLO JE, 1989, TXB CRITICAL CARE ME, P111; PAVEK K, 1979, ACTA PHYSIOL SCAND, V105, P393, DOI 10.1111/j.1748-1716.1979.tb00103.x; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PETRAK RA, 1989, CRIT CARE CLIN, V5, P303; PIPER PJ, 1983, PROSTAGLANDINS, V25, P591, DOI 10.1016/0090-6980(83)90031-X; PISA P, 1990, J INFECT DIS, V161, P988, DOI 10.1093/infdis/161.5.988; POBER JS, 1987, J IMMUNOL, V138, P3319; PRIEUR AM, 1987, LANCET, V2, P1240; RANGES GE, 1988, J EXP MED, V167, P1472, DOI 10.1084/jem.167.4.1472; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; RINALDO JE, 1990, AM J RESP CELL MOL, V3, P207, DOI 10.1165/ajrcmb/3.3.207; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; SAXNE T, 1988, ARTHRITIS RHEUM, V31, P1041, DOI 10.1002/art.1780310816; SCHWARTZ DB, 1989, CHEST, V95, P871, DOI 10.1378/chest.95.4.871; SCUDERI P, 1986, LANCET, V2, P1364; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SILVA AT, 1990, J INFECT DIS, V162, P454, DOI 10.1093/infdis/162.2.454; SMITH JG, 1990, J INFECT DIS, V162, P1349, DOI 10.1093/infdis/162.6.1349; SMITH LJ, 1988, AM REV RESPIR DIS, V137, P1015, DOI 10.1164/ajrccm/137.5.1015; SNAPPER JR, 1984, J CLIN INVEST, V74, P1782, DOI 10.1172/JCI111597; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; SUN XM, 1990, AM J PATHOL, V136, P949; THORNHILL MH, 1990, J IMMUNOL, V144, P3060; TRACEY KJ, 1988, AM REV RESPIR DIS, V138, P1377, DOI 10.1164/ajrccm/138.6.1377; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; UTSUMI K, 1990, J IMMUNOL, V145, P397; VANE JR, 1990, NEW ENGL J MED, V323, P27; WAAGE A, 1986, SCAND J IMMUNOL, V24, P739, DOI 10.1111/j.1365-3083.1986.tb02194.x; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WALLACE JL, 1987, GASTROENTEROLOGY, V93, P765, DOI 10.1016/0016-5085(87)90438-0; WARNER SJC, 1987, J IMMUNOL, V139, P1911; WARREN RS, 1987, ARCH SURG-CHICAGO, V122, P1396; WOLFF SM, 1973, J INFECT DIS, V128, pS259, DOI 10.1093/infdis/128.Supplement_1.S259; Young LS, 1990, PRINCIPLES PRACTICE, P611; ZUCKERMAN SH, 1989, INFECT IMMUN, V57, P3009, DOI 10.1128/IAI.57.10.3009-3013.1989; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213; MMWR, V39, P31; 1989, MONTHLY VITAL STATIS, V37	141	1225	1325	2	84	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					457	469		10.7326/0003-4819-115-6-457	http://dx.doi.org/10.7326/0003-4819-115-6-457			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872494				2022-12-28	WOS:A1991GE81000008
J	SANTOS, RM; VIEIRA, SA; LIMA, DR				SANTOS, RM; VIEIRA, SA; LIMA, DR			EFFECTS OF COFFEE IN ALCOHOLICS	ANNALS OF INTERNAL MEDICINE			English	Letter									UNIV FED RIO DE JANEIRO, INST NEUROL, BR-22290 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro	SANTOS, RM (corresponding author), INST FARMACOL CLIN, BR-21931 RIO DE JANEIRO, BRAZIL.							CURATOLO PW, 1983, ANN INTERN MED, V98, P641, DOI 10.7326/0003-4819-98-5-641; LIMA DR, 1990, COFFEE MED PLANT, P43; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; WYNNE KN, 1987, CLIN EXP PHARMACOL P, V14, P785, DOI 10.1111/j.1440-1681.1987.tb01869.x	4	4	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					499	499		10.7326/0003-4819-115-6-499_1	http://dx.doi.org/10.7326/0003-4819-115-6-499_1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872504				2022-12-28	WOS:A1991GE81000021
J	STRUNK, CL; BAILEY, BJ; SCOTT, BA; CUMMINGS, CW; LUCENTE, FE; BEATTY, CW; NEEL, HB; PILLSBURY, HC; RICE, DH; BRYAN, MD; HOKANSON, JA				STRUNK, CL; BAILEY, BJ; SCOTT, BA; CUMMINGS, CW; LUCENTE, FE; BEATTY, CW; NEEL, HB; PILLSBURY, HC; RICE, DH; BRYAN, MD; HOKANSON, JA			RESIDENT WORK HOURS AND WORKING ENVIRONMENT IN OTOLARYNGOLOGY - ANALYSIS OF DAILY ACTIVITY AND RESIDENT PERCEPTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICINE HOUSE STAFF; SLEEP-DEPRIVATION; PERFORMANCE; PHYSICIANS	Objective. - To analyze the working environment and work hours of a cohort of otolaryngology-head and neck surgery residents. Design. - Environmental analysis questionnaire and a log of daily activities. Setting. - Residents were on a clinical rotation system. Participants. - Fifty-nine residents from six programs, including three public and three private institutions, from geographically diverse regions of the country were involved in the study. Residents were equally distributed from their second year through their fifth year of postgraduate work. All eligible residents participated in and completed the study. Intervention. - The environmental analysis survey was designed to elicit resident perception of different aspects of their working environment. The daily activity log required the resident to report on activities for each half-hour period for 7 consecutive days. Results. - Residents were on call an average of 52.8 hours (2.2 days) and worked 79.4 hours per week. Seventy-five percent believed that the level of faculty supervision and the degree of resident responsibility was about right. Two major inefficiencies were the time involved in completion of paperwork and the lack of nonmedical support services. Thirty-one percent of the residents responded that fatigue resulted in substandard patient care 10% of the time. Forty-seven percent responded that their educational experience was substandard 25% of the time secondary to fatigue. Two thirds responded that the demands of residency training had a negative impact on their family and personal life. Conclusions. - Seventy percent of the otolaryngology-head and neck surgery residents surveyed at six institutions believe that an 80-hour workweek, including being on call every third night with no more than 24 hours of continuous work without sleep, approximates a reasonable, maximum work schedule. Residents working the longest hours expressed concern about rendering substandard care and developing negative attitudes toward patients. Noneducational inefficiencies were identified and solutions were proposed. Demands of residency training, even within guidelines established as reasonable, can have detrimental effects on residents' educational activities and personal life.	UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; NEW YORK EYE & EAR INST, NEW YORK, NY USA; MAYO MED CTR, ROCHESTER, MN USA; UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; UNIV SO CALIF, LOS ANGELES, CA 90089 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Washington; University of Washington Seattle; New York Eye & Ear Infirmary of Mount Sinai; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California								ASCH DA, 1988, NEW ENGL J MED, V318, P771, DOI 10.1056/NEJM198803243181209; CLARK OH, 1990, B AM COLL SURG, V75, P11; Condon R E, 1990, Bull Am Coll Surg, V75, P15; DEACONSON TF, 1988, JAMA-J AM MED ASSOC, V260, P1721, DOI 10.1001/jama.260.12.1721; FRIEDMAN RC, 1971, NEW ENGL J MED, V285, P201, DOI 10.1056/NEJM197107222850405; JACQUES CHM, 1990, J FAM PRACTICE, V30, P223; LEIGHTON K, 1983, LANCET, V1, P1280; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MCCALL TB, 1988, NEW ENGL J MED, V318, P775, DOI 10.1056/NEJM198803243181210; ROBBINS J, 1990, WESTERN J MED, V152, P82; RUBIN R, 1991, J OCCUP ENVIRON MED, V33, P13, DOI 10.1097/00043764-199101000-00007; RUBY ST, 1990, ARCH SURG-CHICAGO, V125, P764; SILBERGER AB, 1988, HEALTH AFFAIR, V7, P121, DOI 10.1377/hlthaff.7.2.121	13	18	18	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1371	1374		10.1001/jama.266.10.1371	http://dx.doi.org/10.1001/jama.266.10.1371			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880867				2022-12-28	WOS:A1991GD80700031
J	ROTH, PB				ROTH, PB			STATUS OF A NATIONAL DISASTER MEDICAL RESPONSE - COMMENTARY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ROTH, PB (corresponding author), UNIV NEW MEXICO, MED CTR, SCH MED, DEPT EMERGENCY MED, 620 CAMINO DESALUD NE, ALBUQUERQUE, NM 87131 USA.							MAHONEY LE, 1986, DISASTER MED ASSISTA; PRETTO EA, 1991, JAMA-J AM MED ASSOC, V266, P1259, DOI 10.1001/jama.266.9.1259	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1266	1266		10.1001/jama.266.9.1266	http://dx.doi.org/10.1001/jama.266.9.1266			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870254				2022-12-28	WOS:A1991GC85800038
J	WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL				WHITE, DJ; CHANG, HG; BENACH, JL; BOSLER, EM; MELDRUM, SC; MEANS, RG; DEBBIE, JG; BIRKHEAD, GS; MORSE, DL			THE GEOGRAPHIC SPREAD AND TEMPORAL INCREASE OF THE LYME-DISEASE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ERYTHEMA CHRONICUM MIGRANS; NEW-YORK; IXODES-DAMMINI; BORRELIA-BURGDORFERI; WESTCHESTER-COUNTY; UNITED-STATES; ENDEMIC AREA; TICK BITES; ARTHRITIS; FEATURES	Objective. - To describe the temporal and geographic progression of the Lyme disease epidemic in New York State from 1977 through 1989. Design. - Communicable disease surveillance system. Setting. - Statewide. Main Outcome Measures. - The progression of the epidemic was examined by analyzing trends in Lyme disease cases reported to the state surveillance system, town and county Lyme disease incidence rates, Lyme disease hospital discharge rates, and the distribution of Ixodes dammini ticks obtained from surveillance efforts and submitted for identification. Main Results. - The number of confirmed Lyme disease cases in New York has increased with concurrent increases in the number of hospital discharges. The number of counties endemic for Lyme disease increased from four to eight between 1985 and 1989. The number of counties with documented I dammini ticks increased from four in 1985 to 22 in 1989. Incidence of the disease also increased within known endemic counties. Conclusions. - Tick surveillance indicated that the range of I dammini has expanded annually into areas up to 384 km from the original known endemic areas of Long Island, NY, and Connecticut. Cumulative data from human surveillance resources document both temporal increases and geographic expansion of the Lyme disease epidemic in New York.			WHITE, DJ (corresponding author), NEW YORK STATE DEPT HLTH, BUR COMMUNICABLE DIS CONTROL, 651 CORNING TOWER, EMPIRE STATE PLAZA, ALBANY, NY 12237 USA.		Birkhead, Guthrie/AAG-9058-2019	Birkhead, Guthrie/0000-0002-6511-6560	NIAID NIH HHS [AI27044] Funding Source: Medline; NIAMS NIH HHS [AR40445] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027044, R01AI027044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040445] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson J F, 1989, Conn Med, V53, P343; ANDERSON JF, 1987, J PARASITOL, V73, P419, DOI 10.2307/3282102; ANDERSON JF, 1986, INFECT IMMUN, V51, P394, DOI 10.1128/IAI.51.2.394-396.1986; BENACH J L, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P477; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BENACH JL, 1988, ANN NY ACAD SCI, V539, P1; BIRKHEAD G, 1990, 4TH INT C LYM BORR S, P12; BIRKHEAD GS, 1990, 4TH INT C LYM BORR S, P67; BISHOPP FC, 1945, J PARASITOL, V31, P1, DOI 10.2307/3273061; BOSLER EM, 1984, YALE J BIOL MED, V57, P651; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Cartter M L, 1989, Conn Med, V53, P320; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Cooley R. A., 1945, NATION INST HEALTH BULL, V184, P1; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; FALCO RC, 1989, AM J PUBLIC HEALTH, V79, P12, DOI 10.2105/AJPH.79.1.12; FALCO RC, 1988, AM J EPIDEMIOL, V127, P826, DOI 10.1093/oxfordjournals.aje.a114865; FISH D, 1990, J WILDLIFE DIS, V26, P339, DOI 10.7589/0090-3558-26.3.339; FISH D, 1990, 4TH INT C LYM BORR S, P50; HABICHT GS, 1987, SCI AM, V257, P78, DOI 10.1038/scientificamerican0787-78; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANRAHAN JP, 1984, YALE J BIOL MED, V57, P643; JAMNBACK H, 1969, STATE MUSEUM SCI SER, V19, P1; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; SMITH PF, 1988, ANN NY ACAD SCI, V539, P289, DOI 10.1111/j.1749-6632.1988.tb31863.x; SMITH RP, 1990, AM J PUBLIC HEALTH, V80, P333, DOI 10.2105/AJPH.80.3.333; SPIELMAN A, 1979, J MED ENTOMOL, V15, P218, DOI 10.1093/jmedent/15.3.218; STANEK G, 1987, LYME BORRELIOSIS, P1; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1979, ANN INTERN MED, V91, P730, DOI 10.7326/0003-4819-91-5-730; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1984, YALE J BIOL MED, V57, P445; Tsai T F, 1989, Conn Med, V53, P324; WALLIS RC, 1978, AM J EPIDEMIOL, V108, P322, DOI 10.1093/oxfordjournals.aje.a112626; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; WEISBROD AR, 1989, APPL ENVIRON MICROB, V55, P1921, DOI 10.1128/AEM.55.8.1921-1924.1989; WILLIAMS CL, 1986, AM J PUBLIC HEALTH, V76, P62, DOI 10.2105/AJPH.76.1.62; 1985, AM HOSP ASS NEWSLETT, V2, P6; 1989, MMWR, V38, P668	48	96	96	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1230	1236		10.1001/jama.266.9.1230	http://dx.doi.org/10.1001/jama.266.9.1230			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870248				2022-12-28	WOS:A1991GC85800031
J	RAMSEY, PG; CARLINE, JD; INUI, TS; LARSON, EB; LOGERFO, JP; NORCINI, JJ; WENRICH, MD				RAMSEY, PG; CARLINE, JD; INUI, TS; LARSON, EB; LOGERFO, JP; NORCINI, JJ; WENRICH, MD			CHANGES OVER TIME IN THE KNOWLEDGE BASE OF PRACTICING INTERNISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine factors affecting the knowledge base of practicing internists. Design.-An 82-item multiple-choice examination with questions from the 1988 American Board of Internal Medicine (ABIM) certifying examination was used to assess the knowledge base of 289 internists. Setting and Participants.-Participants were selected from among practicing internists in New York, New Jersey, and Pennsylvania who had received ABIM certification 5 to 15 years previously Results.-A significant inverse correlation (r= -.30) was found between examination scores and the number of years elapsed since certification. Knowledge declined sharply within 15 years of certification. In addition, procedure-oriented subspecialists (cardiologists and gastroenterologists) had lower scores than other internists in this examination of general medical knowledge. Multivariate analyses showed that independent variables that predicted test performance were initial ABIM certifying examination score, time elapsed since certification, subspecialty classification, medical school type, and residency type. Conclusions.-These results support the recent decision for time-limited certification of internists and raise questions related to content and standard setting for recertification examinations.	AMER BOARD INTERNAL MED, PHILADELPHIA, PA USA; UNIV WASHINGTON, SCH MED, DEPT MED EDUC, SEATTLE, WA 98195 USA	American Board of Internal Medicine; University of Washington; University of Washington Seattle	RAMSEY, PG (corresponding author), UNIV WASHINGTON, SCH MED, DEPT MED, RG-20, SEATTLE, WA 98195 USA.			Norcini, John/0000-0002-8464-4115				CARLINE JD, 1989, ARCH INTERN MED, V149, P2311, DOI 10.1001/archinte.149.10.2311; DAY SC, 1988, P ANN C RES MED ED, V27, P139; FERGUSON GA, 1971, STATISTICAL ANAL PSY, P367; GOURMAN J, 1980, GOURMAN REPORT RATIN, P64; MESKAUSKAS JA, 1975, ANN INTERN MED, V82, P577, DOI 10.7326/0003-4819-82-4-577; NORCINI JJ, 1985, ANN INTERN MED, V102, P385, DOI 10.7326/0003-4819-102-3-385; PETERSDORF RG, 1989, J GEN INTERN MED, V4, P527, DOI 10.1007/BF02599554; RAMSEY PG, 1990, ASSESSMENT CLIN COMP	8	126	133	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1103	1107		10.1001/jama.266.8.1103	http://dx.doi.org/10.1001/jama.266.8.1103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865543				2022-12-28	WOS:A1991GB97500033
J	ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G				ADLER, M; LAZARUS, RA; DENNIS, MS; WAGNER, G			SOLUTION STRUCTURE OF KISTRIN, A POTENT PLATELET-AGGREGATION INHIBITOR AND GP-IIB-IIIA ANTAGONIST	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; DISTANCE GEOMETRY; AQUEOUS-SOLUTION; CELL-ADHESION; GPIIB-IIIA; INTEGRINS; FAMILY; VENOMS	The structure of kistrin, which is a member of a homologous family of glycoprotein IIb-IIIa (GP IIb-IIIa) antagonists and potent protein inhibitors of platelet aggregation, has been determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy. The 68-residue protein consists of a series of tightly packed loops held together by six disulfide bonds and has almost no regular secondary structure. Kistrin has an Arg-Gly-Asp (RGD) adhesion site recognition sequence important for binding to GP IIb-IIIa that is located at the apex of a long loop across the surface of the protein.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, SAN FRANCISCO, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech					NIGMS NIH HHS [GM38608] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038608] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, UNPUB; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARKER PL, 1991, Patent No. 1331; BECKER RC, 1991, CIRCULATION, V83, P1115, DOI 10.1161/01.CIR.83.3.1115; Carter P, UNPUB; DENNIS MR, UNPUB; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; GARSKY VM, 1989, P NATL ACAD SCI USA, V86, P4022, DOI 10.1073/pnas.86.11.4022; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAWIGER J, 1990, ATHER REV, V21, P165; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; MAZUR P, UNPUB; MONTELIONE GT, 1986, J AM CHEM SOC, V108, P6765, DOI 10.1021/ja00281a051; NICHOLS A, 1990, EUR J PHARMACOL, V183, P2019, DOI 10.1016/0014-2999(90)92378-V; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; STEIN B, 1989, J AM COLL CARDIOL, V14, P813, DOI 10.1016/0735-1097(89)90453-1; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; YASUDA T, 1991, CIRCULATION, V83, P1038, DOI 10.1161/01.CIR.83.3.1038	24	249	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					445	448		10.1126/science.1862345	http://dx.doi.org/10.1126/science.1862345			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862345				2022-12-28	WOS:A1991FY28800040
J	DAY, P; KLEIN, R				DAY, P; KLEIN, R			VARIATIONS IN BUDGETS OF FUNDHOLDING PRACTICES	BRITISH MEDICAL JOURNAL			English	Article											DAY, P (corresponding author), UNIV BATH,SCH SOCIAL SCI,CTR ANAL SOCIAL POLICY,BATH BA2 7AY,AVON,ENGLAND.							BUXTON MJ, 1978, ALLOCATING HLTH RESO; Crombie D L, 1988, Health Trends, V20, P53; ROLAND M, 1988, BRIT MED J, V297, P437, DOI 10.1136/bmj.297.6646.437; WILKIN D, 1990, GENERAL PRACTITIONER; WILKIN D, 1987, ANATOMY URBAN GENERA; 1991, CMND1513	6	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					168	170		10.1136/bmj.303.6795.168	http://dx.doi.org/10.1136/bmj.303.6795.168			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878644	Bronze, Green Published			2022-12-28	WOS:A1991FX57800026
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - ANTEPARTUM HEMORRHAGE	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.							CHAMBERLAIN R, BRIT BIRTHS 1970	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1526	1530		10.1136/bmj.302.6791.1526	http://dx.doi.org/10.1136/bmj.302.6791.1526			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855028	Green Published, Bronze			2022-12-28	WOS:A1991FT50500031
J	HADLEY, T; DJULBEGOVIC, B				HADLEY, T; DJULBEGOVIC, B			DISSEMINATED INTRAVASCULAR COAGULATION AFTER FACTOR-IX COMPLEX RESOLVED USING PURIFIED FACTOR-IX CONCENTRATE	ANNALS OF INTERNAL MEDICINE			English	Note						DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR-IX; CHRISTMAS DISEASE; ANTIBODIES, MONOCLONAL; FACTOR-IX COMPLEX	HEMOPHILIA-B	A patient with hemophilia B developed disseminated intravascular coagulation during treatment with factor IX complex. Factor IX complex was withdrawn, and the patient was treated with monoclonal antibody-purified factor IX. The disseminated intravascular coagulation resolved during treatment with purified factor IX, indicating that purified factor IX does not sustain factor IX complex-induced disseminated intravascular coagulation. This is the first reported case of the use of monoclonal antibody factor IX in a patient with factor IX complex-induced disseminated intravascular coagulation.	UNIV LOUISVILLE, JAMES GRAHAM BROWN CANC CTR, DEPT MED DIV MED ONCOL HEMATOL, LOUISVILLE, KY 40292 USA	University of Louisville			Djulbegovic, Benjamin/I-3661-2012	Djulbegovic, Benjamin/0000-0003-0671-1447				ARONSON DL, 1979, SEMIN THROMB HEMOST, V6, P28; CAMPBELL EW, 1978, TRANSFUSION, V18, P94, DOI 10.1046/j.1537-2995.1978.18178118575.x; CONLAN MG, 1990, AM J HEMATOL, V35, P203, DOI 10.1002/ajh.2830350312; HULTIN MB, 1979, BLOOD, V54, P1028; KIM HC, 1990, SEMIN HEMATOL, V27, P30; KIM HC, 1990, BLOOD, V76, pA425; MANNUCCI PM, 1990, BLOOD, V76, P2540	7	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					621	622		10.7326/0003-4819-115-8-621	http://dx.doi.org/10.7326/0003-4819-115-8-621			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892334				2022-12-28	WOS:A1991GJ90200007
J	SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD				SEARS, MR; BURROWS, B; FLANNERY, EM; HERBISON, GP; HEWITT, CJ; HOLDAWAY, MD			RELATION BETWEEN AIRWAY RESPONSIVENESS AND SERUM IGE IN CHILDREN WITH ASTHMA AND IN APPARENTLY NORMAL-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRONCHIAL REACTIVITY; POPULATION-SAMPLE; CHILDHOOD ASTHMA; NEW-ZEALAND; HISTAMINE; METHACHOLINE; ATOPY; HYPERRESPONSIVENESS; PREVALENCE; ALLERGY	Background. Although asthma diagnosed by a physician is known to be related to serum IgE levels, it is not known whether there is a relation between the level of IgE and airway hyperresponsiveness to a methacholine challenge. The characteristics of asymptomatic persons that predispose them to airway hyperresponsiveness are also unknown. Methods. We studied the relation between the serum total IgE level and airway hyperresponsiveness in the presence or absence of asthma and other atopic diseases in a birth cohort of children. Data from a questionnaire regarding respiratory symptoms, plus measurements of the serum total IgE level and airway responsiveness to inhaled methacholine, were obtained for 562 11-year-olds in New Zealand. Results. The boys had a higher prevalence than the girls of current diagnosed asthma (13 percent vs. 6 percent), current symptoms of wheezing (22 percent vs. 15 percent), and airflow obstruction at base line (6 percent vs. 1 percent) and had a wider distribution of IgE levels, although mean IgE levels (120.8 IU per milliliter in the boys and 98.1 IU per milliliter in the girls) did not differ significantly between the sexes. The prevalence of diagnosed asthma was strongly related to the serum IgE level (P for trend < 0.0001). No asthma was reported in children with IgE levels < 32 IU per milliliter, whereas 36 percent of those with IgE levels greater-than-or-equal-to 1000 IU per milliliter were reported to have asthma. This relation with the serum IgE level was not explained by a concomitant diagnosis of allergic rhinitis or eczema. Airway hyperresponsiveness to a methacholine challenge also correlated very highly (P < 0.0001) with the serum IgE level. This relation remained significant even after the exclusion of children with diagnosed asthma (P < 0.0001) and of all children with a history of wheezing, allergic rhinitis, or eczema (P < 0.0001). Conclusions. Even in children who have been asymptomatic throughout their lives and have no history of atopic disease, airway hyperresponsiveness appears to be closely linked to an allergic diathesis, as reflected by the serum total IgE level.	UNIV ARIZONA,COLL MED,DIV RESP SCI,TUCSON,AZ 85721; UNIV OTAGO,SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT PAEDIAT & CHILD HLTH,DUNEDIN,NEW ZEALAND	University of Arizona; University of Otago; University of Otago; University of Otago				Herbison, Graham Peter/0000-0002-5684-024X	NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; DAVIES RJ, 1976, THORAX, V31, P419, DOI 10.1136/thx.31.4.419; GRAINGER DN, 1990, CLIN EXP ALLERGY, V20, P181, DOI 10.1111/j.1365-2222.1990.tb02665.x; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P1520, DOI 10.1164/ajrccm/140.6.1520; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826, DOI 10.1164/ajrccm/137.4.826; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Silva P A, 1990, Paediatr Perinat Epidemiol, V4, P76, DOI 10.1111/j.1365-3016.1990.tb00621.x; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	26	655	670	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1067	1071		10.1056/NEJM199110103251504	http://dx.doi.org/10.1056/NEJM199110103251504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891008				2022-12-28	WOS:A1991GJ10800004
J	MORIN, GB				MORIN, GB			RECOGNITION OF A CHROMOSOME TRUNCATION SITE ASSOCIATED WITH ALPHA-THALASSEMIA BY HUMAN TELOMERASE	NATURE			English	Article							TERMINAL TRANSFERASE-ACTIVITY; PROTOZOAN OXYTRICHA-NOVA; MACRONUCLEAR DNA; TETRAHYMENA; SEQUENCES; BREAKAGE; RIBONUCLEOPROTEIN; IDENTIFICATION; DELETIONS; REPEATS	TELOMERES define the ends of chromosomes; they consist of short tandemly repeated DNA sequences loosely conserved in eukaryotes (G1-8(T/A)1-4) 1. Telomerase is a ribonucleoprotein which, in vitro, recognizes a single-stranded G-rich telomere primer and adds multiple telomeric repeats to its 3' end by using a template in the RNA moiety 2-6. In conjunction with other components, telomerase may balance the loss of telomeric repeats due to DNA replication 7. Another role of telomerase may be the de novo formation of telomeres. In eukaryotes like Tetrahymena, this process is an integral part of the formation of macronuclear chromosomes 8. In other eukaryotes this process stabilizes broken chromosomes. A case of human alpha-thalassaemia is caused by a truncation of chromosome 16 that has been healed by the addition of telomeric repeats (TTAGGG)n (ref. 9). Using an in vitro assay 4, I show here that human telomerase correctly recognizes the chromosome 16 breakpoint sequence and adds (TTAGGG)n repeats. The DNA sequence requirements are minimal and seem to define two modes of DNA recognition by telomerase.	YALE UNIV,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University			Morin, Gregg B/E-9123-2012	Morin, Gregg B/0000-0001-8949-4374				ADAM RD, 1991, MOL CELL BIOL, V11, P3326, DOI 10.1128/MCB.11.6.3326; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BLACKBURN EH, 1986, ANNU REV GENET, V20, P501; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GILLEY D, 1988, MOL CELL BIOL, V8, P4765, DOI 10.1128/MCB.8.11.4765; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUSELLA JF, 1985, NATURE, V318, P75, DOI 10.1038/318075a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HERRICK G, 1987, GENE DEV, V1, P1047, DOI 10.1101/gad.1.10.1047; KAMPER J, 1989, MOL CELL BIOL, V9, P3931; KLOBUTCHER LA, 1986, MOL CELL BIOL, V6, P3606, DOI 10.1128/MCB.6.11.3606; KLOBUTCHER LA, 1984, CELL, V36, P1045, DOI 10.1016/0092-8674(84)90054-0; KLOBUTCHER LA, 1988, NUCLEIC ACIDS RES, V16, P251, DOI 10.1093/nar/16.1.251; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; YAO MC, 1990, CELL, V63, P763, DOI 10.1016/0092-8674(90)90142-2; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	31	191	199	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					454	456		10.1038/353454a0	http://dx.doi.org/10.1038/353454a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896089				2022-12-28	WOS:A1991GH60600065
J	ARMIJOHUSSEIN, NA				ARMIJOHUSSEIN, NA			THE EFFECT OF THE GULF CRISIS ON THE CHILDREN OF IRAQ	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											ARMIJOHUSSEIN, NA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115, USA.		Passey, Megan/AAC-7062-2019	Passey, Megan/0000-0001-5766-0235; Moodie, Alan/0000-0002-8425-7975				Ahtisaari Martti, 1991, REPORT SECRETARY GEN; [Anonymous], 1990, HUMAN DEV REPORT; ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; ELSAMANI F, 1991, MISSION REPORT IRAQ; GEIGER J, 1989, NEW ENGL J MED, V321, P1136, DOI 10.1056/NEJM198910193211629; STEIN Z, FAMINE HUMAN DEV DUT; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; WINICK M, 1979, CURRENT CONCEPTS NUT, V7; 1990, NATIONAL SURVEY VACC; 1989, CHILDREN FRONT LINE	10	24	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					977	980						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF856	1881427				2022-12-28	WOS:A1991GF85600037
J	BISNO, AL				BISNO, AL			GROUP-A STREPTOCOCCAL INFECTIONS AND ACUTE RHEUMATIC-FEVER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHOCK-LIKE SYNDROME; DISSEMINATED INTRAVASCULAR COAGULATION; ALTERNATIVE COMPLEMENT PATHWAY; UPPER RESPIRATORY-TRACT; M-PROTEIN; UNITED-STATES; ACUTE GLOMERULONEPHRITIS; PENICILLIN THERAPY; ERADICATE GROUP; SCARLET FEVER		VET AFFAIRS MED CTR,RES SERV,MIAMI,FL 33125; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33152	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami	BISNO, AL (corresponding author), VET AFFAIRS MED CTR,MED SERV,1201 NW 16TH ST,MIAMI,FL 33125, USA.							ACHARYA U, 1988, LANCET, V1, P595; ANASTASIOUNANA MI, 1986, AM HEART J, V112, P992, DOI 10.1016/0002-8703(86)90311-X; [Anonymous], 1990, MMWR-MORBID MORTAL W, V39, P577; AYOUB EM, 1986, J CLIN INVEST, V77, P2019, DOI 10.1172/JCI112531; BADDOUR LM, 1982, ANN INTERN MED, V97, P493, DOI 10.7326/0003-4819-97-4-493; BADDOUR LM, 1985, AM J MED, V79, P155, DOI 10.1016/0002-9343(85)90003-8; BARG NL, 1985, AM J MED, V78, P569, DOI 10.1016/0002-9343(85)90397-3; BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; Beachey E H, 1972, Trans Assoc Am Physicians, V85, P212; BEACHEY EH, 1977, J EXP MED, V145, P1469, DOI 10.1084/jem.145.6.1469; BEACHEY EH, 1971, J EXP MED, V134, P351, DOI 10.1084/jem.134.2.351; BEACHEY EH, 1983, REV INFECT DIS, V5, pS670; BEACHEY EH, 1976, J EXP MED, V143, P759, DOI 10.1084/jem.143.4.759; BEACHEY EH, 1983, J BIOL CHEM, V258, P3250; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BELANI K, 1991, PEDIATR INFECT DIS J, V10, P351, DOI 10.1097/00006454-199105000-00001; BERRIOS X, 1986, J LAB CLIN MED, V108, P535; BESSEN D, 1989, J EXP MED, V169, P269, DOI 10.1084/jem.169.1.269; BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945; BIBLER MR, 1986, REV INFECT DIS, V8, P941; Bisno A.L., 1980, STREPTOCOCCAL DISEAS, P789; BISNO AL, 1970, NEW ENGL J MED, V283, P561, DOI 10.1056/NEJM197009102831103; BISNO AL, 1977, J INFECT DIS, V136, P278, DOI 10.1093/infdis/136.2.278; BISNO AL, 1989, ARTHRITIS RHEUM, V32, P230, DOI 10.1002/anr.1780320219; BISNO AL, 1982, INFECT IMMUN, V38, P573, DOI 10.1128/IAI.38.2.573-579.1982; BISNO AL, 1990, ANNU REV MED, V41, P319, DOI 10.1146/annurev.me.41.020190.001535; BISNO AL, 1987, INFECT IMMUN, V55, P753, DOI 10.1128/IAI.55.3.753-757.1987; BISNO AL, 1979, INFECT IMMUN, V26, P1172, DOI 10.1128/IAI.26.3.1172-1176.1979; BISNO AL, 1986, RESPIRATORY INFECTIO, V5, P217; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; BREESE BB, 1977, AM J DIS CHILD, V131, P514, DOI 10.1001/archpedi.1977.02120180028003; BROOK I, 1985, PEDIATR INFECT DIS J, V4, P491, DOI 10.1097/00006454-198509000-00010; BROWNELL KD, 1973, JAMA-J AM MED ASSOC, V224, P1593, DOI 10.1001/jama.224.12.1593; BURNS DL, 1987, PEDIATR RES, V21, pA256, DOI 10.1203/00006450-198704010-00533; CEBUL RD, 1986, JAMA-J AM MED ASSOC, V256, P3353, DOI 10.1001/jama.256.24.3353; CHAUDHARY S, 1985, J PEDIATR-US, V106, P481, DOI 10.1016/S0022-3476(85)80687-9; Coburn AF, 1935, J CLIN INVEST, V14, P755, DOI 10.1172/JCI100723; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; CONGENI B, 1987, J PEDIATR-US, V111, P176, DOI 10.1016/S0022-3476(87)80063-X; CONNOLLY T J, 1989, Henry Ford Hospital Medical Journal, V37, P69; CRAVEN DE, 1986, J INFECT DIS, V153, P988, DOI 10.1093/infdis/153.5.988; DAJANI AS, 1988, CIRCULATION, V78, P1082, DOI 10.1161/01.CIR.78.4.1082; DALE JB, 1985, J EXP MED, V162, P583, DOI 10.1084/jem.162.2.583; DAN M, 1990, REV INFECT DIS, V12, P537; DENNY FW, 1957, J CLIN INVEST, V36, P1092, DOI 10.1172/JCI103504; DRABICK JJ, 1989, NEW ENGL J MED, V321, P1545, DOI 10.1056/NEJM198911303212212; FELDMAN S, 1987, J PEDIATR-US, V110, P783, DOI 10.1016/S0022-3476(87)80024-0; FERGUSON GW, IN PRESS J INFECT DI; FIEDEL BA, 1978, INFECT IMMUN, V22, P286, DOI 10.1128/IAI.22.1.286-287.1978; FILLIT HM, 1988, J EXP MED, V168, P971, DOI 10.1084/jem.168.3.971; FILLIT HM, 1986, J EXP MED, V164, P762, DOI 10.1084/jem.164.3.762; FISCHETTI VA, 1989, SCIENCE, V244, P1487, DOI 10.1126/science.2660266; FISCHETTI VA, 1988, REV INFECT DIS, V10, pS356; FRANCIS J, 1988, Q J MED, V68, P603; GASTANADUY AS, 1980, LANCET, V2, P498; GAWORZEWSKA E, 1988, EPIDEMIOL INFECT, V100, P257, DOI 10.1017/S095026880006739X; GAWORZEWSKA ET, 1989, NEW ENGL J MED, V321, P1546; GERBER MA, 1989, PEDIATR INFECT DIS J, V8, P820, DOI 10.1097/00006454-198911000-00032; GORDIS L, 1969, J CHRON DIS, V21, P645, DOI 10.1016/0021-9681(69)90036-8; GORDIS L, 1985, CIRCULATION, V72, P1155, DOI 10.1161/01.CIR.72.6.1155; GORDIS L, 1984, PHARYNGITIS MANAGEME, P13; GREENBLATT J, 1978, INFECT IMMUN, V19, P296, DOI 10.1128/IAI.19.1.296-303.1978; GRIFFITHS SP, 1990, J PEDIATR-US, V116, P882, DOI 10.1016/S0022-3476(05)80644-4; GUIRGUIS N, 1982, AM J EPIDEMIOL, V116, P933, DOI 10.1093/oxfordjournals.aje.a113495; HANSMAN D, 1989, NEW ENGL J MED, V321, P1546; Heggie A D, 1988, Navy Med, V79, P26; HOGE C, 1990, 30TH INT C ANT AG CH; HOLM SE, 1990, 11 LANC S STREPT STR; HOLMBERG SD, 1983, JAMA-J AM MED ASSOC, V250, P2307, DOI 10.1001/jama.250.17.2307; HOSIER DM, 1987, AM J DIS CHILD, V141, P730, DOI 10.1001/archpedi.1987.04460070032015; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; ISPHAHANI P, 1988, J INFECTION, V16, P37; JACKSON MA, 1988, MUCOID GROUP A STREP, V23, pA372; JAMES L, 1971, NEW ENGL J MED, V284, P750, DOI 10.1056/NEJM197104082841403; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KAPLAN EL, 1989, J INFECT DIS, V159, P101, DOI 10.1093/infdis/159.1.101; KAPLAN EL, 1988, J PEDIATR-US, V113, P400, DOI 10.1016/S0022-3476(88)80291-9; KAPLAN EL, 1981, J LAB CLIN MED, V98, P326; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KAVEY REW, 1989, PEDIATRICS, V84, P585; KAVI J, 1988, LANCET, V1, P993; KELLOGG JA, 1986, JAMA-J AM MED ASSOC, V255, P2638, DOI 10.1001/jama.255.19.2638; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; KHANDKE KM, 1987, J EXP MED, V166, P151, DOI 10.1084/jem.166.1.151; KHANNA AK, 1989, J CLIN INVEST, V83, P1710, DOI 10.1172/JCI114071; KIM KS, 1985, J PEDIATR-US, V107, P681, DOI 10.1016/S0022-3476(85)80392-9; KIM YB, 1972, STREPTOCOCCI STREPTO, P33; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; Kuttner AG, 1941, J CLIN INVEST, V20, P273, DOI 10.1172/JCI101220; LANCEFIELD RC, 1959, J EXP MED, V110, P271, DOI 10.1084/jem.110.2.271; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LAND MA, 1983, JAMA-J AM MED ASSOC, V249, P895, DOI 10.1001/jama.249.7.895; LEGGIADRO RJ, 1990, SOUTHERN MED J, V83, P1418, DOI 10.1097/00007611-199012000-00012; LENNON D, 1988, NEW ZEAL MED J, V101, P396; LENTNEK AL, 1990, ARCH INTERN MED, V150, P89, DOI 10.1001/archinte.150.1.89; MAJEED HA, 1988, NEW ZEAL MED J, V101, P398; MARCON MJ, 1988, J CLIN MICROBIOL, V26, P1539, DOI 10.1128/JCM.26.8.1539-1542.1988; MARKOWITZ M, 1985, J PEDIATR-US, V106, P545, DOI 10.1016/S0022-3476(85)80069-X; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; NELSON JD, 1984, PEDIATR INFECT DIS J, V3, P10, DOI 10.1097/00006454-198401000-00004; ODIO A, 1986, WESTERN J MED, V144, P179; PETER G, 1977, NEW ENGL J MED, V297, P311, DOI 10.1056/NEJM197708112970606; PETER G, 1977, NEW ENGL J MED, V297, P365, DOI 10.1056/NEJM197708182970706; PETERSON PK, 1979, J INFECT DIS, V139, P575, DOI 10.1093/infdis/139.5.575; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; PICHICHERO ME, 1991, PEDIATR INFECT DIS J, V10, P275, DOI 10.1097/00006454-199104000-00002; POIRIER TP, 1988, J EXP MED, V168, P25, DOI 10.1084/jem.168.1.25; POTTER EV, 1972, J INFECT DIS, V125, P619, DOI 10.1093/infdis/125.6.619; POTTER EV, 1978, J PEDIATR-US, V92, P325, DOI 10.1016/S0022-3476(78)80036-5; QUINN RW, 1985, PEDIATR INFECT DIS J, V4, P374, DOI 10.1097/00006454-198507000-00008; QUINN RW, 1989, REV INFECT DIS, V11, P928; QUINN RW, 1974, AM J EPIDEMIOL, V99, P273, DOI 10.1093/oxfordjournals.aje.a121612; Rammelkamp C.H., 1952, RHEUMATIC FEVER, P72; RANDOLPH MF, 1985, J PEDIATR-US, V106, P870, DOI 10.1016/S0022-3476(85)80228-6; REGELMANN WE, 1989, J RHEUMATOL, V16, P931; REID RI, 1983, J INFECTION, V6, P219, DOI 10.1016/S0163-4453(83)93549-1; RUBEN FL, 1984, ANN INTERN MED, V101, P494, DOI 10.7326/0003-4819-101-4-494; SCHLIEVERT PM, 1979, INFECT IMMUN, V26, P467, DOI 10.1128/IAI.26.2.467-472.1979; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SCHWARTZ RH, 1983, CLIN PEDIATR, V22, P798, DOI 10.1177/000992288302201202; SHAUNAK S, 1988, Q J MED, V69, P921; SIMPSON WA, 1987, REV INFECT DIS, V9, pS351; SMITH TD, 1987, J PEDIATR-US, V110, P777, DOI 10.1016/S0022-3476(87)80023-9; SMYTH EG, 1988, LANCET, V2, P452; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Stollerman G H, 1990, Adv Intern Med, V35, P1; STOLLERMAN GH, 1983, JAMA-J AM MED ASSOC, V250, P3097, DOI 10.1001/jama.250.22.3097; SWINGLER GR, 1988, LANCET, V1, P1456; TANZ RR, 1985, J PEDIATR-US, V106, P876, DOI 10.1016/S0022-3476(85)80229-8; TANZ RR, 1990, J PEDIATR-US, V117, P859, DOI 10.1016/S0022-3476(05)80122-2; THOMAS JC, 1989, J INFECT DIS, V160, P1086, DOI 10.1093/infdis/160.6.1086; THOMAS RJ, 1988, REV INFECT DIS, V10, P125; TOMAI M, 1990, J EXP MED, V172, P359, DOI 10.1084/jem.172.1.359; TOMPKINS RK, 1977, ANN INTERN MED, V86, P481, DOI 10.7326/0003-4819-86-4-481; TOP FH, 1964, COMMUNICABLE INFECTI, P319; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; VEASY LG, 1990, 11 LANC S STREPT STR; WALD ER, 1987, PEDIATRICS, V80, P371; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; Wannamaker LW, 1953, STREPTOCOCCAL INFECT, P157; WESTLAKE RM, 1990, PEDIATR INFECT DIS J, V9, P97, DOI 10.1097/00006454-199002000-00007; WILLOUGHBY R, 1983, ANN INTERN MED, V98, P559, DOI 10.7326/0003-4819-98-4-559_1; 1982, J EXP MED, V156, P1165; [No title captured]; 1990, MMWR, V39, P3; 1987, MMWR, V36, P108; [No title captured]; 1987, MMWR, V36, P115; 1990, MMWR, V39, P11	151	370	383	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					783	793		10.1056/NEJM199109123251106	http://dx.doi.org/10.1056/NEJM199109123251106			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870652				2022-12-28	WOS:A1991GE45600006
J	SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP				SAKAI, T; OHTANI, N; MCGEE, TL; ROBBINS, PD; DRYJA, TP			ONCOGENIC GERM-LINE MUTATIONS IN SP1 AND ATF SITES IN THE HUMAN RETINOBLASTOMA GENE	NATURE			English	Article							DNA-BINDING; REPORTER GENE; EXPRESSION; SEQUENCE; PROTEINS	THE transcription of a eukaryotic gene is a consequence of intricate interactions between members of a set of transcription factors 1. We describe here evidence indicating that at least two distinct DNA-binding factors play an important part in the transcription of the human retinoblastoma gene (Rb). One of the factors reacts with a sequence overlapping with a potential Sp1 recognition sequence in the promoter region of the gene, the other with a nearby ATF recognition sequence. We have identified two naturally occurring point mutations in these recognition sequences that cause hereditary retinoblastoma. The nuclear factors do not bind to the mutant sequences. We infer that these nuclear factors are necessary for the expression of the Rb gene and the suppression of cancer.	HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Ohtani, Naoko/0000-0001-8934-0797				BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; MACKLIN MT, 1960, AM J HUM GENET, V12, P1; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORITA M, 1989, GENOMICS, V5, P871; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3, P16; SASSONECORSI P, 1990, ONCOGENE, V5, P427	14	214	219	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					83	90		10.1038/353083a0	http://dx.doi.org/10.1038/353083a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881452				2022-12-28	WOS:A1991GD80500065
J	CARCILLO, JA; DAVIS, AL; ZARITSKY, A				CARCILLO, JA; DAVIS, AL; ZARITSKY, A			ROLE OF EARLY FLUID RESUSCITATION IN PEDIATRIC SEPTIC SHOCK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOREPINEPHRINE THERAPY; MYOCARDIAL DEPRESSION; CARDIAC DYSFUNCTION; CANINE MODEL; SEPSIS; CHILDREN	Objective. - To examine the association of the volume of fluid administered at 1 and 6 hours after presentation, with survival and the occurrence of the adult respiratory distress syndrome, cardiogenic pulmonary edema, and persistent hypovolemia during the resuscitation of children with septic shock. Setting and Patients. - All pediatric patients with septic shock presenting to the emergency department over a 6-year period and having a pulmonary artery catheter inserted by 6 hours after presentation were identified. Methods. - Patients were analyzed together and in three groups based on fluid volume in the first hour: group 1, less than 20 mL/kg; group 2,20 to 40 mL/kg; and group 3, more than 40 mL/kg. Adult respiratory distress syndrome was diagnosed by the presence of alveolar infiltrates, hypoxemia, and a pulmonary capillary wedge pressure of 15 mm Hg or less. Cardiogenic pulmonary edema was diagnosed similarly, except the pulmonary capillary wedge pressure was greater than 15 mm Hg. Hypovolemia was diagnosed by the presence of oliguria, hypotension, and a pulmonary capillary wedge pressure of 8 mm Hg or less 6 hours after presentation. Results. - We identified 34 patients (median age, 13.5 months). At 1 and 6 hours, respectively, group 1 (n = 14) received 11 +/- 6 and 71 +/- 29 mL/kg (mean +/- SD) of fluid; group 2 received 32 +/- 5 and 108 +/- 54 mL/kg of fluid; and group 3 received 69 +/- 19 and 117 +/- 29 mL/kg of fluid. Survival in group 3 (eight of nine patients) was significantly better than in group 1 (six of 14 patients) or group 2 (four of 11 patients). Adult respiratory distress syndrome developed in 11 patients (32%) and cardiogenic pulmonary edema developed in five patients (15%). Having adult respiratory distress syndrome was associated with increased mortality, but adult respiratory distress syndrome was not increased in any group. Similarly, cardiogenic pulmonary edema was not associated with the fluid volume received or with decreased survival. Hypovolemia occurred in six patients in group 1 and two patients in group 2; all eight subsequently died. Conclusion. - Rapid fluid resuscitation in excess of 40 mL/kg in the first hour following emergency department presentation was associated with improved survival, decreased occurrence of persistent hypovolemia, and no increase in the risk of cardiogenic pulmonary edema or adult respiratory distress syndrome in this group of pediatric patients with septic shock.	GEORGE WASHINGTON UNIV,CHILDRENS HOSP,NATL MED CTR,DEPT ANESTHESIOL & CRIT CARE MED,WASHINGTON,DC 20010	Children's National Health System; George Washington University								BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOUCEK MM, 1984, J PEDIATR-US, V105, P538, DOI 10.1016/S0022-3476(84)80416-3; CARROLL GC, 1982, AM J PHYSIOL, V243, pR131, DOI 10.1152/ajpregu.1982.243.1.R131; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI, P47; CHERNOW B, 1986, CIRC SHOCK, V18, P141; DESJARS P, 1987, CRIT CARE MED, V15, P134, DOI 10.1097/00003246-198702000-00011; KAUFMAN BS, 1984, CHEST, V85, P336, DOI 10.1378/chest.85.3.336; MEADOWS D, 1988, CRIT CARE MED, V16, P663, DOI 10.1097/00003246-198807000-00003; MONSALVE F, 1984, CRIT CARE MED, V12, P1021, DOI 10.1097/00003246-198412000-00003; NATANSON C, 1986, J CLIN INVEST, V78, P259, DOI 10.1172/JCI112559; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; PARKER MM, 1984, ANN INTERN MED, V100, P483, DOI 10.7326/0003-4819-100-4-483; POWELL KR, 1990, J PEDIATR-US, V117, P515, DOI 10.1016/S0022-3476(05)80682-1; RACKOW EC, 1987, CIRC SHOCK, V22, P11; REILLY JM, 1989, CHEST, V95, P1072, DOI 10.1378/chest.95.5.1072; ROTH BL, 1959, MOL CELLULAR MECHANI, P41; WEIL M, 1977, ANN CLIN RES, V9, P181; WEIL MH, 1978, AM J MED, V64, P920, DOI 10.1016/0002-9343(78)90444-8; WILES JB, 1980, CRIT CARE MED, V8, P55, DOI 10.1097/00003246-198002000-00001; WILSON RF, 1971, ANN SURG, V174, P939, DOI 10.1097/00000658-197112000-00009; [No title captured]; [No title captured]	22	249	257	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1242	1245		10.1001/jama.266.9.1242	http://dx.doi.org/10.1001/jama.266.9.1242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870250				2022-12-28	WOS:A1991GC85800033
J	FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F				FERNANDEZMORENO, MA; CABALLERO, JL; HOPWOOD, DA; MALPARTIDA, F			THE ACT CLUSTER CONTAINS REGULATORY AND ANTIBIOTIC EXPORT GENES, DIRECT TARGETS FOR TRANSLATIONAL CONTROL BY THE BLDA TRANSFER-RNA GENE OF STREPTOMYCES	CELL			English	Article							TETRACYCLINE-RESISTANCE GENE; NUCLEOTIDE-SEQUENCE ANALYSIS; ANION-EXCHANGE PROTEIN; COELICOLOR A3(2); ESCHERICHIA-COLI; TRANSCRIPTIONAL REGULATION; HETEROLOGOUS HOST; CLONING; BIOSYNTHESIS; EXPRESSION	The actII region, flanked by biosynthetic genes in the 25 kb act cluster of S. coelicolor, consists of four open reading frames, including a transcriptional activator for the biosynthetic genes, and genes controlling antibiotic export. A TTA codon (extremely rare in Streptomyces) is present both in actII-ORF2 (encoding a putative transmembrane export protein) and actII-ORF4 (the transcriptional activator gene). Change of the TTA in ORF4 to TTG reverses the normal interruption of actinorhodin synthesis caused by mutation in the pleiotropic regulatory gene bldA (which encodes the cell's tRNA(UUA)Leu). We conclude that initiation of actinorhodin synthesis via the actII-ORF4 product, and the final step in production, antibiotic export, are twin targets via which bldA exerts developmental control of actinorhodin production.	JOHN INNES INST,JOHN INNES INST,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	FERNANDEZMORENO, MA (corresponding author), CTR NACL BIOTECNOL,SERRANO 115,E-28006 MADRID,SPAIN.		Malpartida, Francisco/D-2563-2009; Fernandez-Moreno, Miguel Angel/K-4425-2017; Caballero, José L./L-2067-2014	Fernandez-Moreno, Miguel Angel/0000-0002-3461-0726; Caballero, José L./0000-0002-2678-4849				ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; ANZAI H, 1987, J BACTERIOL, V169, P3482, DOI 10.1128/jb.169.8.3482-3488.1987; BERNARDI A, 1984, NUCLEIC ACIDS RES, V12, P9415, DOI 10.1093/nar/12.24.9415; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CABALLERO JL, 1991, IN PRESS MOL GEN GEN; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; CHATER KF, 1989, TRENDS GENET, V5, P372, DOI 10.1016/0168-9525(89)90172-8; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEITELSON JS, 1983, MOL GEN GENET, V190, P394, DOI 10.1007/BF00331065; GUTHRIE EP, 1990, J BACTERIOL, V172, P6189, DOI 10.1128/jb.172.11.6189-6193.1990; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HARA O, 1983, J GEN MICROBIOL, V129, P2939; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HOPWOOD DA, 1986, REGULATION SECONDARY, P23; HORINOUCHI S, 1990, GENE, V95, P49, DOI 10.1016/0378-1119(90)90412-K; HOSHINO T, 1985, GENE, V37, P131; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KLOCK G, 1985, J BACTERIOL, V161, P326, DOI 10.1128/JB.161.1.326-332.1985; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; LIRAS P, 1990, TRENDS BIOTECHNOL, V8, P184, DOI 10.1016/0167-7799(90)90170-3; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1990, GENE, V93, P91, DOI 10.1016/0378-1119(90)90141-D; MALPARTIDA F, 1984, NATURE, V309, P462, DOI 10.1038/309462a0; Maniatis T., 1982, MOL CLONING; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MARTIN JF, 1980, MICROBIOL REV, V44, P230, DOI 10.1128/MMBR.44.2.230-251.1980; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; NARVA KE, 1990, J BACTERIOL, V172, P326, DOI 10.1128/JB.172.1.326-333.1990; NORMARK S, 1983, ANNU REV GENET, V17, P499, DOI 10.1146/annurev.ge.17.120183.002435; NORRANDER J, 1983, GENE, V26, P102; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; PABO LO, 1984, ANN REV BIOCH, V34, P293; PASSANTINO R, 1991, IN PRESS J GEN MICRO; PEDEN KWC, 1983, GENE, V22, P277, DOI 10.1016/0378-1119(83)90112-9; PIEPERSBERG W, 1988, BIOL ACTINOMYCETES, P92; POSTLE K, 1984, NUCLEIC ACIDS RES, V12, P4849, DOI 10.1093/nar/12.12.4849; REYNES JP, 1988, J GEN MICROBIOL, V134, P585; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; RUDD BAM, 1979, J GEN MICROBIOL, V114, P35, DOI 10.1099/00221287-114-1-35; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SENO ET, 1989, REG SEC MET ACT, P1; STEIN D, 1989, J BACTERIOL, V171, P2258, DOI 10.1128/jb.171.4.2258-2261.1989; WATERS SH, 1983, NUCLEIC ACIDS RES, V11, P6089, DOI 10.1093/nar/11.17.6089; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAZYU H, 1984, J BIOL CHEM, V259, P4320	60	310	335	4	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					769	780		10.1016/0092-8674(91)90120-N	http://dx.doi.org/10.1016/0092-8674(91)90120-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878971				2022-12-28	WOS:A1991GC74500015
J	KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ				KNIGHT, MR; CAMPBELL, AK; SMITH, SM; TREWAVAS, AJ			TRANSGENIC PLANT AEQUORIN REPORTS THE EFFECTS OF TOUCH AND COLD-SHOCK AND ELICITORS ON CYTOPLASMIC CALCIUM	NATURE			English	Article							SUSPENDED CALLUS-CULTURES; ELICITATION; EXPRESSION	METHODS for measuring plant cytoplasmic calcium using microelectrodes or microinjected fluorescent dyes are associated with extensive technical problems, so measurements have been limited to single or small groups of cells in tissue strips or protoplasts 1,2. Aequorin is a calcium-sensitive luminescent protein 3 from the coelenterate Aequorea victoria (A. forskalea) which is formed from apoaequorin, a polypeptide of relative molecular mass approximately 22,000, and coelenterazine, a hydrophobic luminophore 4. Microinjected aequorin has been widely used for intracellular calcium measurement in animal cells 4, but its use in plants has been limited to exceptionally large cells 5. We show here that aequorin can be reconstituted in transformed plants and that it reports calcium changes induced by touch, cold-shock and fungal elicitors. Reconstituted aequorin is cytoplasmic and nonperturbing; measurements can be made on whole plants and a calcium indicator can be constituted in every viable cell. Now that apoaequorin can be targeted to specific organelles, cells and tissues, with the range of coelenterazines with differing calcium sensitivities and properties available 6, this new method could be valuable for determining the role of calcium in intracellular signalling processes in plants.	UNIV WALES COLL MED, DEPT MED BIOCHEM, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	KNIGHT, MR (corresponding author), UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND.		Smith, Steven/HDM-9496-2022; Smith, Steven M/G-7183-2015; Campbell, Anthony K/N-5855-2014	Smith, Steven M/0000-0001-5661-9994; Campbell, Anthony K/0000-0002-2506-5500; Knight, Marc/0000-0002-4830-8608				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Blinks J.R., 1978, Methods in Enzymology, V57, P292; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BROOKS CJW, 1986, PHYTOCHEMISTRY, V25, P1089, DOI 10.1016/S0031-9422(00)81559-9; Campbell A.K, 1983, INTRACELLULAR CALCIU; CAMPBELL AK, 1988, BIOCHEM J, V252, P143, DOI 10.1042/bj2520143; DIXON RA, 1986, BIOL REV, V61, P239, DOI 10.1111/j.1469-185X.1986.tb00719.x; Draper J., 1988, PLANT GENETIC TRANSF; EBEL J, 1988, TRENDS BIOCHEM SCI, V13, P23, DOI 10.1016/0968-0004(88)90014-X; FRANCK A, 1980, CELL, V21, P285, DOI 10.1016/0092-8674(80)90136-1; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GILROY S, 1986, FEBS LETT, V199, P217, DOI 10.1016/0014-5793(86)80483-5; HAHN MG, 1978, PLANT PHYSIOL, V62, P107, DOI 10.1104/pp.62.1.107; HARLOW E, 1988, ANTIBODIES LABORATOR; MAUCH F, 1989, PLANT CELL, V1, P447, DOI 10.2307/3869105; MINORSKY PV, 1985, PLANT CELL ENVIRON, V8, P75, DOI 10.1111/j.1365-3040.1985.tb01226.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; PRASHER DC, 1986, BIOLUMINESCENCE CHEM; Sambrook J, 1989, MOL CLONING LABORATO; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; WATSON DG, 1985, PHYTOCHEMISTRY, V24, P2195, DOI 10.1016/S0031-9422(00)83009-5; WILLIAMSON RE, 1982, NATURE, V296, P647, DOI 10.1038/296647a0	25	921	989	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1991	352	6335					524	526		10.1038/352524a0	http://dx.doi.org/10.1038/352524a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865907				2022-12-28	WOS:A1991GA22600061
J	GE, H; ZUO, P; MANLEY, JL				GE, H; ZUO, P; MANLEY, JL			PRIMARY STRUCTURE OF THE HUMAN SPLICING FACTOR ASF REVEALS SIMILARITIES WITH DROSOPHILA REGULATORS	CELL			English	Article							PRE-MESSENGER-RNA; RIBONUCLEOPROTEIN CONSENSUS SEQUENCE; DETERMINING GENE TRA-2; BINDING PROTEINS; NUCLEAR RIBONUCLEOPROTEIN; SEXUAL-DIFFERENTIATION; TRANSFORMER GENE; DOUBLESEX GENE; SNRNP PROTEIN; 70K PROTEIN	We described previously the purification of a human protein, called alternative splicing factor (ASF), that can switch utilization of alternative 5' splice sites in an SV40 early pre-mRNA. We now report the isolation of a cDNA, designated ASF-1, that encodes this protein. ASF-1 consists of 248 amino acid residues, including an 80 residue RNA-binding domain at its N-terminus and a 50 residue C-terminal region that is 80% serine plus arginine. ASF-1 produced in E. coli can activate splicing in vitro and switch 5' splice-site utilization, establishing that the recombinant protein is sufficient to supply these activities. Analysis of additional cDNAs revealed that ASF pre-mRNA can itself be alternatively spliced, surprisingly, by utilization of a shared 5' splice site and two closely spaced 3' splice sites. Use of the upstream site results in a second mRNA (ASF-2) in which translation of the downstream exon occurs extensively in an alternative reading frame distinct from ASF-1.			GE, H (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459	NCI NIH HHS [CA 33620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA033620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1990, EMBO J, V9, P3619, DOI 10.1002/j.1460-2075.1990.tb07573.x; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BAKER BS, 1980, GENETICS, V94, P384; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BUGLER B, 1987, J BIOL CHEM, V262, P10922; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flint S. J, 1981, DNA TUMOR VIRUSES; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GENTZ R, 1989, P NATL ACAD SCI USA, V86, P821, DOI 10.1073/pnas.86.3.821; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MATTOX W, 1991, IN PRESS GENES DEV; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NOBLE JCS, 1987, CELL, V50, P227, DOI 10.1016/0092-8674(87)90218-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	54	324	329	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					373	382		10.1016/0092-8674(91)90626-A	http://dx.doi.org/10.1016/0092-8674(91)90626-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855257				2022-12-28	WOS:A1991FY71200017
J	GYLLENSTEN, U; WHARTON, D; JOSEFSSON, A; WILSON, AC				GYLLENSTEN, U; WHARTON, D; JOSEFSSON, A; WILSON, AC			PATERNAL INHERITANCE OF MITOCHONDRIAL-DNA IN MICE	NATURE			English	Article							MATERNAL INHERITANCE; CHAIN-REACTION; POLYMERASE; DROSOPHILA; EVOLUTION; DELETIONS; SEQUENCE; STRAINS	FOR nearly 20 years it has been assumed on the basis of low-resolution experiments that mitochondrial (mt)DNA, in contrast to the genes in the nucleus, has an exclusively maternal mode of inheritance in animals 1. Using the polymerase chain reaction 2-3, paternally inherited mtDNA molecules have now been detected in mice at a frequency of 10(-4), relative to the maternal contributions. These mice were hybrids between two inbred strains (C57BL/6J and Mus spretus) whose mtDNAs can be distinguished easily. This new mode of inheritance provides a mechanism for generating heteroplasmy and may explain mitochondrial disorders exhibiting biparental transmission.	NEW YORK ZOOL SOC,BRONX,NY 10460; FORDHAM UNIV,DEPT BIOL SCI,BRONX,NY 10458; UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	Wildlife Conservation Society; Fordham University; University of California System; University of California Berkeley	GYLLENSTEN, U (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MED GENET,BOX 589,S-75123 UPPSALA,SWEDEN.		Klein, Richard G/B-5910-2009					BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; FERRIS SD, 1983, GENETICS, V105, P681; GILLILAND G, 1909, PCR PROTOCOLS GUIDE, P60; GYLLENSTEN U, 1985, J HERED, V76, P321, DOI 10.1093/oxfordjournals.jhered.a110103; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686; HECHT NB, 1984, DEV BIOL, V102, P452, DOI 10.1016/0012-1606(84)90210-0; HOEH WR, 1991, SCIENCE, V251, P1488, DOI 10.1126/science.1672472; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; KONDO R, 1990, GENETICS, V126, P657; MICHAELS GS, 1982, J DEV BIOL, V94, P246; MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOLIGNAC M, 1984, MOL GEN GENET, V197, P183, DOI 10.1007/BF00330961; TSUZUKI T, 1983, GENE, V25, P223, DOI 10.1016/0378-1119(83)90226-3	19	476	497	2	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					255	257		10.1038/352255a0	http://dx.doi.org/10.1038/352255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857422				2022-12-28	WOS:A1991FX18500071
J	WILSON, BS; FINLEY, CC; LAWSON, DT; WOLFORD, RD; EDDINGTON, DK; RABINOWITZ, WM				WILSON, BS; FINLEY, CC; LAWSON, DT; WOLFORD, RD; EDDINGTON, DK; RABINOWITZ, WM			BETTER SPEECH RECOGNITION WITH COCHLEAR IMPLANTS	NATURE			English	Article							PROCESSING STRATEGY; PREVIOUS EXPERIENCE; CONFOUNDING FACTOR; DEAF SUBJECTS; PERFORMANCE; PSYCHOPHYSICS; RECEPTION; SCHEMES; CUES; AID	HIGH levels of speech recognition have been achieved with a new sound processing strategy for multielectrode cochlear implants. A cochlear implant system consists of one or more implanted electrodes for direct electrical activation of the auditory nerve, an external speech processor that transforms a microphone input into stimuli for each electrode, and a transcutaneous (rf-link) or percutaneous (direct) connection between the processor and the electrodes. We report here the comparison of the new strategy and a standard clinical processor. The standard compressed analogue (CA) processor 1,2 presented analogue waveforms simultaneously to all electrodes, whereas the new continuous interleaved sampling (CIS) strategy presented brief pulses to each electrode in a nonoverlapping sequence. Seven experienced implant users, selected for their excellent performance with the CA processor, participated as subjects. The new strategy produced large improvements in the scores of speech reception tests for all subjects. These results have important implications for the treatment of deafness and for minimal representations of speech at the auditory periphery.	DUKE UNIV,MED CTR,DIV OTOLARYNGOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,CTR SPEECH & HEARING DISORDERS,DURHAM,NC 27710; MIT,ELECTR RES LAB,CAMBRIDGE,MA 02139; MASSACHUSETTS EYE & EAR HOSP,COCHLEAR IMPLANT RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OTOL & LARYNGOL,BOSTON,MA 02115	Duke University; Duke University; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	WILSON, BS (corresponding author), RES TRIANGLE INST,NEUROSCI PROGRAM,RES TRIANGLE PK,NC 27709, USA.							BESS FH, 1977, J SPEECH HEAR DISORD, V42, P232, DOI 10.1044/jshd.4202.232; CLARK GM, 1987, ADV OTORHINOLARYNGOL, V38, P1; DEFILIPPO CL, 1978, J ACOUST SOC AM, V63, P1186, DOI 10.1121/1.381827; DORMAN MF, 1989, EAR HEARING, V10, P44, DOI 10.1097/00003446-198902000-00008; DOWELL RC, 1987, ANN OTO RHINOL LARYN, V96, P132, DOI 10.1177/00034894870960S171; DUBNO JR, 1982, J SPEECH HEAR RES, V25, P135, DOI 10.1044/jshr.2501.135; Eddington D K, 1978, Ann Otol Rhinol Laryngol, V87, P1; EDDINGTON DK, 1983, ANN NY ACAD SCI, V405, P241, DOI 10.1111/j.1749-6632.1983.tb31637.x; EDDINGTON DK, 1980, J ACOUST SOC AM, V68, P885, DOI 10.1121/1.384827; Flanagan James L., 1972, SPEECH ANAL SYNTHESI; GANTZ BJ, 1988, LARYNGOSCOPE, V98, P1100; HILL FJ, 1968, J ACOUST SOC AM, V44, P13, DOI 10.1121/1.1911047; MULLER CG, 1983, ANN NY ACAD SCI, V405, P412, DOI 10.1111/j.1749-6632.1983.tb31654.x; OWENS E, 1987, J SPEECH HEAR DISORD, V52, P120, DOI 10.1044/jshd.5202.120; OWENS E, 1985, EAR HEARING, V6, P280, DOI 10.1097/00003446-198511000-00002; PFINGST BE, 1984, ARCH OTOLARYNGOL, V110, P140; REMEZ RE, 1981, SCIENCE, V212, P947, DOI 10.1126/science.7233191; ROBBINS AM, 1985, J SPEECH HEAR RES, V28, P565, DOI 10.1044/jshr.2804.565; ROSEN S, 1989, COCHLEAR IMPLANT ACQ, P3; ROSEN SM, 1981, NATURE, V291, P150, DOI 10.1038/291150a0; SCHINDLER RA, 1987, AM J OTOL, V8, P247; SHANNON RV, 1983, HEARING RES, V11, P157, DOI 10.1016/0378-5955(83)90077-1; SIMMONS FB, 1966, ARCHIV OTOLARYNGOL, V84, P2; SPARKS DW, 1979, J ACOUST SOC AM, V65, P810, DOI 10.1121/1.382502; TONG YC, 1983, J ACOUST SOC AM, V74, P73, DOI 10.1121/1.389620; TYLER RS, 1986, J SPEECH HEAR RES, V29, P282, DOI 10.1044/jshr.2902.282; TYLER RS, 1989, J SPEECH HEAR RES, V32, P887, DOI 10.1044/jshr.3204.887; VANTASELL DJ, 1987, J ACOUST SOC AM, V82, P1152, DOI 10.1121/1.395251; WHITE MW, 1984, ARCH OTOLARYNGOL, V110, P493; Wilson B. S., 1990, COCHLEAR IMPLANTS MO, P339; WILSON BS, 1988, P IEEE, V76, P1143, DOI 10.1109/5.9660; WILSON BS, 1991, AM J OTOL, V12, P56	32	840	908	6	141	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					236	238		10.1038/352236a0	http://dx.doi.org/10.1038/352236a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	FX185	1857418				2022-12-28	WOS:A1991FX18500064
J	FINLAY, I; DALLIMORE, D				FINLAY, I; DALLIMORE, D			YOUR CHILD IS DEAD	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine parents' views on how death of their children should have been handled. Design - Retrospective questionnaire survey of parents who had experienced death of their child. Setting - Charitable organisation of bereaved parents. Subjects - 150 bereaved parents, all members of the organisation, of whom 120 (80%) participated voluntarily in the study. Main outcome measures - Child's age; date and cause of death; details of person breaking the news and handling of the interview; time parents spent with dead child, their attitude to requests for organ donation, and follow up support received. Results - 122 children's deaths were described; the largest single group was due to road traffic accidents, 16 were suicides, and eight were murders. Twice as many interviews were rated as sympathetically or reasonably handled as badly or offensively handled (68 v 34). The interview ratings depended on the sensitivity and personal skills of the interviewers rather than on their previous contact or professional position; police were rated as more sympathetic than doctors and nurses. Of 109 respondents, 81 had seen their child's body, 44 of whom thought that sufficient time had been denied. Of the 28 parents who did not see the body, 17 subsequently stated their regret. In 82 parents organ donation had not been discussed. Only 16 parents recorded any follow up support from hospital staff and very few support at the time. Conclusions - The consistency of the responses suggests a serious need to revise the in service training and education of the police and health professionals in their approach to informing of death; organ donation should be discussed sensitively and parents allowed time with their dead child with fewer restrictions.	COMPASSIONATE FRIENDS,CARDIFF CF4 6XT,WALES		FINLAY, I (corresponding author), HOLME TOWER MARIE CURIE CTR,PENARTH CF6 2AW,S GLAM,WALES.							AWOONORRENNER S, 1991, BRIT MED J, V302, P356, DOI 10.1136/bmj.302.6772.356; GEFFEN T, 1990, HLTH TRENDS, V2, P87; HUGHES S, 1990, DEALING DEATH HOSPIT; Worden J. W, 1983, GRIEF COUNSELLING GR	4	61	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1524	1525		10.1136/bmj.302.6791.1524	http://dx.doi.org/10.1136/bmj.302.6791.1524			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855027	Green Published, Bronze			2022-12-28	WOS:A1991FT50500030
J	RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT				RAMSAY, MEB; CORBEL, MJ; REDHEAD, K; ASHWORTH, LAE; BEGG, NT			PERSISTENCE OF ANTIBODY AFTER ACCELERATED IMMUNIZATION WITH DIPHTHERIA TETANUS PERTUSSIS-VACCINE	BRITISH MEDICAL JOURNAL			English	Article							LINKED IMMUNOSORBENT-ASSAY; TOXIN NEUTRALIZATION TEST; HUMAN-SERA; POLIOMYELITIS; ANTITOXIN; EFFICACY	Objective - To determine the persistence of antibody to diphtheria, tetanus, and pertussis in children receiving an accelerated schedule of primary immunisation. Design - Controlled study of antibody testing of blood samples from children immunised according to various schedules: three doses of triple vaccine completed at 8-13 calendar months, 6-7 calendar months, before 6 calendar months, or three doses followed by diphtheria/tetanus before age 2. Setting - Plymouth Health Authority. Subjects - 129 children aged 4 years who had received three doses of diphtheria/tetanus/pertussis vaccine with or without a diphtheria/tetanus booster. Main outcome measures-Diphtheria and tetanus antitoxin concentrations and antibody titres to pertussis toxin, filamentous haemagglutinin, and agglutinogens 2 and 3. Results - All children had protective concentrations of antitoxin to diphtheria and tetanus (greater-than-or-equal-to 0.01 IU/ml). There was no evidence of a significant difference in diphtheria or tetanus antitoxin concentrations and pertussis antibody titres in children immunised with an accelerated course (third dose of triple vaccine before 6 months) compared with those who received a longer course (third dose at 8-13 months) with no booster (geometric mean antitoxin concentration 0.411 (95% confidence interval 0.273 to 0.618) v 0.426 (0.294 to 0.616) for diphtheria and 0.358 (0.231 to 0.556) v 0.299 (0.197 to 0.453) for tetanus; geometric mean antibody titres 903 (500 to 1631) v 1386 (848 to 2266) for pertussis filamentous haemagglutinin, 179 (130 to 248) v 232 (167 to 322) for pertussis toxin, and 2002 (1276 to 3142) v 3591 (2220 to 5809) for agglutinogens 2 and 3). Conclusion - Immunisation with three doses of triple vaccine at monthly intervals completed before 6 months of age probably provides adequate protection against diphtheria, tetanus, and whooping cough which will persist until the age of the preschool booster.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,IMMUNOL & PATHOL GRP,SALISBURY SP4 0JG,WILTS,ENGLAND	Public Health England			Corbel, Michael/AAI-5520-2020; Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				AGNESE PAD, 1949, PEDIATRICS, V3, P333; BARRETT CD, 1962, PEDIATRICS, V30, P720; CANNON DA, 1960, P S IMMUNISATION CHI; CHURCH MA, 1979, LANCET, V2, P188; COLLIER LH, 1979, LANCET, V1, P1364; HALSEY N, 1985, B WORLD HEALTH ORGAN, V63, P1151; JONES AE, 1989, VACCINE, V7, P300, DOI 10.1016/0264-410X(89)90189-8; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9; MILLER E, 1991, LANCET, P70; MILLER JJ, 1949, PEDIATRICS, V3, P468; NOAH N, 1976, BMJ, V1, P357; SMITH JWG, 1969, BRIT MED BULL, V25, P177, DOI 10.1093/oxfordjournals.bmb.a070689; 1984, IMMUNISATION INFECTI; 1982, BMJ, V285, P357; 1990, CONTROL DIPHTHERIA E; 1990, IMMUNISATION INFECTI; 1988, IMMUNISATION INFECTI; 1951, BMJ, V1, P1463; 1968, STATE PUBLIC HLTH YE	20	31	31	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1489	1491		10.1136/bmj.302.6791.1489	http://dx.doi.org/10.1136/bmj.302.6791.1489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855015	Bronze, Green Published			2022-12-28	WOS:A1991FT50500017
J	LUDMERER, KM				LUDMERER, KM			WASHINGTON-UNIVERSITY AND THE CREATION OF THE TEACHING HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									WASHINGTON UNIV,FAC ARTS & SCI,DEPT HIST,ST LOUIS,MO 63130	Washington University (WUSTL)	LUDMERER, KM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.							BROOKINGS R, 1914, 1914 DED BARN HOSP S, P15; Flexner A., 1910, FLEXNER REPORT; HOUSTON D, 1910, COMMUNICATION   0126; HOUSTON DF, 1910, COMMUNICATION   0330; JARCHO S, 1959, J Mt Sinai Hosp N Y, V26, P339; LUDMERER KM, 1985, LEARNING HEAL; Munger D B, 1968, J Hist Med Allied Sci, V23, P356; OSLER W, 1932, AEQUANIMITAS ADDRESS, P389; Rosenberg Charles E., 1987, CARE STRANGERS RISE; Starr P, 1982, SOCIAL TRANSFORMATIO; VEEDER BS, 1914, RELATION CHILDRENS H, P46; Vogel Morris, 1980, INVENTION MODERN HOS; 1909, 1853 1925 M WASH U B; RS BROOKINGS PAPERS, P8	14	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1981	1983		10.1001/jama.266.14.1981	http://dx.doi.org/10.1001/jama.266.14.1981			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895477				2022-12-28	WOS:A1991GH40600025
J	IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P				IRWIG, L; GLASZIOU, P; WILSON, A; MACASKILL, P			ESTIMATING AN INDIVIDUALS TRUE CHOLESTEROL LEVEL AND RESPONSE TO INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; APOLIPOPROTEIN MEASUREMENTS; SCREENING PROGRAMS; PLASMA-CHOLESTEROL; RELIABILITY; TRIGLYCERIDE; VARIABILITY; PREVALENCE	An individual's blood cholesterol measurement may differ from the true level because of short-term biological and technical measurement variability. Using data on the within-individual and population variance of serum cholesterol, we addressed the following clinical concerns: Given a cholesterol measurement, what is the individual's likely true level? The confidence interval for the true level is wide and asymmetrical around extreme measurements because of regression to the mean. Of particular concern is the misclassification of people with a screening measurement below 5.2 mmol/L who may be advised that their cholesterol level is "desirable" when their true level warrants further action. To what extent does blood cholesterol change in response to an intervention? In general, confidence intervals are too wide to allow decision making and patient feedback about an individual's cholesterol response to a dietary intervention, even with multiple measurements. If no change is observed in an individual's cholesterol value based on three measurements before and three after dietary intervention, the 80% confidence interval ranges from a true increase of 4% to a true decrease of 9%.	WESTMEAD HOSP, DEPT COMMUNITY MED, SYDNEY, AUSTRALIA	University of Sydney	IRWIG, L (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X; Wilson, Andrew/0000-0002-1809-7846; Macaskill, Petra/0000-0001-5879-6193				[Anonymous], 1988, CLIN CHEM, V34, P193; BELSEY R, 1990, JAMA-J AM MED ASSOC, V263, P1250, DOI 10.1001/jama.263.9.1250; Berger J.O., 1985, STAT DECISION THEORY, P74; BYERS T, 1989, AM J EPIDEMIOL, V130, P853; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COOPER GR, 1988, CLIN CHEM, V34, pB95; DEGROOT MH, 1986, PROBABILITY STATISTI; DEMACKER PNM, 1982, ATHEROSCLEROSIS, V45, P259, DOI 10.1016/0021-9150(82)90227-1; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; FULWOOD R, PHS861686 US DEP HLT; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; HJERMANN I, 1981, LANCET, V2, P1303; Hjermann I, 1980, J Oslo City Hosp, V30, P3; JACOBS DR, 1982, AM J EPIDEMIOL, V116, P878, DOI 10.1093/oxfordjournals.aje.a113490; KAUFMAN HW, 1990, JAMA-J AM MED ASSOC, V263, P1245, DOI 10.1001/jama.263.9.1245; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; KINLAY S, 1990, BRIT MED J, V300, P1545, DOI 10.1136/bmj.300.6739.1545; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MORRISON JA, 1979, PEDIATRICS, V64, P197; NAITO HK, 1988, CLIN CHEM, V34, pB84; NAUGHTON MJ, 1990, JAMA-J AM MED ASSOC, V263, P1213, DOI 10.1001/jama.263.9.1213; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, DOI DOI 10.1037/018882; OBRIEN RC, 1990, MED J AUSTRALIA, V152, P480, DOI 10.5694/j.1326-5377.1990.tb125308.x; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; ROBERTS L, 1987, SCIENCE, V238, P482, DOI 10.1126/science.3659924; ROBERTS WC, 1989, AM J CARDIOL, V64, P693, DOI 10.1016/0002-9149(89)90511-0; ROTTERDAM EP, 1987, CLIN CHEM, V33, P1913; SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TUNSTALLPEDOE H, 1989, LANCET, V1, P540; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WEISSFELD JL, 1990, MED DECIS MAKING, V10, P135, DOI 10.1177/0272989X9001000208	33	45	47	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1678	1685		10.1001/jama.266.12.1678	http://dx.doi.org/10.1001/jama.266.12.1678			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886192				2022-12-28	WOS:A1991GF41900035
J	NACLERIO, RM				NACLERIO, RM			DRUG-THERAPY - ALLERGIC RHINITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EOSINOPHIL CATIONIC PROTEIN; BECLOMETHASONE DIPROPIONATE; HISTAMINE-RELEASE; NASAL CHALLENGE; HAY-FEVER; ANTIGEN CHALLENGE; TOPICAL GLUCOCORTICOSTEROIDS; MEDIATOR RELEASE; IMMUNOGLOBULIN-E; RAGWEED POLLEN		JOHNS HOPKINS UNIV, SCH MED, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 31335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; ASSEM ESK, 1969, NATURE, V224, P1028, DOI 10.1038/2241028a0; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BINDER E, 1984, Rhinology (Utrecht), V22, P255; Blackley CH., 1873, EXPT RES CAUSES NATU; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BROOKS CD, 1985, ANN ALLERGY, V55, P557; BROWN MS, 1987, ARCH OTOLARYNGOL, V113, P179; CAPWELL S, 1990, BMJ-BRIT MED J, V300, P1548; CINES DB, 1986, J IMMUNOL, V136, P3433; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRAFT TM, 1986, BRIT MED J, V292, P660, DOI 10.1136/bmj.292.6521.660; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1986, J CLIN INVEST, V78, P1421; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; Douglas WW, 1985, GOODMAN GILMANS PHAR, P605; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289, DOI 10.1159/000234152; FOREMAN JC, 1988, ALLERGY PRINCIPLES P, V1, P766; FRASER CM, 1988, ALLERGY PRINCIPLES P, V1, P636; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GRANGETTE C, 1989, J IMMUNOL, V143, P3580; HARDING SM, 1976, CLIN ALLERGY, V6, P369, DOI 10.1111/j.1365-2222.1976.tb01918.x; HASTIE R, 1979, LAB INVEST, V40, P554; HEDLIN G, 1990, J ALLERGY CLIN IMMUN, V85, P964; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; KARIM SMM, 1978, PROSTAGLANDINS, V15, P457, DOI 10.1016/0090-6980(78)90129-6; KAY AB, 1989, CLIN EXP ALLERGY, V19, P591, DOI 10.1111/j.1365-2222.1989.tb02751.x; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KEMP JP, 1985, ANN ALLERGY, V54, P502; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; MCCLEVE D, 1978, OTOLARYNG HEAD NECK, V86, P851, DOI 10.1177/019459987808600603; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V58, P563, DOI 10.1016/0091-6749(76)90202-5; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; MEDON PJ, 1985, PHARM TIMES      JAN, P80; MELEWICZ FM, 1980, J IMMUNOL, V125, P1026; MYGIND N, 1978, ACTA OTO-LARYNGOL, V85, P437; MYGIND N, 1980, TOPICAL STEROID TREA; Mygind N, 1978, NASAL ALLERGY; Mygind N, 1990, AM J RHINOL, V4, P1; NACLERIO R, 1989, J ALLERGY CLIN IMMUN, V83, P279; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; NORMAN PS, 1989, J ALLERGY CLIN IMMUN, V84, P438, DOI 10.1016/0091-6749(89)90355-2; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P294, DOI 10.1016/0091-6749(88)90737-3; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; NORMAN PS, 1978, IMMUNOLOGICAL DISEAS, P832; OKUDA M, 1988, ANN ALLERGY, V60, P537; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PLATTSMILLS, 1988, J ALLERGY CLIN IMMUN, V82, P887; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; RUMORE MM, 1985, LIFE SCI, V36, P403, DOI 10.1016/0024-3205(85)90252-8; SCHATZ M, 1988, ALLERGY PRINCIPLES P, V2, P1093; SCHLEIMER RP, 1988, ALLERGY PRINCIPLES P, V1, P739; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; Starke K, 1981, Rev Physiol Biochem Pharmacol, V88, P199, DOI 10.1007/BFb0034538; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; TADA T, 1970, Journal of Immunology, V104, P377; THOMAS RHM, 1985, J ALLERGY CLIN IMMUN, V76, P864, DOI 10.1016/0091-6749(85)90761-4; TONNESEN P, 1985, ALLERGY, V40, P616, DOI 10.1111/j.1398-9995.1985.tb00892.x; TRZECIAKOWSKI JP, 1988, ALLERGY PRINCIPLES P, V1, P715; TURNERWARWICK M, 1980, CLIN ALLERGY, V10, P239; VANMETRE TE, 1988, ALLERGY PRINCIPLES P, V2, P1327; WALDEN SM, IN PRESS AM REV RESP; Weiner N., 1985, PHARM BASIS THERAPEU, P145; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; ZWILLICH CW, 1981, AM REV RESPIR DIS, V124, P158; VITAL HLTH STATISTIC, V155; 1990, PHYSICIANS DESK REFE; 1987, MED LETT DRUGS THER, V29, P105; 1989, MED LETT DRUGS THER, V31, P23; 1984, MED LETT DRUGS THER, V26, P65	100	271	279	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					860	869						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875971				2022-12-28	WOS:A1991GF61600006
J	ROBERTS, SB; SEGIL, N; HEINTZ, N				ROBERTS, SB; SEGIL, N; HEINTZ, N			DIFFERENTIAL PHOSPHORYLATION OF THE TRANSCRIPTION FACTOR OCT1 DURING THE CELL-CYCLE	SCIENCE			English	Article							SV40 DNA-REPLICATION; HISTONE H2B GENE; CONSENSUS ELEMENT; MAMMALIAN-CELLS; PROTEIN-KINASE; FISSION YEAST; H-1 GENE; S-PHASE; MITOSIS; ACTIVATION	Orderly progression through the somatic cell division cycle is accompanied by phase-specific transcription of a variety of different genes. During S phase, transcription of mammalian histone H2B genes requires a specific promoter element and its cognate transcription factor Oct1 (OTF1). A possible mechanism for regulating histone H2B transcription during the cell cycle is direct modulation of Oct1 activity by phase-specific posttranslational modifications. Analysis of Oct1 during progression through the cell cycle revealed a complex temporal program of phosphorylation. A p34cdc2-related protein kinase that is active during mitosis may be responsible for one mitotic phosphorylation of Oct1. However, the temporally controlled appearance of Oct1 phosphopeptides suggests the involvement of multiple kinases and phosphatases. These results support the idea that cell cycle-regulated transcription factors may be direct substrates for phase-specific regulatory enzymes.			ROBERTS, SB (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032544, F32GM013752] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32544, GM 13752] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTISHEVSKY A, 1987, NATURE, V328, P823, DOI 10.1038/328823a0; ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1990, TRENDS BIOL SCI, V15, P178; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HEREFORD L, 1982, CELL, V30, P305, DOI 10.1016/0092-8674(82)90036-8; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LABELLA F, 1989, GENE DEV, V3, P982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSE M, 1984, CELL TISSUE KINET, V17, P13, DOI 10.1111/j.1365-2184.1984.tb00564.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; ROBERTS SA, UNPUB; SEGIL N, UNPUB; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7; [No title captured]	48	129	130	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1022	1026		10.1126/science.1887216	http://dx.doi.org/10.1126/science.1887216			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887216				2022-12-28	WOS:A1991GC98200043
J	WADE, MJ; GOODNIGHT, CJ				WADE, MJ; GOODNIGHT, CJ			WRIGHT SHIFTING BALANCE THEORY - AN EXPERIMENTAL-STUDY	SCIENCE			English	Article							GROUP SELECTION; SMALL POPULATIONS; FINITE POPULATIONS; GENETIC VARIANCE; FOUNDER EVENTS; SEX-RATIO; DIFFERENTIATION; MIGRATION; TRIBOLIUM	Experimental confirmation of Wright's shifting balance theory of evolution, one of the most comprehensive theories of adaptive evolution, is presented. The theory is regarded by many as a cornerstone of modern evolutionary thought, but there has been little direct empirical evidence supporting it. Some of its underlying assumptions are viewed as contradictory, and the existence and efficacy of the theory's fundamental adaptive process, interdemic selection, is the focus of controversy. Interdemic selection was imposed on large arrays of laboratory populations of the flour beetle Tribolium castaneum in the manner described by Wright: the differential dispersion of individuals from demes of high fitness into demes of low fitness. A significant increase in average fitness was observed in the experimental arrays when compared to control populations with equivalent but random migration rates. The response was not proportional to the selection differential: The largest response occurred with interdemic selection every two generations rather than every generation or every three generations. The results indicate that the interdemic phase of Wright's shifting balance theory can increase average fitness and suggest that gene interactions are involved in the observed response.	UNIV VERMONT,DEPT ZOOL,BURLINGTON,VT 05405	University of Vermont	WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637, USA.		Goodnight, Charles/K-3208-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22523] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COCKERHAM CC, 1988, P NATL ACAD SCI USA, V85, P1563, DOI 10.1073/pnas.85.5.1563; COLLIAS NE, 1991, ANIM BEHAV, V41, P613, DOI 10.1016/S0003-3472(05)80900-5; CRAIG DM, 1982, EVOLUTION, V36, P271, DOI 10.2307/2408045; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; DOBZHANSKY T, 1977, EVOLUTION, P164; Falconer D. S., 1981, INTRO QUANTITATIVE G; Futuyma DJ, 1986, EVOL BIOL; GOODNIGHT CJ, 1985, EVOLUTION, V39, P545, DOI 10.1111/j.1558-5646.1985.tb00394.x; GOODNIGHT CJ, 1987, EVOLUTION, V41, P80, DOI 10.1111/j.1558-5646.1987.tb05772.x; GOODNIGHT CJ, 1988, EVOLUTION, V42, P441, DOI 10.1111/j.1558-5646.1988.tb04151.x; HARTL DL, 1989, PRINCIPLES POPULATIO, P324; HARTL DL, 1980, PRINCIPLES POPULATIO, P343; HILL WG, 1972, BIOMETRICS, V28, P767, DOI 10.2307/2528761; LOVELESS MD, 1984, ANNU REV ECOL SYST, V15, P65, DOI 10.1146/annurev.es.15.110184.000433; Mettler L.E., 1988, POPULATION GENETICS; NEI M, 1987, MOL EVOLUTIONARY GEN, P422; Provine W., 1986, SEWALL WRIGHT EVOLUT; TACHIDA H, 1989, GENET RES, V53, P63, DOI 10.1017/S0016672300027877; Templeton A.R., 1982, P15; WADE MJ, 1984, GENET RES, V43, P249, DOI 10.1017/S0016672300026045; WADE MJ, 1982, EVOLUTION, V36, P949, DOI 10.1111/j.1558-5646.1982.tb05465.x; WADE MJ, 1984, EVOLUTION, V38, P1047, DOI 10.1111/j.1558-5646.1984.tb00375.x; WADE MJ, 1978, Q REV BIOL, V53, P101, DOI 10.1086/410450; WADE MJ, 1976, P NATL ACAD SCI USA, V73, P4604, DOI 10.1073/pnas.73.12.4604; WADE MJ, 1980, EVOLUTION, V34, P799, DOI [10.2307/2408034, 10.1111/j.1558-5646.1980.tb04019.x]; WADE MJ, 1977, EVOLUTION, V31, P134, DOI 10.1111/j.1558-5646.1977.tb00991.x; WADE MJ, 1980, GENET RES, V36, P10; WADE MJ, 1991, EVOLUTION, V44, P2004; WILSON DS, 1981, EVOLUTION, V35, P882, DOI 10.1111/j.1558-5646.1981.tb04952.x; Wright S, 1931, GENETICS, V16, P0097; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; Wright S., 1969, THEORY GENE FREQUENC, V2, P520; Wright S., 1978, EVOLUTION GENETIC PO; WRIGHT S, 1977, EVOLUTION GENETICS P, V3, P454; [No title captured]	35	113	114	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1015	1018		10.1126/science.1887214	http://dx.doi.org/10.1126/science.1887214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887214				2022-12-28	WOS:A1991GC98200041
J	RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG				RENFRANZ, PJ; CUNNINGHAM, MG; MCKAY, RDG			REGION-SPECIFIC DIFFERENTIATION OF THE HIPPOCAMPAL STEM-CELL LINE HIB5 UPON IMPLANTATION INTO THE DEVELOPING MAMMALIAN BRAIN	CELL			English	Article							FLUORESCENT LATEX MICROSPHERES; INTERMEDIATE FILAMENT PROTEIN; MEDIATED GENE-TRANSFER; CHICKEN OPTIC TECTUM; RAT FASCIA DENTATA; PRECURSOR CELLS; VISUAL-CORTEX; RECOMBINANT RETROVIRUS; COMMON PROGENITOR; MOLECULAR LAYER	Proliferating precursors to the distinct cell types constituting the mammalian brain can be identified by the presence of the nestin intermediate filament. We report the establishment of a nestin-positive cell line, HiB5, from embryonic precursor cells to the rat hippocampus. Since it was immortalized using the temperature-sensitive allele tsA58 of SV40 large T antigen, these cells grow continuously at 33-degrees-C, but not at 39-degrees-C, the body temperature of rodents. To test their developmental capacity, HiB5 cells were implanted into both the neonatal hippocampus and cerebellum. The cells integrated into the host tissue and acquired morphologies characteristic of the neurons and glial cells found at the implant site. HiB5 cells might thus be useful in characterizing the signals regulating cell type determination in the mammalian brain.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)								ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1972, J COMP NEUROL, V145, P353, DOI 10.1002/cne.901450305; ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ANGEVINE JB, 1965, EXP NEUROL        S2, V13, P1; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BJORKLUND A, 1976, NATURE, V262, P787, DOI 10.1038/262787a0; Brodal A, 1981, NEUROLOGICAL ANATOMY; Cajal S.R., 1894, NEW IDEAS STRUCTURE; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CEPKO C, 1988, TRENDS NEUROSCI, V11, P6, DOI 10.1016/0166-2236(88)90039-2; CEPKO CL, 1989, ANNU REV NEUROSCI, V12, P47, DOI 10.1146/annurev.ne.12.030189.000403; CLAIBORNE BJ, 1990, J COMP NEUROL, V302, P206, DOI 10.1002/cne.903020203; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FROTSCHER M, 1983, J COMP NEUROL, V215, P299, DOI 10.1002/cne.902150306; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAY GE, 1988, P NATL ACAD SCI USA, V85, P7356, DOI 10.1073/pnas.85.19.7356; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; KATZ LC, 1990, NEUROSCIENCE, V34, P511, DOI 10.1016/0306-4522(90)90159-2; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; LANDER AD, 1987, MOL NEUROBIOL, V1, P213, DOI 10.1007/BF02936609; LEE HJ, 1990, J NEUROSCI, V10, P1779; LENDAHL U, 1990, TRENDS NEUROSCI, V13, P132, DOI 10.1016/0166-2236(90)90004-T; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOGIN GR, 1985, AM J PATHOL, V120, P230; LUBBERS K, 1987, ANAT EMBRYOL, V177, P1, DOI 10.1007/BF00325285; MCCONNELL SK, 1988, J NEUROSCI, V8, P945; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Palay S. L., 1974, CEREBELLAR CORTEX CY; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROGERS A, 1967, TECHNIQUES QAUTORADI; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDELL JH, 1988, J HISTOCHEM CYTOCHEM, V36, P555, DOI 10.1177/36.5.3356898; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHLESSINGER AR, 1978, ANAT EMBRYOL, V154, P153, DOI 10.1007/BF00304660; SCHLESSINGER AR, 1975, J COMP NEUROL, V159, P149, DOI 10.1002/cne.901590202; SCHLESSINGER J, 1977, SCIENCE, V195, P307, DOI 10.1126/science.556653; SCHMUED LC, 1986, BRAIN RES, V377, P147, DOI 10.1016/0006-8993(86)91199-6; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Witter MP, 1989, HIPPOCAMPUS NEW VIST, P53; YEN SE, 1982, J CELL BIOL, V88, P115	62	440	469	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					713	729		10.1016/0092-8674(91)90116-G	http://dx.doi.org/10.1016/0092-8674(91)90116-G			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878969				2022-12-28	WOS:A1991GC74500011
J	LANGSLEY, DG				LANGSLEY, DG			MEDICAL COMPETENCE AND PERFORMANCE ASSESSMENT - A NEW ERA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRUCTURED CLINICAL EXAMINATION; 4TH-YEAR STUDENTS; SKILLS				LANGSLEY, DG (corresponding author), AMER BOARD MED SPECIALTIES,1 ROTARY CTR,SUITE 805,EVANSTON,IL 60201, USA.							BARROWS HS, 1987, J MED EDUC, V62, P805; BARROWS HS, 1985, NEWER APPROACHES ASS; BORGIEL AEM, 1985, CAN FAM PHYSICIAN, V31, P853; Breaden D G, 1988, Fed Bull, V75, P67; CARLINE JD, 1989, EVAL HEALTH PROF, V12, P409, DOI 10.1177/016327878901200403; CLYMAN SG, 1990, ACAD MED, V65, P235, DOI 10.1097/00001888-199004000-00005; CONN HL, 1989, ACAD MED, V64, P448, DOI 10.1097/00001888-198908000-00007; DECKERT GH, 1991, APR ANN M FED STAT M; HARDEN RM, 1979, MED EDUC, V13, P41; HARLESS WG, 1990, ACAD MED, V65, P327, DOI 10.1097/00001888-199005000-00014; HART I, 1983, ANN R COLL PHYS SURG, V16, P356; MEYER TC, 1990, FEDERATION B, V77, P182; NEWBLE DI, 1986, NEWER DEV ASSESSING, P40; NORMAN GR, 1989, TEACH LEARN MED, V1, P194; PETRUSA ER, 1990, ARCH INTERN MED, V150, P573, DOI 10.1001/archinte.150.3.573; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; STILLMAN PL, 1990, ACAD MED, V65, P320, DOI 10.1097/00001888-199005000-00013; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; 1991, GENERAL REQUIREMENTS; 1991, FUNCTIONS STRUCTURES; 1988, PHYSICIAN REV PROGRA	21	34	34	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					977	980		10.1001/jama.266.7.977	http://dx.doi.org/10.1001/jama.266.7.977			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870227				2022-12-28	WOS:A1991GB20500010
J	FRENKEN, LAM; VANLIER, HJJ; GERLAG, PGG; DENHARTOG, M; KOENE, RAP				FRENKEN, LAM; VANLIER, HJJ; GERLAG, PGG; DENHARTOG, M; KOENE, RAP			ASSESSMENT OF PAIN AFTER SUBCUTANEOUS INJECTION OF ERYTHROPOIETIN IN PATIENTS RECEIVING HEMODIALYSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP NIJMEGEN,DEPT NEPHROL,NIJMEGEN,NETHERLANDS; UNIV HOSP NIJMEGEN,DEPT MED STAT,NIJMEGEN,NETHERLANDS; ST JOSEPH HOSP,DEPT MED,VELDHOVEN,NETHERLANDS; HOSP DE GELDERSE VALLEI,WAGENINGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Gelderse Vallei Hospital	FRENKEN, LAM (corresponding author), UNIV HOSP NIJMEGEN,DEPT MED,NIJMEGEN,NETHERLANDS.							BOMMER J, 1989, CONTRIB NEPHROL, V76, P149; ESCHBACH JW, 1989, NEW ENGL J MED, V321, P158, DOI 10.1056/NEJM198907203210305; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; MACHIN D, 1988, CLIN J PAIN, V4, P161, DOI 10.1097/00002508-198809000-00006; WINEARLS CG, 1986, LANCET, V2, P75	5	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					288	288		10.1136/bmj.303.6797.288	http://dx.doi.org/10.1136/bmj.303.6797.288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888931	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100023
J	LEWIS, JA				LEWIS, JA			CONTROLLED TRIALS IN SINGLE SUBJECTS .2. LIMITATIONS OF USE	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIALS				LEWIS, JA (corresponding author), ICI PLC PHARMACEUT,DEPT MED AFFAIRS,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND.							GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; WALLENSTEIN S, 1990, STATISTICAL ISSUES D; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	3	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					175	176		10.1136/bmj.303.6795.175	http://dx.doi.org/10.1136/bmj.303.6795.175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878647	Bronze, Green Published			2022-12-28	WOS:A1991FX57800029
J	DEFEOJONES, D; HUANG, PS; JONES, RE; HASKELL, KM; VUOCOLO, GA; HANOBIK, MG; HUBER, HE; OLIFF, A				DEFEOJONES, D; HUANG, PS; JONES, RE; HASKELL, KM; VUOCOLO, GA; HANOBIK, MG; HUBER, HE; OLIFF, A			CLONING OF CDNAS FOR CELLULAR PROTEINS THAT BIND TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; SUSCEPTIBILITY GENE; MUTATIONAL ANALYSIS; SV40; IDENTIFICATION; TRANSFORMATION; SEQUENCE; COMPLEX; REGION	THE E7 transforming protein of human papilloma virus-16 binds to the retinoblastoma gene product (pRb) 1,2 through a nine-amino-acid segment of E7 (21-29) 3-5. This segment of E7 is homologous to the pRb-binding domains of the simian virus 40 large T and adenovirus E1A transforming proteins 6-9. Each of these viral transforming proteins bind to the same region of pRb 10-11. To isolate cellular proteins that interact with this viral protein-binding domain on pRb 12,13, we used recombinant pRb to screen a human complementary DNA expression library. Two cDNAs were isolated that encode retinoblastoma binding proteins (RBP-1 and RBP-2). We report here that these RBP genes exist in separate loci and produce discrete messenger RNAs. The predicted amino-acid sequence of these genes showed no homology to known proteins, but both RBPs contain the pRb binding motif conserved between E7, large T and E1A 14. In vitro expression of the RBP cDNAs yielded proteins that specifically bound to pRb. Recombinant E7 protein, the E7 21-29 peptide and the homologous RBP-L peptide inhibited RBP-pRb binding. Mutations introduced into the putative pRb-binding segment in RBP-1 impaired its binding activity. These studies indicate that the cellular RBP-1, RBP-2 and viral E7 proteins interact with pRb through similar domains.	MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486	Merck & Company								BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIGGE J, 1988, J VIROL, V62, P814; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUYNH TV, 1985, DNA CLONING TECHNIQU; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	307	328	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					251	254		10.1038/352251a0	http://dx.doi.org/10.1038/352251a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857421				2022-12-28	WOS:A1991FX18500070
J	TOTO, RD; MITCHELL, HC; LEE, HC; MILAM, C; PETTINGER, WA				TOTO, RD; MITCHELL, HC; LEE, HC; MILAM, C; PETTINGER, WA			REVERSIBLE RENAL-INSUFFICIENCY DUE TO ANGIOTENSIN CONVERTING ENZYME-INHIBITORS IN HYPERTENSIVE NEPHROSCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Article						NEPHROSCLEROSIS; HYPERTENSION; ANTIHYPERTENSIVE AGENTS; KIDNEY FAILURE, ACUTE; ENALAPRIL	ARTERY STENOSIS; RENOVASCULAR HYPERTENSION; GLOMERULAR INJURY; FILTRATION-RATE; CAPTOPRIL; FAILURE; ENALAPRIL; THERAPY; KIDNEY	Objective: To review the incidence of reversible renal insufficiency in patients with hypertensive nephrosclerosis undergoing antihypertensive therapy. Design: Retrospective analysis of 73 patients in a long-term blood pressure control study that compared the effects of an angiotensin converting enzyme (ACE) inhibitor plus conventional antihypertensive agents compared with placebo plus antihypertensive agents. Setting: Hospital-based outpatient treatment center. Interventions: Patients were divided into group 1, which received enalapril plus conventional antihypertensives, and group 2, which received placebo plus conventional antihypertensives. Measurements: Blood pressure and serum creatinine levels were measured, and imaging studies of the main renal arteries were done. Main Results: In group 1, eight of 42 patients (19%, 95% Cl, 9% to 34%) developed reversible renal insufficiency, defined as an unexpected increase in serum creatinine of 88-mu-mol/L or higher. Six episodes of reversible renal insufficiency occurred during July and August when temperatures were 32.2-degrees-C to 37.8-degrees-C (90-degrees-F to 100-degrees-F). Renal artery stenosis was excluded by renal arteriogram or ultrasonic duplex scanning. All eight group-1 patients had a significant decrease in mean arterial pressure below their baseline level during reversible renal insufficiency (mean change, -28 +/- 10 mm Hg, P < 0.001). The increase in the serum creatinine level was inversely correlated with the decrease in the mean arterial pressure (r = -0.68, P < 0.01). Reversible renal insufficiency was successfully managed by withdrawing or reducing enalapril as well as other antihypertensive agents. Subsequently, enalapril was tolerated by seven of the eight patients without recurrence of renal insufficiency. In contrast, none of 31 (Cl, 0% to 11%) patients in group 2 developed reversible renal insufficiency despite the fact that both the incidence of decreases in mean arterial pressure in 6 of 31 patients (19%) and the magnitude of the decreases in mean arterial pressure (mean change, -33 +/- 16 mm Hg) were similar to those observed in group 1. Conclusions: Reversible renal insufficiency in hypertensive nephrosclerosis associated with ACE inhibitor therapy correlates with relative hypotension, is not dependent on renal artery stenosis, and can usually be managed by dose reduction.			TOTO, RD (corresponding author), UNIV TEXAS, SW MED CTR, DIV NEPHROL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Toto, Robert/AAQ-3336-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030339] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL30339] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; ANDERSON S, 1985, J CLIN INVEST, V76, P612, DOI 10.1172/JCI112013; BONER G, 1985, ISRAEL J MED SCI, V21, P892; BRUNNER HR, 1978, LANCET, V2, P704; CURTIS JJ, 1983, NEW ENGL J MED, V308, P377, DOI 10.1056/NEJM198302173080707; FRANKLIN SS, 1985, AM J MED, V79, P14, DOI 10.1016/0002-9343(85)90075-0; HALL JE, 1979, AM J PHYSIOL, V236, pF252, DOI 10.1152/ajprenal.1979.236.3.F252; HALL JE, 1977, AM J PHYSIOL, V233, pF366, DOI 10.1152/ajprenal.1977.233.5.F366; HALL JE, 1977, AM J PHYSIOL, V232, pF215, DOI 10.1152/ajprenal.1977.232.3.F215; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; JACKSON B, 1984, LANCET, V1, P225; KAMPER AL, 1990, SCAND J UROL NEPHROL, V24, P69, DOI 10.3109/00365599009180363; KOHLER TR, 1986, J VASC SURG, V4, P450, DOI 10.1067/mva.1986.avs0040450; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; PETTINGER WA, 1989, AM J HYPERTENS, V2, P349, DOI 10.1093/ajh/2.5.349; PETTINGER WA, 1989, HYPERTENSION, V13, P766, DOI 10.1161/01.HYP.13.6.766; VERBEELEN DL, 1984, BRIT MED J, V289, P20, DOI 10.1136/bmj.289.6436.20	17	98	99	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					513	519		10.7326/0003-4819-115-7-513	http://dx.doi.org/10.7326/0003-4819-115-7-513			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883120				2022-12-28	WOS:A1991GG28300002
J	BONE, RC				BONE, RC			A CRITICAL-EVALUATION OF NEW AGENTS FOR THE TREATMENT OF SEPSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TUMOR-NECROSIS-FACTOR; GRAM-NEGATIVE SHOCK; ACUTE LUNG INJURY; SEPTIC SHOCK; MONOCLONAL-ANTIBODY; HUMAN INTERLEUKIN-1; ESCHERICHIA-COLI; FACTOR-ALPHA; ENDOTHELIAL-CELLS; INTERFERON-GAMMA	Objective. - To evaluate new treatments directed against endotoxin, tumor necrosis factor-alpha, and interleukin 1 for use in sepsis and related disorders (sepsis syndrome and septic shock). Data Sources. - Investigations of these treatments in animal models, healthy human volunteers, and patients with sepsis and related disorders. Study Selection. - Particular attention was paid to studies of patients with sepsis and related disorders, especially randomized, double-blind, controlled trials. Data Extraction. - Animal studies and investigations with human volunteers were judged by how closely the experimental model replicated the clinical disorder (sepsis). Patient trials were assessed by sample size and design. Results of all studies were used to evaluate the likelihood that a given treatment would reduce mortality. Data Synthesis. - Direct comparison of E5 and HA-1A antibody studies is difficult because of differences in their design, definitions of shock, and methods of subgroup analysis. However, both antibodies improve outcome in some subgroups: E5 benefits patients with gram-negative infection (bacteremic or focal) who do not have refractory shock, and HA-1A benefits those with gram-negative bacteremia (regardless of whether shock is present) but not those with focal gram-negative infection. Two agents that may be beneficial in gram-positive and gram-negative infection are monoclonal antibodies to tumor necrosis factor alpha and receptor antagonists to interleukin 1. Preliminary results with both are reviewed. Conclusions. - All three types of treatment may improve outcome in sepsis. The best results will probably be obtained with combination therapy that interrupts multiple points of the inflammatory cascade underlying sepsis.			BONE, RC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT INTERNAL MED,PULM MED SECT,1753 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							BAHRAMI S, 1991, 2ND INT C IMM CONS T; BALAVOINE JF, 1986, J CLIN INVEST, V78, P1120, DOI 10.1172/JCI112669; BAUMGARTNER JD, 1985, LANCET, V2, P59; BERGER D, 1991, 2ND INT C IMM CONS T; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; Bonavida B, 1989, Prog Clin Biol Res, V308, P485; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1125, DOI 10.1001/jama.266.8.1125; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BORM PJA, 1988, AM REV RESPIR DIS, V138, P1589, DOI 10.1164/ajrccm/138.6.1589; CAASEY L, 1991, 2ND INT C IMM CONS T; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CALANDRA T, 1990, J INFECT DIS, V161, P982, DOI 10.1093/infdis/161.5.982; CONTI P, 1986, PROSTAGLANDINS, V32, P111, DOI 10.1016/0090-6980(86)90151-6; COTRAN RS, 1990, J AM SOC NEPHROL, V1, P225; CUNNION RE, 1989, CHEST, V95, P941, DOI 10.1378/chest.95.5.941; DEGROOTE MA, 1989, JAMA-J AM MED ASSOC, V262, P249, DOI 10.1001/jama.262.2.249; DEJANA E, 1987, BLOOD, V69, P695; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; EASTGATE JA, 1988, LANCET, V2, P706; EDEN E, 1986, J CLIN IMMUNOL, V6, P326, DOI 10.1007/BF00917334; EVANS GF, 1989, CIRC SHOCK, V29, P279; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FISCHER E, 1991, 2ND INT C IMM CONS T; FOMSGAARD A, 1989, SCAND J INFECT DIS, V21, P697, DOI 10.3109/00365548909021700; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARRIS RL, 1987, ARCH INTERN MED, V147, P1895, DOI 10.1001/archinte.147.11.1895; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; JACOBS RF, 1989, CRIT CARE CLIN, V5, P9; JOHNSTON RB, 1988, NEW ENGL J MED, V318, P747, DOI 10.1056/NEJM198803243181205; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; LUGER A, 1986, CRIT CARE MED, V14, P458, DOI 10.1097/00003246-198605000-00004; MARKS JD, 1990, AM REV RESPIR DIS, V141, P94, DOI 10.1164/ajrccm/141.1.94; MAZZEI GJ, 1990, EUR J IMMUNOL, V20, P683, DOI 10.1002/eji.1830200332; MICHALEK SM, 1980, J INFECT DIS, V141, P55, DOI 10.1093/infdis/141.1.55; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; NAWROTH PP, 1986, J EXP MED, V163, P1363, DOI 10.1084/jem.163.6.1363; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; OHLSSON K, 1991, 2ND INT C IMM CONS T; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PETRAK RA, 1989, CRIT CARE CLIN, V5, P303; PRIEUR AM, 1987, LANCET, V2, P1240; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SALKIND AR, 1991, J INFECT DIS, V163, P71, DOI 10.1093/infdis/163.1.71; SARAVOLATZ L, 1991, 2ND INT C IMM CONS T; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SECKINGER P, 1988, J EXP MED, V167, P1511, DOI 10.1084/jem.167.4.1511; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SHALABY MR, 1989, CLIN IMMUNOL IMMUNOP, V53, P488, DOI 10.1016/0090-1229(89)90010-X; SILVA AT, 1990, J INFECT DIS, V162, P454, DOI 10.1093/infdis/162.2.454; SILVA AT, 1990, J INFECT DIS, V162, P421, DOI 10.1093/infdis/162.2.421; SIMPSON SQ, 1989, CRIT CARE CLIN, V5, P27; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; SUN XM, 1990, AM J PATHOL, V136, P949; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WAAGE A, 1987, CLIN IMMUNOL IMMUNOP, V45, P348, DOI 10.1016/0090-1229(87)90087-0; WAAGE A, 1986, SCAND J IMMUNOL, V24, P739, DOI 10.1111/j.1365-3083.1986.tb02194.x; WAAGE A, 1987, LANCET, V1, P355; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; WOLFF SM, 1973, J INFECT DIS, V128, pS259, DOI 10.1093/infdis/128.Supplement_1.S259; WOLFF SM, 1991, NEW ENGL J MED, V324, P486, DOI 10.1056/NEJM199102143240709; Young LS, 1990, PRINCIPLES PRACTICE, P611; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZUCKERMAN SH, 1989, EUR J IMMUNOL, V19, P301, DOI 10.1002/eji.1830190213; 1987, MMWR, V39, P777; 1987, MMWR, V39, P31; 1989, ANN SUMAMRY BIRTHS M, V37, P7	82	93	101	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1686	1691		10.1001/jama.266.12.1686	http://dx.doi.org/10.1001/jama.266.12.1686			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886193				2022-12-28	WOS:A1991GF41900036
J	RING, JJ				RING, JJ			THE RIGHT ROAD FOR MEDICINE - PROFESSIONALISM AND THE NEW-AMERICAN-MEDICAL-ASSOCIATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											RING, JJ (corresponding author), AMER MED ASSOC,515 N STATE ST,CHICAGO,IL 60610, USA.							HILFIKER D, 1987, JAMA-J AM MED ASSOC, V258, P3155, DOI 10.1001/jama.258.21.3155; LUNDBERG GD, 1991, JAMA-J AM MED ASSOC, V265, P2566; TUPPER CJ, 1990, JAMA-J AM MED ASSOC, V264, P1150; 1991, JAMA-J AM MED ASSOC, V265, P2437	4	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1694	1694		10.1001/jama.266.12.1694	http://dx.doi.org/10.1001/jama.266.12.1694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886194				2022-12-28	WOS:A1991GF41900038
J	MARK, DB; SHAW, L; HARRELL, FE; HLATKY, MA; LEE, KL; BENGTSON, JR; MCCANTS, CB; CALIFF, RM; PRYOR, DB				MARK, DB; SHAW, L; HARRELL, FE; HLATKY, MA; LEE, KL; BENGTSON, JR; MCCANTS, CB; CALIFF, RM; PRYOR, DB			PROGNOSTIC VALUE OF A TREADMILL EXERCISE SCORE IN OUTPATIENTS WITH SUSPECTED CORONARY-ARTERY DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-DISEASE	Background. The treadmill exercise test identifies patients with different degrees of risk of death from cardiovascular events. We devised a prognostic score, based on the results of treadmill exercise testing, that accurately predicts outcome among inpatients referred for cardiac catheterization. This study was designed to determine whether this score could also accurately predict prognosis in unselected outpatients. Methods. We prospectively studied 613 consecutive outpatients with suspected coronary disease who were referred for exercise testing between 1983 and 1985. Follow-up was 98 percent complete at four years. The treadmill score was calculated as follows: duration of exercise in minutes - (5 x the maximal ST-segment deviation during or after exercise, in millimeters) - (4 x the treadmill angina index). The numerical treadmill angina index was 0 for no angina, 1 for nonlimiting angina, and 2 for exercise-limiting angina. Treadmill scores ranged from -25 (indicating the highest risk) to +15 (indicating the lowest risk). Results. Predicted outcomes for the outpatients, based on their treadmill scores, agreed closely with the observed outcomes. The score accurately separated patients who subsequently died from those who lived for four years (area under the receiver-operating-characteristic curve = 0.849). The treadmill score was a better discriminator than the clinical data and was even more useful for outpatients than it had been for inpatients. Approximately two thirds of the outpatients had treadmill scores indicating low risk (greater-than-or-equal-to +5), reflecting longer exercise times and little or no ST-segment deviation, and their four-year survival rate was 99 percent (average annual mortality rate, 0.25 percent). Four percent of the outpatients had scores indicating high risk (< - 10), reflecting shorter exercise times and more severe ST-segment deviation; their four-year survival rate was 79 percent (average annual mortality rate, 5 percent). Conclusions. The treadmill score is a useful and valid tool that can help clinicians determine prognosis and decide whether to refer outpatients with suspected coronary disease for cardiac catheterization. In this study. it was a better predictor of outcome than the clinical assessment.	DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DIV BIOMETRY,DURHAM,NC 27710	Duke University	MARK, DB (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOL,POB 3485,DURHAM,NC 27710, USA.			Hlatky, Mark/0000-0003-4686-9441; Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-05635, HS-04873, HS-06503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; COX DR, 1972, J R STAT SOC B, V34, P187; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; Froelicher V F, 1988, Dis Mon, V34, P677; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1983, AM HEART J, V105, P749, DOI 10.1016/0002-8703(83)90236-3	16	578	596	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					849	853		10.1056/NEJM199109193251204	http://dx.doi.org/10.1056/NEJM199109193251204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875969				2022-12-28	WOS:A1991GF61600004
J	PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC				PENNINGTON, BF; GILGER, JW; PAULS, D; SMITH, SA; SMITH, SD; DEFRIES, JC			EVIDENCE FOR MAJOR GENE TRANSMISSION OF DEVELOPMENTAL DYSLEXIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							READING-DISABILITY	Objective. - There is strong evidence that developmental dyslexia is both familial and heritable, but the mode of genetic transmission has remained unclear. In this article, we examine specific genetic hypotheses about the mode of transmission of developmental dyslexia by performing complex segregation analyses. Design. - A family study method was applied, whereby the relatives of dyslexic probands were examined for dyslexia. The families studied represent four independently ascertained samples. Setting. - The four samples of families were primarily from rural and suburban communities of Colorado, Washington State, and Iowa. Participants. - A total of 204 families and 1698 individuals in the four samples combined. Main Outcome Measures. - The complex segregation program, POINTER, was used to test competing genetic hypotheses of how a categorical trait (dyslexia) is transmitted in families. Results. - The results were consistent with major locus transmission in three of four samples and with polygenic transmission in the fourth. In these three samples, the estimates of penetrance for the AA, Aa, and aa genotypes (where A is the abnormal allele) were, respectively, 1.000, 1.000, and 0.001 to 0.039 in males, and 0.560 to 1.000, 0.550 to 0.897, and 0.000 in females. The estimated gene frequency of the major locus was between 3% and 5%. Conclusions. - Sex-influenced, additive, or dominant transmission occurs in a significant proportion of dyslexic families. Other evidence indicates, however, that dyslexia is etiologically heterogeneous and that there is genetic heterogeneity even among families selected for apparent dominant transmission. Thus, while no single major locus may account for all of dyslexia, it is important to pursue potential major loci for dyslexia using linkage techniques.	BOYSTOWN NATL INST COMMUN DISORDERS CHILDREN, OMAHA, NE USA; SEQUIM WASHINGTON SCH DISTRICT, SEQUIM, WA USA; YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT HUMAN GENET, NEW HAVEN, CT 06510 USA; UNIV COLORADO, INST BEHAV GENET, DENVER, CO 80202 USA	Yale University; Yale University; University of Colorado System; University of Colorado Denver	PENNINGTON, BF (corresponding author), UNIV DENVER, DEPT PSYCHOL, 2155 S RACE ST, DENVER, CO 80208 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000419] Funding Source: NIH RePORTER; NIMH NIH HHS [MH00419, MH38870, MH15442] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BISGAARD ML, 1987, CLIN GENET, V32, P118; DEFRIES JC, 1987, NATURE, V329, P537, DOI 10.1038/329537a0; DeFries JC, 1991, READING BRAIN BIOL B; Dunn L. M., 1970, MANUAL PEABODY INDIV; EAVES LJ, 1983, AM J HUM GENET, V35, P1179; FINUCCI JM, 1976, ANN HUM GENET, V40, P1, DOI 10.1111/j.1469-1809.1976.tb00161.x; Fisher J. H., 1905, OPHTHALMIC REV, V24, P315; FULKER DW, 1991, READ WRIT INTERDISCI, V4, P107; GILGER J, 1991, READ WRIT, V4, P13; Gray W. S., 1963, GRAY ORAL READING TE; Hallgren B, 1950, ACTA PSYCH NEUROL SU, P1; HIERONYMOUS AN, 1986, MANUAL SCH ADM ITBS, P111; Hinshelwood J, 1911, BRIT MED J, V1911, P608, DOI 10.1136/bmj.1.2620.608; Hinshelwood J, 1907, BRIT MED J, V1907, P1229; HOLLINGSHEAD AB, 1975, 4 FACTOR INDEX SOCIA, V1; Jastak J.F., 1978, WRAT WIDE RANGE ACHI; KERR J, 1896, J R STAT SOC, V60, P613; LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231; LALOUEL JM, 1983, AM J HUM GENET, V35, P816; LEFLY DL, IN PRESS ANN DYSLEXI; LEWITTER FI, 1980, BEHAV GENET, V10, P9, DOI 10.1007/BF01067316; Lindgren SD, 1986, DEV NEUROPSYCHOL, V2, P173, DOI 10.1080/87565648609540340; MCGUFFIN P, 1987, J CHILD PSYCHOL PSYC, V28, P215, DOI 10.1111/j.1469-7610.1987.tb00205.x; MCGUFFIN P, 1990, AM J HUM GENET, V46, P994; Morgan W.P., 1896, BMJ-BRIT MED J, V2, P1543, DOI [10.1136/bmj.2.1871.1378, DOI 10.1136/BMJ.2.1871.1378]; Pennington B.F., 1984, CONTINUITIES DISCONT, P123; PENNINGTON BF, 1990, J CHILD PSYCHOL PSYC, V31, P193, DOI 10.1111/j.1469-7610.1990.tb01561.x; PLOMIN R, 1989, AM PSYCHOL, V44, P105, DOI 10.1037/0003-066X.44.2.105; Raven J. C., 1938, STANDARD PROGRESSIVE; RAVEN JC, 1984, COLOURED PROGR MATRI; REICH T, 1981, GENETIC RES STRATEGI; Reiss AlbertJ JR, 1961, OCCUPATIONS SOCIAL S; Richman L. C., 1983, ADV DEV BEHAVIORAL P, V4, P87; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SLADEN BK, 1970, B ORTON SOC, V20, P30; SMITH SD, 1990, J AM ACAD CHILD PSY, V29, P204, DOI 10.1097/00004583-199003000-00008; SMITH SD, 1983, SCIENCE, V219, P1345, DOI 10.1126/science.6828864; SMITH SD, 1991, READ WRIT, V4, P92; Stephenson S., 1907, OPHTHALMOSCOPE, V5, P482; Thomas C. J., 1905, OPHTHALMOSCOPE, V3, P380; VOGEL SA, 1990, J LEARN DISABIL-US, V23, P44, DOI 10.1177/002221949002300111; 1980, DIAGNOSTIC STATISTIC; MANUAL TEACHERS ADM	43	150	152	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1527	1534		10.1001/jama.266.11.1527	http://dx.doi.org/10.1001/jama.266.11.1527			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880884				2022-12-28	WOS:A1991GE45800033
J	GREENWADE, LE				GREENWADE, LE			SCIENTIFIC VISUALIZATION - PRACTICES AND PROMISES	NATURE			English	Article											GREENWADE, LE (corresponding author), IDAHO NATL ENGN LAB,IDAHO FALLS,ID 83415, USA.							CALVERT TW, 1988, GRAPHICS INTERFACE 8; DEFANTI T, 1990, VISUALIZATION EXPAND; Foley J. D., 1990, COMPUTER GRAPHICS PR; GETZOFF ED, 1989, EVOLUTION CUZN SUPER, V5; HAFERKORN S, 1989, MANIPULATION COMPUTE, V1; Hamming R.W., 1962, NUMERICAL METHODS SC; PARKE FI, 1990, STATE ART FACIAL ANI, V26; ROGERS DF, 1991, STATE ART COMPUTER G, P313; WARD F, 1989, NATIONAL GEOGRAPHIC, V175, P718; [No title captured]	10	0	1	1	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					191	192		10.1038/353191a0	http://dx.doi.org/10.1038/353191a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891047				2022-12-28	WOS:A1991GE73100061
J	MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK				MCCARTY, DR; HATTORI, T; CARSON, CB; VASIL, V; LAZAR, M; VASIL, IK			THE VIVIPAROUS-1 DEVELOPMENTAL GENE OF MAIZE ENCODES A NOVEL TRANSCRIPTIONAL ACTIVATOR	CELL			English	Article							AMINO-ACID-SEQUENCE; ZEA-MAYS-L; ABSCISIC-ACID; WILD-TYPE; POLYACRYLAMIDE GELS; SECONDARY-STRUCTURE; WHEAT EMBRYOS; PROTEIN; EXPRESSION; DNA	The Viviparous-1 (Vp1) gene of maize is specifically required for expression of the maturation program in seed development. We show that Vp1 encodes a 73,335 dalton protein with no detectable homology to known proteins. An acidic transcriptional activation sequence was identified by fusion to the GAL4 DNA-binding domain. Expression of VP1 in maize protoplasts resulted in strong activation (> 130-fold) of a reporter gene fused to the promoter of a presumptive target gene. The acidic domain in VP1 was essential for transactivation and could be functionally replaced by the activator sequence of the herpes simplex virus VP16 protein. Our results indicate that VP1 is a novel transcription factor possibly involved in potentiation of a seed-specific hormone response.			MCCARTY, DR (corresponding author), UNIV FLORIDA, DEPT VEGETABLE CROPS, GAINESVILLE, FL 32611 USA.		Vasil, Indra K/F-6192-2011	Vasil, Indra K/0000-0002-8900-4897				ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CUMING AC, 1984, EUR J BIOCHEM, V145, P351, DOI 10.1111/j.1432-1033.1984.tb08561.x; DOONER HK, 1985, PLANT PHYSIOL, V77, P486, DOI 10.1104/pp.77.2.486; DURE L, 1981, BIOCHEMISTRY-US, V20, P4162, DOI 10.1021/bi00517a033; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JONES RJ, 1987, PLANT PHYSIOL, V83, P905, DOI 10.1104/pp.83.4.905; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIZ AR, 1990, PLANT PHYSIOL, V92, P538, DOI 10.1104/pp.92.2.538; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; Maniatis T., 1982, MOL CLONING; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1989, DEV GENET, V10, P473, DOI 10.1002/dvg.1020100608; MCCARTY DR, 1989, PLANT CELL, V1, P523, DOI 10.1105/tpc.1.5.523; MCCARTY DR, 1991, PHYSIOL PLANTARUM, V81, P267, DOI 10.1111/j.1399-3054.1991.tb02140.x; McCarty DR, 1986, MAIZE GEN COOP NEWSL, V60, P61; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEILL SJ, 1986, PLANTA, V169, P87, DOI 10.1007/BF01369779; NEILL SJ, 1987, PLANTA, V171, P358, DOI 10.1007/BF00398681; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTSON DS, 1955, GENETICS, V40, P744; ROBICHAUD C, 1987, J PLANT PHYSIOL, V130, P181, DOI 10.1016/S0176-1617(87)80222-5; ROBICHAUD C, 1986, J PLANT PHYSIOL, V126, P235, DOI 10.1016/S0176-1617(86)80025-6; ROBICHAUD CS, 1980, DEV GENET, V1, P325, DOI 10.1002/dvg.1020010405; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208	56	547	603	2	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					895	905		10.1016/0092-8674(91)90436-3	http://dx.doi.org/10.1016/0092-8674(91)90436-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889090				2022-12-28	WOS:A1991GE46000009
J	MYERS, J; FROELICHER, VF				MYERS, J; FROELICHER, VF			HEMODYNAMIC DETERMINANTS OF EXERCISE CAPACITY IN CHRONIC HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Review						HEART FAILURE, CONGESTIVE; HEMODYNAMICS; EXERCISE TEST; VENTRICULAR FUNCTION, LEFT; VENTILATION-PERFUSION RATIO	LEFT-VENTRICULAR DYSFUNCTION; NUCLEAR MAGNETIC-RESONANCE; ADRENERGIC-RECEPTOR DENSITY; SKELETAL-MUSCLE METABOLISM; FAILING HUMAN-HEART; BLOOD-FLOW; ISOSORBIDE DINITRATE; SUBMAXIMAL EXERCISE; MYOCARDIAL-INFARCTION; VENTILATORY RESPONSES	Purpose: To synthesize information on hemodynamic determinants of exercise capacity in patients with chronic heart failure. Data Identification: Relevant studies published from the mid-1960s to the present were identified by a manual search of the English-language literature and by bibliographic review of pertinent articles. Study Selection: Both controlled and observational studies that reported measures of either exercise time or oxygen uptake and hemodynamic variables in patients with heart failure were reviewed for quality and included when relevant to the discussion. Data Extraction: Key conclusions or data, or both, were extracted from each article and described. Data Synthesis: Exercise intolerance is a hallmark of chronic congestive heart failure. Studies have emphasized central factors and indices of systolic ventricular function, but poor relations have been consistently found between these measurements and exercise capacity. Recent data suggest that diastolic function (that is, ventricular filling and compliance) is an important factor affecting the ability to increase cardiac output and determining exercise capacity, but this issue needs further study. A clearer picture of histologic and biochemical abnormalities in skeletal muscle has recently emerged; patients with heart failure show greater glycolysis, reduced oxidative phosphorylation, and reduced oxidative enzyme activity. Vasodilatory abnormalities in heart failure were first described more than 20 years ago, and such abnormalities may underlie recently reported reductions in skeletal muscle blood flow during exercise. Relative hyperventilation is commonly observed during exercise in patients with heart failure and is related to ventilation-perfusion mismatching in the lung due to a higher-than-normal fraction of physiologic dead space. Neurohumoral abnormalities include reductions in beta-receptor density and sensitivity and contribute to reduce inotropic and chronotropic responses to exercise. Conclusions: Systolic function and exercise capacity are unrelated in patients with chronic heart failure, but many hemodynamic abnormalities (including those in the heart, lung, and skeletal muscle) overlap, which leads to exercise intolerance in these patients.			MYERS, J (corresponding author), VET AFFAIRS MED CTR, DEPT CARDIOL 111C, 5901 E 7TH ST, LONG BEACH, CA 90822 USA.			Froelicher, Victor/0000-0001-8831-4853				ALICANDRI C, 1986, POSTGRAD MED J, V62, P170; BAKER BJ, 1984, AM J CARDIOL, V54, P596, DOI 10.1016/0002-9149(84)90256-X; BENGE W, 1980, CIRCULATION, V61, P955, DOI 10.1161/01.CIR.61.5.955; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRUCE RA, 1977, NEW ENGL J MED, V296, P671, DOI 10.1056/NEJM197703242961206; BUICK FJ, 1980, J APPL PHYSIOL, V48, P636, DOI 10.1152/jappl.1980.48.4.636; BYLUND AC, 1976, EUR J CLIN INVEST, V6, P425, DOI 10.1111/j.1365-2362.1976.tb00538.x; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COLUCCI WS, 1989, CIRCULATION, V80, P314, DOI 10.1161/01.CIR.80.2.314; COLUCCI WS, 1981, NEW ENGL J MED, V305, P185, DOI 10.1056/NEJM198107233050402; COWLEY AJ, 1986, BRIT HEART J, V55, P75; COYLE EF, 1985, J APPL PHYSIOL, V59, P853, DOI 10.1152/jappl.1985.59.3.853; COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; Dempsey J, 1982, Can J Appl Sport Sci, V7, P4; DIPRAMPERO PE, 1985, J EXP BIOL, V115, P319; DREXLER H, 1987, CIRCULATION, V76, P178; DREXLER H, 1987, CIRCULATION, V76, P1344, DOI 10.1161/01.CIR.76.6.1344; FINK LI, 1986, AM J CARDIOL, V57, P249, DOI 10.1016/0002-9149(86)90900-8; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; FRANCIOSA JA, 1982, AM HEART J, V104, P587, DOI 10.1016/0002-8703(82)90231-9; FRANCIOSA JA, 1984, AM J CARDIOL, V53, P127, DOI 10.1016/0002-9149(84)90696-9; FRANCIOSA JA, 1985, AM HEART J, V110, P807, DOI 10.1016/0002-8703(85)90461-2; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; FRANCIOSA JA, 1979, AM J CARDIOL, V43, P1009, DOI 10.1016/0002-9149(79)90368-0; FRANCIOSA JA, 1980, AM J MED, V69, P559, DOI 10.1016/0002-9343(80)90468-4; FRANCIOSA JA, 1978, JAMA-J AM MED ASSOC, V240, P443, DOI 10.1001/jama.240.5.443; FRANCIS GS, 1985, J AM COLL CARDIOL, V5, P832, DOI 10.1016/S0735-1097(85)80420-4; FRANCIS GS, 1987, CIRCULATION, V76, P11; GAZETOPO.N, 1966, BRIT HEART J, V28, P1; GINSBURG R, 1983, ANN INTERN MED, V98, P603, DOI 10.7326/0003-4819-98-5-603; GINSBURG R, 1983, AM HEART J, V106, P535, DOI 10.1016/0002-8703(83)90698-1; GOLDSMITH RL, 1988, CIRCULATION S2, V78, P56; GREEN HJ, 1980, CAN J PHYSIOL PHARM, V58, P1311, DOI 10.1139/y80-199; HIGGINBOTHAM MB, 1983, AM J CARDIOL, V51, P52, DOI 10.1016/S0002-9149(83)80010-1; HIGGINS CB, 1972, J CLIN INVEST, V51, P715, DOI 10.1172/JCI106865; INGRAM RH, 1976, PROG CARDIOVASC DIS, V19, P109, DOI 10.1016/0033-0620(76)90019-0; KAWASHIMA S, 1991, J AM COLL CARDIOL, V17, P53, DOI 10.1016/0735-1097(91)90703-C; KOIKE A, 1990, J APPL PHYSIOL, V68, P2521, DOI 10.1152/jappl.1990.68.6.2521; LEIER CV, 1983, AM J CARDIOL, V52, P304, DOI 10.1016/0002-9149(83)90128-5; LEIER CV, 1983, CIRCULATION, V67, P817, DOI 10.1161/01.CIR.67.4.817; LEJEMTEL TH, 1986, CIRCULATION, V74, P245, DOI 10.1161/01.CIR.74.2.245; LIANG CS, 1984, CIRCULATION, V69, P113, DOI 10.1161/01.CIR.69.1.113; LIPKIN DP, 1988, INT J CARDIOL, V18, P187, DOI 10.1016/0167-5273(88)90164-7; LIPKIN DP, 1986, BRIT HEART J, V55, P439; LITCHFIELD RL, 1982, CIRCULATION, V66, P129, DOI 10.1161/01.CIR.66.1.129; LONGHURST J, 1976, CIRCULATION, V54, P477, DOI 10.1161/01.CIR.54.3.477; MANCINI DM, 1987, J AM COLL CARDIOL, V10, P845, DOI 10.1016/S0735-1097(87)80279-6; MANCINI DM, 1989, CIRCULATION, V80, P1338, DOI 10.1161/01.CIR.80.5.1338; MANCINI DM, 1988, AM J CARDIOL, V62, P1234, DOI 10.1016/0002-9149(88)90266-4; MASKIN CS, 1983, AM J CARDIOL, V51, P177, DOI 10.1016/S0002-9149(83)80032-0; MASSIE B, 1987, CIRCULATION, V76, P1009, DOI 10.1161/01.CIR.76.5.1009; Massie B M, 1988, Am J Med, V84, P75, DOI 10.1016/0002-9343(88)90208-2; MASSIE BM, 1987, AM J CARDIOL, V60, P309, DOI 10.1016/0002-9149(87)90233-5; MASSIE BM, 1981, CIRCULATION, V64, P1218, DOI 10.1161/01.CIR.64.6.1218; MASSIE BM, 1984, CIRCULATION, V69, P1135, DOI 10.1161/01.CIR.69.6.1135; MCKIRNAN MD, 1984, J AM COLL CARDIOL, V3, P253; MEILER SEL, 1987, AM HEART J, V113, P1207, DOI 10.1016/0002-8703(87)90935-5; MIHEVIC PM, 1981, MED SCI SPORT EXER, V13, P150; MYERS J, 1987, J APPL PHYSIOL, V63, P97, DOI 10.1152/jappl.1987.63.1.97; OREN A, 1981, J APPL PHYSIOL, V51, P185, DOI 10.1152/jappl.1981.51.1.185; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; PARKER GW, 1969, AM J MED SCI, V257, P365, DOI 10.1097/00000441-196906000-00002; Pouleur H., 1990, CIRCULATION, V82, P189; RAJAGOPALAN B, 1988, AM J CARDIOL, V62, pE53, DOI 10.1016/S0002-9149(88)80012-2; RAJFER SI, 1987, CIRCULATION, V76, P46; REED JW, 1978, CLIN SCI MOL MED, V54, P9, DOI 10.1042/cs0540009; ROUBIN GS, 1990, J AM COLL CARDIOL, V15, P986, DOI 10.1016/0735-1097(90)90229-I; Rowell L., 1986, HUMAN CIRCULATION RE; RUBIN SA, 1979, AM J CARDIOL, V44, P1183, DOI 10.1016/0002-9149(79)90186-3; RUBIN SA, 1980, CIRCULATION, V61, P543, DOI 10.1161/01.CIR.61.3.543; RUBIN SA, 1984, AM REV RESPIR DIS, V129, pS63, DOI 10.1164/arrd.1984.129.2P2.S63; RUBIN SA, 1982, CIRCULATION, V66, P143, DOI 10.1161/01.CIR.66.1.143; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHLANT RC, 1986, HEART, P319; SECHER NH, 1977, ACTA PHYSIOL SCAND, V100, P288, DOI 10.1111/j.1748-1716.1977.tb05952.x; SECHER NH, 1974, J APPL PHYSIOL, V36, P515, DOI 10.1152/jappl.1974.36.5.515; SIEGEL LA, 1983, AM HEART J, V106, P1042, DOI 10.1016/0002-8703(83)90650-6; SINOWAY LI, 1987, J APPL PHYSIOL, V62, P1063, DOI 10.1152/jappl.1987.62.3.1063; SINOWAY LI, 1988, AM J CARDIOL, V61, P1076, DOI 10.1016/0002-9149(88)90129-4; SINOWAY LI, 1986, J AM COLL CARDIOL, V7, pA224; SINOWAY LI, 1986, J APPL PHYSIOL, V61, P673, DOI 10.1152/jappl.1986.61.2.673; SISKIND SJ, 1981, CIRCULATION, V64, P966, DOI 10.1161/01.CIR.64.5.966; SMULYAN H, 1974, SURG CLIN N AM, V54, P1077; STEPHENS J, 1978, BRIT HEART J, V40, P832; SULLIVAN M, 1989, J AM COLL CARDIOL, V13, P1138, DOI 10.1016/0735-1097(89)90276-3; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SULLIVAN MJ, 1989, CIRCULATION, V79, P324, DOI 10.1161/01.CIR.79.2.324; SULLIVAN MJ, 1989, CIRCULATION, V80, P769, DOI 10.1161/01.CIR.80.4.769; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; SULLIVAN MJ, 1988, CIRCULATION, V77, P552, DOI 10.1161/01.CIR.77.3.552; Swan H J, 1986, Adv Cardiol, V34, P45; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; TOPIC N, 1982, AM HEART J, V104, P1172, DOI 10.1016/0002-8703(82)90047-3; WEBER KT, 1985, J AM COLL CARDIOL, V6, P717, DOI 10.1016/S0735-1097(85)80472-1; WEBER KT, 1982, CIRCULATION, V65, P1213, DOI 10.1161/01.CIR.65.6.1213; WHITE HD, 1985, AM J CARDIOL, V56, P93, DOI 10.1016/0002-9149(85)90573-9; WIENER DH, 1986, CIRCULATION, V73, P1127, DOI 10.1161/01.CIR.73.6.1127; WILLENS HJ, 1987, AM HEART J, V114, P377, DOI 10.1016/0002-8703(87)90506-0; WILSON JR, 1982, CHEST, V82, P701, DOI 10.1378/chest.82.6.701; WILSON JR, 1983, AM J CARDIOL, V51, P1358, DOI 10.1016/0002-9149(83)90312-0; WILSON JR, 1984, AM J CARDIOL, V53, P1308, DOI 10.1016/0002-9149(84)90085-7; WILSON JR, 1983, CIRCULATION, V68, P425, DOI 10.1161/01.CIR.68.2.425; WILSON JR, 1989, CIRCULATION, V79, P1021, DOI 10.1161/01.CIR.79.5.1021; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; WILSON JR, 1985, CIRCULATION, V72, P72, DOI 10.1161/01.CIR.72.1.72; WILSON JR, 1986, CIRCULATION, V74, P775, DOI 10.1161/01.CIR.74.4.775; WILSON JR, 1985, CIRCULATION, V71, P57, DOI 10.1161/01.CIR.71.1.57; WILSON JR, 1985, J AM COLL CARDIOL, V6, P556, DOI 10.1016/S0735-1097(85)80113-3; YANCY C W JR, 1989, Journal of the American College of Cardiology, V13, p38A; ZELIS R, 1974, CIRCULATION, V50, P137, DOI 10.1161/01.CIR.50.1.137; ZELIS R, 1968, J CLIN INVEST, V47, P960, DOI 10.1172/JCI105788; ZELIS R, 1982, PROG CARDIOVASC DIS, V24, P437, DOI 10.1016/0033-0620(82)90012-3	114	101	102	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					377	386		10.7326/0003-4819-115-5-377	http://dx.doi.org/10.7326/0003-4819-115-5-377			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863029				2022-12-28	WOS:A1991GC06500009
J	ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT				ANDERSON, RM; MAY, RM; BOILY, MC; GARNETT, GP; ROWLEY, JT			THE SPREAD OF HIV-1 IN AFRICA - SEXUAL CONTACT PATTERNS AND THE PREDICTED DEMOGRAPHIC-IMPACT OF AIDS	NATURE			English	Review							HUMAN IMMUNODEFICIENCY VIRUS; PREFERRED NUCLEOTIDE SUBSTITUTIONS; INTRAVENOUS DRUG-USERS; NEW-YORK-CITY; HETEROSEXUAL TRANSMISSION; TRANSMITTED DISEASES; HOUSEHOLD CONTACTS; VIRAL MIXTURES; INFECTION; CHILDREN	The spread of HIV-1 in Africa is examined here in the light of recent information on the main epidemiological and behavioural determinants of transmission. Mathematical models incorporating demographic, epidemiological and behavioural processes are used to assess the potential demographic impact of the disease AIDS. These analyses highlight the significance of patterns of sexual behaviour, and in particular networks of sexual contact, on the predicted spread of infection. Current data reveal substantial variations in the degree of spread between and in countries, but new analyses support earlier predictions that in the worst-afflicted areas AIDS is likely to change population growth rates from positive to negative values in a few decades.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford	ANDERSON, RM (corresponding author), UNIV LONDON IMPERIAL COLL SCI & TECHNOL, DEPT BIOL, PARASITE EPIDEMIOL RES GRP, LONDON SW7 2BB, ENGLAND.		Garnett, Geoffrey P/A-9312-2008	Anderson, Roy/0000-0002-9528-3175; Boily, Marie-Claude/0000-0003-3919-006X				ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185; ANDERSON RM, 1989, ANN NY ACAD SCI, V569, P240, DOI 10.1111/j.1749-6632.1989.tb27374.x; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; ANDERSON RM, 1988, NATURE, V332, P191; ANDIHAN WA, 1990, AIDS, V4, P758; ANDREASSON PA, 1989, 5 INT C AIDS MONTR; ANZALA A, 1989, 5 INT C AIDS MONTR; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BALDWIN JD, 1988, J SEX RES, V25, P181, DOI 10.1080/00224498809551454; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKELY SF, 1989, 4 INT C AIDS ASS CAN; BERKLEY S, 1990, AIDS, V4, P1237, DOI 10.1097/00002030-199012000-00009; BIBERFELD G, 1986, SCAND J INFECT DIS, V18, P497, DOI 10.3109/00365548609021653; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLOWER SM, 1990, J ACQ IMMUN DEF SYND, V3, P763; BOILY MC, IN PRESS IMA J MATH; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; BROWN RC, 1990, AIDS, V4, P1267, DOI 10.1097/00002030-199012000-00014; CARAEL M, IN PRES SADIS; DECOCK KM, 1984, SCIENC, V224, P497; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DEVINCENZI I, 1989, BRIT MED J, V298, P411; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; FRANCE AJ, 1988, BRIT MED J, V296, P526, DOI 10.1136/bmj.296.6621.526; GANORE E, 1990, 6 INT C AIDS MONTR; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; GLASER JB, 1989, ARCH INTERN MED, V149, P645, DOI 10.1001/archinte.149.3.645; GOEDERT JJ, 1989, LANCET, V2, P1351; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; GUAY L, 1990, 6 INT C AIDS SAN FRA; GUPTA S, 1989, AIDS, V3, P807, DOI 10.1097/00002030-198912000-00005; HEWLETT IK, 1990, J ACQ IMMUN DEF SYND, V3, P714; HGSBORG M, IN PRESS ANTHR STUDI; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; HYMAN JM, 1989, MATH BIOSCI, V8, P103; JACQUEZ JA, 1988, MATH BIOSCI, V92, P119, DOI 10.1016/0025-5564(88)90031-4; JOHN JT, 1989, LANCET, V1, P160; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; KILLEWO J, 1990, AIDS, V4, P1081, DOI 10.1097/00002030-199011000-00005; KONINGS E, 1989, AIDS, V3, P245; KREISS J, 1988, GENITOURIN MED, V64, P1; LIFOON AR, 1990, 6 INT C AIDS SAN FRA; LIOMBA NG, 1989, 5 INT C AIDS MONTR; LISSE IM, 1990, AIDS, V4, P1263, DOI 10.1097/00002030-199012000-00013; LPAGE P, 1989, 4 INT C AIDS ASS CAN; MAIGA MK, 1989, 5 INT C AIDS MONTR; MATI J, 1989, 6 INT C AIDS MONTR; MAY RM, 1988, MATH BIOSCI, V90, P475, DOI 10.1016/0025-5564(88)90079-X; MAY RM, 1990, PARASITOLOGY, V100, pS89, DOI 10.1017/S0031182000073042; May RM, 1989, LECT NOTES BIOMATHEM, V81, P220; MAY RM, 1989, CURRENT TOPICS AIDS, V2, P33; MELBYE M, 1986, LANCET, V2, P1113; MURLIE A, 1989, 5 INT C AIDS MONTR; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NOWAK MA, 1990, AIDS, V4, P1095, DOI 10.1097/00002030-199011000-00007; NTOZI JPM, IN PRESS ANTHR STUDI; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PECKHAM CS, 1991, LANCET, V337, P253; PECKHAM CS, 1988, LANCET, V2, P1039; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; POTTS M, IN PRESS LANCET; REEVES GK, 1989, PHIL T R SOC B, V325, P109; REZZA G, 1989, AIDS, V3, P87, DOI 10.1097/00002030-198902000-00006; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SHARP PM, 1988, NATURE, V336, P315, DOI 10.1038/336315a0; TAYLOR JMG, 1991, J ACQ IMMUN DEF SYND, V4, P69; THANGCHARVEN P, 1989, HIV INFECTION THAILA; TOVO PA, 1988, LANCET, V2, P1043; VANDEPERRE P, 1985, LANCET, V2, P524; VANICHSENI S, 1989, 5 INT C AIDS MONTR; WARD J, 1990, 6 INT C AIDS SAN FRA; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; YOKOYAMA S, 1988, MOL BIOL EVOL, V5, P237; 1990, NATIONAL HIV SEROPRE; 1990, HIV AIDS SURVEILLANC; 1989, HIV SEROPREVALENCE B; 1987, MORBIDITY MORTALITY, V36, P593	87	261	262	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					581	589		10.1038/352581a0	http://dx.doi.org/10.1038/352581a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865922				2022-12-28	WOS:A1991GB21100044
J	JOENSUU, H; TOIKKANEN, S				JOENSUU, H; TOIKKANEN, S			COMPARISON OF BREAST CARCINOMAS DIAGNOSED IN THE 1980S WITH THOSE DIAGNOSED IN THE 1940S TO 1960S	BRITISH MEDICAL JOURNAL			English	Article							CANCER INCIDENCE; DNA CONTENT; SURVIVAL; MORTALITY; TRENDS	Objective - To find out if breast carcinomas diagnosed in the 1980s differ from those diagnosed a few decades ago. Design - Retrospective comparative cohort study. Setting - City of Turku, south western Finland. Patients - 439 patients with breast carcinoma diagnosed in 1945-65 with a median follow up of 27 years (95% of all those histologically diagnosed in Turku); and 370 patients with breast carcinoma diagnosed in 1980-4 with a median follow up of 6 years (94% of all those histologically diagnosed in Turku). Main outcome measures - Breast cancer incidence, mortality from breast cancer, age at diagnosis, stage of cancer, seven histological factors, DNA ploidy. Results - Age adjusted incidence of breast cancer increased from 30.8/100 000 person years in 1953-7 to 62.2/100000 in 1983-7; mortality in breast cancer increased from 16.7 to 17.2/100 000 person years. Survival of patients with stages 11 to IV (but not with stage 1) improved. The mean age at diagnosis increased from 55.5 years in 1945-55 to 62.5 years in 1980-4 (p < 0.0001); the proportion of patients with T0-1 carcinomas increased from 13% to 41% (p < 0.0001) and with pN0 carcinomas from 43% to 55% (p = 0.003) from 1945-65 to 1980-4. There was no change in histological type or DNA ploidy of breast cancer, but in the 1980-4 cohort carcinomas were more often well differentiated, had lower mitotic counts and less nuclear pleomorphism, more often had a well defined tumour margin, and had less tumour necrosis. There was, however, no difference between the two cohorts in these histological characteristics except for tumour necrosis when they were compared in a multivariate log linear model at a given size of primary tumour. Conclusion - Improved survival with breast cancer can at least partially be explained by detection of increased numbers of small carcinomas with favourable histological characteristics.	UNIV TURKU,DEPT REHABIL MED,SF-20500 TURKU 50,FINLAND	University of Turku	JOENSUU, H (corresponding author), UNIV TURKU,CENT HOSP,DEPT RADIOTHERAPY & ONCOL,SF-20520 TURKU 52,FINLAND.							ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BRINCKER H, 1988, ACTA ONCOL, V27, P729, DOI 10.3109/02841868809091776; EWERTZ M, 1988, INT J CANCER, V41, P46, DOI 10.1002/ijc.2910410110; Fienberg S. E, 1977, ANAL CROSS CLASSIFIE; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HOST H, 1977, INT J RADIAT ONCOL, V2, P1061, DOI 10.1016/0360-3016(77)90110-9; MILLER AB, 1986, INT J CANCER, V37, P173, DOI 10.1002/ijc.2910370202; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; POLLACK ES, 1980, J NATL CANCER I, V64, P1091; TOIKKANEN S, 1989, BRIT J CANCER, V60, P693, DOI 10.1038/bjc.1989.342; TOIKKANEN S, 1990, APMIS, V98, P1005, DOI 10.1111/j.1699-0463.1990.tb05027.x; WATERHOUSE J, 1976, IARC SCI PUBL, V15, P510; 1988, NEW ENGL J MED, V319, P1681; 1981, INT HISTOLOGICAL CLA, V2; 1987, TNM CLASSIFICATION M	15	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					155	158		10.1136/bmj.303.6795.155	http://dx.doi.org/10.1136/bmj.303.6795.155			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878638	Green Published, Bronze			2022-12-28	WOS:A1991FX57800020
J	HALL, WW; LIU, CRR; SCHNEEWIND, O; TAKAHASHI, H; KAPLAN, MH; ROUPE, G; VAHLNE, A				HALL, WW; LIU, CRR; SCHNEEWIND, O; TAKAHASHI, H; KAPLAN, MH; ROUPE, G; VAHLNE, A			DELETED HTLV-I PROVIRUS IN BLOOD AND CUTANEOUS LESIONS OF PATIENTS WITH MYCOSIS-FUNGOIDES	SCIENCE			English	Article							T-CELL LEUKEMIA; NUCLEOTIDE-SEQUENCE; HUMAN RETROVIRUS; C RETROVIRUS; LYMPHOMA; VIRUS; FEATURES; LINES; IDENTIFICATION; ANTIBODIES	Mycosis fungoides, a rare form of cutaneous T cell leukemia/lymphoma, is suspected of having a viral etiology on the basis of certain similarities to adult T cell leukemia, which is associated with human T cell leukemia/lymphoma virus type I (HTLV-I) infection. Cell lines were established from peripheral blood mononuclear cells (PBMC) of an HTLV-I-seronegative patient with mycosis fungoides. DNA hybridization analysis revealed the presence of HTLV-I-related sequences with unusual restriction endonuclease sites. Sequence analysis of subcloned fragments demonstrated the presence of a monoclonally integrated provirus with a 5.5-kilobase deletion involving large regions of gag and env and all of pol. Additional evidence for the presence of deleted proviruses was found by polymerase chain reaction (PCR) amplification of DNA from cutaneous lesions of five other HTLV-I-seronegative patients. The findings suggest that HTLV-I infection may be involved in the etiology of at least certain cases of mycosis fungoides.	ROCKEFELLER UNIV,NEW YORK,NY 10021; SAHLGRENS UNIV HOSP,DEPT DERMATOL,S-41345 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT CLIN VIROL,S-41124 GOTHENBURG,SWEDEN	Rockefeller University; Sahlgrenska University Hospital; University of Gothenburg	HALL, WW (corresponding author), CORNELL UNIV,N SHORE UNIV HOSP,COLL MED,DIV INFECT DIS,MANHASSET,NY 11030, USA.				NCI NIH HHS [CA51012-01A1] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAUNFALCO O, 1979, ACTA DERM-VENEREOL, V85, P11; BUECHNER SA, 1983, ARCH DERMATOL, V119, P797; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; CLENDENNING W E, 1986, Clinical and Experimental Dermatology, V11, P109; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EPSTEIN EH, 1972, MEDICINE, V51, P61, DOI 10.1097/00005792-197201000-00004; GALLO RC, 1983, CANCER RES, V43, P3892; HALL WW, UNPUB; HALL WW, 1990, HUMAN RETROVIROLOGY, P254; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KANAMORI H, 1990, EMBO J, V9, P4161, DOI 10.1002/j.1460-2075.1990.tb07639.x; KIKOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359; KOBAYASHI N, 1986, Cancer Reviews, V1, P64; KRAJEWSKI AS, 1988, HISTOPATHOLOGY, V13, P19, DOI 10.1111/j.1365-2559.1988.tb02001.x; LANGEWANTZIN G, 1986, J AM ACAD DERMATOL, V15, P598; LEE TH, 1984, SCIENCE, V226, P57, DOI 10.1126/science.6089350; LONGO DL, 1984, NATURE, V310, P505, DOI 10.1038/310505a0; MANN DL, 1984, J CLIN INVEST, V74, P56, DOI 10.1172/JCI111418; MANZARI V, 1987, SCIENCE, V238, P1581, DOI 10.1126/science.2825353; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RATNER L, 1985, J VIROL, V54, P781, DOI 10.1128/JVI.54.3.781-790.1985; SAXINGER WC, 1985, SCAND J HAEMATOL, V34, P455; SAXINGER WC, 1984, HUMAN T CELL LEUKEMI, P323; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SUGAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P7441, DOI 10.1073/pnas.81.23.7441; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YAMAMOTO N, 1982, NATURE, V299, P367, DOI 10.1038/299367a0; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	32	178	183	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					317	320		10.1126/science.1857968	http://dx.doi.org/10.1126/science.1857968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857968				2022-12-28	WOS:A1991FX22400041
J	WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ				WIRAK, DO; BAYNEY, R; RAMABHADRAN, TV; FRACASSO, RP; HART, JT; HAUER, PE; HSIAU, P; PEKAR, SK; SCANGOS, GA; TRAPP, BD; UNTERBECK, AJ			DEPOSITS OF AMYLOID-BETA PROTEIN IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							ALTERNATIVELY SPLICED FORM; PRECURSOR MESSENGER-RNAS; CELL-SURFACE RECEPTOR; ALZHEIMERS-DISEASE; SENILE PLAQUES; GENE; EXPRESSION; BRAIN; LOCALIZATION; QUANTITATION	Alzheimer's disease is characterized by widespread deposition of amyloid in the central nervous system. The 4-kilodalton amyloid beta-protein is derived from a larger amyloid precursor protein and forms amyloid deposits in the brain by an unknown pathological mechanism. Except for aged nonhuman primates, there is no animal model for Alzheimer's disease. Transgenic mice expressing amyloid beta-protein in the brain could provide such a model. To investigate this possibility, the 4-kilodalton human amyloid beta-protein was expressed under the control of the promoter of the human amyloid precursor protein in two lines of transgenic mice. Amyloid beta-protein accumulated in the dendrites of some but not all hippocampal neurons in 1-year-old transgenic mice. Aggregates of the amyloid beta-protein formed amyloid-like fibrils that are similar in appearance to those in the brains of patients with Alzheimer's disease.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University	WIRAK, DO (corresponding author), MOLEC THERAPEUT INC,MILES RES CTR,400 MORGAN LANE,W HAVEN,CT 06516, USA.							BROECKHOVEN CV, 1990, SCIENCE, V248, P1120; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CORK LC, 1990, AM J PATHOL, V137, P1383; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; LEVEY E, 1990, SCIENCE, V248, P1124; MANN DMA, 1988, NEW ENGL J MED, V318, P789; MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; RICHARDS SJ, 1990, EMBO J, V10, P297; ROBAKIS NK, 1987, LANCET, V1, P384; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SISODIA S, 1987, NUCLEIC ACIDS RES, V15, P1999; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TRAPP BD, UNPUB; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIRAK D, UPUB; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	36	118	151	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					323	325		10.1126/science.1857970	http://dx.doi.org/10.1126/science.1857970			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857970				2022-12-28	WOS:A1991FX22400043
J	NICHOLAS, AS; DEBIAS, DA; GREENE, CH				NICHOLAS, AS; DEBIAS, DA; GREENE, CH			SOMATIC COMPONENT TO MYOCARDIAL-INFARCTION - 3 YEAR FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; DYSFUNCTION		PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL & PHARMACOL,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,OSTEOPATH PRINCIPLES & PRACTICE,PHILADELPHIA,PA 19131; PHILADELPHIA COLL OSTEOPATH MED,PHYSIOL,PHILADELPHIA,PA 19131									BEAL MC, 1985, J AM OSTEOPATH ASSOC, V85, P302; BEAL MC, 1983, J AM OSTEOPATH ASSOC, V82, P822; COX JM, 1983, J AM OSTEOPATH ASSOC, V82, P832; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; NICHOLAS AS, 1985, BRIT MED J, V291, P13, DOI 10.1136/bmj.291.6487.13	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1581	1581		10.1136/bmj.302.6792.1581	http://dx.doi.org/10.1136/bmj.302.6792.1581			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855044	Bronze, Green Published			2022-12-28	WOS:A1991FU54900028
J	ZOLTIE, N; HOULT, G				ZOLTIE, N; HOULT, G			ADEQUACY OF GENERAL-PRACTITIONERS PREMISES FOR MINOR SURGERY	BRITISH MEDICAL JOURNAL			English	Article								Objective-Assessment of facilities for minor surgery in general practitioners' premises. Design-Independent inspection of premises and equipment. Setting-Large urban district. Subjects-Premises of all general practitioners who applied to be reimbursed for minor surgery. Main outcome measure-Fulfilment of 14 preselected criteria. Results-69 of 111 premises met all criteria and were approved; 23 failed on only one criterion. The commonest reasons for failure were inadequate record keeping and lack of resuscitation equipment. Twelve practices had out of date adrenaline. Conclusions-Most premises are suitable for minor surgery, some with attention needed to record keeping. Practices must pay careful attention to the expiry date of adrenaline.	LEEDS FAMILY HLTH SERV AUTHOR,MINOR SURG INSPECTORATE,LEEDS LS2 7RB,ENGLAND										0	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1991	302	6782					941	942		10.1136/bmj.302.6782.941	http://dx.doi.org/10.1136/bmj.302.6782.941			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FH487	1888361	Green Published, Bronze			2022-12-28	WOS:A1991FH48700021
J	HARRINGTON, LA; GREIDER, CW				HARRINGTON, LA; GREIDER, CW			TELOMERASE PRIMER SPECIFICITY AND CHROMOSOME HEALING	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL TRANSFERASE; DNA; TETRAHYMENA; IDENTIFICATION	CHROMOSOME healing by de novo telomere addition at non-telomeric sites has been well characterized in several organisms 1-9. The Tetrahymena telomerase ribonucleoprotein uses an internal RNA template to catalyse d(TTGGGG)n telomere addition to the 3' end of telomeric sequence in vitro and in vivo 10,11. Studies of telomerase RNA indicated that hybridization of the RNA template region, 5'-CAACCCCAA-3', to the 3' end of single-stranded telomeric oligonucleotides might be important for primer recognition and utilization 10. The apparent requirement of telomerase for pre-existing telomeric sequence has raised questions regarding its role in chromosome healing 12,13. We report here that Tetrahymena telomerase can specifically elongate single-stranded DNA oligonucleotides whose termini are not complementary to the RNA template sequence 5'-CAACCCCAA-3'. These data suggest that telomerase may be able to heal chromosomes directly in vivo.	COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; FORNEY JD, 1988, MOL CELL BIOL, V8, P251, DOI 10.1128/MCB.8.1.251; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; Maxam A M, 1980, Methods Enzymol, V65, P499; McClintock B, 1941, GENETICS, V26, P234; MCCLINTOCK B, 1942, GENETICS, V28, P458; MURRAY A, 1990, NATURE, V346, P797, DOI 10.1038/346797a0; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SPANGLER EA, 1988, NUCLEIC ACIDS RES, V16, P5569, DOI 10.1093/nar/16.12.5569; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yao MC, 1989, MOBILE DNA, P715; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1990, TRENDS GENET, V6	28	158	169	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					451	454		10.1038/353451a0	http://dx.doi.org/10.1038/353451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896088				2022-12-28	WOS:A1991GH60600064
J	PADIAN, NS; SHIBOSKI, SC; JEWELL, NP				PADIAN, NS; SHIBOSKI, SC; JEWELL, NP			FEMALE-TO-MALE TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HETEROSEXUAL PARTNERS; HIV; ADULTS; WOMEN; AIDS; RISK	Objective. - To examine rates of heterosexual transmission of human immunodeficiency virus (HIV) and associated risk factors and to determine the relative efficiency of female-to-female and male-to-female transmission. Design. - Survey of infected individuals and their heterosexual partners recruited since 1985. Setting. - Participants were recruited from various HIV counseling and testing sites throughout California but were generally interviewed and tested in their homes. Participants. - Data from 379 couples at entry to the study are reported: 72 male partners of infected women and 307 female partners of infected men. The infected index case had a well-established source of risk; couples were eliminated if the direction of transmission could not be established. The majority of couples were monogamous since 1978, white, and in their 30s. Most partners did not know their serostatus at entry into the study. Main Outcome Measure. - HIV serostatus in the exposed sexual partner. Results. - We observed one probable instance (1%) of female-to-male transmission compared with 20% transmission rates in the female partners of infected men. All couples were sampled in the same way. Male index cases were more likely to be symptomatic than female index cases. Conclusions. - The odds of male-to-female transmission were signifiicantly greater than female-to-male transmission. The one case of female-to-male transmission was unique in that the couple reported numerous unprotected sexual contacts and noted several instances of vaginal and penile bleeding during intercourse.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT BIOSTAT,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT STAT,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California Berkeley								ALNOZHA M, 1990, J ACQ IMMUN DEF SYND, V3, P193; BENETUCCI J, 1990, 6TH INT C AIDS SAN F; CHIODO F, 1990, 6TH INT C AIDS SAN F; COSTIGIOLA P, 1989, 5TH INT C AIDS MONTR; DAVIDSON S, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1989, 5TH INT C AIDS MONTR; DEVINCENZI I, 1990, 6TH INT C AIDS SAN F; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; GUINAN ME, 1987, JAMA-J AM MED ASSOC, V257, P2039; HIRA S, 1988, 4TH INT C AIDS STOCK; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; LAGA M, 1988, 4TH INT C AIDS STOCK; LEKATSAS AM, 1987, 3 INT C AIDS WASH; NICOLOSI A, 1990, 6TH INT C AIDS SAN F; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN N, 1989, 5TH INT C AIDS MONTR; PADIAN NS, 1987, REV INFECT DIS, V9, P947; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PAPE JW, 1987, CLIN RES, V35, P486; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; POTTERAT JJ, 1987, JAMA-J AM MED ASSOC, V258, P1727; REHNET S, 1990, 6TH INT C AIDS SAN F; SION FS, 1990, 6TH INT C AIDS SAN F; STASZEWSKI S, 1989, 5 INT C AIDS MONTR; STEIGBIGEL NH, 1988, 4TH INT C AIDS STOCK; STEWART GJ, 1985, LANCET, V2, P581; VIGEVANI GM, 1988, 4TH INT C AIDS STOCK; WYKOFF RF, 1986, JAMA-J AM MED ASSOC, V255, P1704, DOI 10.1001/jama.1986.03370130059011; 1991, HIV AIDS SURVEILLANC	31	221	224	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1664	1667						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886189				2022-12-28	WOS:A1991GF41900032
J	GINES, P; ARROYO, V; VARGAS, V; PLANAS, R; CASAFONT, F; PANES, J; HOYOS, M; VILADOMIU, L; RIMOLA, A; MORILLAS, R; SALMERON, JM; GINES, A; ESTEBAN, R; RODES, J				GINES, P; ARROYO, V; VARGAS, V; PLANAS, R; CASAFONT, F; PANES, J; HOYOS, M; VILADOMIU, L; RIMOLA, A; MORILLAS, R; SALMERON, JM; GINES, A; ESTEBAN, R; RODES, J			PARACENTESIS WITH INTRAVENOUS-INFUSION OF ALBUMIN AS COMPARED WITH PERITONEOVENOUS SHUNTING IN CIRRHOSIS WITH REFRACTORY ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TENSE ASCITES; MASSIVE ASCITES; LEVEEN SHUNT; COMPLICATIONS; CIRRHOTICS; THERAPY	Background. There is no satisfactory treatment for refractory ascites in patients with cirrhosis. Both peritoneovenous shunts and paracentesis have been used, but there is uncertainty about their relative merits. Methods. We studied 89 patients with cirrhosis and refractory ascites who were randomly assigned to receive either repeated large-volume paracentesis plus intravenous albumin or a LeVeen peritoneovenous shunt. Patients in the paracentesis group in whom recurrent tense ascites developed during follow-up were treated with paracentesis, and those in the peritoneovenous-shunt group with diuretic agents or by the insertion of a new shunt if there was shunt obstruction. Results. During the first hospitalization, ascites was removed in all 41 patients in the paracentesis group and in 44 of the 48 patients in the peritoneovenous-shunt group. The mean (+/- SD) duration of hospitalization in the two groups was 11 +/- 5 and 19 +/- 9 days, respectively (P < 0.01). There were no significant differences in the number of patients who had complications or died. During follow-up, 37 patients in each group were hospitalized again. In the paracentesis group, the number of rehospitalizations for any reason (174 vs. 97 in the peritoneovenous-shunt group) or for ascites (125 vs. 38) was significantly higher, and the median time to a first readmission for any reason (1 +/- 1 vs. 2 +/- 2 months) or for ascites (2-2 vs. 8 +/- 17 months) was significantly shorter than in the peritoneovenous-shunt group. The total times in the hospital during follow-up, however, were similar in the two groups (48 +/- 49 and 44 +/- 39 days, respectively). Three patients had obstructions of their peritoneovenous shunts during their first hospitalizations, and 15 patients had a total of 20 obstructions during follow-up. Survival was similar in both groups. Conclusions. The LeVeen shunt and paracentesis are equally effective in relieving refractory ascites. The former may provide better long-term control of ascites, but shunt occlusion is common and survival is not improved.	HOSP CLIN BARCELONA,LIVER UNIT,VILLARROEL 170,E-08036 BARCELONA,SPAIN; HOSP VALL DHEBRO,LIVER UNIT,BARCELONA,SPAIN; HOSP MUTUA,GASTROENTEROL UNIT,TERRASSA,SPAIN; HOSP LA FE,GASTROENTEROL UNIT,VALENCIA,SPAIN; HOSP GERMANS TRIAS & PUJOL,GASTROENTEROL UNIT,BADALONA,SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital Universitario Mutua Terrassa; Hospital Universitari i Politecnic La Fe; Hospital Germans Trias i Pujol			Vargas, Victor/AAD-3303-2020; Arroyo, Vicente/F-9189-2015; Ginès, Pere/C-7730-2014; Vargas Blasco, Victor Manuel/C-9711-2018; Panes, Julian/H-5991-2015	Arroyo, Vicente/0000-0002-2728-1848; Ginès, Pere/0000-0003-4657-4504; Vargas Blasco, Victor Manuel/0000-0002-7190-6948; Viladomiu, Lluis/0000-0002-3434-9847; esteban, rafael/0000-0001-5280-392X; Panes, Julian/0000-0002-4971-6902				ARROYO V, 1975, POSTGRAD MED J, V51, P558, DOI 10.1136/pgmj.51.598.558; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; BERNHOFT RA, 1982, ARCH SURG-CHICAGO, V117, P631; BLENDIS LM, 1979, GASTROENTEROLOGY, V77, P250; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; DIXON WJ, 1985, BMDP STATISTICAL SOF; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; GREIG PD, 1981, GASTROENTEROLOGY, V80, P119; HEYROVSKY A, 1956, CLIN CHIM ACTA, V1, P470, DOI 10.1016/0009-8981(56)90020-1; KIRCHMER N, 1976, ANN SURG, V185, P145; LOPEZ C, 1989, EUR J GASTROEN HEPAT, V1, P51; METZLER M, 1980, SURGERY, V87, P106; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; PLANAS R, 1990, GASTROENTEROLOGY, V99, P1736, DOI 10.1016/0016-5085(90)90481-F; PROKESCH RC, 1983, AM J GASTROENTEROL, V78, P235; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIMOLA A, 1985, HEPATOLOGY, V5, P463, DOI 10.1002/hep.1840050320; RING EJ, 1979, SURG GYNECOL OBSTET, V148, P93; SALERNO F, 1987, J HEPATOL, V5, P102, DOI 10.1016/S0168-8278(87)80067-3; SCHOLZ DG, 1989, AM J GASTROENTEROL, V84, P540; SMAJDA C, 1985, ANN SURG, V201, P488; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; WAPNICK S, 1979, BRIT J SURG, V66, P667, DOI 10.1002/bjs.1800660924; WORMSER GP, 1981, AM J MED, V71, P358, DOI 10.1016/0002-9343(81)90151-0	27	252	258	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					829	835		10.1056/NEJM199109193251201	http://dx.doi.org/10.1056/NEJM199109193251201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875966				2022-12-28	WOS:A1991GF61600001
J	DALESSIO, DJ				DALESSIO, DJ			THYROXINE - TREATMENT FOR HEADACHE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALESSIO, DJ (corresponding author), SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880895				2022-12-28	WOS:A1991GE45800043
J	LEVAY, S				LEVAY, S			A DIFFERENCE IN HYPOTHALAMIC STRUCTURE BETWEEN HETEROSEXUAL AND HOMOSEXUAL MEN	SCIENCE			English	Article							SEXUALLY DIMORPHIC NUCLEUS; HUMAN IMMUNODEFICIENCY VIRUS; MEDIAL PREOPTIC AREA; MALE RHESUS-MONKEYS; FEMALE RATS; HUMAN-BRAIN; BEHAVIOR; DIFFERENTIATION; TESTOSTERONE; INFECTION	The anterior hypothalamus of the brain participates in the regulation of male-typical sexual behavior. The volumes of four cell groups in this region [interstitial nuclei of the anterior hypothalamus (INAH) 1, 2, 3, and 4] were measured in postmortem tissue from three subject groups: women, men who were presumed to be heterosexual, and homosexual men. No differences were found between the groups in the volumes of INAH 1, 2, or 4. As has been reported previously, INAH 3 was more than twice as large in the heterosexual men as in the women. It was also, however, more than twice as large in the heterosexual men as in the homosexual men. This finding indicates that INAH is dimorphic with sexual orientation, at least in men, and suggests that sexual orientation has a biological substrate.			LEVAY, S (corresponding author), SALK INST BIOL STUDIES,SAN DIEGO,CA 92186, USA.			LeVay, Simon/0000-0002-3338-0121				ALLEN LS, 1989, J NEUROSCI, V9, P497; ANDERSON RH, 1986, BRAIN RES, V370, P1, DOI 10.1016/0006-8993(86)91098-X; Bell AP, 1978, HOMOSEXUALITIES STUD; BLOCH GJ, 1988, J COMP NEUROL, V275, P613, DOI 10.1002/cne.902750409; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; DETELS R, 1989, J ACQ IMMUN DEF SYND, V2, P77; DODSON RE, 1988, J COMP NEUROL, V275, P623, DOI 10.1002/cne.902750410; DOHLER KD, 1984, BRAIN RES, V302, P291, DOI 10.1016/0006-8993(84)90242-7; DORNER G, 1975, ARCH SEX BEHAV, V4, P1, DOI 10.1007/BF01541882; FLANNERY A, 1982, DECLARATION CERTAIN, V2, P486; Ford C.S., 1951, PATTERNSEXUAL BEHA; FREUD S, 1959, 3 ESSAYS THEORY SEXU, P125; Friedman RC, 1988, MALE HOMOSEXUALITY C; GORSKI RA, 1978, BRAIN RES, V148, P333, DOI 10.1016/0006-8993(78)90723-0; HENDRICKS SE, 1989, PSYCHONEUROENDOCRINO, V14, P177, DOI 10.1016/0306-4530(89)90015-2; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA; MEYERBAHLBURG HFL, 1984, PROG BRAIN RES, V61, P375; OOMURA Y, 1983, BRAIN RES, V266, P340, DOI 10.1016/0006-8993(83)90666-2; PERACHIO AA, 1979, BRAIN RES, V177, P127, DOI 10.1016/0006-8993(79)90923-5; PRITCHARD M, 1962, J MENT SCI, V108, P616, DOI 10.1192/bjp.108.456.616; RHEES RW, 1990, DEV BRAIN RES, V52, P17, DOI 10.1016/0165-3806(90)90217-M; RUSE M, 1981, J HOMOSEXUAL, V6, P5, DOI 10.1300/J082v06n04_02; SLIMP JC, 1978, BRAIN RES, V142, P105, DOI 10.1016/0006-8993(78)90180-4; SODERSTEN P, 1981, J ENDOCRINOL, V88, P125, DOI 10.1677/joe.0.0880125; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; SWAAB DF, 1985, SCIENCE, V228, P1112, DOI 10.1126/science.3992248; SWAAB DF, 1988, DEV BRAIN RES, V44, P314, DOI 10.1016/0165-3806(88)90231-3; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321	28	728	749	4	185	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1034	1037		10.1126/science.1887219	http://dx.doi.org/10.1126/science.1887219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GC982	1887219				2022-12-28	WOS:A1991GC98200047
J	MEREDITH, IT; BROUGHTON, A; JENNINGS, GL; ESLER, MD				MEREDITH, IT; BROUGHTON, A; JENNINGS, GL; ESLER, MD			EVIDENCE OF A SELECTIVE INCREASE IN CARDIAC SYMPATHETIC ACTIVITY IN PATIENTS WITH SUSTAINED VENTRICULAR ARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE HEART-FAILURE; NOREPINEPHRINE KINETICS; PLASMA NOREPINEPHRINE; MYOCARDIAL-INFARCTION; DEATH; CARDIOMYOPATHY; RELEASE; ABNORMALITIES; NORADRENALINE; FIBRILLATION	Background. Although enhanced efferent cardiac sympathetic nervous activity has been proposed as an important factor in the genesis of ventricular arrhythmias and sudden cardiac death, direct clinical evidence has been lacking. Methods. We measured the rates of total and cardiac norepinephrine spillover into the plasma, which reflect, respectively, overall and cardiac sympathetic nervous activity, in 12 patients who had recovered from a spontaneous, sustained episode of ventricular tachycardia or ventricular fibrillation outside the hospital 4 to 48 days earlier. The results were compared with those from three age-matched reference groups without a history of ventricular arrhythmias: 12 patients with coronary artery disease, 6 patients with chest pain but normal coronary arteries, and 12 healthy, normal subjects. Results. The patients who had had ventricular arrhythmias had reduced left ventricular ejection fractions, as compared with the patients with coronary artery disease or chest pain (mean [+/- SE], 46 +/- 3 percent vs. 58 +/- 4 percent and 69 +/- 5 percent, respectively; P < 0.003). The rates of total norepinephrine spillover into the plasma were similar in the three reference groups, but 80 percent higher in the patients with ventricular arrhythmias (P < 0.005). The rate of cardiac norepinephrine spillover was 450 percent higher in these patients (176 +/- 39 pmol per minute, as compared with 32 +/- 8 pmol per minute in the normal subjects; P < 0.001), a disproportionate increase relative to the increase in total spillover, which indicated selective activation of the cardiac sympathetic outflow. This increase in cardiac norepinephrine spillover was probably caused by a reduction in left ventricular function. Conclusions. These results suggest that in some patients major ventricular arrhythmias are associated with and perhaps caused by sustained and selective cardiac sympathetic activation. We speculate that depressed ventricular function was present before the ventricular arrhythmia occurred, and that this resulted in reflex cardiac sympathetic activation, which in turn contributed to the genesis of the arrhythmia.	ALFRED HOSP,DEPT CARDIOL,MELBOURNE,AUSTRALIA	Florey Institute of Neuroscience & Mental Health	MEREDITH, IT (corresponding author), BAKER MED RES INST,ALFRED & BAKER MED UNIT,HUMAN AUTONOM FUNCT LAB,BOX 348,PRAHRAN,VIC 3181,AUSTRALIA.		Jennings, Garry/B-3914-2009	Jennings, Garry/0000-0002-7865-5483				ARMITAGE P, 1987, STATISTICAL METHODS, P204; BIGGER JT, 1987, CIRCULATION, V75, P28; BLOMBERY PA, 1983, CIRC RES, V53, P688, DOI 10.1161/01.RES.53.5.688; BRADLEY T, 1984, ACTA PHYSIOL SCAND, V122, P369, DOI 10.1111/j.1748-1716.1984.tb07521.x; BRODSKY MA, 1988, AM HEART J, V115, P799, DOI 10.1016/0002-8703(88)90882-4; BRUSH JE, 1989, CIRCULATION, V79, P836, DOI 10.1161/01.CIR.79.4.836; CARLSSON A, 1964, LIFE SCI, V3, P1335, DOI 10.1016/0024-3205(64)90053-0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DAVIES MJ, 1981, BRIT HEART J, V45, P88; DAVIS D, 1988, AM J PHYSIOL, V254, pE760, DOI 10.1152/ajpendo.1988.254.6.E760; Eliasson K, 1983, J Hypertens, V1, P131, DOI 10.1097/00004872-198308000-00004; ESLER M, 1979, LIFE SCI, V25, P1461, DOI 10.1016/0024-3205(79)90371-0; ESLER M, 1982, CLIN SCI, V63, pS285, DOI 10.1042/cs063285s; ESLER M, 1990, PHYSIOL REV, V70, P963, DOI 10.1152/physrev.1990.70.4.963; ESLER M, 1984, AM J PHYSIOL, V247, pE21, DOI 10.1152/ajpendo.1984.247.1.E21; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; GANZ W, 1971, CIRCULATION, V44, P181, DOI 10.1161/01.CIR.44.2.181; GOLDSTEIN DS, 1988, CIRCULATION, V78, P41, DOI 10.1161/01.CIR.78.1.41; HARRIS AS, 1971, J ELECTROCARDIOL, V4, P34, DOI 10.1016/S0022-0736(71)80048-1; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; HOLMES J, 1985, AM J CARDIOL, V55, P146, DOI 10.1016/0002-9149(85)90317-0; KAHAN T, 1984, ACTA PHYSIOL SCAND, V122, P571, DOI 10.1111/j.1748-1716.1984.tb07546.x; KLIKS BR, 1975, AM J CARDIOL, V36, P45, DOI 10.1016/0002-9149(75)90866-8; KULLER LH, 1980, PROG CARDIOVASC DIS, V23, P1, DOI 10.1016/0033-0620(80)90002-X; LEIMBACH WN, 1986, CIRCULATION, V73, P913, DOI 10.1161/01.CIR.73.5.913; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; LOWN B, 1976, NEW ENGL J MED, V294, P1165; OLSSON G, 1984, CIRCULATION, V69, P1129, DOI 10.1161/01.CIR.69.6.1129; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; SCHWARTZ PJ, 1981, J CARDIOVASC PHARM, V3, P1251, DOI 10.1097/00005344-198111000-00012; SCHWARTZ PJ, 1982, ANN NY ACAD SCI, V382, P162, DOI 10.1111/j.1749-6632.1982.tb55214.x; SWEDBERG K, 1979, LANCET, V1, P1374; THOMAS JA, 1978, AM J CARDIOL, V41, P233, DOI 10.1016/0002-9149(78)90162-5; VIQUERAT CE, 1985, AM J MED, V78, P455, DOI 10.1016/0002-9343(85)90338-9; WILSON JR, 1983, J AM COLL CARDIOL, V2, P403, DOI 10.1016/S0735-1097(83)80265-4; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1981, JAMA-J AM MED ASSOC, V246, P2073; 1981, NEW ENGL J MED, V304, P801	38	334	342	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					618	624		10.1056/NEJM199108293250905	http://dx.doi.org/10.1056/NEJM199108293250905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861695				2022-12-28	WOS:A1991GC32800005
J	MORGAN, JP				MORGAN, JP			MECHANISMS OF DISEASE - ABNORMAL INTRACELLULAR MODULATION OF CALCIUM AS A MAJOR CAUSE OF CARDIAC CONTRACTILE DYSFUNCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE HEART-FAILURE; HUMAN VENTRICULAR MYOCARDIUM; POSITIVE INOTROPIC AGENTS; PATHO-PHYSIOLOGY; CLINICAL CORRELATION; STUNNED MYOCARDIUM; MESSENGER SYSTEM; TRANSIENTS; OVERLOAD; MYOCYTES		BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	MORGAN, JP (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001611, R01HL031117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005171] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31117, HL 01611] Funding Source: Medline; NIDA NIH HHS [DA 05171] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUFFERMANN W, 1989, AM HEART J, V118, P1219, DOI 10.1016/0002-8703(89)90013-6; BLINKS JR, 1986, CIRCULATION, V73, P85; BLINKS JR, 1986, HEART CARDIOVASCULAR, V1, P671; BRAUNWALD E, 1965, B NEW YORK ACAD MED, V41, P481; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BRISTOW MR, 1990, CIRCULATION, V82, P12; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; DANIELSEN W, 1989, J CARDIOVASC PHARM, V14, P171, DOI 10.1097/00005344-198907000-00026; EDVINSSON L, 1990, EUR J CLIN INVEST, V20, P85, DOI 10.1111/j.1365-2362.1990.tb01796.x; ERDMANN E, 1988, KLIN WOCHENSCHR, V66, P1, DOI 10.1007/BF01735205; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; FELDMAN MD, 1987, CIRCULATION, V75, P331, DOI 10.1161/01.CIR.75.2.331; GAGE J, 1986, CIRCULATION, V74, P367, DOI 10.1161/01.CIR.74.2.367; GROSSMAN W, 1979, CARDIOVASC RES, V13, P514, DOI 10.1093/cvr/13.9.514; GWATHMEY JK, 1990, J CLIN INVEST, V85, P1599, DOI 10.1172/JCI114611; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; KATZ AM, 1986, CIRCULATION, V73, P184; KATZ AM, 1983, J AM COLL CARDIOL, V2, P143, DOI 10.1016/S0735-1097(83)80387-8; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; KORETSUNE Y, 1990, CIRCULATION, V82, P528, DOI 10.1161/01.CIR.82.2.528; KUSUOKA H, 1987, J CLIN INVEST, V79, P950, DOI 10.1172/JCI112906; KUSUOKA H, 1990, CIRC RES, V66, P1268, DOI 10.1161/01.RES.66.5.1268; LEE HC, 1987, CIRC RES, V61, P934, DOI 10.1161/01.RES.61.6.934; LEE HC, 1988, CIRCULATION, V78, P1047, DOI 10.1161/01.CIR.78.4.1047; LI Q, 1989, Biophysical Journal, V55, p488A; MARBAN E, 1990, HYPERTENSION, V15, P652, DOI 10.1161/01.HYP.15.6.652; MORANO I, 1988, CIRC RES, V62, P632, DOI 10.1161/01.RES.62.3.632; MORGAN JP, 1990, CIRCULATION, V81, P21; NABAUER M, 1988, EUR J CLIN INVEST, V18, P600, DOI 10.1111/j.1365-2362.1988.tb01274.x; NEUMANN J, 1988, LANCET, V2, P936; PACKER M, 1989, AM J CARDIOL, V63, pA41, DOI 10.1016/0002-9149(89)90392-5; PERREAULT CL, 1990, EUR HEART J, V11, P8, DOI 10.1093/eurheartj/11.suppl_C.8; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; REITER M, 1988, PHARMACOL REV, V40, P189; RUEGG JC, 1989, J CARDIOVASC PHARM S, V3, pS20; RUEGG JC, 1988, CALCIUM MUSCLE ACTIV; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SEN L, 1990, CIRC RES, V67, P599, DOI 10.1161/01.RES.67.3.599; SHUB C, 1989, CHEST, V96, P906, DOI 10.1378/chest.96.4.906; SHUB C, 1989, CHEST, V96, P636, DOI 10.1378/chest.96.3.636; STEFENELLI T, 1989, AM HEART J, V118, P1228, DOI 10.1016/0002-8703(89)90014-8; SWYNGHEDAUW B, 1989, EUR HEART J, V10, P935, DOI 10.1093/oxfordjournals.eurheartj.a059405; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467	47	297	303	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					625	632						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861696				2022-12-28	WOS:A1991GC32800006
J	VENKITARAMAN, AR; WILLIAMS, GT; DARIAVACH, P; NEUBERGER, MS				VENKITARAMAN, AR; WILLIAMS, GT; DARIAVACH, P; NEUBERGER, MS			THE B-CELL ANTIGEN RECEPTOR OF THE 5 IMMUNOGLOBULIN CLASSES	NATURE			English	Article							MURINE LYMPHOCYTES-B; SURFACE IGM; MOLECULAR-COMPONENTS; ANTIBODIES; COMPLEX; EXPRESSION; TRANSPORT; TOLERANCE; SECRETION; PROTEINS	Several proteins associate with surface IgM to form the antigen receptor. We show that just two, the alpha and beta associated chains, are sufficient to reconstitute an IgM surface receptor in fibroblasts. Contrary to expectation, a common alpha-chain associates with all five immunoglobulin classes. We propose that B-cell antigen receptors consist of a common alpha/beta heterodimer associated with each immunoglobulin class. But the classes differ both in the glycosylation of their associated alpha-chain and in their dependence on alpha/beta for surface transport.	UNIV MONTPELLIER 2,IMMUNOGENET MOLEC LAB,F-34060 MONTPELLIER,FRANCE	Universite de Montpellier	VENKITARAMAN, AR (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CHEN JZ, 1990, EMBO J, V9, P2117, DOI 10.1002/j.1460-2075.1990.tb07380.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HAUSTEIN D, 1986, EUR J IMMUNOL, V16, P113, DOI 10.1002/eji.1830160122; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1988, J EXP MED, V167, P652, DOI 10.1084/jem.167.2.652; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOCH N, 1983, MOL IMMUNOL, V20, P33, DOI 10.1016/0161-5890(83)90102-5; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LIESEGANG B, 1978, P NATL ACAD SCI USA, V75, P3901, DOI 10.1073/pnas.75.8.3901; MATSUO T, 1991, J IMMUNOL, V146, P1584; NEUBERGER MS, 1981, P NATL ACAD SCI-BIOL, V78, P1138, DOI 10.1073/pnas.78.2.1138; PARKHOUSE RME, 1990, IMMUNOLOGY, V69, P298; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCOTT DW, 1977, J EXP MED, V146, P1473, DOI 10.1084/jem.146.6.1473; SELL S, 1965, J EXP MED, V122, P423, DOI 10.1084/jem.122.2.423; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; VITETTA E, 1980, IMMUNOL REV, V52, P211, DOI 10.1111/j.1600-065X.1980.tb00336.x; VITETTA ES, 1977, J EXP MED, V146, P1804, DOI 10.1084/jem.146.6.1804; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947	32	273	276	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					777	781		10.1038/352777a0	http://dx.doi.org/10.1038/352777a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881434				2022-12-28	WOS:A1991GC96400049
J	BALZER, I; HARDELAND, R				BALZER, I; HARDELAND, R			PHOTOPERIODISM AND EFFECTS OF INDOLEAMINES IN A UNICELLULAR ALGA, GONYAULAX-POLYEDRA	SCIENCE			English	Article							MELATONIN; PINEAL; DINOFLAGELLATE; ANOLIS; CLOCK	Mediation of photoperiodic effects by indoleamines, especially melatonin, is known in higher vertebrates. A similar mechanism may occur in a unicellular alga, the dinoflagellate Gonyaulax polyedra. This organism entered the dormant stage of a cyst upon short-day treatment at lowered temperatures. Interruption of darkness by 2 hours of light prevented cyst formation, even when the overall duration of light was the same as in cyst-inducing short days. When given in a noninducing photoperiod, melatonin and an analog, 5-methoxytryptamine, substances that had previously been shown to occur in Gonyaulax, provoked cyst formation. Methoxylated indoleamines may play a role as mediators of darkness in this unicellular, in a similar way as in vertebrates, suggesting a common biochemical basis of photoperiodism.			BALZER, I (corresponding author), UNIV GOTTINGEN, INST ZOOL, BERLINER STR 28, W-3400 GOTTINGEN, GERMANY.							ANDERSON DM, 1987, NATURE, V325, P616, DOI 10.1038/325616a0; ANDERSON DM, 1989, RED TIDES BIOL ENV S, P461; ARENDT J, 1986, OXFORD REV REPROD B, V8, P266; BALZER I, 1991, COMP BIOCHEM PHYS C, V98, P395, DOI 10.1016/0742-8413(91)90223-G; Balzer I., 1990, EUR J CELL BIOL S30, V51, P52; FINOCCHIARO L, 1988, J NEUROCHEM, V50, P382, DOI 10.1111/j.1471-4159.1988.tb02923.x; HARDELAND R, 1991, Journal of Interdisciplinary Cycle Research, V22, P122; HOFFMANN K, 1973, J COMP PHYSIOL, V85, P267, DOI 10.1007/BF00694233; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; Menaker M., 1982, P1; MORITA M, 1984, J EXP ZOOL, V231, P273, DOI 10.1002/jez.1402310212; POGGELER B, 1989, ACTA ENDOCR-COP   S1, V120, P97; POGGELER B, IN PRESS NATURWISSEN; Reiter R J, 1980, Endocr Rev, V1, P109; REITER RJ, 1984, PINEAL GLAND; REITER RJ, 1985, HDB PHARM METHODOLOG, P331; Taylor F.J.R., 1987, BIOL DINOFLAGELLATES; UEMURA T, 1984, PROGR TRYPTOPHAN SER, P673; UNDERWOOD H, 1985, J COMP PHYSIOL A, V157, P57, DOI 10.1007/BF00611095; VIVIENROELS B, 1984, NEUROSCI LETT, V49, P153, DOI 10.1016/0304-3940(84)90152-6; VOLKNANDT W, 1984, COMP BIOCHEM PHYS B, V77, P493, DOI 10.1016/0305-0491(84)90264-5; WETTERBERG L, 1987, CHRONOBIOLOGIA, V14, P377	22	132	140	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					795	797		10.1126/science.1876838	http://dx.doi.org/10.1126/science.1876838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876838				2022-12-28	WOS:A1991GB29500040
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC MEETING ON DIETARY-SUPPLEMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1991, FED REG         0716, V56, P32436	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-28	WOS:A1991GA07300006
J	KINGSBURY, J; KOSHLAND, D				KINGSBURY, J; KOSHLAND, D			CENTROMERE-DEPENDENT BINDING OF YEAST MINICHROMOSOMES TO MICROTUBULES INVITRO	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; BASE-PAIR MUTATIONS; SACCHAROMYCES-CEREVISIAE; KINETOCHORE INVITRO; S-CEREVISIAE; DNA; PROTEIN; REPLICATION; CHROMATIN; MUTANTS	We present an in vitro assay for yeast centromere function; isolated yeast minichromosomes require a functional centromere to bind to bovine microtubules and sediment with them. Centromere-bovine microtubule complexes form at physiological microtubule concentrations. Two of the three centromere DNA elements, which are necessary for centromere function in vivo, are also necessary for centromeres to bind microtubules in vitro. However, purified centromere DNA alone does not bind to microtubules. These results suggest that microtubule binding must be mediated by the two centromere DNA elements and factors that associate with one or both of them. The percent of centromeres with microtubule-binding activity is 7- to 10-fold higher in lysates made from nocodazole-arrested G2-M cells than from alpha-factor G1 cells, suggesting that this centromere activity is regulated during the cell cycle. The potential of this assay for dissecting centromere assembly, function, and regulation is discussed.			KINGSBURY, J (corresponding author), CARNEGIE INST WASHINGTON, DEPT EMBRYOL, BALTIMORE, MD 21210 USA.							BAKER RE, 1989, J BIOL CHEM, V264, P10843; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAI MJ, 1989, MOL CELL BIOL, V9, P2544, DOI 10.1128/MCB.9.6.2544; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; CLARKE L, 1980, P NATL ACAD SCI-BIOL, V77, P2173, DOI 10.1073/pnas.77.4.2173; DEAN A, 1989, METHOD ENZYMOL, V170, P26; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FITZGERALDHAYES M, 1987, YEAST, V3, P187, DOI 10.1002/yea.320030306; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; HARTWELL LH, 1985, GENETICS, V110, P381; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MAINE GT, 1984, GENETICS, V106, P365; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PETERSON JB, 1976, J CELL SCI, V22, P219; PLARR CM, 1990, NATURE, V345, P263; RATTNER JB, 1990, CELL MOTIL CYTOSKEL, V17, P227, DOI 10.1002/cm.970170309; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SHERO J, 1991, IN PRESS GENES DEV; SPENCER F, 1990, GENETICS, V124, P237; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; Strehler B L, 1968, Methods Biochem Anal, V16, P99, DOI 10.1002/9780470110348.ch2	36	46	46	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					483	495		10.1016/0092-8674(81)90012-X	http://dx.doi.org/10.1016/0092-8674(81)90012-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868546				2022-12-28	WOS:A1991GA94100010
J	MAKELA, M; HELIOVAARA, M				MAKELA, M; HELIOVAARA, M			PREVALENCE OF PRIMARY FIBROMYALGIA IN THE FINNISH POPULATION	BRITISH MEDICAL JOURNAL			English	Article							FIBROSITIS; PAIN	Objective - To obtain descriptive epidemiological data on fibromyalgia and its components in a representative sample of the Finnish population. Design - Cross sectional study of 8000 Finns aged 30 or more invited for screening and a main examination for musculoskeletal disorders and other major disorders. Setting - A mobile clinic. Population - 7217 subjects who attended the screening phase; 3434 subjects positive on screening who attended the main examination for musculoskeletal disorders. Main outcome measures - Musculoskeletal, mental, and other symptoms detected by interview and questionnaire; results of standardised clinical examination of the musculoskeletal system; operational definition of fibromyalgia; mortality at 10 years. Results - The prevalence of fibromyalgia was low (54 cases; 0.75%) and related to age (peak prevalence at 55-64 years), female sex (twice as prevalent in women), occupation (no cases among 1596 white collar professionals), level of education (strong inverse gradient), and high levels of physical stress at work. No significant associations were found with body mass index, smoking, or mental stress at work. The prevalence of fibromyalgia was sensitive to even minor modifications of the definition. Fibromyalgia was strongly coincident with many other disorders, especially musculoskeletal conditions. Fibromyalgia did not predict mortality. Conclusion - Descriptive epidemiological data offer little support for the concept of fibromyalgia.			MAKELA, M (corresponding author), SOCIAL INSURANCE INST,SOCIAL SECUR RES INST,POB 78,SF-00381 HELSINKI,FINLAND.							AROMAA A, 1989, EXECUTION MINIFINL 1; CAMPBELL SM, 1983, ARTHRITIS RHEUM, V26, P817, DOI 10.1002/art.1780260701; CATHEY MA, 1986, AM J MED, V81, P78, DOI 10.1016/0002-9343(86)90882-X; COX DR, 1972, J R STAT SOC B, V34, P187; FORSLIND K, 1990, BRIT J RHEUMATOL, V29, P368; Goldberg DP, 1972, DETECTION PSYCHIAT I; GOLDENBERG DL, 1988, SEMIN ARTHRITIS RHEU, V18, P111, DOI 10.1016/0049-0172(88)90003-0; Haberman S. J., 1978, ANAL QUALITATIVE DAT, V1; HAWLEY DJ, 1988, J RHEUMATOL, V15, P1551; Kish L, 1965, SURVEY SAMPLING; MOLDOFSKY H, 1990, ADV PAIN RES THERAPY, V17; TAKALA J, 1979, ACTA PSYCHIAT SCAND, V59, P294, DOI 10.1111/j.1600-0447.1979.tb06968.x; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; YUNUS M, 1981, SEMIN ARTHRITIS RHEU, V11, P151, DOI 10.1016/0049-0172(81)90096-2; YUNUS MB, 1989, CLIN EXP RHEUMATOL, V7, P63	15	138	145	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					216	219		10.1136/bmj.303.6796.216	http://dx.doi.org/10.1136/bmj.303.6796.216			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884057	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300020
J	MATHIESEN, ER; HOMMEL, E; GIESE, J; PARVING, HH				MATHIESEN, ER; HOMMEL, E; GIESE, J; PARVING, HH			EFFICACY OF CAPTOPRIL IN POSTPONING NEPHROPATHY IN NORMOTENSIVE INSULIN-DEPENDENT DIABETIC-PATIENTS WITH MICROALBUMINURIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; ARTERIAL BLOOD-PRESSURE; GLOMERULAR-FILTRATION RATE; ANTIHYPERTENSIVE TREATMENT; KIDNEY-FUNCTION; INCIPIENT NEPHROPATHY; HYPERTENSION; MELLITUS; TERM; PROTEINURIA	Objective-To assess the effectiveness of angiotensin converting enzyme inhibition in preventing the development of diabetic nephropathy (albuminuria > 300 mg/24 h). Design-Open randomised controlled study of four years' duration. Setting-Outpatient diabetic clinic in tertiary referral centre. Patients-44 normotensive (mean blood pressure 127/78 (SD 12/10) mm Hg) insulin dependent diabetic patients with persistent microalbuminuria (30-300 mg/24 h). Interventions-The treatment group (n = 21) was initially given captopril (25 mg/24 h). The dose was increased to 100 mg/24 h during the first 16 months and thiazide was added after 30 months. The remaining 23 patients were left untreated. Main outcome measures-Albuminuria, kidney function, development of diabetic nephropathy (albuminuria > 300 mg/24 h), and arterial blood pressure. Results-Clinical and laboratory variables were comparable at baseline. Urinary excretion of albumin was gradually reduced from 82 (66-106) to 57 (39-85) mg/24 h (geometric mean (95% confidence interval)) in the captopril treated group, whereas an increase from 105 (77-153) to 166 (83-323) mg/24 h occurred in the control group (p < 0.05). Seven of the untreated patients progressed to diabetic nephropathy, whereas none of the captopril treated patients developed clinical overt diabetic nephropathy (p < 0.05). Systemic blood pressure, glomerular filtration rate, haemoglobin A1c concentration, and urinary excretion of sodium and urea remained practically unchanged in the two groups. Conclusions-The findings suggest that angiotensin converting enzyme inhibition postpones the development of clinical overt diabetic nephropathy in normotensive insulin dependent diabetic patients with persistent microalbuminuria.	GLOSTRUP CTY HOSP, DEPT CLIN PHYSIOL, COPENHAGEN, DENMARK	University of Copenhagen	MATHIESEN, ER (corresponding author), HVIDOVRE UNIV HOSP, DK-2930 KLAMPENBORG, DENMARK.			Hommel, Eva/0000-0001-7570-5919				ANDERSEN AR, 1978, DIABETOLOGIA, V14, P363; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BROCHNERMORTENS.J, 1969, SCAND J CLIN LAB INV, V26, P5; CHAVERS BM, 1989, NEW ENGL J MED, V320, P966, DOI 10.1056/NEJM198904133201503; CHRISTENSEN CK, 1984, DIABETIC NEPHROPATHY, V3, P92; COHEN D, 1987, BRIT MED J, V294, P795, DOI 10.1136/bmj.294.6575.795; COOPER ME, 1989, DIABETOLOGIA, V32, P326, DOI 10.1007/BF00265552; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FOGO A, 1988, J CLIN INVEST, V82, P322, DOI 10.1172/JCI113590; GIESE J, 1981, HETEROGENEITY RENIN, P205; HOMMEL E, 1989, SCAND J CLIN LAB INV, V49, P537, DOI 10.3109/00365518909089133; HOMMEL E, 1986, DIABETOLOGIA, V29, P211, DOI 10.1007/BF00454877; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4; KAPPELGAARD AM, 1976, CLIN CHIM ACTA, V67, P299; LADEGAAR.HJ, 1972, SCAND J CLIN LAB INV, V30, P267, DOI 10.3109/00365517209084289; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1986, DIABETOLOGIA, V29, P640, DOI 10.1007/BF00869263; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MATHIESEN ER, 1988, DIABETIC MED, V5, P145, DOI 10.1111/j.1464-5491.1988.tb00961.x; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MORELLI E, 1990, DIABETES, V39, P76, DOI 10.2337/diabetes.39.1.76; MORSTENSEN HB, 1980, J CHROMATOGR, V182, P325; NIAZY S, 1987, DIABETIC COMPLICATIO, V1, P76; NORGAARD K, 1989, DIABETIC MED, V6, P325, DOI 10.1111/j.1464-5491.1989.tb01173.x; OSTERBY R, 1988, DIABETOLOGIA, V31, P265; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1989, BRIT MED J, V299, P230, DOI 10.1136/bmj.299.6693.230; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; PARVING HH, 1983, METABOLISM, V32, P943, DOI 10.1016/0026-0495(83)90210-X; PARVING HH, 1973, SCAND J CLIN LAB INV, V32, P81, DOI 10.3109/00365517309082454; RASMUSSEN S, 1981, CLIN SCI, V60, P591, DOI 10.1042/cs0600591; RONN B, 1987, DIABETES RES CLIN PR, V3, P191, DOI 10.1016/S0168-8227(87)80038-4; TOCHIKUBO O, 1988, JPN HEART J, V29, P257; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1979, NEW ENGL J MED, V300, P638, DOI 10.1056/NEJM197903223001202; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	51	495	495	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1991	303	6794					81	87		10.1136/bmj.303.6794.81	http://dx.doi.org/10.1136/bmj.303.6794.81			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860008	Green Published, Bronze			2022-12-28	WOS:A1991FW58600018
J	NEILL, MA; OPAL, SM; HEELAN, J; GIUSTI, R; CASSIDY, JE; WHITE, R; MAYER, KH				NEILL, MA; OPAL, SM; HEELAN, J; GIUSTI, R; CASSIDY, JE; WHITE, R; MAYER, KH			FAILURE OF CIPROFLOXACIN TO ERADICATE CONVALESCENT FECAL EXCRETION AFTER ACUTE SALMONELLOSIS - EXPERIENCE DURING AN OUTBREAK IN HEALTH-CARE WORKERS	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT SALMONELLA; BACTERIAL DIARRHEA; CLINICAL EFFICACY; INFECTION; PLACEBO	Objective: To determine the efficacy of ciprofloxacin therapy in eradicating convalescent fecal excretion of salmonellae after acute salmonellosis. Design: Randomized, placebo-controlled, double-blind trial of ciprofloxacin, with prospective follow-up of nonparticipants. Setting: An acute care community hospital experiencing an outbreak of salmonellosis. Patients: Twenty-eight health care workers developed acute infection with Salmonella java; 15 participated in a placebocontrolled trial of ciprofloxacin, beginning on day 9 after infection. Interventions: Eight patients were randomly assigned to receive ciprofloxacin, 750 mg, and 7 patients to receive placebo; both were administered orally twice daily for 14 days. Nonparticipants who received therapy were placed on the same ciprofloxacin regimen. Measurements and Main Results: Study participants had follow-up stool cultures every 3 days initially and then weekly for 3 weeks; nonparticipants were followed until three consecutive cultures were negative. All eight ciprofloxacin recipients showed eradication of S.java from stool cultures within 7 days of beginning therapy (compared with 1 of 7 placebo recipients), and their stool cultures remained negative up to 14 days after discontinuing therapy (P < 0.01). However, 4 of 8 relapsed; their stool cultures became positive between 14 and 21 days after therapy. In addition, 3 of 3 hospitalized patients treated with ciprofloxacin who did not participate in the controlled trial also relapsed. Thus, the total relapse rate was 7 of 11 (64%; 95% CI, 31% to 89%). In 4 of these 7 patients, relapse was associated with a longer duration of fecal excretion of salmonellae than that of the placebo group. Relapse could not be explained on the basis of noncompliance, development of resistance, or presence of biliary disease. Conclusions: Despite its excellent antimicrobial activity against salmonellae and its favorable pharmacokinetic profile, ciprofloxacin at a dosage of 750 mg orally twice daily had an unacceptably high failure rate in patients with acute salmonellosis and may have prolonged fecal excretion of salmonellae. The late occurrence of relapses indicates the need to obtain stool cultures up to 21 days after therapy to document fecal eradication in acute salmonellosis.	BROWN UNIV, PROGRAM MED, PROVIDENCE, RI 02912 USA; US DEPT HLTH, PROVIDENCE, RI USA; CTR DIS CONTROL, ATLANTA, GA 30333 USA	Brown University; Centers for Disease Control & Prevention - USA	NEILL, MA (corresponding author), MEM HOSP, DIV INFECT DIS, 111 BREWSTER ST, PAWTUCKET, RI 02860 USA.							ASERKOFF B, 1969, NEW ENGL J MED, V281, P636, DOI 10.1056/NEJM196909182811202; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRUMFITT W, 1984, ANTIMICROB AGENTS CH, V26, P757, DOI 10.1128/AAC.26.5.757; BRYAN JP, 1986, REV INFECT DIS, V8, P189; BUCHWALD DS, 1984, REV INFECT DIS, V6, P345; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069; ERICSSON CD, 1987, ANN INTERN MED, V106, P216, DOI 10.7326/0003-4819-106-2-216; ESPOSITO S, 1985, INFECTION, V13, P288, DOI 10.1007/BF01645442; FERRECCIO C, 1988, J INFECT DIS, V157, P1235, DOI 10.1093/infdis/157.6.1235; HOLMBERG SD, 1984, SCIENCE, V225, P833, DOI 10.1126/science.6382605; HOOPER DC, 1985, ANTIMICROB AGENTS CH, V28, P716, DOI 10.1128/AAC.28.5.716; KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981; MARTIN SM, ATLAS SALMONELLA US; OPAL SM, 1989, AM J INFECT CONTROL, V17, P141, DOI 10.1016/0196-6553(89)90201-0; PATTON WN, 1985, J ANTIMICROB CHEMOTH, V16, P667, DOI 10.1093/jac/16.5.667; PICHLER H, 1986, EUR J CLIN MICROBIOL, V5, P241, DOI 10.1007/BF02013998; PICHLER HET, 1987, AM J MED, V82, P329; RAMIREZ CA, 1985, ANTIMICROB AGENTS CH, V28, P128, DOI 10.1128/AAC.28.1.128; ROSENSTEIN BJ, 1967, J PEDIATR-US, V70, P1, DOI 10.1016/S0022-3476(67)80159-8; SCHONWALD S, 1986, 1ST P INT CIPR WORKS, P353; SEGRETI J, 1988, REV INFECT DIS S1, V10, pS206; SPERBER SJ, 1987, REV INFECT DIS, V9, P925; TAUXE RV, 1988, J INFECT DIS, V157, P370, DOI 10.1093/infdis/157.2.370; 1970, LANCET, V2, P1159; 1990, MMWR, V38, P877; 1983, INFECT CONTROL, V4, P326	27	107	109	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					195	199		10.7326/0003-4819-114-3-195	http://dx.doi.org/10.7326/0003-4819-114-3-195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1898630				2022-12-28	WOS:A1991EV33900004
J	LEFRAK, S				LEFRAK, S			TUBERCULOSIS SCREENING IN A NURSING-HOME - INDICATIONS FOR PREVENTIVE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LEFRAK, S (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,ST LOUIS,MO 63110, USA.							1990, MMWR, V39, P7; [No title captured]; 1990, MMWR, V39, P1	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	&						0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895483				2022-12-28	WOS:A1991GH40600032
J	TUTEUR, PG				TUTEUR, PG			THE RISK OF SIDESTREAM SMOKE TO PIPE SMOKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PASSIVE SMOKING; TOBACCO-SMOKE; LUNG-CANCER; COTININE; EXPOSURE; CHILDREN				TUTEUR, PG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							DALAGER NA, 1986, CANCER RES, V46, P4808; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; MASI MA, 1988, AM REV RESPIR DIS, V138, P296, DOI 10.1164/ajrccm/138.2.296; MATSUKURA S, 1984, NEW ENGL J MED, V311, P828, DOI 10.1056/NEJM198409273111305; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1988, NEW ENGL J MED, V138, P296; WEISS ST, 1986, AM REV RESPIR DIS, V133, P1; 1982, DHHS PHS8250179 PUBL	10	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2000	2000						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895482				2022-12-28	WOS:A1991GH40600031
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONCENTRATED MORPHINE APPROVED FOR USE IN CONTINUOUS MICROINFUSION DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-28	WOS:A1991GG55100004
J	DAVIS, N; GHOSH, S; SIMMONS, DL; TEMPST, P; LIOU, H; BALTIMORE, D; BOSE, HR				DAVIS, N; GHOSH, S; SIMMONS, DL; TEMPST, P; LIOU, H; BALTIMORE, D; BOSE, HR			REL-ASSOCIATED PP40 - AN INHIBITOR OF THE REL FAMILY OF TRANSCRIPTION FACTORS	SCIENCE			English	Article							NF-KAPPA-B; IMMUNOGLOBULIN ENHANCER-BINDING; TRANSFORMED LYMPHOID-CELLS; ONCOGENE PRODUCT; DNA-BINDING; RETICULOENDOTHELIOSIS VIRUS; PROTOONCOGENE PRODUCT; PROTEINS; IDENTIFICATION; ACTIVATION	The Rel-associated protein pp40 is functionally related to I-kappa-B, an inhibitor of the transcription factor NF-kappa-B. Purified pp40 inhibits the DNA binding activity of the NF-kappa-B protein complex (p50:p65 heterodimers), p50:c-Rel heteromers, and c-Rel homodimers. The sequence of the complementary DNA encoding pp40 revealed similarity to the gene encoding MAD-3, a protein with mammalian I-kappa-B-like activity. Protein sequencing of I-kappa-B purified from rabbit lung confirmed that MAD-3 encodes a protein similar to I-kappa-B. The sequence similarity between MAD-3 and pp40 includes a casein kinase II and consensus tyrosine phosphorylation site, as well as five repeats of a sequence found in the human erythrocyte protein ankyrin. These results suggest that rel-related transcription factors, which are capable of cytosolic to nuclear translocation, may be held in the cytosol by interaction with related cytoplasmic anchor molecules.	UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; BRIGHAM YOUNG UNIV,DEPT CHEM,PROVO,UT 84602; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Texas System; University of Texas Austin; Massachusetts Institute of Technology (MIT); Whitehead Institute; Brigham Young University; Memorial Sloan Kettering Cancer Center; Rockefeller University	DAVIS, N (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.				NCI NIH HHS [CA33192, CA2616, CA09583] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192, T32CA009583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, IN PRESS MOL ASPECTS, V6; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DAVIS JN, 1990, ONCOGENE, V5, P1109; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Ghosh S. K., UNPUB; HASKILL S, 1991, CELL, V65, P1; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	27	247	252	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1268	1271		10.1126/science.1891714	http://dx.doi.org/10.1126/science.1891714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891714				2022-12-28	WOS:A1991GE68900037
J	DUMLER, JS; TAYLOR, JP; WALKER, DH				DUMLER, JS; TAYLOR, JP; WALKER, DH			CLINICAL AND LABORATORY FEATURES OF MURINE TYPHUS IN SOUTH TEXAS, 1980 THROUGH 1987	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOUNTAIN SPOTTED-FEVER; MICROIMMUNOFLUORESCENCE TEST; EPIDEMIOLOGICAL FEATURES	Objective. - The clinical and laboratory features of patients with murine typhus have not been extensively reviewed since 1946. We have updated these findings in patients from south Texas who were examined by modern clinical and laboratory methods from 1980 through 1987. Design. - Patients were identified by serological methods in this case series, and clinical, epidemiologic, laboratory, and therapeutic data were compiled and analyzed. Setting. - The majority of patients (77 of 80) were identified in a primary care community hospital setting; the remainder (3 of 80) were ambulatory hospital outpatients. Patients. - From 1980 through 1987, a total of 345 patients were diagnosed with murine typhus; 90 of these patients were seen at four hospitals in south Texas; of these, 80 had clinical and laboratory data available for review. Main Outcome Measures. - The frequency of common clinical manifestations (eg, headache, fever, and rash) and laboratory findings (eg, leukocyte and platelet counts and serum chemistry abnormalities) of patients with infectious diseases was tabulated. Clinical severity was semiquantitatively assessed and was correlated with clinical, laboratory, and therapeutic results. Results. - Most cases (69%) occurred from April through August. Rash occurred in 54%; the triad of fever, headache, and rash was observed in only 12.5% of patients when first examined by a physician; respiratory and gastrointestinal symptoms were also frequent. Multiple organ involvement was documented by frequent abnormal laboratory findings of the hematologic, respiratory, hepatic, and renal systems. Disease severity was related to older patient age, the presence of renal dysfunction, leukocytosis, and hypoalbuminemia, and previous therapy with sulfa antibiotics. Conclusions. - Infection by Rickettsia typhi causes a systemic illness with clinical and laboratory abnormalities not previously recognized or described. Early clinical diagnosis and treatment are needed to avoid undue morbidity and mortality.	TEXAS DEPT HLTH, DIV EPIDEMIOL, AUSTIN, TX USA	Texas Department of State Health Services	DUMLER, JS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT PATHOL, 101 KEILLER BLDG, F09, GALVESTON, TX 77550 USA.							ALAWADI AR, 1982, B WORLD HEALTH ORGAN, V60, P283; AZAD AF, 1985, AM J TROP MED HYG, V34, P555, DOI 10.4269/ajtmh.1985.34.555; BELTRAN RR, 1991, RICKETTSIAE RICKETTS, P714; BETZ TG, 1983, TEX MED, V79, P48; BINFORD CH, 1947, AM J CLIN PATHOL, V17, P797; BOTROS BAM, 1989, J TROP MED HYG, V92, P373; BROWN AE, 1989, AM J TROP MED HYG, V92, P373; BURGDORFER W, 1976, TROPICAL MED, P110; BUTTERY CMG, 1984, TEX MED, V80, P53; FAN MY, 1987, REV INFECT DIS, V9, P823; FARHANGAZAD A, 1984, J MED ENTOMOL, V21, P675, DOI 10.1093/jmedent/21.6.675; FARHANGAZAD A, 1988, BIOL RICKETTSIAL DIS, V1, P51; GROSS EM, 1984, B WORLD HEALTH ORGAN, V62, P301; HECHEMY KE, 1979, J CLIN MICROBIOL, V9, P292; HECHEMY KE, 1981, J CLIN MICROBIOL, V13, P214, DOI 10.1128/JCM.13.1.214-216.1981; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; Irons J. V., 1944, AMER JOUR TROP MED, V24, P359; KIRK JL, 1990, MEDICINE, V69, P35, DOI 10.1097/00005792-199001000-00003; LOVE GJ, 1960, PUBLIC HEALTH REP, V75, P429, DOI 10.2307/4590821; MAXCY K. F., 1926, Public Health Reports, V41, P2967, DOI 10.2307/4578110; MILLER ES, 1946, MEDICINE, V25, P1; OLDER JJ, 1970, J AMER MED ASSOC, V214, P2011, DOI 10.1001/jama.214.11.2011; PETERSON JC, 1947, J PEDIATR, V30, P495, DOI 10.1016/S0022-3476(47)80046-0; PHILIP RN, 1976, J CLIN MICROBIOL, V3, P51; QUINBY GE, 1953, AM J PUBLIC HEALTH, V43, P160; RAOULT D, 1986, J INFECTION, V12, P111, DOI 10.1016/S0163-4453(86)93508-5; RAOULT D, 1986, AM J TROP MED HYG, V35, P845, DOI 10.4269/ajtmh.1986.35.845; SAMRA Y, 1989, ARCH INTERN MED, V149, P949, DOI 10.1001/archinte.149.4.949; SMADEL JE, 1959, ANN INTERN MED, V51, P421, DOI 10.7326/0003-4819-51-3-421; SNYDER JC, 1946, RICKETTSIAL DISEASES, P169; STASKO T, 1982, J AM ACAD DERMATOL, V7, P377, DOI 10.1016/S0190-9622(82)80318-6; STUART BM, 1945, ANN INTERN MED, V23, P520, DOI 10.7326/0003-4819-23-4-520; TAYLOR JP, 1986, JAMA-J AM MED ASSOC, V255, P2173; Traub R, 1978, Trop Dis Bull, V75, P237; TSELENTIS Y, 1986, J INFECTION, V13, P91, DOI 10.1016/S0163-4453(86)92371-6; WALKER DH, 1989, AM J CLIN PATHOL, V91, P720, DOI 10.1093/ajcp/91.6.720; WALKER DH, 1980, J INFECT DIS, V142, P771, DOI 10.1093/infdis/142.5.771; WOODRUFF PWR, 1988, T ROY SOC TROP MED H, V82, P761, DOI 10.1016/0035-9203(88)90229-5; WOODWARD TE, 1988, BIOL RICKETTSIAL DIS, V1, P79; 1990, MMWR, V38, P47	40	177	184	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1365	1370		10.1001/jama.266.10.1365	http://dx.doi.org/10.1001/jama.266.10.1365			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880866				2022-12-28	WOS:A1991GD80700030
J	HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD				HILGEMANN, DW; NICOLL, DA; PHILIPSON, KD			CHARGE MOVEMENT DURING NA+ TRANSLOCATION BY NATIVE AND CLONED CARDIAC NA+/CA2+ EXCHANGER	NATURE			English	Article							SODIUM-CALCIUM EXCHANGE; SARCOLEMMAL MEMBRANE PATCHES; CURRENT-VOLTAGE RELATIONSHIP; PIG VENTRICULAR MYOCYTES; CA EXCHANGE; GUINEA-PIG; NA/K PUMP; DEPENDENCE; STOICHIOMETRY; TRANSIENTS	Na+/Ca2+ EXCHANGE is electrogenic and moves one net positive charge per cycle 1,2. Although the cardiac exchanger has a three-to-one Na+/Ca2+ stoichiometry 3, details of the reaction cycle are not well defined 2,4-8. Here we associate Na+ translocation by the cardiac exchanger with positive charge movement in giant membrane patches from cardiac myocytes 9,10 and oocytes expressing the cloned cardiac Na+/Ca2+ exchanger 11. The charge movements are initiated by step increments of the cytoplasmic Na+ concentration in the absence of Ca2+. Giant patches from control oocytes lack both steady-state Na/Ca2+ exchange current (I(NaCa)) and Na+-induced charge movements. Charge movements indicate about 400 exchangers per mu-m2 in guinea-pig sarcolemma. Fully activated I(NaCa) densities (20-30-mu-A cm-2) indicate maximum turnover rates of 5,000 s-1. As has been predicted for consecutive exchange models 4-7, the apparent ion affinities of steady state I(NaCa) increase as the counterion concentrations are decreased. Consistent with an electroneutral Ca2+ translocation, we find that voltage dependence of I(NaCa) in both directions is lost as Ca2+ concentration is decreased. The principal electrogenic step seems to be at the extracellular end of the Na+ translocation pathway.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	HILGEMANN, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.							ALLEN TJA, 1986, J PHYSIOL-LONDON, V378, P77, DOI 10.1113/jphysiol.1986.sp016208; ALLEN TJA, 1989, SODIUM CALCIUM EXCHA; BORLINGHAUS R, 1987, J MEMBRANE BIOL, V97, P161, DOI 10.1007/BF01869220; CRESPO LM, 1990, NATURE, V345, P618, DOI 10.1038/345618a0; FENDLER K, 1987, FEBS LETT, V224, P83, DOI 10.1016/0014-5793(87)80427-1; FORBUSH B, 1984, P NATL ACAD SCI-BIOL, V81, P5310, DOI 10.1073/pnas.81.17.5310; GADSBY DC, 1989, J GEN PHYSIOL, V94, P511, DOI 10.1085/jgp.94.3.511; GLYNN IM, 1975, ANNU REV PHYSIOL, V37, P13, DOI 10.1146/annurev.ph.37.030175.000305; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HILGEMANN DW, 1988, PROG BIOPHYS MOL BIO, V51, P1, DOI 10.1016/0079-6107(88)90009-0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LI JM, 1990, J GEN PHYSIOL, V96, P777, DOI 10.1085/jgp.96.4.777; LI ZP, 1991, J BIOL CHEM, V266, P1014; NAKAO M, 1989, J GEN PHYSIOL, V94, P539, DOI 10.1085/jgp.94.3.539; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994	24	191	194	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					715	718		10.1038/352715a0	http://dx.doi.org/10.1038/352715a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876186				2022-12-28	WOS:A1991GC06400058
J	ROBINSON, DR; GULL, K				ROBINSON, DR; GULL, K			BASAL BODY MOVEMENTS AS A MECHANISM FOR MITOCHONDRIAL GENOME SEGREGATION IN THE TRYPANOSOME CELL-CYCLE	NATURE			English	Article							BRUCEI-BRUCEI; MICROTUBULES; INVITRO	THE mitochondrial genome of Trypanosoma brucei is organized in the form of a complex catenated network of circular DNA molecules. This mass of DNA, known as the kinetoplast, is present at a unique site in the single mitochondrion, and is replicated in a discrete, periodic S phase of the cell cycle. The single-copy nature of the kinetoplast suggests that there is a mechanism ensuring segregation fidelity of replicated copies to each daughter cell. Historically, speculation regarding the nature of this mechanism has often attributed significance to the close association between the kinetoplast and the flagellum basal body. We provide here direct evidence that this mitochondrial DNA complex is indeed linked to the basal body, and segregation of the kinetoplast DNA is dependent on a microtubule-mediated separation of the new and old flagellar basal bodies during the cell cycle. This unique system may represent the remnants of an evolutionarily archaic mechanism for genome segregation.	UNIV MANCHESTER, SCH MED, DEPT BIOCHEM & MOLEC BIOL, OXFORD RD, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								BRUN R, 1979, ACTA TROP, V36, P289; CHOW KC, 1988, MOL PHARMACOL, V34, P467; HIRUKI T, 1987, ZBL BAKT-INT J MED M, V264, P392; LEWIS DH, 1975, J PROTOZOOL, V22, P344, DOI 10.1111/j.1550-7408.1975.tb05184.x; MOLYNEUX DH, 1969, PARASITOLOGY, V59, P55, DOI 10.1017/S0031182000069821; OOTSU K, 1980, CANCER RES, V40, P1707; PATEL S, 1990, ANTI-CANCER DRUG DES, V5, P149; Robertson M, 1913, PHILOS T R SOC LON B, V203, P161, DOI 10.1098/rstb.1913.0005; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; SIMPSON L, 1968, J PROTOZOOL, V15, P132, DOI 10.1111/j.1550-7408.1968.tb02097.x; SOUTOPADRON T, 1984, J CELL SCI, V69, P167; Steinert M., 1976, P193; VICKERMAN K., 1962, TRANS ROY SOC TROP MED AND HYG, V56, P487, DOI 10.1016/0035-9203(62)90072-X; WOODS A, 1989, J CELL SCI, V93, P491	16	263	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					731	733		10.1038/352731a0	http://dx.doi.org/10.1038/352731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876188	Green Submitted			2022-12-28	WOS:A1991GC06400064
J	MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P				MUSIERFORSYTH, K; USMAN, N; SCARINGE, S; DOUDNA, J; GREEN, R; SCHIMMEL, P			SPECIFICITY FOR AMINOACYLATION OF AN RNA HELIX - AN UNPAIRED, EXOCYCLIC AMINO GROUP IN THE MINOR GROOVE	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; CHEMICAL SYNTHESIS; RECOGNITION; OLIGORIBONUCLEOTIDES; RESOLUTION; IDENTITY; BINDING; ALANINE	An acceptor stem G3.U70 base pair is a major determinant of the identity of an alanine transfer RNA. Hairpin helices and RNA duplexes consisting of complementary single strands are aminoacylated with alanine if they contain G3.U70. Chemical synthesis of RNA duplexes enabled the introduction of base analogs that tested the role of specific functional groups in the major and minor grooves of the RNA helix. The results of these experiments indicate that an unpaired guanine 2-amino group at a specific position in the minor groove of an RNA helix marks a molecule for aminoacylation with alanine.	MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037641, R37GM015539, R01GM015539] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37641, GM15539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOTT S, 1967, J MOL BIOL, V27, P525, DOI 10.1016/0022-2836(67)90056-3; DOUDNA JA, 1990, J ORG CHEM, V55, P5547, DOI 10.1021/jo00308a003; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCKLYN C, UNPUB; FRANCKLYN CS, 1990, CHEM REV, V90, P1327, DOI 10.1021/cr00105a013; GREEN R, NUCLEIC ACIDS RES; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; MCCLAIN WH, 1988, SCIENCE, V242, P1681, DOI 10.1126/science.2462282; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; OLLIS DL, 1987, CHEM REV, V87, P981, DOI 10.1021/cr00081a006; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PARK SJ, 1989, BIOCHEMISTRY-US, V28, P2740, DOI 10.1021/bi00432a056; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552	20	149	150	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					784	786		10.1126/science.1876835	http://dx.doi.org/10.1126/science.1876835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876835				2022-12-28	WOS:A1991GB29500036
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR DIDEOXYCYTIDINE (DDC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					769	769						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865513				2022-12-28	WOS:A1991GA07300009
J	HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH				HEEMSKERK, J; DINARDO, S; KOSTRIKEN, R; OFARRELL, PH			MULTIPLE-MODES OF ENGRAILED REGULATION IN THE PROGRESSION TOWARDS CELL FATE DETERMINATION	NATURE			English	Article							SEGMENT-POLARITY GENE; DROSOPHILA EMBRYOS; DEVELOPMENTAL COMPARTMENTALIZATION; AUTO-REGULATION; WINGLESS GENE; EXPRESSION; LOCALIZATION; TRANSCRIPTS; PROTEIN; LOCUS	The engrailed gene product of Drosophila specifies the fate of a subset of cells in each segment. Our studies of engrailed regulation suggest that fate determination is an elaborate, multistep process. At the time in embryogenesis when the engrailed-dependent cell fate is probably determined, four modes of control act in an overlapping progression to govern engrailed expression. After activation by pair-rule genes, both an extracellular signal, wingless, and autoregulation are required for engrailed expression. Autoregulation graduates to wingless independence, but is transient, and is superseded by an engrailed- independent mode of maintenance.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Rockefeller University; University of California System; University of California Berkeley	HEEMSKERK, J (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			DiNardo, Stephen/0000-0003-4131-5511; O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193-10, R01 GM037193] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEVELOPMENT, V103, P289; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CLINE TW, 1984, GENETICS, V107, P231; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DURA JM, 1988, DEVELOPMENT, V103, P733; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KASSIS JA, 1990, GENE DEV, V4, P433, DOI 10.1101/gad.4.3.433; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POOLE SJ, 1988, DEVELOPMENT, V104, P85; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J, 1983, EGG EMBRYO; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8	33	240	242	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					404	410		10.1038/352404a0	http://dx.doi.org/10.1038/352404a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861720	Green Accepted			2022-12-28	WOS:A1991FZ34600055
J	KRAMER, H; CAGAN, RL; ZIPURSKY, SL				KRAMER, H; CAGAN, RL; ZIPURSKY, SL			INTERACTION OF BRIDE OF SEVENLESS MEMBRANE-BOUND LIGAND AND THE SEVENLESS TYROSINE-KINASE RECEPTOR	NATURE			English	Article							HOMOPHILIC ADHESION MOLECULE; GROWTH-FACTOR RECEPTOR; DROSOPHILA RETINA; EGF RECEPTOR; CELL FATE; SIGNAL TRANSDUCTION; MESODERM INDUCTION; PUTATIVE RECEPTOR; PATTERN-FORMATION; FASCICLIN-III	During development of the Drosophila retina, the R8 photoreceptor neuron induces a neighbouring cell to assume an R7 cell fate. Genetic data suggest that the induction is mediated by two transmembrane proteins encoded by bride of sevenless and sevenless. A direct interaction between these two proteins was demonstrated by the heterotypic aggregation of cell lines expressing them. In the developing eye the sevenless-dependent internalization of bride of sevenless by the R7 precursor cell provides evidence for a direct interaction between these two proteins in vivo.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	KRAMER, H (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Cagan, Ross Leigh/AAV-9528-2021	Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181; Cagan, Ross/0000-0001-5297-450X				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CAMPOSORTEGA JA, 1979, ROUX ARCH DEV BIOL, V186, P27, DOI 10.1007/BF00848106; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NAGAFUCHI A, 1987, NATURE, V308, P693; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTTE AP, 1991, SCIENCE, V251, P570, DOI 10.1126/science.1990433; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SORACCIA P, 1990, J BIOL CHEM, V265, P4902; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	55	287	294	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					207	212		10.1038/352207a0	http://dx.doi.org/10.1038/352207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857416				2022-12-28	WOS:A1991FX18500053
J	FRASER, RC				FRASER, RC			UNDERGRADUATE MEDICAL-EDUCATION - PRESENT STATE AND FUTURE-NEEDS	BRITISH MEDICAL JOURNAL			English	Article											FRASER, RC (corresponding author), UNIV LEICESTER,LEICESTER ROYAL INFIRM,GEN PRACTICE UNIT,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							ABRAHAMSON S, 1990, TEACH LEARN MED, V2, P120; BROWN G, 1975, MICROTEACHING PROGRA; DAGGETT CJ, 1979, REV EDUC RES, V49, P151; DUBOVSKY SL, 1986, NEW ENGL J MED, V315, P1672, DOI 10.1056/NEJM198612253152609; EDELSTEIN DR, 1990, MED TEACH, V12, P155, DOI 10.3109/01421599009006691; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Fraser RC, 1988, 42 ROYAL COLL GEN PR; GALE J, 1983, MED DIAGNOSIS STUDEN; HAMILTON DP, 1990, SCIENCE, V250, P1331, DOI 10.1126/science.2255902; HARRIES BJ, 1987, LANCET, V2, P746; KAUFMAN A, 1982, SOUTHERN MED J, V75, P1110, DOI 10.1097/00007611-198209000-00021; KESSELL N, 1984, BMJ, V288, P1929; MARINKER M, 1985, HLTH ED GENERAL PRAC; MCMANUS IC, 1989, BRIT MED J, V298, P1051, DOI 10.1136/bmj.298.6680.1051; PICKERING G, 1978, GUEST EXCELLENCE MED; RICHARDS P, 1988, BRIT MED J, V296, P1278, DOI 10.1136/bmj.296.6632.1278; WHITE K, 1988, TASK MED; 1987, REPORT WORKING PARTY; 1984, 28 ASS U TEACH GEN P; 1988, REPORT SURVEY MED ED; 1968, REPORT ROYAL COMMISS; 1989, 1ST STEER GROUP MED	22	64	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					41	43		10.1136/bmj.303.6793.41	http://dx.doi.org/10.1136/bmj.303.6793.41			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859958	Bronze, Green Published			2022-12-28	WOS:A1991FW12800027
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - SMALL-FOR-GESTATIONAL-AGE	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1592	1596		10.1136/bmj.302.6792.1592	http://dx.doi.org/10.1136/bmj.302.6792.1592			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855049	Green Published, Bronze			2022-12-28	WOS:A1991FU54900034
J	KEELEY, D				KEELEY, D			PERSONAL CARE OR THE POLYCLINIC .2.	BMJ-BRITISH MEDICAL JOURNAL			English	Article											KEELEY, D (corresponding author), CAVERSHAM GRP PRACTICE, LONDON NW5 2AJ, ENGLAND.							BUTLER JR, 1987, BMJ-BRIT MED J, V295, P1383, DOI 10.1136/bmj.295.6610.1383; BUTLER JR, 1980, 64 OCC PAP SOC ADM; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; FREEMAN GK, 1990, BMJ-BRIT MED J, V301, P1028, DOI 10.1136/bmj.301.6759.1028; HART JT, 1990, BRIT J GEN PRACT, V40, P441; MARSH G, 1986, TEAM CARE GENERAL PR; McWhinney IR, 1989, TXB FAMILY MED; ROLAND M, 1987, J ROY COLL GEN PRACT, V37, P481; TAYLOR D, 1991, 10 KINGS FUND I NUFF; WILSON A, 1991, BRIT J GEN PRACT, V41, P119; 1986, PRIMARY HLTH CARE AG; 1983, GENERAL PRACTICE BRI; 1972, FUTURE GENERAL PRACT; 1987, 1ST REPORT PRIMARY H; 1986, NEIGHBOURHOOD NURSIN; 1985, QUALITY GENERAL PR S, V2; 1990, REPORT WORKING GROUP	17	11	11	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	1991	302	6791					1514	1516		10.1136/bmj.302.6791.1514	http://dx.doi.org/10.1136/bmj.302.6791.1514			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855024	Green Published, Bronze			2022-12-28	WOS:A1991FT50500027
J	VANDUIJN, CM; HOFMAN, A				VANDUIJN, CM; HOFMAN, A			RELATION BETWEEN NICOTINE INTAKE AND ALZHEIMERS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; RISK-FACTORS; BINDING-SITES; CEREBRAL-CORTEX; HUMAN-BRAIN; DEMENTIA; SMOKING	Objective - To study the association between Alzheimer's disease and nicotine intake through smoking. Design - Population based case-control study. Setting - City of Rotterdam and four northern provinces of The Netherlands. Subjects - 198 patients with early onset Alzheimer's disease, 198 controls matched for age and sex, and families of 17 patients in whom Alzheimer's disease was apparently inherited as an autosomal dominant disorder. Main outcome measures - Age of onset of dementia, relative risk of Alzheimer's disease. Results - 89 of 193 patients with Alzheimer's disease had a history of smoking compared with 102 of 195 controls. Among the patients and controls with a family history of dementia, smoking was significantly less common in those with dementia (40/95 with dementia v 55/96 controls; relative risk 0.35; 95% confidence interval 0.16 to 0.78). The risk of Alzheimer's disease decreased with increasing daily number of cigarettes smoked before onset of disease (relative risk 0.3 in those smoking > 21/day v 1 in non-smokers). In six families in which the disease was apparently inherited as an autosomal dominant disorder, the mean age of onset was 4.17 years later in smoking patients than in non-smoking patients from the same family (p = 0.03). Conclusions - These findings suggest an inverse association between smoking and Alzheimer's disease, although smoking cannot be advocated for other health reasons. We speculate that nicotine may have a role in the aetiology of both Alzheimer's disease and Parkinson's disease.			VANDUIJN, CM (corresponding author), ERASMUS UNIV,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; APPEL SH, 1981, BRAIN NEUROTRANSMITT, P203; Barclay L, 1989, Prog Clin Biol Res, V317, P189; BARON JA, 1986, NEUROLOGY, V36, P1490, DOI 10.1212/WNL.36.11.1490; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CALNE DB, 1986, LANCET, V2, P1067, DOI 10.1016/S0140-6736(86)90469-1; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; DITTER SM, 1987, NEUROLOGY, V37, P754, DOI 10.1212/WNL.37.5.754; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FERRINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; GRAVES AB, IN PRESS INT J EPIDE; GROSSBERG GT, 1989, J AM GERIATR SOC, V37, P822; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1989, NEUROEPIDEMIOLOGY, V8, P296, DOI 10.1159/000110197; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JONES GMM, 1987, J NEUROL NEUROSUR PS, V50, P1383, DOI 10.1136/jnnp.50.10.1383; JOYA CJ, 1990, NEUROBIOL AGING, V11, P296; KELLAR KJ, 1987, BRAIN RES, V436, P62, DOI 10.1016/0006-8993(87)91556-3; LONDON ED, 1989, NEUROCHEM RES, V14, P745, DOI 10.1007/BF00964952; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEWHOUSE PA, 1988, PSYCHOPHARMACOLOGY, V95, P171; PERRY EK, 1989, NEUROSCI RES COMMUN, V5, P117; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PRICE DL, 1986, TRENDS NEUROSCI, V9, P29, DOI 10.1016/0166-2236(86)90011-1; SAHAKIAN B, 1989, BRIT J PSYCHIAT, V154, P797, DOI 10.1192/bjp.154.6.797; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; WHITEHOUSE PJ, 1988, NEUROLOGY, V38, P720, DOI 10.1212/WNL.38.5.720	34	161	175	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1491	1494		10.1136/bmj.302.6791.1491	http://dx.doi.org/10.1136/bmj.302.6791.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855016	Green Published, Bronze			2022-12-28	WOS:A1991FT50500018
J	SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT				SERAFINI, T; STENBECK, G; BRECHT, A; LOTTSPEICH, F; ORCI, L; ROTHMAN, JE; WIELAND, FT			A COAT SUBUNIT OF GOLGI-DERIVED NON-CLATHRIN-COATED VESICLES WITH HOMOLOGY TO THE CLATHRIN-COATED VESICLE COAT PROTEIN BETA-ADAPTIN	NATURE			English	Article							CELL-FREE SYSTEM; LUMINAL ER PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; INTERCOMPARTMENTAL TRANSPORT; SUCCESSIVE COMPARTMENTS; INTRACELLULAR-TRANSPORT; VESICULAR TRANSPORT; SECRETORY PROTEINS	Four high-molecular-weight proteins form the main subunits of the coat of Golgi-derived (non-clathrin) coated vesicles. One of these coat proteins, beta-COP, is identical to a Golgi-associated protein of relative mass 110,000 (110K) that shares homology with the adaptin proteins of clathrin-coated vesicles. This connection, and the comparable molecular weights of the coat proteins of Golgi-derived and clathrin-coated vesicles, indicates that they may be structurally related. The identification of beta-COP as the 110K protein explains the blocking of secretion by the drug brefeldin A.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; UNIV HEIDELBERG,INST BIOCHEM 1,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BIOCHEM,GENZENTRUM,W-8033 MARTINSRIED,GERMANY; UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	Princeton University; Ruprecht Karls University Heidelberg; Max Planck Society; University of Geneva	SERAFINI, T (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.							AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1983, METHOD ENZYMOL, V98, P37; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; JAMIESON JD, 1967, J CELL BIOL, V34, P577, DOI 10.1083/jcb.34.2.577; KARRENBAUER A, 1990, CELL, V63, P259, DOI 10.1016/0092-8674(90)90159-C; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; ORCI L, 1985, P NATL ACAD SCI USA, V82, P5385, DOI 10.1073/pnas.82.16.5385; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; ROTHMAN JE, 1984, J CELL BIOL, V99, P260, DOI 10.1083/jcb.99.1.260; SCHOOK W, 1979, P NATL ACAD SCI USA, V76, P116, DOI 10.1073/pnas.76.1.116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	51	311	318	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 17	1991	349	6306					214	220		10.1038/349215a0	http://dx.doi.org/10.1038/349215a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898984				2022-12-28	WOS:A1991ET51900046
J	KHOURI, RK; KOUDSI, B; REDDI, H				KHOURI, RK; KOUDSI, B; REDDI, H			TISSUE TRANSFORMATION INTO BONE INVIVO - A POTENTIAL PRACTICAL APPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIOLOGICAL PRINCIPLE; INDUCED OSTEOGENESIS; INDUCTIVE PROTEIN; RECONSTRUCTION; DIFFERENTIATION; DEFECTS; GRAFTS; REPAIR; RATS	The transformation of mesenchymal tissue, such as muscle, into cartilage and bone can be induced by the recently purified osteoinductive factor, osteogenin, and by its parent substratum, demineralized bone matrix. We investigated the possibility of transforming readily available muscle flaps into vascularized bone grafts of various shapes that could be used as skeletal replacement parts. In a rat experimental model, thigh adductor muscle island flaps were placed inside bivalved silicone rubber molds. Prior to closure of the mold, 18 flaps were injected with osteogenin and coated with demineralized bone matrix. Five flaps served as controls and were injected with the vehicle only, and not coated with demineralized bone matrix. The molds were implanted subcutaneously in the rats' flanks and reopened 10 days later. The control flaps consisted of intact muscle without any evidence of tissue transformation, whereas the flaps treated with osteogenin and demineralized bone matrix were entirely transformed into cancellous bone that matched the exact shape of the mold. Using tissue transformation, we were able to generate in vivo, autogenous, well-perfused bones in the shapes of femoral heads and mandibles.	NIDR,BONE CELL BIOL SECT,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,PLAST SURG RES LAB,ST LOUIS,MO 63110	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Washington University (WUSTL)	KHOURI, RK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,DIV PLAST SURG,ONE BARNES HOSP PLAZA,SUITE 17424,ST LOUIS,MO 63110, USA.				PHS HHS [22-3335 44901A] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANIS JC, 1984, ARCH SURG-CHICAGO, V119, P673; BLEIBERG I, 1987, EXP HEMATOL, V15, P309; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; FISHER J, 1988, PLAST RECONSTR SURG, V82, P857, DOI 10.1097/00006534-198811000-00021; GLOWACKI J, 1981, LANCET, V1, P959; HABAL MB, 1987, ADV PLASTIC RECONSTR; HIDALGO DA, 1990, PLAST RECONSTR SURG, V86, P492, DOI 10.1097/00006534-199009000-00019; HOLLINGER J, 1989, J ORAL MAXIL SURG, V47, P1182, DOI 10.1016/0278-2391(89)90009-8; KABAN LB, 1989, J ORAL MAXIL SURG, V47, P1187, DOI 10.1016/0278-2391(89)90010-4; KABAN LB, 1984, J DENT RES, V63, P998, DOI 10.1177/00220345840630071801; KHOURI RK, 1989, J TRAUMA, V29, P1086, DOI 10.1097/00005373-198908000-00005; KHOURI RK, 1991, PLAST RECONSTR SURG, V87, P108, DOI 10.1097/00006534-199101000-00017; KHOURI RK, 1988, SURG FORUM, V439, P597; KHOURI RK, 1991, J TRAUMA, P1029; KHOURI RK, 1991, PLASTIC SURGERY, P1029; LACROIX P, 1945, NATURE, V156, P576, DOI 10.1038/156576a0; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MARK DE, 1990, PLAST RECONSTR SURG, V86, P623, DOI 10.1097/00006534-199010000-00001; MULLIKEN JB, 1984, J SURG RES, V37, P487, DOI 10.1016/0022-4804(84)90218-X; MUTHUKUMARAN N, 1988, COLLAGEN REL RES, V8, P433; NILSSON OS, 1986, J BONE JOINT SURG BR, V68, P635, DOI 10.1302/0301-620X.68B4.3733844; REDDI AH, 1987, ORTHOP CLIN N AM, V18, P207; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SPORN MB, 1990, HDB EXPT PHARM; TAYLOR GI, 1983, CLIN PLAST SURG, V10, P185; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1981, CLIN ORTHOP RELAT R, V154, P97; WEILAND AJ, 1984, PLAST RECONSTR SURG, V74, P368, DOI 10.1097/00006534-198409000-00006; WEINTROUB S, 1990, CALCIFIED TISSUE INT, V46, P38; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	32	139	146	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1953	1955		10.1001/jama.266.14.1953	http://dx.doi.org/10.1001/jama.266.14.1953			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895472				2022-12-28	WOS:A1991GH40600020
J	PEASE, RJ; HARRISON, GB; SCOTT, J				PEASE, RJ; HARRISON, GB; SCOTT, J			COTRANSLOCATIONAL INSERTION OF APOLIPOPROTEIN-B INTO THE INNER LEAFLET OF THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; TRANSLATION SYSTEM; STOP-TRANSFER; SEQUENCE; CORONAVIRUS; FRACTIONS; INVITRO	APOLIPOPROTEIN (apo) B100 is required for the distribution of hepatic triglyceride to peripheral tissues as very-low-density lipoproteins. The translocation of apo B100 into the endoplasmic reticulum (ER) and its subsequent assembly into lipoprotein particles is of particular interest as the protein is both very large (relative molecular mass 512,000) and insoluble in water. It has been proposed that apo B translocation occurs in discrete stages and is completed post-translationally 1. Several sites of arrest of translocation were reported to be present in apo B15 (the N-terminal 15% of the protein). We have re-examined this question by in vitro translation coupled with translocation into microsomes, and find no evidence for transmembrane segments in truncated apo B proteins. Translocated apo B17 is strongly associated with the membrane of the ER, being only partially releasable with alkaline carbonate, and remaining bound to the microsomes following disruption with saponin. The efficient binding of short segments of apo B, despite the absence of transmembrane domains, suggests that apo B is cotranslationally inserted into the inner leaflet of the ER. This will obviate problems caused by the size and insolubility of apo B100, because the growing hydrophobic protein chains will never exist in a lipid-free form during translocation. From the inner leaflet, apo B in association with membrane-derived lipid can bud into the lumen of the ER to form nascent lipoprotein particles.			PEASE, RJ (corresponding author), MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							ARMSTRONG J, 1984, NATURE, V308, P751, DOI 10.1038/308751a0; BOSTROM K, 1988, J BIOL CHEM, V263, P4432; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; ROGERS G, 1982, J BIOL CHEM, V257, P4179; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1983, METHOD ENZYMOL, V96, P94; SPIESS M, 1989, J BIOL CHEM, V264, P19117; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	20	76	76	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					448	450		10.1038/353448a0	http://dx.doi.org/10.1038/353448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1896087	Green Published, Bronze			2022-12-28	WOS:A1991GH60600063
J	CAREY, JR				CAREY, JR			ESTABLISHMENT OF THE MEDITERRANEAN FRUIT-FLY IN CALIFORNIA	SCIENCE			English	Article							CERATITIS-CAPITATA; PATTERNS; FLIES	Principles of invasion biology are brought to bear on the question of whether the medfly is established in California. Since its first discovery in 1975, the pest has been captured in the Los Angeles Basin in nine separate years including every year from 1986 through 1990. The trend has become distinct-the intervals between captures are decreasing, the numbers captured are increasing, and the area over which they are detected is expanding. In addition, appearances are seasonal and captures in recent years have occurred in many of the same cities and neighborhoods where medflies were found several years before. Evidence suggests that the medfly may be established in the Los Angeles area and that previous eradication programs did not eradicate the medfly from California. It follows that detection, exclusion, and eradication protocols may need to be reexamined.			CAREY, JR (corresponding author), UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616, USA.							BARINAGA M, 1990, SCIENCE, V247, P1168, DOI 10.1126/science.247.4947.1168; BATEMAN MA, 1972, ANNU REV ENTOMOL, V17, P493, DOI 10.1146/annurev.en.17.010172.002425; CAREY J R, 1989, California Agriculture, V43, P38; CAREY JR, 1982, ECOL MODEL, V16, P125, DOI 10.1016/0304-3800(82)90005-9; CAREY JR, 1984, ECOL ENTOMOL, V9, P261, DOI 10.1111/j.1365-2311.1984.tb00850.x; CHRISTENSON LD, 1960, ANNU REV ENTOMOL, V5, P171, DOI 10.1146/annurev.en.05.010160.001131; CRAWLEY MJ, 1986, PHILOS T ROY SOC B, V314, P711, DOI 10.1098/rstb.1986.0082; DOWELL R.V., 1988, ECOLOGY MANAGEMENT E, P98; DOWELL RV, 1983, HORTSCIENCE, V18, P40; Drake, 1986, ECOLOGY BIOL INVASIO; Elton C. S., 1958, ECOLOGY INVASIONS; ELTON CS, 1985, ECOLOGY INVASIONS AN; ESKAFI FM, 1990, ENVIRON ENTOMOL, V19, P1371, DOI 10.1093/ee/19.5.1371; Gjullin CM, 1931, ECOLOGY, V12, P248, DOI 10.2307/1931632; HILL RP, 1987, BASIC SCI ONCOLOGY, P160; KAHN RP, 1989, PLANT PROTECTION QUA, V1; KLASSEN, 1989, ERADICATION INTRO AR; Knipling E. F., 1978, B ENTOMOL SOC AM, V24, P44, DOI [10.1093/besa/24.1.44, DOI 10.1093/BESA/24.1.44]; LEE BG, 1990, COMMUNICATION   0919; MAELZER DA, 1990, AUST J ZOOL, V38, P439, DOI 10.1071/ZO9900439; MALAVASI A, 1980, Revista Brasileira de Biologia, V40, P9; MALAVASI A, 1980, Revista Brasileira de Biologia, V40, P17; Newsom LD, 1978, B ENTOMOL SOC AM, V24, P35; POPHAM WL, 1958, ANNU REV ENTOMOL, V3, P335, DOI 10.1146/annurev.en.03.010158.002003; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PROKOPY RJ, 1984, AM SCI, V72, P41; ROBINSON AS, 1989, FRUIT FLIES THEIR A, V3; ROBINSON AS, 1989, FRUIT FLIES THEIR B, V3; ROSSLER Y, 1987, FRUIT FLIES, P541; SAILER RI, 1978, B ENTUMOL SOC AM, V23, P3; SILVESTRI F, 1914, TERR HAWAII BOARD AG, V3; SIMBERLOFF D, 1989, BIOL INVASIONS, P00061; TANNOCK IF, 1987, BASIC SCI ONCOLOGY, P140; YEKUTIEL P, 1980, ERADICATION INFECTIO, V2; 1990, MAR P COMM WHOL CONS; 1989, ACTION PLANT MEDITER	36	93	102	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1369	1373						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1896848				2022-12-28	WOS:A1991GF85100029
J	JOLY, E; MUCKE, L; OLDSTONE, MBA				JOLY, E; MUCKE, L; OLDSTONE, MBA			VIRAL PERSISTENCE IN NEURONS EXPLAINED BY LACK OF MAJOR HISTOCOMPATIBILITY CLASS-1 EXPRESSION	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CENTRAL NERVOUS-SYSTEM; CLASS-II REGION; UNIQUE CLEARANCE PATTERN; MESSENGER-RNA LEVELS; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; ANTIGEN PRESENTATION; SURFACE EXPRESSION; INFECTION REVEALS	Viruses frequently persist in neurons, suggesting that these cells can evade immune surveillance. In a mouse model, 5 x 10(6) cytotoxic T lymphocytes (CTLs), specific for lymphocytic choriomeningitis virus (LCMV), did not lyse infected neurons or cause immunopathologic injury. In contrast, intracerebral injection of less than 10(3) CTL caused disease and death when viral antigens were expressed on leptomeningial and choroid plexus cells of the nervous system. The neuronal cell tine OBL21 expresses little or no major histocompatibility (MHC) class I surface glycoproteins and when infected with LCMV, resisted lysis by virus-specific CTLs. Expression of MHC heavy chain messenger RNA was limited, but beta-2-microglobulin messenger RNA and protein was made normally. OBL21 cells were made sensitive to CTL lysis by transfection with a fusion gene encoding another MHC class I molecule. Hence, neuronal cells probably evade immune surveillance by failing to express MHC class I molecules.	SCRIPPS RES INST, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Joly, Etienne/A-5644-2009	Joly, Etienne/0000-0002-7264-2681; Mucke, Lennart/0000-0001-6256-9559				AHMED R, 1990, FIELDS VIROLOGY, V1, P241; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; BROWN P, 1968, ARCH GES VIRUSFORSCH, V24, P220, DOI 10.1007/BF01241294; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DELALUNA S, 1988, GENE, V62, P121; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOHERTY PC, 1984, CONCEPTS VIRAL PATHO, P53; GILDEN DH, 1972, J EXP MED, V135, P874, DOI 10.1084/jem.135.4.874; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JOHNSON RT, 1980, BRAIN, V103, P447, DOI 10.1093/brain/103.3.447; JOLY E, 1991, GENE, V97, P213, DOI 10.1016/0378-1119(91)90054-F; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KLAVINSKIS LS, 1989, J IMMUNOL, V143, P2013; LEHMANNGRUBE F, 1988, ANN NY ACAD SCI, V532, P238, DOI 10.1111/j.1749-6632.1988.tb36343.x; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LIPKIN WI, 1988, BRAIN RES, V451, P333; Mims C.A., 1984, VIRAL PATHOGENESIS I; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MUCKE L, 1991, NEW BIOL, V3, P465; OLDSTONE MB, 1969, J EXP MED, V129, P483, DOI 10.1084/jem.129.3.483; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0889-42; OLDSTONE MBA, 1989, CELL, V56, P517, DOI 10.1016/0092-8674(89)90573-4; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1990, NATURE, V346, P793, DOI 10.1038/346793a0; RAHMSDORF HJ, 1986, J IMMUNOL, V136, P2293; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sambrook J, 1989, MOL CLONING LABORATO; SCHILLING G, UNPUB; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4523, DOI 10.1021/bi00519a003; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1988, J VIROL, V62, P687, DOI 10.1128/JVI.62.3.687-695.1988; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; YOUNG LHY, 1989, J EXP MED, V169, P2159, DOI 10.1084/jem.169.6.2159; ZINKERNAGEL RM, 1977, J EXP MED, V145, P644, DOI 10.1084/jem.145.3.644	49	261	264	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1991	253	5025					1283	1285		10.1126/science.1891717	http://dx.doi.org/10.1126/science.1891717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891717				2022-12-28	WOS:A1991GE68900042
J	FERRIS, FL				FERRIS, FL			PHOTOCOAGULATION FOR DIABETIC-RETINOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FERRIS, FL (corresponding author), NEI, BIOMETRY & EPIDEMIOL PROGRAM, CLIN TRIALS BRANCH, BLDG 31, ROOM 6A24, BETHESDA, MD 20892 USA.							[Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1991, OPHTHALMOLOGY, V98, P807; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1991, Ophthalmology, V98, P834; [Anonymous], 1976, Am J Ophthalmol, V81, P383; [Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015	10	10	12	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1263	1265		10.1001/jama.266.9.1263	http://dx.doi.org/10.1001/jama.266.9.1263			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870253				2022-12-28	WOS:A1991GC85800037
J	MONTESANO, R; SCHALLER, G; ORCI, L				MONTESANO, R; SCHALLER, G; ORCI, L			INDUCTION OF EPITHELIAL TUBULAR MORPHOGENESIS INVITRO BY FIBROBLAST-DERIVED SOLUBLE FACTORS	CELL			English	Article							TUMOR-CELL INVASION; MESENCHYMAL INTERACTIONS; POLARIZED EPITHELIUM; SCATTER FACTOR; GROWTH-FACTOR; MDCK CYSTS; LINE MDCK; MEMBRANE; DIFFERENTIATION; EXPRESSION	We have designed an in vitro system in which Madin-Darby canine kidney (MDCK) epithelial cells are cocultured in collagen gels with fibroblasts under conditions precluding heterocellular contact. Using this experimental approach, we have obtained evidence that fibroblast-derived soluble factors play a crucial role in the control of epithelial morphogenesis. First, MDCK cells suspended alone in collagen gels form spherical cysts, whereas in the presence of fibroblasts they form branching tubules. Second, MDCK cells grown as a monolayer on fibroblast-containing collagen gels invade the underlying matrix, within which they form a network of tubules. Third, fibroblast-conditioned medium mimics the effects of coculture by eliciting tubulogenesis by MDCK cells. These results demonstrate the involvement of diffusible paracrine factors in morphogenetic epithelial-mesenchymal interactions and provide a strategy for their molecular characterization.			MONTESANO, R (corresponding author), UNIV GENEVA, MED CTR, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND.							BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BENNETT DC, 1980, NATURE, V285, P657, DOI 10.1038/285657a0; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; Bernfield M., 1984, ROLE EXTRACELLULAR M, P545; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHAMBARD M, 1981, J CELL BIOL, V91, P157, DOI 10.1083/jcb.91.1.157; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; EDELMAN GM, 1990, MORPHOREGULATORY MOL; Ekblom P, 1984, ROLE EXTRACELLULAR M, P173; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GOSPODAROWICZ D, 1984, J CELL BIOL, V99, P947, DOI 10.1083/jcb.99.3.947; GRANTHAM JJ, 1989, KIDNEY INT, V35, P1379, DOI 10.1038/ki.1989.137; GROBSTEIN C, 1956, ADV CANCER RES, V4, P187, DOI 10.1016/S0065-230X(08)60725-3; GURDON JB, 1987, DEVELOPMENT, V99, P285; HADLEY MA, 1985, J CELL BIOL, V101, P1511, DOI 10.1083/jcb.101.4.1511; HALL HG, 1982, P NATL ACAD SCI-BIOL, V79, P4672, DOI 10.1073/pnas.79.15.4672; HODGES GM, 1982, BR SOC CELL BIOL S, V5, P333; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NAKANISHI Y, 1989, BIOESSAYS, V11, P163, DOI 10.1002/bies.950110602; OJAKIAN GK, 1987, AM J PHYSIOL, V253, pC433, DOI 10.1152/ajpcell.1987.253.3.C433; PICTET RL, 1977, CELL INTERACTIONS DI, P339; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RICHMAN PI, 1988, J PATHOL, V156, P197, DOI 10.1002/path.1711560305; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SAWYER RH, 1983, EPITHELIAL MESENCHYM; Saxen L., 1976, CELL SURFACE ANIMAL, P331; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHOR SL, 1987, BIOESSAYS, V7, P200, DOI 10.1002/bies.950070503; SCHOR SL, 1987, EXP CELL BIOL, V55, P11; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLACK JMW, 1989, LANCET, V1, P1312; SPOONER BS, 1986, REGULATION MATRIX AC, P339; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI Y, 1991, DEVELOPMENT, V111, P327; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; UENO N, 1990, Progress in Growth Factor Research, V2, P113, DOI 10.1016/0955-2235(90)90027-H; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; YANG J, 1979, P NATL ACAD SCI USA, V76, P3401, DOI 10.1073/pnas.76.7.3401	60	460	477	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					697	711		10.1016/0092-8674(91)90115-F	http://dx.doi.org/10.1016/0092-8674(91)90115-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878968				2022-12-28	WOS:A1991GC74500010
J	TRINH, TQ; SINDEN, RR				TRINH, TQ; SINDEN, RR			PREFERENTIAL DNA SECONDARY STRUCTURE MUTAGENESIS IN THE LAGGING STRAND OF REPLICATION IN ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; MUTATION; SEQUENCES; JUNCTION; REPAIR; GENE	WHEN present in single-stranded DNA, palindromic or quasipalindromic sequences have the potential to form complex secondary structures, including hairpins, which may facilitate interstrand misalignment of direct repeats and be responsible for diverse types of replication-based mutations, including deletions, additions, frameshifts and duplications 1-5. In regions of palindromic symmetry, specific deletion events may involve the formation of a hairpin or other DNA secondary structures which can stabilize the misalignment of direct repeats 1,2. One model suggests that these deletions occur during DNA replication by slippage of the template strand and misalignment with the progeny strand 6,7. The concurrent DNA replication model, involving an asymmetric dimeric DNA polymerase III complex which replicates the leading and lagging strands 8, has significant implications for mutagenesis. The intermittent looping of the lagging strand template, and the fact that the lagging strand template may contain a region of single-stranded DNA the length of an Okazaki fragment, provides an opportunity for DNA secondary-structure formation and misalignment. Here we report our design of a palindromic fragment to create an 'asymmetric palindromic insert' in the chloramphenicol acetyltransferase gene of plasmid pBR325. The frequency with which the insert was deleted in Escherichia coli depends on the orientation of the gene in the plasmid. Our results suggest that replication-dependent deletion between direct repeats may occur preferentially in the lagging strand.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,231 BETHESDA AVE,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati			Sinden, Richard/AAE-3086-2019					ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; DRAKE JW, 1983, AM SCI, V71, P621; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1990, EMBO J, V9, P1659, DOI 10.1002/j.1460-2075.1990.tb08286.x; GLICKMAN BW, 1984, P NATL ACAD SCI USA, V81, P4046; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; RIPLEY LS, 1982, P NATL ACAD SCI-BIOL, V79, P4128, DOI 10.1073/pnas.79.13.4128; RIPLEY LS, 1983, UCLA S MOL CELLULAR, V10, P521; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCOTT JR, 1984, MICROBIOL REV, V48, P1; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3	17	210	214	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					544	547		10.1038/352544a0	http://dx.doi.org/10.1038/352544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865910				2022-12-28	WOS:A1991GA22600068
J	WANG, CR; LOVELAND, BE; LINDAHL, KF				WANG, CR; LOVELAND, BE; LINDAHL, KF			H-2M3 ENCODES THE MHC CLASS-I MOLECULE PRESENTING THE MATERNALLY TRANSMITTED ANTIGEN OF THE MOUSE	CELL			English	Article							SITE-SPECIFIC MUTAGENESIS; TOXIC LYMPHOCYTES-T; FOREIGN ANTIGEN; HISTOCOMPATIBILITY ANTIGENS; SELF DETERMINANTS; GENE-EXPRESSION; BINDING SITE; BALB/C MOUSE; SIDE-CHAINS; HMT REGION	Mta, the maternally transmitted antigen of mice, is a hydrophobic, N-formylated mitochondrial peptide, MTF, presented on the cell surface to cytotoxic T lymphocytes by a novel major histocompatibility complex class I molecule, encoded by H-2M3. We have cloned and sequenced two alleles of M3, which differ in their ability to present MTF despite > 99% identity in the coding regions. M3 is as divergent from classical, antigen-presenting H-2 molecules as from other class I genes of the Hmt and the Qa/Tla regions. Amino acids critical for folding of class I molecules are conserved in M3. Noncharged amino acids lining the peptide-binding groove and phenylalanine 171 may explain the unique interaction with MTF, and leucine 95 appears critical for immunological activity.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	WANG, CR (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.							ABE K, 1988, EMBO J, V7, P3441, DOI 10.1002/j.1460-2075.1988.tb03218.x; ALDRICH CJ, 1988, IMMUNOGENETICS, V28, P334, DOI 10.1007/BF00364232; BENACERRAF B, 1988, J IMMUNOL, V141, pS17; BIDDISON WE, 1980, J IMMUNOL, V124, P548; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRORSON KA, 1989, IMMUNOGENETICS, V30, P273, DOI 10.1007/BF02421331; BRORSON KA, 1989, J EXP MED, V170, P1837, DOI 10.1084/jem.170.6.1837; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FISHER DA, 1985, J EXP MED, V162, P528, DOI 10.1084/jem.162.2.528; FOURNEY RM, 1988, FOCUS, V10, P1; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GASTON JSH, 1984, IMMUNOGENETICS, V19, P475, DOI 10.1007/BF00403438; GOULMY E, 1982, J EXP MED, V155, P1567, DOI 10.1084/jem.155.5.1567; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAN AC, 1987, IMMUNOGENETICS, V25, P234, DOI 10.1007/BF00404693; HANDY DE, 1989, J IMMUNOL, V142, P1015; HERMEL E, 1991, INT IMMUNOL, V3, P407, DOI 10.1093/intimm/3.4.407; HOLTKAMP B, 1983, EMBO J, V2, P1943, DOI 10.1002/j.1460-2075.1983.tb01683.x; HOULDEN BA, 1989, COLD SH Q B, V54, P45; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KLEIN J, 1990, IMMUNOGENETICS, V32, P147, DOI 10.1007/BF02114967; KOLLER BH, 1985, J IMMUNOL, V134, P2727; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KVIST S, 1983, EMBO J, V2, P245, DOI 10.1002/j.1460-2075.1983.tb01413.x; LALANNE JL, 1982, NUCLEIC ACIDS RES, V10, P1039, DOI 10.1093/nar/10.3.1039; LINDAHL KF, 1980, J EXP MED, V152, P1583; LINDAHL KF, 1989, COLD SH Q B, V54, P563; LINDAHL KF, 1983, NATURE, V306, P383, DOI 10.1038/306383a0; LINDAHL KF, 1986, J EXP MED, V163, P334, DOI 10.1084/jem.163.2.334; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LINDAHL KF, 1981, SCAND J IMMUNOL, V14, P643, DOI 10.1111/j.1365-3083.1981.tb00607.x; LINDAHL KF, 1987, H2 ANTIGENS GENES MO, P327; LINSK R, 1986, J EXP MED, V164, P794, DOI 10.1084/jem.164.3.794; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; Maniatis T., 1982, MOL CLONING; MATTSON DH, 1987, IMMUNOGENETICS, V26, P190, DOI 10.1007/BF00365911; MATTSON DH, 1989, J IMMUNOL, V143, P1101; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MURPHY DB, 1987, H2 ANTIGENS GENES MO, P359; OBATA Y, 1988, P NATL ACAD SCI USA, V85, P3541, DOI 10.1073/pnas.85.10.3541; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; RICHARDS S, 1989, EMBO J, V8, P3749, DOI 10.1002/j.1460-2075.1989.tb08551.x; ROBINSON PJ, 1988, IMMUNOGENETICS, V27, P79, DOI 10.1007/BF00351079; Rodgers J R, 1986, Adv Immunol, V38, P313, DOI 10.1016/S0065-2776(08)60010-3; RONNE H, 1985, P NATL ACAD SCI USA, V82, P5860, DOI 10.1073/pnas.82.17.5860; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHER BT, 1985, P NATL ACAD SCI USA, V82, P1175, DOI 10.1073/pnas.82.4.1175; SHIMOJO N, 1990, INT IMMUNOL, V2, P193, DOI 10.1093/intimm/2.3.193; SINGER DS, 1988, IMMUNOGENETICS, V28, P13, DOI 10.1007/BF00372524; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SMITH R, 1985, J IMMUNOL, V134, P2191; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TRANSY C, 1987, J EXP MED, V166, P341, DOI 10.1084/jem.166.2.341; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160	70	117	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					335	345		10.1016/0092-8674(91)90623-7	http://dx.doi.org/10.1016/0092-8674(91)90623-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855254				2022-12-28	WOS:A1991FY71200014
J	WOLTHERS, OD; PEDERSEN, S				WOLTHERS, OD; PEDERSEN, S			GROWTH OF ASTHMATIC-CHILDREN DURING TREATMENT WITH BUDESONIDE - A DOUBLE-BLIND TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INHALED BECLOMETHASONE DIPROPIONATE; ALTERNATE-DAY PREDNISONE; LONG-TERM TREATMENT; LOWER LEG LENGTH; CHILDHOOD ASTHMA; LINEAR GROWTH; AEROSOL; THERAPY; CORTICOSTEROIDS; RETARDATION	Objective - To determine whether the inhaled glucocorticosteroid budesonide has any adverse effect on short term linear growth in children with mild asthma. Setting - Outpatient clinic in secondary referral centre. Patients - 15 children aged 6-13 years with normal statural growth velocity during the previous year, no signs of puberty, and no use of systemic or topical steroids in the two months before the study. Design of interventions - Double blind, randomised crossover trial with two active periods in which budesonide was given in divided daily doses of 200-mu-g and 800-mu-g. During run in and two washout periods placebo was given. After the second washout period the children received open treatment with 400-mu-g budesonide daily. All periods were of 18 days' duration. Main outcome measure - Growth of the lower leg as measured twice a week by knemometry. Results - Mean growth velocity of the lower leg was 0.63 mm/week during run in and during washout 0.64 mm/week. Budesonide treatment was associated with a significant dose related reduction of growth velocity: the mean reduction in growth velocity during treatment was 0.11 (95% confidence interval -0.15 to 0.37) mm/week with 200-mu-g budesonide and 0.36 (0.13 to 0.59) mm/week with 800-mu-g budesonide (p < 0.05; Page's test). During treatment with 400-mu-g budesonide a reduction of 0.17 (-0.10 to 0.45) mm/week was found. Conclusions - Treatment with inhaled budesonide is associated with a dose related suppression of short term linear growth in children with mild asthma.	KOLDING CTY HOSP, DEPT PEDIATR, KOLDING, DENMARK	Kolding Hospital								BAHN GL, 1980, LANCET, V1, P76; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; FALLIERS CJ, 1961, J ALLERGY, V32, P420, DOI 10.1016/0021-8707(61)90020-X; FEINSTEINAR, 1977, CLIN BIOSTATISTICS, P320; FRANCIS RS, 1976, THORAX, V31, P309, DOI 10.1136/thx.31.3.309; FRIEDMAN M, 1969, SCAND J RESPIR DIS, VS, P58; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GODFREY S, 1978, J ALLERGY CLIN IMMUN, V62, P335, DOI 10.1016/0091-6749(78)90133-1; GOLDSTEIN DE, 1983, PEDIATRICS, V72, P60; GRAFFLONNEVIG V, 1979, ALLERGY, V34, P57, DOI 10.1111/j.1398-9995.1979.tb02001.x; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P1, DOI 10.1080/03014468800009411; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HILLS M, 1977, BR J CLIN PHARM, V8, P7; HOLLANDER M, 1973, NONPARAMETRIC STAT, P147; HUGHES IA, 1987, BMJ-BRIT MED J, V295, P683, DOI 10.1136/bmj.295.6600.683-a; KERREBIJN KF, 1976, J PEDIATR-US, V89, P821, DOI 10.1016/S0022-3476(76)80816-5; KERREBIJN KF, 1968, ARCH DIS CHILD, V43, P556, DOI 10.1136/adc.43.231.556; LAW CM, 1986, LANCET, V1, P942; LITTLEWOOD JM, 1988, LANCET, V1, P115; MURRAY AB, 1976, LANCET, V2, P197; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; PEDERSEN S, 1989, GLUCOCORTICOIDS MECH, P40; RIBEIRO LB, 1987, GLUCOCORTICOSTEROIDS, P95; SCHULLER CF, 1986, EUR J RESPIR DIS, V69, pA152; SNYDER RD, 1967, CLIN PEDIATR, V6, P389, DOI 10.1177/000992286700600705; STEAD RJ, 1989, BRIT MED J, V298, P403, DOI 10.1136/bmj.298.6671.403; VALK IM, 1983, GROWTH, V47, P53; VAZ R, 1982, J PEDIATR-US, V100, P660, DOI 10.1016/S0022-3476(82)80781-6; WALES JKH, 1987, ARCH DIS CHILD, V62, P166, DOI 10.1136/adc.62.2.166; WALES JKH, 1987, ACTA PAEDIATR SCAND, P37; WILLIAMS H, 1984, ARCH DIS CHILD, V59, P553, DOI 10.1136/adc.59.6.553; WIT JM, 1987, ACTA PAEDIATR SCAND, V76, P974, DOI 10.1111/j.1651-2227.1987.tb17274.x; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504	36	194	196	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1991	303	6795					163	165		10.1136/bmj.303.6795.163	http://dx.doi.org/10.1136/bmj.303.6795.163			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878641	Bronze, Green Published			2022-12-28	WOS:A1991FX57800023
J	POWER, KG; MARKOVA, I; ROWLANDS, A; MCKEE, KJ; ANSLOW, PJ; KILFEDDER, C				POWER, KG; MARKOVA, I; ROWLANDS, A; MCKEE, KJ; ANSLOW, PJ; KILFEDDER, C			SEXUAL-BEHAVIOR IN SCOTTISH PRISONS	BRITISH MEDICAL JOURNAL			English	Article									UNIV GLASGOW,DEPT PSYCHOL MED,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow	POWER, KG (corresponding author), UNIV STIRLING,DEPT PSYCHOL,STIRLING FK9 4LA,SCOTLAND.							FARMER R, 1989, TRANSMISSION HIV PRI; HAMMETT TM, 1988, AIDS CORRECTIONAL FA; HARDING TW, 1987, LANCET, V2, P1260; MCMILLAN A, 1988, BRIT MED J, V297, P873, DOI 10.1136/bmj.297.6653.873; 1988, HIV AIDS PRISONS	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1507	1508		10.1136/bmj.302.6791.1507-a	http://dx.doi.org/10.1136/bmj.302.6791.1507-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855022	Bronze, Green Published			2022-12-28	WOS:A1991FT50500025
J	REDMOND, AD; WATSON, S; NIGHTINGALE, P				REDMOND, AD; WATSON, S; NIGHTINGALE, P			THE SOUTH-MANCHESTER-ACCIDENT-RESCUE-TEAM AND THE EARTHQUAKE IN IRAN, JUNE 1990	BRITISH MEDICAL JOURNAL			English	Article									UNIV HOSP S MANCHESTER,WITHINGTON HOSP,DIV INT,S MANCHESTER ACCID RESCUE TEAM,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital								BETTER OS, 1990, NEW ENGL J MED, V322, P825; BURSZTEIN S, 1986, UPDATE INTENSIVE CAR, V1, P384; REDMOND AD, 1990, INJURY, V21, P21, DOI 10.1016/0020-1383(90)90147-M; REDMOND AD, 1989, LANCET, V1, P660; REDMOND AD, 1989, BRIT MED J, V299, P611, DOI 10.1136/bmj.299.6699.611	5	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1521	1523		10.1136/bmj.302.6791.1521	http://dx.doi.org/10.1136/bmj.302.6791.1521			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855026	Green Published, Bronze			2022-12-28	WOS:A1991FT50500029
J	COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC				COCKRELL, JL; SCHEINMAN, MM; TITUS, C; HELMY, I; LANGBERG, JJ; LEE, MA; GRIFFIN, JC			SAFETY AND EFFICACY OF ORAL FLECAINIDE THERAPY IN PATIENTS WITH ATRIOVENTRICULAR REENTRANT TACHYCARDIA	ANNALS OF INTERNAL MEDICINE			English	Article							PARKINSON-WHITE SYNDROME; SUPRAVENTRICULAR ARRHYTHMIAS; JUNCTIONAL TACHYCARDIAS; ATRIAL-FIBRILLATION; CLINICAL EFFICACY; ACETATE; ENCAINIDE; PATHWAYS; ISOPROTERENOL	Objective: To assess the short- and long-term safety and efficacy of oral flecainide therapy in patients with symptomatic tachycardia and an extranodal accessory pathway. Design: Open-label, uncontrolled trial with a mean follow-up of 24 months. Setting: Referral-based, teaching medical center. Patients: Sixty-three patients with symptomatic tachycardia and an extranodal accessory pathway. Interventions: Patients had electrophysiologic testing before and after the initiation of oral flecainide therapy and were followed long-term for the presence of symptoms, new physical limitations, and adverse effects of therapy. Measurements and Main Results: Flecainide therapy prevented or slowed (324 +/- 59 ms to 398 +/- 55 ms; P < 0.001) inducible sustained atrioventricular reciprocating tachycardia in 44 of 63 patients (70%). Of the 44 patients discharged from the hospital, 33 (75%) have continued to receive flecainide therapy and have shown no adverse effects (mean follow-up, 24 +/- 10 months). Adverse cardiac reactions (proarrhythmia or sinus node suppression) attributable to flecainide occurred in 11 of 63 patients (17%); in 9 (82%) of these 11 patients, events were detected during either in-hospital monitoring or the electrophysiologic study done before discharge. Structural heart disease was detected by two-dimensional echocardiography in 8 of 11 patients who had adverse cardiac events and in 6 of 52 patients who did not have such events (P < 0.001). Isoproterenol reversed the effects of flecainide therapy in 11 of 21 patients; 7 of the 11 patients had spontaneous clinical recurrences of tachycardia or palpitations during the follow-up period, but these symptoms occurred in only 1 of 10 patients who did not show isoproterenol-induced reversal (P = 0.02). Conclusions: Oral flecainide therapy was effective in 33 of 63 patients who had tachycardia and an extranodal accessory connection. Hospital monitoring during initial therapy is recommended, and flecainide should be used with caution, if at all, in patients with structural heart disease. An isoproterenol challenge appears to be helpful in predicting late recurrence of tachycardia.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	COCKRELL, JL (corresponding author), LETTERMAN ARMY MED CTR, DEPT MED, CARDIOL SERV, SAN FRANCISCO, CA 94129 USA.							ABDOLLAH H, 1984, AM J CARDIOL, V54, P544, DOI 10.1016/0002-9149(84)90245-5; AKHTAR M, 1988, AM J CARDIOL, V62, pL45, DOI 10.1016/0002-9149(88)90015-X; ANDERSON JL, 1988, AM J CARDIOL, V62, pD62; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BEXTON RS, 1983, EUR HEART J, V4, P92, DOI 10.1093/oxfordjournals.eurheartj.a061432; BREMBILLAPERROT B, 1985, EUR HEART J, V6, P1074, DOI 10.1093/oxfordjournals.eurheartj.a061812; CRIJNS HJGM, 1988, AM HEART J, V115, P1317, DOI 10.1016/0002-8703(88)90032-4; FAUCHIER JP, 1985, ARCH MAL COEUR VAISS, V78, P81; GOY JJ, 1985, EUR HEART J, V6, P518, DOI 10.1093/oxfordjournals.eurheartj.a061897; HAISSAGUERRE M, 1987, ARCH MAL COEUR VAISS, V80, P357; HELLESTRAND KJ, 1983, AM J CARDIOL, V51, P770, DOI 10.1016/S0002-9149(83)80131-3; HELMY I, 1991, IN PRESS J AM COLL C; KAPPENBERGER LJ, 1985, CLIN CARDIOL, V8, P321, DOI 10.1002/clc.4960080603; KIM SS, 1986, AM J CARDIOL, V58, P80, DOI 10.1016/0002-9149(86)90245-6; NEUSS H, 1988, AM J CARDIOL, V62, pD56; NEUSS H, 1983, EUR HEART J, V4, P347, DOI 10.1093/oxfordjournals.eurheartj.a061472; PRYSTOWSKY EN, 1984, CIRCULATION, V69, P278, DOI 10.1161/01.CIR.69.2.278; TILL JA, 1987, ARCH DIS CHILD, V62, P247, DOI 10.1136/adc.62.3.247; WARD DE, 1986, AM J CARDIOL, V57, P787, DOI 10.1016/0002-9149(86)90614-4; WELLENS HJJ, 1980, AM J CARDIOL, V46, P665, DOI 10.1016/0002-9149(80)90518-4; WREN C, 1987, BRIT HEART J, V57, P171; ZEECHENG CS, 1988, AM J CARDIOL, V62, pD23	22	25	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1991	114	3					189	194		10.7326/0003-4819-114-3-189	http://dx.doi.org/10.7326/0003-4819-114-3-189			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EV339	1898629				2022-12-28	WOS:A1991EV33900003
J	HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA				HAGAN, P; BLUMENTHAL, UJ; DUNN, D; SIMPSON, AJG; WILKINS, HA			HUMAN IGE, IGG4 AND RESISTANCE TO REINFECTION WITH SCHISTOSOMA-HAEMATOBIUM	NATURE			English	Article							PROTECTIVE IMMUNITY; ANTIBODIES; MANSONI; CELLS; RESPONSES; MACROPHAGES; INVITRO; GAMMA	A WELL recognized feature of the immune response to parasitic helminth infections, including schistosomiasis, is the production of large amounts of specific and nonspecific IgE 1,2. Immunological pathways involving IgE can lead to damage to the developing schistosomulum 3-9 and it has been suggested that responses involving IgE could have evolved as protection against helminth infections 10,11. There has been no epidemiological evidence to support this idea and the only significant IgE responses known in man are those involved in the pathogenesis of allergic disease 12. Here we measure serological response during reinfection with S. haematobium and demonstrate that IgE antibodies in man can be beneficial. Our results support the hypothesis that the slow build-up of IgE to high levels and the early production of IgG4 antibodies, which may block IgE pathways 13,14, are responsible for delaying the development of protective immunity to S. haematobium.	UNIV LIVERPOOL, LIVERPOOL SCH TROP MED, LIVERPOOL L3 5QA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, LONDON WC1E 7HT, ENGLAND; MRC LABS, FAJARA, SENEGAMBIA	Liverpool School of Tropical Medicine; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	HAGAN, P (corresponding author), NATL INST MED RES, DIV PARASITOL, LONDON NW7 1AA, ENGLAND.		Simpson, Amelia/HGB-1823-2022	Dunn, David/0000-0003-1836-4446; Hagan, Paul/0000-0002-3516-2283				AURIAULT C, 1990, J CLIN MICROBIOL, V28, P1918, DOI 10.1128/JCM.28.9.1918-1924.1990; Bundy DAP, 1990, PARASITISM HOST BEHA; BUTTERWORTH AE, 1974, NATURE, V252, P503, DOI 10.1038/252503a0; CAPRON A, 1975, NATURE, V253, P474, DOI 10.1038/253474a0; CAPRON A, 1989, CIBA F SYMP, V147, P153; CAPRON A, 1977, AM J TROP MED HYG, V26, P39, DOI 10.4269/ajtmh.1977.26.39; CAPRON A, 1977, PATHOL BIOL, V25, P287; CAPRON A, 1980, AM J TROP MED HYG, V29, P849, DOI 10.4269/ajtmh.1980.29.849; CAPRON A, 1982, PROG ALLERGY, V31, P234; Capron M., 1980, T ROY SOC TROP MED H, V74, P44, DOI [10.1016/0035-9203(80)90272-2, DOI 10.1016/0035-9203(80)90272-2]; CHRETIEN I, 1988, J IMMUNOL, V141, P3128; DEAN DA, 1974, AM J TROP MED HYG, V23, P420, DOI 10.4269/ajtmh.1974.23.420; DESSAINT JP, 1975, CLIN EXP IMMUNOL, V20, P427; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; HAGAN P, 1985, PARASITE IMMUNOL, V7, P625, DOI 10.1111/j.1365-3024.1985.tb00106.x; HAGAN P, 1987, T ROY SOC TROP MED H, V81, P938, DOI 10.1016/0035-9203(87)90359-2; HUSSAIN R, 1986, J IMMUNOL, V136, P1859; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; ISKANDER R, 1981, INT ARCH ALLER A IMM, V66, P200, DOI 10.1159/000232819; JAMES SL, 1982, CELL IMMUNOL, V67, P255, DOI 10.1016/0008-8749(82)90218-0; KHALIFE J, 1986, J EXP MED, V164, P1626, DOI 10.1084/jem.164.5.1626; OGILVIE BM, 1964, NATURE, V204, P91, DOI 10.1038/204091a0; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; STANWORTH D R, 1973, Clinical Allergy, V3, P37, DOI 10.1111/j.1365-2222.1973.tb01307.x; STURROCK RF, 1983, T ROY SOC TROP MED H, V77, P363, DOI 10.1016/0035-9203(83)90166-9; TURNER KJ, 1989, CIBA F SYMP, V147, P205; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WILKINS HA, 1988, BIOL SCHISTOSOMES	30	579	592	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 17	1991	349	6306					243	245		10.1038/349243a0	http://dx.doi.org/10.1038/349243a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ET519	1898985				2022-12-28	WOS:A1991ET51900057
J	MORRISSEY, JF; REICHELDERFER, M				MORRISSEY, JF; REICHELDERFER, M			MEDICAL PROGRESS - GASTROINTESTINAL ENDOSCOPY .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; PROSPECTIVE RANDOMIZED TRIAL; BLEEDING ESOPHAGEAL-VARICES; TERM FOLLOW-UP; MULTIPOLAR ELECTROCOAGULATION; YAG LASER; BALLOON DILATATION; PEPTIC-ULCERS; HEATER PROBE; ESOPHAGOGASTRIC VARICES				MORRISSEY, JF (corresponding author), UNIV WISCONSIN,SCH MED,DEPT MED,600 HIGHLAND AVE,MADISON,WI 53792, USA.							ACHKAR E, 1986, GASTROINTEST ENDOSC, V32, P278, DOI 10.1016/S0016-5107(86)71846-4; AGHA FP, 1986, AM J GASTROENTEROL, V81, P246; ALEXANDER JA, 1988, DIGEST DIS SCI, V33, P1121, DOI 10.1007/BF01535788; BARR H, 1990, GUT, V31, P252, DOI 10.1136/gut.31.3.252; BEAVIS AK, 1979, BRIT MED J, V1, P1387, DOI 10.1136/bmj.1.6175.1387; BEDOGNI G, 1987, GASTROINTEST ENDOSC, V33, P21, DOI 10.1016/S0016-5107(87)71479-5; BORLAND JL, 1991, GASTROINTEST ENDOSC, V37, P205; BORLAND JL, 1990, GASTROINTEST ENDOSC, V36, P416; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, NEW ENGL J MED, V321, P857, DOI 10.1056/NEJM198909283211303; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; CHUNG SCS, 1988, BRIT MED J, V296, P1631, DOI 10.1136/bmj.296.6637.1631; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; COX J, 1986, GUT, V27, P986, DOI 10.1136/gut.27.8.986; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; DANDALIDES SM, 1989, GASTROINTEST ENDOSC, V35, P197, DOI 10.1016/S0016-5107(89)72757-7; DUMON JF, 1985, GASTROINTEST ENDOSC, V31, P379, DOI 10.1016/S0016-5107(85)72252-3; FOUTCH PG, 1990, GASTROINTEST ENDOSC, V36, P337; GASTOUT CJ, 1991, GASTROINTEST ENDOSC, V37, P5; GEAR MWL, 1980, BRIT MED J, V280, P1136, DOI 10.1136/bmj.280.6223.1136; GEAR MWL, 1980, BMJ, V1, P1135; GOFF JS, 1990, CAN J GASTROENTEROL, V9, P639; GOTLIB JP, 1990, CAN J GASTROENTEROL, V4, P637; GRAHAM DY, 1987, GASTROINTEST ENDOSC, V33, P432, DOI 10.1016/S0016-5107(87)71681-2; GRAHAM DY, 1985, GASTROINTEST ENDOSC, V31, P171, DOI 10.1016/S0016-5107(85)72038-X; GRIMM H, 1991, GASTROINTEST ENDOSC, V37, P275; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; HENDERSON JM, 1990, ANN INTERN MED, V112, P262, DOI 10.7326/0003-4819-112-4-262; HO CS, 1988, GASTROENTEROLOGY, V95, P1206, DOI 10.1016/0016-5085(88)90351-4; HOGAN RB, 1986, GASTROINTEST ENDOSC, V32, P253, DOI 10.1016/S0016-5107(86)71841-5; HOGAN WJ, 1988, GASTROINTEST ENDOSC, V34, P485; HSIA PC, 1991, GASTROINTEST ENDOSC, V37, P22, DOI 10.1016/S0016-5107(91)70615-9; HUI WM, 1991, GASTROINTEST ENDOSC, V37, P299, DOI 10.1016/S0016-5107(91)70719-0; INFANTERIVARD C, 1989, GASTROENTEROLOGY, V96, P1087, DOI 10.1016/0016-5085(89)91627-2; JENSEN DM, 1988, GASTROENTEROLOGY, V94, P1263, DOI 10.1016/0016-5085(88)90662-2; JENSEN DM, 1988, GASTROENTEROLOGY, V94, pA208; JENSEN LS, 1990, SCAND J GASTROENTERO, V25, P352, DOI 10.3109/00365529009095498; JOHNSTON JH, 1987, GASTROENTEROLOGY, V92, P1101, DOI 10.1016/S0016-5085(87)91065-1; JOHNSTON JH, 1985, GASTROINTEST ENDOSC, V31, P175, DOI 10.1016/S0016-5107(85)72039-1; JOHNSTON JH, 1987, GASTROINTEST ENDOSC, V33, P349, DOI 10.1016/S0016-5107(87)71636-8; JONES R, 1989, GUT, V30, P893, DOI 10.1136/gut.30.7.893; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; KADAKIA SC, 1991, GASTROINTEST ENDOSC, V37, P183, DOI 10.1016/S0016-5107(91)70682-2; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; KAHN KL, 1986, J CLIN GASTROENTEROL, V8, P346, DOI 10.1097/00004836-198606002-00005; KAPLAN CS, 1989, ARCH INTERN MED, V149, P2095, DOI 10.1001/archinte.149.9.2095; KAWAI K, 1973, ENDOSCOPY, V5, P7, DOI 10.1055/s-0028-1098202; KLEBER G, 1991, GASTROENTEROLOGY, V100, P1332; KORTAN P, 1990, CAN J GASTROENTEROL, V4, P650; KOZAREK RA, 1990, GASTROINTEST ENDOSC, V36, P558, DOI 10.1016/S0016-5107(90)71163-7; KRETZSCHMAR CS, 1987, SURGERY, V102, P443; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LAINE L, 1990, GASTROENTEROLOGY, V99, P1303, DOI 10.1016/0016-5085(90)91154-X; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; LEWIS B, 1991, GASTROINTEST ENDOSC, V37, P277; LIN HJ, 1990, GASTROINTEST ENDOSC, V36, P241, DOI 10.1016/S0016-5107(90)71015-2; LINDOR KD, 1985, GASTROENTEROLOGY, V89, P545, DOI 10.1016/0016-5085(85)90449-4; LOIZOU LA, 1991, GASTROENTEROLOGY, V100, P1303; MCCLAVE SA, 1990, GASTROINTEST ENDOSC, V36, P567, DOI 10.1016/S0016-5107(90)71165-0; MCCLAVE SA, 1990, GASTROINTEST ENDOSC, V36, P272, DOI 10.1016/S0016-5107(90)71022-X; MCJUNKIN B, 1991, GASTROINTEST ENDOSC, V37, P18, DOI 10.1016/S0016-5107(91)70614-7; MONNIER PH, 1985, ACTA ENDOSC, V15, P1; MORRISSEY JF, 1988, ANN INTERN MED, V109, P605, DOI 10.7326/0003-4819-109-8-605; OVERHOLT BF, 1987, GASTROINTEST ENDOSC, V33, P1, DOI 10.1016/S0016-5107(87)71473-4; PAQUET KJ, 1990, AM J SURG, V160, P43, DOI 10.1016/S0002-9610(05)80867-0; PAQUET KJ, 1985, HEPATOLOGY, V5, P580, DOI 10.1002/hep.1840050409; PLANAS R, 1991, GASTROENTEROLOGY, V100, P1078, DOI 10.1016/0016-5085(91)90285-S; PONSKY JL, 1981, GASTROINTEST ENDOSC, V27, P9, DOI 10.1016/S0016-5107(81)73133-X; PONSKY JL, 1989, WORLD J SURG, V13, P165, DOI 10.1007/BF01658394; RESNICK RH, 1990, GASTROENTEROLOGY, V99, P1524, DOI 10.1016/0016-5085(90)91189-D; RUTGEERTS P, 1988, GASTROINTEST ENDOSC, V34, P87, DOI 10.1016/S0016-5107(88)71269-9; RUTGEERTS P, 1987, GASTROINTEST ENDOSC, V33, P199, DOI 10.1016/S0016-5107(87)71558-2; RUTGEERTS P, 1987, GASTROINTEST ENDOSC, V33, P182; SANOWSKI RA, 1987, J CLIN GASTROENTEROL, V9, P504, DOI 10.1097/00004836-198710000-00003; SARGENT IR, 1990, CAN J GASTROENTEROL, V4, P653; SARIN SK, 1987, GUT, V28, P657, DOI 10.1136/gut.28.6.657; SARRE RG, 1987, GUT, V28, P306, DOI 10.1136/gut.28.3.306; SCHAFER LW, 1983, NEW ENGL J MED, V309, P1210, DOI 10.1056/NEJM198311173092003; SCHAFER LW, 1985, MAYO CLIN PROC, V60, P444, DOI 10.1016/S0025-6196(12)60867-2; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SODERLUND C, 1985, ACTA CHIR SCAND, V151, P449; SPECHLER SJ, 1987, ANN INTERN MED, V106, P902, DOI 10.7326/0003-4819-106-6-902; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; SPIGELMAN AD, 1989, LANCET, V2, P783, DOI 10.1016/s0140-6736(89)90840-4; STIEGMANN G, 1990, GASTROINTEST ENDOSC, V36, P118; STIEGMANN GV, 1989, GASTROINTEST ENDOSC, V35, P431, DOI 10.1016/S0016-5107(89)72850-9; STIEGMANN GV, 1990, GASTROINTEST ENDOSC, V36, P575; SUGAWA C, 1986, SURG GYNECOL OBSTET, V162, P159; TEMPLE DM, 1983, PEDIATRICS, V71, P100; TERBLANCHE J, 1989, ANN SURG, V210, P725, DOI 10.1097/00000658-198912000-00006; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; THEISE N D, 1989, Gastroenterology, V96, pA509; TSAI HH, 1991, GUT, V32, P93, DOI 10.1136/gut.32.1.93; TULMAN AB, 1981, GASTROINTEST ENDOSC, V27, P229, DOI 10.1016/S0016-5107(81)73230-9; VANSTOLK R, 1987, ENDOSCOPY, V19, P19, DOI 10.1055/s-2007-1018303; VANTRAPPEN G, 1983, GUT, V24, P1013, DOI 10.1136/gut.24.11.1013; VANTRAPPEN G, 1980, GASTROENTEROLOGY, V79, P144; VOTTELER TP, 1983, JAMA-J AM MED ASSOC, V249, P2504, DOI 10.1001/jama.249.18.2504; WARING JP, 1991, GASTROINTEST ENDOSC, V37, P295; WEBB WA, 1988, GASTROENTEROLOGY, V94, P204, DOI 10.1016/0016-5085(88)90632-4; ZARGAR SA, 1991, GASTROINTEST ENDOSC, V37, P165; ZUCCARO G, 1991, GASTROINTEST ENDOSC, V37, P274; 1987, ANN INTERN MED, V107, P937; 1987, ANN INTERN MED, V107, P772; 1988, GASTROINTEST ENDOS S, V34, pS35; 1987, ANN INTERN MED, V107, P589; 1991, GUT, V32, P95; 1988, GASTROINTEST ENDOS S, V34, pS8; 1989, APPROPRIATE USE GAST, P5; 1988, ANN INTERN MED, V108, P142; 1984, ANN INTERN MED, V100, P608; 1988, GASTROINTEST ENDOS S, V34, pS21; 1985, ANN INTERN MED, V102, P266; 1991, NEW ENGL J MED, V324, P1779; 1989, JAMA-J AM MED ASSOC, V262, P1369; 1984, NEW ENGL J MED, V311, P1594; 1988, GASTROINTEST ENDOS S, V34, pS18; 1991, GASTROINTEST ENDOSC, V37, P122	122	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1142	1149		10.1056/NEJM199110173251606	http://dx.doi.org/10.1056/NEJM199110173251606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891023				2022-12-28	WOS:A1991GK53800006
J	PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK				PARSONNET, J; FRIEDMAN, GD; VANDERSTEEN, DP; CHANG, Y; VOGELMAN, JH; ORENTREICH, N; SIBLEY, RK			HELICOBACTER-PYLORI INFECTION AND THE RISK OF GASTRIC-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; IMMUNE-RESPONSE; CANCER; ASSOCIATION; EPIDEMIOLOGY; POPULATION; STOMACH; DIET	Background. Infection with Helicobacter pylori has been linked with chronic atrophic gastritis, an inflammatory precursor of gastric adenocarcinoma. In a nested case-control study, we explored whether H. pylori infection increases the risk of gastric carcinoma. Methods. From a cohort of 128,992 persons followed since the mid-1960s at a health maintenance organization, 186 patients with gastric carcinoma were selected as case patients and were matched according to age, sex, and race with 186 control subjects without gastric carcinoma. Stored serum samples collected during the 1960s were tested for IgG antibodies to H. pylori by enzyme-linked immunosorbent assay. Data on cigarette use, blood group, ulcer disease, and gastric surgery were obtained from questionnaires administered at enrollment. Tissue sections and pathology reports were reviewed to confirm the histologic results. Results. The mean time between serum collection and the diagnosis of gastric carcinoma was 14.2 years. Of the 109 patients with confirmed gastric adenocarcinoma (excluding tumors of the gastroesophageal junction), 84 percent had been infected previously with H. pylori, as compared with 61 percent of the matched control subjects (odds ratio, 3.6; 95 percent confidence interval, 1.8 to 7.3). Tumors of the gastroesophageal junction were not linked to H. pylori infection, nor were tumors in the gastric cardia. H. pylori was a particularly strong risk factor for stomach cancer in women (odds ratio, 18) and blacks (odds ratio, 9). A history of gastric surgery was independently associated with the development of cancer (odds ratio, 17; P = 0.03), but a history of peptic ulcer disease was negatively associated with subsequent gastric carcinoma (odds ratio, 0.2; P = 0.02). Neither blood group nor smoking history affected risk. Conclusions. Infection with H. pylori is associated with an increased risk of gastric adenocarcinoma and may be a cofactor in the pathogenesis of this malignant condition.	ORENTREICH FDN ADVANCEMENT SCI INC, NEW YORK, NY 10021 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA USA	Stanford University; Kaiser Permanente	PARSONNET, J (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT MED,HRP BLDG, RM 109A, STANFORD, CA 94305 USA.		Chang, Yuan/F-4146-2011	Chang, Yuan/0000-0003-1125-4041; Parsonnet, Julie/0000-0001-7342-5366	NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; ARMIJO R, 1981, INT J EPIDEMIOL, V10, P53, DOI 10.1093/ije/10.1.53; BUIATTI E, 1990, INT J CANCER, V45, P896, DOI 10.1002/ijc.2910450520; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; CORREA P, 1970, J NATL CANCER I, V44, P297; CORREA P, 1983, JNCI-J NATL CANCER I, V70, P673; CORREA P, 1985, SEMIN ONCOL, V12, P2; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1982, EPIDEMIOLOGY CANCER, P58; EVANS DJ, 1989, GASTROENTEROLOGY, V96, P1004, DOI 10.1016/0016-5085(89)91616-8; FAULDE M, 1991, J CLIN MICROBIOL, V29, P323, DOI 10.1128/JCM.29.2.323-327.1991; FORMAN D, 1990, INT J CANCER, V46, P608, DOI 10.1002/ijc.2910460410; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; FRIEDMAN GD, 1974, NEW ENGL J MED, V290, P469, DOI 10.1056/NEJM197402282900901; GAREWAL HS, 1989, PREV MED, V18, P749, DOI 10.1016/0091-7435(89)90046-7; GOODWIN CS, 1987, J INFECT DIS, V155, P488, DOI 10.1093/infdis/155.3.488; GOODWIN CS, 1989, INT J SYST BACTERIOL, V39, P397, DOI 10.1099/00207713-39-4-397; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HIRSCHL AM, 1988, EUR J CLIN MICROBIOL, V7, P570, DOI 10.1007/BF01962618; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JASKIEWICZ K, 1989, S AFR MED J, V75, P417; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LOFFELD RJLF, 1990, HISTOPATHOLOGY, V17, P537, DOI 10.1111/j.1365-2559.1990.tb00793.x; MORRIS A, 1989, J CLIN PATHOL, V42, P727, DOI 10.1136/jcp.42.7.727; MUIR CS, 1987, IARC SCI PUBLICATION, V88; MUNOZ N, 1971, INT J CANCER, V8, P158, DOI 10.1002/ijc.2910080119; MUNOZ N, 1968, INT J CANCER, V3, P809, DOI 10.1002/ijc.2910030614; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PARKIN DM, 1986, IARC SCI PUBLICATION, V75; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PARSONNET J, 1989, CAMPYLOBACTER PYLORI, P51; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; RAUWS EAJ, 1989, CAMPYLOBACTER PYLORI, P187; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SCOTT N, 1990, LANCET, V335, P728, DOI 10.1016/0140-6736(90)90845-V; SIPPONEN P, 1987, SCAND J GASTROENTERO, V22, P865, DOI 10.3109/00365528708991927; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TALLEY NJ, IN PRESS J NATL CANC	41	3410	3524	9	366	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1127	1131		10.1056/NEJM199110173251603	http://dx.doi.org/10.1056/NEJM199110173251603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891020				2022-12-28	WOS:A1991GK53800003
J	SIEGEL, MJ; CAREL, C; SURRATT, S				SIEGEL, MJ; CAREL, C; SURRATT, S			ULTRASONOGRAPHY OF ACUTE ABDOMINAL-PAIN IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACUTE APPENDICITIS; ACUTE ABDOMEN; SONOGRAPHY; US	Objective. To determine the ability of ultrasonography to detect appendicitis and to identify other conditions responsible for symptoms in children with acute abdominal pain. Design. Cohort study. The accuracy of ultrasonographic results was assessed in relation to final diagnoses established by surgery or by composite clinical data and follow-up. Setting. Metropolitan, pediatric hospital; ambulatory and hospitalized patients. Patients. Consecutive sample of 178 pediatric patients who were referred for ultrasonography because of suspected acute appendicitis, but in whom the diagnosis could not be definitely established by clinical criteria. Results. Appendicitis was proven at surgery in 38 patients. Ultrasonography demonstrated the findings of appendicitis (noncompressible appendix with or without concomitant periappendiceal fluid collection or appendicolith) in 31 (82%) of these patients. Among the 140 children without appendicitis, other specific diagnoses were established by clinical, laboratory, and radiologic findings in 58 patients (including gynecologic diseases in 25, gastrointestinal tract abnormalities in 17, renal diseases in six, and extra-abdominal disease in 10). Ultrasonography aided in the diagnosis of other conditions in 34 (59%) of these 58 patients. No definitive clinical diagnosis was established in the remaining 82 patients. There were no false-positive results of ultrasonography. Conclusion. Approximately half of children referred for suspected appendicitis will have a final diagnosis of abdominal pain of unknown origin. In the remainder, ultrasonography is useful, both to establish the diagnosis of appendicitis and to aid in diagnosing other causes of acute abdominal pain.			SIEGEL, MJ (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,510 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.							ABUYOUSEF MM, 1987, AM J ROENTGENOL, V149, P53, DOI 10.2214/ajr.149.1.53; CAMPBELL JPM, 1988, BRIT J SURG, V75, P554, DOI 10.1002/bjs.1800750616; FEEDYSHIN P, 1984, AJR AM J ROENTGENOL, V143, P99; FRANKEN EA, 1989, AM J ROENTGENOL, V153, P921, DOI 10.2214/ajr.153.5.921; GAENSLER EHL, 1989, AM J ROENTGENOL, V152, P49, DOI 10.2214/ajr.152.1.49; JEFFREY RB, 1987, RADIOLOGY, V163, P11, DOI 10.1148/radiology.163.1.3547490; JEFFREY RB, 1988, RADIOLOGY, V167, P327, DOI 10.1148/radiology.167.2.3282253; JOFFE N, 1975, Critical Reviews in Clinical Radiology and Nuclear Medicine, V7, P97; JONES PF, 1976, BRIT MED J, V2, P551, DOI 10.1136/bmj.2.6035.551; MENDELSON RM, 1987, BRIT J RADIOL, V60, P414, DOI 10.1259/0007-1285-60-712-414; PARELUKAR SG, 1983, J ULTRASOUNDMED, V2, P59; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; PUYLAERT JBCM, 1986, RADIOLOGY, V158, P355, DOI 10.1148/radiology.158.2.2934762; RUBIN SZ, 1990, J PEDIATR SURG, V25, P737, DOI 10.1016/S0022-3468(05)80008-9; VIGNAULT F, 1990, RADIOLOGY, V176, P501, DOI 10.1148/radiology.176.2.2195594; WINSEY HS, 1967, BMJ-BRIT MED J, V1, P653, DOI 10.1136/bmj.1.5541.653	16	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1987	1989		10.1001/jama.266.14.1987	http://dx.doi.org/10.1001/jama.266.14.1987			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895479				2022-12-28	WOS:A1991GH40600027
J	YAZIGI, RA; ODEM, RR; POLAKOSKI, KL				YAZIGI, RA; ODEM, RR; POLAKOSKI, KL			DEMONSTRATION OF SPECIFIC BINDING OF COCAINE TO HUMAN SPERMATOZOA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							H-3 COCAINE; ASSOCIATION; RECEPTORS	Exposure of males to cocaine has been linked to abnormal development of their offspring. To investigate the possible role of sperm, this study examined the interaction of cocaine with human spermatozoa. Washed sperm were incubated with tritiated cocaine (6.7 nmol/L) with or without unlabeled cocaine (670-mu-mol/L), and the samples were filtered and the remaining radioactivity quantitated. The specific binding was optimal at 20 minutes and 23-degrees-C. Competition studies with tritiated cocaine (3.4 to 66.6 nmol/L) indicated the presence of approximately 3.6 x 10(3) binding sites per cell, with a high affinity receptor dissociation constant (K(d) = 12.6 nmol/L). Cocaine concentrations as high as 670-mu-mol/L had no detectable effect on either the motility or viability of the cells. These results support the hypothesis that the sperm may act as a vector to transport cocaine into an ovum. This novel mechanism could be involved in the abnormal development of offspring of cocaine-exposed males.	WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	Washington University (WUSTL)	YAZIGI, RA (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT OBSTET & GYNECOL,3401 N BROAD ST,PHILADELPHIA,PA 19140, USA.							ABEL EL, 1987, ALCOHOL CLIN EXP RES, V11, P533, DOI 10.1111/j.1530-0277.1987.tb00168.x; ABEL EL, 1989, J ANDROL, V10, P17; AHMED MS, 1990, LIFE SCI, V46, P553, DOI 10.1016/0024-3205(90)90122-8; BOJA JW, 1989, EUR J PHARMACOL, V173, P215, DOI 10.1016/0014-2999(89)90524-4; BRACKEN MB, 1990, FERTIL STERIL, V53, P315; BRACKETT BG, 1971, P NATL ACAD SCI USA, V68, P353, DOI 10.1073/pnas.68.2.353; BRIGGS M, 1974, ACTA ENDOCRINOL-COP, V75, P785, DOI 10.1530/acta.0.0750785; CALLIGARO DO, 1987, J PHARMACOL EXP THER, V243, P61; CICERO TJ, 1985, ANAL BIOCHEM, V150, P67, DOI 10.1016/0003-2697(85)90441-5; ELMAGHRABI EA, 1988, LIFE SCI, V42, P1675, DOI 10.1016/0024-3205(88)90447-X; ERICSSON RJ, 1967, NATURE, V214, P403, DOI 10.1038/214403a0; FRIEDLER G, 1987, RES COMMUN SUBSTANCE, V8, P109; GERBER N, 1976, LIFE SCI, V19, P782; JATLOW P, 1988, YALE J BIOL MED, V61, P105; LITTLE RE, 1986, NEW ENGL J MED, V314, P1644, DOI 10.1056/NEJM198606193142516; MADRAS BK, 1989, J PHARMACOL EXP THER, V251, P131; MULE SJ, 1977, COCAINE OTHER STIMUL, P215; PAULSON JD, 1977, FERTIL STERIL, V28, P178; REITH MEA, 1980, LIFE SCI, V27, P1055, DOI 10.1016/0024-3205(80)90029-6; REITH MEA, 1980, J NEUROCHEM, V46, P309; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SWEET F, 1987, ENDOCR REV, V8, P154, DOI 10.1210/edrv-8-2-154; WOZNIAK DF, 1991, PSYCHOPHARMACOLOGY, V43, P74; Zaneweld LJD, 1977, TECHNIQUES HUMAN AND, P147	24	65	66	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1956	1959		10.1001/jama.266.14.1956	http://dx.doi.org/10.1001/jama.266.14.1956			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH406	1895473				2022-12-28	WOS:A1991GH40600021
J	RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K				RIZZO, T; METZGER, BE; BURNS, WJ; BURNS, K			CORRELATIONS BETWEEN ANTEPARTUM MATERNAL METABOLISM AND INTELLIGENCE OF OFFSPRING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; INFANT	Background. It is not clear to what extent maternal metabolism during pregnancy affects the cognitive and behavioral function of the offspring by altering brain development in utero. To investigate this question, we correlated measures of metabolism in pregnant diabetic and nondiabetic women with the intellectual development of their offspring. Methods. The study included 223 pregnant women and their singleton offspring: 89 women had diabetes before pregnancy (pregestational diabetes mellitus), 99 had the onset of diabetes during pregnancy (gestational diabetes mellitus), and 35 had normal carbohydrate metabolism during their pregnancy. We correlated measures of maternal glucose and lipid metabolism (fasting plasma glucose levels, hemoglobin A1c levels, episodes of hypoglycemia, episodes of acetonuria, and plasma beta-hydroxybutyrate and free fatty acid levels) with two measures of intellectual development in the offspring - the mental-development index of the Bayley Scales of Infant Development, given at the age of two years, and the Stanford-Binet Intelligence Scale, given at the ages of three, four, and five years and expressed as an average of the three scores. Results. After correction for socioeconomic status, race or ethnic origin, and patient group, the children's mental-development-index scores at the age of two years correlated inversely with the mothers' third-trimester plasma beta-hydroxybutyrate levels (r = -0.21, P < 0.01); the average Stanford-Binet scores correlated inversely with third-trimester plasma beta-hydroxybutyrate (r = -0.20, P < 0.02) and free fatty acid (r = -0.27, P < 0.002) levels. No other correlations were significant. Including various perinatal events (e.g., prematurity and acidemia) in the analyses did not alter the results. Conclusions. Maternal diabetes during pregnancy may affect behavioral and intellectual development in the offspring. The associations between gestational ketonemia in the mother and a lower IQ in the child warrant continued efforts to avoid ketoacidosis and accelerated starvation in all pregnant women.	NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611; NORTHWESTERN UNIV,CTR ENDOCRINOL METAB & NUTR,SCH MED,CHICAGO,IL 60611; NW MEM HOSP,PRENTICE WOMENS HOSP,CHICAGO,IL 60611	Northwestern University; Northwestern University; Northwestern Memorial Hospital	RIZZO, T (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT PSYCHIAT,SEARLE BLDG 10-526,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169, R01DK010699] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11021] Funding Source: Medline; NIDDK NIH HHS [DK10699, DK07169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayley N., 1969, BAYLEY SCALES INFANT; BERENDES HW, 1975, EARLY DIABETES EARLY, P135; BIBERGEIL H, 1975, EARLY DIABETES EARLY, P427; Brazelton T. B., 1973, CLIN DEV MED, V50; Castellan N J Jr, 1965, Psychol Bull, V64, P330; CHURCHIL.JA, 1969, AM J OBSTET GYNECOL, V105, P257, DOI 10.1016/0002-9378(69)90067-2; Cornblath M, 1976, DISORDERS CARBOHYDRA, V2nd; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUBOWITZ LM, 1970, J PEDIATR-US, V77, P1, DOI 10.1016/S0022-3476(70)80038-5; FREINKEL N, 1980, DIABETES, V29, P1023, DOI 10.2337/diabetes.29.12.1023; Freinkel N, 1979, CARBOHYD METABOL, P1; Freinkel N, 1979, CIBA F S, P3; FREINKEL N, 1979, 10TH P C INT DIAB FE, P731; LI PK, 1980, CLIN CHEM, V26, P1713; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; MCCALL RB, 1972, AM PSYCHOL, V27, P728, DOI 10.1037/h0033148; MCNEMAR Q, 1962, PSYCHOL STATISTICS, P139; MENARD L, 1980, CLIN CHEM, V26, P1598; METZGER BE, 1980, DIABETES CARE, V3, P402, DOI 10.2337/diacare.3.3.402; MORRIS MA, 1988, DIABETES S1, V37, pA112; NAEYE RL, 1979, CIBA F S, V63, P227; OSULLIVAN JB, 1964, DIABETES, V13, P278; PEDERSEN J, 1977, PREGNANT DIABETIC HE; PEDERSEN JF, 1984, OBSTET GYNECOL, V64, P351; PETERSEN MB, 1988, BRIT MED J, V296, P598, DOI 10.1136/bmj.296.6622.598; RIZZO T, 1990, AM J OBSTET GYNECOL, V163, P1458, DOI 10.1016/0002-9378(90)90606-8; SCARR S, 1981, RACE SOCIAL CLASS IN; STEHBENS JA, 1977, AM J OBSTET GYNECOL, V127, P408; TERMAN LM, 1973, STANFORDBINET INTELL; TRIVELLI LA, 1971, NEW ENGL J MED, V284, P353, DOI 10.1056/NEJM197102182840703; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Yssing M, 1975, EARLY DIABETES EARLY, P575; 1988, SPSS PCPLUS V2 0 BAS, pB153; 1985, DIABETES S2, V34, P123; 1988, SPSS PCPLUS ADV STAT, P103	35	314	318	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					911	916		10.1056/NEJM199109263251303	http://dx.doi.org/10.1056/NEJM199109263251303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881416				2022-12-28	WOS:A1991GF85600003
J	PHIBBS, CS; BATEMAN, DA; SCHWARTZ, RM				PHIBBS, CS; BATEMAN, DA; SCHWARTZ, RM			THE NEONATAL COSTS OF MATERNAL COCAINE USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; BIRTH-WEIGHT; INTENSIVE-CARE; PREGNANCY; NEWBORN; ALCOHOL; ABUSE; RISK; MARIJUANA; ANOMALIES	Objective. - To examine the added neonatal cost and length of hospital stay associated with fetal cocaine exposure. Design. - All cocaine-exposed infants in the study population (n = 355) were compared with a random sample of unexposed infants (n = 199). Regression analysis was used to control for the independent effects of maternal age, smoking, alcohol consumption, prenatal care, race, gravidity, and sex of the infant. Setting. - A large, public, inner-city hospital studied from 1985 to 1986. Patients. - All infants were routinely tested for illicit substances, records were reviewed for maternal histories of substance abuse, and all known cocaine-exposed singleton infants were included. Main Outcome Measures. - Cost and length of stay until each infant was medically cleared for hospital discharge and cost and length of stay until each infant was actually discharged from the hospital. Results. - Neonatal hospital costs until medically cleared for discharge were $5200 more for cocaine-exposed infants than for unexposed infants (a difference of $7957 vs $2757 [P = .003]). The costs of infants remaining in the nursery while awaiting home and social evaluation or foster care placement increased this difference by more than $3500 (P < .0001). Compared with other forms of cocaine, fetal exposure to crack was associated with much larger cost increases ($6735 vs $1226). Exposure to other illicit substances in addition to cocaine was also associated with much larger cost increases ($8450 vs $1283). Conclusions. - At the national level, we estimate that these individual medical costs add up to about $500 million. The large magnitude of these costs indicates that effective treatment programs for maternal cocaine abusers could yield savings within their first year of operation.	NATL PERINATAL INFORMAT CTR,PROVIDENCE,RI; HARLEM HOSP MED CTR,NEW YORK,NY; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; COLUMBIA UNIV,SCH PUBL HLTH,DIV HLTH POLICY & MANAGEMENT,NEW YORK,NY 10027; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,NEW YORK,NY 10032	University of California System; University of California San Francisco; Columbia University; Columbia University				Phibbs, Ciaran/0000-0002-4353-3507	PHS HHS [P02027-02-0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABEL EL, 1980, HUM BIOL, V52, P593; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; ACKER D, 1983, AM J OBSTET GYNECOL, V146, P220, DOI 10.1016/0002-9378(83)91060-8; BATEMAN D, 1990, IMPROVING THE LIFE CHANCES OF CHILDREN AT RISK, P45; BESHAROV DJ, 1989, PUBLIC WELFARE   FAL, P6; BINGOL N, 1987, J PEDIATR-US, V110, P93, DOI 10.1016/S0022-3476(87)80297-4; CHASNOFF IJ, 1986, J PEDIATR-US, V108, P456, DOI 10.1016/S0022-3476(86)80896-4; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHASNOFF IJ, 1989, JAMA-J AM MED ASSOC, V261, P1741, DOI 10.1001/jama.261.12.1741; CHAVEZ GF, 1989, JAMA-J AM MED ASSOC, V262, P795, DOI 10.1001/jama.262.6.795; DIXON SD, 1989, J PEDIATR-US, V115, P770, DOI 10.1016/S0022-3476(89)80661-4; DOBERCZAK TM, 1988, J PEDIATR-US, V113, P354, DOI 10.1016/S0022-3476(88)80283-X; Gomby DS, 1991, FUTURE CHILD, V1, P17; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; KEITH LG, 1989, OBSTET GYNECOL, V73, P715; KLINE J, 1987, INT J EPIDEMIOL, V16, P44, DOI 10.1093/ije/16.1.44; MACGREGOR SN, 1989, OBSTET GYNECOL, V74, P882; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; PETITTI DB, 1990, AM J PUBLIC HEALTH, V80, P25, DOI 10.2105/AJPH.80.1.25; PHIBBS CS, 1986, PEDIATRICS, V78, P829; PHIBBS CS, 1981, PEDIATRICS, V68, P313; RYAN L, 1987, NEUROTOXICOL TERATOL, V9, P295, DOI 10.1016/0892-0362(87)90018-3; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SCHWARTZ RM, 1989, MCJ44052503 US DEP H; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; STREISSGUTH AP, 1980, SCIENCE, V209, P353, DOI 10.1126/science.6992275; VANDEBOR M, 1990, PEDIATRICS, V85, P30; WILLIAMS RL, 1979, MED CARE, V17, P95, DOI 10.1097/00005650-197902000-00001; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1990, MED PROSPECTIVE PAYM, P39; 1990, GAOHRD90138 GEN ACC; 1987, NEONATAL INTENSIVE C, V38	32	93	93	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1521	1526		10.1001/jama.266.11.1521	http://dx.doi.org/10.1001/jama.266.11.1521			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880883				2022-12-28	WOS:A1991GE45800032
J	ALDHOUS, P				ALDHOUS, P			CLINICAL TRAILS - BLAZING AN ETHICAL TRAIL	NATURE			English	Editorial Material																			0	1	1	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					4	4		10.1038/353004b0	http://dx.doi.org/10.1038/353004b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GD805	1881445	Bronze			2022-12-28	WOS:A1991GD80500006
J	RUDY, DW; VOELKER, JR; GREENE, PK; ESPARZA, FA; BRATER, DC				RUDY, DW; VOELKER, JR; GREENE, PK; ESPARZA, FA; BRATER, DC			LOOP DIURETICS FOR CHRONIC RENAL-INSUFFICIENCY - A CONTINUOUS INFUSION IS MORE EFFICACIOUS THAN BOLUS THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE TOLERANCE; TUBULAR SECRETION; BUMETANIDE; FUROSEMIDE; FAILURE; OTOTOXICITY; DIURESIS; KINETICS	Objective: To test the hypothesis that a continuous, low-dose infusion of a loop diuretic is more efficacious and better tolerated than conventional intermittent bolus therapy in patients with severe chronic renal insufficiency (CRI). Design: Randomized, crossover clinical trial with subjects serving as their own controls. Setting: The General Clinical Research Center of Indiana University Hospital, Indianapolis, Indiana. Patients: Eight adult volunteers with severe stable CRI (mean creatinine clearance, 0.28 mL/s; range, 0.15 to 0.47 mL/s) were recruited from the outpatient nephrology clinics of Indiana University Medical Center. Interventions: On admission, diuretic drugs were withdrawn and patients were equilibrated on an 80 mmol/d sodium, 60 mmol/d potassium metabolic diet. Patients were randomized to receive a 12-mg intravenous dose of bumetanide given either as two 6-mg bolus doses separated by 6 hours or as the same total dose administered as a 12-hour continuous infusion. When sodium balance was re-established, each patient was crossed over to the alternative study limb. All patients completed both phases of the study. Measurements and Results: Comparable amounts of bumetanide appeared in the urine during the study period (infusion, 912 +/- 428-mu-g; bolus, 944 +/- 421-mu-g; difference, 32-mu-g; 95% Cl, - 16-mu-g to 80-mu-g, P = 0.16). The continuous infusion resulted in significantly greater net sodium excretion (infusion, 236 +/- 77 mmol; bolus, 188 +/- 50 mmol; difference, 48 mmol; Cl, 16 mmol to 80 mmol, P = 0.01). No patient had episodes of drug-induced myalgias during the continuous infusion compared with 3 of 8 patients with bolus therapy. Conclusions: In patients with severe CRI, a continuous intravenous infusion of bumetanide is more effective and less toxic than conventional intermittent bolus therapy. Continuous administration will probably be useful in patients with severe CRI who have not achieved an adequate natriuresis or who show evidence of drug toxicity with standard diuretic dosing regimens. A similar benefit may occur in selected diuretic-resistant patients with cardiac or hepatic disease, and studies in these patients seem warranted.	INDIANA UNIV HOSP, INDIANAPOLIS, IN 46223 USA	Indiana University System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037994] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR750-16] Funding Source: Medline; NIDDK NIH HHS [R01 DK37994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIEL SA, 1984, BMJ-BRIT MED J, V283, P1041; BERG KJ, 1976, EUR J CLIN PHARMACOL, V9, P265, DOI 10.1007/BF00561659; BRATER DC, 1986, AM J CARDIOL, V57, pA20; BRATER DC, 1983, ANNU REV PHARMACOL, V23, P45, DOI 10.1146/annurev.pa.23.040183.000401; BRATER DC, 1981, DRUGS, V22, P477, DOI 10.2165/00003495-198122060-00004; BRATER DC, 1986, CLIN PHARMACOL THER, V40, P134, DOI 10.1038/clpt.1986.151; BRATER DC, 1984, KIDNEY INT, V26, P183, DOI 10.1038/ki.1984.153; BRATER DC, 1987, CONTEMP ISS NEPHROL, P115; COOK JA, 1988, PHARMACEUT RES, V5, P86, DOI 10.1023/A:1015984016680; COOK JA, 1987, PHARMACEUT RES, V4, P379, DOI 10.1023/A:1016426110571; COPELAND JG, 1983, AM J SURG, V146, P796, DOI 10.1016/0002-9610(83)90344-6; CUTHBERT MF, 1975, POSTGRAD MED J, V51, P51; GALLAGHER KL, 1979, ANN INTERN MED, V91, P744, DOI 10.7326/0003-4819-91-5-744; Gibaldi M, 1982, PHARMACOKINETICS REV, V2nd, P45; GRANTHAM JJ, 1978, CONTEMP ISS NEPHROL, P178; HAMMARLUND MM, 1985, J PHARMACOL EXP THER, V233, P447; JOHNSON CA, 1987, CLIN PHARMACY, V6, P735; KRASNA MJ, 1986, CHEST, V89, P294, DOI 10.1378/chest.89.2.294; LAU HSH, 1986, CLIN PHARMACOL THER, V39, P635, DOI 10.1038/clpt.1986.112; LAWSON DH, 1978, BRIT MED J, V2, P476, DOI 10.1136/bmj.2.6135.476; MARCANTONIO LA, 1983, BRIT J CLIN PHARMACO, V15, P245, DOI 10.1111/j.1365-2125.1983.tb01493.x; MCINNES GI, 1982, CLIN SCI, V63, pP33; ODLIND B, 1983, CLIN PHARMACOL THER, V34, P805, DOI 10.1038/clpt.1983.253; ODLIND B, 1979, J PHARMACOL EXP THER, V211, P238; PENTIKAINEN PJ, 1985, CLIN PHARMACOL THER, V37, P582, DOI 10.1038/clpt.1985.91; SCHWARTZ GH, 1970, NEW ENGL J MED, V282, P1413, DOI 10.1056/NEJM197006182822506; SMITH D, 1988, PHARMACOKINETICS PHA, V2, P107; VOELKER JR, 1987, KIDNEY INT, V32, P572, DOI 10.1038/ki.1987.246; WILCOX CS, 1983, J LAB CLIN MED, V102, P450	29	120	121	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					360	366		10.7326/0003-4819-115-5-360	http://dx.doi.org/10.7326/0003-4819-115-5-360			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863026				2022-12-28	WOS:A1991GC06500005
J	HOEKSTRA, MF; LISKAY, RM; OU, AC; DEMAGGIO, AJ; BURBEE, DG; HEFFRON, F				HOEKSTRA, MF; LISKAY, RM; OU, AC; DEMAGGIO, AJ; BURBEE, DG; HEFFRON, F			HRR25, A PUTATIVE PROTEIN-KINASE FROM BUDDING YEAST - ASSOCIATION WITH REPAIR OF DAMAGED DNA	SCIENCE			English	Article							ATP-BINDING SITE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; NUCLEAR-LOCALIZATION; RAD52 GENE; RECOMBINATION; PRODUCT; HOMOLOGY; SEQUENCES; STRAINS	In simple eukaryotes, protein kinases regulate mitotic and meiotic cell cycles, the response to polypeptide pheromones, and the initiation of nuclear DNA synthesis. The protein HRR25 from the budding yeast Saccharomyces cerevisiae was defined by the mutation hrr25-1. This mutation resulted in sensitivity to continuous expression of the HO double-strand endonuclease, to methyl methanesulfonate, and to x-irradiation. Homozygotes of hrr25-1 were unable to sporulate and disruption and deletion of HRR25 interfered with mitotic and meiotic cell division. Sequence analysis revealed two distinctive regions in the protein. The NH-2-terminus of HRR25 contains the hallmark features of protein kinases, whereas the COOH-terminus is rich in proline and glutamine. Mutations in HRR25 at conserved residues found in all protein kinases inactivated the gene, and these mutants exhibited the hrr25 null phenotypes. Taken together, the hrr25 mutant phenotypes and the features of the gene product indicate that HRR25 is a distinctive member of the protein kinase superfamily.	YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, NEW HAVEN, CT 06510 USA; OREGON HLTH SCI UNIV, DEPT MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA	Yale University; Oregon Health & Science University	HOEKSTRA, MF (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, LA JOLLA, CA 92186 USA.							ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COLE GM, 1989, MOL CELL BIOL, V9, P3101, DOI 10.1128/MCB.9.7.3101; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; Game J., 1983, YEAST GENETICS FUNDA, P109; HANAWALT PC, 1979, ANNU REV BIOCHEM, V48, P783, DOI 10.1146/annurev.bi.48.070179.004031; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHODS ENYZMOL, V200, P38; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HARTTWELL LH, 1990, SCIENCE, V246, P629; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HOEKSTRA M, UNPUB; HOLLINGSWORTH RE, 1990, P NATL ACAD SCI USA, V87, P6272, DOI 10.1073/pnas.87.16.6272; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; MALONE RE, 1984, GENETICS, V107, P33; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MONTELONE BA, 1988, GENETICS, V119, P289; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; NJAGI GDE, 1982, MOL GEN GENET, V186, P478, DOI 10.1007/BF00337951; PATERSON M, 1986, MOL CELL BIOL, V6, P1590; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; SCHILD D, 1983, CURR GENET, V7, P85, DOI 10.1007/BF00365631; SCHLIESTL R, 1989, MOL CELL BIOL, V9, P1882; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; THOMPSON L, 1989, GENETIC RECOMBINATIO, P597; WEIFFENBACH B, 1981, MOL CELL BIOL, V1, P522, DOI 10.1128/MCB.1.6.522; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; Williamson D H, 1975, Methods Cell Biol, V12, P335; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	47	167	175	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1031	1034		10.1126/science.1887218	http://dx.doi.org/10.1126/science.1887218			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887218				2022-12-28	WOS:A1991GC98200046
J	IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T				IWAKURA, Y; TOSU, M; YOSHIDA, E; TAKIGUCHI, M; SATO, K; KITAJIMA, I; NISHIOKA, K; YAMAMOTO, K; TAKEDA, T; HATANAKA, M; YAMAMOTO, H; SEKIGUCHI, T			INDUCTION OF INFLAMMATORY ARTHROPATHY RESEMBLING RHEUMATOID-ARTHRITIS IN MICE TRANSGENIC FOR HTLV-I	SCIENCE			English	Article							T-CELL LEUKEMIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS TYPE-I; GENE; PROMOTER; PROTEIN; EXPRESSION; ACTIVATION; DISEASE; INVITRO	Human T cell leukemia virus type-I (HTLV-I) is the etiologic agent of adult T cell leukemia and has also been suggested to be involved in other diseases such as chronic arthritis or myelopathy. To elucidate pathological roles of the virus in disease, transgenic mice were produced that carry the HTLV-I genome. At 2 to 3 months of age, many of the mice developed chronic arthritis resembling rheumatoid arthritis. Synovial and periarticular inflammation with articular erosion caused by invasion of granulation tissues were marked. These observations suggest a possibility that HTLV-I is one of the etiologic agents of chronic arthritis in humans.	TOKYO WOMENS MED COLL, INST RHEUMATOL, SHINJUKU KU, TOKYO 163, JAPAN; UNIV TOKYO, FAC MED, BUNKYO KU, TOKYO 113, JAPAN; KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN; KOHNO CLIN MED RES INST, SHINAGAWA KU, TOKYO 140, JAPAN	Tokyo Women's Medical University; University of Tokyo; Kyoto University; Kyoto University	IWAKURA, Y (corresponding author), UNIV TOKYO, INST MED SCI, 4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN.		Takiguchi, Masafumi/E-7468-2013; Iwakura, Yoichiro/E-5457-2011; Yamamoto, Kazuhiko/N-5096-2015	Iwakura, Yoichiro/0000-0002-9934-5775; 				AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BENTIN J, 1990, ARTHRITIS RHEUM, V33, P268, DOI 10.1002/art.1780330217; CHEEVERS WP, 1988, LAB INVEST, V58, P510; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE BC, 1979, ARTHRITIS RHEUM, V22, P1375, DOI 10.1002/art.1780221209; Decker J L, 1984, Ann Intern Med, V101, P810; ESPINOZA LR, 1988, ARTHRITIS RHEUM-US, V31, P1034, DOI 10.1002/art.1780310815; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HANG L, 1982, J EXP MED, V155, P1690, DOI 10.1084/jem.155.6.1690; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; IWAKURA Y, 1988, EMBO J, V7, P3757, DOI 10.1002/j.1460-2075.1988.tb03259.x; IWAKURA Y, UNPUB; KITAJIMA I, 1989, ARTHRITIS RHEUM, V32, P1342, DOI 10.1002/anr.1780321030; KOGA T, 1985, INFECT IMMUN, V50, P27, DOI 10.1128/IAI.50.1.27-34.1985; KRANE SM, 1985, ARTHRITIS ALLIED CON, P593; KRIEG AM, 1990, J AUTOIMMUN, V3, P137, DOI 10.1016/0896-8411(90)90137-H; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIYASAKA N, IN PRESS J AUTOIMMUN; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NISHIOKA K, 1989, LANCET, V1, P441; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; TAKIGUCHI M, UNPUB; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TOSU M, UNPUB; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VANEDEN W, 1985, P NATL ACAD SCI USA, V82, P5117; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; WINCHESTER R, 1987, ANN INTERN MED, V106, P19, DOI 10.7326/0003-4819-106-1-19; ZIEGLER B, 1988, Arthritis and Rheumatism, V31, pS35	32	305	315	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1026	1028		10.1126/science.1887217	http://dx.doi.org/10.1126/science.1887217			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887217				2022-12-28	WOS:A1991GC98200044
J	REITNER, A; SHARPE, LT; ZRENNER, E				REITNER, A; SHARPE, LT; ZRENNER, E			IS COLOR-VISION POSSIBLE WITH ONLY RODS AND BLUE-SENSITIVE CONES	NATURE			English	Article							SPECTRAL SENSITIVITY; ACHROMATOPSIA; MONOCHROMACY	AT night all cats are grey, but with the approach of dawn they take on colour. By starlight, a single class of photoreceptors, the rods, function, whereas by daylight, three classes, the blue-, green- and red-sensitive cones, are active and provide colour vision. Only by comparing the rates of quantal absorption in more than one photoreceptor class is colour vision possible. Although the comparisons generally take place between the cones, they can involve the rods as well 1-4. Here we investigate the wavelength discrimination of an extremely rare group of individuals, blue-cone monochromats, who have only rods and one class of cones 5-8. We find that these individuals can distinguish wavelengths (440 to 500 nm) in the twilight region where the rods and blue-sensitive cones are simultaneously active.	UNIV FREIBURG,NEUROL KLIN,W-7800 FREIBURG,GERMANY; UNIV TUBINGEN,HOSP EYE,DEPT PATHOPHYSIOL VIS & NEUROOPHTHALMOL,W-7400 TUBINGEN 1,GERMANY	University of Freiburg; Eberhard Karls University of Tubingen	REITNER, A (corresponding author), ZWEITE UNIV VIENNA,AUGENKLIN,ALSERSTR 4,A-1090 VIENNA,AUSTRIA.							ALPERN M, 1965, ARCH OPHTHALMOL-CHIC, V74, P334; ALPERN M, 1971, J PHYSIOL-LONDON, V212, P211, DOI 10.1113/jphysiol.1971.sp009318; BLACKWELL HR, 1961, VISION RES, V1, P62, DOI 10.1016/0042-6989(61)90022-0; Boynton R. M., 1979, HUMAN COLOR VISION; Clarke F. J. J., 1960, OPT ACTA, V7, P355; DZMURA M, 1986, VISION RES, V26, P1273, DOI 10.1016/0042-6989(86)90108-2; GOURAS P, 1966, J PHYSIOL-LONDON, V184, P499, DOI 10.1113/jphysiol.1966.sp007928; GOURAS P, 1965, SCIENCE, V147, P1593, DOI 10.1126/science.147.3665.1593; HANSEN E, 1978, NATURE, V276, P390, DOI 10.1038/276390a0; HESS RF, 1989, J PHYSIOL-LONDON, V417, P123, DOI 10.1113/jphysiol.1989.sp017794; INGLING CR, 1977, VISION RES, V17, P1083, DOI 10.1016/0042-6989(77)90014-1; MCCANN JJ, 1972, SCIENCE, V176, P1255, DOI 10.1126/science.176.4040.1255; MOLLON JD, 1977, PHILOS T ROY SOC B, V278, P207, DOI 10.1098/rstb.1977.0038; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; PALMER DA, 1978, J OPT SOC AM, V68, P1501, DOI 10.1364/JOSA.68.001501; REITNER A, IN  PRESS VISION RES; SHARPE LT, 1989, SCIENCE, V244, P354, DOI 10.1126/science.2711186; SMITH VC, 1983, INVEST OPHTH VIS SCI, V24, P451; SMITH VC, 1972, VISION RES, V12, P2059, DOI 10.1016/0042-6989(72)90058-2; SMITH VC, 1977, J OPT SOC AM, V67, P213, DOI 10.1364/JOSA.67.000213; STABELL B, 1974, VISION RES, V14, P1389, DOI 10.1016/0042-6989(74)90013-3; TREZONA PW, 1970, VISION RES, V10, P317, DOI 10.1016/0042-6989(70)90103-3; TREZONA PW, 1973, VISION RES, V13, P9, DOI 10.1016/0042-6989(73)90161-2; van den Berg T J, 1978, Mod Probl Ophthalmol, V19, P341; WILLMER EN, 1960, J THEOR BIOL, V2, P141; Wright WD, 1937, P PHYS SOC, V49, P329, DOI 10.1088/0959-5309/49/4/301; Wyszecki G., 1982, COLOR SCI, V8; YOUNG RSL, 1985, INVEST OPHTH VIS SCI, V26, P1543; ZRENNER E, 1988, KLIN MONATSBL AUGENH, V193, P510, DOI 10.1055/s-2008-1050292	29	75	75	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					798	800		10.1038/352798a0	http://dx.doi.org/10.1038/352798a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881435				2022-12-28	WOS:A1991GC96400058
J	KNOWLES, MR; CLARKE, LL; BOUCHER, RC				KNOWLES, MR; CLARKE, LL; BOUCHER, RC			ACTIVATION BY EXTRACELLULAR NUCLEOTIDES OF CHLORIDE SECRETION IN THE AIRWAY EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-KINASE-C; RESPIRATORY EPITHELIA; LUNG-DISEASE; CHANNELS; PERMEABILITY; TRANSPORT; AMILORIDE	Background. Cystic fibrosis is characterized by abnormal electrolyte transport across the epithelia of the airways. In particular, there is excessive sodium absorption and deficient chloride secretion. Drugs that block excessive sodium absorption may provide clinical benefit in cystic fibrosis, but there are no available therapeutic agents to improve chloride secretion. In vitro studies in cultured human-airway epithelia indicate that triphosphate nucleotides (ATP and UTP) induce chloride secretion through apical-membrane purinergic receptors. Methods. We tested the ability of nucleotides to induce chloride secretion in vivo in 9 normal subjects and 12 patients with cystic fibrosis by measuring responses of nasal transepithelial potential difference (PD) to superfusion of nucleotides. Changes in transepithelial bioelectric properties and the permeability of the apical membrane to chloride in response to extracellular (apical) UTP were determined with ion-selective microelectrodes in cultured nasal epithelia. Results. ATP and UTP induced chloride secretion in vivo in both groups. At their maximal effective concentrations of 10(-4) M, ATP and UTP were more effective chloride secretagogues in the patients with cystic fibrosis (mean [+/- SE] change in PD, -19.8 +/- 1.4 mV and -15.0 +/- 1.7 mV, respectively) than in the normal subjects (-6.9 +/- 0.6 mV and -8.1 +/- 0.9 mV, respectively). Microelectrode studies established that extracellular UTP stimulated a larger increase in PD and chloride secretory current in epithelial cells from patients with cystic fibrosis than in cells from normal subjects, by actions localized to the apical membrane. Conclusions. Extracellular nucleotides are effective in vivo chloride secretagogues in the nasal epithelia of patients with cystic fibrosis. The equipotency of ATP and UTP suggests that the effect is mediated by P2 nucleotide receptors. Selected nucleotides, such as UTP or nucleotide analogues, should be investigated as therapeutic agents for lung disease in cystic fibrosis.			KNOWLES, MR (corresponding author), UNIV N CAROLINA,DEPT MED,DIV PULM DIS,CB 7020,724 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019171, P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-000046] Funding Source: Medline; NHLBI NIH HHS [HL-34322, HL-19171] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; Bean B P, 1990, Ion Channels, V2, P169; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; BURNS RF, 1990, ANN NY ACAD SCI, V603, P211; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHINET T, 1991, FASEB J, V5, pA1763; CLARKE L, 1991, FASEB J, V5, pA1018; CLARKE LL, 1990, PEDIATR PULM S, V5, P216; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P227; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARADISO AM, 1991, AM J PHYSIOL, V261, pL63, DOI 10.1152/ajplung.1991.261.2.L63; RIORDAN JR, 1989, SCIENCE, V245, P1066; WALTNER WE, 1987, TRENDS PHARMACOL SCI, V8, P316, DOI 10.1016/0165-6147(87)90127-1; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1045, DOI 10.1152/ajpcell.1989.256.5.C1045; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; Willumsen NJ, 1989, AM J PHYSIOL, V256, pC1054, DOI 10.1152/ajpcell.1989.256.5.C1054; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P181; 1990, ANN NY ACAD SCI, V603, P1	34	475	498	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					533	538		10.1056/NEJM199108223250802	http://dx.doi.org/10.1056/NEJM199108223250802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857389	Bronze, Green Submitted			2022-12-28	WOS:A1991GB44700002
J	SCHMID, RM; PERKINS, ND; DUCKETT, CS; ANDREWS, PC; NABEL, GJ				SCHMID, RM; PERKINS, ND; DUCKETT, CS; ANDREWS, PC; NABEL, GJ			CLONING OF AN NF-KAPPA-B SUBUNIT WHICH STIMULATES HIV TRANSCRIPTION IN SYNERGY WITH P65	NATURE			English	Article							ENHANCER BINDING-PROTEIN; C-REL; V-REL; RETICULOENDOTHELIOSIS VIRUS; NUCLEOTIDE-SEQUENCE; ONCOGENE; DNA; DORSAL; EXPRESSION; GENE	THE transcription factor NF-kappa-B is a protein complex which comprises a DNA-binding subunit and an associated transactivation protein (of relative molecular masses 50,000 (50K) and 65K, respectively) 1,2. Both the 50K and 65K subunits have similarity with the rel oncogene and the Drosophila maternal effect gene dorsal 3-6. The 50K DNA-binding subunit was previously thought to be a unique protein, derived from the 105K gene product (p105). We now report the isolation of a complementary DNA that encodes an alternative DNA-binding subunit of NF-kappa-B. It is more similar to p105 NF-kappa-B than other family members and defines a new subset of rel-related genes. It is synthesized as a approximately 100K protein (p100) that is expressed in different cell types, contains cell cycle motifs and, like p105, must be processed to generate a 50K form. A 49K product (p49) can be generated independently from an alternatively spliced transcript; it has specific kappa-B DNA-binding activity and can form heterodimers with other rel proteins. In contrast to the approximately 50K protein derived from p105, p49 acts in synergy with p65 to stimulate the human immunodeficiency virus (HIV) enhancer in transiently transfected Jurkat cells. p49/p100 NF-kappa-B could therefore be important in the regulation of HIV and other kappa-B-containing genes.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Andrews, Philip/0000-0001-6843-5420; Duckett, Colin/0000-0001-9413-2263				BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1989, ONCOGENE, V4, P935; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRANZA BR, 1987, NATURE, V330, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; QUEMADA H, 1990, J GEN VIROL, V71, P1451, DOI 10.1099/0022-1317-71-7-1451; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZABEL U, 1991, J BIOL CHEM, V266, P252	26	389	393	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					733	736		10.1038/352733a0	http://dx.doi.org/10.1038/352733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876189	Green Submitted			2022-12-28	WOS:A1991GC06400065
J	SMITH, R				SMITH, R			THE HEALTH OF THE NATION - RESPONSES - 1ST STEPS TOWARDS A STRATEGY FOR HEALTH	BRITISH MEDICAL JOURNAL			English	Article																		[Anonymous], 1979, HLTH PEOPLE SURGEON; ASHTON J, 1991, BRIT MED J, V302, P1413, DOI 10.1136/bmj.302.6790.1413; CATFORD JC, 1991, BMJ, V302, P80; CLEMENTS D, 1991, BRIT MED J, V303, P184, DOI 10.1136/bmj.303.6795.184-a; HARVEYJONES J, 1988, MAKING HAPPEN; HOWARTH PJN, 1991, BMJ, V303, P184; MCGINNIS JM, 1990, ANNU REV PUBL HEALTH, V11, P231; PLAMPING D, 1991, BRIT MED J, V303, P203, DOI 10.1136/bmj.303.6796.203; WALDEGRAVE SRW, 1991, BMJ, V302, P636; 1991, HLTH ED SCOTLAND NAT; 1978, PRIMARY HLTH CARE; 1991, BMJ, V303, P299; 1985, TARGETS HLTH ALL; 1991, UK LEVELS HLTH; 1991, HLTH NATION; 1990, HLTH PROMOTION NO IR; 1990, HLTH WALES HLTH PROM	17	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					297	299		10.1136/bmj.303.6797.297	http://dx.doi.org/10.1136/bmj.303.6797.297			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1888935	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100027
J	CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB				CHUNG, SK; REINHART, PH; MARTIN, BL; BRAUTIGAN, D; LEVITAN, IB			PROTEIN-KINASE ACTIVITY CLOSELY ASSOCIATED WITH A RECONSTITUTED CALCIUM-ACTIVATED POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; PHOSPHORYLATION; MODULATION; NEURONS; CONDUCTANCE; CELLS; BRAIN; FAMILY	Modulation of the activity of potassium and other ion channels is an essential feature of nervous system function. The open probability of a large conductance Ca2+-activated K+ channel from rat brain, incorporated into planar lipid bilayers, is increased by the addition of adenosine triphosphate (ATP) to the cytoplasmic side of the channel. This modulation takes place without the addition of protein kinase, requires Mg2+, and is mimicked by an ATP analog that serves as a substrate for protein kinases but not by a nonhydrolyzable ATP analog. Addition of protein phosphatase 1 reverses the modulation by MgATP. Thus, there may be an endogenous protein kinase activity firmly associated with this K+ channel. Some ion channels may exist in a complex that contains regulatory protein kinases and phosphatases.	BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; BROWN UNIV, DIV BIOL & MED, BIOCHEM SECT, PROVIDENCE, RI 02912 USA	Brandeis University; Brandeis University; Brown University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017910] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31374] Funding Source: Medline; NINDS NIH HHS [NS17910] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BARABAN JM, 1985, P NATL ACAD SCI USA, V82, P2538, DOI 10.1073/pnas.82.8.2538; BERG HC, 1977, BIOPHYS J, V20, P193, DOI 10.1016/S0006-3495(77)85544-6; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; DEPEYER JE, 1982, P NATL ACAD SCI-BIOL, V79, P4207; DOERNER D, 1988, J NEUROSCI, V8, P4069; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; GRAY MA, 1990, J MEMBRANE BIOL, V115, P203, DOI 10.1007/BF01868636; HAUNG K, 1988, J BIOL CHEM, V263, P14839; HSIAO KJ, 1978, J BIOL CHEM, V253, P6901; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KACZMAREK LK, 1988, ADV SEC MESS PHOSPH, V22, P113; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; MEISLER MH, 1969, J BIOL CHEM, V244, P4961; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; REINHART PH, 1991, J NEUROSCI, V11, P1627; REINHART PH, 1989, NEURON, V2, P1031, DOI 10.1016/0896-6273(89)90227-4; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207; WHITTAKER VP, 1964, BIOCHEM J, V90, P293, DOI 10.1042/bj0900293	28	181	186	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					560	562		10.1126/science.1857986	http://dx.doi.org/10.1126/science.1857986			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857986				2022-12-28	WOS:A1991FZ34700038
J	PINKER, S				PINKER, S			RULES OF LANGUAGE	SCIENCE			English	Article							IMPAIRMENT; WORDS	Language and cognition have been explained as the products of a homogeneous associative memory structure or alternatively, of a set of genetically determined computational modules in which rules manipulate symbolic representations. Intensive study of one phenomenon of English grammar and how it is processed and acquired suggests that both theories are partly right. Regular verbs (walk-walked) are computed by a suffixation rule in a neural system for grammatical processing; irregular verbs (run-ran) are retrieved from an associative memory.			PINKER, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.		Pinker, Steven/GPX-7942-2022		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018381] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson S. R., 1988, LINGUISTICS CAMBRIDG, VI, P146; ARONOFF M, 1983, ANNU REV ANTHROPOL, V12, P355, DOI 10.1146/annurev.an.12.100183.002035; BELLUGI U, 1990, AM J MED GENET, P115; BERKO J, 1958, WORD, V14, P150, DOI 10.1080/00437956.1958.11659661; BROWN R, 1973, 1ST LANGUAGE; BYBEE JL, 1983, LANGUAGE, V59, P251, DOI 10.2307/413574; BYBEE JL, 1982, LANGUAGE, V58, P265, DOI 10.2307/414099; Bybee JoanL., 1985, MORPHOLOGY; Chomsky N, 1980, RULES REPRESENTATION; CHOMSKY N, 1990, SOUND PATTERN ENGLIS; CURTISS S, 1988, EXCEPTIONAL BRAIN; EGEDI D, UNPUB; Fodor J. A, 1983, MODULARITY MIND; FRANCIS WN, 1982, FREQUENCY ANAL ENGLI; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; GOPNIK M, IN PRESS COGNITION; GOPNIK M, 1990, LANG ACQUIS, V1, P139; GORDON P, 1985, COGNITION, V21, P73, DOI 10.1016/0010-0277(85)90046-0; HEBB DO, 1949, ORG BEHAVIOR; HICKOK G, UNPUB; Hume D., 1955, INQUIRY HUMAN UNDERS; Jespersen Otto., 1961, MODERN ENGLISH GRAMM; KEMPLEY ST, 1982, BRIT J PSYCHOL, V73, P441, DOI 10.1111/j.2044-8295.1982.tb01826.x; KIM J, IN PRESS PAP REP CHI; KIM JJ, 1991, COGNITIVE SCI, V15, P173, DOI 10.1207/s15516709cog1502_1; Kiparsky Paul, 1982, STRUCTURE PHONOLOGIC, P93; KLIMA E, UNPUB; KUCZAJ SA, 1977, J VERB LEARN VERB BE, V16, P589, DOI 10.1016/S0022-5371(77)80021-2; LACHTER J, 1988, COGNITION, V28, P195, DOI 10.1016/0010-0277(88)90033-9; Leibniz G.W., 1989, PHILOS ESSAYS; LENNEBERG EH, 1967, BIOL F LANGUAGE; MARCUS G, 1990, MIT41 CTR COG SCI OC; MARIN OSM, 1976, ANN NY ACAD SCI, V280, P868, DOI 10.1111/j.1749-6632.1976.tb25550.x; MENCKEN HL, 1936, AM LANGUAGE; NEWELL A, 1961, SCIENCE, V134, P2011, DOI 10.1126/science.134.3495.2011; PINKER S, 1988, COGNITION, V28, P73, DOI 10.1016/0010-0277(88)90032-7; PRASADA S, 1990, 31ST ANN M PSYCH SOC; PRASADA S, UNPUB; Rumelhart D.E., 1986, PARALLEL DISTRIBUTED, DOI DOI 10.7551/MITPRESS/5237.001.0001; Rumelhart DE., 1987, PARALLEL DISTRIBUTED, P318, DOI [DOI 10.7551/MITPRESS/5236.001.0001, 10.1016/b978-1-4832-1446-7.50035-2]; STANNERS RF, 1979, J VERB LEARN VERB BE, V18, P399, DOI 10.1016/S0022-5371(79)90219-6; TALLAL P, 1989, J SPEECH HEAR DISORD, V54, P167, DOI 10.1044/jshd.5402.167; TOMBLIN J, UNPUB; TOMBLIN JB, 1989, J SPEECH HEAR DISORD, V54, P287, DOI 10.1044/jshd.5402.287; ULLMAN M, 1991, MAR SPRING S AAAI ST	45	564	572	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					530	535		10.1126/science.1857983	http://dx.doi.org/10.1126/science.1857983			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	FZ347	1857983				2022-12-28	WOS:A1991FZ34700029
J	KEMP, DS; BOYD, JG; MUENDEL, CC				KEMP, DS; BOYD, JG; MUENDEL, CC			THE HELICAL S-CONSTANT FOR ALANINE IN WATER DERIVED FROM TEMPLATE-NUCLEATED HELICES	NATURE			English	Article							IMMUNOGENIC PEPTIDE-FRAGMENTS; ROTATING-FRAME; ALPHA-HELIX; PROTEINS; H-1-NMR; SPECTROSCOPY	FORMATION of alpha-helices from disordered polypeptides depends on the degree to which amino acids favour the helical state. The folding of helical oligopeptides can be modelled by two parameters: sigma which reflects helix initiation and s which reflects propagation of a pre-existing helix and measures helical bias 1,2. Scheraga has reported s values for oligopeptides of about 1.1, implying a weak helical bias for amino-acid residues 3. By contrast, certain helical peptides studied by Baldwin seem to require much larger s values for alanine 4. Resolution of this inconsistency requires experiments that disentangle the ease of propagation from that of initiation. In this study varying lengths of polyalanine are linked to a 'template' that initiates helical structure and permits study solely of propagation. We report here that the s value for alanine in water is close to 1, supporting the earlier results of Scheraga but not the more recent results of Baldwin.			KEMP, DS (corresponding author), MIT,DEPT CHEM,ROOM 18-584,CAMBRIDGE,MA 02139, USA.							BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; ESPOSITO G, 1987, BIOCHEMISTRY-US, V26, P1043, DOI 10.1021/bi00378a010; KARLE IL, 1987, P NATL ACAD SCI USA, V84, P5087, DOI 10.1073/pnas.84.15.5087; KEMP DS, 1988, TETRAHEDRON LETT, V29, P4931, DOI 10.1016/S0040-4039(00)80644-9; KEMP DS, IN PRESS J ORG CHEM; KEMP DS, 1990, PEPT P AM PEPT S, V11, P677; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; POLARD D, 1970, THEORY HELIX COLI TR; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WUETHRICH K, 1984, J MOL BIOL, V180, P715; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390	21	132	133	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					451	454		10.1038/352451a0	http://dx.doi.org/10.1038/352451a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861726				2022-12-28	WOS:A1991FZ34600072
J	EVANS, A; MASKREY, N; NOLAN, P				EVANS, A; MASKREY, N; NOLAN, P			ADMISSION TO CHILD HEALTH SURVEILLANCE LISTS - THE VIEWS OF FHSA GENERAL MANAGERS AND GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To find out the sources of advice that were helpful to managers of family health services authorities in drawing up the criteria for admission of general practitioners to the child health surveillance lists; to determine the criteria used for admission of general practitioners to the family health services authorities' child health surveillance lists; to find out the changes general practitioners have made in child health surveillance in their practices; to determine the experiences of general practitioners relating to admission to the child health surveillance lists and to training in child health surveillance. Design - Survey by postal questionnaire. Subjects - General managers of all family health services authorities in England and Wales; all general practitioners in Yorkshire and Humberside. Results - Managers of 80 of 93 family health services authorities replied (86%). A total of 62 (78%) found local community paediatricians helpful in compiling criteria for admission to child health surveillance lists, and 46 (57%) found national guidelines helpful. Fifty seven (71%) accepted general practitioners who had completed an approved course, and 45 (56%) accepted those with three or more years' experience of child health surveillance. Of the 1966 questionnaires sent to general practitioners, 1233 were satisfactorily completed (63%). Of the 919 respondents who had applied to be put on child health surveillance lists, 673 (73%) had been permanently accepted; of these, 441 (65%) had done an approved course and 375 (56%) had had three or more years' experience of child health surveillance. Of the 145 (16%) not accepted, 57 (39%) had done an approved course and 71 (49%) had three or more years' experience. Respondents reported variable quality and availability of courses in child health. Conclusions - Acceptance of general practitioners on to child surveillance lists has not been carried out consistently despite national guidelines setting out criteria for acceptance.	MELTHAM RD SURG,HUDDERSFIELD HD1 3UP,ENGLAND		EVANS, A (corresponding author), CLAREMONT SURG,SCARBOROUGH YO11 1XE,ENGLAND.							COLVER AF, 1990, BRIT MED J, V300, P1246, DOI 10.1136/bmj.300.6734.1246; DEARLOVE J, 1990, BRIT MED J, V300, P1177, DOI 10.1136/bmj.300.6733.1177; HALL DMB, 1989, HLTH ALL CHILDREN PR; 1982, RCGP22 ROYAL COLL GE; 1978, J R COLL GEN PRACT, V28, P553; 1989, GUIDELINES TRAINING	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					229	232		10.1136/bmj.303.6796.229	http://dx.doi.org/10.1136/bmj.303.6796.229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884061	Bronze, Green Published			2022-12-28	WOS:A1991FZ56300026
J	OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R				OGRADY, JG; WENDON, J; TAN, KC; POTTER, D; COTTAM, S; COHEN, AT; GIMSON, AES; WILLIAMS, R			LIVER-TRANSPLANTATION AFTER PARACETAMOL OVERDOSE	BRITISH MEDICAL JOURNAL			English	Article							FULMINANT HEPATIC-FAILURE	Objective - To evaluate the role of liver transplantation after paracetamol overdose. Design - Prospective study of consecutive candidates for transplantation and performance of transplantation over 18 months. Setting - Liver unit, King's College Hospital, London. Main outcome measures - Fulfilment of indicators of poor prognosis, selection for transplantation, transplantation, survival. Results - 30 of 37 patients considered to have a reasonable prognosis with intensive medical care survived. Of 14 of 29 patients considered to have a very poor prognosis and registered for urgent liver transplantation, six received liver transplants, four of whom survived, while seven died and one survived without a transplant. Three of 15 patients with poor prognostic indicators but not selected for transplantation survived. Conclusion - Liver transplantation will have a definite but limited role in the management of fulminant hepatic failure induced by paracetamol.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 8RX,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				opoku, anita/0000-0001-7243-8157				BISMUTH H, 1989, TRANSPLANT REV, V3, P47; BREMS JJ, 1987, AM J SURG, V154, P137; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; IWATSUKI S, 1989, TRANSPLANT P, V21, P2431; OGRADY JG, 1989, BAILLIERE CLIN GASTR, V3, P75, DOI 10.1016/0950-3528(89)90047-X; OGRADY JG, 1988, Q J MED, V69, P817; OGRADY JG, 1988, GASTROENTEROLOGY, V94, P1186, DOI 10.1016/0016-5085(88)90011-X; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; SCHAFER DF, 1989, SEMIN LIVER DIS, V9, P189, DOI 10.1055/s-2008-1040512; VICKERS C, 1988, J HEPATOL, V7, P143, DOI 10.1016/S0168-8278(88)80475-6; 1987, LANCET, V2, P1248	13	75	76	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					221	223		10.1136/bmj.303.6796.221	http://dx.doi.org/10.1136/bmj.303.6796.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884059	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300023
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - VITAL-STATISTICS OF BIRTH	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					178	181		10.1136/bmj.303.6795.178	http://dx.doi.org/10.1136/bmj.303.6795.178			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878648	Green Published, Bronze			2022-12-28	WOS:A1991FX57800031
J	JAHN, M; ROGERS, MJ; SOLL, D				JAHN, M; ROGERS, MJ; SOLL, D			ANTICODON AND ACCEPTOR STEM NUCLEOTIDES IN TRANSFER RNAGLN ARE MAJOR RECOGNITION ELEMENTS FOR ESCHERICHIA-COLI GLUTAMINYL-TRANSFER RNA-SYNTHETASE	NATURE			English	Article							IDENTITY; AMINOACYLATION; METHIONINE; INVITRO; SPECIFICITY; PARAMETERS; INVIVO; GLN	THE correct attachment of amino acids to their corresponding (cognate) transfer RNA catalysed by aminoacyl-tRNA synthetases is a key factor in ensuring the fidelity of protein biosynthesis. Previous studies have demonstrated that the interaction of Escherichia coli tRNA(Gln) with glutaminyl-tRNA synthetase (GlnRS) provides an excellent system 1 to study this highly specific recognition process, also referred to as 'tRNA identity' 2. Accurate acylation of tRNA depends mainly on two principles: a set of nucleotides in the tRNA molecule (identity elements) responsible for proper discrimination by aminoacyl-tRNA synthetases 1-3 and competition between different synthetases for tRNAs 4-6. Elements of glutamine identity are located in the anticodon 2,7-9 and in the acceptor stem region, including the discriminator base 5,10-13. We report here the production of more than 20 tRNA2Gln mutants at positions likely to be involved in tRNA discrimination by the enzyme. Unmodified tRNA, containing the wild-type anticodon and U or G at its 5'-terminus, can be aminocylated by GlnRS with similar kinetic parameters to native tRNA2Gln. By in vitro aminoacylation the mutant tRNAs showed decreases of up to 3 x 10(5)-fold in the specificity constant (k(cat)/K(M)) 14 with the major contribution of k(cat). Despite these large changes, some of these mutant tRNAs are efficient amber suppressors in vivo. Our results show that strong elements for glutamine identity reside in the anticodon region and in positions 2 and 3 of the acceptor stem, and that the contribution of different identity elements to the overall discrimination varies significantly. We discuss our data in the light of the crystal structure of the GlnRS:tRNA(Gln) complex 15,16.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University								CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; Fersht A., 1985, ENZYME STRUCTURE MEC; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOBEN PJ, 1984, THESIS YALE U; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; INOKUCHI H, 1984, P NATL ACAD SCI-BIOL, V81, P5076, DOI 10.1073/pnas.81.16.5076; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; REDFIELD AG, 1986, STRUCTURE DYNAMICS R, P99; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SENO T, 1974, BIOCHIM BIOPHYS ACTA, V349, P328, DOI 10.1016/0005-2787(74)90120-8; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; SOLL D, 1990, EXPERIENTIA, V46, P1089; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1988, CELL, V55, P739, DOI 10.1016/0092-8674(88)90127-4	35	189	191	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					258	260		10.1038/352258a0	http://dx.doi.org/10.1038/352258a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857423				2022-12-28	WOS:A1991FX18500072
J	SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG				SHIPLEY, MJ; POCOCK, SJ; MARMOT, MG			DOES PLASMA-CHOLESTEROL CONCENTRATION PREDICT MORTALITY FROM CORONARY HEART-DISEASE IN ELDERLY PEOPLE - 18 YEAR FOLLOW-UP IN WHITEHALL STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To explore the extent to which the relation between plasma cholesterol concentration and risk of death from coronary heart disease in men persists into old age. Design - 18 year follow up of male Whitehall civil servants. Plasma cholesterol concentrations and other risk factors were determined at first examination in 1967-9 when they were aged 40-69. Death of men up to 31 january 1987 was recorded. Subjects-18296 male civil servants, 4155 of whom died during follow up. Main outcome measures - Cause and age of death. Cholesterol concentration in 1967-9 and number of years elapsed between testing and death. Results - 1676 men died of coronary heart disease. The mean cholesterol concentration in these men was 0.32 mmol/l higher than that in all other men (95% confidence interval 0.26 to 0.37 mmol/l). This difference in cholesterol concentrations fell 0.15 mmol/l with every 10 years' increase in age at screening. The risk of raised cholesterol concentration fell with age at death. Compared with other men cholesterol concentration in those who died of coronary heart disease was 0.44 mmol/l higher in those who died aged < 60 and 0.26 mmol/l higher in those aged 60-79 (p = 0.03). For a given age at death the longer the gap between cholesterol measurement and death the more predictive the cholesterol concentration, both for coronary heart disease and all cause mortality (trend test p = 0.06 and 0.03 respectively). Conclusion-Reducing plasma cholesterol concentrations in middle age may influence the risk of death from coronary heart disease in old age.	UCL, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BLOCK WD, 1966, CLIN CHEM, V10, P681; COX DR, 1972, J R STAT SOC B, V34, P187; MARMOT MG, 1986, LANCET, V2, P274; REID DD, 1974, LANCET, V1, P469; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSE G, 1980, LANCET, V1, P523; 1982, JAMA-J AM MED ASSOC, V248, P2853	9	86	86	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					89	92		10.1136/bmj.303.6794.89	http://dx.doi.org/10.1136/bmj.303.6794.89			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860009	Bronze, Green Published			2022-12-28	WOS:A1991FW58600020
J	BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S				BERRY, GT; HEIDENREICH, R; KAPLAN, P; LEVINE, F; MAZUR, A; PALMIERI, MJ; YUDKOFF, M; SEGAL, S			BRANCHED-CHAIN AMINO-ACID FREE PARENTERAL-NUTRITION IN THE TREATMENT OF ACUTE METABOLIC DECOMPENSATION IN PATIENTS WITH MAPLE SYRUP URINE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV PENN,SCH MED,DEPT PEDIAT & MED,PHILADELPHIA,PA 19104	University of Pennsylvania	BERRY, GT (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV BIOCHEM DEV & MOLEC DIS,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.		Levine, Fred/L-2693-2013	Levine, Fred/0000-0002-7336-2526; Berry, Gerard/0000-0001-5299-3313	NCRR NIH HHS [RR240] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Danner DJ, 1989, METABOLIC BASIS INHE, P671; ELSAS LJ, 1988, MODERN NUTRITION HLT, P1337; RUTLEDGE SL, 1990, J PEDIATR-US, V116, P125, DOI 10.1016/S0022-3476(05)81661-0; TOWNSEND I, 1982, AM J CLIN NUTR, V36, P359, DOI 10.1093/ajcn/36.2.359; WENDEL U, 1982, J INHERIT METAB DIS, V5, P25, DOI 10.1007/BF01799811; 1985, WHO TECH REP SER, V724, P71; 1989, RECOMMENDED DIETARY	7	25	27	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					175	179		10.1056/NEJM199101173240307	http://dx.doi.org/10.1056/NEJM199101173240307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER471	1898534				2022-12-28	WOS:A1991ER47100007
J	GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE				GOLDBERG, RJ; GORE, JM; ALPERT, JS; OSGANIAN, V; DEGROOT, J; BADE, J; CHEN, Z; FRID, D; DALEN, JE			CARDIOGENIC-SHOCK AFTER ACUTE MYOCARDIAL-INFARCTION - INCIDENCE AND MORTALITY FROM A COMMUNITY-WIDE PERSPECTIVE, 1975 TO 1988	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AORTIC BALLOON COUNTERPULSATION; TISSUE PLASMINOGEN-ACTIVATOR; LUMINAL CORONARY ANGIOPLASTY; WORCESTER-HEART-ATTACK; CARE UNIT; TRIAL; STREPTOKINASE; PROGNOSIS; EMERGENCY; THERAPY	Background. Cardiogenic shock resulting from acute myocardial infarction is a serious complication with a high mortality rate, but little is known about whether its incidence or outcome has changed over time. As part of an ongoing population-based study of acute myocardial infarction, we examined trends over time in the incidence and mortality rate of cardiogenic shock after acute myocardial infarction. Methods. We studied 4762 patients with acute myocardial infarction who were admitted to 16 hospitals in the Worcester, Massachusetts, metropolitan area between 1975 and 1988. We determined the incidence of and short-term and long-term mortality due to cardiogenic shock in each of six years during this study period. Results. The incidence of cardiogenic shock complicating acute myocardial infarction remained relatively constant, averaging 7.5 percent. Multivariate regression analysis that controlled for variables affecting incidence revealed significant though inconsistent temporal trends in the incidence of cardiogenic shock. As compared with the risk in 1975, the adjusted relative risk (with 95 percent confidence interval) was 0.83 (0.54 to 1.28) in 1978, 0.96 (0.63 to 1.48) in 1981, 0.68 (0.42 to 1.12) in 1984, 1.16 (0.70 to 1.92) in 1986, and 1.65 (0.99 to 2.77) in 1988. The overall in-hospital mortality rate among patients with cardiogenic shock was significantly higher than that among patients without this complication (77.7 percent vs. 13.5 percent, P < 0.001). The in-hospital mortality among the patients with shock did not improve between 1975 (73.7 percent) and 1988 (81.7 percent). Long-term survival during the 14-year follow-up period was significantly worse among patients who survived cardiogenic shock during hospitalization than among patients who did not have shock (P < 0.001). Conclusions. The results of this observational, community-wide study suggest that neither the incidence nor the prognosis of cardiogenic shock resulting from acute myocardial infarction has improved over time. Both in-hospital and long-term survival remain poor for patients with this complication.			GOLDBERG, RJ (corresponding author), UNIV MASSACHUSETTS, SCH MED, DEPT MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035434] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-35434] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFIFI AA, 1974, AM J CARDIOL, V33, P826, DOI 10.1016/0002-9149(74)90628-6; ALONSO DR, 1973, CIRCULATION, V48, P588, DOI 10.1161/01.CIR.48.3.588; ALTHOUSE R, 1990, AM J CARDIOL, V66, P1298, DOI 10.1016/0002-9149(90)91157-2; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, LANCET, V2, P57; BINDER MJ, 1955, AM J MED, V18, P622, DOI 10.1016/0002-9343(55)90463-0; BOLOOKI H, 1990, JAMA-J AM MED ASSOC, V263, P1237, DOI 10.1001/jama.263.9.1237; BRAUNWALD E, 1985, CIRCULATION, V71, P1087, DOI 10.1161/01.CIR.71.6.1087; CAULFIELD JB, 1972, ARCH PATHOL, V93, P532; CHATTERJEE K, 1976, CIRCULATION, V53, P797, DOI 10.1161/01.CIR.53.5.797; CHEITLIN MD, 1988, JAMA-J AM MED ASSOC, V260, P2894, DOI 10.1001/jama.260.19.2894; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COBB LA, 1975, CIRCULATION, V52, P223; DALEN JE, 1984, CHEST, V86, P257, DOI 10.1378/chest.86.2.257; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; GHEORGHIADE M, 1988, AM HEART J, V116, P1212; GOLDBERG R, 1979, JOHNS HOPKINS MED J, V144, P73; GOLDBERG RJ, 1987, AM HEART J, V113, P273, DOI 10.1016/0002-8703(87)90265-1; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDBERG RJ, 1986, JAMA-J AM MED ASSOC, V255, P2774, DOI 10.1001/jama.255.20.2774; GOLDBERG RJ, 1987, CLIN CARDIOL, V10, P3, DOI 10.1002/clc.4960100103; GORE JM, 1987, ARCH INTERN MED, V147, P1729, DOI 10.1001/archinte.147.10.1729; GORE JM, 1989, JAMA-J AM MED ASSOC, V261, P2829; GUNNAR RM, 1974, SHOCK MYOCARDIAL INF, P113; GUTOVITZ AL, 1978, AM J CARDIOL, V41, P469, DOI 10.1016/0002-9149(78)90001-2; GUYTON RA, 1987, CIRCULATION, V76, P22; HARTZLER GO, 1988, AM J CARDIOL, V61, pG33, DOI 10.1016/S0002-9149(88)80030-4; JUGDUTT BI, 1988, CIRCULATION, V78, P906, DOI 10.1161/01.CIR.78.4.906; KENNEDY JW, 1985, AM J CARDIOL, V55, P871, DOI 10.1016/0002-9149(85)90709-X; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KOBAYASHI M, 1984, JPN CIRC J, V48, P650, DOI 10.1253/jcj.48.650; KUHN LA, 1967, AM HEART J, V74, P578, DOI 10.1016/0002-8703(67)90019-1; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LEINBACH RC, 1972, CIRCULATION, V45, P845, DOI 10.1161/01.CIR.45.4.845; MALACH M, 1960, AM J CARDIOL, V5, P487, DOI 10.1016/0002-9149(60)90106-5; MAROKO PR, 1972, CIRCULATION, V45, P1150, DOI 10.1161/01.CIR.45.6.1150; MEINERTZ T, 1988, AM J CARDIOL, V62, P347, DOI 10.1016/0002-9149(88)90956-3; MERRELL M, 1955, J Chronic Dis, V1, P12, DOI 10.1016/0021-9681(55)90018-7; MUELLER H, 1971, J CLIN INVEST, V50, P1885, DOI 10.1172/JCI106681; MUELLER HS, 1990, CLIN CARDIOL, V13, P239, DOI 10.1002/clc.4960130403; MUNDTH ED, 1970, NEW ENGL J MED, V283, P1382, DOI 10.1056/NEJM197012172832506; OROURKE MF, 1981, AM J CARDIOL, V47, P815, DOI 10.1016/0002-9149(81)90179-X; PAGE DL, 1971, NEW ENGL J MED, V285, P133, DOI 10.1056/NEJM197107152850301; REICHENBACH DD, 1975, CIRCULATION, V52, P60; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SCHEIDT S, 1970, AM J CARDIOL, V26, P556, DOI 10.1016/0002-9149(70)90407-8; SCHEIDT S, 1973, NEW ENGL J MED, V288, P979, DOI 10.1056/NEJM197305102881901; SIMOONS ML, 1988, LANCET, V1, P199; TAKANO T, 1984, JPN CIRC J, V48, P678, DOI 10.1253/jcj.48.678; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WILLERSON JT, 1975, AM J MED, V58, P183, DOI 10.1016/0002-9343(75)90568-9; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088	53	334	352	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1117	1122		10.1056/NEJM199110173251601	http://dx.doi.org/10.1056/NEJM199110173251601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891019	Bronze			2022-12-28	WOS:A1991GK53800001
J	NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR				NOVICK, AC; GEPHARDT, G; GUZ, B; STEINMULLER, D; TUBBS, RR			LONG-TERM FOLLOW-UP AFTER PARTIAL REMOVAL OF A SOLITARY KIDNEY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE RENAL-FAILURE; CELL-CARCINOMA; UNILATERAL NEPHRECTOMY; CONSERVATIVE SURGERY; GLOMERULAR INJURY; VERAPAMIL; PROTEIN; DONORS; MASS; RATS	Background. The removal of more than one kidney in animals leads to proteinuria and progressive renal failure due to focal segmental glomerulosclerosis. This injury may be the result of chronic glomerular hyperfiltration. The purpose of this study was to determine the effect of a reduction in renal mass of more than 50 percent on residual renal function and morphology in humans. Methods. We evaluated long-term renal function in 14 patients with a solitary kidney who had undergone partial nephrectomy for renal-cell or transitional-cell carcinoma. In 12, the first kidney had been removed 2 months to 21 years previously for the same type of cancer; in 2, the other kidney was congenitally atrophic. Before surgery, no patient had clinical or histopathological evidence of primary renal disease. All 14 patients underwent partial nephrectomy to remove a localized tumor, with 25 to 75 percent of the solitary kidney being excised. They were evaluated 5 to 17 years after surgery (mean, 7.7). Results. Twelve patients had stable postoperative renal function, and end-stage renal failure developed in two. There were no changes in blood pressure in any patient during follow-up. Nine patients had proteinuria, which was mild (0.15 to 0.8 g of urinary protein per day) in four and moderate to severe (0.9 to 6.7 g per day) in five. The extent of proteinuria was inversely correlated with the amount of remaining renal tissue (P = 0.0065) and directly correlated with the duration of follow-up (P = 0.0005). Four patients with moderate-to-severe proteinuria had renal biopsies, which revealed focal segmental glomerulosclerosis in three patients and global glomerulosclerosis in one. Conclusions. Long-term renal function remains stable in most patients with a reduction in renal mass of more than 50 percent. These patients are, however, at increased risk for proteinuria, glomerulopathy, and progressive renal failure.	CLEVELAND CLIN EDUC FDN,DEPT NEPHROL,CLEVELAND,OH 44106; CLEVELAND CLIN EDUC FDN,DEPT PATHOL & HYPERTENS,CLEVELAND,OH 44106	Cleveland Clinic Foundation; Cleveland Clinic Foundation	NOVICK, AC (corresponding author), CLEVELAND CLIN FDN,DEPT UROL,1 CLIN CTR DR,CLEVELAND,OH 44195, USA.							ANDERSON CF, 1985, MAYO CLIN PROC, V60, P367, DOI 10.1016/S0025-6196(12)60845-3; BOVEE KC, 1979, INVEST UROL, V16, P378; BRAS G, 1969, J INFECT DIS, V120, P131, DOI 10.1093/infdis/120.1.131; BRENNER BM, 1985, AM J PHYSIOL, V249, pF324, DOI 10.1152/ajprenal.1985.249.3.F324; BRUNNER FP, 1989, KIDNEY INT, V36, P969, DOI 10.1038/ki.1989.289; FOSTER MH, 1991, AM J KIDNEY DIS, V17, P261, DOI 10.1016/S0272-6386(12)80471-9; GEPHARDT GN, 1986, ARCH PATHOL LAB MED, V110, P902; GOLDSTEIN AE, 1988, TRANSPLANTATION, V45, P59; HAKIM RM, 1984, KIDNEY INT, V25, P930, DOI 10.1038/ki.1984.112; HARRIS DCH, 1987, KIDNEY INT, V31, P41, DOI 10.1038/ki.1987.6; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1986, KIDNEY INT, V30, P509, DOI 10.1038/ki.1986.215; ICHIKAWA I, 1988, KIDNEY INT, V34, P638, DOI 10.1038/ki.1988.228; KAPPEL B, 1980, VIRCHOWS ARCH A, V387, P271, DOI 10.1007/BF00454830; KASISKE BL, 1988, CIRC RES, V62, P367, DOI 10.1161/01.RES.62.2.367; Kretschmer HL, 1943, J AMER MED ASSOC, V121, P473, DOI 10.1001/jama.1943.02840070001001; LHOTTA K, 1991, AM J KIDNEY DIS, V17, P266, DOI 10.1016/S0272-6386(12)80472-0; MEYER TW, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90077-4; NOVICK AC, 1987, UROL CLIN N AM, V14, P419; NOVICK AC, 1989, J UROLOGY, V141, P835, DOI 10.1016/S0022-5347(17)41026-3; ROBITAILLE P, 1985, LANCET, V1, P1297; SCHIMAMURA T, 1975, AM J PATHOL, V79, P95; SOLOMON LR, 1985, BRIT MED J, V291, P1610, DOI 10.1136/bmj.291.6509.1610; STAHL RAK, 1988, KLIN WOCHENSCHR, V66, P508, DOI 10.1007/BF01876174; VINCENTI F, 1983, TRANSPLANTATION, V36, P626, DOI 10.1097/00007890-198336060-00006; ZIEGELBAUM M, 1987, J UROLOGY, V138, P1146, DOI 10.1016/S0022-5347(17)43529-4	26	250	257	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1058	1062		10.1056/NEJM199110103251502	http://dx.doi.org/10.1056/NEJM199110103251502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891007	Bronze			2022-12-28	WOS:A1991GJ10800002
J	BERK, SL; OSLER, W				BERK, SL; OSLER, W			INTERNATIONAL MEDICAL GRADUATES IN THE UNITED-STATES - AN INTERVIEW WITH OSLER,WILLIAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL SKILLS; FOREIGN; PROGRAM											CONN HL, 1986, J MED EDUC, V61, P863; CUSHING H, 1925, LIFE W OSLER, V1, P222; FEINSTEIN RJ, 1985, SOUTHERN MED J, V78, P340, DOI 10.1097/00007611-198503000-00025; GRAETTINGER JS, 1988, ANN INTERN MED, V108, P101, DOI 10.7326/0003-4819-108-1-101; OSLER W, 1932, COUNSELS IDEALS; RHEE SO, 1986, MED CARE, V3, P24; ROTHMAN AI, 1990, ACAD MED, V65, P391, DOI 10.1097/00001888-199006000-00008; VAL E, 1983, AM J PSYCHIAT, V140, P184; 1991, AM MED NEWS     0513, V34, P2	9	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1760	1761						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GG551	1890708				2022-12-28	WOS:A1991GG55100010
J	RAABE, T; BOLLUM, FJ; MANLEY, JL				RAABE, T; BOLLUM, FJ; MANLEY, JL			PRIMARY STRUCTURE AND EXPRESSION OF BOVINE POLY(A) POLYMERASE	NATURE			English	Article							MESSENGER-RNA PRECURSORS; SULFATE-POLYACRYLAMIDE GELS; 3' UNTRANSLATED REGION; SODIUM DODECYL-SULFATE; HELA-CELLS; BINDING PROTEINS; POLYADENYLATION; SEQUENCE; CLEAVAGE; IDENTIFICATION	Poly(A) polymerase has a critical role in the synthesis of messenger RNA in eukaryotic cells. The isolation and characterization of complementary DNAs encoding bovine poly(A) polymerase is described here. The predicted sequences of the MRNA and protein reveal features that provide insights into how the enzyme functions and how it might be regulated. Poly(A) polymerase expressed from a cloned cDNA is fully functional in in vitro assays, and mutational analyses have identified a putative regulatory domain that enhances, but is not essential for, activity.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	RAABE, T (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Manley, James/0000-0002-8341-1459				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BARDWELL VJ, 1990, MOL CELL BIOL, V10, P846, DOI 10.1128/MCB.10.2.846; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DARNELL JE, 1971, P NATL ACAD SCI USA, V68, P1321, DOI 10.1073/pnas.68.6.1321; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; EDMONDS M, 1960, J BIOL CHEM, V235, P1142; EDMONDS M, 1982, ENZYMES, V15, P217; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JACOB ST, 1983, ENZYMES NUCLEIC ACID, V2, P135; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANGAN TA, 1982, J BIOL CHEM, V257, P4835; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEE SY, 1971, P NATL ACAD SCI USA, V68, P1331, DOI 10.1073/pnas.68.6.1331; LUNDBLAD V, 1990, CELL, V60, P529; MANLEY JL, 1983, CELL, V33, P595, DOI 10.1016/0092-8674(83)90440-3; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MANLEY JL, 1985, MOL CELL BIOL, V5, P373, DOI 10.1128/MCB.5.2.373; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RYNER LC, 1989, MOL CELL BIOL, V9, P4229, DOI 10.1128/MCB.9.10.4229; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TSIAPALIS CM, 1975, J BIOL CHEM, V250, P4486; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	51	140	142	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					229	234		10.1038/353229a0	http://dx.doi.org/10.1038/353229a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896071				2022-12-28	WOS:A1991GF67400049
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACY-LINKED SYSTEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-28	WOS:A1991GE45800005
J	CAMERON, DA; PUGH, EN				CAMERON, DA; PUGH, EN			DOUBLE CONES AS A BASIS FOR A NEW TYPE OF POLARIZATION VISION IN VERTEBRATES	NATURE			English	Article							ORIENTATION; LIGHT; PATTERNS; SENSITIVITY; GOLDFISH; RETINA; FISH	MANY invertebrates 1-4 and vertebrates 5-14 are sensitive to the polarization of light. The biophysical basis of invertebrate polarization sensitivity is an intrinsic dichroism, the alignment of chromophores along the photoreceptor microvilli 3. But such dichroism to axially propagating light is not present in vertebrate photoreceptors, whose chromophores are free to rotate in the plane of the outer-segment disc membranes, and a biophysical mechanism responsible for vertebrate polarization sensitivity has not been established. We hypothesize that the roughly elliptical cross-sectioned double-cone inner segment acts as a birefringent, polarization-sensitive dielectric waveguide, and that the double cone mosaic generates a 'polarization contrast' neural image. Here we confirm three predictions derived from these hypotheses: (1) 90-degrees periodicity for polarization sensitivity; (2) polarization sensitivity maxima corresponding to the absolute orientation of the axes of the double-cone inner-segment cross-sections; and (3) action spectrum for polarization sensitivity corresponding to the absorption spectrum of the double cones. We also present evidence for a polarization-opponent neural encoding in vertebrates.	UNIV PENN,SCH ARTS & SCI,DEPT PSYCHOL,PHILADELPHIA,PA 19104	University of Pennsylvania	CAMERON, DA (corresponding author), UNIV PENN,SCH ARTS & SCI,INST NEUROL SCI,3815 WALNUT ST,PHILADELPHIA,PA 19104, USA.							AALTO E, 1985, MED BIOL ENG COMPUT, V23, P111; ABLE KP, 1982, NATURE, V299, P550, DOI 10.1038/299550a0; ADAMS MJ, 1979, ELECTRON LETT, V15, P298, DOI 10.1049/el:19790212; ADLER K, 1985, J COMP PHYSIOL A, V156, P547, DOI 10.1007/BF00613978; Ali M.A., 1976, RETINAS FISHES ATLAS; BOEHLERT GW, 1978, SCIENCE, V202, P309, DOI 10.1126/science.694534; BRINES ML, 1982, J EXP BIOL, V96, P69; CHARMAN WN, 1973, VISION RES, V13, P1, DOI 10.1016/0042-6989(73)90160-0; DEARRY A, 1987, J GEN PHYSIOL, V89, P745, DOI 10.1085/jgp.89.5.745; Easter S.S. Jr., 1975, P609; ENGSTROM KJELL, 1963, ACTA ZOOL, V44, P179; FRISCH K V, 1949, Experientia, V5, P142; HAWRYSHYN CW, 1987, J COMP PHYSIOL A, V160, P459, DOI 10.1007/BF00615079; HELBIG AJ, 1989, NATURWISSENSCHAFTEN, V76, P227, DOI 10.1007/BF00627697; HUBBARD E, 1971, EXPL EYE RES, V12, P175; KUNZ YW, 1980, EXPERIENTIA, V36, P1371, DOI 10.1007/BF01960104; LYALL AH, 1957, Q J MICROSC SCI, V98, P189; LYTHGOE JN, 1967, NATURE, V213, P893, DOI 10.1038/213893a0; MENZEL R, 1975, LIGHT ECOLOGICAL FAC, P289; Northmore D. P. M., 1975, VISION FISHES, P689; POWERS MK, 1978, VISION RES, V18, P1137, DOI 10.1016/0042-6989(78)90097-4; Snyder A.W., 1975, PHOTORECEPTOR OPTICS; TAYLOR DH, 1973, SCIENCE, V181, P285, DOI 10.1126/science.181.4096.285; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; WALDVOGEL J, 1980, AM CI, V78, P342; WATERMAN TH, 1970, NATURE, V228, P85, DOI 10.1038/228085a0; Waterman TH, 1981, HDB SENSORY PHYSL, VVII/6B, P283; WATERMAN TH, 1975, LIGHT ECOLOGICAL FAC, P305; WEHNER R, 1976, SCI AM, V235, P106, DOI 10.1038/scientificamerican0776-106; WEHNER R, 1989, TRENDS NEUROSCI, V12, P353, DOI 10.1016/0166-2236(89)90043-X	30	100	102	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					161	164		10.1038/353161a0	http://dx.doi.org/10.1038/353161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891046				2022-12-28	WOS:A1991GE73100052
J	REAL, LA				REAL, LA			ANIMAL CHOICE BEHAVIOR AND THE EVOLUTION OF COGNITIVE ARCHITECTURE	SCIENCE			English	Article							FORAGING PREFERENCES; BUMBLE BEES; RISK-AVERSE; GREAT TIT; MEMORY; UNCERTAINTY; REPRESENTATION; FORAGERS; FALLACY; MODEL	Animals process sensory information according to specific computational rules and, subsequently, form representations of their environments that form the basis for decisions and choices. The specific computational rules used by organisms will often be evolutionarily adaptive by generating higher probabilities of survival, reproduction, and resource acquisition. Experiments with enclosed colonies of bumblebees constrained to foraging on artificial flowers suggest that the bumblebee's cognitive architecture is designed to efficiently exploit floral resources from spatially structured environments given limits on memory and the neuronal processing of information. A non-linear relationship between the biomechanics of nectar extraction and rates of net energetic gain by individual bees may account for sensitivities to both the arithmetic mean and variance in reward distributions in flowers. Heuristic rules that lead to efficient resource exploitation may also lead to subjective misperception of likelihoods. Subjective probability formation may then be viewed as a problem in pattern recognition subject to specific sampling schemes and memory constraints.			REAL, LA (corresponding author), UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA.							ANDERSON JR, 1987, BEHAV BRAIN SCI, V10, P467, DOI 10.1017/S0140525X00023554; ANGERMEIER WF, 1984, EVOLUTION OPERANT LE; [Anonymous], 1982, JUDGMENT UNCERTAINTY; BALDA RP, 1989, ANIM BEHAV, V38, P486, DOI 10.1016/S0003-3472(89)80041-7; BARNARD CJ, 1985, BEHAV ECOL SOCIOBIOL, V16, P161, DOI 10.1007/BF00295150; BATTALIO RC, 1990, J RISK UNCERTAINTY, V3, P25; BATTALIO RC, 1985, AM ECON REV, V75, P597; CARACO T, 1983, BEHAV ECOL SOCIOBIOL, V12, P63, DOI 10.1007/BF00296934; CARACO T, 1981, BEHAV ECOL SOCIOBIOL, V8, P213, DOI 10.1007/BF00299833; CARACO T, 1980, ANIM BEHAV, V28, P820, DOI 10.1016/S0003-3472(80)80142-4; CARACO T, 1986, QUANT ANAL BEHAV, V6, P1; CARTAR RV, 1990, BEHAV ECOL SOCIOBIOL, V26, P121, DOI 10.1007/BF00171581; CHENEY D, 1986, SCIENCE, V234, P1361, DOI 10.1126/science.3538419; CHENEY DL, 1990, COGNITION, V37, P167, DOI 10.1016/0010-0277(90)90022-C; CUTHILL IC, 1990, ANIM BEHAV, V40, P625, DOI 10.1016/S0003-3472(05)80692-X; DAVISON MC, 1969, J EXP ANAL BEHAV, V12, P247, DOI 10.1901/jeab.1969.12-247; DUKAS R, UNPUB; DUKAS R, IN PRESS ANIM BEHAV; FEINSINGER P, 1978, ECOL MONOGR, V48, P269, DOI 10.2307/2937231; French Simon, 1986, DECISION THEORY; Gallistel C. R., 1990, ORG LEARNING; GETTY T, 1985, AM NAT, V125, P239, DOI 10.1086/284339; GETTY T, 1985, AM NAT, V125, P39, DOI 10.1086/284327; GILLIAM JF, 1982, AM NAT, V119, P875, DOI 10.1086/283962; HARDER LD, 1987, ECOLOGY, V68, P1104, DOI 10.2307/1938384; HARVEY PH, 1990, SCIENCE, V249, P140, DOI 10.1126/science.2196673; Heinrich B., 1984, Life Sciences Research Report, P135; Henderson J., 1980, MICROECONOMIC THEORY, V3rd; HERRNSTEIN RJ, 1964, J EXP ANAL BEHAV, V7, P179, DOI 10.1901/jeab.1964.7-179; KAGEL JH, 1990, AM ECON REV, V80, P912; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; KARMARKAR US, 1979, ORGAN BEHAV HUM PERF, V24, P67, DOI 10.1016/0030-5073(79)90016-3; Keeney R.L., 1976, DECISIONS MULTIPLE O; KREBS JR, 1990, ANIM BEHAV, V39, P1127, DOI 10.1016/S0003-3472(05)80785-7; KREBS JR, 1991, BEHAVIOURAL ECOLOGY; Loria DE, 1990, BEHAV ECOL, V1, P24, DOI 10.1093/beheco/1.1.24; MACHINA MJ, 1982, ECONOMETRICA, V50, P277, DOI 10.2307/1912631; MACPHAIL EM, 1987, BEHAV BRAIN SCI, V10, P645, DOI 10.1017/S0140525X00054984; Markowitz H. M., 1959, PORTFOLIO SELECTION; MENZEL R, 1979, NATURE, V281, P368, DOI 10.1038/281368a0; Menzel R, 1985, EXPT BEHAV ECOLOGY, P55; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; MOORE FR, 1986, EXPERIENTIA, V42, P1054, DOI 10.1007/BF01940730; Newell A., 1989, FDN COGNITIVE SCI, P93; PEARCE JM, 1987, INTRO ANIMAL COGNITI; PEARCE JM, 1989, ANNU REV PSYCHOL, V40, P155; PLEASANTS JM, 1979, OECOLOGIA, V41, P283, DOI 10.1007/BF00377432; POSSINGHAM HP, 1990, ECOLOGY, V71, P1622, DOI 10.2307/1938298; Pyke G.H., 1983, P7; REAL L, 1987, AM NAT, V130, P399, DOI 10.1086/284717; REAL L, 1990, ECOLOGY, V71, P1625, DOI 10.2307/1938299; REAL L, 1982, ECOLOGY, V63, P1617, DOI 10.2307/1940101; REAL L, 1986, ANNU REV ECOL SYST, V17, P371, DOI 10.1146/annurev.es.17.110186.002103; REAL LA, 1981, ECOLOGY, V62, P20, DOI 10.2307/1936663; REAL LA, UNPUB; REAL LA, 1989, BEHAVIORAL MECHANISM, P1; Richards Robert J., 2016, DEBATING DARWIN; Roitblat H. L., 1987, INTRO COMP COGNITION; ROITBLAT HL, 1982, BEHAV BRAIN SCI, V5, P353, DOI 10.1017/S0140525X00012486; ROSETT RN, 1971, REV ECON STUD, V38, P481, DOI 10.2307/2296691; RUMMELHART DE, 1989, F COGNITIVE SCI, P133; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED; SHERRY DF, 1987, PSYCHOL REV, V94, P439, DOI 10.1037/0033-295X.94.4.439; SHETTLEWORTH SJ, 1983, ADV ANAL BEHAV, P1; Sommer L, 1955, ECONOMETRICA, V23, P235, DOI 10.2307/1907897; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE; Stephens D.W., 1986, pi; TOBIN J, 1957, REV ECON STUD, V25, P65; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TURELLI M, 1982, AM NAT, V119, P879, DOI 10.1086/283963; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VanLehn K., 1989, FDN COGNITIVE SCI, P1; WADDINGTON KD, 1981, ANIM BEHAV, V29, P779, DOI 10.1016/S0003-3472(81)80011-5; WASER NM, 1986, AM NAT, V127, P593, DOI 10.1086/284507; WILSON B, 1985, Q J EXP PSYCHOL-B, V37, P313, DOI 10.1080/14640748508401173; Wuketits FM., 1990, EVOLUTIONARY EPISTEM; WUNDERLE JM, 1985, BEHAV ECOL SOCIOBIOL, V17, P371, DOI 10.1007/BF00293215; YAARI ME, 1965, Q J ECON, V79, P278, DOI 10.2307/1880632	78	255	262	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					980	986		10.1126/science.1887231	http://dx.doi.org/10.1126/science.1887231			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887231				2022-12-28	WOS:A1991GC98200034
J	HANCOCK, SL; COX, RS; MCDOUGALL, IR				HANCOCK, SL; COX, RS; MCDOUGALL, IR			THYROID-DISEASES AFTER TREATMENT OF HODGKINS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NECK IRRADIATION; GRAVES-DISEASE; RADIATION-THERAPY; MANTLE IRRADIATION; FOLLICULAR CARCINOMA; RADIOTHERAPY; DYSFUNCTION; HYPOTHYROIDISM; HYPERTHYROIDISM; OPHTHALMOPATHY	Background and Methods. Thyroid disease, especially hypothyroidism, is common in patients with Hodgkin's disease who have been treated with irradiation. We reviewed the records of 1787 patients (740 women and 1047 men) with Hodgkin's disease who were treated with radiation therapy alone (810 patients), radiation and chemotherapy (920 patients), or chemotherapy alone (57 patients) at Stanford University between 1961 and 1989. Among these patients, 1533 were alive at the last follow-up, and 254 had died of causes other than Hodgkin's disease. Four other patients were excluded from the analysis because they had undergone thyroidectomy before treatment for Hodgkin's disease. The thyroid was irradiated in 1677 patients. Follow-up averaged 9.9 years. Results. A total of 573 patients had clinical or biochemical evidence of thyroid disease. Among the 1677 patients whose thyroid was irradiated, the actuarial risk of thyroid disease 20 years after treatment was 52 percent, and it was 67 percent at 26 years. Hypothyroidism was found in 513 patients. A total of 486 patients received thyroxine therapy for elevated serum thyrotropin concentrations and either low free thyroxine (208 patients) or normal free thyroxine values (278 patients); 27 had transient elevations of the serum thyrotropin level that were not treated. Graves' hyperthyroidism developed in 30 patients (2 of whom had not undergone thyroid irradiation), and ophthalmopathy developed in 17 of these patients. Ophthalmopathy developed in four other patients with Graves' disease during a period of hypothyroidism (n = 3) or euthyroidism (n = 1). The risk of Graves disease was 7.2 to 20.4 times that for normal subjects. Silent thyroiditis with thyrotoxicosis developed in six patients. Forty-four patients were found to have single or multiple thyroid nodules, 26 of whom underwent thyroidectomy. Six of the 44 had papillary or follicular cancers. Among the patients who did not undergo operation, 12 had small functioning nodules, 4 had cysts, and 2 had multinodular goiters. The actuarial risk of thyroid cancer was 1.7 percent. The risk of thyroid cancer was 15.6 times the expected risk. Conclusions. High risks of thyroid disease persist more than 25 years after patients have received radiation therapy for Hodgkin's disease, reinforcing the need for continued clinical and biochemical evaluation. Prolonged follow-up confirms an elevated risk of thyroid cancer and Graves' disease as well as hypothyroidism in these patients.	STANFORD UNIV, MED CTR, SCH MED, DEPT DIAGNOST RADIOL & NUCL MED, STANFORD, CA 94305 USA	Stanford University	HANCOCK, SL (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.				NCI NIH HHS [CA-34233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN R, 1983, BRIT J RADIOL, V56, P768, DOI 10.1259/0007-1285-56-670-768; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BAKRI K, 1983, CANCER, V52, P465, DOI 10.1002/1097-0142(19830801)52:3<465::AID-CNCR2820520315>3.0.CO;2-6; BANTLE JP, 1985, INT J RADIAT ONCOL, V11, P1999, DOI 10.1016/0360-3016(85)90283-4; BERGLUND J, 1990, J INTERN MED, V227, P137, DOI 10.1111/j.1365-2796.1990.tb00132.x; BLITZER JB, 1985, ARCH INTERN MED, V145, P1734, DOI 10.1001/archinte.145.9.1734; CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J; CONSTINE LS, 1982, CLIN NUCL MED, V7, P69, DOI 10.1097/00003072-198202000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; DEAN JW, 1985, BRIT MED J, V290, P1555, DOI 10.1136/bmj.290.6481.1555; EINHORN J, 1967, RADIOLOGY, V88, P326, DOI 10.1148/88.2.326; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GHANDOUR C, 1985, ACTA HAEMATOL-BASEL, V74, P137, DOI 10.1159/000206189; Greene M H, 1985, Natl Cancer Inst Monogr, V68, P191; Groover TA, 1929, J AMER MED ASSOC, V92, P1730, DOI 10.1001/jama.1929.02700470006003; JACKSON R, 1979, CANCER TREAT REP, V63, P1393; JACOBSON DR, 1984, AM J MED SCI, V288, P217, DOI 10.1097/00000441-198412000-00005; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN MM, 1983, AM J MED, V74, P272, DOI 10.1016/0002-9343(83)90626-5; KINSELLA TJ, 1982, CANCER TREAT REP, V66, P991; LOEFFLER JS, 1988, INT J RADIAT ONCOL, V14, P175, DOI 10.1016/0360-3016(88)90065-X; MARCIALVEGA VA, 1990, INT J RADIAT ONCOL, V18, P613, DOI 10.1016/0360-3016(90)90068-U; MARKSON JL, 1965, BRIT MED J, V1, P1228, DOI 10.1136/bmj.1.5444.1228; MAUCH PM, 1983, CANCER-AM CANCER SOC, V51, P925, DOI 10.1002/1097-0142(19830301)51:5<925::AID-CNCR2820510527>3.0.CO;2-O; MCDOUGALL IR, 1980, CANCER-AM CANCER SOC, V45, P2056, DOI 10.1002/1097-0142(19800415)45:8<2056::AID-CNCR2820450812>3.0.CO;2-M; MCHARDYY.S, 1965, BRIT MED J, V2, P230, DOI 10.1136/bmj.2.5455.230-a; MEYER O O, 1971, Wisconsin Medical Journal, V70, P129; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; MOROFF SV, 1986, MED PEDIATR ONCOL, V14, P216, DOI 10.1002/mpo.2950140406; MORTIMER RH, 1986, AUST NZ J MED, V16, P347, DOI 10.1111/j.1445-5994.1986.tb01184.x; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; NICOL F, 1982, POSTGRAD MED J, V58, P180, DOI 10.1136/pgmj.58.677.180; PETERSEN M, 1989, J NUCL MED, V30, P255; PILEPICH MV, 1978, JAMA-J AM MED ASSOC, V240, P1381, DOI 10.1001/jama.240.13.1381; PORTER AT, 1988, J ROY SOC MED, V81, P45, DOI 10.1177/014107688808100119; SCHIMPFF SC, 1980, ANN INTERN MED, V92, P91, DOI 10.7326/0003-4819-92-1-91; SERIES JJ, 1988, CLIN CHIM ACTA, V172, P217, DOI 10.1016/0009-8981(88)90326-9; SHALET SM, 1977, CLIN RADIOL, V28, P511, DOI 10.1016/S0009-9260(77)80066-4; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SMITH RE, 1981, JAMA-J AM MED ASSOC, V245, P46, DOI 10.1001/jama.245.1.46; Storm H H, 1985, Natl Cancer Inst Monogr, V68, P389; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WASNICH RD, 1973, J CLIN ENDOCR METAB, V37, P703, DOI 10.1210/jcem-37-5-703; WESHLER Z, 1978, ACTA RADIOL ONCOL, V17, P383, DOI 10.3109/02841867809128248; YOUNG RC, 1990, J NCI MONOGR, V10, P55; 1986, NATL CANCER I MONOGR, V70, P84	48	368	376	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					599	605		10.1056/NEJM199108293250902	http://dx.doi.org/10.1056/NEJM199108293250902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861693	Bronze			2022-12-28	WOS:A1991GC32800002
J	CLEARY, ML				CLEARY, ML			ONCOGENIC CONVERSION OF TRANSCRIPTION FACTORS BY CHROMOSOMAL TRANSLOCATIONS	CELL			English	Review							ACUTE PROMYELOCYTIC LEUKEMIA; TRANS RETINOIC ACID; RECEPTOR-ALPHA GENE; DNA-BINDING MOTIF; T-CELL LEUKEMIA; PROTEIN; ENCODES; CODES; ERBA				CLEARY, ML (corresponding author), STANFORD UNIV,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.							BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1991, CELL, V66; DUBE ID, 1991, IN PRESS BLOOD; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HEIM S, 1987, CANCER CYTOGENETICS; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY M, 1991, IN PRESS P NATL ACAD; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	26	221	226	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					619	622		10.1016/0092-8674(91)90105-8	http://dx.doi.org/10.1016/0092-8674(91)90105-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878967				2022-12-28	WOS:A1991GC74500002
J	KING, MB; PATTISON, P				KING, MB; PATTISON, P			HOMOSEXUALITY AND PARENTHOOD	BRITISH MEDICAL JOURNAL			English	Article							HETEROSEXUAL MOTHERS; LESBIAN MOTHERS; CHILDREN; FATHERS; GAY		BURTON PATTISON SOLICITORS,LONDON W1X 7AA,ENGLAND		KING, MB (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171				Abel G G, 1988, Bull Am Acad Psychiatry Law, V16, P153; BANCROFT J, 1989, HUMAN SEXUALITY ITS; BELL AP, 1987, SEXUAL PREFERENCE IT; BIGNER JJ, 1989, J HOMOSEXUAL, V18, P173, DOI 10.1300/J082v18n01_09; BOZETT FW, 1989, J HOMOSEXUAL, V18, P137, DOI 10.1300/J082v18n01_07; Bradley D., 1987, INT J LAW FAMILY, V1, P155; BREWAEYS A, 1989, HUM REPROD, V4, P850, DOI 10.1093/oxfordjournals.humrep.a137000; CONTE JR, 1991, CLIN APPROACHES SEX, P11; GOLOMBOK S, 1983, J CHILD PSYCHOL PSYC, V24, P551, DOI 10.1111/j.1469-7610.1983.tb00132.x; GREEN R, 1986, ARCH SEX BEHAV, V15, P167, DOI 10.1007/BF01542224; GREEN R, 1978, PSYCHIATRY, V135, P692; HARRIS MB, 1985, J HOMOSEXUAL, V12, P101; HUGGINS SL, 1989, J HOMOSEXUAL, V18, P123, DOI 10.1300/J082v18n01_06; HUI TY, 1990, INDEPENDENT     1003, P25; Langevin R., 1983, SEXUAL STRANDS UNDER; LESTER D, 1975, UNUSUAL SEXUAL BEHAV; LEWIS KG, 1980, SOC WORK, V25, P198, DOI 10.1093/sw/25.3.198; MILLER B, 1979, FAMILY COORDINAT OCT, P544; MONEY J, 1988, GAY STRAIGHT BETWEEN; Money J., 1972, MAN WOMAN BOY GIRL; RIDDLE DI, 1978, J SOC ISSUES, V34, P38, DOI 10.1111/j.1540-4560.1978.tb02613.x; Socarides C., 1979, SEXUAL DEVIATION, P243; WAKELING A, 1979, SEXUAL DEVIATION, P1; 1980, FAMILY LAW REV, V1, P143; 1987, JAMA-J AM MED ASSOC, V258, P222; 1986, LESBIAN MOTHERS LEGA	26	4	4	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					295	297		10.1136/bmj.303.6797.295	http://dx.doi.org/10.1136/bmj.303.6797.295			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ721	1888934	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100026
J	BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E				BENITO, M; PORRAS, A; NEBREDA, AR; SANTOS, E			DIFFERENTIATION OF 3T3-L1 FIBROBLASTS TO ADIPOCYTES INDUCED BY TRANSFECTION OF RAS ONCOGENES	SCIENCE			English	Article							GROWTH FACTOR-I; FATTY-ACID SYNTHASE; ADIPOSE CELL LINE; H-RAS; MOLECULAR-CLONING; MESSENGER-RNAS; NEURONAL DIFFERENTIATION; RESPONSIVENESS INVITRO; SIGNAL TRANSDUCTION; POTENTIAL MEDIATOR	Mammalian 3T3-L1 cells differentiate into adipocytes after continuous exposure to pharmacological doses of insulin or physiological doses of insulin-like growth factor I (IGF-1). Expression of transfected ras oncogenes led to differentiation of these cells into adipocytes in the absence of externally added insulin or IGF-I. Cells transfected with normal ras genes or the tyrosine kinase trk oncogene did not differentiate. Transfection with a dominant inhibitory ras mutant resulted in inhibition of differentiation. Exposure of untransfected 3T3-L1 cells to insulin stimulated formation of the active Ras.GTP complex. These observations indicate that Ras proteins participate in signal transduction pathways initiated by insulin and IGF-I in these cells.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Porras, Almudena/N-2121-2015; Nebreda, Angel Rodriguez/R-9594-2019; Benito, Manuel/J-5637-2014	Porras, Almudena/0000-0002-6495-3308; Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1982, MOL CELL BIOCHEM, V49, P17; ALLENDE CC, 1988, FEBS LETT, V234, P426, DOI 10.1016/0014-5793(88)80130-3; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; COOK JS, 1988, P NATL ACAD SCI USA, V85, P2949, DOI 10.1073/pnas.85.9.2949; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOZAK LP, 1983, P NATL ACAD SCI-BIOL, V80, P3020, DOI 10.1073/pnas.80.10.3020; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK F, 1990, ONCOGENE, V5, P1281; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PEARSE AGE, 1968, HISTOCHEMISTRY, P697; PINTZAS A, 1989, GENE ANAL TECH, V6, P125, DOI 10.1016/0735-0651(89)90003-4; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TOSCANI A, 1990, J BIOL CHEM, V265, P5722	45	167	169	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					565	568		10.1126/science.1857988	http://dx.doi.org/10.1126/science.1857988			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857988				2022-12-28	WOS:A1991FZ34700040
J	DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D				DALE, C; GALLUS, A; WYCHERLEY, A; LANGLOIS, S; HOWIE, D			PREVENTION OF VENOUS THROMBOSIS WITH MINIDOSE WARFARIN AFTER JOINT REPLACEMENT	BRITISH MEDICAL JOURNAL			English	Article							INTERMITTENT CALF; COMPRESSION		FLINDERS UNIV,MED CTR,DEPT HAEMATOL,HAEMOSTASIS & THROMBOSIS LAB,BEDFORD PK,SA 5042,AUSTRALIA; UNIV ADELAIDE,ADELAIDE,SA 5001,AUSTRALIA; ROYAL ADELAIDE HOSP,RADIOL,ADELAIDE,SA 5000,AUSTRALIA; ROYAL ADELAIDE HOSP,ORTHOPAEDIC SURG & TRAUMA,ADELAIDE,SA 5000,AUSTRALIA; FLINDERS UNIV,MED CTR,NUCL MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; University of Adelaide; Royal Adelaide Hospital; Royal Adelaide Hospital; Flinders University South Australia				Gallus, Alexander/0000-0001-7347-9989; Howie, Donald/0000-0003-1702-3279				BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; GALLUS A, 1983, BRIT J SURG, V70, P17, DOI 10.1002/bjs.1800700106; Gallus A S, 1990, Baillieres Clin Haematol, V3, P651, DOI 10.1016/S0950-3536(05)80023-X; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309	5	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					224	224		10.1136/bmj.303.6796.224	http://dx.doi.org/10.1136/bmj.303.6796.224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884060	Bronze, Green Published			2022-12-28	WOS:A1991FZ56300024
J	MCDEVITT, HO; STORB, U				MCDEVITT, HO; STORB, U			DISSENT ON FORENSIC EVIDENCE	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					184	184						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857406				2022-12-28	WOS:A1991FX18500021
J	DIRITA, VJ; MEKALANOS, JJ				DIRITA, VJ; MEKALANOS, JJ			PERIPLASMIC INTERACTION BETWEEN 2 MEMBRANE REGULATORY PROTEINS, TOXR AND TOXS, RESULTS IN SIGNAL TRANSDUCTION AND TRANSCRIPTIONAL ACTIVATION	CELL			English	Article							ESCHERICHIA-COLI; CHOLERA-TOXIN; VIBRIO-CHOLERAE; GENETIC-ANALYSIS; IDENTIFICATION; DETERMINANTS; COLONIZATION	ToxR is a transmembrane, DNA-binding protein that can activate transcription of genes encoding cholera toxin (ctxAB). Here we characterize ToxS, a 19 kd transmembrane regulatory protein that interacts with ToxR and stimulates its activity. If a portion of the periplasmic domain of ToxR is deleted, productive interaction with ToxS is abolished. A ToxR-PhoA fusion protein that retains most of the ToxR periplasmic region remains dependent on ToxS for its ToxR activity. ToxS protects this fusion from proteolytic cleavage, suggesting that these two proteins interact within the periplasm. Mutations in a short cytoplasmic domain of ToxR were isolated that disrupt the periplasmic interaction between ToxR and ToxS. This domain is shared by other bacterial transcriptional activators, suggesting that it may play a common role in function of these proteins and in the molecular mechanism of signal transduction.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				DiRita, Victor/0000-0003-3617-7011	NIAID NIH HHS [AI08050, AI8045] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; DEGNEN GE, 1974, J BACTERIOL, V117, P477, DOI 10.1128/JB.117.2.477-487.1974; HALL MN, 1981, ANNU REV GENET, V15, P91, DOI 10.1146/annurev.ge.15.120181.000515; HICKMAN RK, 1988, J BACTERIOL, V170, P1715, DOI 10.1128/jb.170.4.1715-1720.1988; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; KUSHNER SR, 1987, ESCHERICHIA COLI SAL, P1225; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; Miller J.H., 1972, EXPT MOL GENETICS; MILLER VL, 1984, P NATL ACAD SCI-BIOL, V81, P3471, DOI 10.1073/pnas.81.11.3471; MILLER VL, 1989, J BACTERIOL, V171, P1288, DOI 10.1128/jb.171.3.1288-1293.1989; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; PETERSON KM, 1988, INFECT IMMUN, V56, P2822, DOI 10.1128/IAI.56.11.2822-2829.1988; SCHLESIN.MJ, 1967, J BIOL CHEM, V242, P1604; Silhavy T. J., 1984, EXPT GENE FUSIONS; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433	23	164	172	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					29	37		10.1016/0092-8674(91)90206-E	http://dx.doi.org/10.1016/0092-8674(91)90206-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898871				2022-12-28	WOS:A1991ET17500006
J	MOLLER, DE; FLIER, JS				MOLLER, DE; FLIER, JS			INSULIN RESISTANCE - MECHANISMS, SYNDROMES, AND IMPLICATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEPENDENT DIABETES-MELLITUS; POLYCYSTIC OVARY SYNDROME; TYROSINE KINASE-ACTIVITY; HUMAN SKELETAL-MUSCLE; GROWTH FACTOR-I; ACANTHOSIS NIGRICANS; GLUCOSE-TRANSPORT; RECEPTOR GENE; MOLECULAR-BIOLOGY; PLASMA-MEMBRANE		BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	MOLLER, DE (corresponding author), BETH ISRAEL HOSP,CHARLES A DANA RES INST,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019		PHS HHS [28082-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; Bar R S, 1979, Adv Intern Med, V24, P23; BAR RS, 1978, NEW ENGL J MED, V298, P1164, DOI 10.1056/NEJM197805252982103; BARBIERI RL, 1988, FERTIL STERIL, V50, P197; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BEYLOT M, 1988, DIABETES METAB, V14, P20; BODEN G, 1988, J CLIN INVEST, V81, P1971, DOI 10.1172/JCI113545; BUDOHOSKI L, 1984, FEBS LETT, V167, P1, DOI 10.1016/0014-5793(84)80820-0; BUTLER PC, 1990, DIABETES, V39, P1373, DOI 10.2337/diabetes.39.11.1373; CAMA A, 1990, J CLIN ENDOCR METAB, V70, P1155, DOI 10.1210/jcem-70-4-1155; CAMA A, 1991, J CELL BIOCHEM, V15, P73; CARALLOPERIN P, 1985, J CLIN INVEST, V75, P1659; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHOI WH, IN PRESS DIABETES; DALY PA, 1991, DIABETES CARE, V14, P240, DOI 10.2337/diacare.14.3.240; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DENTON RM, 1990, NATURE, V348, P286, DOI 10.1038/348286a0; DERCOLE AJ, 1979, J CLIN ENDOCR METAB, V48, P495, DOI 10.1210/jcem-48-3-495; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; DUNAIF A, 1990, J CLIN ENDOCR METAB, V70, P699, DOI 10.1210/jcem-70-3-699; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FELIG P, 1990, ELLENBERG RIFKINS DI; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; FLIER JS, 1982, DIABETES, V31, P132, DOI 10.2337/diabetes.31.2.132; FLIER JS, 1985, ARCH DERMATOL, V121, P193, DOI 10.1001/archderm.121.2.193; FLIER JS, 1985, DIABETES, V34, P101, DOI 10.2337/diabetes.34.2.101; FLIER JS, 1979, NEW ENGL J MED, V300, P413; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; FLIER JS, 1980, NEW ENGL J MED, V303, P970, DOI 10.1056/NEJM198010233031704; FLIER JS, 1975, SCIENCE, V190, P63, DOI 10.1126/science.170678; FLIER JS, 1978, J CLIN ENDOCR METAB, V47, P985, DOI 10.1210/jcem-47-5-985; FLIER JS, 1989, ENDOCRINOLOGY, V2, P1389; FREIDENBERG GR, 1988, J CLIN INVEST, V82, P1398, DOI 10.1172/JCI113744; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GAVIN JR, 1974, P NATL ACAD SCI USA, V71, P84, DOI 10.1073/pnas.71.1.84; GOLDFINE ID, 1973, BIOCHEM BIOPH RES CO, V53, P852, DOI 10.1016/0006-291X(73)90171-X; HAGER SR, 1989, AM J KIDNEY DIS, V14, P272, DOI 10.1016/S0272-6386(89)80201-X; HARING H, 1989, DIABETES METAB REV, V5, P431; HORNER HC, 1987, J BIOL CHEM, V262, P17696; JOHNSON KH, 1991, DIABETES, V40, P310, DOI 10.2337/diabetes.40.3.310; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KAHN BB, 1990, DIABETES CARE, V13, P548, DOI 10.2337/diacare.13.6.548; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KIDA Y, 1990, J CLIN INVEST, V85, P476, DOI 10.1172/JCI114462; KING MJ, 1988, BIOCHEM J, V256, P893, DOI 10.1042/bj2560893; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KUSARI J, 1991, J BIOL CHEM, V266, P5260; KUSARI J, 1991, CLIN RES, V39, pA39; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; MANDARINO LJ, 1986, AM J PHYSIOL, V251, pE489, DOI 10.1152/ajpendo.1986.251.4.E489; MARANGOU AG, 1986, DIABETES, V35, P1383, DOI 10.2337/diabetes.35.12.1383; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; MCCLAIN DA, 1990, DIABETES CARE, V13, P302, DOI 10.2337/diacare.13.3.302; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1991, J BIOL CHEM, V266, P10995; MOLLER DE, 1989, DIABETES, V38, P1496, DOI 10.2337/diabetes.38.11.1496; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OLEFSKY JM, 1981, DIABETES, V30, P148, DOI 10.2337/diab.30.2.148; ORAHILLY S, 1991, DIABETES, V40, P777, DOI 10.2337/diabetes.40.6.777; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PORETSKY L, 1991, ENDOCR REV, V12, P3, DOI 10.1210/edrv-12-1-3; PORETSKY L, 1985, J CLIN ENDOCR METAB, V61, P728, DOI 10.1210/jcem-61-4-728; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; RABSON SM, 1956, AM J CLIN PATHOL, V26, P283; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REDDY SS, 1989, J CLIN INVEST, V84, P1569, DOI 10.1172/JCI114334; REDDY SSK, 1988, J CLIN INVEST, V82, P1359, DOI 10.1172/JCI113739; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; Roth J, 1975, Recent Prog Horm Res, V31, P95; ROTHMAN DL, 1990, DIABETES S1, V39, pA12; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SATO N, 1990, ENDOCRINOLOGY, V127, P1072, DOI 10.1210/endo-127-3-1072; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SENIOR B, 1964, PEDIATRICS, V33, P593; SHIMADA F, 1990, LANCET, V335, P1179, DOI 10.1016/0140-6736(90)92695-E; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SMITH U, 1984, J BIOL CHEM, V259, P8758; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; STOUT RW, 1985, METABOLISM, V34, P7, DOI 10.1016/S0026-0495(85)80003-2; STUART CA, 1989, AM J MED, V87, P269; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAYLOR SI, 1989, ENDOCRIN METAB CLIN, V18, P123, DOI 10.1016/S0889-8529(18)30392-X; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; TSOKOS GC, 1985, ANN INTERN MED, V102, P176, DOI 10.7326/0003-4819-102-2-176; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WACHSLICHTRODBARD H, 1981, J CLIN ENDOCR METAB, V52, P416, DOI 10.1210/jcem-52-3-416; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; YOKOTA A, 1990, DIABETES S1, V39, pA235; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	110	708	742	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					938	948						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881419				2022-12-28	WOS:A1991GF85600007
J	BURGER, SK; SAUL, RF; SELHORST, JB; THURSTON, SE				BURGER, SK; SAUL, RF; SELHORST, JB; THURSTON, SE			TRANSIENT MONOCULAR BLINDNESS CAUSED BY VASOSPASM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CORONARY-ARTERY SPASM; AMAUROSIS FUGAX; SUBARACHNOID HEMORRHAGE; MIGRAINE; VASOCONSTRICTION; ATHEROSCLEROSIS; INFARCTION; PATIENT; VARIANT; ADULTS		ST LOUIS UNIV, SCH MED,DEPT NEUROL,SOUERS STROKE INST,BOX 15250, 3635 VISTA & GRAND, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, SCH MED, DEPT OPHTHALMOL, ST LOUIS, MO 63110 USA; GEISINGER MED CTR, DEPT NEUROL, DANVILLE, PA 17822 USA; GEISINGER MED CTR, DEPT OPHTHALMOL, DANVILLE, PA 17822 USA	Saint Louis University; Saint Louis University; Geisinger Medical Center; Geisinger Medical Center								APPLETON R, 1988, AM J DIS CHILD, V142, P331, DOI 10.1001/archpedi.1988.02150030105032; BELL MR, 1989, J AM COLL CARDIOL, V14, P523, DOI 10.1016/0735-1097(89)90211-8; BERNSTEIN EF, 1990, STROKE, V21, P201; BRODERICK JP, 1987, ARCH NEUROL-CHICAGO, V44, P868, DOI 10.1001/archneur.1987.00520200070022; BRUNO A, 1990, STROKE, V21, P34, DOI 10.1161/01.STR.21.1.34; Carroll D, 1970, Headache, V10, P9, DOI 10.1111/j.1526-4610.1970.hed1001009.x; Corbett J J, 1983, Neurol Clin, V1, P973; Cowers W, 1875, LANCET, V2, P794; EADIE MJ, 1968, LANCET, V1, P319; EDWARDS EA, 1987, DERMATOLOGY GENERAL, V2, P2022; ELLENBERGER C, 1986, SEMIN NEUROL, V6, P185, DOI 10.1055/s-2008-1041462; FELDMAN RL, 1987, AM J CARDIOL, V59, P1187, DOI 10.1016/0002-9149(87)90873-3; Fisher C M, 1977, Neurosurgery, V1, P245; FISHER CM, 1980, CAN J NEUROL SCI, V7, P9; FISHER CM, 1959, NEUROLOGY, V9, P333, DOI 10.1212/WNL.9.5.333; FISHER M, 1952, AMA ARCH OPHTHALMOL, V47, P167; GOODMAN BW, 1979, AM J MED, V67, P839, DOI 10.1016/0002-9343(79)90744-7; HUPP SL, 1989, SURV OPHTHALMOL, V33, P221, DOI 10.1016/0039-6257(82)90149-7; IMES RK, 1989, J CLIN NEURO-OPHTHAL, V9, P178; KLINE LB, 1980, HEADACHE, V20, P253, DOI 10.1111/j.1526-4610.1980.hed2005253.x; KUGIYAMA K, 1987, AM J CARDIOL, V60, P1009, DOI 10.1016/0002-9149(87)90343-2; LONGFELLOW DW, 1962, ARCH OPHTHALMOL-CHIC, V67, P554, DOI 10.1001/archopht.1962.00960020554005; MARSHALL J, 1968, BRAIN, V91, P419, DOI 10.1093/brain/91.3.419; MASERI A, 1990, CIRCULATION, V81, P1983, DOI 10.1161/01.CIR.81.6.1983; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; NEWMAN NM, 1974, ARCH OPHTHALMOL-CHIC, V91, P367, DOI 10.1001/archopht.1974.03900060379006; OLSEN T, 1985, DERMATOLOGY, V1, P1001; Priollet P, 1989, Vasa Suppl, V27, P23; RICKELS E, 1990, EXP NEUROL, V107, P178, DOI 10.1016/0014-4886(90)90156-M; ROTHROCK JF, 1988, ARCH NEUROL-CHICAGO, V45, P63, DOI 10.1001/archneur.1988.00520250069023; SCHWARTZ ND, 1986, ARCH INTERN MED, V146, P2059, DOI 10.1001/archinte.146.10.2059; TIPPIN J, 1989, ANN NEUROL, V26, P69, DOI 10.1002/ana.410260111; TOMSAK RL, 1987, HEADACHE, V27, P66, DOI 10.1111/j.1526-4610.1987.hed2702066.x; TROOST BT, 1976, CLIN OPHTHALMOLOGY, V2, P11; Vayssairat M, 1989, Vasa Suppl, V27, P31; Von Graefe A., 1859, ARCH OPHTHALMOL-CHIC, V5, P136; VONHOLST H, 1988, ACTA NEUROCHIR, V94, P32, DOI 10.1007/BF01406612; VVONHOLST H, 1908, ACTA NEUROCHIR WIEN, V94, P129; Walsh FB, 1969, CLIN NEUROOPHTHALMOL, P1671; Zareba A, 1988, Neurol Neurochir Pol, V22, P439	40	72	73	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					870	873		10.1056/NEJM199109193251207	http://dx.doi.org/10.1056/NEJM199109193251207			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875972				2022-12-28	WOS:A1991GF61600007
J	BROOK, RH				BROOK, RH			QUALITY OF CARE - DO WE CARE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						QUALITY OF HEALTH CARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH-CARE); QUALITY OF LIFE; REGIONAL HEALTH PLANNING; PHYSICIAN-PATIENT RELATIONS	CAROTID ENDARTERECTOMY; SERVICES; APPROPRIATENESS; MORTALITY; PATTERNS	The quality of U.S. health care must improve. Practicing physicians need to become involved in generating new knowledge about what does and does not work in medical practice. Physicians might, for example, participate in building national databases on chronic and acute conditions using data from their patients or might help to enroll patients in cohort studies or experimental trials. Furthermore, our knowledge is now sufficient to support a substantial investment of funds in improving what physicians now do in medical practice and in developing publicly available standards of medical practice. Such standards or guidelines could be used by both physicians and patients as part of an explicit process to assess the medical appropriateness of expensive or dangerous procedures before they are done. In addition, the competence with which care is delivered also needs to be measured. Both of these assessments should be used prospectively by physicians to help patients choose the referral source that will maximize their preferences.	UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	BROOK, RH (corresponding author), RAND CORP, 1700 MAIN ST, POB 2138, SANTA MONICA, CA 90407 USA.							Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1989, ACAD MED, V64, P124, DOI 10.1097/00001888-198903000-00004; BROOK RH, 1970, NEW ENGL J MED, V283, P904, DOI 10.1056/NEJM197010222831705; BROOK RH, 1987, J CHRON DIS, V40, pS131, DOI 10.1016/S0021-9681(87)80042-5; BROOK RH, 1990, HEALTH POLICY, V14, P225, DOI 10.1016/0168-8510(90)90037-E; BROOK RH, 1985, MED CARE, V23, P710, DOI 10.1097/00005650-198505000-00030; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; BROOK RH, 1979, MED CARE S, P17; BROOK RH, 1988, QUALITY CARE TECHNOL, P21; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHASSIN MR, 1989, APPROPRIATENESS USE; Donabedian, 1985, EXPLORATIONS QUALITY, V3; Donabedian A., 1982, EXPLORATIONS QUALITY, VII; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EDDY DM, 1988, HEALTH AFFAIR, V7, P19, DOI 10.1377/hlthaff.7.1.19; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FINK A, 1987, WESTERN J MED, V147, P609; HANKS GE, 1983, CANCER, V51, P959, DOI 10.1002/1097-0142(19830301)51:5<959::AID-CNCR2820510533>3.0.CO;2-K; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; LOHR KN, 1986, MED CARE, V24, pUS1; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; McClure W, 1984, Health Aff (Millwood), V3, P120, DOI 10.1377/hlthaff.3.2.120; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MERRICK NJ, 1986, JAMA-J AM MED ASSOC, V256, P2531, DOI 10.1001/jama.256.18.2531; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; WILLIAMSON JW, 1977, IMPROVING MED PRACTI; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201	32	30	30	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					486	490		10.7326/0003-4819-115-6-486	http://dx.doi.org/10.7326/0003-4819-115-6-486			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872496				2022-12-28	WOS:A1991GE81000011
J	AINSWORTH, MA; ROGERS, LP; MARKUS, JF; DORSEY, NK; BLACKWELL, TA; PETRUSA, ER				AINSWORTH, MA; ROGERS, LP; MARKUS, JF; DORSEY, NK; BLACKWELL, TA; PETRUSA, ER			STANDARDIZED PATIENT ENCOUNTERS - A METHOD FOR TEACHING AND EVALUATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRUCTURED CLINICAL EXAMINATION; 4TH-YEAR STUDENTS; MEDICAL-STUDENTS; PERFORMANCE; SKILLS; COMPETENCE; RELIABILITY; RESIDENTS; SCHOOLS	The primary goal of medical education is to foster development of clinical competence in trainees at all levels. Variable clinical experience, inconsistent methods of instruction, and ambiguous evaluation criteria undermine this goal. Standardized patients, trained to consistently portray a wide variety of clinical cases, can help overcome many of these educational problems. This article describes the development and application of standardized patients throughout medical training at The University of Texas Medical Branch, Galveston, in the freshman interviewing course, the second-year physical diagnosis course, third-year clerkships, a fourth-year final exercise, and residency training. Development of this program is discussed in the context of a broader literature in medical education, and investigation of variables affecting standardized patient and student performance is reported. Future directions for use of standardized patients in monitoring and promoting the development of clinical competence are discussed.	UNIV TEXAS,MED BRANCH,OFF EDUC DEV,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	AINSWORTH, MA (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,UTMB BOX 172,GALVESTON,TX 77550, USA.							BARROWS HS, 1987, J MED EDUC, V62, P805; BLACKWELL TA, 1990, 4TH P OTT C ASS CLIN; BRADFORD WD, 1986, J MED EDUC, V61, P157; CONN HL, 1989, ACAD MED, V64, P448, DOI 10.1097/00001888-198908000-00007; DAUPHINEE WD, 1990, ACAD MED, V65, pS68, DOI 10.1097/00001888-199009000-00046; DORSEY NK, 1989, 3RD P INT C TEACH AS, P213; HARDEN RM, 1988, MED TEACH, V10, P19, DOI 10.3109/01421598809019321; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; HODDER RV, 1989, MED EDUC, V23, P184, DOI 10.1111/j.1365-2923.1989.tb00884.x; KASSEBAUM DG, 1990, ACAD MED, V65, P293, DOI 10.1097/00001888-199005000-00003; KAUFMAN A, 1989, ACAD MED, V64, P285, DOI 10.1097/00001888-198906000-00001; KEYNAN A, 1987, MED EDUC, V21, P477, DOI 10.1111/j.1365-2923.1987.tb01406.x; LEVINE MK, 1990, THESIS U SANTA BARBA; LLOYD JS, 1990, ACAD MED, V65, pS51, DOI 10.1097/00001888-199009000-00040; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; NEWBLE DI, 1988, MED EDUC, V22, P200, DOI 10.1111/j.1365-2923.1988.tb00007.x; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; PAINVIN C, 1979, P ANN C RES MED ED, V18, P73; PERKOWSKIROGERS L, 1989, 3RD P INT C TEACH AS, P364; PETRUSA ER, 1987, J MED EDUC, V62, P859; PETRUSA ER, 1987, AM J MED, V83, P34, DOI 10.1016/0002-9343(87)90494-3; PETRUSA ER, 1990, ARCH INTERN MED, V150, P573, DOI 10.1001/archinte.150.3.573; PETRUSA ER, 1987, P ANN C RES MED ED, V26, P269; RETTIE CS, 1989, P ANN C RES MED ED, V28, P153; ROGERS LP, 1989, 10TH ANN C GEN MED E; RUTALA PJ, 1990, ACAD MED, V65, pS53, DOI 10.1097/00001888-199009000-00041; STILLMAN PL, 1990, ACAD MED, V65, P288, DOI 10.1097/00001888-199005000-00002; STILLMAN PL, 1990, ACAD MED, V65, P320, DOI 10.1097/00001888-199005000-00013; STILLMAN PL, 1987, ARCH INTERN MED, V147, P1981, DOI 10.1001/archinte.147.11.1981; STILLMAN PL, 1986, ANN INTERN MED, V105, P762, DOI 10.7326/0003-4819-105-5-762; STILLMAN PL, 1987, ARCH INTERN MED, V147, P1049, DOI 10.1001/archinte.147.6.1049; Swanson DB, 1989, TEACH LEARN MED, V1, P158; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; VU NV, 1987, J MED EDUC, V62, P1000; WILLIAMS RG, 1987, MED EDUC, V21, P482, DOI 10.1111/j.1365-2923.1987.tb01407.x; 1984, PHYSICIANS 21ST CENT, P14; 1989, AAMC CURRICULUM DIRE	37	87	88	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1390	1396		10.1001/jama.266.10.1390	http://dx.doi.org/10.1001/jama.266.10.1390			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880869				2022-12-28	WOS:A1991GD80700034
J	HAQUE, AK; COWAN, WT; SMITH, JH				HAQUE, AK; COWAN, WT; SMITH, JH			THE DECEDENT AFFAIRS OFFICE - A UNIQUE CENTRALIZED SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LABORATORY MEDICINE; DEATH CERTIFICATE; AUTOPSY; PATHOLOGY; TIME	The success of a centralized decedent affairs office depends on support by clinicians, the department chairman, and hospital administration. The benefits to the institution include improved public relations with a decedent's family, compliance with state and federal laws, increased organ donations, and better risk management programs. The only drawback of establishing such an office is the additional personnel necessary for 24-hour coverage. However, modifications in the functions and staffing levels of a decedent affairs office may be made, depending on the needs of individual institutions. We hypothesized that consent for autopsy would be easier to obtain and cause less emotional upheaval for family members if procedures were well established and specially trained individuals were involved in the process. With these ideas in mind, we established a decedent affairs office at The University of Texas Medical Branch in 1984.			HAQUE, AK (corresponding author), UNIV TEXAS,MED BRANCH,DEPT PATHOL,RTE G47,GALVESTON,TX 77550, USA.							ANDERSON RE, 1984, ARCH PATHOL LAB MED, V108, P490; ANGRIST A, 1968, B NEW YORK ACAD MED, V44, P830; BURROWS S, 1975, JAMA-J AM MED ASSOC, V233, P441, DOI 10.1001/jama.233.5.441; CAPLAN AL, 1984, HUM PATHOL, V15, P1105, DOI 10.1016/S0046-8177(84)80304-4; GALL EA, 1968, B NEW YORK ACAD MED, V44, P808; GAMBINO SR, 1984, ARCH PATHOL LAB MED, V108, P444; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1002; HAQUE AK, 1990, AUTOPSY PERFORMANCE, P45; HILL RB, 1988, AUTOPSY MED PRACTICE, P43; KAPLAN RA, 1978, HUM PATHOL, V9, P127, DOI 10.1016/S0046-8177(78)80102-6; KATZ JL, 1973, NEW YORK STATE J MED, V73, P2591; KIRCHER T, 1987, JAMA-J AM MED ASSOC, V258, P349, DOI 10.1001/jama.258.3.349; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; LANDEFELD CS, 1988, NEW ENGL J MED, V318, P1249, DOI 10.1056/NEJM198805123181906; LUNDBERG GD, 1988, JAMA-J AM MED ASSOC, V260, P3488; LUNDBERG GD, 1984, JAMA-J AM MED ASSOC, V252, P390; LUNDBERG GD, 1987, JAMA-J AM MED ASSOC, V258, P378; MCGOOGAN E, 1978, SCOT MED J, V23, P19, DOI 10.1177/003693307802300106; MCPHEE SJ, 1986, AM J MED, V80, P665, DOI 10.1016/0002-9343(86)90822-3; ROBERTS WC, 1978, NEW ENGL J MED, V299, P332, DOI 10.1056/NEJM197808172990704; ROBINSON MJ, 1983, HUM PATHOL, V14, P566, DOI 10.1016/S0046-8177(83)80201-9; Smith J H, 1986, Pathologist, V40, P22; SZANTO PB, 1976, INT SURG, V61, P326; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; VALASKE MJ, 1984, ARCH PATHOL LAB MED, V108, P462; WILLIAMS MJ, 1978, AM J CLIN PATHOL, V69, P215; WILSON RR, 1966, JAMA-J AM MED ASSOC, V196, P193	27	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1397	1399		10.1001/jama.266.10.1397	http://dx.doi.org/10.1001/jama.266.10.1397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880870				2022-12-28	WOS:A1991GD80700035
J	DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M				DALONZO, GE; BARST, RJ; AYRES, SM; BERGOFSKY, EH; BRUNDAGE, BH; DETRE, KM; FISHMAN, AP; GOLDRING, RM; GROVES, BM; KERNIS, JT; LEVY, PS; PIETRA, GG; REID, LM; REEVES, JT; RICH, S; VREIM, CE; WILLIAMS, GW; WU, M			SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION, PULMONARY; VENTRICULAR FUNCTION, RIGHT; ATRIAL FUNCTION, RIGHT; RAYNAUDS DISEASE; HEART-LUNG TRANSPLANTATION	UNUSUALLY LONG DURATION; NATURAL-HISTORY	Objective: To characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival. Design: Registry with prospective follow-up. Setting: Thirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. Patients: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. Measurements: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. Main Results: The estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DL(CO)). Drug therapy at entry or discharge was not associated with survival duration. Conclusions: Mortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.	NHLBI, DIV LUNG DIS, WESTWOOD BLDG, ROOM 6A09, BETHESDA, MD 20892 USA; UNIV TEXAS, MED CTR, DIV PULM, HOUSTON, TX 77030 USA; BABYS HOSP S, NEW YORK, NY 10032 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA; SUNY STONY BROOK, HLTH SCI CTR, DIV PULM CRIT CARE, STONY BROOK, NY 11794 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, TORRANCE, CA 90509 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; UNIV PENN, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19104 USA; NYU, DEPT MED, NEW YORK, NY 10016 USA; UNIV HOSP DENVER, DIV CARDIOL, DENVER, CO 80262 USA; UNIV ILLINOIS, SCH PUBL HLTH, CHICAGO, IL 60680 USA; HOSP UNIV PENN, DEPT PATHOL & MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP MED CTR, MED CTR, DEPT PATHOL, BOSTON, MA 02115 USA; UNIV COLORADO, HLTH SCI CTR, CARDIOVASC PULM RES LAB, DENVER, CO 80262 USA; UNIV ILLINOIS, DEPT MED, CARDIOL SECT, CHICAGO, IL 60680 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; NIH, DIV HEART LUNG & BLOOD INST, MATH & STAT BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; New York University; University of Colorado System; University of Colorado Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Boston Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA				goldring, roberta/0000-0003-3319-4932	DIVISION OF LUNG DISEASES [N01HR014000] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR-14000] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham M T, 1981, Indian Heart J, V33, P5; BOURDILLON PDV, 1976, BRIT HEART J, V38, P264; CHARTERS AD, 1970, BRIT HEART J, V32, P130; FUJII A, 1981, BRIT HEART J, V46, P574; FUSTER V, 1981, AM J CARDIOL, V47, P422, DOI 10.1016/0002-9149(81)90761-X; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GLANVILLE AR, 1987, CHEST, V91, P675, DOI 10.1378/chest.91.5.675; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANEMOTO N, 1979, JPN HEART J, V20, P395; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; LEE ET, 1980, STATISTICAL METHODS; MCCAFFREY R M, 1964, Obstet Gynecol Surv, V19, P567, DOI 10.1097/00006254-196408000-00001; NELSON DM, 1983, OBSTET GYNECOL, V62, pS58; OAKLEY C, 1968, LANCET, V1, P890; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; ROZKOVEC A, 1986, BRIT HEART J, V55, P449; SUAREZ LD, 1979, BRIT HEART J, V41, P702; TRELL E, 1973, ACTA MED SCAND, V193, P137; VOELKEL N, 1979, PULMONARY VASCULAR D, V14, P573; WALCOTT G, 1970, AM J MED, V49, P70, DOI 10.1016/S0002-9343(70)80115-2; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	24	2616	2742	1	71	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					343	349		10.7326/0003-4819-115-5-343	http://dx.doi.org/10.7326/0003-4819-115-5-343			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863023				2022-12-28	WOS:A1991GC06500002
J	LAMARCO, K; THOMPSON, CC; BYERS, BP; WALTON, EM; MCKNIGHT, SL				LAMARCO, K; THOMPSON, CC; BYERS, BP; WALTON, EM; MCKNIGHT, SL			IDENTIFICATION OF ETS-RELATED AND NOTCH-RELATED SUBUNITS IN GA BINDING-PROTEIN	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; IMMEDIATE-EARLY GENE; CELL-CYCLE CONTROL; DNA-BINDING; REGULATORY SEQUENCES; GEL-ELECTROPHORESIS; THYMIDINE KINASE; INDUCIBLE GENE; GROWTH-FACTOR; REL ONCOGENE	Recombinant cDNA clones that encode two distinct subunits of the transcription factor GA binding protein (GABP) have been isolated. The predicted amino add sequence of one subunit, GABP-alpha, exhibits similarity to the sequence of the product of the ets-1 proto-oncogene in a region known to encompass the Ets DNA binding domain. The sequence of the second subunit, GABP-beta, contains four 33-amino acid repeats located dose to the NH2-terminus of the subunit. The sequences of these repeats are similar to repeats in several transmembrane proteins, including Notch from Drosophila melanogaster and Glp-1 and Lin-12 from Caenorhabditis elegans. Avid, sequence-specific binding to DNA required the presence of both polypeptides, revealing a conceptual convergence of nuclear transforming proteins and membrane-anchored proteins implicated in developmentally regulated signal transduction processes.			LAMARCO, K (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,HOWARD HUGHES RES LABS,BALTIMORE,MD 21210, USA.							ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Ausubel FM, 1988, MOL REPROD DEV; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BZIK DJ, 1986, NUCLEIC ACIDS RES, V14, P929, DOI 10.1093/nar/14.2.929; CAO Z, IN PRESS GENES DEV; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDINGLEY MG, 1983, NUCLEIC ACIDS RES, V11, P2347, DOI 10.1093/nar/11.8.2347; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILLARD S, 1986, P NATL ACAD SCI USA, V83, P5573, DOI 10.1073/pnas.83.15.5573; GOEBL MG, 1990, CELL, V61, P116; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACKEM S, 1982, J VIROL, V44, P939, DOI 10.1128/JVI.44.3.939-949.1982; MACKEM S, 1982, P NATL ACAD SCI-BIOL, V79, P4917, DOI 10.1073/pnas.79.16.4917; OHARE P, 1987, J VIROL, V61, P190, DOI 10.1128/JVI.61.1.190-199.1987; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; POST LE, 1981, CELL, V24, P555, DOI 10.1016/0092-8674(81)90346-9; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECTOR D, 1990, P NATL ACAD SCI USA, V87, P5268, DOI 10.1073/pnas.87.14.5268; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STONE KL, 1991, LABORATORY METHODOLO; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	48	341	349	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					789	792		10.1126/science.1876836	http://dx.doi.org/10.1126/science.1876836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876836				2022-12-28	WOS:A1991GB29500038
J	GILL, GV; ALBERTI, KGMM				GILL, GV; ALBERTI, KGMM			OUTCOME OF BRITTLE DIABETES	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	GILL, GV (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; GILL GV, 1981, DIABETOLOGIA, V21, P507; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; TATTERSALL R, 1991, BRIT MED J, V302, P1240, DOI 10.1136/bmj.302.6787.1240; WILLIAMS G, 1988, DIABETES RES CLIN EX, V7, P13	5	10	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					285	286		10.1136/bmj.303.6797.285	http://dx.doi.org/10.1136/bmj.303.6797.285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888928	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100020
J	LEE, C; LEVITT, M				LEE, C; LEVITT, M			ACCURATE PREDICTION OF THE STABILITY AND ACTIVITY EFFECTS OF SITE-DIRECTED MUTAGENESIS ON A PROTEIN CORE	NATURE			English	Article							FREE-ENERGY CALCULATIONS; T4 LYSOZYME; STAPHYLOCOCCAL NUCLEASE; HYDROPHOBIC CORE; PACKING; THERMOSTABILITY; REPRESSOR	THEORETICAL prediction of the structure, stability and activity of proteins, an important unsolved problem in molecular biology, would be of use for guiding site-directed mutagenesis and other protein-engineering techniques. X-ray diffraction studies have provided extensive structural information for many proteins, challenging theorists to develop reliable techniques able to use such knowledge as a base for prediction of mutants' characteristics. Here we report theoretical calculation of stabilization energies for 78 triple-site sequence variants of lambda-repressor characterized experimentally by Lim and Sauer 1. The calculated energies correlate with the mutants' measured activities; active and inactive mutations are discriminated with 92% reliability. They correlate even more directly with the mutants' thermostabilities, correctly identifying two of the mutants to be more stable than the wild type.			LEE, C (corresponding author), STANFORD UNIV,MED CTR,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305, USA.		Levitt, Michael/E-4582-2012	Levitt, Michael/0000-0002-8414-7397				BASH PA, 1987, SCIENCE, V236, P564, DOI 10.1126/science.3576184; DAGGETT V, IN PRESS PROTEIN ENG; DANG LX, 1989, J AM CHEM SOC, V111, P8505, DOI 10.1021/ja00204a027; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; MALCOLM BA, 1990, NATURE, V345, P86, DOI 10.1038/345086a0; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; McCammon JA, 1991, CURR OPIN STRUC BIOL, V1, P196; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SHORTLE D, 1989, ARCH BIOCHEM BIOPHYS, V272, P103, DOI 10.1016/0003-9861(89)90200-2; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; TIDOR B, 1991, BIOCHEMISTRY-US, V30, P3217, DOI 10.1021/bi00227a009	19	161	172	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					448	451		10.1038/352448a0	http://dx.doi.org/10.1038/352448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861725				2022-12-28	WOS:A1991FZ34600071
J	PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F				PIEKEN, WA; OLSEN, DB; BENSELER, F; AURUP, H; ECKSTEIN, F			KINETIC CHARACTERIZATION OF RIBONUCLEASE-RESISTANT 2'-MODIFIED HAMMERHEAD RIBOZYMES	SCIENCE			English	Article							SELF-CLEAVAGE; RNA; OLIGORIBONUCLEOTIDES	The incorporation of 2'-fluoro- and 2'-aminonucleotides into a hammerhead ribozyme was accomplished by automated chemical synthesis. The presence of 2'-fluorouridines, 2'-fluorocytidines, or 2'-aminouridines did not appreciably decrease catalytic efficiency. Incorporation of 2'-aminocytidines decreased ribozyme activity approximately by a factor of 20. The replacement of all adenosines with 2'-fluoroadenosines abolished catalysis in the presence of MgCl2 within the limits of detection, but some activity was retained in the presence of MnCl2. This effect on catalysis was localized to a specific group of adenines within the conserved single-stranded region of the ribozyme. The decrease in catalytic efficiency was caused by a decrease in the rate constant; the Michaelis constant was unaltered. The 2'-fluoro and 2'-amino modifications conferred resistance toward ribonuclease degradation. Ribozymes containing 2'-fluoro- or 2'-aminonucleotides at all uridine and cytidine positions were stabilized against degradation in rabbit serum by a factor of at least 10(3) compared to unmodified ribozyme.	MAX PLANCK INST EXPTL MED,CHEM ABT,HERMANN REIN STR 3,W-3400 GOTTINGEN,GERMANY	Max Planck Society				olsen, david/0000-0001-5521-0206				BEIJER B, 1990, NUCLEIC ACIDS RES, V18, P5143, DOI 10.1093/nar/18.17.5143; BENSELER F, UNPUB; CODINGTON JF, 1964, J ORG CHEM, V29, P558, DOI 10.1021/jo01026a009; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; DOERR IL, 1967, J ORG CHEM, V32, P1462, DOI 10.1021/jo01280a035; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HOBBS J, 1973, BIOCHEMISTRY-US, V12, P5138, DOI 10.1021/bi00749a018; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; IKEHARA M, 1978, CHEM PHARM BULL, V26, P2449; IMAZAWA M, 1979, J ORG CHEM, V44, P2039, DOI 10.1021/jo01326a037; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; Mengel R., 1978, ANGEW CHEM, V90, P557; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, UNPUB; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VERHEYDEN JP, 1971, J ORG CHEM, V36, P250; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027	27	407	552	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					314	317		10.1126/science.1857967	http://dx.doi.org/10.1126/science.1857967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857967				2022-12-28	WOS:A1991FX22400040
J	PINOLROMA, S; DREYFUSS, G				PINOLROMA, S; DREYFUSS, G			TRANSCRIPTION-DEPENDENT AND TRANSCRIPTION-INDEPENDENT NUCLEAR TRANSPORT OF HNRNP PROTEINS	SCIENCE			English	Article							RNA-BINDING PROTEINS; HELIX-DESTABILIZING PROTEIN; RIBONUCLEOPROTEIN-PARTICLES; MONOCLONAL-ANTIBODIES; CDNA CLONING; COMPLEXES; ENVELOPE; REVEALS; CELLS; SNRNA	Heterogeneous nuclear RNAs and specific nuclear proteins form heterogeneous nuclear ribonucleoprotein complexes (hnRNPs), one of the most abundant components of the nucleus. In mitosis, as the nuclear envelope breaks down, hnRNPs disperse throughout the cell. At the end of mitosis, hnRNPs dissociate and their proteins are transported into the daughter cell nuclei separately. Some are transported immediately (early group), white others are transported later (late group). Transport of the late group appears to require transcription by RNA polymerase II, in that inhibitors of this polymerase cause the late proteins to remain in the cytoplasm. Thus, there are two modes, transcription-dependent and transcription-independent, for the transport of nuclear proteins.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania	PINOLROMA, S (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; CHOI YD, 1984, J CELL BIOL, V99, P1997; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DEROBERTIS EM, 1982, NATURE, V295, P572, DOI 10.1038/295572a0; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EGYHAZI E, 1982, EUR J BIOCHEM, V122, P445; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HARLOW E, 1988, ANTIBODIES LABORATOR; LAHIRI DK, 1985, J BIOL CHEM, V260, P598; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LESER GP, 1987, J CELL BIOL, V105, P2083, DOI 10.1083/jcb.105.5.2083; MARTIN TE, 1981, CELL NUCLEUS, V9, P119; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; PINOLROMA S, 1990, METHOD ENZYMOL, V181, P317; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, UNPUB; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZELLER R, 1983, CELL, V32, P425, DOI 10.1016/0092-8674(83)90462-2; ZIEVE GW, 1986, J CELL PHYSIOL, V128, P85, DOI 10.1002/jcp.1041280114; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	31	188	189	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					312	314		10.1126/science.1857966	http://dx.doi.org/10.1126/science.1857966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857966				2022-12-28	WOS:A1991FX22400039
J	DYE, S; ISAACS, C				DYE, S; ISAACS, C			INTRAVENOUS DRUG MISUSE AMONG PRISON-INMATES - IMPLICATIONS FOR SPREAD OF HIV	BRITISH MEDICAL JOURNAL			English	Article											DYE, S (corresponding author), ST MARYS HOSP,SCH MED,DEPT IMMUNOL,LONDON W2 1PG,ENGLAND.			Dye, Stephen/0000-0002-0535-5332				CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; 1989, HIV AIDS PRISONS; 1988, HIV AIDS PRISONS	4	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1506	1506		10.1136/bmj.302.6791.1506	http://dx.doi.org/10.1136/bmj.302.6791.1506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FT505	1855020	Bronze, Green Published			2022-12-28	WOS:A1991FT50500023
J	SMITH, RA; LING, S; ALEXANDER, FW				SMITH, RA; LING, S; ALEXANDER, FW			GOLF RELATED HEAD-INJURIES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,DEPT PAEDIAT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital								JENNETT B, 1977, Lancet, V2, P696; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MILLER JD, 1968, LANCET, V2, P991; STRANG I, 1978, INJURY, V10, P154	4	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1505	1506		10.1136/bmj.302.6791.1505	http://dx.doi.org/10.1136/bmj.302.6791.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855019	Green Published, Bronze			2022-12-28	WOS:A1991FT50500022
J	MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV				MORRIS, F; TORDOFF, SG; WALLIS, D; SKINNER, DV			CARDIOPULMONARY-RESUSCITATION SKILLS OF PREREGISTRATION HOUSE OFFICERS - 5 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT ANAESTHESIA,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London	MORRIS, F (corresponding author), ST BARTHOLOMEWS HOSP,DEPT ACCID & EMERGENCY,LONDON EC1A 7BE,ENGLAND.							BASKETT PJF, 1985, BRIT MED J, V290, P1531, DOI 10.1136/bmj.290.6481.1531; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CURRY L, 1987, CAN MED ASSOC J, V137, P491; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; 1987, J R COLL PHYSICIANS, V21, P175	5	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 16	1991	302	6777					626	627		10.1136/bmj.302.6777.626	http://dx.doi.org/10.1136/bmj.302.6777.626			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC071	1878021	Green Published, Bronze			2022-12-28	WOS:A1991FC07100022
J	HILLNER, BE; SMITH, TJ				HILLNER, BE; SMITH, TJ			EFFICACY AND COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY IN WOMEN WITH NODE-NEGATIVE BREAST-CANCER - A DECISION-ANALYSIS MODEL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; THERAPY; SURVIVAL; CARCINOMA	Background. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy. Acceptance of this recommendation is controversial, since many women who would not have a recurrence would be treated. Methods. Using a decision-analysis model, we studied the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women with node-negative breast cancer by calculating life expectancy as adjusted for quality of life. The analysis evaluated different scenarios of the benefit of therapy: improved disease-free survival for five years, with a lesser effect on overall survival (base line); a lifelong benefit from chemotherapy; and a benefit in disease-free survival with no change in overall survival by year 10. The base-line analysis assumed a 30 percent reduction in the relative risk of recurrence for five years after treatment. Results. For the 45-year-old woman, the base-line analysis found an average lifetime benefit from chemotherapy of 5.1 quality-months at a cost of $15,400 per quality-year. The 60-year-old women gained 4.0 quality months at a cost of $18,800 per quality-year. Under the more and less optimistic scenarios, the benefit of chemotherapy varied from 1.4 to 14.0 quality-months for both groups. Conclusions. Chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely accepted therapies. This benefit decreases markedly if the changes in long-term survival are less than in disease-free survival. Given its uncertain duration, the benefit may be too small for many women to choose chemotherapy. Selective use of chemotherapy to maximize the benefit to individual patients may be possible with refinements in risk stratification and explicit assessment of the patients' risk preferences.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,JOHN N DALTON ONCOL CLIN,RICHMOND,VA 23298	Virginia Commonwealth University	HILLNER, BE (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV GEN INTERNAL MED,BOX 170,MCV STN,RICHMOND,VA 23298, USA.		Hillner, Bruce/A-6852-2009	Smith, Thomas/0000-0003-3040-6434				BAKER MS, 1989, CANCER CARE AND COST, P127; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BONADONNA G, 1987, SEMIN ONCOL, V14, P8; BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; DURBIN M, 1988, PEDIATRICS, V82, P774; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; FISHER B, 1975, SURG GYNECOL OBSTET, V140, P528; FISHER ER, 1986, NATL CANCER I MONOGR, V1, P29; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; GINSBURG AD, 1989, CAN MED ASSOC J, V141, P381; GOLDSMITH M, 1987, ONCOLOGY, V1, P54; HENDERSON IC, 1987, J CLIN ONCOL, V5, P1135, DOI 10.1200/JCO.1987.5.8.1135; HENDERSON IC, 1987, SEMIN ONCOL, V14, P34; HENDERSON IC, 1988, NEW ENGL J MED, V318, P443, DOI 10.1056/NEJM198802183180709; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; INGLE JN, 1990, NEW ENGL J MED, V322, P329, DOI 10.1056/NEJM199002013220511; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MULLEY AG, 1989, MED CARE, V27, pS269, DOI 10.1097/00005650-198903001-00021; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; NORTON L, 1985, SEMIN ONCOL, V12, P231; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMES RJ, 1989, P AN M AM SOC CLIN, V8, P52; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192; Sox HC, 1988, MED DECISION MAKING; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SULKES A, 1979, J NATL CANCER I, V62, P513, DOI 10.1093/jnci/62.3.513; TANNOCK IF, 1989, NEW ENGL J MED, V321, P471; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WEINSTEIN ND, 1989, SCIENCE, V246, P1232, DOI 10.1126/science.2686031; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; [No title captured]; 1989, STATISTICAL ABSTRACT, P73; 1988, CLIN ALERT; 1985, JAMA-J AM MED ASSOC, V254, P3461; 1988, NEW ENGL J MED, V319, P1681; 1989, NEW ENGL J MED, V320, P491	47	193	194	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 17	1991	324	3					160	168		10.1056/NEJM199101173240305	http://dx.doi.org/10.1056/NEJM199101173240305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ER471	1898533				2022-12-28	WOS:A1991ER47100005
J	COX, JL; BOINEAU, JP; SCHUESSLER, RB; FERGUSON, TB; CAIN, ME; LINDSAY, BD; CORR, PB; KATER, KM; LAPPAS, DG				COX, JL; BOINEAU, JP; SCHUESSLER, RB; FERGUSON, TB; CAIN, ME; LINDSAY, BD; CORR, PB; KATER, KM; LAPPAS, DG			SUCCESSFUL SURGICAL-TREATMENT OF ATRIAL-FIBRILLATION - REVIEW AND CLINICAL UPDATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							FOLLOW-UP; ARRHYTHMIAS; PREVALENCE; POPULATION; SAMPLE	Atrial fibrillation is the most common of all sustained cardiac arrhythmias, yet it has no effective medical or surgical therapy. During the past decade, multipoint computerized electrophysiological mapping systems were used to map both experimental and human artrial fibrillation. On the basis of these studies, a new surgical procedure was developed for atrial fibrillation. Between September 25, 1987, and July 1, 1991, this procedure was applied in 22 patients with paroxysmal atrial flutter (n = 2), paroxysmal atrial fibrillation (n = 11), or chronic atrial fibrillation (n = 9) of 2 to 21 years' duration. All patients were refractory to all antiarrhythmic medications, and each patient failed to receive the desired therapeutic benefits of an average of five drugs administered preoperatively. There were no operative deaths and all perioperative morbidity resolved. All 22 patients have been successfully treated for atrial fibrillation with surgery alone. Three patients developed one late isolated episode of atrial flutter at 5, 6, and 15 months postoperatively, and each of these patient's symptoms is now controlled by a single antiarrhythmic drug. Preservation of atrial transport function has been documented in all patients postoperatively, and all have experienced marked clinical improvement.	WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, DIV CARDIOTHORAC ANESTHESIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, DIV QUANTUM CHEM, ST LOUIS, MO 63110 USA; BARNES HOSP, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	COX, JL (corresponding author), WASHINGTON UNIV, SCH MED,DEPT SURG,DIV CARDIOTHORAC SURG, ONE BARNES HOSP PLAZA, SUITE 3108, ST LOUIS, MO 63110 USA.				NHLBI NIH HHS [R01 HL32257, R01 HL33722] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032257, R01HL033722] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMERON A, 1988, AM J CARDIOL, V61, P714, DOI 10.1016/0002-9149(88)91053-3; COBLER JL, 1984, ARCH INTERN MED, V144, P1758, DOI 10.1001/archinte.144.9.1758; COX JL, 1991, J THORAC CARDIOV SUR, V101, P584; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; DIAMANTOPOULOS EJ, 1987, EUR HEART J, V8, P17, DOI 10.1093/eurheartj/8.suppl_D.17; FISHER CM, 1982, ATRIAL FIBRILLATION, P192; GUIRAUDON GM, 1985, CIRCULATION, V72, P220; Hirosawa K, 1987, Heart Vessels Suppl, V2, P14; MARTIN A, 1984, EUR HEART J, V5, P592, DOI 10.1093/oxfordjournals.eurheartj.a061710; ONUNDARSON PT, 1987, EUR HEART J, V8, P521; SAVAGE DD, 1983, AM J CARDIOL, V51, P1375, DOI 10.1016/0002-9149(83)90315-6; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SMITH PK, 1985, SURG CLIN N AM, V65, P553; Tammaro A E, 1983, Minerva Med, V74, P1313; TRESEDER AS, 1986, AGE AGEING, V15, P89, DOI 10.1093/ageing/15.2.89; WILLIAMS JM, 1980, J THORAC CARDIOV SUR, V80, P373	17	206	215	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1976	1980		10.1001/jama.266.14.1976	http://dx.doi.org/10.1001/jama.266.14.1976			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895476				2022-12-28	WOS:A1991GH40600024
J	RELMAN, AS				RELMAN, AS			SHATTUCK LECTURE - THE HEALTH-CARE INDUSTRY - WHERE IS IT TAKING US	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEX											BROMBERG MD, 1981, NEW ENGL J MED, V304, P233; ENGELHARDT HT, 1988, NEW ENGL J MED, V319, P1086, DOI 10.1056/NEJM198810203191610; GRAY B, 1986, FOR PROFIT ENTERPRIS; KLETKE PR, 1987, DEMOGRAPHICS PHYSICI; Langwell K M, 1990, Health Care Financ Rev, V12, P71; LEVIT KR, 1991, HEALTH AFFAIR, V10, P117, DOI 10.1377/hlthaff.10.1.117; LEWIN LS, 1988, NEW ENGL J MED, V318, P1212, DOI 10.1056/NEJM198805053181829; Relman A S, 1983, Health Aff (Millwood), V2, P5, DOI 10.1377/hlthaff.2.2.5; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; SADE RM, 1971, NEW ENGL J MED, V258, P1288; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1990, HRD9084 GAO PUBL	13	109	109	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					854	859		10.1056/NEJM199109193251205	http://dx.doi.org/10.1056/NEJM199109193251205			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875970				2022-12-28	WOS:A1991GF61600005
J	CHAVKIN, W				CHAVKIN, W			MANDATORY TREATMENT FOR DRUG-USE DURING PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIVIL COMMITMENT; INTERVENTIONS; RETENTION; ADDICTION		COLUMBIA UNIV,SCH PUBL HLTH,NEW YORK,NY 10027	Columbia University	CHAVKIN, W (corresponding author), BETH ISRAEL MED CTR,INST CHEM DEPENDENCY,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							Allen A E, 1990, Womens Health Issues, V1, P37, DOI 10.1016/S1049-3867(05)80014-3; ANGLIN MD, 1988, RES MONOGRAPH SERIES, P8; BARRY E, 1989, HARVARD WOM LAW J, V12, P198; BENARIES O, 1986, INT J LAW PSYCHIAT, V8, P31; BESCHNER G, 1981, RES MONOGRAPH SERIES; BROWN BS, 1988, J DRUG ISSUES, V18, P663, DOI 10.1177/002204268801800410; BROWN SS, 1991, CHILDREN PARENTAL IL; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; Chavkin W, 1990, J Am Med Womens Assoc (1972), V45, P55; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; CHAVKIN W, 1991, J CLIN ETHICS, V1, P140; CHAVKIN W, 1991, EVALUATIVE STUDY EFF; DELEON G, 1988, RES MONOGRAPH SERIES, P160; FAMULARO R, 1989, CHILD ABUSE NEGLECT, V13, P507, DOI 10.1016/0145-2134(89)90054-9; FIZEK LS, 1988, EMPLOYEE ASSISTANCE, V4, P31; FOSTERCOOK L, 1988, RES MONOGRAPH SERIES, P99; FRANK B, 1990, CURRENT DRUG USE TRE; GERNSTEIN DR, 1990, I MED TREATING DRUG, V1; GURNACK AM, 1989, J ALCOHOL DRUG EDUC, V35, P45; HABEL L, 1988, NOV AM PUBL HLTH ASS; HATCH M, 1984, WOMENS HLTH HAZARDS, P161; HOLDEN RT, 1983, J RES CRIME DELINQ, V20, P55, DOI 10.1177/002242788302000105; HUBBARD RL, 1988, RES MONOGRAPH SERIES, P56; INCIARDI JA, 1988, RES MONOGRAPH SERIES, P126; IRUESTEMONTES AM, 1988, CHILD ABUSE NEGLECT, V12, P33, DOI 10.1016/0145-2134(88)90005-1; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; LEUKEFELD CG, 1988, RES MONOGRAPH SERIES, P236; MADDUX JF, 1988, RES MONOGRAPH SERIES, P35; MARINER WK, 1990, CRIM JUST ETHICS WIN, P30; MASI PA, 1987, EMPLOYEE ASSISTANCE, V12, P33; MCCARTY DA, 1986, J STUD ALCOHOL, V49, P1; MCNULTY M, 1987, REV LAW SOC CHANGE, V16, P277; MOISE R, 1981, INT J ADDICT, V16, P1295, DOI 10.3109/10826088109039187; MOORE KG, 1990, SUBSTANCE ABUSE PREG, P9; Moss Kary, 1990, Harv Women's Law J, V13, P278; NEWMAN RG, 1972, CONTEMP DRUG PROBL, V1, P183; NEWMAN RG, 1973, YALE REV LAW SOC ACT, V3, P246; NEWMAN RG, 1977, DRUG FORUM, V5, P1976; PALTROW L, 1989, CASE OVERVIEW ARGUME; PALTROW L, 1990, STATE STATE SUMMARY; PALTROW LM, 1990, CRIM JUST ETHICS WIN, P41; PLATT JJ, 1988, J DRUG ISSUES, V18, P505, DOI 10.1177/002204268801800402; POMPI KF, 1987, AM J DRUG ALCOHOL AB, V13, P309, DOI 10.3109/00952998709001516; PORTER L, 1986, LAW TREATMENT DRUG A; REED B, 1979, FAMILY DYNAMICS SELF, P114; ROOT MPP, 1989, AM J ORTHOPSYCHIAT, V59, P542, DOI 10.1111/j.1939-0025.1989.tb02744.x; ROSENTHAL MP, 1988, J DRUG ISSUES, V18, P641, DOI 10.1177/002204268801800409; RUBENSTEIN LS, 1986, AM J PSYCHIAT, V143, P1264; SCHOTTENFELD RS, 1989, PSYCHIATRY, V52, P164, DOI 10.1080/00332747.1989.11024441; SIMPSON D, 1988, RES MONOGRAPH SERIES, P81; WINICK C, 1988, J DRUG ISSUES, V19, P561; MASS ANNOTATED LAWS, P35; 1990, GAOHRD90138 GEN ACC; 1990, ADM901711; 1990, STATE STATE SURVEY C; 1990, WOM HLTH ISSUES  FAL, V1, P13; 1967, TASK FORCE REPORT NA; 1988, GUIDELINES IMPLEMENT; 1990, JAMA-J AM MED ASSOC, V264, P2663	59	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1556	1561		10.1001/jama.266.11.1556	http://dx.doi.org/10.1001/jama.266.11.1556			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880889				2022-12-28	WOS:A1991GE45800038
J	JOHNSON, ID				JOHNSON, ID			OCCURRENCE VS CLAIMS-MADE MEDICAL PROFESSIONAL LIABILITY INSURANCE POLICIES - FUNDAMENTAL DIFFERENCES IN THE CONCEPT OF COVERAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, ID (corresponding author), AMER MED ASSOC,CHICAGO,IL 60610, USA.							GUIDE MED PROFESSION	1	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1570	1572						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880893				2022-12-28	WOS:A1991GE45800042
J	KING, AC; HASKELL, WL; TAYLOR, CB; KRAEMER, HC; DEBUSK, RF				KING, AC; HASKELL, WL; TAYLOR, CB; KRAEMER, HC; DEBUSK, RF			GROUP-BASED VS HOME-BASED EXERCISE TRAINING IN HEALTHY OLDER MEN AND WOMEN - A COMMUNITY-BASED CLINICAL-TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY LEVELS; ALL-CAUSE MORTALITY; CIGARETTE USE; LEISURE-TIME; RISK FACTOR; FITNESS; STRATEGIES; INTENSITY	Objective. - To determine the effectiveness of group- vs home-based exercise training of higher and lower intensities among healthy, sedentary older adults. Design. - Year-long randomized, controlled trial comparing (1) higher-intensity group-based exercise training; (2) higher-intensity home-based exercise training; (3) lower-intensity home-based exercise training; or (4) assessment-only control. Setting. - General community located in northern California. Participants. - One hundred sixty women and 197 men 50 to 65 years of age who were sedentary and free of cardiovascular disease. One out of nine persons contacted through a community random-digit-dial telephone survey and citywide promotion were randomized. Interventions. - For higher-intensity exercise training, three 40-minute endurance training sessions per week were prescribed at 73% to 88% of peak treadmill heart rate. For lower-intensity exercise training, five 30-minute endurance training sessions per week were prescribed at 60% to 73% of peak treadmill heart rate. Main Outcome Measures. - Treadmill exercise test performance, exercise participation rates, and heart disease risk factors. Results. - Compared with controls, subjects in all three exercise training conditions showed significant improvements in treadmill exercise test performance at 6 and 12 months (P < .03). Lower-intensity exercise training achieved changes comparable with those of higher-intensity exercise training. Twelve-month exercise adherence rates were better for the two home-based exercise training conditions relative to the group-based exercise training condition (P < .0005). There were no significant training-induced changes in lipid levels, weight, or blood pressure. Conclusions. - We conclude that (1) this community-based exercise training program improved fitness but not heart disease risk factors among sedentary, healthy older adults; (2) home-based exercise was as effective as group exercise in producing these changes; (3) lower-intensity exercise training was as effective as higher-intensity exercise training in the home setting; and (4) the exercise programs were relatively safe.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT PSYCHIAT,PALO ALTO,CA 94304	Stanford University; Stanford University	KING, AC (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,STANFORD CTR RES DIS PREVENT,730 WELCH RD,SUITE B,PALO ALTO,CA 94304, USA.			Taylor, C. Barr/0000-0002-4564-6548; King, Abby/0000-0002-7949-8811	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036272] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36272] Funding Source: Medline; NIA NIH HHS [AG-00440] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKER MH, 1985, MED CARE, V23, P539, DOI 10.1097/00005650-198505000-00014; BLAIR SN, 1990, EXERCISE, FITNESS, AND HEALTH, P385; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLAIR SN, 1983, AM J EPIDEMIOL, V118, P352, DOI 10.1093/oxfordjournals.aje.a113642; BLUMENTHAL JA, 1989, J GERONTOL, V44, pM147, DOI 10.1093/geronj/44.5.M147; BLUMENTHAL JA, 1991, AM J CARDIOL, V67, P633, DOI 10.1016/0002-9149(91)90904-Y; BORG G, 1974, EXERCISE SPORTS SCI, V2; Bouchard C., 1990, EXERCISE FITNESS HLT; BRAY GA, 1990, EXERCISE, FITNESS, AND HEALTH, P497; BROZEK J, 1963, ANN NY ACAD SCI, V110, P113, DOI 10.1111/j.1749-6632.1963.tb17079.x; BUSKIRK ER, 1990, EXERCISE, FITNESS, AND HEALTH, P687; CASPERSEN CJ, 1986, PUBLIC HEALTH REP, V101, P587; DEBUSK RF, 1979, AM J CARDIOL, V44, P1223, DOI 10.1016/0002-9149(79)90433-8; DISHMAN RK, 1985, PUBLIC HEALTH REP, V100, P158; DISHMAN RK, 1990, EXERCISE, FITNESS, AND HEALTH, P75; Dishman RK., 1988, EXERCISE ADHERENCE I; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.2307/2334377; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FORTMANN SP, 1984, PREV MED, V13, P127, DOI 10.1016/0091-7435(84)90045-8; GOSSARD D, 1986, AM J CARDIOL, V57, P446, DOI 10.1016/0002-9149(86)90770-8; HARRIS RB, 1988, JUN P SOC EP RES VAN; HARRIS S S, 1989, Journal of the American Medical Association, V261, P3590; HEINZELMANN F, 1970, PUBLIC HEALTH REP, V85, P905, DOI 10.2307/4594000; IVERSON DC, 1985, PUBLIC HEALTH REP, V100, P212; JUNEAU M, 1987, AM J CARDIOL, V60, P66, DOI 10.1016/0002-9149(87)90986-6; KATCH F, 1967, J APPL PHYSIOL, V23, P811, DOI 10.1152/jappl.1967.23.5.811; KING AC, 1990, HEALTH EDUC QUART, V17, P269, DOI 10.1177/109019819001700304; KING AC, 1990, ARCH INTERN MED, V150, P1841, DOI 10.1001/archinte.150.9.1841; KING AC, 1989, ARCH INTERN MED, V149, P2741, DOI 10.1001/archinte.149.12.2741; LAROSA JC, 1982, ARCH INTERN MED, V142, P2269, DOI 10.1001/archinte.142.13.2269; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MATARAZZO JD, 1984, BEHAVIORAL HLTH HDB; MORRIS JN, 1980, LANCET, V2, P1207; MUELLER JK, 1986, AM J CARDIOL, V57, P441, DOI 10.1016/0002-9149(86)90769-1; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RIPPE JM, 1988, JAMA-J AM MED ASSOC, V259, P2720, DOI 10.1001/jama.259.18.2720; SIRI WE, 1961, TECHNIQUES MEASURING, V223, P244; SPECTOR PC, 1985, SAS USERS GUIDE STAT, P433; WOOD PD, 1983, METABOLISM, V32, P31, DOI 10.1016/0026-0495(83)90152-X; WOOD PD, 1990, EXERCISE, FITNESS, AND HEALTH, P409; 1989, PROMOTING HLTH PREVE; 1984, NIH75628 DHEW PUBL; 1989, MMWR, V38, P700; 1986, GUIDE LINES EXERCISE	46	434	437	2	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1535	1542		10.1001/jama.266.11.1535	http://dx.doi.org/10.1001/jama.266.11.1535			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GE458	1880885				2022-12-28	WOS:A1991GE45800034
J	BOWEN, BW; MEYLAN, AB; AVISE, JC				BOWEN, BW; MEYLAN, AB; AVISE, JC			EVOLUTIONARY DISTINCTIVENESS OF THE ENDANGERED KEMPS RIDLEY SEA-TURTLE	NATURE			English	Article							RESTRICTION ENDONUCLEASES; MITOCHONDRIAL-DNA	THE endangered Kemp's ridley sea turtle (Lepidochelys kempi) nests almost exclusively at a single locality in the western Gulf of Mexico, whereas the olive ridley (L. olivacea) nests globally in warm oceans. Morphological similarities between kempi and olivacea, and a geographical distribution that ". . . makes no sense at all under modern conditions of climate and geography" 1, raise questions about the degree of evolutionary divergence between these taxa. Analysis of mitochondrial (mt) DNA restriction sites shows that Kemp's ridley is distinct from the olive ridley in matriarchal phylogeny, and that the two are sister taxa with respect to other marine turtles. Separation of olive and the Kemp's ridley lineages may date to formation of the Isthmus of Panama, whereas the global spread of the olive ridley lineage occurred recently. In contrast to recent examples in which molecular genetic assessments challenged systematic assignments underlying conservation programmes 2-6, our mtDNA data corroborate the taxonomy of an endangered form.	UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; FLORIDA MARINE RES INST,ST PETERSBURG,FL 33701	University System of Georgia; University of Georgia								Avise J.C., 1990, Oxford Surveys in Evolutionary Biology, V7, P45; AVISE JC, 1989, TRENDS ECOL EVOL, V4, P279, DOI 10.1016/0169-5347(89)90203-6; AVISE JC, 1989, SCIENCE, V243, P646, DOI 10.1126/science.243.4891.646; BOWEN BW, 1989, P NATL ACAD SCI USA, V86, P573, DOI 10.1073/pnas.86.2.573; Briggs J. C., 1974, CIMAC C SHANGH CHIN, DOI 10.2307/1442613; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Carr A. F., 1942, PROC NEW ENGLAND ZOOL CLUB, V21, P1; CARR AF, 1967, EXCELLENT FISH NATUR; DAUGHERTY CH, 1990, NATURE, V347, P177, DOI 10.1038/347177a0; DITMARS RL, 1936, REPTILES N AM; Garman S., 1880, B MUS COMP ZOOL HARV, V6, P123; HENDRICKSON JR, 1980, AM ZOOL, V20, P597; HILDEBRAND HENRY H., 1963, CIENCIA [MEXICO], V22, P105; HUGHES G R, 1972, Biological Conservation, V4, P128, DOI 10.1016/0006-3207(72)90014-6; LAERM J, 1982, J WILDLIFE MANAGE, V46, P513, DOI 10.2307/3808669; LANSMAN RA, 1981, J MOL EVOL, V17, P214, DOI 10.1007/BF01732759; LOVERIDGE ARTHUR, 1957, BULL MUS COMP ZOOL HARVARD UNIV, V115, P163; Magnuson J.J., 1990, DECLINE SEA TURTLES; Mayr E., 1963, ANIMAL SPECIES EVOLU; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; Nei M., 1987, MOL EVOLUTIONARY GEN; OBRIEN SJ, 1991, SCIENCE, V251, P1187, DOI 10.1126/science.251.4998.1187; Pritchard P.C.H., 1984, TURTLES VENEZUELA CO, V2; PRITCHARD PCH, 1969, THESIS U FLORIDA GAI; Ross J. P., 1989, STATUS KEMPS RIDLEY; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; Swofford David L., 1990, P411; WOODY JB, 1986, AUDUBON WILDLIFE REP, P919; ZANGERL RAINER, 1955, FIELDIANA ZOOL, V37, P345	29	56	61	1	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					709	711		10.1038/352709a0	http://dx.doi.org/10.1038/352709a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876185				2022-12-28	WOS:A1991GC06400056
J	HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM				HILL, AVS; ALLSOPP, CEM; KWIATKOWSKI, D; ANSTEY, NM; TWUMASI, P; ROWE, PA; BENNETT, S; BREWSTER, D; MCMICHAEL, AJ; GREENWOOD, BM			COMMON WEST AFRICAN HLA ANTIGENS ARE ASSOCIATED WITH PROTECTION FROM SEVERE MALARIA	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; FRAGMENT-LENGTH-POLYMORPHISM; CD8+ T-CELLS; MHC POLYMORPHISM; MIXED ANCESTRY; DQ ANTIGENS; SELECTION; SUBSTITUTION; HAPLOTYPES; ALLELES	A large case-control study of malaria in West African children shows that a human leucocyte class I antigen (HLA-Bw53) and an HLA class II haplotype (DRB1*1302-DQB1*0501), common in West Africans but rare in other racial groups, are independently associated with protection from severe malaria. In this population they account for as great a reduction in disease incidence as the sickle-cell haemoglobin variant. These data support the hypothesis that the extraordinary polymorphism of major histocompatibility complex genes has evolved primarily through natural selection by infectious pathogens.	MRC LABS, FAJARA, SENEGAMBIA; UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, LONDON WC1E 7HT, ENGLAND; ROYAL VICTORIA HOSP, BANJUL, SENEGAMBIA	University of London; London School of Hygiene & Tropical Medicine	HILL, AVS (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MOLEC IMMUNOL GRP, OXFORD OX3 9DU, ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIZAWA M, 1986, HLA ASIA OCEANIA; ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BENGTSSON BO, 1981, TISSUE ANTIGENS, V18, P356, DOI 10.1111/j.1399-0039.1981.tb01404.x; BIDWELL J, 1988, IMMUNOL TODAY, V9, P18, DOI 10.1016/0167-5699(88)91351-5; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1991, TISSUE ANTIGENS, V37, P97, DOI 10.1111/j.1399-0039.1991.tb01853.x; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BRILES WE, 1977, SCIENCE, V195, P193, DOI 10.1126/science.831269; BROWN PJ, 1981, HUM BIOL, V53, P367; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; CARLSSON B, 1987, HUM IMMUNOL, V20, P95, DOI 10.1016/0198-8859(87)90025-5; CLARKE B, 1966, NATURE, V211, P999, DOI 10.1038/211999a0; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; COLOMBO B, 1985, J MED GENET, V22, P291, DOI 10.1136/jmg.22.4.291; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Dupont B, 1989, IMMUNOBIOLOGY HLA, V1st; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; DUTOIT ED, 1988, TISSUE ANTIGENS, V31, P109; FAREWELL VT, 1984, BIOMETRICS, V40, P547, DOI 10.2307/2531409; FERNANDEZVINA M, 1990, HUM IMMUNOL, V28, P51, DOI 10.1016/0198-8859(90)90102-U; FESTENSTEIN H, 1972, HISTOCOMPATIBILITY T, P175; FIGUEROA F, 1988, NATURE, V335, P265, DOI 10.1038/335265a0; GILLESPIE JH, 1985, THEOR POPUL BIOL, V27, P222, DOI 10.1016/0040-5809(85)90011-5; GORSKI J, 1989, J EXP MED, V170, P1027, DOI 10.1084/jem.170.3.1027; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; GREENWOOD BM, 1990, PARASITOL TODAY, V6, P188, DOI 10.1016/0169-4758(90)90351-4; GREENWOOD BM, IN PRESS PARASITOL T; GYLLENSTEN UB, 1990, P NATL ACAD SCI USA, V87, P1835, DOI 10.1073/pnas.87.5.1835; Haldane J. B. S., 1963, Journal of Genetics, V58, P237, DOI 10.1007/BF02986143; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HEDRICK PW, 1983, GENETICS, V104, P449; HEDRICK PW, 1988, GENETICS, V119, P205; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; HILL AVS, IN PRESS MOL EVOLUTI; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; KLITZ W, 1986, AM J HUM GENET, V39, P340; KWIATKOWSKI D, 1991, P NATL ACAD SCI USA, V88, P5111, DOI 10.1073/pnas.88.12.5111; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; LEE KW, 1990, HUM IMMUNOL, V29, P202; LEE KW, 1990, J IMMUNOL, V145, P3119; LEE TD, 1990, TISSUE ANTIGENS, V35, P64, DOI 10.1111/j.1399-0039.1990.tb01758.x; MARTELL RW, 1989, HUM IMMUNOL, V26, P237, DOI 10.1016/0198-8859(89)90002-5; MARTELL RW, 1990, HUM IMMUNOL, V28, P32, DOI 10.1016/0198-8859(90)90100-4; MCPHERSON GG, 1988, AM J PATHOL, V119, P385; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MOLYNEUX ME, 1989, Q J MED, V71, P441; OKOYE RC, 1985, TISSUE ANTIGENS, V25, P142; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PIAZZA A, 1985, ANN HUM GENET, V49, P47, DOI 10.1111/j.1469-1809.1985.tb01675.x; PLAYFAIR JHL, 1982, BRIT MED BULL, V38, P153, DOI 10.1093/oxfordjournals.bmb.a071752; RESTREPO M, 1988, REV I MED TROP, V30, P323, DOI 10.1590/S0036-46651988000500001; RILEY EM, 1991, PARASITOL TODAY, V7, P5, DOI 10.1016/0169-4758(91)90076-Z; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; RONNINGEN KS, 1990, HUM IMMUNOL, V29, P275, DOI 10.1016/0198-8859(90)90041-M; SCHARF SJ, 1989, P NATL ACAD SCI USA, V86, P6215, DOI 10.1073/pnas.86.16.6215; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHREUDER GMT, 1989, IMMUNOBIOLOGY HLA, V1, P252; SERJEANTSON SW, 1989, TRANSPL P, V21, P598; SERJEANTSON SW, 1989, COLONIZATION PACIFIC, P120; SNELL GD, 1968, FOLIA BIOL-PRAGUE, V14, P335; Sy N E, 1984, Southeast Asian J Trop Med Public Health, V15, P1; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1981, GENETICS, V98, P427; TIWARI JL, 1985, HLA DISEASE ASS; VRIES RRPD, 1979, J IMMUNOGENET, V6, P271; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WORDSWORTH BP, 1990, IMMUNOGENETICS, V32, P413; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; [No title captured]	75	1238	1263	1	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1991	352	6336					595	600		10.1038/352595a0	http://dx.doi.org/10.1038/352595a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1865923	Bronze			2022-12-28	WOS:A1991GB21100046
J	HOOFNAGLE, JH				HOOFNAGLE, JH			THROMBOCYTOPENIA DURING INTERFERON ALFA THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CHRONIC HEPATITIS; ALPHA-INTERFERON				HOOFNAGLE, JH (corresponding author), NIH,BETHESDA,MD 20892, USA.							ALEXANDER GJM, 1987, LANCET, V2, P66; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; PERRILLO RP, 1990, NEW ENGL J MED, V323, P337	4	35	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					849	849		10.1001/jama.266.6.849	http://dx.doi.org/10.1001/jama.266.6.849			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865526				2022-12-28	WOS:A1991GA07300042
J	VALENTA, R; DUCHENE, M; PETTENBURGER, K; SILLABER, C; VALENT, P; BETTELHEIM, P; BREITENBACH, M; RUMPOLD, H; KRAFT, D; SCHEINER, O				VALENTA, R; DUCHENE, M; PETTENBURGER, K; SILLABER, C; VALENT, P; BETTELHEIM, P; BREITENBACH, M; RUMPOLD, H; KRAFT, D; SCHEINER, O			IDENTIFICATION OF PROFILIN AS A NOVEL POLLEN ALLERGEN - IGE AUTOREACTIVITY IN SENSITIZED INDIVIDUALS	SCIENCE			English	Article							BIRCH POLLEN; SEQUENCE; ACTIN; CDNA; PROTEINS; CLONING; GENE; DNA	A complementary DNA encoding a pollen allergen from white birch (Betula verrucosa) that was isolated from a pollen complementary DNA library with serum immunoglobulin E from a birch pollen-allergic individual revealed significant sequence homology to profilins. The recombinant protein showed high affinity to poly-L-proline. Immunoglobulin E antibodies from allergic individuals bound to natural and recombinant birch profilin and also to human profilin. In addition, birch and human profilin induced histamine release from blood basophils of profilin-allergic individuals, but not of individuals sensitized to other plant allergens. The structural similarity of conserved proteins might therefore be responsible for maintaining immunoglobulin E antibody titers in type I allergy.	UNIV VIENNA,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST SPECIF PROPHYLAXIS & TROP MED,A-1095 VIENNA,AUSTRIA; UNIV VIENNA,INST CLIN CHEM & LAB DIAGNOST,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT MED 1,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MICROBIOL & GENET,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST GEN & EXPTL PATHOL,A-1095 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna; University of Vienna			Test, PV/U-9451-2019; Valent, Peter/B-8533-2016; Duchêne, Michael/G-6659-2019; Gamperl, Susi/V-2715-2019; Test, Test/Y-7921-2019	Valent, Peter/0000-0003-0456-5095; Duchêne, Michael/0000-0003-1232-3600; Gamperl, Susi/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365				AMPE C, 1985, J BIOL CHEM, V260, P834; AMPE C, 1988, FEBS LETT, V228, P17, DOI 10.1016/0014-5793(88)80575-1; AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART GA, 1989, EPITOPES ATOPIC ALLE, P83; TAKAGI T, 1990, EUR J BIOCHEM, V192, P777, DOI 10.1111/j.1432-1033.1990.tb19289.x; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, UNPUB; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WIDADA JS, 1989, NUCLEIC ACIDS RES, V17, P2855, DOI 10.1093/nar/17.7.2855	21	579	611	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					557	560		10.1126/science.1857985	http://dx.doi.org/10.1126/science.1857985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857985				2022-12-28	WOS:A1991FZ34700037
J	CRESSWELL, JE; STLEGERDOWSE, M				CRESSWELL, JE; STLEGERDOWSE, M			WOMEN AND SCUBA DIVING	BRITISH MEDICAL JOURNAL			English	Article							DECOMPRESSION-SICKNESS; HYPERBARIC-OXYGEN; PREGNANT PATIENT; SHEEP; FETAL				CRESSWELL, JE (corresponding author), DEPT COMMUNITY CHILD HLTH,15-17 CARLTON TERRACE,EDINBURGH,SCOTLAND.							BAKKEVIG MK, 1989, 15TH ANN M EUR UND B, P137; BANGASSER S, 1978, 10TH P NAT ASS UND I, P31; Bassett BE, 1980, AEROSPACE MED ASS AN, P12; BERNHARDT TL, 1988, CRIT CARE MED, V16, P729, DOI 10.1097/00003246-198807000-00017; BETTS J, 1985, DIVER, V30, P14; BOLTON ME, 1980, UNDERSEA BIOMED RES, V7, P183; BOLTONKLUG ME, 1983, AM J OBSTET GYNECOL, V146, P48, DOI 10.1016/0002-9378(83)90925-0; BOVERMAN DM, 1981, J COMP PHYSIOL PSYCH, V4, P646; CHEN V, 1974, THESIS AM U; DIXON GA, 1988, AVIATION SPACE E DEC, P1146; FIFE WP, 1978, UNDERSEA BIOMED RES, V5, P287; GILMAN SC, 1983, AVIATION SPACE ENV M, V9, P297; GORDON HW, 1986, CORTEX, V22, P399, DOI 10.1016/S0010-9452(86)80004-1; JENNINGS RT, 1987, AVIAT SPACE ENVIR MD, V58, P370; LEDINGHAM IM, 1968, BMJ-BRIT MED J, V4, P285, DOI 10.1136/bmj.4.5626.285; NEWHALL JF, 1981, AM J OBSTET GYNECOL, V140, P893, DOI 10.1016/0002-9378(81)90081-8; POWELL MR, 1985, UNDERSEA BIOMED RES, V12, P59; RUDGE FW, 1990, AVIATION SPACE E JUL, P657; SMITH KC, 1978, NATIONAL OCEANIC OCT; SOMMER B, 1983, DOES MENSTRUATION AF, P53; TELFORD IR, 1969, LANCET, V2, P220; TURNER G, 1982, LANCET, V1, P905; VANHOESEN KB, 1989, JAMA-J AM MED ASSOC, V261, P1039, DOI 10.1001/jama.261.7.1039; VANINA LV, 1983, 7TH P INT C HYP MED, V1, P26; WALIGORA JM, 1986, AER MED ASS ANN SCI, P511; WEIEN RW, 1990, AVIAT SPACE ENVIR MD, V61, P833; Wilson JR, 1983, UNDERSEA BIOMED RES, V10, P11; WILSON JR, 1983, EFFECT REPEATED HYPE; ZWINGELBERG KM, 1987, UNDERSEA BIOMED RES, V14, P311	29	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1590	1591		10.1136/bmj.302.6792.1590	http://dx.doi.org/10.1136/bmj.302.6792.1590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855048	Green Published, Bronze			2022-12-28	WOS:A1991FU54900032
J	DEDOMBAL, FT; DALLOS, V; MCADAM, WAF				DEDOMBAL, FT; DALLOS, V; MCADAM, WAF			CAN COMPUTER-AIDED TEACHING PACKAGES IMPROVE CLINICAL CARE IN PATIENTS WITH ACUTE ABDOMINAL-PAIN	BRITISH MEDICAL JOURNAL			English	Article							ACUTE ABDOMEN; DIAGNOSIS	Objective - To compare three methods of support for inexperienced staff in their diagnosis and management of patients with acute abdominal pain -namely, with (a) structured data collection forms, (b) real time computer aided decision support, and (c) computer based teaching packages. Design - Prospective assessment of effects of methods of support on groups of doctors in one. urban hospital and one rural hospital. Setting - Accident and emergency department at Whipps Cross Hospital, London, and surgical wards of Airedale General Hospital, West Yorkshire. Patients - Consecutive prospective series of all patients presenting to each hospital in specified time periods with acute abdominal pain; total patients in the various periods were 12 506. Main outcome measures - Diagnostic accuracy of participating doctors, admission rates of patients with non-specific abdominal pain, perforation rates in patients with appendicitis, negative laparotomy rates. Results - Use of any one modality resulted in improved diagnostic accuracy and decision making performance. Use of structured forms plus computer feedback resulted in better performance than use of forms alone. Use of structured forms plus a computer teaching package gave results at least as good as those with direct feedback by computer. Conclusions - The results confirm earlier studies in suggesting that the use of computer aided decision support improves diagnostic and decision making performance when dealing with patients suffering from acute abdominal pain. That use of the computer for teaching gave results at least as good as with its use for direct feedback may be highly relevant for those who are apprehensive about the real time use of diagnostic computers in a clinical setting.	WHIPPS CROSS HOSP & CHEST CLIN,DEPT ACCID & EMERGENCY,LONDON E11,ENGLAND; AIREDALE DIST GEN HOSP,STEETON BD20 6TD,W YORKSHIRE,ENGLAND		DEDOMBAL, FT (corresponding author), UNIV LEEDS,CLIN INFORMAT SCI UNIT,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.							ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; BALLA JI, 1989, BRIT MED J, V298, P579, DOI 10.1136/bmj.298.6673.579; BOOM R, 1980, P MEDINFO 80 AMSTERD, P1760; CLIFFORD PC, 1986, ANN ROY COLL SURG, V68, P182; DEDOMBAL FT, 1988, SCAND J GASTROENTERO, V23, P35; DEDOMBAL FT, 1972, BMJ-BRIT MED J, V2, P9, DOI 10.1136/bmj.2.5804.9; Gunn A A, 1976, J R Coll Surg Edinb, V21, P170; Hancock DM, 1987, THEOR SURG, V2, P99; HEWETT DJ, 1990, HOSPITAL UPDATE, V16, P283; HOFFMANN J, 1989, BRIT J SURG, V76, P774, DOI 10.1002/bjs.1800760803; LEAPER DJ, 1973, BMJ-BRIT MED J, V3, P569, DOI 10.1136/bmj.3.5880.569; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; MCADAM WAF, 1990, ANN ROY COLL SURG, V72, P140; MCADAM WAF, 1981, 6 YEARS EXPERIENCE C; MORRIS F, 1990, BRIT MED J, V300, P165, DOI 10.1136/bmj.300.6718.165; PATERSONBROWN S, 1990, BRIT J SURG, V77, P13, DOI 10.1002/bjs.1800770105; ROWSELL KV, IN PRESS THEORETICAL; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; STANILAND JR, 1972, BMJ-BRIT MED J, V3, P393, DOI 10.1136/bmj.3.5823.393; WILSON PD, 1975, BMJ-BRIT MED J, V2, P73, DOI 10.1136/bmj.2.5962.73	20	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1495	1497		10.1136/bmj.302.6791.1495	http://dx.doi.org/10.1136/bmj.302.6791.1495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855017	Green Published, Bronze			2022-12-28	WOS:A1991FT50500019
J	STREET, P; GANNON, MJ; HOLT, EM				STREET, P; GANNON, MJ; HOLT, EM			COMMUNITY OBSTETRIC CARE IN WEST BERKSHIRE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONER OBSTETRICS; PAPER	Objective-To assess the effects of a revised obstetric booking policy whereby all low risk pregnant women received their antenatal care entirely in the community. Design-Comparison of the distribution of antenatal clinic attendances, transfers, and perinatal mortality rates for 1987 and 1989, before and after introduction of the revised policy. Setting-West Berkshire Health District. Subjects-All women who delivered with a registrable birth in the district in 1987 (5817 women) and 1989 (5372). Main outcome measures-Attendances at community and consultant antenatal clinics; bookings transferred from community care to consultant care; perinatal mortality rates. Results-Of 5372 women delivering in West Berkshire in 1989, 3185 (58.3%) were originally booked for general practitioner-midwife care, of whom 1567 (49.2% of general practitioner-midwife bookings) were transferred to consultant care. 1618 women (30.1% of all women delivered) received their entire obstetric care from general practitioners and midwives. Attendance at hospital antenatal clinics was reduced by 16%. In 1989 the perinatal mortality rates (1987 values) for the district were 6.3 (7.6) per 1000 births overall; 8.2 (8.3) per 1000 consultant bookings; 5.0 (4.7) per 1000 for community bookings; and 10.2 (14.4) per 1000 for women transferred to consultant care. Conclusion-Antenatal care of low risk pregnant women may safely be provided by their general practitioner and midwife.			STREET, P (corresponding author), ROYAL BERKSHIRE HOSP,DEPT OBSTET & GYNAECOL,READING RG1 5AN,BERKS,ENGLAND.							BRUDENELL JM, 1983, J ROY SOC MED, V76, P197, DOI 10.1177/014107688307600309; BRYCE FC, 1990, BRIT MED J, V300, P725, DOI 10.1136/bmj.300.6726.725; BULL M, 1989, PRACTITIONER, V233, P211; CHAMBERLAIN G, 1989, BRIT MED J, V298, P1702, DOI 10.1136/bmj.298.6689.1702; DRIFE JO, 1988, BRIT MED J, V297, P1208; LOUDON I, 1990, BRIT MED J, V301, P703, DOI 10.1136/bmj.301.6754.703; MARSH GN, 1985, BRIT MED J, V290, P901, DOI 10.1136/bmj.290.6472.901; REYNOLDS JL, 1988, J ROY COLL GEN PRACT, V38, P307; SANGALA V, 1990, BRIT MED J, V301, P418, DOI 10.1136/bmj.301.6749.418; TAYLOR A, 1986, J ROY COLL GEN PRACT, V36, P157; TAYLOR GW, 1980, LANCET, V2, P1287; 1990, WOMENS HLTH CHARTER	12	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1991	302	6778					698	700		10.1136/bmj.302.6778.698	http://dx.doi.org/10.1136/bmj.302.6778.698			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FE333	1878023	Green Published, Bronze			2022-12-28	WOS:A1991FE33300026
J	KASISKE, BL; NEYLAN, JF; RIGGIO, RR; DANOVITCH, GM; KAHANA, L; ALEXANDER, SR; WHITE, MG				KASISKE, BL; NEYLAN, JF; RIGGIO, RR; DANOVITCH, GM; KAHANA, L; ALEXANDER, SR; WHITE, MG			THE EFFECT OF RACE ON ACCESS AND OUTCOME IN TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE RENAL-DISEASE; KIDNEY-TRANSPLANT; UNITED-STATES; RACIAL-DIFFERENCES; BLACK RECIPIENTS; GRAFT-SURVIVAL; RISK-FACTORS; ALLOGRAFT SURVIVAL; AMERICAN-INDIANS; EXPERIENCE		UNIV MINNESOTA, HENNEPIN CTY MED CTR, MINNEAPOLIS, MN 55415 USA; EMORY UNIV, ATLANTA, GA 30322 USA; CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA; UNIV S FLORIDA, TAMPA, FL 33620 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; DALLAS NEPHROL ASSOCIATES, DALLAS, TX USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Emory University; Cornell University; State University System of Florida; University of South Florida; University of California System; University of California Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BAUER MP, 1980, HISTOCOMPATIBILITY T, P993; Callender C O, 1982, J Natl Med Assoc, V74, P807; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DAWIDSON IJA, 1990, TRANSPLANTATION, V49, P63, DOI 10.1097/00007890-199001000-00014; DIETHELM AG, 1988, ANN SURG, V207, P538, DOI 10.1097/00000658-198805000-00008; DUNN J, 1989, TRANSPLANT P, V21, P3946; EASTERLING RE, 1977, T AM SOC ART INT ORG, V23, P28; Eggers P W, 1984, Health Care Financ Rev, V5, P69; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; FERGUSON R, 1987, AM J PUBLIC HEALTH, V77, P864, DOI 10.2105/AJPH.77.7.864; FIRST MR, 1989, TRANSPLANT P, V21, P3949; GARVIN PJ, 1983, ARCH SURG-CHICAGO, V118, P1441; GREENSTEIN SM, 1989, TRANSPLANT P, V21, P3874; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HOY WE, 1989, TRANSPLANT P, V21, P3909; HOY WE, 1987, AM J KIDNEY DIS, V9, P485, DOI 10.1016/S0272-6386(87)80075-6; IWAKI Y, 1983, TRANSPLANTATION, V35, P506, DOI 10.1097/00007890-198305000-00026; JOHN D, 1989, TRANSPLANT P, V21, P1422; JOHNSON AH, 1989, TRANSPLANT P, V21, P3872; KJELLSTRAND C M, 1988, Archives of Internal Medicine, V148, P1305, DOI 10.1001/archinte.148.6.1305; KNECHTLE SJ, 1989, TRANSPLANT P, V21, P3931; KRAKAUER H, 1983, NEW ENGL J MED, V308, P1558, DOI 10.1056/NEJM198306303082603; KRAKAUER H, 1983, TRANSPLANTATION, V36, P372, DOI 10.1097/00007890-198310000-00005; LAUDICINA SS, 1988, MEDICAID COVERAGE PA; LAZDA VA, 1989, TRANSPLANT P, V21, P1415; MAUSNER JS, 1978, AM J PUBLIC HEALTH, V68, P166, DOI 10.2105/AJPH.68.2.166; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; MEGILL DM, 1989, TRANSPLANT P, V21, P3902; MILFORD EL, 1987, TRANSPLANT P, V19, P30; MILGROM M, 1989, TRANSPLANT P, V21, P3934; NELSON RG, 1989, TRANSPLANT P, V21, P3913; NEWMAN JM, 1990, AM J PUBLIC HEALTH, V80, P318, DOI 10.2105/AJPH.80.3.318; OPELZ G, 1977, TRANSPLANT P, V9, P137; OPELZ G, 1989, TRANSPLANT P, V21, P3918; OPELZ G, 1989, TRANSPLANT P, V21, P3881; PERDUE ST, 1982, TRANSPLANTATION, V34, P75, DOI 10.1097/00007890-198208000-00002; PEREZ LM, 1988, TRANSPLANTATION, V46, P553, DOI 10.1097/00007890-198810000-00017; PIRSCH JD, 1989, TRANSPLANT P, V21, P3926; POLLAK R, 1986, TRANSPLANT P, V18, P399; PUGH JA, 1988, AM J EPIDEMIOL, V127, P135, DOI 10.1093/oxfordjournals.aje.a114773; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; ROVELLI M, 1989, TRANSPLANT P, V21, P3979; SALVATIERRA O, 1989, TRANSPLANT P, V21, P3916; SANFILIPPO F, 1986, TRANSPLANTATION, V42, P28, DOI 10.1097/00007890-198607000-00006; SAUNDERS PH, 1984, TRANSPLANTATION, V37, P359, DOI 10.1097/00007890-198404000-00008; SHAPIRO R, 1989, TRANSPLANT P, V21, P3921; SMITH SM, 1985, HUM PATHOL, V16, P181, DOI 10.1016/S0046-8177(85)80067-8; SOMMER BG, 1989, TRANSPLANT P, V21, P3929; SUGIMOTO T, 1984, AM J PUBLIC HEALTH, V74, P14, DOI 10.2105/AJPH.74.1.14; SUMRANI NB, 1989, TRANSPLANT P, V21, P3943; SUTHERLAND DER, 1989, TRANSPLANT P, V21, P3968; TAKEMOTO S, 1989, TRANSPLANT P, V21, P3865; TEPERMAN L, 1989, TRANSPLANT P, V21, P3963; TEUTSCH S, 1989, AM J KIDNEY DIS, V13, P11, DOI 10.1016/S0272-6386(89)80106-4; VINCENTI F, 1978, NEW ENGL J MED, V299, P793, DOI 10.1056/NEJM197810122991502; WARREN E, 1982, SEMIN NEPHROL, V2, P186; WELLER JM, 1987, AM J KIDNEY DIS, V9, P191, DOI 10.1016/S0272-6386(87)80054-9; WELLER JM, 1985, AM J NEPHROL, V5, P84, DOI 10.1159/000166912; WIDMANN FK, 1985, TECHNICAL MANUAL AM, P114; WRD HJ, 1987, TRANSPL P, V19, P1546; 1990, DHHS OEI018900550 PU; 1987, US PUBLIC ATTITUDES; 1989, NIH USRDS1989 NAT I; 1983, ATTITUDES OPINIONS A; 1988, DHHS ADM901682 NAT I	65	194	194	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					302	307		10.1056/NEJM199101313240505	http://dx.doi.org/10.1056/NEJM199101313240505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1898431	Bronze			2022-12-28	WOS:A1991EU92200005
J	STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML				STEINHERZ, LJ; STEINHERZ, PG; TAN, CTC; HELLER, G; MURPHY, ML			CARDIAC TOXICITY 4 TO 20 YEARS AFTER COMPLETING ANTHRACYCLINE THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGESTIVE HEART-FAILURE; DOXORUBICIN CARDIOTOXICITY; ADRIAMYCIN CARDIOTOXICITY; WEEKLY SCHEDULE; DAUNOMYCIN; EXPERIENCE; CHILDREN	Objective. - To assess the cardiac status of long-term survivors of pediatric malignancies who received chemotherapy, including anthracyclines. Design and Method. - Patients were evaluated by echocardiogram from 4 to 20 years (median, 7 years) after completion of anthracyclines, with prospective and retrospective analysis. Patients. - The consecutive sample of 201 patients had received a total anthracycline dose of 200 to 1275 mg/m2 (median, 450 mg/m2), and 51 patients had mediastinal radiotherapy. Main Outcome Measures. - The overall incidence and severity of abnormal systolic cardiac function were determined for the entire cohort. Risk factors of total anthracycline dose, mediastinal radiotherapy, age during treatment, and length of follow-up were examined. Results. - Twenty-three percent (47/201) of the cohort had abnormal cardiac function on noninvasive testing at long-term follow-up. Correlation between total cumulative dose, length of follow-up, and mediastinal irradiation with incidence of abnormalities was significant. Fifty-six patients were followed up for 10 years or more (median, 12 years), with a median anthracycline dose of 495 mg/m2. Thirty-eight percent (21/56) of these patients, compared with 18% (26/145) of patients evaluated after less than 10 years, had abnormal findings. Sixty-three percent of patients followed up for 10 years or more after receiving 500 mg/m2 or more of anthracyclines had abnormal findings. Nine of 201 patients had late symptoms, including cardiac failure and dysrhythmia, and three patients died suddenly. Microscopic examination of the myocardium on biopsy and autopsy revealed fibrosis. Conclusion. - The 23% incidence of late cardiac abnormalities warrants continued evaluation of patients after anthracyclines to guide patient care and the design of future chemotherapeutic protocols.	MEM SLOAN KETTERING CANC CTR,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	STEINHERZ, LJ (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,1275 YORK AVE,NEW YORK,NY 10021, USA.							BLOOM KR, 1978, CANCER, V41, P1265, DOI 10.1002/1097-0142(197804)41:4<1265::AID-CNCR2820410408>3.0.CO;2-R; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; BROSTOW MR, 1980, ANTHRACYCLINES CURRE, P255; DRESDALE A, 1983, CANCER, V52, P51, DOI 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO;2-#; GILLADOGA AC, 1976, CANCER, V37, P1070, DOI 10.1002/1097-0142(197602)37:2+<1070::AID-CNCR2820370814>3.0.CO;2-6; LEFRAK EA, 1973, CANCER-AM CANCER SOC, V32, P302, DOI 10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; LIPSHULTZ S E, 1988, Journal of the American College of Cardiology, V11, p135A; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA153; LIPSHULTZ SE, 1987, BLOOD, V70, pA234; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; SCHWARTZ RG, 1987, AM J MED, V82, P1109, DOI 10.1016/0002-9343(87)90212-9; SINGER J W, 1978, Cancer Treatment Reports, V62, P945; STEINHERZ L, 1985, WORLD C PEDIATR CARD, V2, P58; STEINHERZ L, 1986, PEDIATRIC CARDIOL, P1056; STEINHERZ L, 1989, P AN M AM SOC CLIN, V8, P296; STEINHERZ L, 1984, P AM SOC CLIN ONCOL, V3, P198; STEINHERZ LJ, 1987, MED PEDIATR ONCOL, V15, P326; TAN C, 1967, CANCER-AM CANCER SOC, V20, P333, DOI 10.1002/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K; TORTI FM, 1983, ANN INTERN MED, V99, P745, DOI 10.7326/0003-4819-99-6-745; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEISS AJ, 1977, CANCER, V40, P2046, DOI 10.1002/1097-0142(197711)40:5<2046::AID-CNCR2820400508>3.0.CO;2-5	23	766	783	2	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1672	1677		10.1001/jama.266.12.1672	http://dx.doi.org/10.1001/jama.266.12.1672			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886191				2022-12-28	WOS:A1991GF41900034
J	SURKS, MI				SURKS, MI			THYROID-STIMULATING HORMONE - REFERENCE RANGE VALIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							THYROTROPIN				SURKS, MI (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,BRONX,NY 10467, USA.							CHOPRA IJ, 1990, METABOLISM, V39, P538, DOI 10.1016/0026-0495(90)90014-4; NICOLOFF JT, 1990, J CLIN ENDOCR METAB, V71, P553, DOI 10.1210/jcem-71-3-553	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1573	1573						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880894				2022-12-28	WOS:A1991GE45800044
J	BENDAVID, Y; BERNSTEIN, A				BENDAVID, Y; BERNSTEIN, A			FRIEND VIRUS-INDUCED ERYTHROLEUKEMIA AND THE MULTISTAGE NATURE OF CANCER	CELL			English	Review							ERYTHROPOIETIN RECEPTOR; ETS ONCOGENE; ACTIVATION; GP55; GLYCOPROTEIN; RESISTANCE; EXPRESSION; MARROW; CELLS; SPI-1		MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto	BENDAVID, Y (corresponding author), SUNNYBROOK MED CTR, DIV CANC RES, TORONTO M4N 3M5, ONTARIO, CANADA.							BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; DELRIZZO DF, 1988, P NATL ACAD SCI USA, V85, P4320; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1991, IN PRESS ONCOGENE; LEVINE AJ, 1991, NATURE, V312, P649; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SILVER J, 1981, J EXP MED, V154, P126, DOI 10.1084/jem.154.1.126; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	24	258	264	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					831	834		10.1016/0092-8674(91)90428-2	http://dx.doi.org/10.1016/0092-8674(91)90428-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889087				2022-12-28	WOS:A1991GE46000003
J	SNINSKY, CA; CORT, DH; SHANAHAN, F; POWERS, BJ; SESSIONS, JT; PRUITT, RE; JACOBS, WH; LO, SK; TARGAN, SR; CERDA, JJ; GREMILLION, DE; SNAPE, WJ; SABEL, J; JINICH, H; SWINEHART, JM; DEMICCO, MP				SNINSKY, CA; CORT, DH; SHANAHAN, F; POWERS, BJ; SESSIONS, JT; PRUITT, RE; JACOBS, WH; LO, SK; TARGAN, SR; CERDA, JJ; GREMILLION, DE; SNAPE, WJ; SABEL, J; JINICH, H; SWINEHART, JM; DEMICCO, MP			ORAL MESALAMINE (ASACOL) FOR MILDLY TO MODERATELY ACTIVE ULCERATIVE-COLITIS - A MULTICENTER STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							INFLAMMATORY BOWEL-DISEASE; 5-AMINOSALICYLIC ACID; ACETYLATOR PHENOTYPE; PATIENTS INTOLERANT; SULPHASALAZINE; SULFASALAZINE; METABOLISM; MESALAZINE; THERAPY; RELEASE	Objective: To evaluate the efficacy and safety of a pH-sensitive, polymer-coated oral preparation of mesalamine in patients with mildly to moderately active ulcerative colitis. Design: A multicenter, double-blind, placebo-controlled randomized trial. Setting: Five university-based medical centers, one inflammatory bowel disease center, and three private practice sites. Patients: A total of 158 patients with newly or previously diagnosed active ulcerative colitis. Intervention: A pH-sensitive, polymer-coated oral preparation of mesalamine (5-aminosalicylic acid) was used at 1.6 and 2.4 g/d for 6 weeks. Measurements: Efficacy was measured by scores for stool frequency, rectal bleeding, patient's functional assessment, sigmoidoscopic findings, and physician's global assessment. Stringent criteria for disease activity were established prospectively. Results: The analysis of protocol-compliant patients showed a significant improvement at 3 weeks in patients taking 2.4 g/d of mesalamine compared with patients taking placebo (32% versus 9%; P = 0.003). At 6 weeks, both the 1.6 g/d (43%) and 2.4 g/d (49%) doses were significantly superior to placebo (23%) (P = 0.03 and P = 0.003, respectively). In addition, more patients worsened in the placebo group compared with the 2.4 g/d group (50% versus 19%; P = 0.003); however, there was no statistically significant difference in worsening between the 1.6 g/d mesalamine group and the placebo group. The oral mesalamine tablet was well tolerated, and no clinically significant changes were observed in hematologic, hepatic, or renal laboratory profiles. Conclusion: Colon-targeted oral mesalamine at 2.4 g/d is effective therapy for mildly to moderately active ulcerative colitis. It is well tolerated and should provide a viable therapeutic alternative to sulfasalazine.	UNIV FLORIDA, CTR HLTH, GAINESVILLE, FL 32610 USA; DIGEST DIS CONSULTANTS, CHESTERFIELD, MO 63017 USA; UNIV CALIF LOS ANGELES, CTR HLTH SCI, LOS ANGELES, CA 90024 USA; ARAPAHOE GASTROENTEROL, ENGLEWOOD, CO 80110 USA; UNIV N CAROLINA, CHAPEL HILL, NC 27599 USA; MED RES INST, NASHVILLE, TN 37211 USA; MENORAH MED CTR, KANSAS CITY, MO 64110 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR, CTR IBD, TORRANCE, CA 90502 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; S DENVER GASTROENTEROL, ENGLEWOOD, CO 80110 USA; UNIV CALIF SAN DIEGO, SAN DIEGO, CA 92103 USA; COLORADO MED RES CTR, DENVER, CO 80210 USA	State University System of Florida; University of Florida; University of California System; University of California Los Angeles; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California System; University of California San Diego	SNINSKY, CA (corresponding author), VET AFFAIRS MED CTR, GASTROENTEROL SECT 111C, GAINESVILLE, FL 32608 USA.		Shanahan, Fergus/ABF-2390-2020	Shanahan, Fergus/0000-0003-0467-0936				AUSTIN CA, 1984, LANCET, V1, P917; AZADKHAN AK, 1977, LANCET, V2, P892; CAMPIERI M, 1981, LANCET, V2, P270; DAS KM, 1973, NEW ENGL J MED, V289, P491, DOI 10.1056/NEJM197309062891001; DAS KM, 1973, GUT, V14, P631, DOI 10.1136/gut.14.8.631; DEW MJ, 1983, LANCET, V2, P801; DEW MJ, 1982, BMJ-BRIT MED J, V285, P1012, DOI 10.1136/bmj.285.6347.1012; DEW MJ, 1983, BRIT J CLIN PHARMACO, V16, P185, DOI 10.1111/j.1365-2125.1983.tb04983.x; DONALD IP, 1985, POSTGRAD MED J, V61, P1047, DOI 10.1136/pgmj.61.722.1047; Fleiss JL., 1981, STAT METHODS RATES P, P14; KLOTZ U, 1980, NEW ENGL J MED, V303, P1499, DOI 10.1056/NEJM198012253032602; NIELSEN OH, 1983, BRIT J CLIN PHARMACO, V16, P738; PEPPERCORN MA, 1972, J PHARMACOL EXP THER, V181, P555; PEPPERCORN MA, 1990, ANN INTERN MED, V112, P50, DOI 10.7326/0003-4819-112-1-50; RAO SS, 1987, SCAND J GASTROENTERO, V22, P332, DOI 10.3109/00365528709078600; RASMUSSEN SN, 1982, GASTROENTEROLOGY, V83, P1062; RILEY SA, 1988, GUT, V29, P669, DOI 10.1136/gut.29.5.669; RILEY SA, 1988, GASTROENTEROLOGY, V94, P1383, DOI 10.1016/0016-5085(88)90677-4; SCHRODER H, 1972, GUT, V13, P278, DOI 10.1136/gut.13.4.278; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; SCHWARTZ AG, 1982, NEW ENGL J MED, V306, P409, DOI 10.1056/NEJM198202183060708; SUTHERLAND LR, 1987, GASTROENTEROLOGY, V92, P1894, DOI 10.1016/0016-5085(87)90621-4; TAFFET SL, 1983, DIGEST DIS SCI, V28, P833, DOI 10.1007/BF01296907; VANHEES PAM, 1980, GUT, V21, P632, DOI 10.1136/gut.21.7.632; WILLOUGHBY CP, 1982, GUT, V23, P1081, DOI 10.1136/gut.23.12.1081	25	173	174	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					350	355		10.7326/0003-4819-115-5-350	http://dx.doi.org/10.7326/0003-4819-115-5-350			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863024				2022-12-28	WOS:A1991GC06500003
J	ROWLEY, BD; BALDWIN, DC; MCGUIRE, MB				ROWLEY, BD; BALDWIN, DC; MCGUIRE, MB			SELECTED CHARACTERISTICS OF GRADUATE MEDICAL-EDUCATION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DIV MED EDUC RES & INFORMAT,CHICAGO,IL 60610	American Medical Association	ROWLEY, BD (corresponding author), AMER MED ASSOC,DEPT DATA SYST,CHICAGO,IL 60610, USA.							CROWLEY A E, 1986, Journal of the American Medical Association, V256, P1585, DOI 10.1001/jama.256.12.1585; CROWLEY AE, 1981, JAMA-J AM MED ASSOC, V246, P2938	2	45	45	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					933	943		10.1001/jama.266.7.933	http://dx.doi.org/10.1001/jama.266.7.933			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870222				2022-12-28	WOS:A1991GB20500005
J	WORTHINGTON, WC				WORTHINGTON, WC			A STUDY IN POST-FLEXNER SURVIVAL - THE MEDICAL-COLLEGE-OF-THE-STATE-OF-SOUTH-CAROLINA, 1913	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Flexner report of 1910 resulted in the closing of many marginal medical schools and opened a new era in medical education in the United States. Caught in Abraham Flexner's net were several old schools with long histories and, as he said, "traditions and a certain present dignity" that lacked the minimum resources needed to meet the standards of the Council on Medical Education of the American Medical Association. One example was the Medical College of the State of South Carolina. It was consigned to oblivion in Flexner's plan, but survived. Dean Robert Wilson, MD, in his efforts to save his school, turned politician, enlisted the aid of the state's highly controversial governor, and initiated an effective lobbying campaign in the state legislature. The Council on Medical Education became involved unofficially in the person of its secretary, Nathan P. Colwell, MD. His presence in South Carolina was turned to advantage by Wilson and others and contributed substantially to the success of their efforts.			WORTHINGTON, WC (corresponding author), MED UNIV S CAROLINA,WARING HIST LIB,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							BURNSIDE RD, 1963, THESIS INDIANA U BLO; Flexner A, 1910, MED ED US CANADA, P85; HOLLIS DW, 1969, S CAROLINA HIST MAGA, V70, P33; HOLLIS DW, 1956, U S CAROLINA, V2, P250; LYNCH KM, 1970, MED SCH S CAROLINA, P72; WALLACE DD, 1951, S CAROLINA SHORT HIS, P657; WARING JI, 1971, HIST MED S CAROLINA, P174; WILSON R, UNPUB PERSONAL RECOL; WILSON R, 1913, UNPUB COMMUNICA 0107; WILSON R, 1910, COMMUNICATION   0106; 1912, UNPUB DEC M BOARD TR; 1936, JAMA-J AM MED ASSOC, V106, P231	12	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					981	984						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870228				2022-12-28	WOS:A1991GB20500011
J	KELLEHER, KC				KELLEHER, KC			FREE CLINICS - A SOLUTION THAT CAN WORK ... NOW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									BRADLEY FREE CLIN,ROANOKE,VA		KELLEHER, KC (corresponding author), BACK CREEK FAMILY PRACTICE,LEWIS GALE CLIN,7119 BENT MTN RD,ROANOKE,VA 24018, USA.							BESS GM, 1990, DIRECTORY FREE COMMU; ROCKEFELLER JD, 1990, NEW ENGL J MED, V323, P1005, DOI 10.1056/NEJM199010043231429	2	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					838	840		10.1001/jama.266.6.838	http://dx.doi.org/10.1001/jama.266.6.838			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865524				2022-12-28	WOS:A1991GA07300038
J	NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI				NOVELLO, AC; CLINTON, JJ; WISE, PH; MITCHELL, WI			CARING FOR CHILDREN WITH HIV-INFECTION - THE NEED FOR A COMMON EMBRACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									OFF SURGEON GEN,HUBERT H HUMPHREY BLDG,ROOM 718-E,WASHINGTON,DC 20201									NOVELLO AC, GUIDE FAMILY CTR COM	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					770	770						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865514				2022-12-28	WOS:A1991GA07300010
J	RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M				RESNICK, NM; MALOY, WL; GUY, HR; ZASLOFF, M			A NOVEL ENDOPEPTIDASE FROM XENOPUS THAT RECOGNIZES ALPHA-HELICAL SECONDARY STRUCTURE	CELL			English	Article							EUKARYOTIC SIGNAL PEPTIDASE; CLEAVAGE SITE; SECRETORY GRANULES; HORMONE PRECURSORS; SINGLE ARGININE; LIPID BILAYERS; LAEVIS SKIN; SUBSTRATE; SEQUENCE; FORMS	The magainin peptides of Xenopus laevis are broad-spectrum antimicrobial agents. Upon discharge from the skin glands, these basic, amphipathic peptides are each further processed at a single Xaa-Lys bond into half-peptides by a cosecreted protease. We describe the characterization and purification to homogeneity of this endopeptidase from Xenopus skin. The enzyme is a metalloprotease 110 kd in size. Analyses of substrate specificity revealed that the endopeptidase recognizes peptides that share the ability to adopt an amphipathic, alpha-helical motif composed of at least 12 residues, with one face strongly hydrophobic. Cleavage occurs on the amino side of a specific lysine that must be precisely positioned relative to the hydrophobic face of the alpha-helix. This enzyme, which we propose to call "magaininase," represents a novel class of endopeptidases that hydrolyzes peptides on the basis of specific secondary structure rather than primary amino acid sequence.	UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; MAGAININ SCI INC,PLYMOUTH MEETING,PA 19462; NCI,MATH BIOL LAB,BETHESDA,MD 20892	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RESNICK, NM (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET,PHILADELPHIA,PA 19104, USA.							BECHINGER B, 1991, IN PRESS J BIOMOL NM; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BEINFELD MC, 1989, J BIOL CHEM, V264, P4460; BEK E, 1990, BIOCHEMISTRY-US, V29, P178, DOI 10.1021/bi00453a024; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1989, J BIOL CHEM, V264, P5852; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRAKCH N, 1989, J BIOL CHEM, V264, P15912; CAULFIELD MP, 1989, J BIOL CHEM, V264, P15813; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DARBY NJ, 1991, EUR J BIOCHEM, V195, P65, DOI 10.1111/j.1432-1033.1991.tb15676.x; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; Gabriel, 1971, METHOD ENZYMOL, V22, P565, DOI 10.1016/0076-6879(71)22041-3; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GLUSCHANKOF P, 1988, FEBS LETT, V234, P149, DOI 10.1016/0014-5793(88)81322-X; GLUSCHANKOF P, 1987, NEUROCHEM RES, V12, P951, DOI 10.1007/BF00966318; GOMEZ S, 1989, EMBO J, V8, P2911, DOI 10.1002/j.1460-2075.1989.tb08440.x; HURT EC, 1987, J BIOL CHEM, V262, P1420; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KAISER ET, 1987, ANN REV BIOPHYS CHEM, V16, P562; KUKS PFM, 1989, J BIOL CHEM, V264, P14609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH YP, 1988, MOL MECHANISMS SECRE, P525; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MIZUNO K, 1986, BIOCHEM BIOPH RES CO, V137, P984, DOI 10.1016/0006-291X(86)90322-0; MOLLAY C, 1986, EUR J BIOCHEM, V160, P31, DOI 10.1111/j.1432-1033.1986.tb09935.x; OCHS D, 1983, ANAL BIOCHEM, V135, P470, DOI 10.1016/0003-2697(83)90714-5; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL YC, 1981, ENDOCRINOLOGY, V109, P1943, DOI 10.1210/endo-109-6-1943; PLEVRAKIS I, 1989, BIOCHEMISTRY-US, V28, P2705, DOI 10.1021/bi00432a051; POULTER L, 1988, J BIOL CHEM, V263, P3279; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; RICHTER K, 1986, J BIOL CHEM, V261, P3676; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SURES I, 1984, P NATL ACAD SCI-BIOL, V81, P380, DOI 10.1073/pnas.81.2.380; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; THORNE BA, 1990, J BIOL CHEM, V265, P8436; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZAKARIAN S, 1982, BIOCHEM J, V202, P561, DOI 10.1042/bj2020561; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	52	76	78	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					541	554		10.1016/0092-8674(81)90017-9	http://dx.doi.org/10.1016/0092-8674(81)90017-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868549	hybrid			2022-12-28	WOS:A1991GA94100015
J	HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD				HSU, VW; YUAN, LC; NUCHTERN, JG; LIPPINCOTTSCHWARTZ, J; HAMMERLING, GJ; KLAUSNER, RD			A RECYCLING PATHWAY BETWEEN THE ENDOPLASMIC-RETICULUM AND THE GOLGI-APPARATUS FOR RETENTION OF UNASSEMBLED MHC CLASS-I MOLECULES	NATURE			English	Article							HEAVY-CHAINS; BREFELDIN-A; PROTEINS; ER; ANTIBODIES; RECEPTOR; COMPLEX	ASSEMBLY of Class I major histocompatibility complex (MHC) molecules involves the interaction of two distinct polypeptides (the heavy and light chains) with peptide antigen. Cell lines synthesizing both chains but expressing low levels of MHC class I molecules on their surface as a result of a failure in assembly and transport have been identified 1. We now report that although the apparent steady-state distribution in these cells of class I molecules is in the endoplasmic reticulum (ER), the molecules in fact are recycled between the ER and Golgi, rather than retained in the ER. This explains the failure of class I molecules to negotiate the secretory pathway. Class I molecules do not seem to be modified by Golgi enzymes, suggesting that the proteins do not reach the Golgi apparatus during recycling. But morphological and subcellular fractionation evidence indicates that they pass through the cis Golgi or a Golgi-associated organelle, which we postulate to be the recycling organelle. This compartment, which we call the 'cis-Golgi network', would thereby be a sorting organelle that selects proteins for return to the ER.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	HSU, VW (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189	14	161	161	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					441	444		10.1038/352441a0	http://dx.doi.org/10.1038/352441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861723				2022-12-28	WOS:A1991FZ34600069
J	CHAMBERLAIN, G				CHAMBERLAIN, G			ABC OF ANTENATAL CARE - PRETERM LABOR	BRITISH MEDICAL JOURNAL			English	Article											CHAMBERLAIN, G (corresponding author), ST GEORGE HOSP,SCH MED,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND.							1988, BR J OBSTET GYNAECOL, V95, P437	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					44	48		10.1136/bmj.303.6793.44	http://dx.doi.org/10.1136/bmj.303.6793.44			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859959	Green Published, Bronze			2022-12-28	WOS:A1991FW12800028
J	KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P				KOLETZKO, S; GRIFFITHS, A; COREY, M; SMITH, C; SHERMAN, P			INFANT-FEEDING PRACTICES AND ULCERATIVE-COLITIS IN CHILDHOOD	BRITISH MEDICAL JOURNAL			English	Article							CROHNS-DISEASE		UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DIV GASTROENTEROL,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT NURSING,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Sherman, Philip/0000-0002-4733-6690				ACHESON ED, 1961, BRIT MED J, V2, P929, DOI 10.1136/bmj.2.5257.929; CHANDRA RK, 1989, NUTR RES, V9, P1, DOI 10.1016/S0271-5317(89)80098-3; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; KOLETZKO S, 1989, BRIT MED J, V298, P1617, DOI 10.1136/bmj.298.6688.1617; WHORWELL PJ, 1979, BRIT MED J, V1, P382, DOI 10.1136/bmj.1.6160.382	5	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1580	1581		10.1136/bmj.302.6792.1580	http://dx.doi.org/10.1136/bmj.302.6792.1580			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855043	Green Published, Bronze			2022-12-28	WOS:A1991FU54900027
J	BAUER, G; LUEF, G; MAROSI, M; SAILER, U; BOHR, K				BAUER, G; LUEF, G; MAROSI, M; SAILER, U; BOHR, K			PHENYTOIN FOR THE PREVENTION OF POSTTRAUMATIC SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							TOLERANCE				BAUER, G (corresponding author), UNIV INNSBRUCK,A-6020 INNSBRUCK,AUSTRIA.							FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; GENT JP, 1985, LIFE SCI, V37, P849, DOI 10.1016/0024-3205(85)90520-X; ROSENBERG HC, 1989, EPILEPSIA, V30, P276, DOI 10.1111/j.1528-1157.1989.tb05299.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801	4	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					341	341						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1898770				2022-12-28	WOS:A1991EU92200028
J	LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC				LERMAN, A; EDWARDS, BS; HALLETT, JW; HEUBLEIN, DM; SANDBERG, SM; BURNETT, JC			CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN ADVANCED ATHEROSCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; INCREASED PLASMA ENDOTHELIN; ARTERIES; PROLIFERATION; PATHOGENESIS; RESPONSES; PRIMATES; DISEASE; ANGINA	Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (+/- SD) plasma endothelin concentration was 1.4 +/- 0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2 +/- 1.2 pmol per liter (P < 0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P < 0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a marker for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.	MAYO CLIN & MAYO FDN,DIV CARDIOVASC SURG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT SURG,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	LERMAN, A (corresponding author), MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,CARDIORENAL RES LAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.				NHLBI NIH HHS [HL36634, HL07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO K, 1989, FEBS LETT, V245, P164, DOI 10.1016/0014-5793(89)80213-3; ARENDT RM, 1990, CIRCULATION, V82, P248; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CAVERO PG, 1990, AM J PHYSIOL, V259, pF312, DOI 10.1152/ajprenal.1990.259.2.F312; DREXLER H, 1990, Journal of the American College of Cardiology, V15, p158A; Dubin D, 1989, J VASC MED BIOL, V1, P150; EDWARDS BS, 1990, AM J HYPERTENS, V3, pA64; FINGERLE J, 1987, INT ANGIOL, V6, P65; GOETZ KL, 1988, AM J PHYSIOL, V255, pR1064, DOI 10.1152/ajpregu.1988.255.6.R1064; GUYTON JR, 1979, AM J PATHOL, V94, P585; HEUBLEIN DM, 1989, AM J HYPERTENS, V2, pA37; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; HIROE M, 1989, PEPTIDES, V10, P1281, DOI 10.1016/0196-9781(89)90021-1; KON V, 1989, CIRCULATION S2, V80, P483; LERMAN A, 1991, TRANSPLANTATION, V51, P646, DOI 10.1097/00007890-199103000-00020; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; LOPEZ JAG, 1989, CLIN RES, V37, pA883; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; LUSCHER TF, 1989, EUR HEART J, V10, P847; LUSCHER TF, 1989, J CARDIOVASC PHARM, V14, pS63; MILLER WL, 1989, J CLIN INVEST, V83, P317, DOI 10.1172/JCI113876; MIYAUCHI T, 1989, LANCET, V2, P53, DOI 10.1016/S0140-6736(89)90303-6; MIYAUCHI T, 1990, CIRCULATION, V81, P1874, DOI 10.1161/01.CIR.81.6.1874; OBRIEN RF, 1987, J CELL PHYSIOL, V132, P263, DOI 10.1002/jcp.1041320210; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V168, P1303, DOI 10.1016/0006-291X(90)91171-N; ROBERTS WC, 1982, AM J CARDIOL, V50, P203, DOI 10.1016/0002-9149(82)90030-3; ROSS R, 1981, ARTERIOSCLEROSIS, V1, P293, DOI 10.1161/01.ATV.1.5.293; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SAITO T, 1989, Japanese Journal of Pharmacology, V49, p215P; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SCHICHIRI M, 1989, CIRUCLATION S2, V80, P125; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; TAKAGI Y, 1990, BIOCHEM BIOPH RES CO, V168, P537, DOI 10.1016/0006-291X(90)92354-3; VITA J A, 1990, Journal of the American College of Cardiology, V15, p158A; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANG ZH, 1990, CIRCULATION, V82, P188, DOI 10.1161/01.CIR.82.1.188; YASUDA M, 1990, AM HEART J, V119, P801, DOI 10.1016/S0002-8703(05)80315-1	40	940	994	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					997	1001		10.1056/NEJM199110033251404	http://dx.doi.org/10.1056/NEJM199110033251404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886637	Green Submitted			2022-12-28	WOS:A1991GH44700004
J	BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF				BOWTON, DL; SCUDERI, PE; HARRIS, L; HAPONIK, EF			PULSE OXIMETRY MONITORING OUTSIDE THE INTENSIVE-CARE UNIT - PROGRESS OF PROBLEM	ANNALS OF INTERNAL MEDICINE			English	Article						OXIMETRY; ANOXEMIA; RESPIRATORY THERAPY; MONITORING, PHYSIOLOGICAL; ARRHYTHMIAS	VENTRICULAR ECTOPY; OXYGEN-SATURATION; DESATURATION	Objective: To evaluate the use of continuous pulse oximetry monitoring in general care units. Design: Hemoglobin oxygen saturation data collected prospectively by use of pulse oximetry with concurrent review of the medical record. Setting: General medical-surgical nursing units in a large, tertiary care university hospital. Patients: Forty patients on two nursing units monitored with continuous, bedside pulse oximetry at the request of their primary physicians. Measurements: All patients had continuous pulse oximetry monitoring. A research associate visited the bedside two or three times daily and recorded saturation compared with time data from the previous 8.75 hours. Patients were studied for 36 hours or until pulse oximetry monitoring was discontinued. Episodes of desaturation were counted. Patient charts were reviewed for documentation of desaturation in either nursing or physician notes. Orders adjusting oxygen therapy or other respiratory therapy within 12 hours of any desaturation episode were also recorded. Main Results: Thirty of the 40 patients (75%) had at least one episode of desaturation to less than 90%; 23 (58%) had at least one episode to less than 85%. Desaturation episodes were documented in nursing notes for only 33% of those patients who desaturated to less than 90% and in physician notes in only 7% of cases. Changes in respiratory therapy were ordered in 20% of patients who desaturated to less than 90% and in only 26% who desaturated to less than 85%. Conclusions: Despite their repeated occurrence, episodes of hypoxemia were rarely documented in either nursing or physician notes. Further, even in patients who had episodic desaturation, pulse oximetry monitoring had little effect on changes in physician-directed respiratory care.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT ANESTHESIA, CRIT CARE SECT, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	BOWTON, DL (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, PULM & CRIT CARE MED SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.		Bowton, David/AAZ-2916-2020					DODSON SR, 1988, CHEST, V94, P28, DOI 10.1378/chest.94.1.28; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; MCKAY WPS, 1988, CAN J ANAESTH, V35, P265, DOI 10.1007/BF03010621; MIHM FG, 1985, ANESTHESIOLOGY, V62, P85, DOI 10.1097/00000542-198501000-00020; NEFF TA, 1988, CHEST, V94, P227, DOI 10.1378/chest.94.2.227a; PROUGH DS, 1990, CRITICAL CARE STATE, P271; SCHNAPP LM, 1990, CHEST, V98, P1244, DOI 10.1378/chest.98.5.1244; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; SHEPARD JW, 1985, AM J MED, V78, P28, DOI 10.1016/0002-9343(85)90457-7; TRASK CH, 1962, NEW ENGL J MED, V266, P639, DOI 10.1056/NEJM196203292661303; TREMPER KK, 1989, ANESTHESIOLOGY, V70, P98, DOI 10.1097/00000542-198901000-00019; TYLER IL, 1985, ANESTH ANALG, V64, P1108	12	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					450	454		10.7326/0003-4819-115-6-450	http://dx.doi.org/10.7326/0003-4819-115-6-450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872492				2022-12-28	WOS:A1991GE81000006
J	SMITH, RC; HOPPE, RB				SMITH, RC; HOPPE, RB			THE PATIENTS STORY - INTEGRATING THE PATIENT-CENTERED AND PHYSICIAN-CENTERED APPROACHES TO INTERVIEWING	ANNALS OF INTERNAL MEDICINE			English	Article						PHYSICIAN-PATIENT RELATIONS; INTERVIEWS; COMMUNICATION; MEDICAL HISTORY TAKING; SOCIAL SUPPORT	MEDICAL INTERVIEW; ELICITING FEELINGS; CLINICAL METHOD; COMMUNICATION; BEHAVIOR; CARE; PROVIDER; MODEL; SATISFACTION; MANAGEMENT	Patients produce biopsychosocial stories that integrate material from the medical and personal aspects of their lives. Capturing the personal aspect of the story requires that a patient-centered approach to clinical interviewing complement the equally important physician-centered approach. Patient-centered interviewing actively involves the patient and ensures that his or her perceptions, needs, and concerns are articulated during the physician-patient interaction. In our article, we define patient-centered interviewing and provide a rationale for using it. We also describe how patient-centered interviewing is done, how it is integrated with the physician-centered approach, and how to understand the product of this complementary approach to clinical interviewing, the patient's biopsychosocial story.			SMITH, RC (corresponding author), MICHIGAN STATE UNIV, B220 LIFE SCI BLDG, E LANSING, MI 48824 USA.		Smith, Robert/CAF-1930-2022	Smith, Robert/0000-0001-6996-9037				BARSKY AJ, 1981, ANN INTERN MED, V94, P492, DOI 10.7326/0003-4819-94-4-492; BARTLETT EE, 1984, J CHRON DIS, V37, P755, DOI 10.1016/0021-9681(84)90044-4; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BILLINGS JA, 1989, CLIN ENCOUNTER GUIDE; BIRD J, 1983, GEN HOSP PSYCHIAT, V5, P247, DOI 10.1016/0163-8343(83)90003-8; Bird J., 1991, MODELS TEACHING CONS, P65; BRODY H, 1982, ANN INTERN MED, V97, P112, DOI 10.7326/0003-4819-97-1-112; BURACK RC, 1983, J FAM PRACTICE, V16, P749; CARTER WB, 1982, MED CARE, V20, P550, DOI 10.1097/00005650-198206000-00002; CASSEL EJ, 1985, TALKING PATIENTS; COHENCOLE SA, 1986, QUALITY LIFE CARDIOV, V3, P53; COHENCOLE SA, 1991, MED ITNERVIEW 3 FUNC; COULEHAN JL, 1987, MED ITNERVIEW PRIMER; COX A, 1988, BRIT J PSYCHIAT, V152, P64, DOI 10.1192/bjp.152.1.64; COX A, 1981, BRIT J PSYCHIAT, V139, P144, DOI 10.1192/bjp.139.2.144; COX A, 1981, BRIT J PSYCHIAT, V139, P29, DOI 10.1192/bjp.139.1.29; DiMatteo M R, 1980, J Community Health, V6, P18; DUFFY DL, 1980, ANN INTERN MED, V93, P354, DOI 10.7326/0003-4819-93-2-354; EGBERT LD, 1964, NEW ENGL J MED, V270, P825, DOI 10.1056/NEJM196404162701606; ENELOW AJ, 1986, INTERVIEWING PATIENT; Engel G.L., 1969, CLIN APPROACH PATIEN; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGEL GL, 1977, JOHNS HOPKINS MED J, V140, P222; ENGEL GL, 1987, AM J MED, V82, P107, DOI 10.1016/0002-9343(87)90384-6; ERAKER SA, 1984, ANN INTERN MED, V100, P258, DOI 10.7326/0003-4819-100-2-258; Francis V., 1987, ENCOUNTERS PATIENTS, P259; FRANKEL R, 1989, COMMUNICATING MED PA, P86; FRANKEL RM, 1984, DISCOURSE PROCESS, V7, P135, DOI 10.1080/01638538409544587; FREELING P, 1983, DOCTOR PATIENT COMMU, P161; FREEMON B, 1971, PEDIATR RES, V5, P298; GILLUM RF, 1974, JAMA-J AM MED ASSOC, V228, P1563; GREENE WA, 1970, PSYCHOSOM MED, V32, P599, DOI 10.1097/00006842-197011000-00005; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HAYNES RB, 1982, HYPERTENSION, V4, P415; HOPKINSON K, 1981, BRIT J PSYCHIAT, V138, P406, DOI 10.1192/bjp.138.5.406; JASPARS J, 1983, DOCTOR PATIENT COMMU, P139; Kahana RJ., 1964, PERSONALITY TYPES ME, P108; Kaplan SH, 1989, COMMUNICATING MED PA, P228; KASTELER J, 1976, J HEALTH SOC BEHAV, V17, P328, DOI 10.2307/2136711; KATON W, 1982, AM J MED, V72, P127, DOI 10.1016/0002-9343(82)90599-X; KING J, 1983, DOCTOR PATIENT COMMU, P110; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; Kleinman A, 1987, ENCOUNTERS PATIENTS, P273; Koffka K, 1935, PRINCIPLES GESTALT P; KORSCH BM, 1968, PEDIATRICS, V42, P855; Ku┬hler W., 1947, GESTALT PSYCHOL; LAZARE A, 1975, ARCH GEN PSYCHIAT, V32, P553; LAZARE A, 1987, ENCOUNTERS PATIENTS, P413; LAZARE A, 1990, IN PRESS MED INTERVI; Levenstein J.H., 1989, COMMUNICATING MED PA, P107; LEVENSTEIN JH, 1986, FAM PRACT, V3, P24, DOI 10.1093/fampra/3.1.24; Lewin K., 1951, FIELD THEORY SOCIAL; Ley P, 1976, J R Coll Gen Pract, V26, P720; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; LIPKIN M, 1987, J GEN INTERN MED, V2, P363, DOI 10.1007/BF02596178; LIPKIN M, 1990, IN PRESS MED ITNERVI; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; LIPP M, 1977, RESPECTFUL TREATMENT; McWhinney I., 1989, COMMUNICATING MEDICA, P25; McWhinney IR., 1981, INTRO FAMILY MED; Mishler EG, 1984, DISCOURSE MED DIALEC; OXMAN TE, 1988, AM J PSYCHIAT, V145, P464; PLATT FW, 1979, ANN INTERN MED, V91, P898, DOI 10.7326/0003-4819-91-6-898; PUTNAM SM, 1985, MED CARE, V23, P74, DOI 10.1097/00005650-198501000-00008; PUTNAM SM, 1988, J GEN INTERN MED, V3, P38, DOI 10.1007/BF02595755; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; Reiser David, 1980, PATIENT INTERVIEWING; ROGERS CR, 1951, CLIENT CENTERED THER; Roter D, 1989, COMMUNICATING MED PA, P183; ROTER DL, 1988, PATIENT EDUC COUNS, V12, P99, DOI 10.1016/0738-3991(88)90057-2; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; SCHWARTZ MA, 1985, PERSPECT BIOL MED, V28, P331; Shapiro D., 1965, NEUROTIC STYLES; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; SINGER MT, 1974, PSYCHOSOM MED, V36, P1; SLAVNEY PR, 1984, PERSPECT BIOL MED, V27, P279; SNOW LF, 1983, WESTERN J MED, V139, P820; STEWART MA, 1984, SOC SCI MED, V19, P167, DOI 10.1016/0277-9536(84)90284-3; STOECKLE JD, 1987, J GEN INTERN MED, V2, P119, DOI 10.1007/BF02596310; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TATE P, 1983, DOCTOR PATIENT COMMU, P75; VACCARINO JM, 1977, JAMA-J AM MED ASSOC, V238, P861, DOI 10.1001/jama.238.8.861; WAITZKIN H, 1984, JAMA-J AM MED ASSOC, V252, P2441, DOI 10.1001/jama.252.17.2441; WALLACE ER, 1988, AM J PSYCHIAT, V145, P137; Weston WW, 1989, COMMUNICATING MED PA, P43; 1986, DIAGNOSTIC MANUAL ME	88	176	181	2	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					470	477		10.7326/0003-4819-115-6-470	http://dx.doi.org/10.7326/0003-4819-115-6-470			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1872495				2022-12-28	WOS:A1991GE81000009
J	IGLEHART, JK				IGLEHART, JK			HEALTH-POLICY REPORT - THE STRUGGLE OVER PHYSICIAN-PAYMENT REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		Frech H.E., 1991, REGULATING DOCTORS F; HSIAO WC, 1989, HEALTH AFFAIR, V8, P72, DOI 10.1377/hlthaff.8.4.72; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1985, NEW ENGL J MED, V312, P132, DOI 10.1056/NEJM198501103120237; IGLEHART JK, 1991, NEW ENGL J MED, V324, P1750, DOI 10.1056/NEJM199106133242428; Reinhardt U E, 1985, QRB Qual Rev Bull, V11, P366; RICH S, 1991, WASHINGTON POST 0606, pA4; RICH S, 1991, WASHINGTON POST 0824, pA2; 1991, FEE UPDATE MEDICARE; 1991, COMMENTS NOTICE PROP	11	9	9	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					823	828		10.1056/NEJM199109123251126	http://dx.doi.org/10.1056/NEJM199109123251126			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870663				2022-12-28	WOS:A1991GE45600032
J	KELSEY, RC; SAKER, A; MORGAN, M				KELSEY, RC; SAKER, A; MORGAN, M			CARDIAC LYMPHOMA IN A PATIENT WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note						ACQUIRED IMMUNODEFICIENCY SYNDROME; LYMPHOMA, NON-HODGKINS; HEART NEOPLASMS; HUMAN IMMUNODEFICIENCY VIRUS; CONGESTIVE HEART FAILURE	ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKINS LYMPHOMA	The association between human immunodeficiency virus (HIV) infection and extranodal involvement of malignant lymphoma is well known. We report a case of malignant lymphoma with cardiac involvement in a patient with the acquired immunodeficiency syndrome (AIDS). The patient had life-threatening arrhythmias and heart failure at presentation, and a diagnosis of malignant lymphoma was made by cytologic examination of pleural fluid. The patient was treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. A complete response was achieved, and the patient remains asymptomatic 12 months after diagnosis. This case is of interest because of the unusual presentation and the complete response to chemotherapy.	UNIV S FLORIDA, DEPT PATHOL, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida	KELSEY, RC (corresponding author), UNIV S FLORIDA, DEPT MED, BOX 19, 12901 BRUCE B DOWNS BLVD, TAMPA, FL 33612 USA.							GILL PS, 1987, J CLIN ONCOL, V5, P216, DOI 10.1200/JCO.1987.5.2.216; GOLDFARB A, 1989, AM HEART J, V118, P1340, DOI 10.1016/0002-8703(89)90030-6; GUARNER J, 1987, ARCH PATHOL LAB MED, V111, P254; ZIEGLER JL, 1984, ANN NY ACAD SCI, V437, P412, DOI 10.1111/j.1749-6632.1984.tb37161.x; 1982, MMWR, V31, P277	5	31	31	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					370	371		10.7326/0003-4819-115-5-370	http://dx.doi.org/10.7326/0003-4819-115-5-370			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863027				2022-12-28	WOS:A1991GC06500007
J	POTTER, WZ; RUDORFER, MV; MANJI, H				POTTER, WZ; RUDORFER, MV; MANJI, H			DRUG-THERAPY - THE PHARMACOLOGICAL TREATMENT OF DEPRESSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DEXAMETHASONE SUPPRESSION TEST; BETA-ADRENERGIC RECEPTORS; OBSESSIVE-COMPULSIVE DISORDER; MONOAMINE-OXIDASE INHIBITORS; RESEARCH DIAGNOSTIC-CRITERIA; PLATELET ADENYLATE-CYCLASE; ENDOGENOUS-DEPRESSION; UNIPOLAR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; ELECTROCONVULSIVE-THERAPY				POTTER, WZ (corresponding author), NIMH,EXPTL THERAPEUT BRANCH,CLIN PHARMACOL SECT,BLDG 10,RM 2D46,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ABERGWISTEDT A, 1982, ACTA PSYCHIAT SCAND, V66, P66, DOI 10.1111/j.1600-0447.1982.tb00915.x; ANGST J, 1985, PSYCHOPATHOLOGY, V18, P140, DOI 10.1159/000284227; ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193; BALDESSARINI RJ, 1989, J CLIN PSYCHIAT, V50, P117; BECH P, 1988, ADV BIOL PSYCHIAT, V17, P58; BECKMANN H, 1975, ARCH GEN PSYCHIAT, V32, P17; BLACK DW, 1987, COMPR PSYCHIAT, V28, P169, DOI 10.1016/0010-440X(87)90082-4; BROTMAN AW, 1987, PSYCHOPHARMACOLOGY 3, P1031; BROWNE JL, 1986, DRUG INTEL CLIN PHAR, V20, P837, DOI 10.1177/106002808602001102; CARROLL BJ, 1981, ARCH GEN PSYCHIAT, V38, P15; CHARNEY DS, 1982, ARCH GEN PSYCHIAT, V39, P290; CHARNEY DS, 1981, AM J PSYCHIAT, V138, P328; COOPER SJ, 1985, BRIT J PSYCHIAT, V147, P23, DOI 10.1192/bjp.147.1.23; CORYELL W, 1985, J AFFECT DISORDERS, V9, P149, DOI 10.1016/0165-0327(85)90094-1; COWLEY G, 1990, NEWSWEEK        0326, P38; CROWE RR, 1984, NEW ENGL J MED, V311, P163, DOI 10.1056/NEJM198407193110307; DAVIS JM, 1987, AM PSYCHIAT ASS ANN, V6, P159; DELINISTULA A, 1988, CURRENT TRENDS PSYCH, P147; DEMONTIGNY C, 1983, ARCH GEN PSYCHIAT, V40, P1327; DUNCAN WC, 1979, AM J PSYCHIAT, V136, P1424; EBSTEIN RP, 1988, BRIT J PSYCHIAT, V152, P665, DOI 10.1192/bjp.152.5.665; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; EXTEIN I, 1979, PSYCHIAT RES, V1, P191, DOI 10.1016/0165-1781(79)90061-1; EXTEIN I, 1984, NEUROBIOLOGY MOOD DI, V1, P297; EXTEIN IL, 1989, TREATMENT TRICYCLIC, P27; FAIRCHILD CJ, 1986, PSYCHIAT RES, V18, P217, DOI 10.1016/0165-1781(86)90109-5; FEINBERG M, 1982, BIOL MARKERS PSYCHIA, P241; Fink M, 1979, CONVULSIVE THERAPY T; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; GARCIASEVILLA JA, 1990, ARCH GEN PSYCHIAT, V47, P125; GILES DE, 1986, BIOL PSYCHIAT, V21, P1340, DOI 10.1016/0006-3223(86)90319-7; GILES DE, 1987, BIOL PSYCHIAT, V22, P872, DOI 10.1016/0006-3223(87)90085-0; GILLIN JC, 1978, PSYCHOPHARMACOLOGY, V59, P267, DOI 10.1007/BF00426633; GITLIN MJ, 1987, J AFFECT DISORDERS, V13, P267, DOI 10.1016/0165-0327(87)90046-2; GITLIN MJ, 1984, J CLIN PSYCHIAT, V45, P387; GLASSMAN AH, 1977, ARCH GEN PSYCHIAT, V34, P197; GOLDEN RN, 1988, ARCH GEN PSYCHIAT, V45, P145; GOODWIN FK, 1987, APA ANN REV, V6, P81; GRAM LF, 1974, AM J PSYCHIAT, V131, P863; HALL H, 1981, EUR J PHARMACOL, V70, P393, DOI 10.1016/0014-2999(81)90172-2; HALPER JP, 1988, ARCH GEN PSYCHIAT, V45, P241; HIMMELHOCH JM, 1991, AM J PSYCHIAT, V148, P910; HOCHLI D, 1986, BIOL PSYCHIAT, V21, P1217, DOI 10.1016/0006-3223(86)90227-1; JOFFE RT, 1990, PSYCHIAT RES, V32, P241, DOI 10.1016/0165-1781(90)90029-5; JOYCE PR, 1989, ARCH GEN PSYCHIAT, V46, P89; KAHN RJ, 1986, ARCH GEN PSYCHIAT, V43, P79; KATZ MM, 1987, PSYCHOL MED, V17, P297, DOI 10.1017/S0033291700024831; KELLER MB, 1982, JAMA-J AM MED ASSOC, V248, P1848, DOI 10.1001/jama.248.15.1848; KELLER MB, 1983, AM J PSYCHIAT, V140, P689; Khan Arifulla, 1987, Convuls Ther, V3, P93; KIRKEGAARD C, 1981, PSYCHONEUROENDOCRINO, V6, P189, DOI 10.1016/0306-4530(81)90029-9; KLERMAN GL, 1989, ARCH GEN PSYCHIAT, V46, P856; KOCSIS JH, 1988, ARCH GEN PSYCHIAT, V45, P253; KOSLOW SH, 1983, ARCH GEN PSYCHIAT, V40, P999; KRAGHSORENSEN P, 1976, PSYCHOPHARMACOLOGIA, V45, P305, DOI 10.1007/BF00421145; Kramer Peter, 1990, PSYCHIATRIC TIME MAR, P45; Kroessler David, 1985, Convuls Ther, V1, P173; KUPFER DJ, 1981, AM J PSYCHIAT, V138, P429; LIEBOWITZ MR, 1988, ARCH GEN PSYCHIAT, V45, P129; MAAS JW, 1984, AM J PSYCHIAT, V141, P1159; MAAS JW, 1972, ARCH GEN PSYCHIAT, V26, P252; MANN JJ, 1985, NEW ENGL J MED, V313, P715, DOI 10.1056/NEJM198509193131202; MANN JJ, 1989, ARCH GEN PSYCHIAT, V46, P45; MCGRATH PJ, 1984, AM J PSYCHIAT, V141, P288; MENDIS N, 1981, PSYCHOPHARMACOLOGY, V73, P87, DOI 10.1007/BF00431109; MENDLEWICZ J, 1984, BRIT J PSYCHIAT, V145, P383, DOI 10.1192/bjp.145.4.383; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MOONEY JJ, 1988, BIOL PSYCHIAT, V23, P543, DOI 10.1016/0006-3223(88)90002-9; MURPHY DL, 1974, AM J PSYCHIAT, V131, P1389; MURPHY DL, 1987, PSYCHOPHARMACOLOGY 3, P545; NELSON JC, 1984, ARCH GEN PSYCHIAT, V41, P663; NELSON JC, 1990, J AFFECT DISORDERS, V18, P157; NIERENBERG AA, 1989, J CLIN PSYCHOPHARM, V9, P42; O'SHEA B, 1989, Irish Journal of Psychological Medicine, V6, P89; PANDEY GN, 1989, PSYCHOPHARMACOL BULL, V25, P257; PANDEY GN, 1979, AM J PSYCHIAT, V136, P675; PARE CM, 1985, BRIT J PSYCHIAT, V146, P76; PAYKEL ES, 1982, ARCH GEN PSYCHIAT, V39, P1041; PAYKEL ES, 1972, BRIT J PSYCHIAT, V120, P147, DOI 10.1192/bjp.120.555.147; PAYKEL ES, 1989, BRIT J PSYCHIAT, V155, P754, DOI 10.1192/bjp.155.6.754; PERRY PJ, 1982, J AFFECT DISORDERS, V4, P195, DOI 10.1016/0165-0327(82)90003-9; POTTER WZ, 1985, ARCH GEN PSYCHIAT, V42, P1171; POTTER WZ, 1984, DRUGS, V28, P127, DOI 10.2165/00003495-198428020-00003; POTTER WZ, 1990, AM PSYCHIATRIC PRESS, V9, P145; PRANGE AJ, 1987, PSYCHOPHARMACOLOGY 3, P629; PRICE LH, 1989, TREATMENT TRICYCLIC, P49; PRICE LH, 1990, AM PSYCHIATRIC PRESS, V1, P116; PRIEN RF, 1986, AM J PSYCHIAT, V143, P18; QUITKIN F, 1979, ARCH GEN PSYCHIAT, V36, P749; QUITKIN FM, 1991, ARCH GEN PSYCHIAT, V48, P319; QUITKIN FM, 1984, ARCH GEN PSYCHIAT, V41, P238; QUITKIN FM, 1981, J CLIN PSYCHOPHARM, V1, P70, DOI 10.1097/00004714-198103000-00005; RASKIN A, 1976, PSYCHOL MED, V6, P59, DOI 10.1017/S0033291700007509; RAVARIS CL, 1980, ARCH GEN PSYCHIAT, V37, P1075; Reynolds C. F., 1987, PSYCHOPHARMACOLOGY 3, P647; RICHELSON E, 1984, J PHARMACOL EXP THER, V230, P94; RICHELSON E, 1984, PSYCHOPHARMACOL BULL, V20, P213; ROBINSON DS, 1974, CLASSIFICATION PREDI, P259; RUDORFER M, 1989, TREATMENT TRICYCLIC, P81; RUDORFER MV, 1989, DRUGS, V37, P713, DOI 10.2165/00003495-198937050-00006; RUDORFER MV, 1987, PSYCHOPHARMACOLOGY 3, P1353; SHAPIRO S, 1984, ARCH GEN PSYCHIAT, V41, P971; SIEVER LJ, 1984, PSYCHIAT RES, V11, P287, DOI 10.1016/0165-1781(84)90003-9; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; STERNBACH H, 1991, AM J PSYCHIAT, V148, P705; STERNBACH H, 1988, LANCET, V2, P850; Stewart J W, 1980, Psychopharmacol Bull, V16, P52; STEWART JW, 1983, ARCH GEN PSYCHIAT, V40, P202; STEWART JW, 1989, ARCH GEN PSYCHIAT, V46, P1080; SUCHOWERSKY O, 1990, CAN J PSYCHIAT, V35, P571, DOI 10.1177/070674379003500632; SUNDERLAND T, 1985, PSYCHOPHARMACOLOGY, V86, P432, DOI 10.1007/BF00427904; SUNDERLAND T, 1987, PSYCHOPHARMACOLOGY, V91, P293, DOI 10.1007/BF00518180; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; THASE ME, 1986, ARCH GEN PSYCHIAT, V43, P886; Thase ME, 1987, ADV HUMAN PSYCHOPHAR, V4, P93; THOREN P, 1980, ARCH GEN PSYCHIAT, V37, P1289; TIPTON KF, 1986, CELL BIOCHEM FUNCT, V4, P79, DOI 10.1002/cbf.290040202; TOLLEFSON GD, 1983, J CLIN PSYCHOPHARM, V3, P231; TURNER SM, 1985, J CLIN PSYCHOPHARM, V5, P207; UPRICHARD DC, 1978, SCIENCE, V199, P197, DOI 10.1126/science.202024; VALLEJO J, 1987, BRIT J PSYCHIAT, V151, P639, DOI 10.1192/bjp.151.5.639; VANPRAAG HM, 1982, COMPR PSYCHIAT, V23, P216, DOI 10.1016/0010-440X(82)90069-4; WEHR TA, 1987, AM J PSYCHIAT, V144, P1403; WEILBURG JB, 1989, J CLIN PSYCHIAT, V50, P447; WEISSMAN M M, 1979, American Journal of Psychiatry, V136, P555; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILLIAMS GH, 1987, HARRISONS PRINCIPLES, P1024; Youdim M B, 1983, Mod Probl Pharmacopsychiatry, V19, P63; ZIMMERMAN M, 1989, ARCH GEN PSYCHIAT, V46, P361; ZIMMERMAN M, 1986, AM J PSYCHIAT, V143, P98; ZISOOK S, 1985, J CLIN PSYCHOPHARM, V5, P131; ZORNBERG GL, 1991, LANCET, V337, P246, DOI 10.1016/0140-6736(91)92219-R; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P104; 1987, DIAGNOSTIC STATISTIC; 1985, AM J PSYCHIAT, V142, P155; 1985, JAMA-J AM MED ASSOC, V254, P2103	138	196	197	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					633	642						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC328	1861697				2022-12-28	WOS:A1991GC32800007
J	HA, I; LANE, WS; REINBERG, D				HA, I; LANE, WS; REINBERG, D			CLONING OF A HUMAN GENE ENCODING THE GENERAL TRANSCRIPTION INITIATION FACTOR-IIB	NATURE			English	Article							RNA POLYMERASE-II; ADENOVIRUS MAJOR LATE; NUCLEOTIDE-SEQUENCE; SIGMA-FACTORS; FUNCTIONAL-ANALYSIS; ESCHERICHIA-COLI; DNA; PURIFICATION; ACTIVATION; BINDING	Transcription factor IIB (TFIIB) has a central role in transcription of class II genes. The purification of the human TFIIB protein and isolation of a complementary DNA encoding TFIIB activity is reported here. The sequence of TFIIB, which seems to be encoded by a single gene, contains a repeated motif, in addition to a motif with similarity to the prokaryotic sigma-factors. The recombinant protein expressed in bacteria substituted for all the functions attributed to the human TFIIB protein.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University				Reinberg, Danny/0000-0003-4288-2016				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLUMBERG BM, 1988, VIROLOGY, V164, P487, DOI 10.1016/0042-6822(88)90563-6; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON Z, 1981, NUCLEIC ACIDS RES, V9, P2889, DOI 10.1093/nar/9.12.2889; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, IN PRESS P NATN ACAD; CELESTE YP, 1985, GENE, V33, P103; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGEL JN, 1990, J BACTERIOL, V172, P2447, DOI 10.1128/jb.172.5.2447-2455.1990; ERICKSON BD, 1985, GENE, V40, P67, DOI 10.1016/0378-1119(85)90025-3; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, IN PRESS P NATN ACAD; GITT MA, 1985, J BIOL CHEM, V260, P7178; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; INOUYE S, 1990, J BACTERIOL, V172, P80, DOI 10.1128/JB.172.1.80-85.1990; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, IN PRESS  NATN ACAD; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL P, 1989, SCIENCE, V345, P371; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA ZM, 1990, NATURE, V341, P410; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUKA R, 1990, FEBS LETT, V261, P223; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TORDO N, 1988, VIROLOGY, V165, P565, DOI 10.1016/0042-6822(88)90600-9; WEIL PA, 1979, CELL, V18, P469; YAMASHITA M, 1989, VIROLOGY, V171, P458, DOI 10.1016/0042-6822(89)90615-6; YUSOFF K, 1987, NUCLEIC ACIDS RES, V15, P3961, DOI 10.1093/nar/15.10.3961; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	51	247	250	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					689	695		10.1038/352689a0	http://dx.doi.org/10.1038/352689a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876184				2022-12-28	WOS:A1991GC06400048
J	BARRETT, SCH; CHARLESWORTH, D				BARRETT, SCH; CHARLESWORTH, D			EFFECTS OF A CHANGE IN THE LEVEL OF INBREEDING ON THE GENETIC LOAD	NATURE			English	Article							PLANT-POPULATIONS; DELETERIOUS MUTATIONS; DEPRESSION; EVOLUTION; RATES; LOCUS	"THE effects of inbreeding may not be as noticeable in the first generation as the invigoration immediately apparent after crossing" 1. This statement, published in 1919, has received little attention, and has apparently never been tested empirically, although the reduction of the genetic load of populations by inbreeding is well known in theoretical terms 2-5. Because inbreeding increases homozygosity, and hence the effectiveness of selection against recessive or partially recessive detrimental alleles, changes in levels of inbreeding can lead to a reduction in the frequencies of such mutant alleles. This results in equilibration at higher population mean fitness 6 and is referred to as 'purging' populations of their genetic load. Severe inbreeding can also reduce genetic load due to overdominant alleles, provided selection coefficients are not symmetrical at all loci, because alleles giving lower fitness will be reduced in frequency at equilibrium 7-8. With either fitness model, however, reduction in genetic load takes time, and the initial effect of an increase in inbreeding is reduced fitness due to homozygosity. There are few data relating to the extent to which fitness is reduced during inbreeding in a set of lines and to how long the reduction lasts before increasing again to the initial level, or higher. Inbreeding experiments involving sib mating in mice and Drosophila subobscura 10, and successive bottlenecks in house flies 11 have yielded some evidence consistent with the purging hypothesis. Here, we report results of an experiment demonstrating a prolonged time-course of recovery of mean fitness under self-fertilization of a naturally outcrossing plant, and also compare our results with expectations derived by computer calculations. Our results show that the genetic load present in an outcrossing population can be explained only with a high mutation rate to partially recessive deleterious alleles, and that inbreeding purges the population of mutant alleles.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago	BARRETT, SCH (corresponding author), UNIV TORONTO,DEPT BOT,25 WILLCOCKS ST,TORONTO M5S 3B2,ONTARIO,CANADA.		Barrett, Spencer CH/M-3751-2013; Barrett, Spencer C.H./S-5782-2019; Charlesworth, Deborah/F-3071-2011	Barrett, Spencer C.H./0000-0002-7762-3455; 				BARRETT S C H, 1990, Plant Species Biology, V5, P41, DOI 10.1111/j.1442-1984.1990.tb00191.x; BROWN AHD, 1979, THEOR POPUL BIOL, V15, P1, DOI 10.1016/0040-5809(79)90025-X; BRYANT EH, 1990, AM NAT, V136, P542, DOI 10.1086/285112; CHARLESWORTH B, 1990, NATURE, V347, P380, DOI 10.1038/347380a0; CHARLESWORTH D, 1987, ANNU REV ECOL SYST, V18, P237, DOI 10.1146/annurev.es.18.110187.001321; CHARLESWORTH D, 1990, EVOLUTION, V44, P870, DOI 10.1111/j.1558-5646.1990.tb03811.x; CHARLESWORTH D, 1990, EVOLUTION, V44, P1469, DOI 10.1111/j.1558-5646.1990.tb03839.x; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; CROW JF, 1948, GENETICS, V33, P477; EAST EM, 1919, INBREEDING OUTBREEDI, P147; FALCONER DS, 1972, GENET RES CAMB, V17, P215; GLOVER DE, 1987, HEREDITY, V59, P7, DOI 10.1038/hdy.1987.91; GRIFFIN AR, 1985, THEOR APPL GENET, V71, P334, DOI 10.1007/BF00252077; HOLLINGSWORTH M. J., 1955, JOUR GENETICS, V53, P295, DOI 10.1007/BF02993984; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1985, GENETICS, V111, P635; LANDE R, 1985, EVOLUTION, V39, P24, DOI [10.2307/2408514, 10.1111/j.1558-5646.1985.tb04077.x]; OHTA T, 1974, GENET RES, V23, P191, DOI 10.1017/S0016672300014816; SHULL GH, 1950, HETEROSIS, P14; SING CF, 1973, GENETICS, V75, P381; TEMPLETON AR, 1984, ZOO BIOL, V3, P177, DOI 10.1002/zoo.1430030302; WILTON AN, 1989, GENET RES, V54, P129; Wright S., 1977, EVOLUTION GENETICS P, V3; ZIEHE M, 1989, GENETICS, V121, P861	24	343	348	0	86	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					522	524		10.1038/352522a0	http://dx.doi.org/10.1038/352522a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865906				2022-12-28	WOS:A1991GA22600060
J	WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP				WILLIAMS, DA; RIOS, M; STEPHENS, C; PATEL, VP			FIBRONECTIN AND VLA-4 IN HEMATOPOIETIC STEM-CELL MICROENVIRONMENT INTERACTIONS	NATURE			English	Article							HUMAN-PLASMA FIBRONECTIN; BONE-MARROW; GROWTH-FACTOR; PRECURSOR CELLS; ADHERENT CELLS; ADHESION; PROLIFERATION; IDENTIFICATION; HEMATOPOIESIS; RECEPTOR	THE self-renewal and differentiation of haematopoietic stem cells occurs in vivo and in vitro in direct contact with cells making up the haematopoietic microenvironment 1-4. In this study we used adhesive ligands and blocking antibodies to identify stromal cell-derived extracellular matrix proteins involved in promoting attachment of murine haematopoietic stem cells. Here we report that day-12 colony-forming-unit spleen (CFU-S12) 5 cells and reconstituting haematopoietic stem cells attach to the C-terminal, heparin-binding fragment of fibronectin by recognizing the CS-1 peptide of the alternatively spliced non-type III connecting segment (IIICS) of human plasma fibronectin. Furthermore, CFU-S12 stem cells express the alpha-4 subunit of the VLA-4 integrin receptor, which is known to be a receptor for the CS-1 sequence, and monoclonal antibodies against the integrin alpha-4 subunit of VLA-4 block adhesion of CFU-S12 stem cells to plates coated with the C-terminal fibronectin fragment. Finally, polyclonal antibodies against the integrin beta-1 subunit of VLA-4 inhibit the formation of CFU-S12-derived spleen colonies and medullary haematopoiesis in vivo following intravenous infusion of antibody-treated bone marrow cells.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School								AIZAWA S, 1988, P NATL ACAD SCI USA, V85, P3180, DOI 10.1073/pnas.85.9.3180; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; GORDON MY, 1989, BONE MARROW TRANSPL, V4, P335; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HO MK, 1982, J IMMUNOL, V128, P2281; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; KENNETT RH, 1980, MONOCLONAL ANTIBODIE; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; LAMBERTSEN RH, 1984, BLOOD, V63, P287; LORD BI, 1975, BLOOD, V46, P65; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCCARTHY JB, 1986, J CELL BIOL, V102, P179, DOI 10.1083/jcb.102.1.179; PATEL VP, 1986, J CELL BIOL, V102, P449, DOI 10.1083/jcb.102.2.449; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; TRENTIN JJ, 1967, PROLIFERATION SPREAD, V713; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; ZIPORI D, 1988, HEMATOPOIESIS LONG T, P27; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUCKERMAN KS, 1983, BLOOD, V61, P540	34	452	472	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					438	441		10.1038/352438a0	http://dx.doi.org/10.1038/352438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861722				2022-12-28	WOS:A1991FZ34600068
J	FORDYCE, MJF; BAKER, AS; STADDON, GE				FORDYCE, MJF; BAKER, AS; STADDON, GE			EFFICACY OF FIXED MINIDOSE WARFARIN PROPHYLAXIS IN TOTAL HIP-REPLACEMENT	BRITISH MEDICAL JOURNAL			English	Article							DEEP-VEIN THROMBOSIS; LOW-DOSE HEPARIN; PREVENTION; FAILURE	Objective - To determine whether a small fixed perioperative dose of warfarin would prevent deep vein thrombosis after total hip replacement. Design - Prospective, randomised, double blind placebo controlled trial. Setting - Winford Orthopaedic Hospital, Bristol. Subjects - 148 patients having primary total hip replacement. Intervention - Warfarin 1 mg given daily for one week before and three weeks after surgery. Main outcome measure - Deep vein thrombosis diagnosed by the iodine-125 labelled fibrinogen uptake method. Results - Deep vein thrombosis occurred in 25 (34%) of the patients given warfarin and 19 (26%) of the controls (difference 8%; 95% confidence interval -6.8% to 22.8%). Conclusion - Fixed minidose warfarin does not prevent deep vein thrombosis after total hip replacement.	WINFORD ORTHOPAED HOSP,BRISTOL,ENGLAND									AITKEN RJ, 1987, J BONE JOINT SURG BR, V69, P775, DOI 10.1302/0301-620X.69B5.3680341; BERGQVIST D, 1983, POSTOPERATIVE THROMB, P20; BRENKEL I, 1989, BRIT J HOSP MED, V42, P282; EVARTS CM, 1973, JAMA-J AM MED ASSOC, V225, P515, DOI 10.1001/jama.225.5.515; HAMPSON WGJ, 1974, LANCET, V2, P795; HARRIS WH, 1974, J BONE JOINT SURG AM, VA 56, P1552, DOI 10.2106/00004623-197456080-00002; HARRIS WH, 1984, J BONE JOINT SURG AM, V66A, P1388, DOI 10.2106/00004623-198466090-00011; JOHNSON R, 1977, CLIN ORTHOP RELAT R, V127, P123; KAKKAR VV, 1970, LANCET, V1, P540; MAGNUSSEN P A, 1988, Journal of Bone and Joint Surgery British Volume, V70, P150; MORRIS GK, 1974, LANCET, V2, P797; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; SEVITT S, 1959, LANCET, V2, P981; SIKORSKI JM, 1981, J BONE JOINT SURG BR, V63, P171, DOI 10.1302/0301-620X.63B2.7217137	14	49	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					219	220		10.1136/bmj.303.6796.219	http://dx.doi.org/10.1136/bmj.303.6796.219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884058	Bronze, Green Published			2022-12-28	WOS:A1991FZ56300021
J	HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M				HARPER, V; MACINNES, R; CAMPBELL, D; HALL, M			INCREASED BIRTH-WEIGHT IN NORTHERLY ISLANDS - IS FISH CONSUMPTION A RED HERRING	BRITISH MEDICAL JOURNAL			English	Article									HLTH CTR,KIRKWALL,ORKNEY,SCOTLAND		HARPER, V (corresponding author), UNIV ABERDEEN,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.							BARBER SA, 1986, HUM NUTR-APPL NUTR, V40A, P462; OLSEN SF, 1985, J EPIDEMIOL COMMUN H, V39, P27, DOI 10.1136/jech.39.1.27; OLSEN SF, 1986, LANCET, V2, P367; PIRANI DH, 1978, OBSTET GYNECOL SURV, V33, P1	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					166	166		10.1136/bmj.303.6795.166	http://dx.doi.org/10.1136/bmj.303.6795.166			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878642	Bronze, Green Published			2022-12-28	WOS:A1991FX57800024
J	BAKER, R				BAKER, R			THE FUTURE OF GENERAL-PRACTICE - AUDIT AND STANDARDS IN NEW GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							QUALITY; CARE; PRACTITIONERS; SATISFACTION		UNIV BRISTOL,DEPT & EPIDEMIOL PUBL HLTH MED,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol								[Anonymous], 1990, BMJ, V301, P651; BAKER R, 1990, BRIT MED J, V300, P378, DOI 10.1136/bmj.300.6721.378; BAKER R, 1990, PRACTICE AUDIT PLAN; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BROOK RH, 1976, ANN INTERN MED, V85, P509, DOI 10.7326/0003-4819-85-4-509; CASANOVA JE, 1990, MED CARE, V28, P1104, DOI 10.1097/00005650-199011000-00010; DONABEDIAN A, 1986, PURSUIT QUALITY, P146; FITZPATRICK R, 1991, BMJ, V302, P885; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; FLEMING DM, 1983, BRIT MED J, V287, P1852, DOI 10.1136/bmj.287.6408.1852; FRASER RC, 1985, BRIT MED J, V291, P1473, DOI 10.1136/bmj.291.6507.1473; GROL R, 1990, BRIT J GEN PRACT, V40, P361; GROL R, 1988, J ROY COLL GEN PRACT, V38, P10; HARRIS CM, 1985, J ROY COLL GEN PRACT, V35, P284; HARRIS CM, 1984, 24 ROYAL COLL GEN PR; HUGHES J, 1990, MED AUDIT SERIES, V3; HUTCHINS D, 1990, PURSUIT QUALITY PART; IRVINE D, 1990, MED AUDIT SERIES, V2; IRVINE DH, 1990, BRIT J GEN PRACT, V40, P75; IRVINE DH, 1986, PURSUIT QUALITY, P146; Kahn KL, 1989, STRUCTURED IMPLICIT; Kincey J, 1975, J R Coll Gen Pract, V25, P558; LEMBCKE PA, 1956, JAMA-J AM MED ASSOC, V162, P646, DOI 10.1001/jama.1956.72970240010009; LYDEARD S, 1991, FAM PRACT, V8, P84, DOI 10.1093/fampra/8.1.84; MAITLAND JM, 1991, BRIT J GEN PRACT, V41, P144; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; MARSH GN, 1988, BRIT MED J, V296, P173, DOI 10.1136/bmj.296.6616.173; MARTIN E, 1985, UPDATE, V30, P887; MITCHELL MW, 1985, J ROY COLL PHYS LOND, V19, P251; MOURIN K, 1986, PURSUIT QUALITY, P67; NIGHTINGALE F, 1860, PROPOSAL UNIFORM HOS; Oakland J., 1990, TOTAL QUALITY MANAGE; PRINGLE M, 1988, BRIT MED J, V296, P397, DOI 10.1136/bmj.296.6619.397; PRITCHARD P, 1981, 17 ROYAL COLL GEN PR; SCOTT EA, 1991, J PUBLIC HEALTH MED, V13, P35, DOI 10.1093/oxfordjournals.pubmed.a042575; SMITH NA, 1987, PATIENT EDUC COUNS, V10, P279, DOI 10.1016/0738-3991(87)90129-7; STANDING P, 1984, BRIT MED J, V289, P883, DOI 10.1136/bmj.289.6449.883; TOOZE K, 1990, POSTGRAD MED J, V66, pS38; WATKINS CS, 1980, THESIS U LONDON LOND; WRIGHT A, 1987, BRIT MED J, V294, P1661, DOI 10.1136/bmj.294.6588.1661; 1985, QUALITY GENERAL PRAC	42	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					32	34		10.1136/bmj.303.6793.32	http://dx.doi.org/10.1136/bmj.303.6793.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859955	Green Published, Bronze			2022-12-28	WOS:A1991FW12800025
J	DISLA, E; BRAR, H; TARANTA, A				DISLA, E; BRAR, H; TARANTA, A			HYDROXYCHLOROQUINE IN SYSTEMIC LUPUS-ERYTHEMATOSUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											DISLA, E (corresponding author), CABRINI MED CTR,NEW YORK,NY 10003, USA.							TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x; WEBSTER LT, 1985, GOODMAN GILMANS PHAR, P1033; 1991, NEW ENGL J MED, V324, P150	3	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					1046	1046						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886629				2022-12-28	WOS:A1991GH44700026
J	SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F				SIMILOWSKI, T; YAN, S; GAUTHIER, AP; MACKLEM, PT; BELLEMARE, F			CONTRACTILE PROPERTIES OF THE HUMAN DIAPHRAGM DURING CHRONIC HYPERINFLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; PHRENIC-NERVE STIMULATION; LUNG-VOLUME; EMPHYSEMATOUS HAMSTERS; RESPIRATORY MUSCLES; BODY-WEIGHT; ADAPTABILITY; ACTIVATION; PRESSURE; STRENGTH	Background. In patients with chronic obstructive pulmonary disease (COPD) and hyperinflation of the lungs, dysfunction of the diaphragm may contribute to respiratory decompensation. We evaluated the contractile function of the diaphragm in well-nourished patients with stable COPD, using supramaximal, bilateral phrenic-nerve stimulation, which provides information about the strength and inspiratory action of the diaphragm. Methods. In eight patients with COPD and five control subjects of similar age, the transdiaphragmatic pressure generated by the twitch response to phrenic-nerve stimulation was recorded at various base-line lung volumes, from functional residual capacity to total lung capacity, and during relaxation and graded voluntary efforts at functional residual capacity (twitch occlusion). Results. At functional residual capacity, the twitch transdiaphragmatic pressure ranged from 10.9 to 26.6 cm of water (1.07 to 2.60 kPa) in the patients and from 19.8 to 37.1 cm of water (1.94 to 3.64 kPa) in the controls, indicating considerable overlap between the two groups. The ratio of esophageal pressure to twitch transdiaphragmatic pressure, an index of the inspiratory action of the diaphragm, was -0.50 +/- 0.05 in the patients, as compared with -0.43 +/- 0.02 in the controls (indicating more efficient inspiratory action in the patients than in the controls). At comparable volumes, the twitch transdiaphragmatic pressure and esophageal-to-transdiaphragmatic pressure ratio were higher in the patients than in normal subjects, indicating that the strength and inspiratory action of the diaphragm in the patients were actually better than in the controls. Twitch occlusion (a measure of the maximal activation of the diaphragm) indicated near-maximal activation in the patients with COPD, and the maximal transdiaphragmatic pressure was 106.9 +/- 13.8 cm of water (10.48 +/- 1.35 kPa). Conclusions. The functioning of the diaphragms of the patients with stable COPD is as good as in normal subjects at the same lung volume. Compensatory phenomena appear to counterbalance the deleterious effects of hyperinflation on the contractility and inspiratory action of the diaphragm in patients with COPD. Our findings cast doubt on the existence of chronic fatigue of the diaphragm in such patients and therefore on the need for therapeutic interventions aimed at improving diaphragm function.	MCGILL UNIV, ROYAL VICTORIA HOSP, MEAKINS CHRISTIE LABS, 3626 ST URBAIN ST, MONTREAL H2X 2P2, QUEBEC, CANADA; MCGILL UNIV, CTR HOSP THORAC MONTREAL, MONTREAL H3A 2T5, QUEBEC, CANADA	McGill University; Royal Victoria Hospital; McGill University								AGOSTONI E, 1960, J APPL PHYSIOL, V15, P1087, DOI 10.1152/jappl.1960.15.6.1087; AGOSTONI E, 1985, THORAX A, V29, P259; ARORA NS, 1982, J APPL PHYSIOL, V52, P64, DOI 10.1152/jappl.1982.52.1.64; AUBIER M, 1985, J APPL PHYSIOL, V58, P58, DOI 10.1152/jappl.1985.58.1.58; BELLEMARE F, 1984, RESP PHYSIOL, V58, P263, DOI 10.1016/0034-5687(84)90003-3; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BELLEMARE F, 1986, J APPL PHYSIOL, V61, P1153, DOI 10.1152/jappl.1986.61.3.1153; BRAUN NMT, 1982, J APPL PHYSIOL, V53, P405, DOI 10.1152/jappl.1982.53.2.405; BUTLER C, 1976, AM REV RESPIR DIS, V114, P155; DAVIS JN, 1967, J NEUROL NEUROSUR PS, V30, P420, DOI 10.1136/jnnp.30.5.420; DELHEZ L, 1965, ARCH INT PHYS BIOCH, V73, P832, DOI 10.3109/13813456509084906; FARKAS GA, 1983, J APPL PHYSIOL, V54, P1635, DOI 10.1152/jappl.1983.54.6.1635; FARKAS GA, 1982, J APPL PHYSIOL, V53, P1263, DOI 10.1152/jappl.1982.53.5.1263; GANDEVIA SC, 1990, J PHYSIOL-LONDON, V428, P387, DOI 10.1113/jphysiol.1990.sp018218; GIBSON GJ, 1981, AM REV RESPIR DIS, V124, P685; HUBMAYR RD, 1989, AM REV RESPIR DIS, V139, P647, DOI 10.1164/ajrccm/139.3.647; ISHIKAWA S, 1973, AM REV RESPIR DIS, V108, P135; LAPORTA D, 1985, J APPL PHYSIOL, V58, P1469, DOI 10.1152/jappl.1985.58.5.1469; LORING SH, 1985, J APPL PHYSIOL, V59, P1961, DOI 10.1152/jappl.1985.59.6.1961; LORING SH, 1982, J APPL PHYSIOL, V53, P756, DOI 10.1152/jappl.1982.53.3.756; MACKLEM PT, 1983, J APPL PHYSIOL, V55, P547, DOI 10.1152/jappl.1983.55.2.547; MERTON PA, 1954, J PHYSIOL-LONDON, V123, P553, DOI 10.1113/jphysiol.1954.sp005070; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; OLIVEN A, 1986, J APPL PHYSIOL, V60, P225, DOI 10.1152/jappl.1986.60.1.225; ROCHESTER DF, 1979, AM REV RESPIR DIS, V119, P151; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SARNOFF SJ, 1951, SURG GYNECOL OBSTET, V93, P190; SIMILOWSKI T, 1989, J APPL PHYSIOL, V67, P1311, DOI 10.1152/jappl.1989.67.4.1311; SMITH J, 1987, J APPL PHYSIOL, V62, P1893, DOI 10.1152/jappl.1987.62.5.1893; SUPINSKI GS, 1982, J CLIN INVEST, V70, P978, DOI 10.1172/JCI110709; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; THURLBECK WM, 1978, THORAX, V33, P483, DOI 10.1136/thx.33.4.483	34	301	311	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					917	923		10.1056/NEJM199109263251304	http://dx.doi.org/10.1056/NEJM199109263251304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881417	Bronze			2022-12-28	WOS:A1991GF85600004
J	KLEVIT, RE				KLEVIT, RE			RECOGNITION OF DNA BY CYS2, HIS2 ZINC FINGERS	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR-IIIA; YEAST ADR1; BINDING; DOMAIN; PROTEIN				KLEVIT, RE (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM SJ-70,SEATTLE,WA 98195, USA.		Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X				BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; XU RX, 1991, BIOCHEMISTRY-US, V30, P3365, DOI 10.1021/bi00228a003	14	122	124	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1367	&		10.1126/science.1896847	http://dx.doi.org/10.1126/science.1896847			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1896847				2022-12-28	WOS:A1991GF85100028
J	[Anonymous]				[Anonymous]			NATURES MANIFESTO FOR BRITISH SCIENCE	NATURE			English	Article																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					105	112						8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891041				2022-12-28	WOS:A1991GE73100022
J	RILEY, WA; SCHNECKENBURGER, WA				RILEY, WA; SCHNECKENBURGER, WA			THE MARYLAND EXPERIENCE AND A PRACTICAL PROPOSAL TO EXPAND EXISTING MODELS IN AMBULATORY PRIMARY CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Two unique models for caring for the uninsured and underinsured are operating in Maryland. The first is a group practice, primary care model with a unique ambulatory Medicare waiver that has had a positive impact on patients and physicians. The second is a financial model - an all-payer prospective rate-setting system for all critical care inpatient hospitals that, during a 13-year period from 1977 through 1989, has saved the citizens of the state approximately $5.361 billion, has allowed hospitals to provide $1.657 billion of charity care and bad debts, and has earned $517 million in net profits. The reasons for the success of each of the models are discussed and form the basis for a practical and politically feasible proposal: merge the best aspects of each model into an ambulatory primary care - based model financed through an all-payer prospective charge system.			RILEY, WA (corresponding author), GREATER BALTIMORE MED CTR,DEPT MED,6701 N CHARLES ST,BALTIMORE,MD 21204, USA.							1986, 5 CITY PROGRAM IMPRO, V1, P13; 1989, HOSPITAL STATISTICS	2	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1118	1122		10.1001/jama.266.8.1118	http://dx.doi.org/10.1001/jama.266.8.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865546				2022-12-28	WOS:A1991GB97500037
J	DIMICHELE, L; PAYNTER, KT; POWERS, DA				DIMICHELE, L; PAYNTER, KT; POWERS, DA			EVIDENCE OF LACTATE DEHYDROGENASE-B ALLOZYME EFFECTS IN THE TELEOST, FUNDULUS-HETEROCLITUS	SCIENCE			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; GENETIC-VARIATION; LDH-B; GENOTYPES; POLYMORPHISM; LOCI; ADAPTATION; FISH; CELL	The evolutionary significance of protein polymorphisms has long been debated. Exponents of the balanced theory advocate that selection operates to maintain polymorphisms, whereas the neoclassical school argues that most genetic variation is neutral. Some studies have suggested that protein polymorphisms are not neutral, but their significance has been questioned because one cannot eliminate the possibility that linked loci were responsible for the observed differences. Evidence is presented that an enzymatic phenotype can affect carbon flow through a metabolic pathway. Glucose flux differences between lactate dehydrogenase-B phenotypes of Fundulus heteroclitus were reversed by substituting the Ldh-B gene product of one homozygous genotype with that of another.	JOHNS HOPKINS UNIV,CHESAPEAKE BAY INST,SHADY SIDE,MD 20764; STANFORD UNIV,HOPKINS MARINE STN,PACIFIC GROVE,CA 93950	Johns Hopkins University; Stanford University	DIMICHELE, L (corresponding author), TEXAS A&M UNIV SYST,DEPT WILDLIFE & FISHERIES SCI,COLLEGE STN,TX 77843, USA.		Paynter, Kennedy/F-9717-2013					BURTON RS, 1983, BIOCHEM GENET, V21, P239, DOI 10.1007/BF00499136; CAVENER DR, 1981, P NATL ACAD SCI-BIOL, V78, P4444, DOI 10.1073/pnas.78.7.4444; DIMICHELE L, 1986, AM ZOOL, V26, P201; DIMICHELE L, 1982, NATURE, V296, P563, DOI 10.1038/296563a0; DIMICHELE L, 1984, PHYSIOL ZOOL, V57, P52, DOI 10.1086/physzool.57.1.30155967; GONZALEZVILLASENOR LI, 1990, EVOLUTION, V44, P27, DOI 10.1111/j.1558-5646.1990.tb04277.x; HARRIS H, 1976, FED PROC, V35, P2079; HILBISH TJ, 1982, NATURE, V298, P688, DOI 10.1038/298688a0; KACSER H, 1981, GENETICS, V97, P639; KLYACHKO OS, 1982, J EXP ZOOL, V222, P137, DOI 10.1002/jez.1402220205; KOEHN RK, 1980, P NATL ACAD SCI-BIOL, V77, P5385, DOI 10.1073/pnas.77.9.5385; KOEHN RK, 1986, AM SCI, V74, P659; LANGRIDGE R, 1985, BIOCHEMISTRY-US, V24, P629; Lewontin RC, 1974, GENETIC BASIS EVOLUT; Nei M, 1983, EVOLUTION GENES PROT; Newsholme EA, 1973, REGULATION METABOLIS; PLACE AR, 1978, BIOCHEM GENET, V16, P577, DOI 10.1007/BF00484221; PLACE AR, 1979, P NATL ACAD SCI USA, V76, P2354, DOI 10.1073/pnas.76.5.2354; PLACE AR, 1984, J BIOL CHEM, V76, P1304; PLACE AR, 1978, BIOCH GENET, V16, P593; PLACE AR, 1984, J BIOL CHEM, V76, P1299; POWERS DA, 1983, ISOZYMES-CURR T BIOL, V10, P147; POWERS DA, 1986, AM ZOOL, V26, P131; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1989, P NATL ACAD SCI USA, V86, P6464, DOI 10.1073/pnas.86.17.6464; SRIVASTAVA DK, 1985, BIOCHEMISTRY-US, V24, P623, DOI 10.1021/bi00324a013; SRIVASTAVA DK, 1984, BIOCHEMISTRY-US, V23, P4538, DOI 10.1021/bi00315a006; WATT WB, 1983, GENETICS, V103, P725; WATT WB, 1985, GENETICS, V109, P157; WATT WB, 1983, ISOZYMES, V15, P27; ZAMMER WE, 1989, P NATL ACAD SCI USA, V86, P2737; ZOUROS E, 1983, ISOZYMES, V13, P1; 1988, SAS STAT USERS GUIDE, P549	33	48	48	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					898	900		10.1126/science.1876847	http://dx.doi.org/10.1126/science.1876847			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876847				2022-12-28	WOS:A1991GC15200043
J	WEISSMANN, C				WEISSMANN, C			A UNIFIED THEORY OF PRION PROPAGATION	NATURE			English	Review							CREUTZFELDT-JAKOB DISEASE; GERSTMANN-STRAUSSLER SYNDROME; DEPENDENT RNA-POLYMERASE; INFECTED HAMSTER BRAIN; HEPATITIS-DELTA-VIRUS; DEFECTIVE INTERFERING PARTICLES; MURINE ERYTHROLEUKEMIA-CELLS; SCRAPIE-ASSOCIATED FIBRILS; MOLECULAR WEIGHT PROTEIN; NUCLEIC-ACID	There is now very persuasive evidence that the transmissible agent for spongiform encephalopathies such as scrapie, consists of a modified form of the normal host protein PrP(C), devoid of any nucleic acid. On the other hand, because there are many different strains of scrapie agent with distinct phenotypes which can be propagated in animals homozygous for the PrP(C) gene, it has been suggested that a nucleic acid must be a component of the agent. Can the two views be reconciled?			WEISSMANN, C (corresponding author), UNIV ZURICH, INST MOLEK BIOL 1, CH-8093 ZURICH, SWITZERLAND.							AIKEN JM, 1990, J VIROL, V64, P3265, DOI 10.1128/JVI.64.7.3265-3268.1990; AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; AIKEN JM, 1989, J VIROL, V63, P1686, DOI 10.1128/JVI.63.4.1686-1694.1989; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; ALPER T, 1966, BIOCHEM BIOPH RES CO, V22, P278, DOI 10.1016/0006-291X(66)90478-5; ALPER T, 1978, J GEN VIROL, V41, P503, DOI 10.1099/0022-1317-41-3-503; BARRETT ADT, 1986, CURR TOP MICROBIOL, V128, P55; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BELLINGERKAWAHARA C, 1987, VIROLOGY, V160, P271, DOI 10.1016/0042-6822(87)90072-9; BELLINGERKAWAHARA C, 1987, J VIROL, V61, P159, DOI 10.1128/JVI.61.1.159-166.1987; BELLINGERKAWAHARA CG, 1988, VIROLOGY, V164, P537, DOI 10.1016/0042-6822(88)90569-7; BIEBRICH.CK, 1973, P NATL ACAD SCI USA, V70, P934, DOI 10.1073/pnas.70.3.934; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, P164; BRAIG HR, 1985, EMBO J, V4, P2309, DOI 10.1002/j.1460-2075.1985.tb03931.x; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BROWN P, 1990, J INFECT DIS, V161, P467, DOI 10.1093/infdis/161.3.467; BROWN P, 1986, J INFECT DIS, V153, P1145, DOI 10.1093/infdis/153.6.1145; BRUCE ME, 1987, J GEN VIROL, V68, P79, DOI 10.1099/0022-1317-68-1-79; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BRUCE ME, IN PRESS SCRAPIE CJD; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; CARLSON GA, 1988, MOL CELL BIOL, V8, P5528, DOI 10.1128/MCB.8.12.5528; CARP RI, 1991, J GEN VIROL, V72, P293, DOI 10.1099/0022-1317-72-2-293; CASPAR D L D, 1991, Current Biology, V1, P30, DOI 10.1016/0960-9822(91)90119-H; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DEES C, 1985, J VIROL, V55, P126, DOI 10.1128/JVI.55.1.126-132.1985; DEES C, 1985, J GEN VIROL, V66, P845, DOI 10.1099/0022-1317-66-4-845; Dickinson A. G., 1976, Slow virus diseases of animals and man,, P209; Dickinson A. G., 1979, Slow transmissible diseases of the nervous system. Volume 1., P367; DICKINSON AG, 1971, MOL GEN GENET, V112, P73, DOI 10.1007/BF00266934; DICKINSON AG, 1972, NATURE-NEW BIOL, V237, P244, DOI 10.1038/newbio237244a0; DICKINSON AG, 1975, NATURE, V253, P556, DOI 10.1038/253556a0; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DICKINSON AG, 1969, GENET RES, V13, P213, DOI 10.1017/S0016672300002895; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DICKINSON AG, 1977, SLOW VIRUS INFECTION, P3; DIEDRICH J, 1987, MICROB PATHOGENESIS, V2, P435, DOI 10.1016/0882-4010(87)90050-7; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DOHURA K, 1989, BIOCHEM BIOPH RES CO, V163, P974, DOI 10.1016/0006-291X(89)92317-6; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; FIELD EJ, 1966, BRIT MED J, V2, P564, DOI 10.1136/bmj.2.5513.564; FRANCKI RIB, 1985, ANNU REV MICROBIOL, V39, P151, DOI 10.1146/annurev.mi.39.100185.001055; Fraser H., 1976, Slow virus diseases of animals and man,, P267; FRASER H, 1968, J COMP PATHOL, V78, P301, DOI 10.1016/0021-9975(68)90006-6; FRASER H, 1973, J COMP PATHOL, V83, P29, DOI 10.1016/0021-9975(73)90024-8; GABIZON R, 1988, P NATL ACAD SCI USA, V85, P6617, DOI 10.1073/pnas.85.18.6617; GADANI F, 1990, ARCH VIROL, V115, P1, DOI 10.1007/BF01310619; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; GERMAN TL, 1985, J GEN VIROL, V66, P839, DOI 10.1099/0022-1317-66-4-839; GIACHETTI C, 1989, VIROLOGY, V170, P264, DOI 10.1016/0042-6822(89)90375-9; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; GIBBS CJ, 1968, SCIENCE, V161, P388, DOI 10.1126/science.161.3839.388; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; GOLDFARB LG, 1990, EXP NEUROL, V108, P247, DOI 10.1016/0014-4886(90)90130-K; GOLDFARB LG, 1990, LANCET, V336, P514, DOI 10.1016/0140-6736(90)92073-Q; GOLDFARB LG, 1990, LANCET, V336, P174, DOI 10.1016/0140-6736(90)91693-5; GOLDFARB LG, 1990, LANCET, V336, P637, DOI 10.1016/0140-6736(90)93443-S; GOLDGABER D, 1991, NATURE, V351, P106, DOI 10.1038/351106a0; GOLDGABER D, 1989, EXP NEUROL, V106, P204, DOI 10.1016/0014-4886(89)90095-2; Gordon W. S., 1946, VET REC, V58, P516; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HOPE J, IN PRESS SEMIN NEURO, V3; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K K, 1990, Neurology, V40, P388; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Hunter G. D., 1979, Slow transmissible diseases of the nervous system. Volume 2., P365; HUNTER GD, 1972, J INFECT DIS, V125, P427, DOI 10.1093/infdis/125.4.427; HUNTER N, 1987, J GEN VIROL, V68, P2711, DOI 10.1099/0022-1317-68-10-2711; HURST LD, 1991, NATURE, V351, P21, DOI 10.1038/351021d0; KIM YS, 1987, J GEN VIROL, V68, P695, DOI 10.1099/0022-1317-68-3-695; Kimberlin R.H., 1990, SE VIROL, V1, P153; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1985, INTERVIROLOGY, V23, P74, DOI 10.1159/000149588; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KIMBERLIN RH, 1983, J NEUROL SCI, V59, P355, DOI 10.1016/0022-510X(83)90021-7; KIMBERLIN RH, 1988, NOVEL INFECTIOUS AGE, P37; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1990, CELL, V63, P609, DOI 10.1016/0092-8674(90)90456-O; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LATARJET R, 1970, NATURE, V227, P1341, DOI 10.1038/2271341a0; MANUELIDIS L, 1987, EMBO J, V6, P341, DOI 10.1002/j.1460-2075.1987.tb04760.x; MANUELIDIS L, 1988, CIBA F SYMP, V135, P117; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MCKINLEY M P, 1990, Journal of Cell Biology, V111, p316A; MCKINLEY MP, 1989, NEUROLOGY, V39, P1319, DOI 10.1212/WNL.39.10.1319; MCKINLEY MP, 1983, PHOTOCHEM PHOTOBIOL, V37, P539, DOI 10.1111/j.1751-1097.1983.tb04515.x; MCLAIN L, 1988, J GEN VIROL, V69, P1415, DOI 10.1099/0022-1317-69-6-1415; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MULTHAUP G, 1985, EMBO J, V4, P1495, DOI 10.1002/j.1460-2075.1985.tb03808.x; MURDOCH GH, 1990, J VIROL, V64, P1477, DOI 10.1128/JVI.64.4.1477-1486.1990; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OESCH B, 1988, CIBA F SYMP, V135, P209; Outram G W, 1976, Front Biol, V44, P325; OWEN F, 1990, MOL BRAIN RES, V7, P273, DOI 10.1016/0169-328X(90)90038-F; OWEN F, 1989, LANCET, V1, P51; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PATTISON IH, 1966, RES VET SCI, V7, P207; PATTISON IH, 1965, J COMP PATHOL THERAP, V75, P159, DOI 10.1016/0021-9975(65)90006-X; PATTISON IH, 1967, VET REC, V80, P2, DOI 10.1136/vr.80.1.2; Perrault J, 1981, Curr Top Microbiol Immunol, V93, P151; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1990, MONOGR PATHOL, V32, P86; RACE RE, 1990, J GEN VIROL, V71, P493, DOI 10.1099/0022-1317-71-2-493; RACKWITZ HR, 1981, NATURE, V291, P297, DOI 10.1038/291297a0; ROBAKIS NK, 1986, P NATL ACAD SCI USA, V83, P6377, DOI 10.1073/pnas.83.17.6377; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; ROHWER RG, 1986, NATURE, V320, P381, DOI 10.1038/320381a0; ROHWER RG, 1984, NATURE, V308, P658, DOI 10.1038/308658a0; SAFAR J, 1990, P NATL ACAD SCI USA, V87, P6373, DOI 10.1073/pnas.87.16.6373; Scott J, 1989, CURR OPIN CELL BIOL, V1, P1141, DOI 10.1016/S0955-0674(89)80064-X; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SEMANCIK JS, 1984, P NATL ACAD SCI-BIOL, V81, P4429, DOI 10.1073/pnas.81.14.4429; SKLAVIADIS T, 1990, ARCH VIROL, V112, P215, DOI 10.1007/BF01323166; SKLAVIADIS T, 1986, P NATL ACAD SCI USA, V83, P6146, DOI 10.1073/pnas.83.16.6146; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; SPEER MC, 1991, GENOMICS, V9, P366, DOI 10.1016/0888-7543(91)90266-H; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAMP J. T., 1959, JOUR COMP PATHOL AND THERAP, V69, P268, DOI 10.1016/S0368-1742(59)80026-6; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TAYLOR JM, 1990, CELL, V61, P371, DOI 10.1016/0092-8674(90)90516-H; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; VOLLOCH V, 1987, J CELL BIOL, V105, P137, DOI 10.1083/jcb.105.1.137; VOLLOCH V, 1986, P NATL ACAD SCI USA, V83, P1208, DOI 10.1073/pnas.83.5.1208; WEISSMANN C, 1989, NATURE, V338, P298, DOI 10.1038/338298a0; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WIETGREFE S, 1985, SCIENCE, V230, P1177, DOI 10.1126/science.3840915; WILLS PR, 1989, MICROB PATHOGENESIS, V6, P235, DOI 10.1016/0882-4010(89)90098-3	148	276	282	5	24	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					679	683		10.1038/352679a0	http://dx.doi.org/10.1038/352679a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876183				2022-12-28	WOS:A1991GC06400046
J	CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX				CHEN, ZM; PETO, R; COLLINS, R; MACMAHON, S; LU, JR; LI, WX			SERUM-CHOLESTEROL CONCENTRATION AND CORONARY HEART-DISEASE IN POPULATION WITH LOW CHOLESTEROL CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article							FACTOR INTERVENTION TRIAL; PLASMA-CHOLESTEROL; CANCER MORTALITY; FOLLOW-UP; RISK; DEATH; MEN; REGRESSION; STROKE; LIPOPROTEIN	Objective-To examine the relation between serum cholesterol concentration and mortality (from coronary heart disease and from other causes) below the range of cholesterol values generally seen in Western populations. Design-Prospective observational study based on 8-13 years of follow up of subjects in a population with low cholesterol concentrations. Setting-Urban Shanghai, China. Subjects-9021 Chinese men and women aged 35-64 at baseline. Main outcome measure-Death from coronary heart disease and other causes. Results-The average serum cholesterol concentration was 4.2 mmol/l at baseline examination, and only 43 (7%) of the deaths that occurred during 8-13 years of follow up were attributed to coronary heart disease. There was a strongly positive, and apparently independent, relation between serum cholesterol concentration and death from coronary heart disease (z = 3.47, p < 0.001), and within the range of usual serum cholesterol concentration studied (3.8-4.7 mmol/l) there was no evidence of any threshold. After appropriate adjustment for the regression dilution bias, a 4 (SD 1)% difference in usual cholesterol concentration was associated with a 21 (SD 6)% (95% confidence interval 9% to 35%) difference in mortality from coronary heart disease. There was no significant relation between serum cholesterol concentration and death from stroke or all types of cancer. The 79 deaths due to liver cancer or other chronic liver disease were inversely related to cholesterol concentration at baseline. Conclusion-Blood cholesterol concentration was directly related to mortality from coronary heart disease even in those with what was, by Western standards, a "low" cholesterol concentration. There was no good evidence of an adverse effect of cholesterol on other causes of death.	SHANGHAI CHEST HOSP,SHANGHAI,PEOPLES R CHINA; SHANGHAI MED UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,SHANGHAI,PEOPLES R CHINA	Shanghai Jiao Tong University; Fudan University	CHEN, ZM (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,MRC,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND.							USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BEAGLEHOLE R, 1980, BMJ-BRIT MED J, V280, P285, DOI 10.1136/bmj.280.6210.285; BEASLEY RP, 1981, LANCET, V2, P1129; BERKSON J, 1950, J AM STAT ASSOC, V45, P164, DOI 10.2307/2280676; CHEN DY, 1987, CHIN MED J, V7, P382; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; EDERER F, 1972, J CHRON DIS, V25, P277, DOI 10.1016/0021-9681(72)90164-6; FEINLEIB M, 1981, AM J EPIDEMIOL, V114, P5, DOI 10.1093/oxfordjournals.aje.a113173; GOLDBOURT U, 1985, BMJ-BRIT MED J, V290, P1239, DOI 10.1136/bmj.290.6477.1239; HAN QQ, 1984, ACTA ACAD MED PRIMAE, V11, P181; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JIANG YT, 1982, VIRAL HEPATITIS, P121; KEIL U, 1989, INT J EPIDEMIOL, V18, pS46; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LI SC, 1985, NEUROLOGY, V35, P1708, DOI 10.1212/WNL.35.12.1708; LI WX, 1979, ACTA ACAD MED PRIMAE, V6, P65; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER MF, 1981, LANCET, V2, P1090; PEARSON S, 1953, ANAL CHEM, V25, P813, DOI 10.1021/ac60077a041; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1985, CIRCULATION, V72, P451; RAGLAND DR, 1988, AM J EPIDEMIOL, V127, P462, DOI 10.1093/oxfordjournals.aje.a114823; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; ROSE G, 1980, LANCET, V1, P523; SCHATZKIN A, 1987, LANCET, V2, P298; SHERWIN RW, 1987, JAMA-J AM MED ASSOC, V257, P943; SIMONS LA, 1986, AM J CARDIOL SG, V57, P5; SOLONEN JT, 1982, AM J EPIDEMIOL, V116, P622; Speizer, 1976, NATURAL HIST CHRONIC, P218; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SZATROWSKI TP, 1984, J CHRON DIS, V37, P569, DOI 10.1016/0021-9681(84)90007-9; TORNBERG SA, 1986, NEW ENGL J MED, V315, P1629, DOI 10.1056/NEJM198612253152601; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZAK B, 1954, AM J CLIN PATHOL, V24, P1307, DOI 10.1093/ajcp/24.11_ts.1307; [No title captured]; 1982, JAMA-J AM MED ASSOC, V248, P2853	44	469	488	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					276	282		10.1136/bmj.303.6797.276	http://dx.doi.org/10.1136/bmj.303.6797.276			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888927	Green Published, Bronze			2022-12-28	WOS:A1991FZ72100018
J	WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN				WILLIAMS, DRR; BYRNE, C; CLARK, PMS; COX, L; DAY, NE; RAYMAN, G; WANG, T; HALES, CN			RAISED PROINSULIN CONCENTRATION AS EARLY INDICATOR OF BETA-CELL DYSFUNCTION	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QQ,ENGLAND; ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	WILLIAMS, DRR (corresponding author), ADDENBROOKES HOSP,DEPT COMMUNITY MED,CAMBRIDGE CB2 2QQ,ENGLAND.			Byrne, Christopher D/0000-0001-6322-7753				SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; TEMPLE RC, 1989, LANCET, V1, P293, DOI 10.1016/S0140-6736(89)91306-8; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, WHO TECH REP SER, V727	4	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					95	96		10.1136/bmj.303.6794.95-a	http://dx.doi.org/10.1136/bmj.303.6794.95-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1860012	Green Published, Bronze			2022-12-28	WOS:A1991FW58600023
J	BREITNER, JCS				BREITNER, JCS			CLINICAL GENETICS AND GENETIC-COUNSELING IN ALZHEIMER-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						ALZHEIMERS DISEASE; DEMENTIA, SENILE; DOWNS SYNDROME; GENETIC COUNSELING; TRISOMY	AGE-DEPENDENT EXPRESSION; BETA-PROTEIN GENE; FAMILIAL RISK; 1ST-DEGREE RELATIVES; DEMENTIA; ONSET; AGGREGATION; LINKAGE; CDNA; ASSOCIATION	Because of growing evidence for genetic causes of Alzheimer disease, clinicians are often asked about risks for this disorder among relatives of patients. This paper briefly reviews the evidence for genetic and other causes of Alzheimer disease, including specifically its typical late-onset variant. Several recent developments in the molecular genetics of early-onset Alzheimer disease are described briefly. These findings, however, may not apply to more typical, late-onset Alzheimer disease. Genetic studies of the latter disorder are complicated by the censorship of any inherited predisposition to disease by death from other causes. Hence, heritable disease may be apparent only in families with large numbers of elderly relatives at risk. Relying on empiric observations of risk among relatives from several recent studies of pooled Alzheimer families, curves are presented describing theoretic age-specific risks in relatives of patients and unaffected controls. Real (current) lifetime risks of Alzheimer disease are then estimated by modification of the theoretic figures with corresponding current age-specific mortality characteristics of the U.S. population. The lifetime incidence among relatives of patients with Alzheimer disease is estimated to be 19%, or three to four times the risk among control relatives. Because both mortality of and risk for Alzheimer disease change rapidly with advancing age, it may be possible to reduce the current morbidity from Alzheimer disease by 50% if onset can be postponed by only 5 years.			BREITNER, JCS (corresponding author), DUKE UNIV, MED CTR, DEPT PSYCHIAT, BOX 3925, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE ON AGING [R35AG007922, R03AG005849] Funding Source: NIH RePORTER; NIA NIH HHS [AG-05128, AG-05849, AG-07922] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1989, J NEURAL TRANSM GEN, V1, P3; BREITNER JCS, 1990, ANN NEUROL, V27, P338, DOI 10.1002/ana.410270321; BREITNER JCS, 1988, AM J EPIDEMIOL, V128, P536, DOI 10.1093/oxfordjournals.aje.a115001; BREITNER JCS, 1988, NEUROLOGY, V38, P207; BREITNER JCS, 1989, GENET EPIDEMIOL, V6, P663, DOI 10.1002/gepi.1370060603; BREITNER JCS, 1990, NEUROBIOL AGING, V11, P641, DOI 10.1016/0197-4580(90)90030-4; BREITNER JCS, 1984, PSYCHOL MED, V14, P63, DOI 10.1017/S0033291700003081; BREITNER JCS, 1986, J PSYCHIAT RES, V20, P31, DOI 10.1016/0022-3956(86)90021-X; BREITNER JCS, 1986, J PSYCHIAT RES, V20, P45, DOI 10.1016/0022-3956(86)90022-1; BREITNER JCS, 1987, PSYCHOPHARMACOLOGY 3, P929; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CHASE GA, 1983, AM J EPIDEMIOL, V117, P590, DOI 10.1093/oxfordjournals.aje.a113581; COOK RH, 1979, NEUROLOGY, V29, P1402, DOI 10.1212/WNL.29.10.1402; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FARRER LA, 1989, ANN NEUROL, V25, P485, DOI 10.1002/ana.410250511; FELDMAN RG, 1963, NEUROLOGY, V13, P811, DOI 10.1212/WNL.13.10.811; FOLSTEIN MF, 1981, JOHNS HOPKINS MED J, V149, P145; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GAUTRIN D, 1989, CAN J NEUROL SCI, V16, P375, DOI 10.1017/S0317167100029425; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOATE AM, 1989, LANCET, V1, P352; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAVES AB, 1990, J CLIN EPIDEMIOL, V43, P35, DOI 10.1016/0895-4356(90)90053-R; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GRAVES AB, 1987, AM J EPIDEMIOL, V126, P754; Gross AJ, 1975, SURVIVAL DISTRIBUTIO; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HENDERSON AS, 1988, ACTA PSYCHIAT SCAND, V78, P257, DOI 10.1111/j.1600-0447.1988.tb06336.x; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HESTON LL, 1983, BIOL ASPECTS ALZHEIM, P183; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HUFF FJ, 1988, NEUROLOGY, V38, P786, DOI 10.1212/WNL.38.5.786; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; LARSSON T, 1963, ACTA PSYCHIAT SCAND, V39, P1; MARTIN RL, 1988, ARCH GEN PSYCHIAT, V45, P894; MEGGENDORFER F, 1925, ZENTRALBL GES NEOROL, V40, P359; MOHS RC, 1987, ARCH GEN PSYCHIAT, V44, P405; NEE LE, 1987, NEUROLOGY, V37, P359, DOI 10.1212/WNL.37.3.359; NEE LE, 1983, ARCH NEUROL-CHICAGO, V40, P203, DOI 10.1001/archneur.1983.04050040033004; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; Powell D, 1984, J NEUROGENET, V1, P189, DOI 10.3109/01677068409107085; REISBERG B, 1984, NEW ENGL J MED, V311, P1318; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROSES AD, 1986, NEUROBIOL AGING, V7, P466, DOI 10.1016/0197-4580(86)90072-2; SADOVNICK AD, 1989, GENET EPIDEMIOL, V6, P633, DOI 10.1002/gepi.1370060508; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Sjogren T, 1952, ACTA PSYCH NEUROL SC, V82, P9; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; WHALLEY LJ, 1989, CURRENT OPINION PSYC, V2, P526; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; ZUBENKO GS, 1988, ARCH GEN PSYCHIAT, V45, P889	60	51	54	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					601	606		10.7326/0003-4819-601	http://dx.doi.org/10.7326/0003-4819-601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892331				2022-12-28	WOS:A1991GJ90200004
J	POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C				POWARS, DR; ELLIOTTMILLS, DD; CHAN, L; NILAND, J; HITI, AL; OPAS, LM; JOHNSON, C			CHRONIC-RENAL-FAILURE IN SICKLE-CELL DISEASE - RISK-FACTORS, CLINICAL COURSE, AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; ANEMIA, SICKLE CELL; HEMOGLOBIN-SC DISEASE; HYPERTENSION; NEPHROTIC SYNDROME	NATURAL-HISTORY; CONFIDENCE-INTERVAL; ENDOTHELIAL-CELLS; FETAL HEMOGLOBIN; BLOOD-PRESSURE; GLOBIN GENE; ANEMIA; NEPHROPATHY; TRANSPLANTATION; ERYTHROCYTES	Objective: To determine the incidence, clinical course, and risk factors associated with the onset of chronic renal failure in sickle cell anemia and sickle C disease. Design: A prospective, 25-year longitudinal demographic and clinical cohort study. A matched case-control study was conducted to determine risk factors. Patients: A total of 725 patients with sickle cell anemia and 209 patients with sickle C disease who received medical care from the hematology service in a large municipal hospital. Most were observed from birth or early childhood. Measurements: Thirty-six patients developed sickle renal failure: 4.2% of patients with sickle cell anemia and 2.4% of patients with sickle C disease. The median age of disease onset for these patients was 23.1 and 49.9 years, respectively. Survival time for patients with sickle cell anemia after the diagnosis of sickle renal failure, despite dialysis, was 4 years, and the median age at the time of death was 27 years. Relative risk for mortality was 1.42 (95% CI, 1.12 to 1.81; P = 0.02) compared with patients who did not develop renal insufficiency. Main Results: Histopathologic studies showed characteristic lesions of glomerular "drop out" and glomerulosclerosis. Case-control analysis showed that ineffective erythropoiesis with increasingly severe anemia, hypertension, proteinuria, the nephrotic syndrome, and microscopic hematuria were significant pre-azotemic predictors of chronic renal failure. The risk for sickle renal failure was increased in patients who had inherited the Central African Republic beta-S-gene cluster haplotype. Conclusions: The pre-azotemic manifestations of hypertension, proteinuria, and increasingly severe anemia predict end-stage renal failure in patients with sickle cell disease. The rate of progression of renal insufficiency is genetically determined. Treatment of the uremic phase has been dismal, underscoring the need for the development of useful pre-azotemic therapeutic modalities.			POWARS, DR (corresponding author), UNIV SO CALIF, SCH MED, PEDIAT PAVILION, 1129 N STATE ST, ROOM 2E19, LOS ANGELES, CA 90033 USA.				NHLBI NIH HHS [HL 15162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PEDIATRICS, V79, P1; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P853, DOI 10.1073/pnas.81.3.853; BARANOWSKI T, 1988, PEDIATR RES, V23, P270, DOI 10.1203/00006450-198803000-00008; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; BRESLOW NE, 1984, INT J EPIDEMIOL, V13, P112, DOI 10.1093/ije/13.1.112; BUCKALEW VM, 1974, ARCH INTERN MED, V133, P660, DOI 10.1001/archinte.133.4.660; CHAN LS, 1982, J CHRON DIS, V35, P401, DOI 10.1016/0021-9681(82)90010-8; CHATTERJEE SN, 1987, TRANSPLANT P, V19, P33; COE FL, 1976, KIDNEY, V2, P767; CRUZ IA, 1982, J NATL MED ASSOC, V74, P1103; Dean A. G., 1990, EPI INFO VERSION 5 W; DEJONG PE, 1985, KIDNEY INT, V27, P711, DOI 10.1038/ki.1985.70; Diggs LW, 1934, SOUTH MED J, V27, P839; EATON WA, 1987, BLOOD, V70, P1245; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FLEISS JL, 1973, STATISTICAL METHODS; FREEDMAN BI, 1990, AM J KIDNEY DIS, V15, P361, DOI 10.1016/S0272-6386(12)80082-5; FRIEDMAN EA, 1974, NEW ENGL J MED, V291, P431, DOI 10.1056/NEJM197408292910902; GONZALEZCARRILLO M, 1982, CLIN NEPHROL, V18, P209; GREEN MA, 1988, J CLIN INVEST, V81, P1669, DOI 10.1172/JCI113504; HADDY TB, 1982, AM J PEDIAT HEMATOL, V4, P191; HENDERSON AB, 1950, AM J MED, V9, P757, DOI 10.1016/0002-9343(50)90291-9; HOWE GR, 1983, BIOMETRICS, V39, P325, DOI 10.2307/2531005; HOWE GR, 1986, INT J EPIDEMIOL, V15, P257, DOI 10.1093/ije/15.2.257; JOHNSON CS, 1981, ARCH INTERN MED, V141, P891, DOI 10.1001/archinte.141.7.891; KAPLOW LS, 1968, J AMER MED ASSOC, V203, P1135; KAUL DK, 1989, P NATL ACAD SCI USA, V86, P3356, DOI 10.1073/pnas.86.9.3356; KEIDAN AJ, 1989, BRIT J HAEMATOL, V71, P551, DOI 10.1111/j.1365-2141.1989.tb06316.x; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KOSHY M, 1989, BLOOD, V74, P1403; LINDEMAN RD, 1990, AM J KIDNEY DIS, V16, P275, DOI 10.1016/S0272-6386(12)80002-3; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCCOY RC, 1969, LAB INVEST, V21, P85; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MINER DJ, 1987, AM J KIDNEY DIS, V10, P306, DOI 10.1016/S0272-6386(87)80027-6; MOHANDAS N, 1984, BLOOD, V64, P282; MORGAN AG, 1981, BMJ-BRIT MED J, V282, P1181, DOI 10.1136/bmj.282.6271.1181; NAGEL RL, 1990, SEMIN HEMATOL, V27, P342; NAGPAL KC, 1977, SURV OPHTHALMOL, V21, P391, DOI 10.1016/0039-6257(77)90042-X; Nduke N, 1987, Folia Haematol Int Mag Klin Morphol Blutforsch, V114, P508; NISSENSON AR, 1989, Q J MED, V73, P1055; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POWARS D, 1978, AM J MED, V65, P461, DOI 10.1016/0002-9343(78)90772-6; POWARS D, 1990, SEMIN HEMATOL, V27, P360; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; POWARS DR, 1989, ANN NY ACAD SCI, V565, P262, DOI 10.1111/j.1749-6632.1989.tb24174.x; POWARS DR, 1975, SEMIN HEMATOL, V12, P267; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; QUADRACCI LJ, 1976, KIDNEY INT, V10, P179, DOI 10.1038/ki.1976.93; REID CDL, 1988, BRIT J HAEMATOL, V70, P375, DOI 10.1111/j.1365-2141.1988.tb02497.x; SANDLER DP, 1989, NEW ENGL J MED, V320, P1238, DOI 10.1056/NEJM198905113201903; SCHROEDER WA, 1989, HEMOGLOBIN, V13, P325, DOI 10.3109/03630268909003397; SCHROEDER WA, 1980, CHROMATOGRAPHY HEMOG; SHERWOOD JB, 1986, BLOOD, V67, P46; SPECTOR D, 1978, AM J MED, V64, P835, DOI 10.1016/0002-9343(78)90524-7; Statius van Eps LW, 1970, LANCET, V1, P450; STRAUSS J, 1986, NEPHRON, V43, P241, DOI 10.1159/000183848; STRAUSS J, 1975, AM J MED, V58, P382, DOI 10.1016/0002-9343(75)90604-X; SZWED JJ, 1980, AM J MED SCI, V279, P169, DOI 10.1097/00000441-198005000-00006; TEJANI A, 1985, NEPHRON, V39, P352, DOI 10.1159/000183404; WALKER BR, 1971, J AMER MED ASSOC, V215, P437, DOI 10.1001/jama.215.3.437; WEINSTEIN R, 1990, BLOOD, V76, P2146; WESTNEY LS, 1984, OBSTET GYNECOL, V63, P752; WICK TM, 1987, J CLIN INVEST, V80, P905, DOI 10.1172/JCI113151	64	242	249	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					614	620		10.7326/0003-4819-115-8-614	http://dx.doi.org/10.7326/0003-4819-115-8-614			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892333				2022-12-28	WOS:A1991GJ90200006
J	COHEN, AF; KROON, R; SCHOEMAKER, R; HOOGKAMER, H; VANVLIET, A				COHEN, AF; KROON, R; SCHOEMAKER, R; HOOGKAMER, H; VANVLIET, A			INFLUENCE OF GASTRIC-ACIDITY ON THE BIOAVAILABILITY OF DIGOXIN	ANNALS OF INTERNAL MEDICINE			English	Article						DIGOXIN; GASTRIC ACID; HEART FAILURE, CONGESTIVE; OMEPRAZOLE; PENTAGASTRIN	OMEPRAZOLE; BIOTRANSFORMATION; METABOLITES; PH; INTOXICATION; HYDROLYSIS; SECRETION; EXCRETION; DIAZEPAM; URINE	Objective: To study how changes in gastric acidity induced by omeprazole and pentagastrin affect the absorption of unchanged digoxin and its hydrolytic breakdown products. Design: Double-blind, double-dummy, randomized, crossover study. Setting: Academic department of clinical pharmacology. Subjects: Six healthy male volunteers. Interventions: Subjects received digoxin, 1 mg orally, on three separate occasions: first, after pretreatment with omeprazole; second, after pretreatment with pentagastrin; and third, after "pretreatment" with placebo. Measurements: The in-vitro decomposition of digoxin was studied using a standard dissolution test. The urinary excretion of digoxin over a 120-hour period was measured using selective high-pressure liquid chromatography (HPLC) and a polarization enzyme immunoassay (EIA). Plasma concentrations were measured at 2 hours with the EIA. Main Results: Digoxin was rapidly released from the tablets in the in-vitro test. At acid pH, decomposition (as measured with HPLC) was rapid. Pentagastrin reduced the urinary excretion of unchanged digoxin, as measured by HPLC, from 34% to 21.4% of the dose (difference, -12.6%; 95% Cl, -23.5 to -1.8; P < 0.05), whereas omeprazole increased urinary excretion to 47.4% (difference, 13.4%; 95 Cl, 2.5% to 24.4%; P < 0.05). However, such differences were not found with the nonselective polarization EIA. Conclusions: Our data suggest that gastric acidity causes the breakdown of digoxin to products that cross-react in the assay (EIA) that is commonly used clinically. In patients with reduced gastric acidity, increased plasma concentrations of unchanged digoxin may not be detected because of limitations of the EIA, which may invalidate the quantitative use of the plasma digoxin concentration as a predictor of digoxin toxicity. Omeprazole, and presumably other gastric-acid inhibitors, may increase the bioavailability of unchanged digoxin.			COHEN, AF (corresponding author), LEIDEN UNIV HOSP, CTR HUMAN DRUG RES, BLDG 50A, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Cohen, Adam/G-3756-2010	Schoemaker, Rik/0000-0002-7538-3005				BELLER GA, 1971, NEW ENGL J MED, V284, P989, DOI 10.1056/NEJM197105062841801; BOTTCHER H, 1973, EUR J PHARMACOL, V22, P109, DOI 10.1016/0014-2999(73)90192-1; BROWN DD, 1976, CLIN PHARMACOL THER, V20, P395; CLARK DR, 1974, DRUG METAB DISPOS, V2, P148; CLISSOLD SP, 1986, DRUGS, V32, P15, DOI 10.2165/00003495-198632010-00002; GAULT H, 1982, CLIN PHARMACOL THER, V31, P695, DOI 10.1038/clpt.1982.98; GAULT H, 1981, CLIN PHARMACOL THER, V29, P181, DOI 10.1038/clpt.1981.29; GAULT H, 1980, CLIN PHARMACOL THER, V27, P16, DOI 10.1038/clpt.1980.3; GAULT MH, 1977, J PHARM PHARMACOL, V29, P27, DOI 10.1111/j.2042-7158.1977.tb11232.x; GAULT MH, 1984, CLIN PHARMACOL THER, V35, P74, DOI 10.1038/clpt.1984.11; GIBSON TP, 1980, CLIN PHARMACOL THER, V27, P219, DOI 10.1038/clpt.1980.34; GJERDRUM K, 1970, ACTA MED SCAND, V187, P371; GOODMANGILMAN A, 1985, PHARMACOL BASIS THER, P735; GUGLER R, 1985, GASTROENTEROLOGY, V89, P1235, DOI 10.1016/0016-5085(85)90638-9; GUGLER R, 1984, LANCET, V1, P969; KUHLMANN J, 1974, EUR J CLIN PHARMACOL, V7, P87, DOI 10.1007/BF00561320; LIND T, 1983, GUT, V24, P270, DOI 10.1136/gut.24.4.270; LINDENBAUM J, 1981, NEW ENGL J MED, V305, P789, DOI 10.1056/NEJM198110013051403; MAGNUSSON JO, 1982, BIOPHARM DRUG DISPOS, V3, P211, DOI 10.1002/bdd.2510030304; Mann H, 1971, Eur J Pharmacol, V14, P204; MARCUS FI, 1975, J LAB CLIN MED, V85, P610; OOSTERHUIS B, 1991, IN PRESS BR J CLIN P; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64, DOI 10.1016/S0016-5085(85)80133-5; RODIN SM, 1988, CLIN PHARMACOKINET, V15, P227, DOI 10.2165/00003088-198815040-00003; SHEPARD TA, 1986, J CHROMATOGR, V380, P89, DOI 10.1016/S0378-4347(00)83627-0; SMITH TW, 1970, J CLIN INVEST, V49, P2377, DOI 10.1172/JCI106457; SONOBE T, 1980, J PHARM SCI, V69, P410, DOI 10.1002/jps.2600690412; STEINESS E, 1974, CIRCULATION, V50, P103, DOI 10.1161/01.CIR.50.1.103	28	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					540	545		10.7326/0003-4819-115-7-540	http://dx.doi.org/10.7326/0003-4819-115-7-540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883123				2022-12-28	WOS:A1991GG28300006
J	SHRAGER, JB				SHRAGER, JB			3 WOMEN AT JOHNS-HOPKINS - PRIVATE PERSPECTIVES ON MEDICAL COEDUCATION IN THE 1890S	ANNALS OF INTERNAL MEDICINE			English	Article						HISTORICAL BIOGRAPHY; HISTORY OF MEDICINE, 19TH CENT; PHYSICIANS, WOMEN; EDUCATION, MEDICAL; SOCIAL SUPPORT		The recent sharp increase in the number of women entering the medical profession in the United States has brought to the forefront issues that were first raised by the first female physicians a century ago. Although they rarely objected publicly, female students who attended coeducational medical schools during these early years were significantly affected by the pervasive sexism that surrounded them. Only by examining private letters and diaries written by the female students can we fully appreciate the difficult circumstances under which these persons studied medicine. The available personal archival materials of Dorothy Reed Mendenhall, Margaret Long, and Florence Sabin, written in the 1890s during their medical school years at Johns Hopkins, provide glimpses of the interaction between these women and the male world they were entering. Despite their increasing numbers, contemporary female students and physicians may face similar obstacles.			SHRAGER, JB (corresponding author), HOSP UNIV PENN, DEPT SURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.							DRACHMAN VG, 1976, WOMEN DOCTORS WOMENS, P161; DRACHMAN VG, 1976, WOMEN DOCTORS WOMENS, P217; DRACHMAN VG, 1976, WOMEN DOCRORS WOMENS, P147; DRACHMAN VG, 1976, WOMEN DOCTORS WOMENS, P173; DRACHMAN VG, 1976, WOMEN DOCTORS WOMENS, P7; LEVINSON DJ, 1978, ESASONS MANS LIFE; LOPATE C, 1968, WOMEN MED, P4; MANDENHALL DR, 1896, COMMUNICATION   1003; MENDEHALL DR, 1990, COMMUNICATION   0615; MENDENHALL DR, 1899, COMMUNICATION   0827; MENDENHALL DR, 1896, COMMUNICATION   1029; MENDENHALL DR, 1896, COMMUNICATION   0812; MENDENHALL DR, 1893, POESIE; MENDENHALL DR, 1897, COMMUNICATION   0219; MENDENHALL DR, 1896, COMMUNICATION   0216; MENDENHALL DR, 1897, COMMUNICATION   0125; MENDENHALL DR, 1896, COMMUNICATION   1130; MENDENHALL DR, 1894, COMMUNICATION; MENDENHALL DR, 1895, COMMUNICATION   0930; MORANTZSANCHEZ RM, 1985, SYMPATHY SCI WOMEN P, P125; PHELAN MK, 1969, PROBING UNKNOWN STOR; POPE EF, 1881, PRACTICE MED WOMEN U, P12; Smith-Rosenberg Carroll, 1985, DISORDERLY CONDUCT V, P53; THOMAS EB, 1975, WOMEN MED STUDENTS 1	24	3	3	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					564	569		10.7326/0003-4819-115-7-564	http://dx.doi.org/10.7326/0003-4819-115-7-564			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883127				2022-12-28	WOS:A1991GG28300010
J	BRYAN, GT				BRYAN, GT			PHYSICIANS AND MEDICAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BRYAN, GT (corresponding author), UNIV TEXAS,MED BRANCH,528 ADM BLDG,GALVESTON,TX 77550, USA.							AINSWORTH MA, 1991, JAMA-J AM MED ASSOC, V266, P1390, DOI 10.1001/jama.266.10.1390	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1407	1408						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880872				2022-12-28	WOS:A1991GD80700038
J	JAEHNING, JA				JAEHNING, JA			SIGMA-FACTOR RELATIVES IN EUKARYOTES	SCIENCE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION INITIATION-FACTOR; BINDS				JAEHNING, JA (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.							CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JANG S, UNPUB; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	12	25	25	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					859	859		10.1126/science.1876846	http://dx.doi.org/10.1126/science.1876846			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876846				2022-12-28	WOS:A1991GC15200032
J	JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD				JULIAN, BA; LASKOW, DA; DUBOVSKY, J; DUBOVSKY, EV; CURTIS, JJ; QUARLES, LD			RAPID LOSS OF VERTEBRAL MINERAL DENSITY AFTER RENAL-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE HISTOMORPHOMETRIC DATA; INDUCED OSTEOPOROSIS; ILIAC BONE; OSTEOMALACIA; RESORPTION; OSTEOPENIA; ALUMINUM	Background. Osteopenia is a major complication of renal transplantation. Immunosuppressive regimens including cyclosporine, which permit the use of lower doses of glucocorticoids, may reduce glucocorticoid-induced osteopenia. Methods. We prospectively studied the magnitude, distribution, and mechanism of bone loss in 20 adults who received renal allografts from living related donors, who had good renal function, and who were treated with azathioprine, cyclosporine, and low doses of prednisone. We measured serum biochemical markers of bone metabolism, determined the bone mineral density of the second, third, and fourth lumbar vertebrae and the shaft of the radius, and analyzed the histomorphometric features of iliac bone at the time of transplantation and six months later. Measurements of vertebral mineral density were repeated 18 months after transplantation in 17 of the patients. Results. After transplantation, the mean serum concentrations of Parathyroid hormone, phosphorus, and alkaline phosphatase decreased and the serum calcitriol concentration increased. The mean (+/- SD) bone mineral density of the vertebrae had decreased 6.8 +/- 5.6 percent 6 months after transplantation (P < 0.05) and 8.8 +/- 7.0 percent 18 months after transplantation. In contrast, the bone mineral density of the radius had increased six months after transplantation (P < 0.05). The histomorphometric studies showed that the rate of bone formation decreased from 50.5 +/- 44.8 to 23.1 +/- 13.8-mu-m3 per square micrometer per year (P < 0.05), and the formation period lengthened from 70 +/- 42 to 146 +/- 144 days (P < 0.05). Consequently, the amount of bone replaced during a remodeling cycle diminished. Conclusions. Osteopenia associated with renal transplantation remains a problem in the cyclosporine era. The loss of vertebral bone in our subjects was due to an imbalance in bone remodeling consistent with a toxic effect of glucocorticoids.	UNIV ALABAMA, DEPT SURG, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT RADIOL, BIRMINGHAM, AL 35294 USA; DUKE UNIV, DEPT MED, DURHAM, NC 27706 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Duke University	JULIAN, BA (corresponding author), UNIV ALABAMA, DEPT MED, DIV NEPHROL, THT 643, UAB STN, BIRMINGHAM, AL 35294 USA.			Quarles, L. Darryl/0000-0002-5082-7896	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037308] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00032] Funding Source: Medline; NIAMS NIH HHS [2 ROI AR 37308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BONOMINI V, 1975, J UROL NEPHROL, V81, P941; BRINER V, 1987, KIDNEY INT, V32, P431; DEMPSTER DW, 1983, CALCIFIED TISSUE INT, V35, P410, DOI 10.1007/BF02405069; DUBOVSKY J, 1987, OSTEOPOROSIS 1987, V1, P60; EASTELL R, 1990, J BONE MINER RES, V5, P1237; EISMAN JA, 1976, ARCH BIOCHEM BIOPHYS, V176, P235, DOI 10.1016/0003-9861(76)90161-2; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; KANIS JA, 1990, J BONE MINER RES, V5, P209, DOI 10.1002/jbmr.5650050302; KIMMEL DB, 1990, BONE MINER, V11, P217, DOI 10.1016/0169-6009(90)90061-J; KLEEREKOPER M, 1983, INT C SERIES, V617, P200; LOERTSCHER R, 1983, TRANSPLANTATION, V36, P115; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LYLES KW, 1982, CALCIFIED TISSUE INT, V34, P125, DOI 10.1007/BF02411222; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P449, DOI 10.1007/BF02411283; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MCCARRON DA, 1982, KIDNEY INT, V22, P662, DOI 10.1038/ki.1982.227; MOORHEAD JF, 1974, LANCET, V1, P694; MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo-123-5-2571; NETER J, 1974, APPLIED LINEAR STATI; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PARFITT AM, 1986, CPC SERIES CASES MET, P1; PECK WA, 1967, P NATL ACAD SCI USA, V57, P1599, DOI 10.1073/pnas.57.6.1599; POCOCK NA, 1987, ANN INTERN MED, V107, P319, DOI 10.7326/0003-4819-107-2-319; QUARLES LD, 1989, J BONE MINER RES, V4, P671; QUARLES LD, 1988, J CLIN INVEST, V81, P1056, DOI 10.1172/JCI113417; RECKER RR, 1988, J BONE MINER RES, V3, P133; SCHWARTZ MP, 1981, CALCIFIED TISSUE INT, V33, P561, DOI 10.1007/BF02409492; SKJODT H, 1984, Calcified Tissue International, V36, pS50; SLATOPOLSKY E, 1984, ADV EXP MED BIOL, V171, P353; STEIN B, 1991, ENDOCRINOLOGY, V128, P1369, DOI 10.1210/endo-128-3-1369; STEWART PJ, 1986, J BONE MINER RES, V1, P285; STEWART PJ, 1989, CALCIFIED TISSUE INT, V45, P222, DOI 10.1007/BF02556041; VILLANUEVA AR, 1974, STAIN TECHNOL, V49, P1, DOI 10.3109/10520297409116928	34	556	568	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					544	550		10.1056/NEJM199108223250804	http://dx.doi.org/10.1056/NEJM199108223250804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857390	Bronze			2022-12-28	WOS:A1991GB44700004
J	WANK, R; THOMSSEN, C				WANK, R; THOMSSEN, C			HIGH-RISK OF SQUAMOUS-CELL CARCINOMA OF THE CERVIX FOR WOMEN WITH HLA-DQW3	NATURE			English	Article							HERPES-SIMPLEX VIRUS; CLASS-II MOLECULES; HLA-DR ANTIGEN; ANKYLOSING-SPONDYLITIS; ASSOCIATION; SPECIFICITIES; H-2-COMPLEX; COMPLEX; LOCUS	MANY immune responses are controlled by genes of the major histocompatibility complex (MHC) 1. In man these include the loci encoding the HLA-A, -B, -C, -DR, -DQ and -DP antigens, and many diseases have been linked with these 2-5. But attempts to identify HLA genes in man that might explain why an immune response against malignant tumours should be ineffective have so far been disappointing, apart from the association reported between the HLA-DRI antigen and a susceptibility to a rare carcinoma of the thyroid gland 6. Here we describe another strong connection between a common malignant tumour and an HLA antigen, namely between HLA-DQw3 and squamous cell carcinoma of the cervix: from the 1988 United States tumour registry, 1 in every 63 newborn girls will develop this invasive cancer 7. We found that 88% of 66 patients had the leukocyte antigen HLA-DQw3 when it would normally be expected in only 50% of individuals. In animals the immune system and the MHC act in defence against virally induced tumours, but until now there has been no evidence that they do so in humans 8: as squamous cell carcinoma is probably virally induced, our discovery of its association with an HLA antigen will be important to the understanding of the immunogenetic basis of a susceptibility to this tumour.	TECH UNIV MUNICH, DEPT OBSTET & GYNAECOL, W-8000 MUNICH 80, GERMANY	Technical University of Munich	WANK, R (corresponding author), UNIV MUNICH, DEPT IMMUNOL, GOETHESTR 31, W-8000 MUNICH 2, GERMANY.		Thomssen, Christoph/ABC-3102-2021					BARBER HRK, 1989, MANUAL GYNAECOLOGIC, P212; BAUR MP, 1984, HISTOCOMPATIBILITY T, P333; BODMER JG, 1990, TISSUE ANTIGENS, V35, P1, DOI 10.1111/j.1399-0039.1990.tb01749.x; Bodmer W. F., 1989, IMMUNOBIOLOGY HLA, V1, P72; BOYUM A, 1968, SCAND J CLIN LAB I S, V97, P21; BREWERTON DA, 1973, LANCET, V1, P904; CHESEBRO B, 1974, J EXP MED, V140, P1457, DOI 10.1084/jem.140.6.1457; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; FESTENSTEIN H, 1986, NATURE, V322, P64, DOI 10.1038/322064a0; GISSMANN L, 1986, ORIGINS FEMALE GENIT, P217; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; JOHNSON JP, 1987, TISSUE ANTIGENS, V29, P26; JOHNSON JP, 1984, J EXP MED, V160, P1350, DOI 10.1084/jem.160.5.1350; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAMPGEN E, 1988, ARCH DERMATOL, V124, P1372, DOI 10.1001/archderm.124.9.1372; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KJAER SK, 1988, INT J CANCER, V41, P518, DOI 10.1002/ijc.2910410408; KLEIN J, 1981, NATURE, V291, P455, DOI 10.1038/291455a0; KNOWLES RW, 1989, IMMUNOBIOLOGY HLA, V1, P365; KOENIG UD, 1976, LANCET, V2, P857; LACHMAN PJ, 1982, CLIN ASPECTS IMMUNOL, P1263; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; LONAI P, 1980, IMMUNOGENETICS, V11, P21, DOI 10.1007/BF01567766; MAEDA H, 1984, TISSUE ANTIGENS, V23, P163; MILFORD EL, 1989, IMMUNOBIOLOGY HLA HI, V1, P93; PANZA N, 1982, TISSUE ANTIGENS, V20, P155; PARK MS, 1978, TRANSPLANT P, V10, P823; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; TAIT BD, 1989, IMMUNOBIOLOGY HLA, V1, P269; TERMIJTELEN A, 1980, TISSUE ANTIGENS, V16, P140; TIWARI JL, 1985, HLA DISEASE ASS; VEGA MA, 1986, J IMMUNOL, V137, P3557; Zur Hausen H, 1982, LANCET, V2, P1370, DOI DOI 10.1016/S0140-6736(82)91273-9	33	240	248	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 22	1991	352	6337					723	725		10.1038/352723a0	http://dx.doi.org/10.1038/352723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1876187				2022-12-28	WOS:A1991GC06400061
J	HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H				HUESMANN, M; SCOTT, B; KISIELOW, P; VONBOEHMER, H			KINETICS AND EFFICACY OF POSITIVE SELECTION IN THE THYMUS OF NORMAL AND T-CELL RECEPTOR TRANSGENIC MICE	CELL			English	Article							RESTRICTED ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; DIFFERENTIATION; EXPRESSION; PROLIFERATION	DNA-labeling studies in alpha-beta T cell receptor (TCR) transgenic mice show that the lifespan of immature CD4+8+ thymocytes is 3.5 days irrespective of whether they are selected for maturation or not. While nonselected cells die, the binding of the TCR to thymic major histocompatibility complex molecules rescues CD4+8+ cells from programmed cell death and induces first upregulation of the TCR level and then differentiation into CD4+8- or CD4-8+ cells in the absence of any cell division. When most CD4+8+ thymocytes express a selectable transgenic TCR the formation of mature cells with high TCR levels is 10-20 times as efficient as observed in normal mice, yet still only 20% of the CD4+8+ cells become mature. This is due to the limited availability of selecting 'niches': most CD4+8+ thymocytes with a selectable transgenic TCR will undergo maturation when they represent only 5% or less of all CD4+8+ cells.			HUESMANN, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.							BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CEREDIG R, 1990, INT IMMUNOL, V2, P859, DOI 10.1093/intimm/2.9.859; CRISTANTI A, 1986, EMBO J, V5, P2837, DOI 10.1002/j.1460-2075.1986.tb04577.x; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GONCHOROFF NJ, 1985, CYTOMETRY, V6, P506, DOI 10.1002/cyto.990060604; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KISIELOW P, 1984, J IMMUNOL, V133, P1117; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; MATSUYAMA M, 1966, J EXP MED, V123, P559, DOI 10.1084/jem.123.3.559; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8663; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PENIT C, 1990, INT IMMUNOL, V2, P629, DOI 10.1093/intimm/2.7.629; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; SCOLLAY R, 1978, NATURE, V276, P79, DOI 10.1038/276079a0; SCOTT B, 1989, NATURE, V338, P595; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1974, CELL IMMUNOL, V12, P230, DOI 10.1016/0008-8749(74)90075-6; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VANEWIJK W, 1990, EUR J IMMUNOL, V20, P129, DOI 10.1002/eji.1830200119; VONBOEHMER H, 1986, IMMUNOL TODAY, V7, P333; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJSTRA M, 1990, NATURE, V344, P742	34	352	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					533	540		10.1016/0092-8674(81)90016-7	http://dx.doi.org/10.1016/0092-8674(81)90016-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868548				2022-12-28	WOS:A1991GA94100014
J	BOSANQUET, N				BOSANQUET, N			FAMILY DOCTORS AND PAYMENT SYSTEMS - THE LOCAL OPTION .6.	BRITISH MEDICAL JOURNAL			English	Article											BOSANQUET, N (corresponding author), UNIV LONDON,LISSON GROVE HLTH CTR,HLTH POLICY UNIT,LONDON NW8 8EG,ENGLAND.							BOSANQUET N, 1989, FAMILY DOCTORS EC IN; BOSANQUET N, 1990, INVESTING HLTH CARE; IRVINE D, 1990, MANAGING QUALITY GEN; LEESE B, 1990, MED LAB SCI, V47, P256; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932	5	5	5	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					233	234		10.1136/bmj.303.6796.233	http://dx.doi.org/10.1136/bmj.303.6796.233			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884062	Bronze, Green Published			2022-12-28	WOS:A1991FZ56300028
J	FUJII, J; OTSU, K; ZORZATO, F; DELEON, S; KHANNA, VK; WEILER, JE; OBRIEN, PJ; MACLENNAN, DH				FUJII, J; OTSU, K; ZORZATO, F; DELEON, S; KHANNA, VK; WEILER, JE; OBRIEN, PJ; MACLENNAN, DH			IDENTIFICATION OF A MUTATION IN PORCINE RYANODINE RECEPTOR ASSOCIATED WITH MALIGNANT HYPERTHERMIA	SCIENCE			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CA-2+ RELEASE CHANNEL; MOLECULAR-CLONING; CA-RELEASE; SUSCEPTIBILITY; DNA; MECHANISM; GENE; EXPRESSION; ASSIGNMENT	Malignant hyperthermia (MH) causes neurological, liver, and kidney damage and death in humans and major economic losses in the swine industry. A single point mutation in the porcine gene for the skeletal muscle ryanodine receptor (ryr1) was found to be correlated with MH in five major breeds of lean, heavily muscled swine. Haplotyping suggests that the mutation in all five breeds has a common origin. Assuming that this is the causal mutation for MH, the development of a noninvasive diagnostic test will provide the basis for elimination of the MH gene or its controlled inclusion in swine breeding programs.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA; UNIV GUELPH,ONTARIO VET COLL,DEPT PATHOL,GUELPH N1G 2W1,ONTARIO,CANADA	University of Toronto; University of Guelph			O'Brien, Peter James/AAE-4798-2020	O'Brien, Peter James/0000-0003-4290-3585				BRITT BA, 1987, MALIGNANT HYPERTHERM, P11; DAVIES W, 1988, ANIM GENET, V19, P203, DOI 10.1111/j.1365-2052.1988.tb00809.x; ELIZONDO G, 1977, J ANIM SCI, V45, P1272, DOI 10.2527/jas1977.4561272x; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; FILL M, 1990, BIOPHYS J, V50, P471; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HARBITZ I, 1990, GENOMICS, V8, P243, DOI 10.1016/0888-7543(90)90278-3; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; MACKENZIE AE, 1990, AM J HUM GENET, V46, P1082; MACLENNAN DH, 1983, METHOD ENZYMOL, V96, P570; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; Maniatis T., 1982, MOL CLONING; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OBRIEN PJ, 1987, VET RES COMMUN, V11, P527, DOI 10.1007/BF00396370; OBRIEN PJ, 1990, AM J VET RES, V51, P1038; OBRIEN PJ, 1985, AM J VET RES, V46, P1451; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; OBRIEN PJ, 1990, MOL CELL BIOCHEM, V93, P53; OBRIEN PJ, 1990, CAN J VET RES, V54, P83; OHNISHI ST, 1983, FEBS LETT, V161, P103; OTSU K, 1990, J BIOL CHEM, V265, P13472; PHILLIPS M, UNPUB; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEELER DC, 1983, CAN J COMP MED, V47, P284; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	1248	1341	0	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					448	451		10.1126/science.1862346	http://dx.doi.org/10.1126/science.1862346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862346				2022-12-28	WOS:A1991FY28800041
J	BIZZI, E; MUSSAIVALDI, FA; GISZTER, S				BIZZI, E; MUSSAIVALDI, FA; GISZTER, S			COMPUTATIONS UNDERLYING THE EXECUTION OF MOVEMENT - A BIOLOGICAL PERSPECTIVE	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; SUPERIOR COLLICULUS; ARM MOVEMENTS; ALERT CAT; REDUNDANT MANIPULATORS; TRAJECTORY FORMATION; MUSCLE LENGTH; EYE-MOVEMENTS; HEAD; STIMULATION	To execute voluntary movements, the central nervous system must transform the neural representation of the direction, amplitude, and velocity of the limb, represented by the activity of cortical and subcortical neurons, into signals that activate the muscles that move the limb. This task is equivalent to solving an "ill-posed" computational problem because the number of degrees of freedom of the musculoskeletal apparatus is much larger than that specified in the plan of action. Some of the mechanisms and circuitry underlying the transformation of motor plans into motor commands are described. A central feature of this transformation is a coarse map of limb postures in the premotor areas of the spinal cord. Vectorial combination of motor outputs among different areas of the spinal map may produce a large repertoire of motor behaviors.			BIZZI, E (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR026710, R01AR026710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009343] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR26710] Funding Source: Medline; NINDS NIH HHS [NS09343] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSTERMARK B, 1981, EXP BRAIN RES, V42, P299, DOI 10.1007/BF00237496; BAILLIEUL J, 1985, 1985 P IEEE INT C RO, P722; BERTERO M, 1988, P IEEE, V76, P869, DOI 10.1109/5.5962; BIZZI E, 1982, EXP BRAIN RES, V46, P139; BIZZI E, 1976, J NEUROPHYSIOL, V39, P435, DOI 10.1152/jn.1976.39.2.435; BIZZI E, 1984, J NEUROSCI, V4, P2738; BIZZI E, 1986, PROG BRAIN RES, V64, P345; Brady M, 1982, ROBOT MOTION PLANNIN; CAMINITI R, 1990, J NEUROSCI, V10, P2039; FEL'DMAN A. G., 1966, BIOFIZIKA, V11, P667; FELDMAN AG, 1974, BIOFIZIKA+, V19, P749; FELDMAN AG, 1974, BIOFIZIKA+, V19, P534; FELDMAN AG, 1979, CENTRAL REFLEX MECHA; FLASH T, 1987, BIOL CYBERN, V57, P257, DOI 10.1007/BF00338819; FUKSON OI, 1980, SCIENCE, V209, P1261, DOI 10.1126/science.7403886; GEORGOPOULOS A, 1988, J NEUROSCI, V8, P2913; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GISZTER E, IN PRESS ANAL MODELL; GISZTER SF, 1989, J NEUROPHYSIOL, V62, P750, DOI 10.1152/jn.1989.62.3.750; GISZTER SF, IN PRESS VISUAL STRU; GISZTER SF, IN PRESS EXP BRAIN R; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; GUITTON D, 1980, EXP BRAIN RES, V39, P63; HOLLERBACH JM, 1985, 1985 P IEEE INT C RO, P1016; JORDAN MI, 1989, FDN COGNITIVE SCI, P727; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KAWATO M, 1989, ATR TRA0056 ADV TEL; KLEIN CA, 1983, IEEE T SYST MAN CYB, V13, P245, DOI 10.1109/TSMC.1983.6313123; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MCILWAIN JT, 1986, J NEUROPHYSIOL, V55, P97, DOI 10.1152/jn.1986.55.1.97; MUSSAIVALDI FA, 1985, J NEUROSCI, V5, P2732; MUSSAIVALDI FA, 1988, BIOL CYBERN, V60, P1; MUSSAIVALDI FA, 1991, IN PRESS 5TH P INT C; MUSSAIVALDI FA, 1988, S QUANTITATIVE BIOL, V55, P827; MUSSAIVALDI FA, IN PRESS INT J ROBOT; OSTRY D J, 1989, Society for Neuroscience Abstracts, V15, P173; OSTRY DJ, 1991, J NEUROPHYSIOL, V65, P547, DOI 10.1152/jn.1991.65.3.547; POGGIO T, 1985, NATURE, V317, P314, DOI 10.1038/317314a0; PREPARATA F. P, 1988, COMPUTATIONAL GEOMET, P185; RACK PMH, 1969, J PHYSIOL-LONDON, V204, P443, DOI 10.1113/jphysiol.1969.sp008923; ROUCOUX A, 1980, EXP BRAIN RES, V39, P75; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAGREY M, 1977, J NEUROPHYSIOL, V40, P156, DOI 10.1152/jn.1977.40.1.156; SCHOTLAND JL, 1989, EXP BRAIN RES, V78, P649; SHAMIR T, 1988, IEEE T AUTOMAT CONTR, V33, P1004, DOI 10.1109/9.14412; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; STEIN PSG, 1983, S SOC EXP BIOL, V37, P383; Tikhonov A., 1977, SOLUTIONS ILL POSED; WAMPLER CW, 1985, 1987 IEEE INT C ROB, P610; WHITNEY DE, 1969, IEEE T MAN MACHINE, VMM10, P47, DOI 10.1109/TMMS.1969.299896; YOSHIKAWA T, 1985, 1985 P IEEE INT C RO, P1004	53	385	386	9	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					287	291		10.1126/science.1857964	http://dx.doi.org/10.1126/science.1857964			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857964				2022-12-28	WOS:A1991FX22400032
J	HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F				HAROUSE, JM; BHAT, S; SPITALNIK, SL; LAUGHLIN, M; STEFANO, K; SILBERBERG, DH; GONZALEZSCARANO, F			INHIBITION OF ENTRY OF HIV-1 IN NEURAL CELL-LINES BY ANTIBODIES AGAINST GALACTOSYL CERAMIDE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY SYNDROME; PRODUCTIVE INFECTION; HTLV-III/LAV; MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; AIDS RETROVIRUS; CD4 RECEPTOR; T4 MOLECULE; SOLUBLE CD4	Although the CD4 molecule is the principal cellular receptor for the human immunodeficiency virus (HIV), several CD4-negative cell lines are susceptible to infection with one or more HIV strains. These findings indicate that there are alternate modes of viral entry, perhaps involving one or more receptor molecules. Antibodies against galactosyl ceramide (galactocerebroside, or GalC) inhibited viral internalization and infection in two CD4-negative cell lines derived from the nervous system: U373-MG and SK-N-MC. Furthermore, recombinant HIV surface glycoprotein gp120 bound to GalC but not to other glycolipids. These results suggest a role for GalC or a highly related molecule in HIV entry into neural cells.	UNIV PENN,MED CTR,DEPT NEUROL,CLIN RES BLDG,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Spitalnik, Steven/0000-0002-8528-4561	NCI NIH HHS [CA-45690] Funding Source: Medline; NINDS NIH HHS [NS-11037, NS-27405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011037, F32NS011037, P01NS027405, P50NS027405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BENJAMINS JA, 1987, J NEUROIMMUNOL, V14, P325, DOI 10.1016/0165-5728(87)90019-1; BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; BERMAN PW, 1985, SCIENCE, V227, P1490, DOI 10.1126/science.2983428; BHAT S, 1991, T AM SOC NEUROCHEM, V22, P183; BHAT S, IN PRESS P NATL ACAD; BHAT SA, UNPUB; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DYER CA, 1988, J NEUROSCI, V8, P4307; GABUZDA DH, 1986, ANN NEUROL, V20, P289, DOI 10.1002/ana.410200304; GRAY F, 1991, NEUROLOGY, V41, P105, DOI 10.1212/WNL.41.1.105; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, UNPUB; JAMESON BA, 1988, SCIENCE, V240, P1335, DOI 10.1126/science.2453925; JANSSEN RS, 1988, SCIENCE, V239, P586; JAVAHERIAN K, 1989, P NATL ACAD SCI USA, V86, P6768, DOI 10.1073/pnas.86.17.6768; JOHNSON RT, 1986, TRENDS NEUROSCI, V9, P91, DOI 10.1016/0166-2236(86)90030-5; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; LASKY LA, 1984, BIO-TECHNOL, V2, P527, DOI 10.1038/nbt0684-527; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P195; MCCUNE JM, 1988, CELL, V55; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, AIDS, V4, P307, DOI 10.1097/00002030-199004000-00004; RAFF M, 1978, NATURE, V276, P813; RANCHST B, 1982, P NATL ACAD SCI USA, V79, P2709; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; SPITALNIK SL, 1985, BLOOD, V66, P319; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZURBRIGGEN A, 1987, ACTA NEUROPATHOL, V74, P366, DOI 10.1007/BF00687214	51	497	514	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					320	323		10.1126/science.1857969	http://dx.doi.org/10.1126/science.1857969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1857969				2022-12-28	WOS:A1991FX22400042
J	ASHBY, J; MORROD, RS				ASHBY, J; MORROD, RS			DETECTION OF HUMAN CARCINOGENS	NATURE			English	Editorial Material							RODENT CARCINOGENS; CHEMICALS; BIOASSAYS; MUTAGENS; TOO				ASHBY, J (corresponding author), ICI PLC,CENT TOXICOL LAB,MACCLESFIELD SK10 4TJ,ENGLAND.							AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; ASHBY J, 1986, MUTAGENESIS, V1, P3, DOI 10.1093/mutage/1.1.3; BARTSCH H, 1989, CELL BIOL TOXICOL, V5, P115, DOI 10.1007/BF00122647; BRIDGES BA, 1976, MUTAT RES, V41, P71, DOI 10.1016/0027-5107(76)90075-0; BUTTERWORTH BE, 1990, MUTAT RES, V239, P117, DOI 10.1016/0165-1110(90)90033-8; CAGLIANO VJ, 1991, SCIENCE, V251, P606; CLAYSON DB, 1991, MUTAT RES, V257, P91, DOI 10.1016/0165-1110(91)90020-V; CLAYSON DB, 1989, MUTAT RES, V221, P53, DOI 10.1016/0165-1110(89)90045-6; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DIETRICH DR, 1991, MUTAT RES, V248, P239, DOI 10.1016/0027-5107(91)90060-2; GRIESEMER RA, 1991, MUTAT RES, V257, P207, DOI 10.1016/0165-1110(91)90001-C; HASEMAN JK, 1987, CANCER LETT, V37, P125, DOI 10.1016/0304-3835(87)90154-6; HAY A, 1991, NATURE, V350, P555, DOI 10.1038/350555a0; HILL RN, 1989, FUND APPL TOXICOL, V12, P629, DOI 10.1016/0272-0590(89)90001-8; HUGG JE, 1991, CELL BIOL TOXIC, V7, P67; MALLING HV, 1974, CHEM CARCINOGENESIS; PETO R, 1985, ASSESSMENT RISK LOW, P3; ROBERTS L, 1991, SCIENCE, V252, P911, DOI 10.1126/science.2035022; SHELBY MD, 1990, MUTAT RES, V234, P257, DOI 10.1016/0165-1161(90)90022-G; TENNANT RW, 1990, MUTAGENESIS, V5, P3, DOI 10.1093/mutage/5.1.3; WEINSTEIN IB, 1991, SCIENCE, V251, P387, DOI 10.1126/science.1989073; WEISBURGER JH, 1981, FOOD COSMET TOXICOL, V19, P561, DOI 10.1016/0015-6264(81)90506-X; YAMASAKI H, 1988, TUMOUR PROMOTERS	25	89	89	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					185	186		10.1038/352185a0	http://dx.doi.org/10.1038/352185a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857407				2022-12-28	WOS:A1991FX18500022
J	BOWDEN, D; WALSHE, K				BOWDEN, D; WALSHE, K			WHEN MEDICAL AUDIT STARTS TO COUNT	BRITISH MEDICAL JOURNAL			English	Article									BRIGHTON GEN HOSP,DEPT PUBL HLTH,CASPE RES,BRIGHTON BN2 3EW,ENGLAND; BRIGHTON HLTH AUTHOR,BRIGHTON,ENGLAND	Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital				Walshe, Kieran/0000-0002-0696-480X				BENNETT J, 1990, BRIT MED J, V300, P1248, DOI 10.1136/bmj.300.6734.1248; BOWDEN D, 1988, J ROY SOC ARTS, P333; Buck N, 1987, REPORT CONFIDENTIAL; GRUER R, 1986, LANCET, V1, P23; GUMPERT R, 1990, BRIT MED J, V301, P162, DOI 10.1136/bmj.301.6744.162; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; WALSHE K, 1990, GUIDELINES MED AUDIT	7	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 13	1991	303	6794					101	103		10.1136/bmj.303.6794.101	http://dx.doi.org/10.1136/bmj.303.6794.101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW586	1859983	Bronze, Green Published			2022-12-28	WOS:A1991FW58600025
J	SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC				SMALL, PM; SCHECTER, GF; GOODMAN, PC; SANDE, MA; CHAISSON, RE; HOPEWELL, PC			TREATMENT OF TUBERCULOSIS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HAITIAN PATIENTS; PULMONARY TUBERCULOSIS; THERAPY; CHEMOTHERAPY; FLORIDA; HIV	Background and Methods. Infection with the human immunodeficiency virus (HIV) increases the risk of tuberculosis and may interfere with the effectiveness of antituberculosis chemotherapy. To examine the outcomes in patients with both diagnoses, we conducted a retrospective study of all 132 patients listed in both the acquired immunodeficiency syndrome (AIDS) and tuberculosis case registries in San Francisco from 1981 through 1988. Results. At the time of the diagnosis of tuberculosis, 78 patients (59 percent) did not yet have a diagnosis of AIDS, 18 patients (14 percent) were given a concomitant diagnosis of AIDS (as determined by the presence of an AIDS-defining disease other than tuberculosis), and the remaining 36 patients (27 percent) already had AIDS. The manifestations of tuberculosis were entirely pulmonary in 50 patients (38 percent), entirely extrapulmonary in 40 patients (30 percent), and both pulmonary and extrapulmonary in 42 patients (32 percent). The treatment regimens were as follows: isoniazid and rifampin supplemented by ethambutol for the first two months, 52 patients; isoniazid and rifampin supplemented by pyrazinamide and ethambutol for the first two months, 39 patients; isoniazid and rifampin, 13 patients; isoniazid and rifampin supplemented by pyrazinamide for the first two months, 4 patients; and other drug regimens, 17 patients. The intended duration of treatment for patients whose regimen included pyrazinamide was six months, and for patients who did not receive pyrazinamide, nine months. Seven patients received no treatment because tuberculosis was first diagnosed after death. Sputum samples became clear of acid-fast organisms after a median of 10 weeks of therapy. Abnormalities on all chest radiographs taken after three months of treatment were stable or improved except for those of patients who had new nontuberculous infections. The only treatment failure occurred in a man infected with multiple drug-resistant organisms who did not comply with therapy. Adverse drug reactions occurred in 23 patients (18 percent). For all 125 treated patients, median survival was 16 months from the diagnosis of tuberculosis. Tuberculosis was a major contributor to death in 5 of the 7 untreated patients and 8 of the 125 treated patients. Three of 58 patients who completed therapy had a relapse (5 percent); compliance was poor in all 3. Conclusions. Tuberculosis causes substantial mortality in patients with advanced HIV infection. In patients who comply with the regimen, conventional therapy results in rapid sterilization of sputum, radiographic improvement, and low rates of relapse.	SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT RADIOL,SAN FRANCISCO,CA 94110; DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT RADIOL,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [5-T32-GM07546] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUDNEY K, 1989, 5TH INT C AIDS MONTR; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DUTT AK, 1981, CHEST, V80, P724, DOI 10.1378/chest.80.6.724; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; ISEMAN MD, 1987, AM REV RESPIR DIS, V136, P1326, DOI 10.1164/ajrccm/136.6.1325; KOVACS JA, 1988, J INFECT DIS, V158, P254, DOI 10.1093/infdis/158.1.254; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PERRIENS J, 1989, 5 INT C AIDS MONTR; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SLUTKIN G, 1988, AM REV RESPIR DIS, V138, P1622, DOI 10.1164/ajrccm/138.6.1622; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; WURTZ RM, 1989, LANCET, V1, P955; 1987, AM REV RESPIR DIS, V136, P492; 1989, MMWR, V38, P236	20	448	454	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 31	1991	324	5					289	294		10.1056/NEJM199101313240503	http://dx.doi.org/10.1056/NEJM199101313240503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU922	1898769				2022-12-28	WOS:A1991EU92200003
J	HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE				HOOTON, TM; HILLIER, S; JOHNSON, C; ROBERTS, PL; STAMM, WE			ESCHERICHIA-COLI BACTERIURIA AND CONTRACEPTIVE METHOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-TRACT INFECTION; SEXUAL INTERCOURSE; DIAPHRAGM USE; RISK-FACTORS; YOUNG-WOMEN; COLONIZATION; ASSOCIATION; FLORA	We evaluated the effects of contraceptive method on the occurrence of bacteriuria and vaginal colonization with Escherichia coli in 104 women who were evaluated prior to having sexual intercourse, the morning after intercourse, and 24 hours later. After intercourse, the prevalence of E coli bacteriuria increased slightly in oral contraceptive users but dramatically in both foam and condom users and diaphragm-spermicide users. Twenty-four hours later, the prevalence of bacteriuria remained significantly elevated only in the latter two groups. Similarly, vaginal colonization with E coli was more dramatic and persistent in users of diaphragm-spermicide and foam and condoms. Vaginal colonization with Candida species, enterococci, and staphylococci also increased significantly in diaphragm-spermicide users after intercourse. We conclude that use of the diaphragm with spermicidal jelly or use of a spermicidal foam with a condom markedly alters normal vaginal flora and strongly predisposes users to the development of vaginal colonization and bacteriuria with E coli.	UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98104	Harborview Medical Center; University of Washington; University of Washington Seattle	HOOTON, TM (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,SCH MED,DEPT MED,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI012192] Funding Source: NIH RePORTER; NIAID NIH HHS [AI12192] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADATTO K, 1979, JAMA-J AM MED ASSOC, V241, P2525, DOI 10.1001/jama.241.23.2525; BUCKLEY RM, 1978, NEW ENGL J MED, V298, P321, DOI 10.1056/NEJM197802092980607; ELSTER AB, 1981, SOUTHERN MED J, V74, P704, DOI 10.1097/00007611-198106000-00018; EVANS DA, 1978, NEW ENGL J MED, V299, P536, DOI 10.1056/NEJM197809072991009; FIHN SD, 1986, J UROLOGY, V136, P853, DOI 10.1016/S0022-5347(17)45104-4; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; HSIAO V, 1986, J ADOLESCENT HEALTH, V7, P381, DOI 10.1016/S0197-0070(86)80238-8; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; KUNIN CM, 1968, NEW ENGL J MED, V278, P635, DOI 10.1056/NEJM196803212781201; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; LEIBOVICI L, 1987, ARCH INTERN MED, V147, P345, DOI 10.1001/archinte.147.2.345; MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159; NICOLLE LE, 1982, J INFECT DIS, V146, P579, DOI 10.1093/infdis/146.5.579; PEDDIE BA, 1984, AUST NZ J OBSTET GYN, V24, P217, DOI 10.1111/j.1479-828X.1984.tb01494.x; PERCIVALSMITH R, 1983, CONTRACEPTION, V27, P497, DOI 10.1016/0010-7824(83)90046-X; REMIS RS, 1987, AM J EPIDEMIOL, V126, P685, DOI 10.1093/oxfordjournals.aje.a114708; Sobel J D, 1987, Infect Dis Clin North Am, V1, P751; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STONE KM, 1986, AM J OBSTET GYNECOL, V155, P180, DOI 10.1016/0002-9378(86)90108-0; STROM BL, 1987, ANN INTERN MED, V107, P816, DOI 10.7326/0003-4819-107-6-816; Svanborg Eden C, 1987, Infect Dis Clin North Am, V1, P731; VESSEY MP, 1987, INT J EPIDEMIOL, V16, P441, DOI 10.1093/ije/16.3.441; 1988, MMWR, V37, P133; 1985, ADV DATA, V128, P1	25	102	104	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 2	1991	265	1					64	69		10.1001/jama.265.1.64	http://dx.doi.org/10.1001/jama.265.1.64			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EP555	1859519				2022-12-28	WOS:A1991EP55500029
J	ARDISSINO, D; BARBERIS, P; DESERVI, S; MERLINI, PA; BRAMUCCI, E; FALCONE, C; SPECCHIA, G				ARDISSINO, D; BARBERIS, P; DESERVI, S; MERLINI, PA; BRAMUCCI, E; FALCONE, C; SPECCHIA, G			ABNORMAL CORONARY VASOCONSTRICTION AS A PREDICTOR OF RESTENOSIS AFTER SUCCESSFUL CORONARY ANGIOPLASTY IN PATIENTS WITH UNSTABLE ANGINA-PECTORIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VARIANT ANGINA; BLOOD-INSTITUTE; PTCA REGISTRY; HYPERVENTILATION; ARTERY; EXPERIENCE; FELODIPINE; DISEASE; SPASM; MEN	Background. High rates of restenosis after coronary angioplasty have been reported in patients with vasospastic angina. This study was designed to determine whether the occurrence of abnormal coronary vasoconstriction, detected by means of hyperventilation testing before angioplasty, influences the risk of restenosis after successful dilation. Methods. Hyperventilation testing was performed 0 to 4 days before coronary angioplasty in 106 consecutive patients with unstable angina and single-vessel coronary artery disease. Abnormal coronary vasoconstriction was considered present if hyperventilation-induced myocardial ischemia occurred during the recovery phase of the test. All patients had follow-up angiography 8 to 12 months after angioplasty. Results. Abnormal coronary vasoconstriction was observed in 48 patients (group 1), whereas 58 patients (group 2) had either a negative response throughout the test or a positive response only during the overbreathing phase of the hyperventilation test. Angioplasty was successful in 40 patients in group 1 and 51 in group 2. Restenosis was documented in 29 patients (73 percent) in group 1 and 13 (25 percent) in group 2 (relative risk of restenosis, 2.84; 95 percent confidence interval, 1.69 to 4.28; P < 0.001). In a multivariate analysis, the following three characteristics were independently related to the risk of restenosis (in descending order of importance): ST-segment elevation during spontaneous ischemic attacks (P < 0.001), hyperventilation-induced abnormal coronary vasoconstriction (P < 0.001), and the presence of a lesion more than 10 mm long in the left anterior descending coronary artery (P < 0.05). Conclusions. In patients with unstable angina and single-vessel coronary artery disease who have been selected for coronary angioplasty, the presence of hyperventilation-induced abnormal coronary vasoconstriction identifies a subgroup at high risk for restenosis.	OSPED MAGGIORE CA GRANDA,DIV CARDIOL 2,MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico	ARDISSINO, D (corresponding author), UNIV PAVIA,POLICLIN SAN MATTEO,INST RICOVERO & CURA CARATTERE SCI,DIV CARDIOL,I-27100 PAVIA,ITALY.		Ardissino, Diego/AAC-4041-2022; De+Servi, Stefano/AAT-2631-2021	solinas, emilia/0000-0003-3532-1317				ARDISSINO D, 1990, AM J CARDIOL, V66, P1304, DOI 10.1016/0002-9149(90)91158-3; ARDISSINO D, 1989, AM J CARDIOL, V63, P104, DOI 10.1016/0002-9149(89)91087-4; ARDISSINO D, 1989, J AM COLL CARDIOL, V13, P804, DOI 10.1016/0735-1097(89)90220-9; BERTRAND ME, 1986, J AM COLL CARDIOL, V8, P504, DOI 10.1016/S0735-1097(86)80174-7; CASTANEDAZUNIGA WR, 1982, RADIOLOGY, V144, P75, DOI 10.1148/radiology.144.1.6211691; CONSIGNY PM, 1986, ARTERIOSCLEROSIS, V6, P265, DOI 10.1161/01.ATV.6.3.265; CORCOS T, 1985, J AM COLL CARDIOL, V5, P1046, DOI 10.1016/S0735-1097(85)80004-8; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DAVID PR, 1982, CIRCULATION, V66, P695, DOI 10.1161/01.CIR.66.4.695; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DOUGLAS JS, 1987, AM J CARDIOL, V60, pB29; ERNST S, 1987, BRIT HEART J, V7, P220; GALAN KM, 1988, AM J CARDIOL, V61, P260, DOI 10.1016/0002-9149(88)90927-7; HOLLMAN J, 1983, J AM COLL CARDIOL, V2, P1039, DOI 10.1016/S0735-1097(83)80327-1; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; JACOBS WF, 1974, ANN INTERN MED, V81, P479, DOI 10.7326/0003-4819-81-4-479; KENT KM, 1982, AM J CARDIOL, V49, P2011, DOI 10.1016/0002-9149(82)90223-5; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LEIMGRUBER PP, 1985, CIRCULATION, V72, P530, DOI 10.1161/01.CIR.72.3.530; LEISCH F, 1986, BRIT HEART J, V56, P341; LEVINE S, 1985, AM J CARDIOL, V55, P673, DOI 10.1016/0002-9149(85)90134-1; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452; PREVITALI M, 1989, AM J CARDIOL, V63, P17, DOI 10.1016/0002-9149(89)91068-0; ROBERTS WC, 1982, AM J CARDIOL, V50, P203, DOI 10.1016/0002-9149(82)90030-3; ROUBIN GS, 1987, AM J CARDIOL, V60, pB39; VAL PG, 1987, AM J CARDIOL, V60, pB50	27	36	36	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1053	1057		10.1056/NEJM199110103251501	http://dx.doi.org/10.1056/NEJM199110103251501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891006	Bronze			2022-12-28	WOS:A1991GJ10800001
J	SOUMERAI, SB; ROSSDEGNAN, D; AVORN, J; MCLAUGHLIN, TJ; CHOODNOVSKIY, I				SOUMERAI, SB; ROSSDEGNAN, D; AVORN, J; MCLAUGHLIN, TJ; CHOODNOVSKIY, I			EFFECTS OF MEDICAID DRUG-PAYMENT LIMITS ON ADMISSION TO HOSPITALS AND NURSING-HOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED TRIAL; EXPERIENCE; THERAPY; CARE	Background. Many state Medicaid programs limit the number of reimbursable medications that a patient can receive. We hypothesized that such limitations may lead to exacerbations of illness or to admissions to institutions where there are no caps on drug reimbursements. Methods. We analyzed 36 months of Medicaid claims data from New Hampshire, which had a three-drug limit per patient for 11 of those months, and from New Jersey, which did not. The study patients in New Hampshire (n = 411) and a matched comparison cohort in New Jersey (n = 1375) were Medicaid recipients 60 years of age or older who in a base-line year had been taking three or more medications per month, including at least one maintenance drug for certain chronic diseases. Survival (defined as remaining in the community) and time-series analyses were conducted to determine the effect of the reimbursement cap on admissions to hospitals and nursing homes. Results. The base-line demographic characteristics of the cohorts were nearly identical. In New Hampshire, the 35 percent decline in the use of study drugs after the cap was applied was associated with an increase in rates of admission to nursing homes; no changes were observed in the comparison cohort (RR = 1.8; 95 percent confidence interval, 1.2 to 2.6). There was no significantly increased risk of hospitalization. Among the patients in New Hampshire who regularly took three or more study medications at base line, the relative risk of admission to a nursing home during the period of the cap was 2.2 (95 percent confidence interval, 1.2 to 4.1), and the risk of hospitalization was 1.2 (95 percent confidence interval, 0.8 to 1.6). When the cap was discontinued after 11 months, the use of medications returned nearly to base-line levels, and the excess risk of admission to a nursing home ceased. In general, the patients who were admitted to nursing homes did not return to the community. Conclusions. Limiting reimbursement for effective drugs puts frail, low-income, elderly patients at increased risk of institutionalization in nursing homes and may increase Medicaid costs.	HARVARD UNIV, SCH MED, PROGRAM ANAL CLIN STRATEGIES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	SOUMERAI, SB (corresponding author), HARVARD UNIV, SCH MED, DEPT SOCIAL MED, 643 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	AHRQ HHS [HSO5947] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1970, JAMA, V213, P1143; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; COX DR, 1972, J R STAT SOC B, V34, P187; FEDERSPIEL CF, 1976, MED CARE, V14, P166, DOI 10.1097/00005650-197602000-00006; FITZGERALD JF, 1987, JAMA-J AM MED ASSOC, V258, P218; Harrington C, 1988, Health Care Financ Rev, V9, P81; HOLAHAN J, 1986, MEDICAID TRADE COST; Hsiao W C, 1986, Health Aff (Millwood), V5, P32, DOI 10.1377/hlthaff.5.2.32; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVY M, 1982, INT J CLIN PHARM TH, V20, P600; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Ray W A, 1989, Health Care Financ Rev, V10, P51; RAY WA, 1987, MED CARE, V25, P738, DOI 10.1097/00005650-198708000-00007; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STASON WB, 1977, NEW ENGL J MED, V296, P732, DOI 10.1056/NEJM197703312961307; STRANDBERG LR, 1984, AM HLTH CARE ASS J, V10, P20; 1984, MED DATA SOURCE POST, V1; 1987, HCFA03249 PUBL, P87; 1989, DHHS PHS893448 PUBL; 1985, HCFA03204 PUBL	25	416	418	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1072	1077		10.1056/NEJM199110103251505	http://dx.doi.org/10.1056/NEJM199110103251505			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ108	1891009	Green Published			2022-12-28	WOS:A1991GJ10800005
J	HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM				HOLMES, SJ; LUCAS, AH; OSTERHOLM, MT; FROESCHLE, JE; GRANOFF, DM			IMMUNOGLOBULIN DEFICIENCY AND IDIOTYPE EXPRESSION IN CHILDREN DEVELOPING HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE AFTER VACCINATION WITH CONJUGATE VACCINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; HEMOPHILUS DISEASE; ANTIBODIES; EFFICACY; SUBCLASS; AGE; IMMUNOGENICITY; IMMUNIZATION; MINNESOTA; INFANTS	Objective. Haemophilus influenzae type b (Hib) conjugate vaccines are effective in preventing Haemophilus disease in most children. The reasons why the vaccination fails in some children are unknown. This study investigated host factors in children who developed the disease despite conjugate vaccination. Design, Patients, Outcome Measures. A convenience sample of 23 patients in whom Hib disease developed 14 days or more after conjugate vaccination was investigated for the presence of subnormal serum immunoglobulin concentrations and anticapsular antibody responses to Hib disease. We also investigated expression of the Hib idiotype 1 (Hibld-1), a serological marker of a V(K)II chain that comprises a major portion of the normal variable region repertoire of the antibody response to Hib polysaccharide. The results were compared with those of 149 patients in whom the unconjugated Hib polysaccharide vaccine failed and of 90 unvaccinated patients who developed the disease. Results. Compared with children in whom the unconjugated polysaccharide vaccination failed, the relative risk of a subnormal serum concentration of IgM, IgA, IgG, and/or IgG2 in the children in whom the conjugate vaccination failed was 4.9 (95% confidence interval [Cl], 1.8 to 14; P < .003) and of IgG2 was 22 (95% Cl, 3.5 to 146; P < .001). With the exception of the children with subnormal serum immunoglobulin concentrations, most of the children with conjugate vaccination failure showed normal or high anticapsular antibody responses to the disease, whereas the children with polysaccharide vaccination failure showed impaired responses. The Hibld-1 was expressed by the majority of the children in both vaccination failure groups and of the unvaccinated patients. Conclusions. In most patients, vaccination failure is not attributable to lack of expression of the variable region gene encoding Hibld-1. However, children in whom conjugate vaccination has failed frequently have subnormal serum immunoglobulin concentrations and should be evaluated for immunodeficiency.	WASHINGTON UNIV,SCH MED,ST LOUIS CHILDRENS HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN; CONNAUGHT LABS INC,SWIFTWATER,PA; CHILDRENS HOSP OAKLAND RES INST,OAKLAND,CA	St. Louis Children's Hospital; Washington University (WUSTL); Minnesota Department of Health (MHD); Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842, R37AI025008, R01AI025008, R01AI017962] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25008, AI 21842, AI 17962] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDERSON EE, 1991, J IMMUNOL, V147, P1667; BLACK SB, 1988, PEDIATR INFECT DIS J, V7, P149, DOI 10.1097/00006454-198803000-00003; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; GRANOFF DM, 1989, J PEDIATR-US, V114, P925, DOI 10.1016/S0022-3476(89)80432-9; GRANOFF DM, 1986, NEW ENGL J MED, V315, P1584, DOI 10.1056/NEJM198612183152505; GRANOFF DM, 1988, MONOGR ALLERGY, V23, P256; GRANOFF DM, 1986, J INFECT DIS, V154, P257, DOI 10.1093/infdis/154.2.257; GRANOFF DM, 1989, J INFECT DIS, V159, P908, DOI 10.1093/infdis/159.5.908; GRANOFF DM, 1988, PEDIATR RES, V24, P180, DOI 10.1203/00006450-198808000-00008; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HALDANE JBS, 1956, ANN HUM GENET, V20, P309; HARRISON LH, 1988, JAMA-J AM MED ASSOC, V260, P1413, DOI 10.1001/jama.260.10.1413; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KAYHTY H, 1988, J INFECT DIS, V158, P973, DOI 10.1093/infdis/158.5.973; LUCAS AH, 1990, J CLIN INVEST, V85, P1158, DOI 10.1172/JCI114548; LUCAS AH, IN PRESS J CLIN INVE; MADASSERY JV, 1988, CLIN CHEM, V34, P1407; MADORE DV, 1990, PEDIATRICS, V86, P527; MURPHY TV, 1990, FEB W SOC PED RES CA; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; OSTERHOLM MT, 1989, 29TH INT C ANT AG CH; PELTOLA H, 1977, PEDIATRICS, V60, P730; SCOTT MG, 1989, J IMMUNOL, V143, P293; SHACKELFORD PG, 1990, J PEDIATR-US, V116, P529, DOI 10.1016/S0022-3476(05)81598-7; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; SHAPIRO ED, 1990, 30TH INT C ANT AG CH; WEINBERG GA, 1990, PEDIATRICS, V86, P617	27	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1960	1965		10.1001/jama.266.14.1960	http://dx.doi.org/10.1001/jama.266.14.1960			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895474				2022-12-28	WOS:A1991GH40600022
J	PANZA, JA; EPSTEIN, SE; QUYYUMI, AA				PANZA, JA; EPSTEIN, SE; QUYYUMI, AA			CIRCADIAN VARIATION IN VASCULAR TONE AND ITS RELATION TO ALPHA-SYMPATHETIC VASOCONSTRICTOR ACTIVITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; ATHEROSCLEROTIC CORONARY-ARTERIES; ACUTE MYOCARDIAL-INFARCTION; ESSENTIAL-HYPERTENSION; MORNING INCREASE; ANGINA-PECTORIS; ADRENERGIC VASOCONSTRICTION; MEDIATED VASOCONSTRICTION; PLATELET AGGREGABILITY; DIURNAL-VARIATION	Background. The frequency of several cardiovascular events, such as myocardial infarction, sudden death, and stroke, is increased during the early morning hours. There is also a similar circadian pattern in several physiologic variables, including blood pressure, suggesting that certain dynamic processes may contribute to the circadian distribution and onset of acute events. Methods. To determine whether there are circadian variations in vascular tone and to investigate their underlying mechanisms, we measured blood flow and vascular resistance in the forearm and their responses to phentolamine (an alpha-adrenergic-antagonist drug) and sodium nitroprusside (a direct vasodilator) in 12 normal subjects 7 men and 5 women; mean age [+/- SD], 44 +/- 9 years) at three different times of day (7 a.m., 2 p.m., and 9 p.m.). The drugs were infused into the brachial artery, and the responses were measured by strain-gauge plethysmography. Results. The basal forearm vacular resistance was significantly higher, and the blood flow significantly lower, in the morning than in the afternoon and evening (mean vascular resistance, 31 +/- 8, 25 +/- 6, and 22 +/- 7 mm Hg per milliliter per minute per 100 ml of forearm volume, respectively; P < 0.01). The vasodilator effect of phentolamine was also significantly greater in the morning (mean decrease in vascular resistance, 38 +/- 6 percent) than in the afternoon (26 +/- 6 percent) and evening (21 +/- 7 percent) (P < 0.05). Consequently, there was no circadian variation in vascular resistance or blood flow after the infusion of this drug. In contrast, the vasodilation in response to sodium nitroprusside was similar at all three times of day. Conclusions. There is a circadian rhythm in basal vascular tone, due either partly or entirely to increased alpha-sympathetic vasoconstrictor activity during the morning. This variation may contribute to higher blood pressure and the increased incidence of cardiovascular events at this time of day.			PANZA, JA (corresponding author), NHLBI,BLDG 10,RM 7B-15,BETHESDA,MD 20892, USA.							AMANN FW, 1981, HYPERTENSION, V3, P119; ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BERKENBOOM GM, 1986, AM J CARDIOL, V57, P195, DOI 10.1016/0002-9149(86)90889-1; Bohme E, 1978, Adv Cyclic Nucleotide Res, V9, P131; BREZINSKI DA, 1988, CIRCULATION, V78, P35, DOI 10.1161/01.CIR.78.1.35; BROWN BG, 1984, CIRCULATION, V70, P18, DOI 10.1161/01.CIR.70.1.18; COCKS TM, 1983, NATURE, V305, P627, DOI 10.1038/305627a0; COHEN RA, 1988, AM J PHYSIOL, V254, pH871, DOI 10.1152/ajpheart.1988.254.5.H871; COLLINS P, 1985, BRIT HEART J, V53, P488; EGAN B, 1987, J CLIN INVEST, V80, P812, DOI 10.1172/JCI113138; EPSTEIN SE, 1981, AM J CARDIOL, V48, P797, DOI 10.1016/0002-9149(81)90160-0; FUJITA M, 1987, CIRCULATION, V76, P488, DOI 10.1161/01.CIR.76.2.488; GORDON RD, 1966, J CLIN INVEST, V45, P1587, DOI 10.1172/JCI105464; GREENFIELD ADM, 1963, BRIT MED BULL, V19, P101, DOI 10.1093/oxfordjournals.bmb.a070026; HOKANSON DE, 1975, IEEE T BIO-MED ENG, VBM22, P25, DOI 10.1109/TBME.1975.324535; KANEKO M, 1968, J APPL PHYSIOL, V25, P109, DOI 10.1152/jappl.1968.25.2.109; KERSLAKE DM, 1949, J PHYSIOL-LONDON, V108, P451, DOI 10.1113/jphysiol.1949.sp004348; KIOWSKI W, 1981, CLIN SCI, V60, P483, DOI 10.1042/cs0600483; KUKOVETZ WR, 1979, N-S ARCH PHARMACOL, V310, P129, DOI 10.1007/BF00500277; LINSELL CR, 1985, J CLIN ENDOCR METAB, V60, P1210, DOI 10.1210/jcem-60-6-1210; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MILLARCRAIG MW, 1978, LANCET, V1, P795; MUDGE GH, 1976, NEW ENGL J MED, V295, P1333, DOI 10.1056/NEJM197612092952401; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NABEL EG, 1988, CIRCULATION, V77, P43, DOI 10.1161/01.CIR.77.1.43; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; ROCCO MB, 1987, CIRCULATION, V75, P395, DOI 10.1161/01.CIR.75.2.395; ROSENDORFF C, 1981, CIRC RES, V48, P320, DOI 10.1161/01.RES.48.3.320; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; SCHULTZ KD, 1977, NATURE, V265, P750, DOI 10.1038/265750a0; TESFAMARIAM B, 1988, CIRC RES, V63, P720, DOI 10.1161/01.RES.63.4.720; THOMPSON DR, 1985, INT J CARDIOL, V7, P139, DOI 10.1016/0167-5273(85)90354-7; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YASUE H, 1979, CIRCULATION, V59, P938, DOI 10.1161/01.CIR.59.5.938	43	469	477	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					986	990		10.1056/NEJM199110033251402	http://dx.doi.org/10.1056/NEJM199110033251402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886635				2022-12-28	WOS:A1991GH44700002
J	SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J				SCHAPIRA, DV; KUMAR, NB; LYMAN, GH; CAVANAGH, D; ROBERTS, WS; LAPOLLA, J			UPPER-BODY FAT DISTRIBUTION AND ENDOMETRIAL CANCER RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREMENOPAUSAL WOMEN; ADIPOSE-TISSUE; BREAST-CANCER; OBESITY; ASSOCIATION; METABOLISM; WEIGHT; TOPOGRAPHY; CARCINOMA; ESTROGEN	Study Objective. - To determine if body fat distribution affected endometrial cancer risk. Design. - Case-control study. Setting. - This study was carried out at the H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, where all patients in the case group received their diagnoses and histological confirmations. Patients. - Forty consecutive women newly diagnosed with endometrial cancer and 40 controls matched for age and Quetelet index. Main Outcome Measures. - Anthropometric measurements were taken for the abdomen, thigh, suprailiac, subscapular, biceps, and triceps skin fold thicknesses; waist and hip circumferences, weight, and height. Relative risks for endometrial cancer were calculated according to these anthropometric measurements. Results. - Case patients with endometrial cancer had significantly greater waist-to-hip circumference ratios (P < .001), abdomen-to-thigh skin fold ratios (P < .01), and suprailiac-to-thigh skin fold ratios (P = .02) compared with control subjects matched for age and Quetelet index. The relative risk for endometrial cancer increased with an increasing waist-to-hip circumference ratio (less-than-or-equal-to 1.14 = 1.0; > 1.14 = 15.0), with an increasing abdomen-to-thigh skin fold ratio (less-than-or-equal-to 0.82 = 1.0; > 0.82 = 5.0), and with an increasing suprailiac to-thigh skin fold thickness ratio (less-than-or-equal-to 0.67 = 1.0; > 0.67 = 3.50). Conclusion. - Upper-body fat localization is a significant risk factor for endometrial cancer in women matched for age and Quetelet index.			SCHAPIRA, DV (corresponding author), UNIV S FLORIDA,COLL MED,H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,TAMPA,FL 33612, USA.		Lyman, Gary H/K-5227-2019; Kumar, Nagi/AGI-6573-2022	Lyman, Gary H/0000-0002-0823-8086; 				AUSTIN H, 1991, CANCER RES, V51, P568; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; Behnke AR, 1974, EVALUATION REGULATIO; Cornfield J, 1961, B INT STAT I, V38, P97; ELLIOTT EA, 1990, GYNECOL ONCOL, V39, P253, DOI 10.1016/0090-8258(90)90247-I; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; ENRIORI CL, 1984, GYNECOL ONCOL, V17, P1, DOI 10.1016/0090-8258(84)90055-6; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; EVANS DJ, 1984, METABOLISM, V33, P68, DOI 10.1016/0026-0495(84)90164-1; FOLSOM AR, 1989, CANCER RES, V49, P6828; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; KALKHOFF RK, 1983, J LAB CLIN MED, V102, P621; KATCH FI, 1980, RES Q EXERCISE SPORT, V51, P249, DOI 10.1080/02701367.1980.10609286; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P71; KEYS A, 1956, HUM BIOL, V28, P111; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P430; LAPIDUS L, 1988, INT J OBESITY, V12, P361; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; NISKER JA, 1980, AM J OBSTET GYNECOL, V138, P637, DOI 10.1016/0002-9378(80)90080-0; PAGEL J, 1984, DAN MED BULL, V31, P333; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; PETTERSSON B, 1985, ACTA U UPPSAL, V6, P1; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHAPIRA DV, 1991, CANCER, V67, P523, DOI 10.1002/1097-0142(19910115)67:2<523::AID-CNCR2820670234>3.0.CO;2-O; SCHAPIRA DV, 1991, CANCER, V67, P2622, DOI 10.1002/1097-0142(19910515)67:10<2622::AID-CNCR2820671037>3.0.CO;2-J; SEGAL KR, 1987, J CLIN INVEST, V80, P1050, DOI 10.1172/JCI113159; SIITERI PK, 1978, CANCER RES, V38, P4360; SJOSTROM L, 1972, METABOLISM, V21, P1143, DOI 10.1016/0026-0495(72)90109-6; SMITH U, 1979, EUR J CLIN INVEST, V9, P327, DOI 10.1111/j.1365-2362.1979.tb00892.x; SPENGLER RF, 1981, AM J EPIDEMIOL, V114, P497, DOI 10.1093/oxfordjournals.aje.a113215; WYNDER EL, 1966, CANCER, V19, P489, DOI 10.1002/1097-0142(196604)19:4<489::AID-CNCR2820190406>3.0.CO;2-W	37	85	86	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1808	1811		10.1001/jama.266.13.1808	http://dx.doi.org/10.1001/jama.266.13.1808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890709				2022-12-28	WOS:A1991GG55100033
J	DRESSLER, F; YOSHINARI, NH; STEERE, AC				DRESSLER, F; YOSHINARI, NH; STEERE, AC			THE T-CELL PROLIFERATIVE ASSAY IN THE DIAGNOSIS OF LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; LYMPHOCYTES-T; BORRELIA-BURGDORFERI; T-CELL PROLIFERATIVE ASSAY; ARTHRITIS	LINKED IMMUNOSORBENT-ASSAY; POLYMERASE CHAIN-REACTION; BORRELIA-BURGDORFERI; IMMUNE-COMPLEXES; NEUROLOGIC MANIFESTATIONS; ARTHRITIS; ANTIBODY; RESPONSES; LYMPHOCYTES; EVOLUTION	Objective: To determine the sensitivity and specificity of the T-cell proliferative assay as a diagnostic test in Lyme disease. Design: Cross-sectional study of patients with Lyme arthritis or chronic neuroborreliosis who had a history of erythema migrans, positive antibody responses to Borrelia burgdorferi by enzyme-linked immunosorbent assay (ELISA), or both; patients with other diseases; and healthy subjects. Setting: Diagnostic Lyme disease clinic in a university hospital. Patients: Forty-two of the 67 patients with active Lyme arthritis or chronic neuroborreliosis who were seen during the study period; 16 patients with inactive late Lyme disease; 77 patients with other rheumatologic or neurologic diseases; 9 workers from the Borrelia laboratory; and 9 healthy subjects. Measurements and Main Results: Nineteen of 42 patients with Lyme arthritis or chronic neuroborreliosis and 4 of 77 patients with other diseases had positive T-cell proliferative responses to B. burgdorferi antigens. The sensitivity of the proliferative assay was 45% (95% Cl, 30% to 60%) and the specificity was 95% (95% Cl, 87% to 99%). Twelve of 27 patients with active Lyme arthritis, 7 of 15 patients with chronic neuroborreliosis, 4 of 16 patients with inactive Lyme disease, 4 of 9 healthy Borrelia laboratory workers, and 0 of 9 healthy subjects had positive responses. Three of five patients with Lyme disease who had negative or indeterminant antibody responses by ELISA had positive T-cell proliferative responses. Conclusion: The T-cell proliferative assay may be a helpful diagnostic test in the small subset of patients with late Lyme disease who have negative or indeterminant antibody responses by ELISA.	TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University			Yoshinari, Natalino Hajime/E-8853-2012	Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020358, R01AR040576] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-40576, AR-20358] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1988, ANN NY ACAD SCI, V539, P93, DOI 10.1111/j.1749-6632.1988.tb31842.x; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HARDIN JA, 1979, J CLIN INVEST, V63, P468, DOI 10.1172/JCI109324; HARDIN JA, 1979, NEW ENGL J MED, V301, P1358, DOI 10.1056/NEJM197912203012502; KRAUSE A, 1991, ARTHRITIS RHEUM-US, V34, P393, DOI 10.1002/art.1780340404; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI E, 1990, Arthritis and Rheumatism, V33, pS37; NEUMANN A, 1989, RHEUMATOL INT, V9, P237; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PACHNER AR, 1985, NEUROLOGY, V35, P1642, DOI 10.1212/WNL.35.11.1642; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PREACMURSIC V, 1989, INFECTION, V17, P355, DOI 10.1007/BF01645543; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; SIGAL LH, 1986, ARTHRITIS RHEUM, V29, P761, DOI 10.1002/art.1780290609; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; YOSHINARI NH, 1991, ARTHRITIS RHEUM-US, V34, P707, DOI 10.1002/art.1780340611; ZOSCHKE DC, 1991, ANN INTERN MED, V114, P285, DOI 10.7326/0003-4819-114-4-285	30	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					533	539		10.7326/0003-4819-115-7-533	http://dx.doi.org/10.7326/0003-4819-115-7-533			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883122				2022-12-28	WOS:A1991GG28300005
J	PARSELL, DA; SANCHEZ, Y; STITZEL, JD; LINDQUIST, S				PARSELL, DA; SANCHEZ, Y; STITZEL, JD; LINDQUIST, S			HSP104 IS A HIGHLY CONSERVED PROTEIN WITH 2 ESSENTIAL NUCLEOTIDE-BINDING SITES	NATURE			English	Article							ATP-DEPENDENT PROTEASE; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; CLP PROTEASE; COMPONENT; SUBUNITS; TI; PURIFICATION; FIBROBLASTS; SEQUENCES	MOST eukaryotic cells produce proteins with relative molecular masses in the range of 100,000 to 110,000 after exposure to high temperatures 1. These proteins have been studied only in yeast and mammalian cells. In Saccharomyces cerevisiae, heat-shock protein hsp104 is vital for tolerance to heat, ethanol and other stresses (ref. 2, and Y.S. et al., manuscript submitted). The mammalian hsp110 protein is nucleolar and redistributes with growth state, nutritional conditions and heat shock 3-5. The relationships between hsp110, hsp104 and the high molecular mass heat-shock proteins of other organisms were unknown. We report here that hsp104 is a member of the highly conserved ClpA/ClpB protein family first identified in Escherichia coli 6 and that additional heat-inducible members of this family are present in Schizosaccharomyces pombe and in mammals. Mutagenesis of two putative nucleotide-binding sites in hsp104 indicates that both are essential for function in thermotolerance.	UNIV CHICAGO, HOWARD HUGHES MED INST, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago			Sanchez, Yolanda/L-2847-2014	Sanchez, Yolanda/0000-0002-7650-9319				BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GILMAN M, 1987, CURRENT PROTOCOLS MO, P441; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIU QY, 1988, VIROLOGY, V163, P638, DOI 10.1016/0042-6822(88)90308-X; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHYY TT, 1986, CANCER RES, V46, P4738; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; SUBJECK JR, 1983, J CELL BIOL, V97, P1389, DOI 10.1083/jcb.97.5.1389; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V164, P1253, DOI 10.1016/0006-291X(89)91804-4; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; XIA ZG, 1990, J BIOL CHEM, V265, P6517	30	225	235	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1991	353	6341					270	273		10.1038/353270a0	http://dx.doi.org/10.1038/353270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896074				2022-12-28	WOS:A1991GF67400064
J	ALOIMONOS, Y; ROSENFELD, A				ALOIMONOS, Y; ROSENFELD, A			COMPUTER VISION	SCIENCE			English	Article							COMPUTATIONAL VISION; POSED PROBLEMS; IMAGE; REGULARIZATION	The field of computer vision is devoted to discovering algorithms, data representations, and computer architectures that embody the principles underlying visual capabilities. This article describes how the field of computer (and robot) vision has evolved, particularly over the past 20 years, and introduces its central methodological paradigms.			ALOIMONOS, Y (corresponding author), UNIV MARYLAND,CTR AUTOMAT RES,COLLEGE PK,MD 20742, USA.		Aloimonos, Yiannis/AAI-2969-2020; Ng, Tian Seng/AAF-1959-2019	Aloimonos, Yiannis/0000-0002-8152-4281; Ng, Tian Seng/0000-0001-9319-7858				ALOIMONOS J, 1989, INTEGRATION VISUAL M; ALOIMONOS J, 1990, P DARPA IMAGE UNDERS, P816; ALOIMONOS J, 1987, ADV COMPUTER VISION, V1, P115; ALOIMONOS J, 1988, INT J COMPUT VISION, V2, P333; [Anonymous], 1987, VISUAL RECONSTRUCTIO; BAJCSY R, 1985, 3 IEEE WORKSH COMP V, P55; BALLARD DH, 1991, ARTIF INTELL, V48, P57, DOI 10.1016/0004-3702(91)90080-4; Ballard DH, 1982, COMPUTER VISION; BERTERO M, 1988, P IEEE, V76, P869, DOI 10.1109/5.5962; Binford T. O., 1982, INT J ROBOT RES, V1, P18; BRADY M, 1982, COMPUT SURV, V14, P3, DOI 10.1145/356869.356871; BROOKS RA, 1986, MIT AI899 ART INT LA; DAVIS LS, 1981, ARTIF INTELL, V17, P245, DOI 10.1016/0004-3702(81)90026-6; Dickmanns E.D., 1988, MACH VISION APPL, V1, P241; Farah M.J., 1990, VISUAL AGNOSIA DISOR; FAUGERAS OD, 1981, IEEE T PATTERN ANAL, V3, P412, DOI 10.1109/TPAMI.1981.4767127; FRANKOT RT, 1988, IEEE T PATTERN ANAL, V10, P439, DOI 10.1109/34.3909; Frisby J.P., 1979, SEEING ILLUSION BRAI; GEMAN S, 1984, IEEE T PATTERN ANAL, V6, P721, DOI 10.1109/TPAMI.1984.4767596; HARALICK RM, 1985, COMPUT VISION GRAPH, V29, P100, DOI 10.1016/S0734-189X(85)90153-7; Horn BK, 1986, ROBOT VISION, V1st; Horn BKP, 1989, SHAPE SHADING; HUANG TS, 1981, IMAGE SEQUENCE ANAL; HURLBERT AC, 1988, SCIENCE, V239, P482, DOI 10.1126/science.3340834; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; Koenderink J., 1990, SOLID SHAPE; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; LECLERC YG, 1989, INT J COMPUT VISION, V3, P73, DOI 10.1007/BF00054839; LEE D, 1988, IEEE T PATTERN ANAL, V10, P822, DOI 10.1109/34.9105; Marr D., 1982, VISION COMPUTATIONAL, DOI [10.7551/mitpress/9780262514620.001.0001, DOI 10.7551/MITPRESS/9780262514620.001.0001]; MARROQUIN J, 1987, J AM STAT ASSOC, V82, P76, DOI 10.2307/2289127; MUMFORD D, 1990, IMAGE UNDERSTANDING, P19; NAGEL HH, 1986, IEEE T PATTERN ANAL, V8, P565, DOI 10.1109/TPAMI.1986.4767833; POGGIO T, 1988, SCIENCE, V242, P436, DOI 10.1126/science.3175666; POGGIO T, 1985, NATURE, V317, P314, DOI 10.1038/317314a0; Rosenfeld A., 1982, DIGITAL PICTURE PROC; SPETSAKIS M, 1990, P DARPA IM UND WORKS, P271; THORPE C, 1988, IEEE T PATTERN ANAL, V10, P362, DOI 10.1109/34.3900; Tikhonov A., 1977, SOLUTIONS ILL POSED; TSOTSOS, 1987, ENCY ARTIFICIAL INTE, P389; ULLMAN S, 1984, COGNITION, V18, P97, DOI 10.1016/0010-0277(84)90023-4; Ullman S., 1979, PROC R SOC SER B-BIO, DOI 10.7551/mitpress/3877.003.0009; VERRI A, 1987, 1ST P INT C COMP VIS, P171; WAXMAN AM, 1987, IEEE J ROBOTIC AUTOM, V3, P249	44	23	24	47	159	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1249	1259		10.1126/science.1891713	http://dx.doi.org/10.1126/science.1891713			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891713				2022-12-28	WOS:A1991GE68900032
J	HAGAR, JM; RAHIMTOOLA, SH				HAGAR, JM; RAHIMTOOLA, SH			CHAGAS HEART-DISEASE IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN IMMIGRANTS	Background and Methods. Chagas' heart disease is believed to be rare in the United States, although many persons from countries where the disease is endemic reside here. We performed a retrospective case review and prospective follow-up of 25 patients with Chagas' heart disease and no obstructive coronary artery disease on angiography. Results. The patients mainly presented with symptomatic atrioventricular block, congestive heart failure, anginal chest pain, sudden death averted by resuscitation, or sustained ventricular tachycardia. Of the 25 patients, 18 had been treated for coronary artery disease or idiopathic dilated cardiomyopathy for up to 108 months before the diagnosis of Chagas' disease was considered. The electrocardiograms frequently suggested coronary artery disease. Six of the seven patients who had exercise thallium-perfusion scans had abnormalities suggesting ischemia or infarction. A left ventricular aneurysm was found in 14 of the 25 patients, segmental akinesia or hypokinesia in 5, and diffuse hypokinesia in 3. Programmed ventricular stimulation performed in 13 patients induced sustained ventricular tachycardia in 9 and nonsustained ventricular tachycardia in 2. Actuarial survival (mean +/- SE) after four years for the entire group was 56 +/- 12 percent; it was 32 +/- 16 percent among those with global left ventricular dysfunction, and 78 +/- 14 percent among those without such dysfunction (P = 0.03). Only patients with left ventricular dysfunction or an aneurysm died (four-year survival, 45 +/- 14 percent, as compared with 100 percent for the remaining patients; P = 0.0002). Heart failu8re and left ventricular aneurysm or dysfunction were the only independent predictors of death. Nine patients required permanent pacemakers. Conclusions. In the United States, Chagas' heart disease commonly mimics coronary artery disease or idiopathic dilated cardiomyopathy. The prognosis is poor for patients with heart failure or left ventricular aneurysm or dysfunction. The disease may be underdiagnosed in the United States.	UNIV SO CALIF, LOS ANGELES CTY MED CTR,DEPT MED,DIV CARDIOL, 2025 ZONAL AVE, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Hagar, Mohamed Esam/0000-0003-0169-7738				ACQUATELLA H, 1987, CIRCULATION, V76, P556, DOI 10.1161/01.CIR.76.3.556; ACQUATELLA H, 1980, CIRCULATION, V62, P787, DOI 10.1161/01.CIR.62.4.787; AMORIM DS, 1979, PROGR CARDIOLOGY, V8, P235; ANSELMI A, 1966, AM HEART J, V72, P469, DOI 10.1016/0002-8703(66)90104-9; ANSELMI A, 1974, CIBA F S, V20, P125; CAMARGO ME, 1988, LABORATORY DIAGNOSIS, V1, P744; COURA JR, 1976, SCI PUBLICATION PAN, V318, P378; DEOLIVEIRA JAM, 1972, ARQ BRAS CARDIOL, V25, P17; DEPAOLA AAV, 1990, AM J CARDIOL, V65, P360, DOI 10.1016/0002-9149(90)90302-H; EARLAM RJ, 1972, AM J DIG DIS, V17, P559, DOI 10.1007/BF02231217; EDMISTON WA, 1978, WESTERN J MED, V128, P248; ESPINOSA R, 1985, INT J CARDIOL, V8, P45, DOI 10.1016/0167-5273(85)90262-1; FEIT A, 1983, ARCH INTERN MED, V143, P144, DOI 10.1001/archinte.143.1.144; KIRCHHOFF LV, 1987, AM J MED, V82, P915, DOI 10.1016/0002-9343(87)90152-5; KIRCHHOFF LV, 1985, JAMA-J AM MED ASSOC, V254, P3058, DOI 10.1001/jama.254.21.3058; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; LORENZAN.R, 1967, AM J CLIN PATHOL, V48, P39; MAGUIRE JH, 1987, CIRCULATION, V75, P1140, DOI 10.1161/01.CIR.75.6.1140; MAHMOUD AAF, 1975, J INFECT DIS, V132, P121, DOI 10.1093/infdis/132.1.121; Marsden P D, 1971, Int Rev Trop Med, V4, P97; MARSDEN PD, 1984, REV INFECT DIS, V6, P855; MASSUMI RA, 1965, ARCH INTERN MED, V116, P531, DOI 10.1001/archinte.116.4.531; MORRIS SA, 1990, CIRCULATION, V82, P1900, DOI 10.1161/01.CIR.82.6.1900; OLIVEIRA JSM, 1985, AM HEART J, V110, P1092, DOI 10.1016/0002-8703(85)90222-4; OLIVEIRA JSM, 1981, BRIT HEART J, V46, P432, DOI 10.1136/hrt.46.4.432; PEARLMAN JD, 1983, AM J MED, V75, P1057, DOI 10.1016/0002-9343(83)90888-4; Prata A, 1986, Rev Soc Bras Med Trop, V19, P9, DOI 10.1590/S0037-86821986000100003; PRATA AR, 1976, SCI PUBLICATION PAN, V318, P191; PUIGBO JJ, 1968, B WORLD HEALTH ORGAN, V39, P341; PUIGBO JJ, 1966, B WORLD HEALTH ORGAN, V34, P655; ROSENBAUM MB, 1964, PROG CARDIOVASC DIS, V7, P199, DOI 10.1016/S0033-0620(64)80020-7; ROSENBAUM MB, 1955, AM HEART J, V50, P492, DOI 10.1016/0002-8703(55)90296-9; SHAFII A, 1977, NEW YORK STATE J MED, V77, P418; TAKLE GB, 1989, CURR TOP MICROBIOL, V145, P79; 1990, SCI PUBLICATION 524, V1, P160; 1990, BUREAU CENSUS STATIS, P41	36	123	134	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1991	325	11					763	768		10.1056/NEJM199109123251103	http://dx.doi.org/10.1056/NEJM199109123251103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE456	1870649				2022-12-28	WOS:A1991GE45600003
J	FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP				FLEURY, S; LAMARRE, D; MELOCHE, S; RYU, SE; CANTIN, C; HENDRICKSON, WA; SEKALY, RP			MUTATIONAL ANALYSIS OF THE INTERACTION BETWEEN CD4 AND CLASS-II MHC - CLASS-II ANTIGENS CONTACT CD4 ON A SURFACE OPPOSITE THE GP120-BINDING SITE	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL HYBRIDOMA; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; POSSIBLE INVOLVEMENT; STRUCTURAL-ANALYSIS; LYMPHOCYTES-T; BINDING-SITE; HLA ANTIGENS; SB ANTIGENS	Using functional and adhesion assays, we have studied the ability of 30 human CD4 mutants to interact with class II major histocompatibility complex (MHC) molecules and also with gp120 from human immunodeficiency virus. The mutants cover the four domains (D1-D4) of CD4 and include several single-site substitutions. Analysis of the results, in the context of the CD4 crystal structure, shows that mutations that affect the interaction with class II MHC molecules are located on three exposed loops from CD4 domains 1 and 2. The specifically implicated residues, 19, 89, and 165, are separated from one another by 9 angstrom, 24 angstrom, and 24 angstrom on one face of the CD4 molecule. Moreover, the class II binding site does not include residues 43 to 49 of the CD4 molecule, a region on an opposite face known to be involved in the binding of gp120.	UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10027 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10027 USA	Universite de Montreal; Columbia University; Columbia University; Howard Hughes Medical Institute	FLEURY, S (corresponding author), INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BIDDISON WE, 1983, J IMMUNOL, V131, P152; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BOWMAN MR, 1990, P NATL ACAD SCI USA, V87, P9052, DOI 10.1073/pnas.87.22.9052; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EGLITIS MA, 1988, BIOTECHNIQUES, V6, P608; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENSTEIN JL, 1984, J EXP MED, V159, P1213, DOI 10.1084/jem.159.4.1213; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MAZEROLLES F, 1988, CELL, V55, P497, DOI 10.1016/0092-8674(88)90036-0; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P3181; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2839; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; ROSENSTEIN Y, 1990, J IMMUNOL, V144, P526; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SWAIN SL, 1984, J IMMUNOL, V132, P1118; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VONHOEGEN P, 1989, J EXP MED, V170, P1879, DOI 10.1084/jem.170.6.1879; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILDE DB, 1983, J IMMUNOL, V131, P2178; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	53	150	157	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1991	66	5					1037	1049		10.1016/0092-8674(91)90447-7	http://dx.doi.org/10.1016/0092-8674(91)90447-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889086				2022-12-28	WOS:A1991GE46000020
J	BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R				BORNER, C; FILIPUZZI, I; WEINSTEIN, IB; IMBER, R			FAILURE OF WILD-TYPE OR A MUTANT FORM OF PROTEIN KINASE-C-ALPHA TO TRANSFORM FIBROBLASTS	NATURE			English	Article							RAS ONCOGENE; CELLS; GROWTH	A MUTANT form of the alpha-isoform of protein kinase C (PKC) was recently isolated from an ultraviolet radiation-induced murine fibrosarcoma cell line and reported to transform mouse BALB/c 3T3 fibroblasts on transfection 1. Four point mutations in the regulatory domain were assumed to be responsible for its oncogenicity and unusual preference for membrane localization. Here, we report that overexpression of the reported mutant PKC-alpha complementary DNA in three fibroblast cell lines, including BALB/c 3T3, does not enable these cells to grow in soft agar or nude mice. In addition, this mutant PKC-alpha form seems to be indistinguishable from the wild-type PKC-alpha with respect to its dependence on cofactors, phorbol ester binding, subcellular distribution and its effects on growth and morphology. These results fail to confirm the previous study 1 and indicate that overexpression of either the wild-type or the reported mutant form of PKC-alpha does not transform rodent fibroblasts.	COLUMBIA UNIV,CTR COMPREHENS CANC,NEW YORK,NY 10032; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV BASEL CLIN,SCH MED,MOLEC TUMORBIOL LAB,CH-4031 BASEL,SWITZERLAND	Columbia University; Columbia University; University of Basel								BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BORNER C, 1990, CELL GROWTH DIFFER, V1, P653; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COSTA SD, 1985, BIOCHEM BIOPH RES CO, V133, P814, DOI 10.1016/0006-291X(85)90977-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; IMBER R, 1991, CANCER RES, V51, P632; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; REGAZZI R, 1986, INT J CANCER, V37, P731, DOI 10.1002/ijc.2910370514; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	12	82	83	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					78	80		10.1038/353078a0	http://dx.doi.org/10.1038/353078a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881450				2022-12-28	WOS:A1991GD80500063
J	DEBAKEY, ME				DEBAKEY, ME			THE NATIONAL-LIBRARY-OF-MEDICINE - EVOLUTION OF A PREMIER INFORMATION-CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								From a small collection of medical publications in the Surgeon General's Office in 1836, the National Library of Medicine has developed into the leading repository of medical information in the world. Despite strong opposition and impediments from certain quarters, involving considerable machinations and intrigue, the determination of interested medical leaders and sympathetic members of Congress triumphed in having this remarkable institution established on the campus of the National Institutes of Health, Bethesda, Md. As a participant in many of the negotiations preceding that decision, I have happily witnessed the transformation of the Library, long housed in cramped, makeshift quarters, to its present magnificent structures in the heart of our nation's foremost medical research center. Its prodigious collection of print, audiovisual, and electronic information; its imaginative research projects; its excellent outreach program; and its innovative services and products are indispensable to all practicing health professionals, scientists, and medical educators, as well as to journalists, government officials, and others. The ultimate beneficiary, of course, is the patient.			DEBAKEY, ME (corresponding author), BAYLOR COLL MED,DEPT SURG,OFF CHANCELLOR,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							[Anonymous], 1949, HOOVER COMMISSION RE; CONFUCIUS, 1937, ANALECTS CONVERSATIO; DE BAKEY M E, 1951, Bull Med Libr Assoc, V39, P122; DEBAKEY ME, 1964, NATIONAL PROGRAM CON, V1, P75; DEBAKEY ME, 1987, READERS DIG, V131, P110; DEBAKEY ME, 1963, MED WORLD NEWS, V4, P58; DEBAKEY ME, 1963, MED WORLD NEWS, V4, P61; DEBAKEY ME, 1989, IMPROVING HLTH PROFE, P6; KLUMPP TG, 1974, RESIDENT STAFF PHYSI, V20, P58; MEHNERT RB, 1986, AM J HOSP PHARM, V43, P2991, DOI 10.1093/ajhp/43.12.2991; METCALF KD, 1944, NATIONAL MED LIBRARY; MILES WD, 1982, HIST NATIONAL LIBRAR, P71; ROGERS FB, 1987, PAST PRESENT FUTURE, P16; 1955, 99 COMM ORG EX BRANC, P63	14	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1252	1258		10.1001/jama.266.9.1252	http://dx.doi.org/10.1001/jama.266.9.1252			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GC858	1870251				2022-12-28	WOS:A1991GC85800035
J	MANGO, SE; MAINE, EM; KIMBLE, J				MANGO, SE; MAINE, EM; KIMBLE, J			CARBOXY-TERMINAL TRUNCATION ACTIVATES GLP-1 PROTEIN TO SPECIFY VULVAR FATES IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							C-ELEGANS; CELL-INTERACTIONS; GROWTH-FACTOR; LIN-12 GENE; MUTATIONS; NEMATODE; DROSOPHILA; INDUCTION; STABILITY; DECISION	THE glp-1 and lin-12 genes encode homologous transmembrane proteins 1,2 that may act as receptors for cell interactions during development 3,4. The glp-1 product is required for induction of germ-line proliferation and for embryogenesis 3,5. By contrast, lin-12 mediates somatic cell interactions, including those between the precursor cells that form the vulval hypodermis (VPCs) 6. Here we analyse an unusual allele of glp-1, glp-1(q35), which displays a semidominant multivulva phenotype (Muv), as well as the typical recessive, loss-of-function Glp phenotypes (sterility and embryonic lethality) 3. We find that the effects of glp-1(q35) on VPC development mimic those of dominant lin-12 mutations, even in the absence of lin-12 activity. The glp-1(q35) gene bears a nonsense mutation predicted to eliminate the 122 C-terminal amino acids, including a ProGluSerThr (PEST) sequence thought to destabilize proteins. We suggest that the carboxy terminus bears a negative regulatory domain which normally inactivates glp-1 in the VPCs. We propose that inappropriate glp-1(q35) activity can substitute for lin-12 to determine vulval fate, perhaps by driving the VPCs to proliferate.	UNIV WISCONSIN,MOLEC BIOL LAB,1525 LINDEN DR,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13214	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Syracuse University				Mango, Susan/0000-0002-2146-3237				AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BRENNER S, 1974, GENETICS, V77, P71; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HODGKIN J, 1989, GENETICS, V123, P301; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PRIESS JR, 1987, CELL, V51, P610; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1990, CELL, V61, P939, DOI 10.1016/0092-8674(90)90060-R; SEYDOUX G, 1991, THESIS U PRINCETON; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	27	60	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					811	815		10.1038/352811a0	http://dx.doi.org/10.1038/352811a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881436	Green Submitted			2022-12-28	WOS:A1991GC96400063
J	KATZ, SJ; MIZGALA, HF; WELCH, HG				KATZ, SJ; MIZGALA, HF; WELCH, HG			BRITISH-COLUMBIA SENDS PATIENTS TO SEATTLE FOR CORONARY-ARTERY SURGERY - BYPASSING THE QUEUE IN CANADA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURVIVAL	Concern about waiting lists for elective procedures has become a highly visible challenge to the universal health insurance program in Canada. In response to lengthening queues for patients waiting for cardiac surgery, British Columbia made contracts with four Seattle hospitals to send a total of 200 patients for coronary artery bypass surgery This article examines the cause of the queue for cardiac surgery in British Columbia and the events that led to outside contracting. Global hospital budgets and restrictions on capital expansion have limited hospital capacity for cardiac surgery This constrained supply, combined with periodic shortages in critical care nurses and cardiac perfusion technologists, has resulted in a rapid increase in the waiting list. Reducing wide variations in the lengths of queues for individual surgeons may afford an opportunity to reduce long waits. While the patient queue for cardiac surgery has sparked a public debate about budget limits and health care needs, its clinical impact remains uncertain.	UNIV BRITISH COLUMBIA,DIV CARDIOL,VANCOUVER V6T 1W5,BC,CANADA; VANCOUVER GEN HOSP,VANCOUVER V5Z 1M9,BC,CANADA; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03756; DEPT VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; UNIV WASHINGTON,SEATTLE,WA 98195	University of British Columbia; University of British Columbia; Dartmouth College; Dartmouth College; University of Washington; University of Washington Seattle	KATZ, SJ (corresponding author), UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV GEN MED,3116 TAUBMAN,BOX 0376,ANN ARBOR,MI 48109, USA.		KATZ, STEVEN/ABH-8886-2020					ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; EVANS RG, 1982, RESOURCES HLTH TECHN; LEBOURDAIS E, 1990, CAN MED ASSOC J, V143, P306; NAYLOR CD, 1990, AM J PUBLIC HEALTH, V80, P1246, DOI 10.2105/AJPH.80.10.1246; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; WHALEN RE, 1982, CIRCULATION, V65, P49, DOI 10.1161/01.CIR.65.7.49; 1988, REPORT MINISTRY HLTH; 1984, NEW ENGL J MED, V311, P1333	8	52	52	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1108	1111		10.1001/jama.266.8.1108	http://dx.doi.org/10.1001/jama.266.8.1108			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865544				2022-12-28	WOS:A1991GB97500034
J	RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A				RAJU, U; KOUMENIS, C; NUNEZREGUEIRO, M; ESKIN, A			ALTERATION OF THE PHASE AND PERIOD OF A CIRCADIAN OSCILLATOR BY A REVERSIBLE TRANSCRIPTION INHIBITOR	SCIENCE			English	Article							PROTEIN-SYNTHESIS; SUPRACHIASMATIC NUCLEUS; GENE-EXPRESSION; APLYSIA EYE; RHYTHM; PACEMAKER; INVOLVEMENT; SEROTONIN; SHIFTS; CAMP	A function for transcription in the mechanism of a circadian oscillator was investigated with the reversible transcription inhibitor 5,6-dichloro-1-beta-D-ribobenzimidazole (DRB). Two-hour treatments with DR-B shifted the phase of the circadian rhythm of the isolated eye of Aplysia, and continuous treatments of DRB lengthened the free running period of this rhythm. Camptothecin, an inhibitor of transcription that is structurally unrelated to DRB, had similar effects on the circadian rhythm. These results suggest that transcription may be part of the circadian oscillating mechanism.	UNIV HOUSTON, DEPT BIOCHEM & BIOPHYS SCI, HOUSTON, TX 77204 USA	University of Houston System; University of Houston			Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NIMH NIH HHS [MH41979] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041979, R37MH041979] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; DUNLAP JC, 1990, TRENDS GENET, V6, P159, DOI 10.1016/0168-9525(90)90151-U; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ESKIN A, 1977, J COMP PHYSIOL, V117, P1, DOI 10.1007/BF00605521; ESKIN A, 1983, SCIENCE, V220, P82, DOI 10.1126/science.6298939; ESKIN A, 1984, P NATL ACAD SCI-BIOL, V81, P7637, DOI 10.1073/pnas.81.23.7637; ESKIN A, 1982, P NATL ACAD SCI-BIOL, V79, P660, DOI 10.1073/pnas.79.2.660; FELDMAN JF, 1967, P NATL ACAD SCI USA, V57, P1080, DOI 10.1073/pnas.57.4.1080; GRANICK D, 1975, J CELL BIOL, V65, P398, DOI 10.1083/jcb.65.2.398; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARTWIG R, 1985, P NATL ACAD SCI USA, V82, P6899, DOI 10.1073/pnas.82.20.6899; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JACKLET JW, 1977, SCIENCE, V198, P69, DOI 10.1126/science.897685; JACKLET JW, 1984, INT REV CYTOL, V89, P251, DOI 10.1016/S0074-7696(08)61305-4; JACKLET JW, 1979, J EXP BIOL, V63, P222; KARAKASHIAN MW, 1962, P NATL ACAD SCI USA, V48, P2130, DOI 10.1073/pnas.48.12.2130; KHALSA SBS, 1988, J COMP PHYSIOL A, V164, P195, DOI 10.1007/BF00603950; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; KOUMENIS C, IN PRESS SOC NEUR AB; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; NAKASHIMA J, 1986, J BIOL RHYTHM, V1, P163; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6812, DOI 10.1073/pnas.86.17.6812; RAJU U, 1990, AM J PHYSIOL, V258, pR256, DOI 10.1152/ajpregu.1990.258.1.R256; ROBERTS MH, 1989, BRAIN RES, V504, P211, DOI 10.1016/0006-8993(89)91359-0; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROTHMAN BS, 1976, J GEN PHYSIOL, V68, P359, DOI 10.1085/jgp.68.4.359; ROTHMAN BS, 1977, FED PROC, V36, P2050; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; STRUMWASSER F, 1988, J PHYSIOLOGY PARIS, V83, P246; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TAMM I, 1978, ADV VIRUS RES, V22, P188; TECHEL D, 1990, J COMP PHYSIOL B, V159, P695, DOI 10.1007/BF00691715; WOOLUM JC, 1983, J COMP PHYSIOL, V151, P253, DOI 10.1007/BF00623902; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YEUNG SJ, 1987, P NATL ACAD SCI USA, V84, P279, DOI 10.1073/pnas.84.1.279; YEUNG SJ, 1988, J BIOL RHYTHM, V3, P225, DOI 10.1177/074873048800300301; ZWARTJES RE, 1990, J NEUROBIOL, V21, P376, DOI 10.1002/neu.480210210	39	72	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1991	253	5020					673	675		10.1126/science.1871602	http://dx.doi.org/10.1126/science.1871602			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871602				2022-12-28	WOS:A1991GA30400041
J	FISHER, BM; HEATLEY, C; SMALL, M				FISHER, BM; HEATLEY, C; SMALL, M			REUSE OF DISPOSABLE PLASTIC INSULIN SYRINGES	BRITISH MEDICAL JOURNAL			English	Article									GARTNAVEL ROYAL HOSP,DIABET CLIN,GLASGOW G12 0YN,SCOTLAND	Gartnavel Royal Hospital								ALEXANDER WD, 1988, BRIT MED J, V296, P877, DOI 10.1136/bmj.296.6626.877; BLOOM A, 1985, BRIT MED J, V290, P727, DOI 10.1136/bmj.290.6470.727; HEATLEY C, 1990, PRACTICAL DIABETES, V7, P33; LESTER E, 1984, BRIT MED J, V289, P1498, DOI 10.1136/bmj.289.6457.1498-a; 1983, BMJ, V286, P369	5	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					286	287		10.1136/bmj.303.6797.286	http://dx.doi.org/10.1136/bmj.303.6797.286			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888929	Green Published, Bronze			2022-12-28	WOS:A1991FZ72100021
J	SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B				SZCZYLIK, C; SKORSKI, T; NICOLAIDES, NC; MANZELLA, L; MALAGUARNERA, L; VENTURELLI, D; GEWIRTZ, AM; CALABRETTA, B			SELECTIVE-INHIBITION OF LEUKEMIA-CELL PROLIFERATION BY BCR-ABL ANTISENSE OLIGODEOXYNUCLEOTIDES	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; NORMAL HUMAN HEMATOPOIESIS; PHILADELPHIA-CHROMOSOME; SYNTHETIC OLIGONUCLEOTIDES; KINASE-ACTIVITY; PROTEIN; MICE; RNA; TRANSFORMATION	To determine the role of the BCR-ABL gene in the proliferation of blast cells of patients with chronic myelogenous leukemia, leukemia blast cells were exposed to synthetic 18-mer oligodeoxynucleotides complementary to two identified BCR-ABL junctions. Leukemia colony formation was suppressed, whereas granulocyte-macrophage colony formation from normal marrow progenitors was unaffected. When equal proportions of normal marrow progenitors and blast cells were mixed, exposed to the oligodeoxynucleotides, and assayed for residual colony formation, the majority of residual cells were normal. These findings demonstrate the requirement for a functional BCR-ABL gene in maintaining the leukemic phenotype and the feasibility of gene-targeted selective killing of neoplastic cells.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV PENN,DEPT PATHOL & MED,PHILADELPHIA,PA 19103; INST REGINA ELENA STUDIO & CURA TUMORI,I-00165 ROME,ITALY; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Malaguarnera, Lucia/K-5530-2018	Malaguarnera, Lucia/0000-0002-4516-7571; MANZELLA, Livia/0000-0002-9908-6443	NATIONAL CANCER INSTITUTE [R23CA036896, T32CA009644, R01CA036896, R01CA046782] Funding Source: NIH RePORTER; NCI NIH HHS [CA36896, CA46782, CA09644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KOEFFLER HP, 1981, NEW ENGL J MED, V304, P1201, DOI 10.1056/NEJM198105143042004; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P316; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; NOWELL PC, 1960, SCIENCE, V132, P1497; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROSENTHAL S, 1977, AM J MED, V63, P542, DOI 10.1016/0002-9343(77)90199-1; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, ANNU REV GENET, V14, P17, DOI 10.1146/annurev.ge.14.120180.000313; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; SZCZYLIK C, UNPUB; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZAMECNIK PC, 1986, P NATL ACAD SCI USA, V83, P4143, DOI 10.1073/pnas.83.12.4143	34	322	353	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					562	565		10.1126/science.1857987	http://dx.doi.org/10.1126/science.1857987			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857987				2022-12-28	WOS:A1991FZ34700039
J	ARMSTRONG, P; KEEVIL, SF				ARMSTRONG, P; KEEVIL, SF			MAGNETIC-RESONANCE-IMAGING .1. BASIC PRINCIPLES OF IMAGE PRODUCTION	BRITISH MEDICAL JOURNAL			English	Review							FLIP-ANGLE; MR				ARMSTRONG, P (corresponding author), ST BARTHOLOMEWS HOSP,ACAD DEPT RADIOL,LONDON EC1A 7BE,ENGLAND.							BLOCH F, 1946, PHYS REV, V69, P127, DOI 10.1103/PhysRev.69.127; BYDDER GM, 1982, AM J ROENTGENOL, V139, P215, DOI 10.2214/ajr.139.2.215; DAMADIAN R, 1971, SCIENCE, V171, P1151, DOI 10.1126/science.171.3976.1151; DIXON WT, 1988, RADIOLOGY, V168, P566, DOI 10.1148/radiology.168.2.3393682; EDELSTEIN WA, 1980, PHYS MED BIOL, V25, P751, DOI 10.1088/0031-9155/25/4/017; HAACKE EM, 1990, AM J ROENTGENOL, V155, P951, DOI 10.2214/ajr.155.5.2120964; HAACKE EM, 1989, RADIOLOGY, V173, P611, DOI 10.1148/radiology.173.3.2813760; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; PURCELL EM, 1946, PHYS REV, V69, P37, DOI 10.1103/PhysRev.69.37; STEHLING MJ, 1989, RADIOLOGY, V170, P257, DOI 10.1148/radiology.170.1.2909106; STEINER RE, 1983, CLIN RADIOL, V34, P13, DOI 10.1016/S0009-9260(83)80371-7; WINKLER ML, 1988, RADIOLOGY, V166, P17, DOI 10.1148/radiology.166.1.3275967	15	10	10	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					35	40		10.1136/bmj.303.6793.35	http://dx.doi.org/10.1136/bmj.303.6793.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW128	1859956	Green Published, Bronze			2022-12-28	WOS:A1991FW12800026
J	MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD				MANASCO, PK; GIRTON, ME; DIGGS, RL; DOPPMAN, JL; FEUILLAN, PP; BARNES, KM; CUTLER, GB; LORIAUX, DL; ALBERTSON, BD			A NOVEL TESTIS-STIMULATING FACTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LUTEINIZING-HORMONE; SEXUAL PRECOCITY; LEYDIG; RADIOIMMUNOASSAY; GONADOTROPIN; TESTOSTERONE; THERAPY	Background. Familial male precocious puberty is a gonadotropin-independent form of precocious puberty that occurs only in males. The cause of the disorder is unknown. To examine the hypothesis that the plasma of boys with familial male precocious puberty contains a novel stimulator of testicular testosterone production, we developed a bioassay using adult male cynomolgus monkeys. Methods. We collected plasma from 12 boys with familial male precocious puberty, 7 normal prepubertal boys of similar ages and with similar plasma gonadotropin levels, and 1 boy with hypogonadotropic hypogonadism and infused it into the testicular artery of adult male cynomolgus monkeys that had been pretreated with gonadotropin-releasing-hormone antaganist to inhibit the endogenous secretion of gonadotropins. Testicular venous effluent was collected at 15-minute intervals for 3 to 5 hours for the measurement of testosterone. Results. The mean (+/- SE) peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from the 12 boys with familial male precocious puberty than in the monkeys infused with plasma from the 7 normal prepubertal boys and the boy with hypogonadotropic hypogonadism (385 +/- 51 vs. 184 +/- 25 percent, P < 0.005) in the three-hour studies. Plasma from 92 percent of the boys with familial male precocious puberty and 12.5 percent of the normal prepubertal boys stimulated a response greater than 195 percent of base-line values. In the animals studied for five hours after receiving a second dose of antagonist, the mean peak testosterone response, as compared with base line, was significantly greater in the monkeys infused with plasma from three boys with familial male precocious puberty than in the monkeys infused with plasma from three normal prepubertal boys (363 +/- 81 vs. 115 +/- 6 percent, P < 0.01). The mean area under the testosterone-response curve wa significantly larger in the monkeys infused with plasma from the boys with familial male precocious puberty in the five-hour studies (154 +/- 34 vs. -58 +/- 10 percent, P < 0.005), but not in the three-hour studies. Conclusions. These findings support the presence of a circulating testis-stimulating factor in the plasma of boys with familial male precocious puberty. The production of such a factor would explain the biologic nature of the disorder.	NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT RADIOL,BETHESDA,MD 20892; GEORGETOWN UNIV HOSP,DEPT RADIOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Georgetown University								ADAMS LA, 1986, J CLIN ENDOCR METAB, V62, P58, DOI 10.1210/jcem-62-1-58; DUFAU ML, 1974, J CLIN ENDOCR METAB, V39, P610, DOI 10.1210/jcem-39-3-610; Greulich WW., 1959, CALIF MED, V91, P53; HOLLAND F J, 1988, Pediatric Research, V23, p278A; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; NIESCHLAG E, 1972, Z KLIN CHEM KLIN BIO, V10, P164; NISWENDER GD, 1971, ENDOCRINOLOGY, V88, P1327, DOI 10.1210/endo-88-6-1327; ODELL WD, 1967, J LAB CLIN MED, V70, P973; ODELL WD, 1967, J CLIN INVEST, V46, P248, DOI 10.1172/JCI105527; PESCOVITZ OH, 1986, J PEDIATR-US, V108, P47, DOI 10.1016/S0022-3476(86)80767-3; REITER EO, 1984, NEW ENGL J MED, V311, P515, DOI 10.1056/NEJM198408233110807; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; WIERMAN ME, 1985, NEW ENGL J MED, V312, P65, DOI 10.1056/NEJM198501103120201	14	20	20	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 24	1991	324	4					227	231		10.1056/NEJM199101243240404	http://dx.doi.org/10.1056/NEJM199101243240404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EU022	1898671				2022-12-28	WOS:A1991EU02200004
J	KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP				KRASNOW, MA; CUMBERLEDGE, S; MANNING, G; HERZENBERG, LA; NOLAN, GP			WHOLE ANIMAL-CELL SORTING OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; FUSHI-TARAZU; EXPRESSION; PROTEINS; GENE; MELANOGASTER; ELEMENTS; CULTURES; INSITU; PCR	Use of primary culture cells has been limited by the inability to purify most types of cells, particularly cells from early developmental stages. In whole animal cell sorting (WACS), live cells derived from animals harboring a lacZ transgene are purified according to their level of beta-galactosidase expression with a fluorogenic beta-galactosidase substrate and fluorescence-activated cell sorting. With WACS, incipient posterior compartment cells that express the engrailed gene were purified from early Drosophila embryos. Neuronal precursor cells were also purified, and they differentiated into neurons with high efficiency in culture. Because there are many lacZ strains, it may be possible to purify most types of Drosophila cells. The same approach is also applicable to other organisms for which germ-line transformation is possible.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA	Stanford University	KRASNOW, MA (corresponding author), STANFORD UNIV, DEPT BIOCHEM, STANFORD, CA 94305 USA.		Manning, Gerard/C-8308-2009; Nolan, Garry/AAE-7903-2019	Nolan, Garry/0000-0002-8862-9043; Manning, Gerard/0000-0002-5087-9151	NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI S, 1987, CYTOMETRY, V8, P114, DOI 10.1002/cyto.990080203; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; CHEN CH, COMMUNICATION; CUMBERLEDGE S, UNPUB; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FEDOROFF S, 1977, CELL TISSUE ORGAN CU; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FURST A, 1985, DEV BIOL, V109, P184, DOI 10.1016/0012-1606(85)90359-8; FURST A, 1985, DEV BIOL, V112, P467, DOI 10.1016/0012-1606(85)90419-1; GURDON JB, 1987, DEVELOPMENT, V99, P285; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HIROMI Y, COMMUNICATION; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KOELLE M, COMMUNICATION; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRASNOW MA, UNPUB; MOORE W, 1986, HDB EXPT IMMUNOLOGY, V1; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARKS DR, 1989, FUNDAMENTAL IMMUNOLO, P781; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Sang JH, 1981, ADV CELL CULT, V1, P125; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STORTI RV, 1978, CELL, V13, P589, DOI 10.1016/0092-8674(78)90210-6; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1	36	37	43	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 4	1991	251	4989					81	85		10.1126/science.1898782	http://dx.doi.org/10.1126/science.1898782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ603	1898782				2022-12-28	WOS:A1991EQ60300032
J	PHILLIPS, DP; KANTER, EJ; BEDNARCZYK, B; TASTAD, PL				PHILLIPS, DP; KANTER, EJ; BEDNARCZYK, B; TASTAD, PL			IMPORTANCE OF THE LAY PRESS IN THE TRANSMISSION OF MEDICAL KNOWLEDGE TO THE SCIENTIFIC COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CITATION ANALYSIS	Background. Efficient, undistorted communication of the results of medical research is important to physicians, the scientific community, and the public. Information that first appears in the scientific literature is frequently retransmitted in the popular press. Does popular coverage of medical research in turn amplify the effects of that research on the scientific community? Methods. To test the hypothesis that researchers are more likely to cite papers that have been publicized in the popular press, we compared the number of references in the Science Citation Index to articles in the New England Journal of Medicine that were covered by The New York Times with the number of references to similar articles that were not covered by the Times. We also performed the comparison during a three-month period when the Times was on strike but continued to prepare an "edition of record" that was not distributed; doing so enabled us to address the possibility that coverage in the Times was simply a marker of the most important articles, which would therefore be cited more frequently, even without coverage in the popular press. Results. Articles in the Journal that were covered by the Times received a disproportionate number of scientific citations in each of the 10 years after the Journal articles appeared. The effect was strongest in the first year after publication, when Journal articles publicized by the Times received 72.8 percent more scientific citations than control articles. This effect was not present for articles published during the strike; articles covered by the Times during this period were no more likely to be cited than those not covered. Conclusions. Coverage of medical research in the popular press amplifies the transmission of medical information from the scientific literature to the research community.			PHILLIPS, DP (corresponding author), UNIV CALIF SAN DIEGO,DEPT SOCIOL,LA JOLLA,CA 92093, USA.		White, Howard D/A-7034-2009					[Anonymous], 1978, METRIC SCI ADVENT SC; BODDE T, 1982, BIOSCIENCE, V32, P173, DOI 10.1093/bioscience/32.3.173; GARFIELD E, 1979, CITATION INDEXING; Hoaglin D.C., 1983, UNDERSTANDING ROBUST; KING J, 1987, J INFORM SCI, V13, P261, DOI 10.1177/016555158701300501; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OKEEFE MT, 1970, JOURNALISM QUART, V47, P95, DOI 10.1177/107769907004700113; PERLMAN D, 1974, DAEDALUS, V103, P207; RICE RE, 1989, SCIENTOMETRICS, V15, P257, DOI 10.1007/BF02017202; SHAW DL, 1967, JOURNALISM QUART, V44, P548, DOI 10.1177/107769906704400319; SHAW JG, 1987, SCIENTOMETRICS, V12, P101, DOI 10.1007/BF02016692; STETSON D, 1978, NY TIMES        1106, P1; TROAN J, 1960, SCIENCE, V131, P1193, DOI 10.1126/science.131.3408.1193; WHITE HD, 1989, ANNU REV INFORM SCI, V24, P119; ZUCKERMAN H, 1987, SCIENTOMETRICS, V12, P329, DOI 10.1007/BF02016675	15	285	292	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1180	1183		10.1056/NEJM199110173251620	http://dx.doi.org/10.1056/NEJM199110173251620			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GK538	1891034				2022-12-28	WOS:A1991GK53800030
J	CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL				CHOW, JW; FINE, MJ; SHLAES, DM; QUINN, JP; HOOPER, DC; JOHNSON, MP; RAMPHAL, R; WAGENER, MM; MIYASHIRO, DK; YU, VL			ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; SEPTICEMIA; AMINOGLYCOSIDES	SERIOUS BACTERIAL-INFECTIONS; GRAM-NEGATIVE BACTERIA; INDUCIBLE BETA-LACTAMASES; CEFTRIAXONE THERAPY; CEPHALOSPORINS; CEFTAZIDIME; CLOACAE; CEFAMANDOLE; PSEUDOMONAS; GENTAMICIN	Objectives: To study the effect of previously administered antibiotics on the antibiotic susceptibility profile of Enterobacter, the factors affecting mortality, and the emergence of antibiotic resistance during therapy for Enterobacter bacteremia. Design: Prospective, observational study of consecutive patients with Enterobacter bacteremia. Setting: Three university tertiary care centers, one major university-affiliated hospital, and two university-affiliated Veterans Affairs medical centers. Patients: A total of 129 adult patients were studied. Measurements: The two main end points were emergence of resistance during antibiotic therapy and death. Main Results: Previous administration of third-generation cephalosporins was more likely to be associated with multiresistant Enterobacter isolates in an initial, positive blood culture (22 of 32, 69%) than was administration of antibiotics that did not include a third-generation cephalosporin (14 of 71, 20%; P < 0.001). Isolation of multiresistant Enterobacter sp. in the initial blood culture was associated with a higher mortality rate (12 of 37, 32%) than was isolation of a more sensitive Enterobacter sp. (14 of 92, 15%; P = 0.03). Emergence of resistance to third-generation cephalosporin therapy (6 of 31, 19%) occurred more often than did emergence of resistance to aminoglycoside (1 of 89, 0.01%; P = 0.001) or other beta-lactam (0 of 50; P = 0.002) therapy. Conclusions: More judicious use of third-generation cephalosporins may decrease the incidence of nosocomial multiresistant Enterobacter spp., which in turn may result in a lower mortality for Enterobacter bacteremia. When Enterobacter organisms are isolated from blood, it may be prudent to avoid third-generation cephalosporin therapy regardless of in-vitro susceptibility.	UNIV PITTSBURGH, SCH MED, 968 SCAIFE, PITTSBURGH, PA 15261 USA; PITTSBURGH DEPT VET AFFAIRS MED CTR, PITTSBURGH, PA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; CLEVELAND DEPT VET AFFAIRS MED CTR, CLEVELAND, OH USA; MICHAEL REESE HOSP & MED CTR, CHICAGO, IL 60616 USA; UNIV FLORIDA, GAINESVILLE, FL 32611 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Michael Reese Hospital & Medical Center; State University System of Florida; University of Florida			Chow, Joseph W/W-4164-2017	Chow, Joseph W/0000-0002-5934-5877	PHS HHS [5T32A107333] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; BECKWITH DG, 1980, J CLIN MICROBIOL, V12, P517, DOI 10.1128/JCM.12.4.517-520.1980; BITTNER MJ, 1983, ANTIMICROB AGENTS CH, V23, P261, DOI 10.1128/AAC.23.2.261; BOUZA E, 1985, ARCH INTERN MED, V145, P1024, DOI 10.1001/archinte.145.6.1024; BRYAN CS, 1985, AM J DIS CHILD, V139, P1086, DOI 10.1001/archpedi.1985.02140130024022; BURCHARD KW, 1986, SURGERY, V100, P857; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; DWORZACK DL, 1987, EUR J CLIN MICROBIOL, V6, P456, DOI 10.1007/BF02013110; ERON LJ, 1983, J ANTIMICROB CHEMOTH, V12, P65, DOI 10.1093/jac/12.1.65; FOLLATH F, 1987, EUR J CLIN MICROBIOL, V6, P446, DOI 10.1007/BF02013108; FUNG CP, 1988, CHUNG HUA I HSUEH TS, V42, P297; GALLAGHER PG, 1990, REV INFECT DIS, V12, P808; GASTON MA, 1988, J HOSP INFECT, V11, P197, DOI 10.1016/0195-6701(88)90098-9; GRIBBLE MJ, 1983, ANTIMICROB AGENTS CH, V24, P388, DOI 10.1128/AAC.24.3.388; HILF M, 1989, AM J MED, V87, P540, DOI 10.1016/S0002-9343(89)80611-4; JARLIER V, 1984, PATHOL BIOL, V32, P399; KORVICK J, 1988, ANN M AM SOC MICROBI; KORVICK JA, 1991, SURGERY, V109, P62; LANDESMAN SH, 1981, AM J MED, V71, P693, DOI 10.1016/0002-9343(81)90240-0; LEVINE LR, 1978, J INFECT DIS, V137, pS125, DOI 10.1093/infdis/137.Supplement.S125; Maniatis T, 1982, MOL CLONING LABORATO, P89; MARIER RL, 1982, J ANTIMICROB CHEMOTH, V9, P85, DOI 10.1093/jac/9.suppl_B.85; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MILATOVIC D, 1987, EUR J CLIN MICROBIOL, V6, P234, DOI 10.1007/BF02017607; Miller G., 1980, DEV IND MICROBIOL, V21, P91; MURPHY TF, 1982, ANTIMICROB AGENTS CH, V21, P568, DOI 10.1128/AAC.21.4.568; MURRAY PR, 1983, J INFECT DIS, V147, P590, DOI 10.1093/infdis/147.3.590; NEU HC, 1990, AM J MED, V88, pS3, DOI 10.1016/0002-9343(90)90321-4; OLSON B, 1983, J ANTIMICROB CHEMOTH, V11, P299, DOI 10.1093/jac/11.4.299; PECHERE JC, 1983, J ANTIMICROB CHEMOTH, V12, P181, DOI 10.1093/jac/12.suppl_A.181; PERKINS RL, 1978, J INFECT DIS, V137, pS110, DOI 10.1093/infdis/137.Supplement.S110; QUINN JP, 1989, ANTIMICROB AGENTS CH, V33, P1451, DOI 10.1128/AAC.33.9.1451; QUINN JP, 1987, J INFECT DIS, V155, P942, DOI 10.1093/infdis/155.5.942; SANDERS CC, 1982, J INFECT DIS, V145, P118, DOI 10.1093/infdis/145.1.118; SANDERS CC, 1985, J INFECT DIS, V151, P399, DOI 10.1093/infdis/151.3.399; SANDERS CC, 1983, REV INFECT DIS, V5, P639; SANDERS WE, 1988, REV INFECT DIS, V10, P830; SCULLY BE, 1984, ARCH INTERN MED, V144, P57, DOI 10.1001/archinte.144.1.57; SPRATT BG, 1977, EUR J BIOCHEM, V72, P341, DOI 10.1111/j.1432-1033.1977.tb11258.x; WATANAKUNAKORN C, 1989, SCAND J INFECT DIS, V21, P1, DOI 10.3109/00365548909035673; WEINSTEIN RA, 1986, INFECT CONT HOSP EP, V7, P120, DOI 10.1017/S0195941700065632; Young LS, 1990, PRINCIPLES PRACTICE, P611; 1983, MMWR, V22, P155; 1988, PROPHET STATISTICS U, P115	44	709	725	1	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					585	590		10.7326/0003-4819-115-8-585	http://dx.doi.org/10.7326/0003-4819-115-8-585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892329				2022-12-28	WOS:A1991GJ90200001
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA-800 MEDICAL ADVERTISING INFORMATION LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-28	WOS:A1991GG55100005
J	ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S				ALLEN, S; LINDAN, C; SERUFILIRA, A; VANDEPERRE, P; RUNDLE, AC; NSENGUMUREMYI, F; CARAEL, M; SCHWALBE, J; HULLEY, S			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN URBAN RWANDA - DEMOGRAPHIC AND BEHAVIORAL-CORRELATES IN A REPRESENTATIVE SAMPLE OF CHILDBEARING WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; RISK-FACTORS; HETEROSEXUAL TRANSMISSION; FEMALE PROSTITUTES; GENITAL ULCERS; CENTRAL-AFRICA; AIDS; SEROPOSITIVITY; UGANDA	Objective. - To determine behavioral and demographic risk factors for human immunodeficiency virus (HIV) infection in central Africa. Design. - Cross-sectional survey. Setting. - Kigali, Rwanda. Participants. - A representative sample of 1458 childbearing women aged 19 to 37 years who were recruited from outpatient prenatal and pediatric clinics at the only community hospital in the city. Main Outcome Measure. - Antibodies to HIV assessed by enzyme immuno-assay and confirmed by Western blot or indirect immunofluorescence. Results. - The HIV seroprevalence was 32% overall. Infection rates were higher in women who were single, in those in steady relationships that began after 1981, and in the 33% of women reporting more than one lifetime sexual partner. Women in legal marriages or monogamous partnerships had lower rates of infection, but even low-riskrisk women had prevalences on the order of 20%. History of venereal diseases in the past 5 years, although the strongest risk factor in a multiple logistic analysis (odds ratio, 2.7; 95% confidence interval, 2.0 to 3.7), was reported by only 30% of those infected. Having a male sexual partner who drank alcohol or who had higher income were significant risk factors for HIV infection in the multivariate analysis, but use of oral contraceptives and having an uncircumcised partner were not. Conclusions. - The epidemic of the acquired immunodeficiency syndrome in Rwanda has spread beyond high-risk groups to the general population of women without known risk factors. For most of these women, a steady male partner is the source of their HIV risk and therefore a vital target for intervention efforts.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; MINIST HLTH,NATL AIDS PROGRAM,KIGALI,RWANDA; GLOBAL PROGRAMME AIDS,GENEVA,SWITZERLAND; MINIST HLTH,PROJET SAN FRANCISCO,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLEN, S (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,UCSF BOX 0886,SAN FRANCISCO,CA 94143, USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; BUGINGO G, 1988, REV MED RWANDAISE, V20, P37; CARAEL M, 1988, AIDS, V2, P201; CARSWELL JW, 1987, AIDS, V1, P223; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; CLUMECK N, 1985, NEW ENGL J MED, V313, P182; CLUMECK N, 1985, JAMA-J AM MED ASSOC, V254, P2599, DOI 10.1001/jama.254.18.2599; Clumeck N, 1987, Antibiot Chemother (1971), V38, P41; COLEBUNDERS RL, 1989, EUR J CLIN MICROBIOL, V8, P505, DOI 10.1007/BF01967468; DELALLA F, 1988, AIDS, V2, P317, DOI 10.1097/00002030-198808000-00013; FLEMING AF, 1988, BIOMED PHARMACOTHER, V42, P309; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HUDSON CP, 1988, AIDS, V2, P255, DOI 10.1097/00002030-198808000-00003; LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006; MANN JM, 1988, AIDS, V2, P249, DOI 10.1097/00002030-198808000-00002; MELBYE M, 1986, LANCET, V2, P1113; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; NGALY B, 1988, J ACQ IMMUN DEF SYND, V1, P551; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; PIOT P, 1989, BRIT MED J, V298, P623, DOI 10.1136/bmj.298.6674.623; PIOT P, 1987, AIDS, V1, P199; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; PIOT P, 1988, BRIT MED BULL, V44, P68, DOI 10.1093/oxfordjournals.bmb.a072247; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; QUINN TC, 1986, SCIENCE, V234, P955, DOI 10.1126/science.3022379; RWANDAN HIV, 1989, LANCET, V1, P941; SCHMUTZHARD E, 1989, AM J EPIDEMIOL, V130, P309, DOI 10.1093/oxfordjournals.aje.a115337; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; VANDEPERRE P, 1987, AIDS, V1, P213; VANDEPERRE P, 1984, LANCET, V2, P62; VANDEPERRE P, 1985, LANCET, V2, P524; VANDEPERRE P, 1987, AIDS, V1, P207; VANDEPERRE P, 1988, GENITOURIN MED, V64, P30; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1988, MMWR, V37, P565; 1990, AIDS, V4, P1305	42	181	181	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1657	1663		10.1001/jama.266.12.1657	http://dx.doi.org/10.1001/jama.266.12.1657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GF419	1886188				2022-12-28	WOS:A1991GF41900031
J	PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC				PETRENKO, AG; PERIN, MS; DAVLETOV, BA; USHKARYOV, YA; GEPPERT, M; SUDHOF, TC			BINDING OF SYNAPTOTAGMIN TO THE ALPHA-LATROTOXIN RECEPTOR IMPLICATES BOTH IN SYNAPTIC VESICLE EXOCYTOSIS	NATURE			English	Article							WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; LONG-TERM POTENTIATION; PROTEIN KINASE-C; NERVE-TERMINALS; PURIFICATION; MEMBRANE	A VERTEBRATE neurotoxin, alpha-latrotoxin, from black widow spider venom causes synaptic vesicle exocytosis and neurotransmitter release from presynaptic nerve terminals 1-4. Although the mechanism of action of alpha-latrotoxin is not known, it does require binding of alpha-latrotoxin to a high-affinity receptor on the presynaptic plasma membrane 5. The alpha-latrotoxin receptor seems to be exclusively at the presynaptic plasmamembrane 6. Here we report that the alpha-latrotoxin receptor specifically binds to a synaptic vesicle protein, synaptotagmin, and modulates its phosphorylation. Synaptotagmin is a synaptic vesicle-specific membrane protein that binds negatively charged phospholipids and contains two copies of a putative Ca2+-binding domain from protein kinase C (the C2-domain), suggesting a regulatory role in synaptic vesicle fusion 7,8. Our findings suggest that a physiological role of the alpha-latrotoxin receptor may be the docking of synaptic vesicles at the active zone. The direct interaction of the alpha-latrotoxin receptor with a synaptic vesicle protein also suggests a mechanism of action for this toxin in causing neurotransmitter release.	UNIV TEXAS,SW MED CTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; SHEMYAKIN BIOORGAN CHEM INST,MOSCOW 117871,USSR	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Davletov, Bazbek/ABA-8569-2021; Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275; Petrenko, Alexander/0000-0002-6689-6546				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLARK AW, 1970, NATURE, V225, P703, DOI 10.1038/225703a0; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; OKAMOTO M, 1971, SCIENCE, V172, P733, DOI 10.1126/science.172.3984.733; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PUMPLIN DW, 1977, J PHYSIOL-LONDON, V273, P443, DOI 10.1113/jphysiol.1977.sp012103; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WANG JKT, 1988, J NEUROSCI, V8, P281	20	228	228	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					65	68		10.1038/353065a0	http://dx.doi.org/10.1038/353065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1881448				2022-12-28	WOS:A1991GD80500058
J	LEVENTHAL, BG; KASHIMA, HK; MOUNTS, P; THURMOND, L; CHAPMAN, S; BUCKLEY, S; WOLD, D				LEVENTHAL, BG; KASHIMA, HK; MOUNTS, P; THURMOND, L; CHAPMAN, S; BUCKLEY, S; WOLD, D			LONG-TERM RESPONSE OF RECURRENT RESPIRATORY PAPILLOMATOSIS TO TREATMENT WITH LYMPHOBLASTOID INTERFERON ALFA-N1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JUVENILE LARYNGEAL PAPILLOMATOSIS; LEUKOCYTE INTERFERON; TRIAL; THERAPY	Background, We earlier reported that patients with recurrent respiratory papillomatosis responded to six months of treatment with lymphoblastoid interferon alfa-n1. Because another study of patients treated for one year with leukocyte interferon alfa-n3 found that the growth rate of papillomas was slowed in the first six months but returned to base line during months 7 through 12 despite persistent interferon treatment, we now report the long-term results in our original study patients who were followed for a median of four years after the original one-year crossover study. Methods. After the patients in our study had completed the first study year, their physicians could continue or recommence treatment with lymphoblastoid interferon alfa-n1 in a dose of either 2 MU per square meter of body-surface area per day or 4 MU per square meter every other day. The extent of disease was measured by endoscopy when clinically indicated. Results. Data on late-follow-up were obtained for 60 of the 66 patients. There were 22 complete remissions and 25 partial remissions; 13 patients had no response. The median duration of the complete remissions was 550 days, and 15 patients continued to be in complete remission. The median duration of partial remissions was 400 days, and seven patients were still in partial remission. Thirteen of 28 patients responded to a second course of interferon after an interruption in treatment of at least one month. The rate of response in the 11 of 53 patients who had neutralizing antibody to interferon was the same as in the patients without the antibody. Conclusions. Patients with severe recurrent respiratory papillomatosis may have a sustained or repeated response to treatment with lymphoblastoid interferon alfa-n1. We recommend that patients with recurrent respiratory papillomatosis who require surgery every two to three months be given a six-month trial of interferon alfa-n1.	BURROUGHS WELLCOME CO,DEPT EXPTL THERAPY,RES TRIANGLE PK,NC 27709; BURROUGHS WELLCOME CO,DEPT CLIN IMMUNOL,RES TRIANGLE PK,NC 27709; BURROUGHS WELLCOME CO,DEPT CLIN STAT,RES TRIANGLE PK,NC 27709; JOHNS HOPKINS UNIV,DEPT ONCOL & PEDIAT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,DEPT OTOLARYNGOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218	Burroughs Wellcome Fund; Burroughs Wellcome Fund; Burroughs Wellcome Fund; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								GALTON JE, 1989, LANCET, V2, P572; GOEPFERT H, 1982, ANN OTO RHINOL LARYN, V91, P431, DOI 10.1177/000348948209100422; HAGLUND S, 1981, ARCH OTOLARYNGOL, V107, P327; HEALY GB, 1988, NEW ENGL J MED, V319, P401, DOI 10.1056/NEJM198808183190704; Kashima H., 1985, PAPILLOMAVIRUSES MOL, V32, P125; LEVENTHAL BG, 1988, ARCH OTOLARYNGOL, V114, P1163; MCCABE BF, 1983, ANN OTO RHINOL LARYN, V92, P2, DOI 10.1177/000348948309200102; MOUNTS P, 1984, PROG MED VIROL, V29, P90; MOUNTS P, 1984, LARYNGOSCOPE, V94, P28, DOI 10.1002/lary.5540940106; REICHMAN RC, 1988, ANN INTERN MED, V108, P675, DOI 10.7326/0003-4819-108-5-675; STEINBERG BM, 1983, NEW ENGL J MED, V308, P1261, DOI 10.1056/NEJM198305263082104; THURMOND LM, IN PRESS J LAB CLIN; VONWUSSOW P, 1987, LANCET, V2, P635; ZENNER HP, 1985, ONCOLOGY, V42, P15, DOI 10.1159/000226079; ZOON KC, 1986, BIOL INTERFERON SYST, P55	15	84	90	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1991	325	9					613	617		10.1056/NEJM199108293250904	http://dx.doi.org/10.1056/NEJM199108293250904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC328	1861694				2022-12-28	WOS:A1991GC32800004
J	BAKER, DW; STEVENS, CD; BROOK, RH				BAKER, DW; STEVENS, CD; BROOK, RH			PATIENTS WHO LEAVE A PUBLIC HOSPITAL EMERGENCY DEPARTMENT WITHOUT BEING SEEN BY A PHYSICIAN - CAUSES AND CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Objective.-To determine whether patients who sought care at a public hospital emergency department and left without being seen by a physician needed immediate medical attention and whether they obtained care after leaving. Design.-Follow-up study of patients who left without being seen and of patients who waited to be seen by a physician. Setting.-A public hospital's emergency department in Torrance, Calif. Patients.-All patients who registered for care and left without being seen (n = 186) and a 20% random sample of patients who waited until they were seen (n = 211) in a 2-week period during spring 1990. Main Outcome Measures.-At time of presentation: triage nurse urgency assessment, clinical acuity rating, and self-reported health status. At follow-up: hospitalization rates. Results.-Patients who left reported that they had waited 6.4 hours before leaving; those who stayed reported a 6.2-hour wait before being seen. There were no differences between those who left and those who stayed in chief complaint, triage nurse assessment, acuity ratings, or self-reported health status. Forty-six percent of those who left were judged to need immediate medical attention, and 29% needed care within 24 to 48 hours. Eleven percent of those who left were hospitalized within the next week, and three patients required emergency surgery. Nine percent of those who waited to be seen were hospitalized. Forty-nine percent of patients who left did not see a physician during the 1-week follow-up period. Conclusion.-Overcrowding in this public hospital's emergency department restricts access to needed ambulatory medical care for the poor and uninsured.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT HLTH SERV,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT EMERGENCY MED,TORRANCE,CA 90509; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA 90406	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; RAND Corporation	BAKER, DW (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,LOS ANGELES,CA 90024, USA.							[Anonymous], 1990, ANN EMERG MED, V19, P944; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; DERSHEWITZ RA, 1986, ANN EMERG MED, V15, P717, DOI 10.1016/S0196-0644(86)80432-2; DICKINSON G, 1989, CAN MED ASSOC J, V140, P270; GIBSON G, 1978, JACEP-J AM COLL EMER, V7, P47, DOI 10.1016/S0361-1124(78)80035-5; GIFFORD MJ, 1980, ANN EMERG MED, V9, P502, DOI 10.1016/S0196-0644(80)80187-9; KOSKA MT, 1989, HOSPITALS, V63, P66; LYNN SG, 1991, ANN EMERG MED, V20, P287, DOI 10.1016/S0196-0644(05)80942-4; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WEINERMAN RE, 1966, AM J PUBLIC HEALTH, V56, P1037; WOLCOTT BW, 1979, JACEP-J AM COLL EMER, V8, P241; 1990, ANN EMERG MED, V19, P336	13	266	268	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1085	1090		10.1001/jama.266.8.1085	http://dx.doi.org/10.1001/jama.266.8.1085			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1865540				2022-12-28	WOS:A1991GB97500030
J	BREO, DL				BREO, DL			DIMOND,E.,GREY - THE COUNTERCULTURE MEDICAL EDUCATOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					1019	1022		10.1001/jama.266.7.1019	http://dx.doi.org/10.1001/jama.266.7.1019			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870219				2022-12-28	WOS:A1991GB20500015
J	JONAS, HS; ETZEL, SI; BARZANSKY, B				JONAS, HS; ETZEL, SI; BARZANSKY, B			EDUCATIONAL-PROGRAMS IN UNITED-STATES MEDICAL-SCHOOLS, 1990-1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT DIRECTORIES & PUBLICAT,CHICAGO,IL 60610	American Medical Association	JONAS, HS (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,CHICAGO,IL 60610, USA.							RUHE CHW, 1980, JAMA	1	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					913	920		10.1001/jama.266.7.913	http://dx.doi.org/10.1001/jama.266.7.913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870221				2022-12-28	WOS:A1991GB20500002
J	GIFFORD, RW				GIFFORD, RW			MANAGEMENT OF HYPERTENSIVE CRISES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL BLOOD-FLOW; CONTROLLED TRIAL; INTRAVENOUS NITROGLYCERIN; ARTERIAL-HYPERTENSION; SODIUM-NITROPRUSSIDE; URGENT HYPERTENSION; ORAL NIFEDIPINE; AUTOREGULATION; EMERGENCIES; CIRCULATION	The availability of potent antihypertensive drugs that will decrease markedly elevated blood pressure within minutes to hours has changed the concepts of definition and therapy of hypertensive emergencies and urgencies. Intravenous infusion of sodium nitroprusside can be used in the truly emergent situation and is effective, reliable, and safe. While oral therapy is more convenient, it is not as consistently effective as parenteral administration and can lead to excessive reductions in blood pressure that are more difficult to manage than when short-acting agents are given intravenously.			GIFFORD, RW (corresponding author), CLEVELAND CLIN FDN, DEPT HYPERTENS & NEPHROL, DESK A-101, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							[Anonymous], 1988, ARCH INTERN MED, V148, P1023; ASFOURA JY, 1991, CHEST, V99, P724, DOI 10.1378/chest.99.3.724; BERTEL O, 1985, AM J MED, V79, P31, DOI 10.1016/0002-9343(85)90498-X; BROTT T, 1989, STROKE, V20, P694, DOI 10.1161/01.STR.20.5.694; BRUNO A, 1988, STROKE, V19, P135, DOI 10.1161/01.STR.19.10.1300; CALHOUN DA, 1990, NEW ENGL J MED, V323, P1177; CLARY C, 1987, J CLIN PSYCHIAT, V48, P249; COHN JN, 1979, ANN INTERN MED, V91, P752, DOI 10.7326/0003-4819-91-5-752; CRESSMAN MD, 1984, AM HEART J, V107, P980, DOI 10.1016/0002-8703(84)90838-X; DELCASTILLO AC, 1988, J CLIN PHARMACOL, V28, P667, DOI 10.1002/j.1552-4604.1988.tb03196.x; ECKSTEIN RW, 1971, J APPL PHYSIOL, V30, P488, DOI 10.1152/jappl.1971.30.4.488; ESTAFANOUS FG, 1980, AM J CARDIOL, V46, P685, DOI 10.1016/0002-9149(80)90521-4; FAGAN TC, 1989, ARCH INTERN MED, V149, P2169, DOI 10.1001/archinte.149.10.2169; FELDMANN E, 1991, INTRACEREBRAL HEMORR, P26; FERGUSON RK, 1989, ARCH INTERN MED, V149, P257, DOI 10.1001/archinte.149.2.257; FLAHERTY JT, 1982, CIRCULATION, V65, P1072, DOI 10.1161/01.CIR.65.6.1072; FLAHERTY JT, 1983, AM J MED, V74, P53, DOI 10.1016/0002-9343(83)90855-0; GARCIA JY, 1987, DRUGS, V34, P263, DOI 10.2165/00003495-198734020-00004; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; GIFFORD RW, 1974, PROG CARDIOVASC DIS, V17, P115, DOI 10.1016/0033-0620(74)90026-7; GIFFORD RW, 1983, HYPERTENSION, V5, P17; GIFFORD RW, 1983, HYPERTENSION, P1127; GIFFORD RW, 1990, AM J OBSTET GYNECOL, V163, P1689; HAYES JM, 1977, MED J AUSTRALIA, V2, P30, DOI 10.5694/j.1326-5377.1977.tb107763.x; HOGAN PJ, 1990, TEX HEART I J, V17, P281; HOROWITZ D, 1965, P COUNC HIGH BLOOD P, V12, P39; HOUSTON MC, 1989, PROG CARDIOVASC DIS, V32, P99, DOI 10.1016/0033-0620(89)90022-4; JAKER M, 1989, ARCH INTERN MED, V149, P260, DOI 10.1001/archinte.149.2.260; JAMES TN, 1975, CIRCULATION, V52, P179, DOI 10.1161/01.CIR.52.2.179; KANADA SA, 1976, ANN INTERN MED, V84, P696, DOI 10.7326/0003-4819-84-6-696; KOCHWESER J, 1976, NEW ENGL J MED, V294, P1271, DOI 10.1056/NEJM197606032942306; KONTOS HA, 1981, ANNU REV PHYSIOL, V43, P397, DOI 10.1146/annurev.ph.43.030181.002145; KUMAR GK, 1976, JAMA-J AM MED ASSOC, V235, P275; LASSEN NA, 1972, SCAND J CLIN LAB INV, V30, P113, DOI 10.3109/00365517209081099; MANN T, 1978, CIRCULATION, V57, P732, DOI 10.1161/01.CIR.57.4.732; MARTINEZVILA E, 1990, STROKE, V21, P1023, DOI 10.1161/01.STR.21.7.1023; MCALLISTER RG, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90787-4; NIBBELINK DW, 1975, CEREBRAL VASCULAR DI, P155; NIGHTINGALE SL, 1991, JAMA-J AM MED ASSOC, V265, P847, DOI 10.1001/jama.265.7.847; OMAILIA JJ, 1987, ANN INTERN MED, V107, P185, DOI 10.7326/0003-4819-107-2-185; Paulson O B, 1987, Agressologie, V28, P367; RUBENSTEIN EB, 1989, CRIT CARE CLIN, V5, P477; SCHWARTZ M, 1990, ARCH INTERN MED, V150, P686, DOI 10.1001/archinte.150.3.686; STINSON EB, 1975, CIRCULATION, V52, P26; STRANDGAARD S, 1976, CIRCULATION, V53, P720, DOI 10.1161/01.CIR.53.4.720; STRANDGAARD S, 1973, BMJ-BRIT MED J, V1, P507, DOI 10.1136/bmj.1.5852.507; TETTENBORN D, 1990, STROKE, V21, P85; Tettenborn D, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P84; VANHARTEN J, 1987, LANCET, V2, P1363; Wheat M W Jr, 1987, Cardiovasc Clin, V17, P241; WILSON DJ, 1982, CARDIOVASC CLIN, V12, P79; ZELLER KR, 1989, ARCH INTERN MED, V149, P2186, DOI 10.1001/archinte.149.10.2186	52	99	103	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					829	835		10.1001/jama.266.6.829	http://dx.doi.org/10.1001/jama.266.6.829			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865522				2022-12-28	WOS:A1991GA07300036
J	RUSTGI, AK; DYSON, N; BERNARDS, R				RUSTGI, AK; DYSON, N; BERNARDS, R			AMINO-TERMINAL DOMAINS OF C-MYC AND N-MYC PROTEINS MEDIATE BINDING TO THE RETINOBLASTOMA GENE-PRODUCT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; DNA-BINDING; SUSCEPTIBILITY GENE; TRANSFORMATION; ONCOPROTEINS; MUTATIONS; ONCOGENES; REGIONS	THE proteins encoded by the myc gene family are involved in the control of cell proliferation and differentiation, and aberrant expression of myc proteins has been implicated in the genesis of a variety of neoplasms 1. In the carboxyl terminus, myc proteins have two domains that encode a basic domain/helix-loop-helix and a leucine zipper motif, respectively. These motifs are involved both in DNA binding and in protein dimerization 2-5. In addition, myc protein family members share several regions of highly conserved amino acids in their amino termini that are essential for transformation 6,7. We report here that an N-terminal domain present in both the c-myc and N-myc proteins mediates binding to the retinoblastoma gene product, pRb. We show that the human papilloma virus E7 protein competes with c-myc for binding to pRb, indicating that these proteins share overlapping binding sites on pRb. Furthermore, a mutant Rb protein from a human tumour cell line that carried a 35-amino-acid deletion in its C terminus failed to bind to c-myc. Our results suggest that c-myc and pRb cooperate through direct binding to control cell proliferation.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC ONCOL,BOSTON,MA 02150; MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02150; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	RUSTGI, AK (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,149 13TH ST,BOSTON,MA 02150, USA.			Bernards, Rene/0000-0001-8677-3423				BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PENDERGAST GC, 1991, SCIENCE, V251, P186; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	27	327	333	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					541	544		10.1038/352541a0	http://dx.doi.org/10.1038/352541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865909	Green Submitted			2022-12-28	WOS:A1991GA22600067
J	SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R				SCHAFER, DA; GELLES, J; SHEETZ, MP; LANDICK, R			TRANSCRIPTION BY SINGLE MOLECULES OF RNA-POLYMERASE OBSERVED BY LIGHT-MICROSCOPY	NATURE			English	Article							TERNARY COMPLEXES; MOVEMENTS; TRACKING	THE kinetics of transcription by Escherichia coli RNA polymerase relate directly to the regulation of transcription and to the properties of processive enzymes in general 1, but analysis of RNA polymerase movement along the DNA template has so far been limited to the study of populations of enzyme molecules. The ability to view nanometre-sized particles with the light microscope 2,3 suggested a method of monitoring transcription by individual RNA polymerase molecules. We describe here the behaviour of 40-nm-diameter particles of colloidal gold attached to the ends of DNA molecules being transcribed by RNA polymerase immobilized on a glass surface. The tethered gold particles are released from the surface at times after addition of nucleoside triphosphates that are consistent with the kinetics of transcription by RNA polymerase in solution. Analysis of the brownian motion of the gold particles enabled us to measure the movement along the template DNA of individual polymerase molecules.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63130; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63130; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Washington University (WUSTL); Washington University (WUSTL); Duke University; Brandeis University; Brandeis University				Gelles, Jeff/0000-0001-7910-3421				ALLEN RD, 1983, J MICROSC-OXFORD, V129, P3, DOI 10.1111/j.1365-2818.1983.tb04157.x; GEERTS H, 1987, BIOPHYS J, V52, P775, DOI 10.1016/S0006-3495(87)83271-X; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDICK R, 1987, J MOL BIOL, V196, P363, DOI 10.1016/0022-2836(87)90697-8; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; Vetterling W.T., 1988, NUMERICAL RECIPES C; YAGER TD, 1989, CELLULAR MOL BIOL, P1241	13	239	246	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1991	352	6334					444	448		10.1038/352444a0	http://dx.doi.org/10.1038/352444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861724				2022-12-28	WOS:A1991FZ34600070
J	ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA				ANDERSON, FA; WHEELER, HB; GOLDBERG, RJ; HOSMER, DW; FORCIER, A; PATWARDHAN, NA			PHYSICIAN PRACTICES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Article						HEPARIN; INTERMITTENT CALF COMPRESSION; THROMBOEMBOLISM; VENA CAVA FILTER; WARFARIN	PULMONARY-EMBOLISM; SURGICAL PATIENTS; UNITED-STATES; MORTALITY; DIAGNOSIS	Objective: To determine the rate of use of prophylaxis for venous thromboembolism in high-risk hospital patients. Design: A retrospective medical record review. Setting: A community-wide study in 16 short-stay hospitals in central Massachusetts. Patients: A total of 2017 patients with multiple risk factors for venous thromboembolism. Measurements and Main Results: On the basis of age, length of hospitalization, and the presence of at least one additional major risk factor, 17% of 151 349 discharges (25 410 patients) were identified as being at high risk for venous thromboembolism. Eight percent of these discharges were randomly selected for medical record review. Prophylaxis for venous thromboembolism was received by 32% of these high-risk patients. Prophylaxis use among the 16 study hospitals varied widely, ranging from 9% to 56%, and was higher in teaching hospitals than in nonteaching hospitals (44% compared with 19%; P < 0.001). One or more of the following methods of prophylaxis was used: low-dose heparin (78%), intermittent calf compression (13%), warfarin (12%), and inferior vena caval filter (3%). Use of prophylaxis increased with the number of risk factors identified (P < 0.001). Conclusion: Prophylaxis for venous thromboembolism is underused, particularly in nonteaching hospitals.			ANDERSON, FA (corresponding author), UNIV MASSACHUSETTS, MED CTR, SCH MED, 55 LAKE AVE N, WORCESTER, MA 01655 USA.				NHLBI NIH HHS [HL RO1-35862] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035862] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1975, LANCET, V2, P45; BERGQVIST D, 1985, BRIT J SURG, V72, P105, DOI 10.1002/bjs.1800720211; BERGQVIST D, 1983, POSTOPERATIVE THROMB, P156; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Carter C, 1982, HEMOSTASIS THROMBOSI, P805; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; CONTI S, 1982, ARCH SURG-CHICAGO, V117, P1036; CONTI S, 1980, VASCULAR SURG, V14, P382, DOI 10.1177/153857448001400604; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; DISMUKE SE, 1986, JAMA-J AM MED ASSOC, V255, P2039, DOI 10.1001/jama.255.15.2039; GILLUM RF, 1987, AM HEART J, V114, P1262, DOI 10.1016/0002-8703(87)90212-2; GOLDHABER SZ, 1982, AM J MED, V73, P822, DOI 10.1016/0002-9343(82)90764-1; GOLDHABER SZ, 1982, AM HEART J, V104, P305, DOI 10.1016/0002-8703(82)90207-1; HIRSH J, 1981, VENOUS THROMBOEMBOLI, P1; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; NICOLAIDES AN, 1975, THROMBOEMBOLISM AETI, P193; SEVITT S, 1959, LANCET, V2, P981; SIMON TL, 1974, CLIN ORTHOP RELAT R, V102, P181; 1985, SAS USERS GUIDE STAT; 1977, CIRCULATION, V55, P423; 1975, AMA HEIGHT WEIGHT TA	24	176	180	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					591	595		10.7326/0003-4819-591	http://dx.doi.org/10.7326/0003-4819-591			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892330				2022-12-28	WOS:A1991GJ90200002
J	MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD				MILNER, MR; HAWLEY, RJ; JACHIM, M; LINDSAY, J; FLETCHER, RD			VENTRICULAR LATE POTENTIALS IN MYOTONIC-DYSTROPHY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOTONIA DYSTROPHY; ELECTROCARDIOGRAPHY; VENTRICULAR LATE POTENTIALS; HEART CONDUCTION SYSTEM; ARRHYTHMIA	SIGNAL-AVERAGED ELECTROCARDIOGRAM; CARDIAC INVOLVEMENT; MUSCULAR-DYSTROPHY; CONDUCTION SYSTEM; NATURAL-HISTORY; SUDDEN-DEATH; TACHYCARDIA; DISEASE; ELECTROGRAMS; SURFACE	Objective: To determine the prevalence of ventricular late potentials, as determined by signal-averaged electrocardiography, in patients with myotonic dystrophy. Design: Cross sectional, with blinded analysis of all electrocardiographic data. Setting: Outpatient departments of a Veterans Affairs medical center and a tertiary care private hospital. Participants: Twenty-four patients with myotonic dystrophy. Patients were excluded from the study if they had either a history suggestive of significant ventricular arrhythmias or electrocardiographic evidence of a bundle-branch block. Two comparison groups were also formed; one group included 44 healthy employees at the tertiary hospital and the other, 30 cardiac patients with inducible ventricular tachycardia. Main Results: A time-domain analysis of the signal-averaged electrocardiograms showed that 75% of patients with myotonic dystrophy met one criterion for the presence of late potentials, 67% met two criteria, and 29% met all three criteria. Spectrotemporal mapping in these patients showed markedly abnormal spectral peaks with a mean factor of normality that was significantly lower than that of the normal volunteers; the frequency of electrocardiographic abnormalities approached that seen in patients with known ventricular tachycardia. The presence of late potentials correlated directly with the length of the PR interval and inversely with left ventricular fractional shortening. Conclusions: In our study, the prevalence of late potentials on signal-averaged electrocardiography in patients with myotonic dystrophy approached that seen in cardiac patients with inducible ventricular tachycardia. It is possible that ventricular arrhythmias play a role in the occurrence of sudden death in some patients with myotonic dystrophy.	GEORGETOWN UNIV, WASHINGTON HOSP CTR, VET AFFAIRS MED CTR, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20052 USA	Georgetown University; MedStar Washington Hospital Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University								BACIARELLO G, 1986, AM HEART J, V111, P413, DOI 10.1016/0002-8703(86)90162-6; CANNOM DS, 1984, J AM COLL CARDIOL, V4, P625, DOI 10.1016/S0735-1097(84)80112-6; DENNISS AR, 1987, AM J CARDIOL, V59, P586, DOI 10.1016/0002-9149(87)91174-X; GARDNER PI, 1985, CIRCULATION, V72, P596, DOI 10.1161/01.CIR.72.3.596; GOMES JA, 1987, J AM COLL CARDIOL, V10, P349; GRIGG LE, 1985, J AM COLL CARDIOL, V6, P254, DOI 10.1016/S0735-1097(85)80286-2; HABERL R, 1989, EUR HEART J, V10, P316, DOI 10.1093/oxfordjournals.eurheartj.a059488; HAWLEY RJ, 1991, NEUROLOGY, V41, P259, DOI 10.1212/WNL.41.2_Part_1.259; HIROMASA S, 1988, AM HEART J, V115, P914, DOI 10.1016/0002-8703(88)90901-5; KUCHAR DL, 1987, J AM COLL CARDIOL, V9, P531, DOI 10.1016/S0735-1097(87)80045-1; MELACINI P, 1988, CLIN CARDIOL, V11, P231, DOI 10.1002/clc.4960110407; MIELKE U, 1985, J NEUROL, V232, P271, DOI 10.1007/BF00313863; MILNER MR, 1989, CLIN RES, V37, pA280; MOTTA J, 1979, AM J MED, V67, P467, DOI 10.1016/0002-9343(79)90795-2; MUNSAT TL, 1967, NEUROLOGY, V17, P359, DOI 10.1212/WNL.17.4.359; NGUYEN HH, 1988, J AM COLL CARDIOL, V11, P662, DOI 10.1016/0735-1097(88)91547-1; OLOFSSON BO, 1988, BRIT HEART J, V59, P47; PERLOFF JK, 1984, AM J CARDIOL, V54, P1074, DOI 10.1016/S0002-9149(84)80147-2; PRYSTOWSKY EN, 1979, CIRCULATION, V60, P1360, DOI 10.1161/01.CIR.60.6.1360; RENAUD JF, 1987, BIOCHIMIE, V69, P407, DOI 10.1016/0300-9084(87)90032-0; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SIMSON MB, 1983, AM J CARDIOL, V51, P105, DOI 10.1016/S0002-9149(83)80020-4; STREIB EW, 1985, MUSCLE NERVE, V8, P650, DOI 10.1002/mus.880080804; WALTON JN, 1981, DISORDERS VOLUNTARY, P510	24	24	24	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					607	613		10.7326/0003-4819-115-8-607	http://dx.doi.org/10.7326/0003-4819-115-8-607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892332				2022-12-28	WOS:A1991GJ90200005
J	GRUNSTEIN, RR; HO, KY; SULLIVAN, CE				GRUNSTEIN, RR; HO, KY; SULLIVAN, CE			SLEEP-APNEA IN ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; SLEEP APNEA SYNDROMES; SOMATOTROPIN; INSULIN-LIKE GROWTH FACTOR-I; HYPERTENSION	EPIDEMIOLOGY; MORTALITY	Objective: To provide information on the nature, prevalence, and severity of sleep apnea in patients with acromegaly. Design: Consecutive case series. Setting: Tertiary referral hospital. Patients: Fifty-three patients with acromegaly were consecutively referred: 33 patients were referred because of clinical suspicion of sleep apnea and 20 patients were referred without suspected apnea. Measurements: Sleep studies as well as growth hormone and insulin-like growth factor 1 (IGF-1) measurements were done. Main Results: Thirty-one patients (93%; 95% Cl, 85% to 100%) referred because of suspicion of sleep apnea had sleep apnea compared with 12 patients (60%; Cl, 37% to 83%) referred without suspected sleep apnea. Patients with sleep apnea did not have biochemical evidence of increased disease activity (random growth hormone, 12.7 +/- 4.4-mu-g/L; mean growth hormone at 24-hour sampling, 10.8 +/- 8.4-mu-g/L; IGF-1, 90.0 +/- 7.5 nmol/L) compared with patients without sleep apnea (random growth hormone, 14.2 +/- 4.9-mu-g/L, P > 0.2; mean growth hormone, 12.4 +/- 3.5-mu-g/L, P > 0.2; IGF-1, 90.0 +/- 10.0 nmol/L, P > 0.2). Central sleep apnea was the predominant type of apnea in 33% (Cl, 18% to 47%) of patients and was associated with higher random growth hormone and IGF-1 levels than was obstructive apnea (random growth hormone, 23.4 +/- 3.9 compared with 8.8 +/- 3.1-mu-g/L, P < 0.001; IGF-1, 126 +/- 17.5 compared with 72.5 +/- 7.5 nmol/L, P < 0.01). Conclusions: Sleep apnea is common in acromegaly. The rate of central sleep apnea was unexpectedly high in patients with acromegaly, and biochemical evidence of increased disease activity was associated with the presence of central apnea rather than with the degree of sleep apnea. Altered respiratory control is a possible mechanism producing sleep apnea in acromegaly.	ST VINCENTS HOSP, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	GRUNSTEIN, RR (corresponding author), ROYAL PRINCE ALFRED HOSP, SLEEP DISORDERS CTR, MISSENDEN RD, SYDNEY, NSW 2050, AUSTRALIA.							ALEXANDER L, 1980, CLIN ENDOCRINOL, V12, P71, DOI 10.1111/j.1365-2265.1980.tb03135.x; BAXTER RC, 1982, CLIN CHEM, V28, P488; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; BENGTSSON BA, 1989, CLIN ENDOCRINOL, V30, P121, DOI 10.1111/j.1365-2265.1989.tb03733.x; BRADLEY TD, 1986, AM REV RESPIR DIS, V134, P217; CHAPPEL W, 1896, J LARYNGOL OTOL, V10, P142; DAUGHADAY WH, 1987, ACROMEGALY CENTURY S, P129; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HART TB, 1985, ARCH INTERN MED, V145, P865, DOI 10.1001/archinte.145.5.865; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; HEDNER J, 1988, J HYPERTENS, V6, pS529, DOI 10.1097/00004872-198812040-00166; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; KALIA M, 1984, BRAIN RES, V296, P339, DOI 10.1016/0006-8993(84)90070-2; KARLBERG BE, 1982, ACTA ENDOCRINOL-COP, V100, P581, DOI 10.1530/acta.0.1000581; LAROCHE C, 1976, ANN MED INTERNE, V127, P381; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; Marie P., 1986, REV MED LIEGE, V6, P297; MEZON BJ, 1980, AM J MED, V69, P615, DOI 10.1016/0002-9343(80)90477-5; PEKKARINEN T, 1987, CLIN ENDOCRINOL, V27, P649, DOI 10.1111/j.1365-2265.1987.tb02947.x; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; Phillipson E.A., 1989, AM REV RESPIR DIS, V139, P559, DOI 10.1164/ajrccm/139.2.559; ROXBURGH F, 1896, BRIT MED J, V2, P63; SHEPARD JW, 1989, PRINCIPLES PRACTICE, P537; Sullivan C, 1984, LUNG BIOL HLTH DIS S, V21, P299; SULLIVAN CE, 1985, CLIN CHEST MED, V6, P633; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; WHITE DP, 1989, PRINCIPLES PRACTICE, P513; WRIGHT AD, 1970, Q J MED, V39, P1	29	162	166	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					527	532		10.7326/0003-4819-115-7-527	http://dx.doi.org/10.7326/0003-4819-115-7-527			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883121				2022-12-28	WOS:A1991GG28300004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA ADOPTS COMMON FEDERAL-POLICY FOR PROTECTION OF HUMAN-SUBJECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P28023	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-28	WOS:A1991GE45800003
J	GERMAIN, RN; HENDRIX, LR				GERMAIN, RN; HENDRIX, LR			MHC CLASS-II STRUCTURE, OCCUPANCY AND SURFACE EXPRESSION DETERMINED BY POST-ENDOPLASMIC RETICULUM ANTIGEN-BINDING	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL ALLOANTIGENS; HLA-DR ANTIGENS; INVARIANT CHAIN; MONOCLONAL-ANTIBODIES; T-CELLS; IMMUNOGENIC PEPTIDES; IA ANTIGENS; MOLECULES; RECOGNITION	Class II major histocompatibility complex molecules undergo a change in structure upon stable binding of peptide antigen. Analysis of the site and extent of this change among class II molecules of splenic antigen-presenting cells reveals the preference of class II for peptide acquisition outside the endoplasmic reticulum and indicates that the class II presentation system is not saturated with self peptides. There are numerous empty class II molecules on the cell surface and peptide antigen is evidently important in regulating surface class II expression.			GERMAIN, RN (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019					BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, IN PRESS EUR J IMMUN; BILLING RJ, 1976, J IMMUNOL, V117, P1589; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; CULLEN SE, 1984, METHOD ENZYMOL, V108, P523; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1990, P NATL ACAD SCI USA, V87, P5553, DOI 10.1073/pnas.87.14.5553; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; HOLT GD, 1985, J IMMUNOL, V135, P399; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LEE JM, 1990, J IMMUNOL, V144, P1829; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LONG EO, 1989, IMMUNOL TODAY, V10, P232, DOI 10.1016/0167-5699(89)90259-4; LORENZ RG, 1990, J IMMUNOL, V144, P1600; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MACHAMER CE, 1984, P NATL ACAD SCI-BIOL, V81, P1287, DOI 10.1073/pnas.81.5.1287; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MURPHY DB, 1989, NATURE, V338, P76; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; RESKE K, 1985, EUR J IMMUNOL, V15, P1229, DOI 10.1002/eji.1830151216; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403; SOBEL RA, 1986, J IMMUNOL, V137, P2132; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; SRINIVASAN M, 1990, P NATL ACAD SCI USA, V87, P919, DOI 10.1073/pnas.87.3.919; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J	63	405	414	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					134	139		10.1038/353134a0	http://dx.doi.org/10.1038/353134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1891045				2022-12-28	WOS:A1991GE73100043
J	HAYWARD, RSA; ROCKWOOD, K; SHEEHAN, GJ; BASS, EB				HAYWARD, RSA; ROCKWOOD, K; SHEEHAN, GJ; BASS, EB			A PHENOMENOLOGY OF SCUT	ANNALS OF INTERNAL MEDICINE			English	Article						SCUT; INTERNSHIP AND RESIDENCY; FACULTY, MEDICAL; EDUCATION, MEDICAL; HOSPITALS, TEACHING	TIME; RESIDENTS; EDUCATION; PROGRAMS; SERVICE; STRESS; CALL	Objective: To identify, describe, and quantify the night-call duties that residents in internal medicine call "scutwork" and to compare faculty and residents' perceptions of scutwork. Design: Prospective, cross-sectional study. Setting: General internal medicine training program at a university-affiliated tertiary care hospital. Participants: Forty-eight residents who spent 3 months or more on an internal medicine teaching unit during the previous year and 41 faculty members who spent 2 months or more on one of these units. Interventions: Postcall surveys and night-call diaries were used to analyze residents' activities, to derive a definition of scutwork, and to estimate its prevalence. Residents and faculty then completed a detailed questionnaire that included ratings of the educational value, "scut content," and residents' responsibility for 20 specific tasks. Main Results: Eighty-three percent of residents found scutwork and education to be mutually exclusive for the 20 tasks, although 20% indicated that scutwork was an appropriate task for residents. Residents' ratings of tasks as scut varied according to the context of the task. For example, obtaining routine consent from someone else's patient was considered scutwork by 98% of residents, whereas obtaining such consent from the resident's own patient was rated as scutwork by only 52% (P < 0.01). Similarly, performing intravenous cannulation at the request of ward staff was rated as scut by 94% of residents, whereas performing cannulation at another resident's request was rated as scut by 56% (P < 0.01). Night-time admission of a patient for an elective procedure was rated as scut by 75% of residents, whereas admission of such a patient after discussion with a faculty member was labeled scut by only 44% (P < 0.01). Faculty ratings of such admissions did not show the same variation (24% for both). Faculty were more likely than residents to assess tasks as educational (50% compared with 26%, P < 0.01) but were less likely to consider tasks as scutwork (47% compared with 62%, P = 0.12) or as work that should be done by nonresidents (35% compared with 46%, P > 0.2). Conclusions: Our results suggest that the characteristics of scutwork can be identified, that the perception of scut varies between faculty and residents, and that the context of a task often determines whether residents perceive it as scut.	CAMP HILL MED CTR, DIV GERIATR MED, HALIFAX B3H 3G2, NS, CANADA; UNIV ALBERTA, WALTER C MACKENZIE HLTH SCI CTR, DEPT MED, DIV INTERNAL MED, EDMONTON T6G 2J7, ALBERTA, CANADA	Dalhousie University; University of Alberta	HAYWARD, RSA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DIV INTERNAL MED, ROOM 8042, 1830 E MONUMENT ST, BALTIMORE, MD 21205 USA.		Rockwood, Kenneth/AAD-8951-2019	Bass, Eric/0000-0001-9106-527X				ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; ASTILL JL, 1987, LANCET, V1, P1363; BUTTERFIELD PS, 1988, ARCH INTERN MED, V148, P1428, DOI 10.1001/archinte.148.6.1428; FREIBERG A, 1988, ANN ROYAL COLLEGE PH, V21, P415; GILLANDERS W, 1971, J MED EDUC, V46, P142; HARRELL RA, 1988, EFFECTIVE SCUTBOY; JAFFE BM, 1991, RESIDENT STAFF PHYSI, V37, P18; KATZ MH, 1988, NEW ENGL J MED, V319, P1585, DOI 10.1056/NEJM198812153192406; LURIE N, 1989, NEW ENGL J MED, V320, P1673, DOI 10.1056/NEJM198906223202507; MAUDSLEY RF, 1986, CAN MED ASSOC J, V135, P449; MEAGHER TW, 1988, CAN MED ASSOC J, V138, P705; PAYSON HE, 1961, NEW ENGL J MED, V264, P439, DOI 10.1056/NEJM196103022640906; SQUIRES BP, 1989, CAN MED ASSOC J, V140, P18; WALLACE EZ, 1988, ARCH INTERN MED, V148, P1296; WARNER BW, 1990, J SURG RES, V48, P606, DOI 10.1016/0022-4804(90)90239-X; 1987, RESPONSE NEW YORK ST	16	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					372	376		10.7326/0003-4819-115-5-372	http://dx.doi.org/10.7326/0003-4819-115-5-372			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863028				2022-12-28	WOS:A1991GC06500008
J	CROW, JF				CROW, JF			WAS WRIGHT RIGHT	SCIENCE			English	Editorial Material											CROW, JF (corresponding author), UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706, USA.							BARTON NH, IN PRESS EVOLUTION; CROW JF, 1990, EVOLUTION, V44, P233, DOI [10.2307/2409403, 10.1111/j.1558-5646.1990.tb05194.x]; Fisher R.A., 1930, GENETICAL THEORY NAT; Haldane J. B. S., 1959, DARWINS BIOL WORK SO, P101; Provine William B., 1986, S WRIGHT EVOLUTIONAR; WADE MJ, 1991, SCIENCE, V253, P1015, DOI 10.1126/science.1887214; WRIGHT S, 1988, AM NAT, V131, P115, DOI 10.1086/284777; Wright S, 1931, GENETICS, V16, P0097	8	12	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					973	973		10.1126/science.1887230	http://dx.doi.org/10.1126/science.1887230			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1887230				2022-12-28	WOS:A1991GC98200032
J	CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD				CHUTE, CG; CHUANG, TY; BERGSTRALH, EJ; SU, WPD			THE SUBSEQUENT RISK OF INTERNAL CANCER WITH BOWENS DISEASE - A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL CARCINOMA; MALIGNANCY; DERMATOMYOSITIS; ROCHESTER; MINNESOTA	Objective.-To address the subsequent risk of internal cancer in a population-based cohort of patients with Bowen's disease. Design.-Incident cases of skin cancers other than malignant melanoma occurring in a defined population were classified as basal cell carcinoma, squamous cell carcinoma, or Bowen's disease. Through medical records, all patients were followed up for the development of subsequent internal cancer until they died, moved from Rochester, Minn, or January 1, 1986, whichever came first. Incidence rates of skin cancer and subsequent cancer were computed; the subsequent rate of internal cancer was compared with that prevailing in the community Patients.-Enrolled were all permanent residents in the population base of Rochester, Minn, who developed basal cell carcinoma (n = 657), squamous cell carcinoma (n = 169), or Bowen's disease (n = 71) on the basis of pathologic examination and clinical presentation from 1976 through 1984. Main Outcome Measure.-The relative risk of subsequent internal cancer among patients with Bowen's disease compared with that of the population base from which they arose was 1.1 (95% confidence limits, 0.5, 1.6). Results.-Annual incidence rates, adjusted to the 1980 US white population, were 14.9 per 100 000 for Bowen's disease, 38.8 for squamous cell carcinoma, and 146 for basal cell carcinoma. The estimated relative risk for subsequent cancer was 0.9 (95% confidence limits, 0.5, 1.6) among patients with squamous cell carcinoma and 1.0 (95% confidence limits, 0.7, 1.3) for patients with basal cell carcinoma. These risks were not significantly different for various durations of follow-up or for sun-exposed vs sun-protected sites. Conclusions.-We find no evidence in these population-based cohort data of an increased risk of subsequent internal cancer associated with Bowen's disease or other forms of nonmelanomatous skin cancer.	WRIGHT STATE UNIV,DEPT DERMATOL,4100 W 3RD ST,BLDG 307,ROOM 128,DAYTON,OH 45428; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905	Wright State University Dayton; Mayo Clinic; Mayo Clinic					NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN SL, 1973, ARCH DERMATOL, V108, P367, DOI 10.1001/archderm.108.3.367; ARBESMAN H, 1987, JAMA-J AM MED ASSOC, V257, P516, DOI 10.1001/jama.257.4.516; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; CALLEN JP, 1980, ARCH DERMATOL, V116, P422, DOI 10.1001/archderm.116.4.422; CALLEN JP, 1988, ARCH DERMATOL, V124, P675, DOI 10.1001/archderm.124.5.675; CHUANG TY, 1988, J AM ACAD DERMATOL, V19, P47, DOI 10.1016/S0190-9622(88)70150-4; CHUANG TY, 1990, J AM ACAD DERMATOL, V22, P413, DOI 10.1016/0190-9622(90)70056-N; CHUANG TY, 1990, ARCH DERMATOL, V126, P185, DOI 10.1001/archderm.126.2.185; CHUANG TY, 1990, AM J PREV MED, V6, P238, DOI 10.1016/S0749-3797(18)31010-9; EEDY DJ, 1987, BRIT J DERMATOL, V117, P715, DOI 10.1111/j.1365-2133.1987.tb07351.x; EPSTEIN E, 1960, ARCH DERMATOL, V80, P349; GRAHAM JH, 1959, ARCH DERMATOL, V80, P133, DOI 10.1001/archderm.1959.01560200001001; GRAHAM JH, 1961, ARCH DERMATOL, V83, P738, DOI 10.1001/archderm.1961.01580110026004; HAYNES HA, 1983, HARRISONS PRINCIPLES, P829; HUGO NE, 1967, PLAST RECONSTR SURG, V39, P190, DOI 10.1097/00006534-196702000-00011; ISSELBACHER KJ, 1980, HARRISONS PRINCIPLES, V1, P802; JOHNSON ML, 1982, CECIL TXB MED, P1029; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; KURLAND LT, 1973, USES EPIDEMIOLOGY PL, P164; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; MARFING TE, 1987, DIS COLON RECTUM, V30, P782, DOI 10.1007/BF02554627; MIKI Y, 1982, J AM ACAD DERMATOL, V6, P26, DOI 10.1016/S0190-9622(82)70003-9; MYERS M, 1980, NIH802044 PUBL, P53; PETERKA ES, 1961, ARCH DERMATOL, V84, P623, DOI 10.1001/archderm.1961.01580160087015; RAGOZZINO MW, 1982, NEW ENGL J MED, V307, P393, DOI 10.1056/NEJM198208123070701; RAGOZZINO MW, 1984, MAYO CLIN P, V59, P720; REES JL, 1988, BRIT J DERMATOL, V119, P113; REYMANN F, 1988, ARCH DERMATOL, V124, P677, DOI 10.1001/archderm.124.5.677; SCHROEDER DJ, 1982, MAYO CLIN TECH REP S; Stone J L, 1986, Hawaii Med J, V45, P281; THESTRUPPEDERSEN K, 1988, ACTA DERM-VENEREOL, V68, P236	32	55	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					816	819		10.1001/jama.266.6.816	http://dx.doi.org/10.1001/jama.266.6.816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865520				2022-12-28	WOS:A1991GA07300033
J	GALLOWAY, RF				GALLOWAY, RF			HOUSE CALLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					786	786						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865515				2022-12-28	WOS:A1991GA07300014
J	LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB				LUISI, BF; XU, WX; OTWINOWSKI, Z; FREEDMAN, LP; YAMAMOTO, KR; SIGLER, PB			CRYSTALLOGRAPHIC ANALYSIS OF THE INTERACTION OF THE GLUCOCORTICOID RECEPTOR WITH DNA	NATURE			English	Article							TRANSCRIPTION FACTOR-IIIA; STEROID-HORMONE RECEPTOR; TARGET GENE SPECIFICITY; ZINC-BINDING DOMAINS; MAMMARY-TUMOR VIRUS; CRYSTAL-STRUCTURE; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; AMINO-ACIDS; RESOLUTION	Two crystal structures of the glucocorticoid receptor DNA-binding domain complexed with DNA are reported. The domain has a globular fold which contains two Zn-nucleated substructures of distinct conformation and function. When it binds DNA, the domain dimerizes, placing the subunits in adjacent major grooves. In one complex, the DNA has the symmetrical consensus target sequence; in the second, the central spacing between the target's half-sites is larger by one base pair. This results in one subunit interacting specifically with the consensus target half-site and the other nonspecifically with a noncognate element. The DNA-induced dimer fixes the separation of the subunits' recognition surfaces so that the spacing between the half-sites becomes a critical feature of the target sequence's identity.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Yale University; Howard Hughes Medical Institute; Yale University; University of California System; University of California San Francisco			Otwinowski, Zbyszek/F-3665-2011	Otwinowski, Zbyszek/0000-0003-3640-8545				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P274; BRUNGER AT, 1988, CRYSTALLOGRAPHIC COM, V4; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FREEDMAN LP, 1988, CELL, V54, P444, DOI 10.1016/0092-8674(88)90063-3; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SAENGER W, 1984, PRINCIPLES NUCLEIC A, V120; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHEVITZ RW, 1981, ACTA CRYSTALLOGR A, V37, P669, DOI 10.1107/S0567739481001526; SCHULTZ S, IN PRESS SCIENCE; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SOMERS WA, 1991, THESIS U LEEDS; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	55	1273	1292	0	50	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					497	505		10.1038/352497a0	http://dx.doi.org/10.1038/352497a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865905				2022-12-28	WOS:A1991GA22600052
J	FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR				FERGUSON, CJ; WILLIAMS, JD; SILVER, A; WOODHEAD, JS; SALAMAN, JR			EFFECTS OF PARATHYROID-HORMONE ON DELAYED RENAL-ALLOGRAFT FUNCTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT MED BIOCHEM,CARDIFF CF4 4XN,S GLAM,WALES; CARDIFF ROYAL INFIRM,INST NEPHROL,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff University; Cardiff Royal Infirmary	FERGUSON, CJ (corresponding author), CARDIFF ROYAL INFIRM,DEPT SURG,CARDIFF CF2 1SZ,S GLAM,WALES.							BROWN RC, 1987, J CLIN ENDOCR METAB, V65, P407, DOI 10.1210/jcem-65-3-407; CHARBON GA, 1974, ENDOCRINOLOGY, V95, P621, DOI 10.1210/endo-95-2-621; ELLISON DH, 1984, AM J PHYSIOL, V246, pF551, DOI 10.1152/ajprenal.1984.246.5.F551; PANG PKT, 1983, ENDOCRINOLOGY, V112, P284, DOI 10.1210/endo-112-1-284; VARGHESE Z, 1988, BRIT MED J, V296, P393, DOI 10.1136/bmj.296.6619.393	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					287	288		10.1136/bmj.303.6797.287	http://dx.doi.org/10.1136/bmj.303.6797.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888930	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100022
J	MARTIN, E; RUSSELL, D; GOODWIN, S; CHAPMAN, R; NORTH, M; SHERIDAN, P				MARTIN, E; RUSSELL, D; GOODWIN, S; CHAPMAN, R; NORTH, M; SHERIDAN, P			WHY PATIENTS CONSULT AND WHAT HAPPENS WHEN THEY DO	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study patients' perceptions of why they consulted the doctor, how ill they thought they were, and what happened in the consultation. To compare patients' perceptions before and after the consultation and to compare these perceptions with those of the doctor. Design-Patients filled in a questionnaire before and after the consultation. The doctor filled a questionnaire in after the consultation. Setting-Three general practices in Bedfordshire and one in Hertfordshire. Patients-500 consecutive patients consulting in each practice. Main outcome measures-Changes in patients' perceptions and differences between the perceptions of patients and doctors. Results-Doctors perceived patients to be less ill than the patients themselves did. Patients from social classes IV and V and children perceived themselves to be more ill than the average. Patients perceived themselves to be less ill after the consultation. A third of patients attended because doctors had told them to, and a quarter of patients had already tried to treat their problem themselves when they attended the consultation. Doctors' perceptions of the consultation emphasised listening, supporting, and giving advice. Patients' perceptions emphasised prescribing, reassuring, and referring to a consultant. Doctors perceived that they listened, examined, and gave advice less to social classes IV and V than to social classes I, II, and III and gave explanations more often to men than to women. Patients perceived external factors rather than lifestyle factors as being more important in causing their problems. Conclusion-Doctors' perceptions of patients' problems differed from those of patients expressed both before and after their consultation. Doctors' and patients' perceptions also differed about the consultation itself. The consultation reassured some patients.	UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen								ALJUMAIL S, 1983, UPDATE, V27, P959; BELSON W, 1962, APPL STAT, V11, P120; BRETT AS, 1982, J FAM PRACTICE, V15, P277; COULTER A, 1987, J ROY COLL GEN PRACT, V37, P533; JOHNSON SM, 1978, J FAM PRACTICE, V6, P855; MCWHINNEY IR, 1983, FAM PRACT, V1, P3; Stewart M A, 1975, J Fam Pract, V2, P411; Walker R D, 1982, J R Coll Gen Pract, V32, P163; ZOLA IK, 1973, SOC SCI MED, V7, P677, DOI 10.1016/0037-7856(73)90002-4	9	50	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					289	292		10.1136/bmj.303.6797.289	http://dx.doi.org/10.1136/bmj.303.6797.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888932	Bronze, Green Published			2022-12-28	WOS:A1991FZ72100024
J	COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ				COBBE, SM; REDMOND, MJ; WATSON, JM; HOLLINGWORTH, J; CARRINGTON, DJ			HEARTSTART SCOTLAND - INITIAL EXPERIENCE OF A NATIONAL SCHEME FOR OUT OF HOSPITAL DEFIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY MEDICAL TECHNICIANS; AUTOMATIC EXTERNAL DEFIBRILLATOR; CARDIAC-ARREST; CLINICAL-EXPERIENCE; MANAGEMENT; RESUSCITATION; CARE	Objective - To determine the outcome of out of hospital defibrillation in Scotland during the year after the introduction of automated external defibrillators in October 1988. Design - Retrospective analysis of ambulance service reports and hospital records. Setting - Scottish Ambulance Service and acute receiving hospitals throughout Scotland. Main outcome measures - Delay from cardiac arrest to first defibrillator shock; vital state on arrival at hospital accident and emergency department; survival to hospital discharge. Results - During the study period 268 defibrillators were purchased by public subscription and 96% of the 2000 ambulance crew underwent an eight hour training programme in cardiopulmonary resuscitation and defibrillation. A total of 1111 cardiac arrests were recorded, and defibrillation was indicated and undertaken in 602 (54%) patients, mean age 63 (range 14-92) years. A spontaneous pulse was present on arrival at hospital in 180 (30%) of the defibrillated patients, and 75 (12.5%) were subsequently discharged alive. As expected, the likelihood of survival was inversely related to the delay from the onset of cardiac arrest to the time of the first shock and was greater in the case of witnessed arrest. If ventricular fibrillation occurred after the arrival of the ambulance, survival to discharge was 33%. Conclusions - An effective scheme for out of hospital defibrillation can be introduced rapidly, and with limited training implications and costs, by the use of automated external defibrillators in ambulances.	FIFE LOTHIAN & BORDERS SCOTTISH AMBULANCE SERV,EDINBURGH EH10 5SA,SCOTLAND		COBBE, SM (corresponding author), ROYAL INFIRM,DEPT MED CARDIOL,GLASGOW G31 2ER,SCOTLAND.							ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BEAGLEHOLE R, 1986, BMJ-BRIT MED J, V292, P33, DOI 10.1136/bmj.292.6512.33; COBB LA, 1986, MANAGEMENT ACUTE COR, P105; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1989, ANN EMERG MED, V18, P1269, DOI 10.1016/S0196-0644(89)80257-4; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1982, NEW ENGL J MED, V306, P1340, DOI 10.1056/NEJM198206033062206; GRAY AJ, 1987, BMJ, V295, P1133; HAMPTON JR, 1978, BRIT MED J, V1, P1118, DOI 10.1136/bmj.1.6120.1118; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P123; MACKINTOSH AF, 1978, BRIT MED J, V1, P1115, DOI 10.1136/bmj.1.6120.1115; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; VUKOV LF, 1988, ANN EMERG MED, V17, P318, DOI 10.1016/S0196-0644(88)80771-6; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; 1990, 1989 GEN REG OFF ANN; 1976, HN76204 DHSS DEP HLT; 1987, EXTENDED TRAINING AM; 1984, DA8412 DHSS DEP HLTH	25	78	78	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1517	1520		10.1136/bmj.302.6791.1517	http://dx.doi.org/10.1136/bmj.302.6791.1517			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855025	Bronze, Green Published			2022-12-28	WOS:A1991FT50500028
J	JACOBS, LGH; BARTON, MAJ; WALLACE, WA; FERROUSIS, J; DUNN, NA; BOSSINGHAM, DH				JACOBS, LGH; BARTON, MAJ; WALLACE, WA; FERROUSIS, J; DUNN, NA; BOSSINGHAM, DH			INTRAARTICULAR DISTENSION AND STEROIDS IN THE MANAGEMENT OF CAPSULITIS OF THE SHOULDER	BRITISH MEDICAL JOURNAL			English	Article							FROZEN SHOULDER; NATURAL-HISTORY	Objective - To determine whether there is any synergistic effect in the administration of intra-articular steroids with distension in the management of early capsulitis of the shoulder. Design - Prospective randomised trial of three treatments - namely distension only, steroid only, and steroid with distension. Setting - Academic department of orthopaedic and accident surgery at Queen's Medical Centre, Nottingham. Subjects - 47 patients (30 women) with capsulitis affecting 50 shoulders. Interventions - Three intra-articular injections into the shoulder given at six week intervals by the same technique. Main outcome measures - Passive range of abduction, forward flexion, and external rotation; results of shoulder dynamometry measuring work done and torque produced; pain levels at rest and with resisted movement. Results - All patients reported improvement during the study. Analysis of the mean improvements in abduction and forward flexion showed these to be significantly greater in the steroid with distension and steroid only groups than in the distension only group (mean improvements in abduction (degrees/week (95% confidence interval)) 4.3 (3.4 to 5.2), 3.4 (2.4 to 4.5), and 1.0 (-0.8 to 2.8) in the three groups respectively; mean improvements in flexion (degrees/week (95% confidence interval)) 3.6 (3.2 to 4.0), 3.3 (2.3 to 4.3), and 1.5 (0.5 to 2.5) respectively). Shoulder dynamometry failed to show a significant difference among the treatment groups. No severe complications occurred as a result of the injections, but two patients reported facial flushing related to the use of steroids. Conclusion - Intra-articular steroid injections have a useful role in the outpatient management of early capsulitis.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT ORTHOPAED & ACCID SURG,NOTTINGHAM NG7 2UH,ENGLAND; CITY HOSP NOTTINGHAM,DEPT RHEUMATOL,NOTTINGHAM NG5 1PD,ENGLAND	University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital								ANDREN L, 1965, ACTA ORTHOP SCAND, V36, P45, DOI 10.3109/17453676508989370; BARTON MAJ, 1986, PROGR REPORTS ELECTR, P185; BASSEY EJ, 1989, EUR J APPL PHYSIOL O, V58, P353, DOI 10.1007/BF00643509; BAYLEY JIL, 1988, SHOULDER, P118; BINDER AI, 1984, ANN RHEUM DIS, V43, P361, DOI 10.1136/ard.43.3.361; BULGEN DY, 1984, ANN RHEUM DIS, V43, P353, DOI 10.1136/ard.43.3.353; Codman EA, 1934, SHOULDER; CYRIAX J, 1977, TXB ORTHOPAEDIC MED, V2, P164; CYRIAX J, 1975, TXB ORTHOPAEDIC MED, V1, P229; DACRE JE, 1989, ANN RHEUM DIS, V48, P322, DOI 10.1136/ard.48.4.322; Duplay, 1872, ARCH GEN MED, V20, P513; Fareed DO, 1989, CLIN ORTHOP RELAT R, V242, P177; Germain N W, 1983, Am Correct Ther J, V37, P156; GREY RG, 1978, J BONE JOINT SURG AM, V60, P564; Haines J F, 1982, J R Coll Surg Edinb, V27, P271; LEE PN, 1974, ANN RHEUM DIS, V33, P116, DOI 10.1136/ard.33.2.116; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MURNAGHAN GF, 1955, LANCET, V2, P798; OLDER MWJ, 1982, SHOULDER SURG, P123; PATTRICK M, 1987, BRIT MED J, V295, P1380, DOI 10.1136/bmj.295.6610.1380; REEVES B, 1975, SCAND J RHEUMATOL, V4, P193, DOI 10.3109/03009747509165255; ROBINSON ND, 1987, THESIS U NOTTINGHAM; Rowe C., 1988, SHOULDER, P155; SIMMONDS FA, 1949, J BONE JOINT SURG BR, V31, P426, DOI 10.1302/0301-620X.31B3.426; WALLACE WA, 1987, 3RD P INT C SURG SHO, P204; 1985, LANCET, V1, P87; 1985, NZ MED J, V98, P1039	27	67	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 22	1991	302	6791					1498	1501		10.1136/bmj.302.6791.1498	http://dx.doi.org/10.1136/bmj.302.6791.1498			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855018	Green Published, Bronze			2022-12-28	WOS:A1991FT50500020
J	REAGAN, DR; DOEBBELING, BN; PFALLER, MA; SHEETZ, CT; HOUSTON, AK; HOLLIS, RJ; WENZEL, RP				REAGAN, DR; DOEBBELING, BN; PFALLER, MA; SHEETZ, CT; HOUSTON, AK; HOLLIS, RJ; WENZEL, RP			ELIMINATION OF COINCIDENT STAPHYLOCOCCUS-AUREUS NASAL AND HAND CARRIAGE WITH INTRANASAL APPLICATION OF MUPIROCIN CALCIUM OINTMENT	ANNALS OF INTERNAL MEDICINE			English	Article							PSEUDOMONIC ACID; HEMODIALYSIS-PATIENTS; TOPICAL MUPIROCIN; RESISTANT; INFECTIONS; COLONIZATION; CARRIERS; RIFAMPIN; OUTBREAK; CIPROFLOXACIN	Objective: To determine the safety and efficacy of mupirocin calcium ointment in the elimination of Staphylococcus aureus nasal and hand carriage in healthy persons. Design: A double-blind, placebo-controlled, randomized trial. Setting: Clinical research unit of a tertiary medical center. Subjects: Health care workers with stable S. aureus nasal carriage. Interventions: Subjects (n = 68) were randomly assigned to receive either mupirocin or placebo intranasally twice daily for 5 days. Measurements and Main Results: Cultures of the hands and nares were obtained at baseline and 72 hours after therapy. The nares were also cultured 1, 2, 4, and 12 weeks after therapy. Antimicrobial susceptibility testing and restriction endonuclease analysis of plasmid DNA were used to confirm strain identity. There were no serious side effects. Mupirocin decreased the frequency of S. aureus nasal carriage at each time interval: At 3 months, 71% of subjects receiving mupirocin remained free of nasal S. aureus compared with 18% of controls. This difference (53%; 95% CI, 26% to 80%) was significant (P < 0.0001). Additionally, analysis of plasmid patterns showed that 79% of subjects in the mupirocin group were free of the initial colonizing strain at 3 months. The proportion of hand cultures positive for S. aureus in the mupirocin group after therapy was lower than in the placebo group (2.9% compared with 57.6%). This difference (53%; 95 CI, 30% to 80%) was significant, after adjustment for the frequency of hand carriage at baseline (P < 0.0001). Conclusions: When applied intranasally for 5 days, mupirocin calcium ointment is safe and effective in eliminating S. aureus nasal carriage in healthy persons for up to 3 months and appears to have a corresponding effect on hand carriage at 72 hours after therapy.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, C-41GH, IOWA CITY, IA 52242 USA; DEPT VET AFFAIRS MED CTR, IOWA CITY, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System			Doebbeling, Bradley/C-6620-2009; Doebbeling, Bradley/AAC-1063-2022; Doebbeling, Bradley/L-9155-2019	Doebbeling, Bradley/0000-0003-3504-3468; 	NCRR NIH HHS [RR59] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AEILTS GD, 1982, J CLIN MICROBIOL, V16, P218, DOI 10.1128/JCM.16.2.218-223.1982; ARROYO JC, 1982, AM J MED, V72, P112, DOI 10.1016/0002-9343(82)90595-2; BAIRD D, 1987, LANCET, V2, P387; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; BOELAERT JR, 1989, NEPHROL DIAL TRANSPL, V4, P278, DOI 10.1093/oxfordjournals.ndt.a091872; BORIS M, 1964, AM J DIS CHILD, V108, P252, DOI 10.1001/archpedi.1964.02090010254006; BRYAN CS, 1980, INFECT CONT HOSP EP, V1, P153, DOI 10.1017/S0195941700052875; CASEWELL MW, 1987, J ANTIMICROB CHEMOTH, V19, P1, DOI 10.1093/jac/19.1.1; CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V17, P365, DOI 10.1093/jac/17.3.365; CHOW JW, 1989, ARCH INTERN MED, V149, P1258, DOI 10.1001/archinte.149.6.1258; CZARLINSKY DK, 1979, AM J EPIDEMIOL, V109, P218, DOI 10.1093/oxfordjournals.aje.a112676; DACRE J, 1986, J HOSP INFECT, V7, P130, DOI 10.1016/0195-6701(86)90055-1; DAVIES EA, 1987, J HOSP INFECT, V10, P120, DOI 10.1016/0195-6701(87)90137-X; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; DRUTZ DJ, 1966, NEW ENGL J MED, V275, P1161, DOI 10.1056/NEJM196611242752104; DUCKWORTH GJ, 1988, J HOSP INFECT, V11, P1, DOI 10.1016/0195-6701(88)90034-5; ELLISON RT, 1984, WESTERN J MED, V140, P735; FRANK U, 1989, J HOSP INFECT, V13, P117, DOI 10.1016/0195-6701(89)90017-0; GOULD J. C., 1955, JOUR HYG, V53, P379; Horan T., 1988, Antimicrobic Newsletter, V5, P65, DOI 10.1016/0738-1751(88)90027-5; KAVI J, 1987, LANCET, V2, P1472; LIGHT IJ, 1967, AM J DIS CHILD, V113, P291, DOI 10.1001/archpedi.1967.02090180051001; MCANALLY TP, 1984, ANTIMICROB AGENTS CH, V25, P422, DOI 10.1128/AAC.25.4.422; Miles AA, 1944, J PATHOL BACTERIOL, V56, P513, DOI 10.1002/path.1700560405; MULLIGAN ME, 1987, AM J MED, V82, P215; NAHAIE MR, 1984, J MICROBIOL METH, V2, P73, DOI 10.1016/0167-7012(84)90032-0; NOBLE WC, 1988, J ANTIMICROB CHEMOTH, V22, P771, DOI 10.1093/jac/22.5.771-a; RAHMAN M, 1989, EPIDEMIOL INFECT, V102, P261, DOI 10.1017/S0950268800029939; ROCCAFORTE JS, 1988, AM J INFECT CONTROL, V16, P141, DOI 10.1016/0196-6553(88)90024-7; SANDE MA, 1975, ANTIMICROB AGENTS CH, V7, P294, DOI 10.1128/AAC.7.3.294; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1437, DOI 10.1056/NEJM198405313102206; SMITH GE, 1988, J ANTIMICROB CHEMOTH, V21, P141, DOI 10.1093/jac/21.1.141; SMITH SM, 1988, INFECTION, V16, P95, DOI 10.1007/BF01644311; SMITH SM, 1989, ANTIMICROB AGENTS CH, V33, P181, DOI 10.1128/AAC.33.2.181; WACHSMUTH K, 1986, REV INFECT DIS, V8, P682; WHEAT LJ, 1981, J INFECT DIS, V144, P177, DOI 10.1093/infdis/144.2.177; WHEAT LJ, 1984, AM J MED, V76, P187, DOI 10.1016/0002-9343(84)90263-8; WHITE A, 1964, AM J MED SCI, V248, P52, DOI 10.1097/00000441-196407000-00008; WILLIAMS JD, 1967, LANCET, V2, P390; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963; YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204; ZIERDT CH, 1982, J CLIN MICROBIOL, V16, P517, DOI 10.1128/JCM.16.3.517-520.1982; 1988, ANTIMICROB NEWSLET, V5, P11	43	242	246	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1991	114	2					101	106		10.7326/0003-4819-114-2-101	http://dx.doi.org/10.7326/0003-4819-114-2-101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ER534	1898585				2022-12-28	WOS:A1991ER53400001
J	GRECO, PJ; SCHULMAN, KA; LAVIZZOMOUREY, R; HANSENFLASCHEN, J				GRECO, PJ; SCHULMAN, KA; LAVIZZOMOUREY, R; HANSENFLASCHEN, J			THE PATIENT SELF-DETERMINATION ACT AND THE FUTURE OF ADVANCE DIRECTIVES	ANNALS OF INTERNAL MEDICINE			English	Article						ADVANCE DIRECTIVES; LIVING WILLS; PATIENT PARTICIPATION; LIFE SUPPORT CARE; ETHICS	NOT-RESUSCITATE ORDERS; CRITICALLY ILL; DECISIONS; CARE	Living wills and other advance directives currently play a limited role in medical decision making. A new federal law, the Patient Self-Determination Act, will require health care providers in hospitals, nursing homes, and other facilities to inquire about the presence of advance directives, to record patient preferences in the medical record, and to develop institutional policies regarding the implementation of these directives. Unfortunately, the law does little to promote discussion or preparation of advance directives before hospitalization. Additional efforts to promote the use of advance directives can take place in the outpatient medical care system, in attorneys' offices, or through health insurers. Because most people have not yet prepared an advance directive, we suggest that institutions develop treatment policies for situations in which the wishes of patients who lack decisional capacity are not known. These policies should be designed to promote the patients' best interests, as defined by the consensus of the institutions' staff and members of the surrounding community.	HOSP UNIV PENN, DIV CARDIOVASC PULM, 894 MALONEY BLDG, 3600 SPRUCE ST, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine				Hansen-Flaschen, John/0000-0003-1989-7244	NIA NIH HHS [K08AG0036704] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arnett R H 3rd, 1990, Health Care Financ Rev, V11, P1; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BERGMAN AB, 1990, AM J DIS CHILD, V144, P727, DOI 10.1001/archpedi.1990.02150300127033; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; CAPRON AM, 1990, HASTINGS CENT REP, V20, P35, DOI 10.2307/3562537; CRANFORD RE, 1988, HASTINGS CENT REP, V18, P27, DOI 10.2307/3562014; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; EMANUEL EJ, 1987, HASTINGS CENT REP, V17, P15, DOI 10.2307/3562665; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FLAY BR, 1987, AM J PUBLIC HEALTH, V77, P153, DOI 10.2105/AJPH.77.2.153; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; LEVY MR, 1984, WESTERN J MED, V140, P111; LEWIS T, 1990, NY TIMES        1227, P15; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; LO B, 1985, ARCH INTERN MED, V145, P1115, DOI 10.1001/archinte.145.6.1115; ROSEN JM, 1990, NY TIMES        0818, P34; ROWLAND M, 1990, NY TIMES        1111, P17; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; STEIBER SR, 1987, HOSPITALS, V61, P72; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; VANMCCRARY S, 1989, JAMA-J AM MED ASSOC, V262, P2411, DOI 10.1001/jama.1989.03430170073031; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; 1982, MAKING HLTH CARE DEC, P217; 1990, NY TIMES        0626, P18; 1988, AM MED NEWS     0603, P9; 1990, STATISTICAL ABSTRACT, P100; 1987, HDB LIVING WILL LAWS, P5; 1983, RECIDING FOREGO LIFE, P17; 1983, DECIDING FOREGO LIFE, P132	34	139	141	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1991	115	8					639	643		10.7326/0003-4819-115-8-639	http://dx.doi.org/10.7326/0003-4819-115-8-639			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GJ902	1892335				2022-12-28	WOS:A1991GJ90200009
J	STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E				STANLEY, SL; JACKSON, TFHG; REED, SL; CALDERON, J; KUNZJENKINS, C; GATHIRAM, V; LI, E			SERODIAGNOSIS OF INVASIVE AMEBIASIS USING A RECOMBINANT ENTAMOEBA-HISTOLYTICA PROTEIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ANTIBODY RESPONSE; ZYMODEMES; ANTIGEN	One hundred eight serum samples from 106 patients were examined by Western blot analysis for the presence of antibodies to a recombinant fusion protein containing the sequence of the newly described serine-rich Entamoeba histolytica protein (SREHP). Among patients with invasive amebiasis from Durban, Republic of South Africa; San Diego, Calif; Mexico City, Mexico; and St Louis, Mo, 53 (82%) of 65 had antibodies to SREHP. In contrast, only one patient (2%) of 43 without acute invasive amebiasis had antibodies to SREHP. The predictive value of a positive test for anti-SREHP antibodies in the detection of acute invasive amebiasis was most marked when analyzed in the patients from Durban, where 11 (92%) of 12 patients who were seropositive for SREHP had acute invasive amebiasis vs 17 (65%) of 26 patients who had a positive serologic diagnosis as determined by agar gel diffusion. The use of a serologic test based on the recombinant SREHP fusion protein may be a useful adjunct to the diagnosis of acute invasive amebiasis in endemic regions.	S AFRICAN MRC,DIS TROP ENVIRONM RES INST,DURBAN,SOUTH AFRICA; NATL POLYTECH INST,CTR INVEST & ESTUDIOS AVANZADOS,MEXICO CITY 14,DF,MEXICO; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOCHEM & BIOPHYS,ST LOUIS,MO 63110; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103	South African Medical Research Council; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Diego; University of California System; University of California San Diego	STANLEY, SL (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,BOX 8051,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							GATHIRAM V, 1985, LANCET, V1, P719; JACKSON TFHG, 1985, LANCET, V1, P716; JACKSON TFHG, 1984, T ROY SOC TROP MED H, V78, P342, DOI 10.1016/0035-9203(84)90115-9; JUNIPER K, 1972, AM J TROP MED HYG, V21, P157, DOI 10.4269/ajtmh.1972.21.157; KRUPP IM, 1970, AM J TROP MED HYG, V19, P57, DOI 10.4269/ajtmh.1970.19.57; KRUPP IM, 1971, AM J TROP MED HYG, V20, P421, DOI 10.4269/ajtmh.1971.20.421; LOBEL HO, 1978, ANNU REV MICROBIOL, V32, P329, DOI 10.1146/annurev.mi.32.100178.001553; STANLEY SL, 1990, P NATL ACAD SCI USA, V87, P4976, DOI 10.1073/pnas.87.13.4976; TORIAN BE, 1989, J INFECT DIS, V159, P794, DOI 10.1093/infdis/159.4.794; Walsh J.A., 1988, P93	10	39	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1984	1986		10.1001/jama.266.14.1984	http://dx.doi.org/10.1001/jama.266.14.1984			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895478				2022-12-28	WOS:A1991GH40600026
J	MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H				MAKITA, Z; RADOFF, S; RAYFIELD, EJ; YANG, Z; SKOLNIK, E; DELANEY, V; FRIEDMAN, EA; CERAMI, A; VLASSARA, H			ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS WITH DIABETIC NEPHROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOSE-MODIFIED PROTEINS; SURFACE BINDING-PROTEIN; CHRONIC-HEMODIALYSIS; HUMAN COLLAGEN; COMPLICATIONS; RECEPTOR; MELLITUS; DISEASE; TISSUE; BETA-2-MICROGLOBULIN	Background. Glucose reacts nonenzymatically with proteins in vivo, chemically forming covalently attached glucose-addition products and cross-links between proteins. The excessive accumulation of rearranged late-glucose-addition products, or advanced glycosylation end products (AGEs), is believed to contribute to the chronic complications of diabetes mellitus. Methods. To elucidate the relation of AGEs to diabetic complications, we used a radioreceptor assay to measure serum and tissue AGEs in diabetic (Types I and II) and nondiabetic patients with different levels of renal function. Serum AGEs were measured as a low-molecular-weight (less-than-or-equal-to 10 kd) peptide fraction and a high-molecular-weight (> 10 kd) protein fraction. Results. The mean (+/- SD) AGE content of samples of arterial-wall collagen from 9 diabetic patients was significantly higher than that of samples from 18 nondiabetic patients (14.5 +/- 5.2 vs. 3.6 +/- 1.5 AGE units per milligram, P < 0.001). Moreover, diabetic patients with end-stage renal disease had almost twice as much AGE in tissue as diabetic patients without renal disease (21.3 +/- 2.8 vs. 11.5 +/- 1.9 AGE units per milligram, P < 0.001). The AGE levels in both serum fractions were elevated in the patients with-diabetes, and the levels of AGE peptides correlated directly with serum creatinine (P < 0.001) and inversely with creatinine clearance (P < 0.005), suggesting that levels of AGE peptides increased with the severity of diabetic nephropathy. In six patients with diabetes who required hemodialysis, the levels of AGE peptides were five times higher than in eight normal subjects (82.8 +/- 9.4 vs. 15.6 +/- 3.4 AGE units per milliliter, P < 0.001). In another group of diabetic patients, the mean serum creatinine level decreased by 75 percent during a session of hemodialysis, whereas the level of AGE peptides decreased by only 24 percent. Serum levels of AGE peptides were normal in two patients with normal serum creatinine levels after renal transplantation. Conclusions. AGEs accumulate at a faster-than-normal rate in arteries and the circulation of patients with diabetes; the increase in circulating AGE peptides parallels the severity of renal functional impairment in diabetic nephropathy.	SUNY DOWNSTATE MED CTR HOSP, DEPT MED, DIV RENAL DISEASES, NEW YORK, NY USA; ROCKEFELLER UNIV, MED BIOCHEM LAB, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008245, R01AG006943] Funding Source: NIH RePORTER; NIA NIH HHS [AG6943, AG8245] Funding Source: Medline; NIDDK NIH HHS [DK19655] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABB AL, 1971, T AM SOC ART INT ORG, V17, P81; BERGSTROM J, 1986, REPLACEMENT RENAL FU, P354; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN M, 1989, J BIOL CHEM, V264, P20947; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CERAMI A, 1987, SCI AM, V256, P90, DOI 10.1038/scientificamerican0587-90; DAVIS JE, 1978, DIABETES, V27, P102, DOI 10.2337/diabetes.27.2.102; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; FARMAR JG, 1988, J ORG CHEM, V53, P2346, DOI 10.1021/jo00245a039; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, KIDNEY INT, V30, P385, DOI 10.1038/ki.1986.196; GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HAMMER C, 1988, COMP BIOCHEM PHYS B, V90, P7, DOI 10.1016/0305-0491(88)90030-2; JACOBS C, 1981, P EUR DIAL TRANS, V18, P4; JEBSEN RH, 1967, NEW ENGL J MED, V277, P327, DOI 10.1056/NEJM196708172770702; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; MAKITA Z, 1990, DIABETES S, V39, pA29; MERIMEE TJ, 1990, NEW ENGL J MED, V322, P978, DOI 10.1056/NEJM199004053221406; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1988, DIABETES, V37, P867, DOI 10.2337/diabetes.37.7.867; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; NAKAYAMA H, 1987, J IMMUNOL METHODS, V99, P95; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; RADOFF S, 1990, DIABETES, V39, P1510, DOI 10.2337/diabetes.39.12.1510; RADOFF S, 1988, ARCH BIOCHEM BIOPHYS, V263, P418, DOI 10.1016/0003-9861(88)90654-6; RADOFF S, IN PRESS DIABETES; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; VISHWANATH V, 1986, DIABETES, V35, P916, DOI 10.2337/diabetes.35.8.916; VLASSARA H, 1989, J CLIN INVEST, V84, P1813, DOI 10.1172/JCI114366; VLASSARA H, 1986, J EXP MED, V164, P1301, DOI 10.1084/jem.164.4.1301; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WING AJ, 1986, REPLACEMENT RENAL FU, P850; WOLFF SP, 1989, MAILLARD REACTION AG, P259	38	784	805	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1991	325	12					836	842		10.1056/NEJM199109193251202	http://dx.doi.org/10.1056/NEJM199109193251202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF616	1875967				2022-12-28	WOS:A1991GF61600002
J	KEISER, HR				KEISER, HR			SURREPTITIOUS SELF-ADMINISTRATION OF EPINEPHRINE RESULTING IN PHEOCHROMOCYTOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTITIOUS ILLNESS				KEISER, HR (corresponding author), NHLBI,BLDG 10,ROOM 8C-103,BETHESDA,MD 20892, USA.							AGUILARP.E, 1971, J AMER MED ASSOC, V218, P884, DOI 10.1001/jama.1971.03190190070023; BRANDENBURG RO, 1979, ANN INTERN MED, V90, P795, DOI 10.7326/0003-4819-90-5-795; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; FOLKS DG, 1985, PSYCHIAT CLIN N AM, V8, P263; GROSSMAN E, 1991, HYPERTENSION, V17, P733, DOI 10.1161/01.HYP.17.6.733; KOOIMAN CG, 1987, COMPR PSYCHIAT, V28, P499, DOI 10.1016/0010-440X(87)90015-0; LAWRENCE AM, 1967, ANN INTERN MED, V66, P1091, DOI 10.7326/0003-4819-66-6-1091; LURVEY A, 1973, J CLIN ENDOCR METAB, V36, P766, DOI 10.1210/jcem-36-4-766; MOLL LV, 1987, J NUCL MED, V28, P979; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; SHAPIRO B, 1985, J NUCL MED, V26, P576; YOUNG MJ, 1989, J GEN INTERN MED, V4, P273, DOI 10.1007/BF02597394; 1987, DIAGNOSTIC STATISTIC	13	19	19	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1553	1555		10.1001/jama.266.11.1553	http://dx.doi.org/10.1001/jama.266.11.1553			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880888				2022-12-28	WOS:A1991GE45800037
J	GABRIELSEN, OS; SENTENAC, A; FROMAGEOT, P				GABRIELSEN, OS; SENTENAC, A; FROMAGEOT, P			SPECIFIC DNA-BINDING BY C-MYB - EVIDENCE FOR A DOUBLE HELIX-TURN-HELIX-RELATED MOTIF	SCIENCE			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; CRYSTAL-STRUCTURE; PROTEIN; COMPLEX; ONCOGENE; SEQUENCE; DOMAIN; DIFFERENTIATION; PROTOONCOGENE; EXPRESSION	The c-Myb protein is a sequence-specific DNA binding protein that activates transcription in hematopoietic cells. Three imperfect repeats (R1, R2, and R3) that contain regularly spaced tryptophan residues form the DNA binding domain of c-Myb. A fragment of c-Myb that contained the R2 and R3 regions bound specifically to a DNA sequence recognized by c-Myb plus ten additional base pairs at the 3' end of the element. The R2R3 fragment was predicted to contain two consecutive helix-turn-helix (HTH) motifs with unconventional turns. Mutagenesis of amino acids in R2R3 at positions that correspond to DNA-contacting amino acids in other HTH-containing proteins abolished specific DNA binding without affecting nonspecific DNA interactions.	CTR ETUD SACLAY,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE		GABRIELSEN, OS (corresponding author), CTR ETUD SACLAY,INGN PROT LAB,F-91191 GIF SUR YVETTE,FRANCE.							BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GABRIELSEN OS, UNPUB; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0	30	139	144	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1140	1143		10.1126/science.1887237	http://dx.doi.org/10.1126/science.1887237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1887237				2022-12-28	WOS:A1991GD80800033
J	GUPTA, GC				GUPTA, GC			STUDENT ATTRITION - A CHALLENGE FOR ALLIED HEALTH-EDUCATION PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The Committee on Allied Health Education and Accreditation (CAHEA) attrition data, collected annually by the American Medical Association (AMA), are nationally representative and constitute the largest source of information on attrition and retention in allied health education. These data provide a cornerstone for education and manpower planning. Consistent with previous years, men who were enrolled in CAHEA-accredited allied health education programs for the 1989-1990 academic year were significantly more likely to be lost to attrition than were women. When compared with all other categories of race and ethnic origin, black students not of Hispanic origin showed a significantly higher attrition rate (25.4%), while students designated as Asian or Pacific Islander showed a significantly lower rate (13%). Congruent with attrition data documented in the literature, CAHEA attrition data show wide variances across 26 allied health occupations and within the three disciplinary groupings that comprise approximately 75% of all CAHEA-accredited programs. Attrition rates measured by the type of sponsoring institution range from 7.1% (academic health centers and medical schools) to 24.3% (vocational and technical schools). Programs sponsored by for-profit institutions and federal government-owned institutions report substantially higher attrition rates, 25.1% and 21.1%, respectively.			GUPTA, GC (corresponding author), AMER MED ASSOC,DEPT INFORMAT ANAL & PUBLICAT,MED EDUC,CHICAGO,IL 60610, USA.							Astin A., 1975, PREVENTING STUDENTS; ASTIN AW, 1972, COLLEGE DROPOUTS NAT; BILLSON JM, 1987, COLL UNIV, V62, P290; BURROWS WR, 1989, ALLIED HLTH ED DIREC, P259; BYNUM JE, 1983, COLL UNIV, V59, P39; CARROLL D, 1989, COLLEGE PERSISTENCE; CROSS KP, 1976, ADULTS LEARNERS; GUPTA GC, 1990, JAMA-J AM MED ASSOC, V264, P843; GUPTA GC, 1991, ALLIED HLTH ED DIREC, V4, P271; LEA DH, 1979, NASPA J, P17; PARKS R, 1990, ALLIED HLTH ED DIREC, P281; RUG EA, 1982, PERS GUID J, V61, P232; TINTO V, 1975, REV EDUC RES, V45, P89, DOI 10.2307/1170024; Webb M., 1989, COMMUNITY COLL REV, V16, P42; WEBB W, 1988, COMMUNITY JUNIOR COL, V12, P213; 1991, CHRONICLE HIGHE 0703, pA18; 1989, ALLIED HLTH SERVICES, P7; 1991, CHRONICLE HIGHE 0327, pA15; 1991, CHRONICLE HIGHE 0703, pA15	19	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					963	967		10.1001/jama.266.7.963	http://dx.doi.org/10.1001/jama.266.7.963			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870225				2022-12-28	WOS:A1991GB20500008
J	STITHAM, S				STITHAM, S			EDUCATIONAL MALPRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					905	906		10.1001/jama.266.7.905	http://dx.doi.org/10.1001/jama.266.7.905			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870220				2022-12-28	WOS:A1991GB20500001
J	WEITHAUS, B; FAUSER, JJ				WEITHAUS, B; FAUSER, JJ			COMMITTEE-ON-ALLIED-HEALTH-EDUCATION-AND-ACCREDITATION - ASSESSING EDUCATIONAL OUTCOMES AND ASSURING QUALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WEITHAUS, B (corresponding author), AMER MED ASSOC,DEPT EDUC,DIV ALLIED HLTH & ACCREDITAT,CHICAGO,IL 60610, USA.							GUPTA GC, 1990, JAMA-J AM MED ASSOC, V264, P843; GUPTA GC, 1991, ALLIED HLTH ED DIREC, P1	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					968	969		10.1001/jama.266.7.968	http://dx.doi.org/10.1001/jama.266.7.968			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870226				2022-12-28	WOS:A1991GB20500009
J	WENTZ, DK; OSTEEN, AM; GANNON, MI				WENTZ, DK; OSTEEN, AM; GANNON, MI			REFOCUSING SUPPORT AND DIRECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,OFF PHYSICIAN CREDENTIALS & QUALIFICAT,CHICAGO,IL 60610	American Medical Association	WENTZ, DK (corresponding author), AMER MED ASSOC,DIV CONTINUING MED EDUC,CHICAGO,IL 60610, USA.							1990, ANN INTERN MED, V112, P624; 1991, JAMA-J AM MED ASSOC, V265, P501	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1991	266	7					953	956						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB205	1870223				2022-12-28	WOS:A1991GB20500006
J	JACKSON, R; SCRAGG, R; BEAGLEHOLE, R				JACKSON, R; SCRAGG, R; BEAGLEHOLE, R			ALCOHOL-CONSUMPTION AND RISK OF CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							U-SHAPED CURVE; MORTALITY; MEN	Objective - To investigate the hypothesis that the apparent protective effect of habitual alcohol consumption on coronary heart disease is due to drinkers at high risk of coronary heart disease becoming non-drinkers. Design - Case-control population based study. Data were obtained from interviews with patients with non-fatal myocardial infarction and their controls and with the next of kin of those who had died of coronary heart disease and their controls. Setting - Auckland, New Zealand. Subjects - Two groups of cases were studied. The first comprised 227 men and 72 women with non-fatal myocardial infarction identified from a population based surveillance programme for coronary heart disease; controls were 525 men and 341 women randomly selected from the same population group and matched for age and sex. The second group comprised 128 men and 30 women who had died of coronary heart disease and had been identified from the surveillance programme; controls were a sample of the previous control group and comprised 330 men and 214 women matched for age and sex. All participants were aged 25-64 years and without diagnosed coronary heart disease. Main outcome measures - Regular alcohol consumption; high density lipoprotein cholesterol and low density lipoprotein concentrations. Results - Men with myocardial infarction and men who had died of coronary heart disease were more likely to have been never drinkers (had never drunk more than once a month) than controls (18% v 12% and 23% v 13% respectively). After possible confounding factors had been controlled for, people in all categories of drinking (up to more than 56 drinks per week) had at least a 40% reduction in risk of fatal and non-fatal coronary heart disease compared with never drinkers. Former drinkers also had a lower risk of non-fatal myocardial infarction than never drinkers (relative risks 0.41 and 0.10 in men and women respectively) but a similar risk of death from coronary heart disease. The reduction in risk was consistently greater in women than in men in all drinking categories but there was no clear dose-response effect in either sex. Conclusions - The results support the hypothesis that light and moderate alcohol consumption reduces the risk of coronary heart disease. This protective effect in this population was not due to the misclassification of former drinkers with a high risk of coronary heart disease as non-drinkers.			JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND.			Scragg, Robert/0000-0003-0013-2620; Jackson, Rod/0000-0001-5914-6934				ALANKO T, 1984, RES ADV ALCOHOL DRUG, V8, P299; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; FRASER G, 1986, PREVENTIVE CARDIOLOG; HARREL F, 1983, LOGIST PROCEDURE; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; JACKSON R, 1988, NEW ZEAL MED J, V101, P658; JACKSON R, 1987, BRIT MED J, V294, P1588, DOI 10.1136/bmj.294.6587.1588; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KOZAREVIC DJ, 1981, LANCET, V1, P613; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MARMOT MG, 1981, LANCET, V1, P580; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; PEARCE NE, 1983, NEW ZEAL MED J, V96, P281; Rose G, 1982, CARDIOVASCULAR SURVE; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1988, J CLIN EPIDEMIOL, V41, P105	25	202	203	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					211	216		10.1136/bmj.303.6796.211	http://dx.doi.org/10.1136/bmj.303.6796.211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ563	1884056	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300019
J	GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J				GODDEN, JW; TURLEY, S; TELLER, DC; ADMAN, ET; LIU, MY; PAYNE, WJ; LEGALL, J			THE 2.3 ANGSTROM X-RAY STRUCTURE OF NITRITE REDUCTASE FROM ACHROMOBACTER-CYCLOCLASTES	SCIENCE			English	Article							PROTEINS	The three-dimensional crystal structure of the copper-containing nitrite reductase (NIR) from Achromobacter cycloclastes has been determined to 2.3 angstrom (angstrom) resolution by isomorphous replacement. The monomer has two Greek key beta-barrel domains similar to that of plastocyanin and contains two copper sites. The enzyme is a trimer both in the crystal and in solution. The two copper atoms in the monomer comprise one type I copper site (Cu-I; two His, one Cys, and one Met ligands) and one putative type II copper site (Cu-II; three His and one solvent ligands). Although ligated by adjacent amino acids Cu-I and Cu-II are approximately 12.5 angstrom apart. Cu-II is bound with nearly perfect tetrahedral geometry by residues not within a single monomer, but from each of two monomers of the trimer. The Cu-II site is at the bottom of a 12 angstrom deep solvent channel and is the site to which the substrate (NO2-) binds, as evidenced by difference density maps of substrate-soaked and native crystals.	UNIV WASHINGTON, DEPT BIOL STRUCT SM20, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08268-02, GM31770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman E.T., 1985, METALLOPROTEINS ME 1, P1; BRANDEN CI, 1990, NATURE, V343, P687, DOI 10.1038/343687a0; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DENARIAZ G, 1991, BIOCHIM BIOPHYS ACTA, V1056, P225, DOI 10.1016/S0005-2728(05)80053-2; DOOLEY DM, 1988, J BIOL CHEM, V263, P14625; FENDERSON FF, 1991, BIOCHEMISTRY-US, V30, P7180, DOI 10.1021/bi00243a020; Golterman H. L., 1985, Denitrification in the nitrogen cycle, P1; HULSE CL, 1988, ANAL BIOCHEM, V172, P420, DOI 10.1016/0003-2697(88)90464-2; IWASAKI H, 1972, J BIOCHEM, V71, P645; IWASAKI H, 1975, J BIOCHEM-TOKYO, V78, P355, DOI 10.1093/oxfordjournals.jbchem.a130915; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KASHEM MA, 1987, BIOCHEM BIOPH RES CO, V145, P563, DOI 10.1016/0006-291X(87)91357-X; LIU MY, 1986, J BACTERIOL, V166, P604, DOI 10.1128/jb.166.2.604-608.1986; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Payne W. J., 1985, Denitrification in the nitrogen cycle, P47; SHAPLEIGH JP, 1987, BIOCHIM BIOPHYS ACTA, V911, P334, DOI 10.1016/0167-4838(87)90074-4; SHAPLEIGH JP, 1985, FEMS MICROBIOL LETT, V26, P275; SOLOMON EI, 1983, COPPER COORDINATION, P1; SUZUKI S, 1989, BIOCHEM BIOPH RES CO, V164, P1366, DOI 10.1016/0006-291X(89)91820-2; Teller D C, 1973, Methods Enzymol, V27, P346; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; WANG BC, 1985, METHOD ENZYMOL, V115, P90	26	344	348	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					438	442		10.1126/science.1862344	http://dx.doi.org/10.1126/science.1862344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862344				2022-12-28	WOS:A1991FY28800038
J	KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM				KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; XUONG, NH; TAYLOR, SS; SOWADSKI, JM			STRUCTURE OF A PEPTIDE INHIBITOR BOUND TO THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE-MONOPHOSPHATE DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; ACTIVE-SITE; SECONDARY STRUCTURE; SUBSTRATE; BINDING; 3',5'-MONOPHOSPHATE; IDENTIFICATION; CONFORMATION; HOMOLOGY; DOMAINS	The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.	UNIV CALIF SAN DIEGO,DEPT MED,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; SAN DIEGO SUPERCOMP CTR,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09523] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BRAMSON HN, 1987, BIOCHEMISTRY-US, V26, P4466, DOI 10.1021/bi00388a042; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P5997, DOI 10.1021/bi00393a008; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GLASS DB, 1989, J BIOL CHEM, V264, P14579; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; GRANOT J, 1981, J BIOL CHEM, V255, P4569; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HJELMQUIST G, 1974, BIOCHEM BIOPH RES CO, V61, P559, DOI 10.1016/0006-291X(74)90993-0; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; NELSON NC, 1983, J BIOL CHEM, V258, P981; PARELLO J, IN PRESS J MOL BIOL; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REED J, 1989, BIOCHEM J, V264, P371, DOI 10.1042/bj2640371; REED J, 1987, BIOCHEMISTRY-US, V26, P7641, DOI 10.1021/bi00398a017; ROSEVEAR PR, 1984, BIOCHEMISTRY-US, V23, P3161, DOI 10.1021/bi00309a009; SALERNO A, 1990, J BIOL CHEM, V265, P18079; SHOJI S, 1979, J BIOL CHEM, V254, P6211; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4461, DOI 10.1021/bi00388a041; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; VANPATTEN SM, 1987, J BIOL CHEM, V262, P3398; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WELDON SL, 1985, J BIOL CHEM, V260, P4203; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO W, IN PRESS METHODS ENZ; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZOLLER MN, 1981, J BIOL CHEM, V256, P10387	42	883	946	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 26	1991	253	5018					414	420		10.1126/science.1862343	http://dx.doi.org/10.1126/science.1862343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862343				2022-12-28	WOS:A1991FY28800031
J	MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ				MISSIAEN, L; TAYLOR, CW; BERRIDGE, MJ			SPONTANEOUS CALCIUM RELEASE FROM INOSITOL TRISPHOSPHATE-SENSITIVE CALCIUM STORES	NATURE			English	Article							INTRACELLULAR CALCIUM; CA-2+ RELEASE; FURA-2-LOADED HEPATOCYTES; OSCILLATIONS; CELLS; 1,4,5-TRISPHOSPHATE; MITOCHONDRIA; PHOSPHATES; RETICULUM; BINDING	Inositol 1,4,5-trisphosphate (InsP3) functions as a second messenger to mobilize Ca2+ from intracellular reservoirs 1. The release mechanism displays all-or-none characteristics 2,3, that may account for other observations that the InsP3-induced mobilization of Ca2+ is quantal 4-6. Quantal release may depend on the sensitivity of the InsP3 receptor being regulated by the Ca2+ concentration in the lumen of the endoplasmic reticulum 7. We report here that the InsP3-sensitive store in hepatocytes discharges spontaneously when overloaded with Ca2+. The release, which is blocked by heparin, is preceded by an increasing sensitivity of the InsP3 receptor to endogenous InsP3, and is promoted by those sulphydryl reagents (oxidized glutathione and thimerosal) that induce Ca2+ oscillations in intact cells (ref. 8, and T. A. Rooney, D. C. Renard, E. J. Sass and A. P. Thomas, manuscript in preparation). This novel process could have a role in generating both Ca2+ oscillations and Ca2+ waves.	UNIV CAMBRIDGE, DEPT PHARMACOL, CAMBRIDGE CB2 1QJ, ENGLAND	University of Cambridge	MISSIAEN, L (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BECKER GL, 1980, J BIOL CHEM, V255, P9009; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KURTZ A, 1989, P NATL ACAD SCI USA, V86, P3423, DOI 10.1073/pnas.86.9.3423; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; OHNISHI ST, 1979, J BIOCHEM, V86, P1147, DOI 10.1093/oxfordjournals.jbchem.a132609; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; STUENKEL EL, 1990, AM J PHYSIOL, V258, pC289, DOI 10.1152/ajpcell.1990.258.2.C289; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1990, CELL CALCIUM, V11, P353, DOI 10.1016/0143-4160(90)90038-V; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; ZHAO H, 1990, J BIOL CHEM, V265, P14822	28	335	340	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1991	352	6332					241	244		10.1038/352241a0	http://dx.doi.org/10.1038/352241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857419				2022-12-28	WOS:A1991FX18500066
J	SLEZAK, SE; MUIRHEAD, KA				SLEZAK, SE; MUIRHEAD, KA			RADIOACTIVE CELL-MEMBRANE LABELING	NATURE			English	Article							FLUORESCENT				SLEZAK, SE (corresponding author), ZYNAXIS CELL SCI,371 PHOENIXVILLE PIKE,MALVERN,PA 19355, USA.							GRAY G, 1991, J NUCL MED, V32, P1092; HOFER KH, 1984, BLOOD CELLS NUCL M 2, P224; HORAN PK, 1990, FLOW CYTOMETRY, V30, P469; KOPIA GA, 1990, CIRCULATION, V82, P175; MEINICOFF MJ, 1988, J LEUKOCYTE BIOL, V43, P387; OLZEWSKI WL, 1987, IN VIVO MIGRATION IM, P223; PALMER LD, 1991, FASEB J, V5, pA639; ROWLINSONBUSZA G, 1991, CANCER RES, V51, P3251; SLEZAK SE, 1989, J IMMUNOL METHODS, V117, P205, DOI 10.1016/0022-1759(89)90142-7; SLEZAK SE, 1989, BLOOD, V74, P2171; TEARE GF, 1991, CELL IMMUNOL, V134, P157, DOI 10.1016/0008-8749(91)90339-D; YUAN Y, 1990, MICROVASC RES, V40, P218, DOI 10.1016/0026-2862(90)90021-I	12	20	21	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					261	262		10.1038/352261a0	http://dx.doi.org/10.1038/352261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857424				2022-12-28	WOS:A1991FX18500073
J	HIBBS, J; PERPER, J; WINEK, CL				HIBBS, J; PERPER, J; WINEK, CL			AN OUTBREAK OF DESIGNER DRUG RELATED DEATHS IN PENNSYLVANIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								3-Methylfentanyl ("China White") is a "designer" opiate that has caused more than 100 overdose deaths in California since 1979, but that has not been associated previously with deaths east of the Rocky Mountains. During 1988, 3-methylfentanyl was identified in 16 fatal overdose cases in Allegheny County, Pennsylvania, contributing to a fourfold rise in overdose mortality during October of that year. Morphine was detected in the blood of five persons (31%) and cocaine in the blood of three persons (19%) dying of 3-methylfentanyl overdoses; these were demographically similar to 99 other fatal overdose cases investigated by the county coroner from 1986 through 1988. This documents the contribution of 3-methylfentanyl to overdose mortality in an eastern city and the use of 3-methylfentanyl with other illegal drugs. Drug abusers in the northeastern United States should be considered at risk for more "designer drug" overdose outbreaks in the future.	CTR DIS CONTROL, DIV FIELD SERV, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; ALLEGHENY CTY CORONERS OFF, PITTSBURGH, PA USA; ALLEGHENY CTY DEPT LABS, PITTSBURGH, PA USA	Centers for Disease Control & Prevention - USA								AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; FROEDE RC, 1980, MICROSCOPIC DIAGNOSI, P149; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Janssen P.A., 1985, OPIOIDS ANESTHESIA, P37; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARTIN ML, 1989, ANN EMERG MED, V18, P446; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; RUTTENBER AJ, 1984, SCIENCE, V226, P14, DOI 10.1126/science.6474188; VANBEVER WF, 1974, J MED CHEM, V17, P1047, DOI 10.1021/jm00256a003	11	51	51	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 27	1991	265	8					1011	1013		10.1001/jama.265.8.1011	http://dx.doi.org/10.1001/jama.265.8.1011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	EY432	1867667				2022-12-28	WOS:A1991EY43200031
J	VEENSTRA, RJ; GLUCK, JC				VEENSTRA, RJ; GLUCK, JC			ACCESS TO INFORMATION ABOUT AIDS	ANNALS OF INTERNAL MEDICINE			English	Article								Medical information related to human immunodeficiency virus (HIV) infection is highly diverse, and the practicing physician or researcher may find specific information difficult to locate. To provide timely access to medical information on topics related to the acquired immunodeficiency syndrome (AIDS), several computer-based products have recently been developed. Some are available from vendors of online information systems, whereas others are available only on CD-ROM or floppy disk. We review several computer-based products. AIDSLINE is the most comprehensive bibliographic index, AIDSTRIALS contain specific information about ongoing unpublished investigational studies, and AIDS Knowledge Base from San Francisco General Hospital is an up-to-date electronic textbook covering all aspects of AIDS. COMPACT LIBRARY: AIDS operates on a microcomputer and combines several database, including full-text AIDS-related articles from nine major medical journals. AIDS References from the Bureau of Hygiene and Tropical Diseases provides critical analysis of publications worldwide. Although smaller in size than AIDSLINE, about one third of the publications covered by this resource are not covered by AIDSLINE.	MANCHESTER MEM HOSP, MANCHESTER, CT 06040 USA		VEENSTRA, RJ (corresponding author), HARTFORD HOSP, HLTH SCI LIB, 80 SEYMOUR ST, HARTFORD, CT 06115 USA.							BIND N, 1990, ONLINE 89 LOGON, V13, P9; Centers for Disease Control (CDC), 1981, MMWR-MORBID MORTAL W, V30, P250; CLANCY S, 1988, ONLINE, V12, P93; DUPONT G, 1989, NLM TECH B, V242, P1; DUPONT G, 1989, NLM TECH B, V242, P4; DUTCHER GA, 1989, NLM TECH B, V243, P17; MARMION D, 1990, LIBR SOFTWARE REV, V9, P139; SHORT R, 1989, BRIT J HOSP MED, V42, P166; 1989, CURRENT AIDS LIT, V2, P594	9	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1991	114	4					320	324		10.7326/0003-4819-114-4-320	http://dx.doi.org/10.7326/0003-4819-114-4-320			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EX521	1888346				2022-12-28	WOS:A1991EX52100012
J	HANTSCH, CE; TANUS, T				HANTSCH, CE; TANUS, T			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS WITH ADENOPATHY	ANNALS OF INTERNAL MEDICINE			English	Note						ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ADENOPATHY; ASTHMA; IMMUNOBLASTIC LYMPHADENOPATHY; HYPERSENSITIVITY		Allergic bronchopulmonary aspergillosis is a serious hypersensitivity disease seen in patients with an underlying pulmonary disorder, most commonly asthma. Diagnosis is based on a combination of clinical, radiologic, and immunologic features. Radiologic findings include perihilar infiltrates, air fluid levels, cavitation, and central bronchiectasis. We describe a case of allergic bronchopulmonary aspergillosis with surgically confirmed mediastinal adenopathy and radiologically evident perihilar adenopathy. We know of no previous case of allergic bronchopulmonary aspergillosis associated with true lymphadenopathy. Allergic bronchopulmonary aspergillosis should be included in the differential diagnosis of hilar adenopathy in predisposed patients. After serologic confirmation of the disease, prompt initiation of treatment results in improved prognosis.	NORTHWESTERN UNIV, MCGAW MED CTR, CHICAGO, IL 60611 USA; EVANSTON HOSP CORP, EVANSTON, IL 60201 USA	Northwestern University; NorthShore University Health System								GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; MINTZER RA, 1978, RADIOLOGY, V127, P301, DOI 10.1148/127.2.301; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450	5	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					546	547		10.7326/0003-4819-115-7-546	http://dx.doi.org/10.7326/0003-4819-115-7-546			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883124				2022-12-28	WOS:A1991GG28300007
J	BRANCATI, FL				BRANCATI, FL			MORNING DISTORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1991	266	12					1627	1627		10.1001/jama.266.12.1627	http://dx.doi.org/10.1001/jama.266.12.1627			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF419	1886180				2022-12-28	WOS:A1991GF41900011
J	LOCKWOOD, CJ; SENYEI, AE; DISCHE, MR; CASAL, D; SHAH, KD; THUNG, SN; JONES, L; DELIGDISCH, L; GARITE, TJ				LOCKWOOD, CJ; SENYEI, AE; DISCHE, MR; CASAL, D; SHAH, KD; THUNG, SN; JONES, L; DELIGDISCH, L; GARITE, TJ			FETAL FIBRONECTIN IN CERVICAL AND VAGINAL SECRETIONS AS A PREDICTOR OF PRETERM DELIVERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY FDC-6; EXTRACELLULAR-MATRIX; ONCOFETAL	Background. Preterm delivery is the leading cause of neonatal mortality in the United States, but efforts to address the problem are hampered by the inability to predict accurately which pregnancies are at risk. We postulated that damage to the fetal membranes may release fetal fibronectin into the cervix and vagina, giving rise to a biochemical marker for preterm delivery. Methods. We measured fetal-fibronectin concentrations in cervical and vaginal secretions, amniotic fluid, and maternal plasma with a sensitive immunoassay using the monoclonal antibody FDC-6. Immunohistochemical studies were used to determine the distribution of fetal fibronectin in the placenta and amniochorionic membranes and to ascertain its cell of origin. Results. Women with uncomplicated pregnancies (n = 163) who delivered at term rarely had cervicovaginal fetal-fibronectin concentrations above 0.05-mu-g per milliliter between 21 and 37 weeks of gestation (11 of 267 cervical samples [4 percent] and 9 of 267 vaginal samples [3 percent]). High levels of fetal fibronectin were detected in amniotic fluid and in the cervical or vaginal secretions of 93.8 percent of the women with preterm rupture of membranes (n = 65). Cervical or vaginal fetal fibronectin was also present in 50.4 percent of the women with preterm uterine contractions and intact membranes (n = 117), and its presence identified the women who delivered before term (n = 60) with a sensitivity of 81.7 percent and a specificity of 82.5 percent. In the placenta and membranes, fetal fibronectin was found at points of contact with the uterine wall. Conclusions. The presence of cervicovaginal fetal fibronectin in the second and third trimesters of pregnancy identifies a subgroup of women who are at high risk for preterm delivery. This phenomenon may reflect the separation of the chorion from the decidual layer of the uterus, with the release of intact or degraded chorionic components of the extracellular matrix into the cervical and vaginal secretions.	CUNY MT SINAI SCH MED,DEPT PATHOL,NEW YORK,NY 10029; ADEZA BIOMED,SUNNYVALE,CA; UNIV CALIF IRVINE,DEPT OBSTET & GYNECOL,IRVINE,CA 92717	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California Irvine	LOCKWOOD, CJ (corresponding author), CUNY MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.							FOLKVORD JM, 1989, J HISTOCHEM CYTOCHEM, V37, P105, DOI 10.1177/37.1.2461979; MAIN DM, 1985, AM J OBSTET GYNECOL, V151, P892, DOI 10.1016/0002-9378(85)90667-2; MATSUURA H, 1985, P NATL ACAD SCI USA, V82, P6517, DOI 10.1073/pnas.82.19.6517; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCGREGOR JA, 1987, OBSTET GYNECOL, V69, P167; SIBILLE Y, 1986, AM REV RESPIR DIS, V134, P134; YEH IT, 1989, LAB INVEST, V61, P1; ZHU BCR, 1987, ARCH BIOCHEM BIOPHYS, V252, P1, DOI 10.1016/0003-9861(87)90001-4	10	501	536	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					669	674		10.1056/NEJM199109053251001	http://dx.doi.org/10.1056/NEJM199109053251001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1870640	Bronze			2022-12-28	WOS:A1991GD49700001
J	ROTHERAMBORUS, MJ; KOOPMAN, C; HAIGNERE, C; DAVIES, M				ROTHERAMBORUS, MJ; KOOPMAN, C; HAIGNERE, C; DAVIES, M			REDUCING HIV SEXUAL RISK BEHAVIORS AMONG RUNAWAY ADOLESCENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY	Objective. - Reductions in runaways' sexual risk behaviors were evaluated in response to an intensive program to prevent human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Design. - In a nonrandomized control trial, sexual risk behaviors among 78 runaways at one residential shelter who received up to 30 HIV/AIDS intervention sessions were compared with 67 runaways at a nonintervention shelter with sexual behaviors assessed at baseline and 3 and 6 months. Setting. - Runaways were recruited from the only two publicly funded shelters in New York, NY. Participants. - The runaways were aged 11 to 18 years, 64% female, and predominantly black or Hispanic. Intervention. - The intervention addressed general knowledge about HIV/AIDS, coping skills, access to health care and other resources, and individual barriers to safer sex. Main Outcome Measures. - Consistent condom use, a high-risk pattern of sexual behavior, and sexual abstinence over a 3-month time frame were assessed. Main Results. - As the number of intervention sessions increased, runaways' reports of consistent condom use increased significantly (at 3 months, unique R2 = .06, P < .05; at 6 months, unique R2 = .09, P < .05), and their reports of engaging in a high-risk pattern of sexual behavior decreased significantly (at 3 months, unique R2 = .03, P =.06; at 6 months, unique R2 = .04, P < .05). Abstinence did not change. Conclusions. - The demonstrated effectiveness of the intensive HIV/AIDS program highlights the importance of enlarging the scope of most current HIV/AIDS prevention programs.	NEW YORK STATE PSYCHIAT INST & HOSP, HIV CTR CLIN & BEHAV STUDIES, NEW YORK, NY 10032 USA; NEW YORK STATE PSYCHIAT INST & HOSP, DIV CHILD PSYCHIAT, NEW YORK, NY 10032 USA	New York State Psychiatry Institute; New York State Psychiatry Institute	ROTHERAMBORUS, MJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT CHILD & YOUTH PSYCHIAT, 722 W 168TH ST, NEW YORK, NY 10032 USA.				NIMH NIH HHS [5-P50-MH43520] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLAKE S, 1989, 5TH INT C AIDS OTT; BOTVIN GJ, 1980, PREV MED, V9, P135, DOI 10.1016/0091-7435(80)90064-X; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; GARLAND FC, 1989, JAMA-J AM MED ASSOC, V262, P3161, DOI 10.1001/jama.262.22.3161; HERSCH P, 1988, PSYCHOL TODAY    JAN, P28; HUDSON RA, 1989, 5TH INT C AIDS OTT; JOSEPH JG, 1985, PSYCHOL HEALTH, V75, P493; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KELLY JA, 1989, J CONSULT CLIN PSYCH, V57, P60, DOI 10.1037/0022-006X.57.1.60; KIPKE M, 1989, 5TH INT C AIDS OTT; Koopman C, 1990, AIDS Educ Prev, V2, P58; MEYERBAHLBURG HFL, 1988, SEXUAL RISK BEHAVIOR; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; ROBERTSON M, 1989, HOMELESS YOUTH HOLLY; ROTHERAM MJ, 1982, AM J COMMUN PSYCHOL, V10, P567, DOI 10.1007/BF00894145; ROTHERAMBORUS MJ, 1991, AM J PUBLIC HEALTH, V81, P206, DOI 10.2105/AJPH.81.2.208; ROTHERAMBORUS MJ, 1990, ADOLESCENT STRESS, P181; ROTHERAMBORUS MJ, 1989, TROUBLED ADOLESCENTS, P37; ROTHERAMBORUS MJ, IN PRESS AM PSYCHOL; SCHALWITZ J, 1990, 6TH INT C AIDS SAN F; SHAFFER D, 1984, RUNAWAY HOMELESS YOU; STLOUIS ME, 1989, 5TH INT C AIDS OTT; STRICOF RL, 1991, AM J PUBLIC HEALTH, V81, P50, DOI 10.2105/AJPH.81.Suppl.50; VALDISERRI RO, 1989, AIDS, V3, P21, DOI 10.1097/00002030-198903010-00005; WILLIAMS VGT, 1989, 5TH INT C AIDS OTT; YATES GL, 1988, AM J PUBLIC HEALTH, V78, P820, DOI 10.2105/AJPH.78.7.820; 1990, AIDS SURVEILLANCE RE; 1990, HIV AIDS SURVEILLANC	28	264	266	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1237	1241		10.1001/jama.266.9.1237	http://dx.doi.org/10.1001/jama.266.9.1237			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870249				2022-12-28	WOS:A1991GC85800032
J	RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM				RAMAIYA, KL; SWAI, ABM; MCLARTY, DG; BHOPAL, RS; ALBERTI, KGMM			PREVALENCES OF DIABETES AND CARDIOVASCULAR-DISEASE RISK-FACTORS IN HINDU INDIAN SUBCOMMUNITIES IN TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; ASIAN COMMUNITY; EAST LONDON; MORTALITY; CHINESE; SINGAPORE; MORBIDITY; MELLITUS; PATTERNS	Objectives-To seek differences in the prevalence of diabetes mellitus and other coronary heart disease risk factors, and to identify factors associated with these differences within a Hindu Indian community. Design-Population based cross sectional survey. Setting-Dar-es-Salaam, Tanzania. Subjects-Of 20 Hindu subcommunities categorised by caste in Dar-es-Salaam, seven were randomly selected. 1147 (76.7%) of 1495 subjects aged 15 or over participated. Main outcome measures-Blood glucose concentrations (fasting and two hours after oral glucose loading), serum total cholesterol and serum triglyceride concentrations, blood pressure, and height and weight. Results-The subcommunities differed substantially in socioeconomic characteristics and lifestyle. Overall, 9.8% of subjects (109/1113) had diabetes, 17.0% (189/1113) impaired glucose tolerance, 14.5% (166/1143) hypertension, and 13.3% (151/1138) were obese. The mean fasting blood glucose concentration was 4.9 mmol/l, the blood glucose concentration two hours after oral loading (75 g) 6.0 mmol/l, the total cholesterol concentration 4.9 mmol/l, the serum triglyceride concentration 1.4 mmol/l, and body mass index (weight/height2; kg/m2) 24.3. Systolic and diastolic blood pressures were 121 and 77 mm Hg respectively. There were important intercommunity differences even after standardisation for age, sex, and body mass index - for example, in mean fasting blood glucose concentration (range 4.5 (Jains) to 5.9 mmol/l (Patels)), serum total cholesterol concentration (range 4.5 (Jains) to 6.2 mmol/l (Suthars)), systolic blood pressure (range 110 (Limbachias) to 127 mm Hg (Bhatias)), and prevalences of diabetes (range 3.4% (3/87 Limbachias) to 18% (20/111 Navnats)) and hypertension (range 5.7% (5/87 Limbachias) to 19.4% (43/222 Bhatias). Variables which showed significant linear correlation with subcommunity variations were entered into a multiple regression model. Intercommunity variations persisted. The Limbachia and Jain communities had the lowest prevalence of and mean values for coronary heart disease risk factors and the Bhatia and Patel communities had the highest. Conclusions-In this series intercommunity variations in disease and risk factors might have been related to genetic, dietary, socioeconomic, and lifestyle differences but could not be explained by the characteristics studied. Studies of Indian subcommunities are warranted to confirm and extend these descriptive findings and explore the genetic basis of diabetes. Communities of Indian origin should not be perceived as homogeneous.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,ENGLAND; HINDU MANDAL HOSP,DAR ES SALAAM,TANZANIA; UNIV NEWCASTLE UPON TYNE,SCH MED,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA	Newcastle University - UK; Newcastle University - UK; University of Dar es Salaam								ADELSTEIN AM, 1963, BRIT J PREV SOC MED, V17, P29; ARMITAGE P, 1987, STATISTICAL METHODS, P194; ARMITAGE P, 1987, STATISTICAL METHODS, P204; BALARAJAN R, 1984, BRIT MED J, V289, P1185, DOI 10.1136/bmj.289.6453.1185; BECKLES GLA, 1986, LANCET, V1, P1298; BHOPAL RS, 1986, COMMUNITY MED, V8, P315; Chen A J, 1980, Ann Acad Med Singap, V9, P411; DEEG R, 1982, CLIN CHEM, V28, P1574; DONALDSON LJ, 1983, BRIT MED J, V286, P949, DOI 10.1136/bmj.286.6369.949; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; Gupta O P, 1978, Adv Metab Disord, V9, P147; HENLEY A, 1979, ASIAN PATIENTS HOSPI; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P24, DOI 10.1136/jech.44.1.24; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29; MALHOTRA SL, 1967, BRIT HEART J, V29, P895; MALHOTRA SL, 1988, BMJ, V207, P977; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1988, BRIT HEART J, V60, P390; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, DIABETIC MED S1, V6, pA41; MEGRAM ER, 1982, CLIN CHEM, V25, P273; MELIA RJW, 1988, BRIT MED J, V296, P1438, DOI 10.1136/bmj.296.6634.1438; NORUSIS MJ, 1986, SPSS IBM PC XT AT; OMAR MAK, 1985, S AFR MED J, V67, P924; PYORALA K, 1987, Diabetes Metabolism Reviews, V3, P463; SHAPER AG, 1959, LANCET, V2, P534; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; SILMAN A, 1985, J EPIDEMIOL COMMUN H, V39, P301, DOI 10.1136/jech.39.4.301; SIMMONS D, 1989, BRIT MED J, V298, P18, DOI 10.1136/bmj.298.6665.18; SWAI ABM, 1990, DIABETES RES CLIN PR, V8, P227, DOI 10.1016/0168-8227(90)90121-9; THAI A C, 1987, Journal of the Medical Association of Thailand, V70, P63; TUOMILEHTO J, 1984, B WORLD HEALTH ORGAN, V62, P133; WYNDHAM CH, 1982, S AFR MED J, V61, P987; ZIMMET P, 1983, AM J EPIDEMIOL, V118, P673, DOI 10.1093/oxfordjournals.aje.a113678; 1978, WHO TECH REP SER, V628; 1985, WHO TECH REP SER, V727	37	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1991	303	6797					271	276		10.1136/bmj.303.6797.271	http://dx.doi.org/10.1136/bmj.303.6797.271			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FZ721	1888926	Green Submitted, Green Published, Bronze			2022-12-28	WOS:A1991FZ72100017
J	HIGHTOWER, LE				HIGHTOWER, LE			HEAT-SHOCK, STRESS PROTEINS, CHAPERONES, AND PROTEOTOXICITY	CELL			English	Editorial Material							DIFFERENTIAL SCANNING CALORIMETRY; ESCHERICHIA-COLI; THERMAL-ANALYSIS; COGNATE PROTEIN; INDUCTION; ATP				HIGHTOWER, LE (corresponding author), UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269, USA.							BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; Ellis R J, 1990, Semin Cell Biol, V1, P1; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GUPTA RS, 1990, TRENDS BIOCHEM SCI, V15, P415, DOI 10.1016/0968-0004(90)90276-H; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEPOCK JR, 1990, BIOCHIM BIOPHYS ACTA, V1055, P19, DOI 10.1016/0167-4889(90)90086-S; LEPOCK JR, 1988, J CELL PHYSIOL, V137, P14, DOI 10.1002/jcp.1041370103; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; Morimoto RI, 1990, STRESS PROTEINS BIOL; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NOVER L., 1991, HEAT SHOCK RESPONSE; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; PELHAM HRB, 1990, STRESS PROTEINS BIOL, P287; PETERSEN NS, 1990, ADV GENETICS GENOMIC, P275; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; Schultz R.J., 1989, P69; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; VANBOGELEN RA, 1990, P NATL ACAD SCI USA, V87, P5589, DOI 10.1073/pnas.87.15.5589	29	968	1014	0	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					191	197		10.1016/0092-8674(91)90611-2	http://dx.doi.org/10.1016/0092-8674(91)90611-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855252				2022-12-28	WOS:A1991FY71200002
J	JOHANNESSEN, T				JOHANNESSEN, T			CONTROLLED TRIALS IN SINGLE SUBJECTS .1 VALUE IN CLINICAL MEDICINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED TRIALS; DYSPEPSIA				JOHANNESSEN, T (corresponding author), UNIV TRONDHEIM, DEPT COMMUNITY MED & GEN PRACTICE, N-7030 TRONDHEIM, NORWAY.							Barlow D., 1984, SINGLE CASE EXPT DES; COLINJONES DG, 1988, LANCET, V1, P576; EDGINGTON ES, 1984, PROG BEHAV MODIFIC, V16, P83; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; JOHANNESSEN T, 1988, SCAND J GASTROENTERO, V23, P327, DOI 10.3109/00365528809093874; JOHANNESSEN T, 1991, Scandinavian Journal of Primary Health Care, V9, P23, DOI 10.3109/02813439109026577; JOHANNESSEN T, 1991, Scandinavian Journal of Primary Health Care, V9, P17, DOI 10.3109/02813439109026576; JOHANNESSEN T, IN PRESS SCAND J GAS; MCLEOD RS, 1986, LANCET, V1, P726; PETTI TA, 1981, AM J PSYCHIAT, V138, P515; SPIEGELHALTER DJ, 1988, SCAND J GASTROENTERO, V23, P40, DOI 10.3109/00365528809099158	13	36	37	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1991	303	6795					173	174		10.1136/bmj.303.6795.173	http://dx.doi.org/10.1136/bmj.303.6795.173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878646	Green Published, Bronze			2022-12-28	WOS:A1991FX57800028
J	FORREST, F; FLOREY, CD; TAYLOR, D; MCPHERSON, F; YOUNG, JA				FORREST, F; FLOREY, CD; TAYLOR, D; MCPHERSON, F; YOUNG, JA			REPORTED SOCIAL ALCOHOL-CONSUMPTION DURING PREGNANCY AND INFANTS DEVELOPMENT AT 18 MONTHS	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL ALCOHOL; FOLLOW-UP; MOTOR DEVELOPMENT; REACTION-TIME; CHILDREN; NICOTINE; EXPOSURE; AGE; ATTENTION; CAFFEINE	Objective-To determine the relation between mothers' self reported drinking habits before, during, and after pregnancy and infants' mental and motor development at 18 months of age. Design-Follow up study of all singleton live births born to primigravidas living in Dundee and booked into antenatal clinics from 1 May 1985 to 30 April 1986. Setting-District of Dundee. Subjects-846 children aged 18 months, of whom 592 attended for assessment. Main outcome measures - Scores on Bayley scales of infant mental and motor development. Results-For full term children, maternal alcohol consumption was not significantly related to any adverse effect on the children's mental or motor development measures at age 18 months. After confounding factors had been controlled for, alcohol consumption before pregnancy and after pregnancy was significantly related to better motor performance and mental performance. Conclusion-Pregnant women probably need not abstain from alcohol altogether as no detectable adverse relation was found between the child's mental and physical development and the mother's weekly consumption at levels in excess of 100 g absolute alcohol. However, to allow for a margin of safety and taking into account the findings of an earlier phase of this study on the immediate effects on the newborn, it is recommended that pregnant women should drink no more than eight units of alcohol a week, the equivalent of about one drink a day.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT OBSTET & GYNAECOL,DUNDEE DD1 9SY,SCOTLAND; ROYAL DUNDEE LIFF HOSP,DEPT CLIN PSYCHOL,LIFF DD2 5NF,ANGUS,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CHILD HLTH,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee; University of Dundee								BARR HM, 1984, PEDIATRICS, V74, P336; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; COLES C D, 1987, Advances in Alcohol and Substance Abuse, V6, P87; FORREST F, 1989, NEEDS PARENTS INFANT, P31; FORREST FML, 1991, THESIS U DUNDEE DUND; FORREST FML, 1991, THESIS U DUNDEE; FRIED PA, 1988, NEUROTOXICOL TERATOL, V10, P305, DOI 10.1016/0892-0362(88)90032-3; GRISSO JA, 1984, J EPIDEMIOL COMMUN H, V38, P232, DOI 10.1136/jech.38.3.232; GUSELLA JL, 1984, NEUROBEH TOXICOL TER, V6, P13; JONES KL, 1973, LANCET, V2, P999; KAMINSKI M, 1981, NEUROBEH TOXICOL TER, V3, P173; KUZMA JW, 1982, ALCOHOL CLIN EXP RES, V6, P396, DOI 10.1111/j.1530-0277.1982.tb04998.x; KYLLERMAN M, 1983, NEUROPEDIATRICS, V2, P121; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; LARSSON G, 1985, ARCH DIS CHILD, V60, P316, DOI 10.1136/adc.60.4.316; LITTLE RE, 1989, NEW ENGL J MED, V321, P425, DOI 10.1056/NEJM198908173210703; MAU G, 1980, EUR J PEDIATR, V133, P233, DOI 10.1007/BF00496082; OCONNOR MJ, 1986, PEDIATRICS, V78, P444; PLANT M, 1987, WOMEN DRINKING PREGN; ROMAN R, 1988, ISSUES REV TERATOLOG, V4, P205; SPOHR HL, 1984, CIBA F SYMP, V105, P197; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1989, DEV PSYCHOL, V25, P3, DOI 10.1037/0012-1649.25.1.3; STREISSGUTH AP, 1983, CHILD DEV, V54, P1109, DOI 10.2307/1129667; STREISSGUTH AP, 1986, NEUROTOXICOL TERATOL, V8, P717; STREISSGUTH AP, 1980, ALCOHOL CLIN EXP RES, V4, P152, DOI 10.1111/j.1530-0277.1980.tb05630.x; STREISSGUTH AP, 1984, DEV PSYCHOL, V20, P533, DOI 10.1037/0012-1649.20.4.533; SULAIMAN ND, 1988, BRIT MED J, V296, P1500, DOI 10.1136/bmj.296.6635.1500	28	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 6	1991	303	6793					22	26		10.1136/bmj.303.6793.22	http://dx.doi.org/10.1136/bmj.303.6793.22			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FW128	1859950	Bronze, Green Published			2022-12-28	WOS:A1991FW12800021
J	CONWELL, Y; CAINE, ED				CONWELL, Y; CAINE, ED			RATIONAL SUICIDE AND THE RIGHT-TO-DIE - REALITY AND MYTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL PATIENTS; ILL PATIENTS; DEPRESSION; PHYSICIANS				CONWELL, Y (corresponding author), UNIV ROCHESTER,SCH MED,ROCHESTER,NY 14642, USA.		Conwell, Yeates/C-9347-2011	Conwell, Yeates/0000-0001-8517-2132				BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; BARRACLOUGH BM, 1971, BR J PSYCHIATRY S, V6, P87; BROMBERG S, 1983, J AM GERIATR SOC, V31, P698, DOI 10.1111/j.1532-5415.1983.tb04157.x; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; BUTLER RN, 1982, AGING MENTAL HLTH; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHYNOWETH R, 1980, AUST NZ J PSYCHIAT, V14, P37, DOI 10.3109/00048678009159352; CONWELL Y, 1991, ELDERLY CHRONIC MENT, P31; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; KNIGHTS EB, 1977, ANN INTERN MED, V87, P723, DOI 10.7326/0003-4819-87-6-723; MALCOLM A, 1990, NY TIMES        0614, pA6; MOFFIC HS, 1975, BRIT J PSYCHIAT, V126, P346, DOI 10.1192/bjp.126.4.346; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; OKIMOTO JT, 1982, AM J PSYCHIAT, V139, P799; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; Shneidman E. S., 1986, SOME ESSENTIALS SUIC, P1; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1987, VITAL HLTH STATIST 3, V25; 1987, NIH872950 PUBL, P37	21	99	101	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1991	325	15					1100	1103		10.1056/NEJM199110103251511	http://dx.doi.org/10.1056/NEJM199110103251511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	GJ108	1891013				2022-12-28	WOS:A1991GJ10800011
J	BREO, DL				BREO, DL			THE LASKER AWARDS - HONORING THE SPIRIT OF MEDICAL SCIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1843	1845		10.1001/jama.266.13.1843	http://dx.doi.org/10.1001/jama.266.13.1843			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890714				2022-12-28	WOS:A1991GG55100041
J	KOREN, G; KLEIN, N				KOREN, G; KLEIN, N			BIAS AGAINST NEGATIVE STUDIES IN NEWSPAPER REPORTS OF MEDICAL-RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective. - To assess if the reporting of controversial medical journal articles by newspapers reflects the existence of a bias against negative studies (those showing no effect), we compared the rates of newspaper reporting of two studies, one negative and one positive, published back-to-back in the March 20, 1991, issue of JAMA. Both studies analyzed an area of public health concern, radiation as a risk for cancer. Design. - Seven computerized on-line databases were screened for daily newspapers published in North America during the week following JAMA's publication of the two studies. These databases had full-text access to 168 daily newspapers. Newspapers identified with reports of the two studies were analyzed for length and quality of the reports. Results. - Seventeen newspapers, publishing 19 reports on the two studies, were identified. Nine reports were dedicated solely to the positive study and 10 reports covered both studies. None of the reports were dedicated to the negative study only. In reports covering both studies, the mean length of the positive reports was significantly longer than the mean length of the negative reports (354 +/- 181 words vs 192 +/- 178 words; P = .04). The mean quality score of the positive reports was significantly higher than that of the negative reports (10.1 +/- 3.4 vs 5.9 +/- 4.9; P = .02). Conclusions. - The number, length, and quality of newspaper reports on the positive study were greater than news reports on the negative study, which suggests a bias against news reports of studies showing no effects or no adverse effects.	UNIV TORONTO,DEPT PEDIAT & PHARMACOL,TORONTO M5S 1A1,ONTARIO,CANADA; ONTARIO MINIST HLTH,TORONTO M5W 1R5,ONTARIO,CANADA	University of Toronto	KOREN, G (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,DIV CLIN PHARMACOL & TOXICOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; JABLON S, 1991, JAMA-J AM MED ASSOC, V265, P1403; KOREN G, 1989, LANCET, V2, P1440; Rosenthal R., 1984, META ANAL PROCEDURES; TRICHOPOULOS D, 1987, BMJ, V295, P100; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397	7	106	107	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1824	1826		10.1001/jama.266.13.1824	http://dx.doi.org/10.1001/jama.266.13.1824			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890712				2022-12-28	WOS:A1991GG55100036
J	STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL				STRICKBERGER, SA; CANTILLON, CO; FRIEDMAN, PL			WHEN SHOULD PATIENTS WITH LETHAL VENTRICULAR ARRHYTHMIA RESUME DRIVING - AN ANALYSIS OF STATE REGULATIONS AND PHYSICIAN PRACTICES	ANNALS OF INTERNAL MEDICINE			English	Article						ARRHYTHMIA; ELECTRIC COUNTERSHOCK; DEATH, SUDDEN; AUTOMOBILE DRIVING; LEGISLATION, MEDICAL	IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; HOSPITAL CARDIAC-ARREST; FOLLOW-UP; SURVIVORS; FIBRILLATION; THERAPY	Most states have specific laws governing whether patients with seizure disorders can drive. To learn whether similar laws exist for patients with lethal ventricular arrhythmias, we surveyed the Departments of Motor Vehicles in all 50 states. In addition, either an arrhythmia specialist (n = 25) or a general cardiologist (n = 25) was chosen randomly from each state and interviewed to study physician awareness of such laws and physician attitudes toward driving by patients with arrhythmias. Forty-two states (84%) have laws restricting driving by patients who have seizures; only 8 states (16%) have specific laws for patients with arrhythmias. No state makes a distinction between driving by patients with arrhythmias who are managed with an implantable cardioverter-defibrillator (ICD) compared with patients who are managed medically. Seventy-four percent of physicians did not know their own state's laws about driving by patients who have ventricular arrhythmias. Cardiologists were more likely to advise no driving restriction for medically treated patients than for ICD-treated patients. Cardiologists were also more likely to advise permanent restriction for patients with ICDs than for patients treated medically. We conclude that greater legal and medical consensus is needed to guide physicians in advising patients with lethal ventricular arrhythmias about driving restrictions.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								AXTELL KA, 1990, CIRCULATION, V82, P211; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; ECHT DS, 1985, CIRCULATION, V71, P289, DOI 10.1161/01.CIR.71.2.289; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; LARSEN GC, 1990, CIRCULATION, V82, P83; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; MYERBURG RJ, 1982, JAMA-J AM MED ASSOC, V247, P1485, DOI 10.1001/jama.247.10.1485; MYERBURG RJ, 1987, CARDIAC ARRHYTHMIAS, P505; ROY D, 1983, AM J CARDIOL, V52, P969, DOI 10.1016/0002-9149(83)90514-3; RUSKIN JN, 1980, NEW ENGL J MED, V303, P607, DOI 10.1056/NEJM198009113031103; SKALE BT, 1986, AM J CARDIOL, V57, P113, DOI 10.1016/0002-9149(86)90962-8; TCHOU PJ, 1988, ANN INTERN MED, V109, P529, DOI 10.7326/0003-4819-109-7-529; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0	15	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					560	563		10.7326/0003-4819-115-7-560	http://dx.doi.org/10.7326/0003-4819-115-7-560			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883126				2022-12-28	WOS:A1991GG28300009
J	SQUIRE, LR; ZOLAMORGAN, S				SQUIRE, LR; ZOLAMORGAN, S			THE MEDIAL TEMPORAL-LOBE MEMORY SYSTEM	SCIENCE			English	Article							COMBINED AMYGDALO-HIPPOCAMPAL; TRANSIENT FOREBRAIN ISCHEMIA; VISUAL RECOGNITION; AMNESIC SYNDROME; BASAL FOREBRAIN; DIENCEPHALIC AMNESIA; IMPLICIT MEMORY; WORKING-MEMORY; RHESUS-MONKEY; IMPAIR MEMORY	Studies of human amnesia and studies of an animal model of human amnesia in the monkey have identified the anatomical components of the brain system for memory in the medial temporal lobe and have illuminated its function. This neural system consists of the hippocampus and adjacent, anatomically related cortex, including entorhinal, perirhinal, and parahippocampal cortices. These structures, presumably by virtue of their widespread and reciprocal connections with neocortex, are essential for establishing long-term memory for facts and events (declarative memory). The medial temporal lobe memory system is needed to bind together the distributed storage sites in neocortex that represent a whole memory. However, the role of this system is only temporary. As time passes after learning, memory stored in neocortex gradually becomes independent of medial temporal lobe structures.	UNIV CALIF SAN DIEGO, DEPT PSYCHIAT, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	SQUIRE, LR (corresponding author), VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH024600, R37MH024600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019063] Funding Source: NIH RePORTER; NIMH NIH HHS [MH24600] Funding Source: Medline; NINDS NIH HHS [NS19063] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGGLETON JP, 1988, NEUROPSYCHOLOGIA, V26, P265, DOI 10.1016/0028-3932(88)90079-6; AGGLETON JP, 1985, EXP BRAIN RES, V58, P190; AGGLETON JP, 1983, NEUROPSYCHOLOGIA, V21, P189, DOI 10.1016/0028-3932(83)90037-4; ALVAREZROYO P, IN PRESS J NEUROSCI; Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; [Anonymous], 1987, HDB PHYSL 1 NERVOUS; AUER RN, 1989, J NEUROSCI, V9, P1641; BACHEVALIER J, 1985, EXP BRAIN RES, V57, P554; BACHEVALIER J, 1985, EXP BRAIN RES, V57, P547; BECKER JT, 1980, BRAIN RES, V200, P307, DOI 10.1016/0006-8993(80)90922-1; BENSON DF, 1974, ACTA NEUROL SCAND, V50, P133; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CIRILLO RA, 1989, BEHAV BRAIN RES, V34, P55, DOI 10.1016/S0166-4328(89)80090-7; CLOWER R, IN PRESS SOC NEUR AB; CLOWER R P, 1990, Society for Neuroscience Abstracts, V16, P616; Cohen N. J., 1984, NEUROPSYCHOLOGY MEMO, P83; CORKIN S, 1984, SEMIN NEUROL, V4, P249, DOI 10.1055/s-2008-1041556; CORRELL RE, 1965, J COMP PHYSIOL PSYCH, V60, P175, DOI 10.1037/h0022290; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P263, DOI 10.1001/archneur.1985.04060030081013; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; Damasio H, 1989, LESION ANAL NEUROPSY; DAVIS HP, 1986, PHYSIOL BEHAV, V37, P387, DOI 10.1016/0031-9384(86)90195-2; DAVIS HP, 1990, SYMP MED H, V23, P477; DAVIS M, 1986, BEHAV NEUROSCI, V100, P814, DOI 10.1037/0735-7044.100.6.814; DAVIS M, 1982, SCIENCE, V218, P688, DOI 10.1126/science.7134967; DeJong R N, 1968, Trans Am Neurol Assoc, V93, P31; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; DUYCKAERTS C, 1985, ANN NEUROL, V18, P314, DOI 10.1002/ana.410180307; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; EICHENBAUM H, 1986, J NEUROSCI, V6, P1876; FAGG GE, 1985, TRENDS NEUROSCI, V8, P207, DOI 10.1016/0166-2236(85)90080-3; FRIEDMAN HR, 1988, J NEUROSCI, V8, P4693; GAFFAN D, 1974, J COMP PHYSIOL PSYCH, V86, P1100, DOI 10.1037/h0037649; GAFFAN D, 1987, J NEUROSCI, V7, P2285; GALLAGHER M, 1990, J NEUROSCI, V10, P1906; Glees P, 1952, MON PSYCHIATR NEUROL, V123, P193; GRAFFRADFORD NR, 1990, BRAIN, V113, P1, DOI 10.1093/brain/113.1.1; Grunthal E, 1947, MON PSYCHIATR NEUROL, V113, P1; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HINTZMAN DL, 1990, ANNU REV PSYCHOL, V41, P109, DOI 10.1146/annurev.psych.41.1.109; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; HOREL JA, 1987, BEHAV BRAIN RES, V23, P29, DOI 10.1016/0166-4328(87)90240-3; HOREL JA, 1982, J NEUROPHYSIOL, V47, P11, DOI 10.1152/jn.1982.47.1.11; HOREL JA, 1978, BRAIN, V101, P403, DOI 10.1093/brain/101.3.403; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; INSAUSTI R, 1987, J COMP NEUROL, V264, P356, DOI 10.1002/cne.902640306; Isaacson R, 2013, THE LIMBIC SYSTEM; Iversen S D, 1976, Int Rev Neurobiol, V19, P1, DOI 10.1016/S0074-7742(08)60700-X; JARRARD LE, 1986, HIPPOCAMPUS, V4, P93; KESNER RP, IN PRESS AMYGDALA; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; LEATON RN, 1986, SCIENCE, V232, P513, DOI 10.1126/science.3961494; MAHUT H, 1982, J NEUROSCI, V2, P1214; MAHUT H, 1981, NEUROPSYCHOLOGIA, V19, P201, DOI 10.1016/0028-3932(81)90105-6; MAHUT H, 1984, NEUROPSYCHOLOGY MEMO, P297; MALAMUT BL, 1984, BEHAV NEUROSCI, V98, P759, DOI 10.1037/0735-7044.98.5.759; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; McNaughton BL, 1990, NEUROSCIENCE CONNECT, P1; MELDRUM B, 1985, TRENDS NEUROSCI, V8, P47, DOI 10.1016/0166-2236(85)90024-4; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; Milner B, 1972, Clin Neurosurg, V19, P421; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; MILNER B, 1974, NEUROSCIENCES 3 STUD, P00075; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MISHKIN M, 1982, TREATMENT ALZHEIMERS, P235; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MOSCOVITCH M, 1982, HUMAN MEMORY AMNESIA, P337; MURRAY E, IN PRESS AMYGDALA; MURRAY EA, 1986, J NEUROSCI, V6, P1991; MURRAY EA, 1984, J NEUROSCI, V4, P2565; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; OLTON DS, 1987, BRAIN RES, V404, P180, DOI 10.1016/0006-8993(87)91369-2; ORBACH J, 1960, ARCH NEUROL-CHICAGO, V3, P320; OVERMAN WH, 1990, EXP BRAIN RES, V79, P18; PACKARD MG, 1989, J NEUROSCI, V9, P1465; Petri HL, 1984, NEUROPSYCHOLOGY MEMO, P287; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; REMPEL N, IN PRESS SOC NEUR AB; RINGO JL, 1988, BEHAV NEUROSCI, V102, P173, DOI 10.1037/0735-7044.102.1.173; ROSE FC, 1960, BRAIN, V83, P195, DOI 10.1093/brain/83.2.195; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SALMON DP, 1987, PSYCHOBIOLOGY, V15, P37; SAUNDERS RC, 1984, NEUROPSYCHOLOGIA, V22, P785, DOI 10.1016/0028-3932(84)90103-9; SAUNDERS RC, 1989, BEHAV BRAIN RES, V35, P85, DOI 10.1016/S0166-4328(89)80109-3; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1982, ANNU REV NEUROSCI, V5, P241, DOI 10.1146/annurev.ne.05.030182.001325; SQUIRE LR, 1988, BEHAV NEUROSCI, V102, P210, DOI 10.1037/0735-7044.102.2.210; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; SQUIRE LR, 1988, TRENDS NEUROSCI, V11, P170, DOI 10.1016/0166-2236(88)90144-0; SQUIRE LR, IN PRESS PSYCHOL REV; SQUIRE LR, 1983, PHYSL BASIS MEMORY, P199; SQUIRE LR, IN PRESS SOC NEUR AB; SQUIRE LR, 1989, NEURAL MODELS PLASTI, P208; SQUIRE LR, 1990, BIOL MEMORY, P643; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; SUTHERLAND RJ, 1989, BEHAV NEURAL BIOL, V52, P331, DOI 10.1016/S0163-1047(89)90457-3; SUTHERLAND RJ, 1990, BEHAV BRAIN RES, V37, P57, DOI 10.1016/0166-4328(90)90072-M; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; Van Hoesen G W, 1991, Hippocampus, V1, P1, DOI 10.1002/hipo.450010102; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; VICTOR M, 1961, ARCH NEUROL-CHICAGO, V5, P244, DOI 10.1001/archneur.1961.00450150010002; Victor M., 1989, WERNICKE KORSAKOFF S, V2nd; VOLPE BT, 1984, STROKE, V15, P558, DOI 10.1161/01.STR.15.3.558; VONCRAMON DY, 1985, BRAIN, V108, P993, DOI 10.1093/brain/108.4.993; WANG J, 1990, Society for Neuroscience Abstracts, V16, P617; WEISKRANTZ L, 1987, HUM NEUROBIOL, V6, P93; WEISKRANTZ L, 1971, COGNITIVE PROCESS, P25; WOODS BT, 1982, J NEUROL NEUROSUR PS, V45, P243, DOI 10.1136/jnnp.45.3.243; Zola-Morgan S, 1991, Hippocampus, V1, P207, DOI 10.1002/hipo.450010208; ZOLA-MORGAN S, 1989, Society for Neuroscience Abstracts, V15, P341; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P1922; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P898; ZOLAMORGAN S, 1984, J NEUROSCI, V4, P1072; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355; ZOLAMORGAN S, 1982, SCIENCE, V218, P1337, DOI 10.1126/science.6890713; ZOLAMORGAN S, 1990, SYMP MED H, V23, P509; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZOLAMORGAN S, 1991, DEV NEURAL BASIS COG, P434; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	134	2218	2249	2	244	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1991	253	5026					1380	1386		10.1126/science.1896849	http://dx.doi.org/10.1126/science.1896849			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1896849	Green Submitted			2022-12-28	WOS:A1991GF85100031
J	KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD				KALLEN, J; SPITZFADEN, C; ZURINI, MGM; WIDER, G; WIDMER, H; WUTHRICH, K; WALKINSHAW, MD			STRUCTURE OF HUMAN CYCLOPHILIN AND ITS BINDING-SITE FOR CYCLOSPORINE-A DETERMINED BY X-RAY CRYSTALLOGRAPHY AND NMR-SPECTROSCOPY	NATURE			English	Article							CIS-TRANS ISOMERASE; PROTEIN; REFINEMENT	THE protein cyclophilin is the major intracellular receptor for the immunosuppressive drug cyclosporin A (ref. 1). Cyclosporin A acts as an inhibitor of T-cell activation and can prevent graft rejection in organ and bone marrow transplantation 2. Cyclophilin may be responsible for mediating this immunosuppressive response. Cyclophilin also catalyses the interconversion of the cis and trans isomers of the peptidyl-prolyl amide bonds of peptide and protein substrates 3,4. Here we report the X-ray crystal structure of human recombinant cyclophilin complexed with a tetrapeptide and the identification, by nuclear magnetic resonance spectroscopy, of the specific binding site for cyclosporin A. Cyclophilin has an eight-stranded antiparallel beta-barrel structure. The prolyl isomerase substrate-binding site is coincident with the cyclosporin-binding site. These results may help to provide a structural basis for rationalizing the immunosuppressive function of the cyclosporin-cyclophilin system and will also be important in the design of improved immunosuppressant drugs.	SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; SWISS FED INST TECHNOL,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Novartis; Sandoz; Swiss Federal Institutes of Technology Domain; ETH Zurich			walkinshaw, malcolm/AAB-7497-2019	Wider, Gerhard/0000-0001-9366-7645; walkinshaw, malcolm/0000-0001-5955-9325				BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLUNDELL TL, 1976, PROTEIN CRYSTALLOGRA, P357; BOREL JF, 1989, PHARMACOL REV, V41, P259; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KE H, IN PRESS P NATN ACAD; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, IN PRESS FEBS LETT; ZURINI M, 1990, FEBS LETT, V276, P63, DOI 10.1016/0014-5793(90)80507-F; 1986, CCP4 SUITE PROGRAMS	22	255	261	3	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1991	353	6341					276	279		10.1038/353276a0	http://dx.doi.org/10.1038/353276a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF674	1896075				2022-12-28	WOS:A1991GF67400066
J	DAUNICHT, WJ				DAUNICHT, WJ			AUTOASSOCIATION AND NOVELTY DETECTION BY NEUROMECHANICS	SCIENCE			English	Article							NETWORKS	Many biomechanical systems contain ball joints with several clastic actuators (muscles) obliquely attached to the links. The problem, of calculating the optimum actuator commands to achieve a desired link orientation is a difficult one for any control system; however, the elasticity of the actuators may be part of the solution. Mechanoreceptors such as those found in muscles and tendons are capable of performing operations that can be regarded as autoassociation and novelty detection, respectively, by minimization of potential energy. The information provided by such sensors may then be exploited for optimization of muscle coordination.			DAUNICHT, WJ (corresponding author), UNIV DUSSELDORF,INST PHYS BIOL,BIOKYBERNET ABT,W-4000 DUSSELDORF 1,GERMANY.							ABUMOSTAFA YS, 1987, SCI AM, V256, P88, DOI 10.1038/scientificamerican0387-88; BENISRAEL A, 1974, GENERALIZED INVERSES; COOPER S, 1949, BRAIN, V72, P1, DOI 10.1093/brain/72.1.1; DAUNICHT WJ, 1988, BIOL CYBERN, V58, P225, DOI 10.1007/BF00364128; DAUNICHT WJ, UNPUB; GRAF HP, 1988, COMPUTER, V21, P41, DOI 10.1109/2.30; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KIRKPATRICK S, 1978, PHYS REV B, V17, P4384, DOI 10.1103/PhysRevB.17.4384; KLEIN CA, 1983, IEEE T SYST MAN CYB, V13, P245, DOI 10.1109/TSMC.1983.6313123; KOHONEN T, 1976, BIOL CYBERN, V21, P85, DOI 10.1007/BF01259390; KOHONEN T, 1989, SELF ORG ASS MEMORY, pCH4; MAEKAWA K, 1980, BRAIN RES, V191, P313, DOI 10.1016/0006-8993(80)91283-4; PELLIONISZ A, 1980, NEUROSCIENCE, V5, P1125, DOI 10.1016/0306-4522(80)90191-8; PELLIONISZ A, 1985, ADAPTIVE MECHANISMS, P281; REILLY DL, 1990, INTRO NEURAL ELECT N, P227; RICHMOND FJR, 1984, INVEST OPHTH VIS SCI, V25, P471; Volkmann A., 1869, BER VERH K SAECHS GE, V21, P28	17	10	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1289	1291		10.1126/science.1891718	http://dx.doi.org/10.1126/science.1891718			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891718				2022-12-28	WOS:A1991GE68900044
J	KUNA, ST; SANTAMBROGIO, G				KUNA, ST; SANTAMBROGIO, G			PATHOPHYSIOLOGY OF UPPER AIRWAY-CLOSURE DURING SLEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRICOARYTENOID MUSCLE-ACTIVITY; RESPIRATORY MOTOR-ACTIVITY; APNEA SYNDROME; NORMAL ADULTS; ELECTROMYOGRAPHIC ACTIVITY; OXYGEN DESATURATION; CLOSING PRESSURES; OBESE PATIENTS; UVULOPALATOPHARYNGOPLASTY; OCCLUSION	While the upper airway normally remains patent during quiet breathing in wakefulness and sleep, patients with obstructive sleep apnea have repetitive periods of upper airway closure during sleep. The upper airway closures usually occur at various sites in the pharynx. The patency of the potentially collapsible pharynx during inspiration depends on the balance between subatmospheric pressure in the pharyngeal airway and airway dilating forces generated by pharyngeal muscles. The pressure required to collapse the upper airway in the absence of upper airway muscle activity, ie, closing pressure, is normally subatmospheric. In obstructive sleep apnea, positive pressures are required to maintain patency of the passive upper airway. The pathophysiologic mechanisms underlying upper airway closures during sleep form the basis for the treatment of obstructive sleep apnea. In general, these treatment modalities attempt to (1) raise the pharyngeal pressure above the closing pressure, (2) decrease the closing pressure, or (3) increase upper airway muscle activity.	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston	KUNA, ST (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV PULM,E-61,GALVESTON,TX 77550, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027520, R01HL020122, K04HL002353] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20122, HL-02353, HL-27520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCH A M, 1981, Electromyography and Clinical Neurophysiology, V21, P317; BASNER RC, 1990, J APPL PHYSIOL, V69, P1098, DOI 10.1152/jappl.1990.69.3.1098; BASNER RC, 1989, J APPL PHYSIOL, V66, P1766, DOI 10.1152/jappl.1989.66.4.1766; BONORA M, 1985, AM REV RESPIR DIS, V131, P41; BONORA M, 1984, AM REV RESPIR DIS, V130, P156; BROUILLETTE RT, 1979, J APPL PHYSIOL, V46, P772, DOI 10.1152/jappl.1979.46.4.772; BROWNELL LG, 1982, NEW ENGL J MED, V307, P1037, DOI 10.1056/NEJM198210213071701; CARLO WA, 1985, J APPL PHYSIOL, V59, P847, DOI 10.1152/jappl.1985.59.3.847; CHABAN R, 1988, LARYNGOSCOPE, V98, P641; COHEN G, 1987, J APPL PHYSIOL, V62, P2026; CONWAY W, 1985, CHEST, V88, P385, DOI 10.1378/chest.88.3.385; CRAVATH RE, 1977, PEDIATRICS, V59, P865; DICKSON RI, 1987, LARYNGOSCOPE, V97, P1054; DOLLY FR, 1982, AM J MED, V73, P239, DOI 10.1016/0002-9343(82)90185-1; ELBAYADI S, 1990, CHEST, V98, P554, DOI 10.1378/chest.98.3.554; FUJITA S, 1981, OTOLARYNG HEAD NECK, V89, P923, DOI 10.1177/019459988108900609; FUJITA S, 1985, LARYNGOSCOPE, V95, P70; GISLASON T, 1988, ARCH OTOLARYNGOL, V114, P45; GOTHE B, 1985, CHEST, V87, P11, DOI 10.1378/chest.87.1.11; GUILLEMINAULT C, 1981, LUNG, V159, P275, DOI 10.1007/BF02713925; GUILLEMINAULT C, 1983, B EUR PHYSIOPATH RES, V19, P595; GUILLEMINAULT C, 1989, PRINCIPLES PRACTICE, P525; HOLLOWELL D E, 1989, American Review of Respiratory Disease, V139, pA448; HORNER RL, 1989, EUR RESPIR J, V2, P613; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P15, DOI 10.1113/jphysiol.1991.sp018536; HORNER RL, 1991, J PHYSIOL-LONDON, V436, P31, DOI 10.1113/jphysiol.1991.sp018537; HUDGEL D W, 1989, American Review of Respiratory Disease, V139, pA374; HUDGEL DW, 1988, AM REV RESPIR DIS, V138, P1542, DOI 10.1164/ajrccm/138.6.1542; HUDGEL DW, 1987, AM REV RESPIR DIS, V135, P899, DOI 10.1164/arrd.1987.135.4.899; HUDGEL DW, 1988, J APPL PHYSIOL, V64, P1930, DOI 10.1152/jappl.1988.64.5.1930; HUDGEL DW, 1986, J APPL PHYSIOL, V61, P1403, DOI 10.1152/jappl.1986.61.4.1403; HYLAND RH, 1981, AM REV RESPIR DIS, V124, P180; ISSA FG, 1984, J APPL PHYSIOL, V57, P520, DOI 10.1152/jappl.1984.57.2.520; ISSA FG, 1983, J APPL PHYSIOL, V55, P1113, DOI 10.1152/jappl.1983.55.4.1113; ISSA FG, 1984, J APPL PHYSIOL, V57, P528, DOI 10.1152/jappl.1984.57.2.528; JEFFRIES B, 1984, AM REV RESPIR DIS, V129, P696, DOI 10.1164/arrd.1984.129.5.696; KUNA ST, 1988, AM REV RESPIR DIS, V138, P969, DOI 10.1164/ajrccm/138.4.969; KUNA ST, 1988, AM REV RESPIR DIS, V137, P656, DOI 10.1164/ajrccm/137.3.656; KUNA ST, 1990, J APPL PHYSIOL, V68, P1746, DOI 10.1152/jappl.1990.68.4.1746; KUNA ST, 1988, J APPL PHYSIOL, V65, P1332, DOI 10.1152/jappl.1988.65.3.1332; LAUNOIS S H, 1990, American Review of Respiratory Disease, V141, pA861; LEITER JC, 1990, J APPL PHYSIOL, V68, P2581, DOI 10.1152/jappl.1990.68.6.2581; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MCNICHOLAS WT, 1987, AM REV RESPIR DIS, V135, P1316; MIKI H, 1988, AM REV RESPIR DIS, V137, pA125; NISHINO T, 1984, ANESTHESIOLOGY, V60, P19, DOI 10.1097/00000542-198401000-00005; OLSEN KD, 1990, MAYO CLIN PROC, V65, P1095, DOI 10.1016/S0025-6196(12)62722-0; ONAL E, 1986, J APPL PHYSIOL, V61, P1438, DOI 10.1152/jappl.1986.61.4.1438; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; RAJAGOPAL KR, 1984, ANN INTERN MED, V101, P491, DOI 10.7326/0003-4819-101-4-491; Remmers J E, 1980, Sleep, V3, P447; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; REMMERS JE, 1989, PRINCIPLES PRACTICE, P525; RIVLIN J, 1984, AM REV RESPIR DIS, V129, P355; RYAN CF, 1990, LARYNGOSCOPE, V100, P248; SANTAMBROGIO FB, 1985, J APPL PHYSIOL, V58, P1298, DOI 10.1152/jappl.1985.58.4.1298; SAUERLAND E K, 1981, Electromyography and Clinical Neurophysiology, V21, P307; SAUERLAND EK, 1976, EXP NEUROL, V51, P160, DOI 10.1016/0014-4886(76)90061-3; SHEPARD JW, 1990, AM REV RESPIR DIS, V141, P1350, DOI 10.1164/ajrccm/141.5_Pt_1.1350; SIMONDS AK, 1985, THORAX, V40, P213; SMITH PL, 1985, ANN INTERN MED, V103, P850, DOI 10.7326/0003-4819-103-6-850; STROHL KP, 1986, AM REV RESPIR DIS, V134, P555; STROHL KP, 1978, NEW ENGL J MED, V299, P969, DOI 10.1056/NEJM197811022991801; STROHL KP, 1985, J APPL PHYSIOL, V58, P452, DOI 10.1152/jappl.1985.58.2.452; SULLIVAN CE, 1981, LANCET, V1, P862; SULLIVAN CE, 1984, B EUR PHYSIOPATH RES, V20, P49; SURATT PM, 1983, AM REV RESPIR DIS, V127, P487, DOI 10.1164/arrd.1983.127.4.487; SURATT PM, 1985, J APPL PHYSIOL, V58, P1252, DOI 10.1152/jappl.1985.58.4.1252; TAASAN VC, 1981, AM J MED, V71, P240; VANDEGRAAFF WB, 1984, J APPL PHYSIOL, V57, P197, DOI 10.1152/jappl.1984.57.1.197; VANLUNTEREN E, 1983, RESP PHYSIOL, V53, P87, DOI 10.1016/0034-5687(83)90018-X; VANLUNTEREN E, 1984, J APPL PHYSIOL, V56, P746, DOI 10.1152/jappl.1984.56.3.746; WIEGAND DA, 1990, J APPL PHYSIOL, V69, P1262, DOI 10.1152/jappl.1990.69.4.1262; WIEGAND L, 1989, J APPL PHYSIOL, V66, P1800, DOI 10.1152/jappl.1989.66.4.1800; WILSON SL, 1980, J APPL PHYSIOL, V48, P500, DOI 10.1152/jappl.1980.48.3.500	75	63	76	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1991	266	10					1384	1389		10.1001/jama.266.10.1384	http://dx.doi.org/10.1001/jama.266.10.1384			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD807	1880868				2022-12-28	WOS:A1991GD80700033
J	SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML				SENIE, RT; ROSEN, PP; RHODES, P; LESSER, ML			TIMING OF BREAST-CANCER EXCISION DURING THE MENSTRUAL-CYCLE INFLUENCES DURATION OF DISEASE-FREE SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; MENSTRUAL CYCLE; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; FOLLICULAR PHASE	PERIPHERAL-BLOOD; SURGICAL CURE; CARCINOMA; EPIDEMIOLOGY; WOMEN	Objective: To study disease-free survival at 10 years in relation to timing of breast tumor excision during the menstrual cycle. Design: A prospective study of consecutively treated patients with primary breast cancer. Setting: Memorial Sloan-Kettering Cancer Center, New York. Patients: Two hundred and eighty-three premenopausal patients treated by mastectomy and axillary dissection. Main Results: When the tumor was excised during the follicular phase, approximated by setting the putative day of ovulation on day 14 after the onset of last menses, a higher recurrence risk (43%) was observed compared with excision later in the menstrual cycle (29%, P = 0.02). The rate peaked among patients treated between days 7 and 14 and was lowest between days 20 and 30. Multivariate analysis using the Cox regression model to control for tumor size, nodal status, estrogen receptor status, adjuvant chemotherapy, and family history indicated that the hazard rate of breast cancer recurrence after excision during the follicular phase was 1.53 (95% Cl, 1.02 to 2.29). Stratification by nodal status indicated that the effect of phase was statistically significant only among patients with positive nodes (hazard ratio, 2.10; Cl, 1.19 to 3.70). Conclusions: Our results support the hypothesis that the risk for recurrence may be affected by the hormonal milieu of the menstrual cycle; these findings must be confirmed, however, by a prospective study in which cycle phase at time of tumor excision is biochemically documented.	MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, MANHASSET, NY 11030 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital	SENIE, RT (corresponding author), CTR DIS CONTROL, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.							AKSEL S, 1981, FERTIL STERIL, V36, P521; ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; AXELROD DM, 1988, CANCER INVEST, V6, P7, DOI 10.3109/07357908809077024; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BIEGLMAYER C, 1990, FERTIL STERIL, V53, P842; BROWN JB, 1989, INT J GYNECOL OBSTET, P111; CHIAZZE L, 1968, J AMER MED ASSOC, V203, P377, DOI 10.1001/jama.203.6.377; COX DR, 1972, J R STAT SOC B, V34, P187; GELBER RD, 1989, LANCET, V2, P1344; HEISE E, 1982, ONCOLOGY, V39, P340, DOI 10.1159/000225667; HRUSHESKY WJM, 1988, J NATL CANCER I, V80, P1232, DOI 10.1093/jnci/80.15.1232; HRUSHESKY WJM, 1989, LANCET, V2, P949; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LESSER ML, 1982, SURGERY, V91, P234; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; METCALF MG, 1983, NEW ZEAL MED J, V96, P645; POWLES TJ, 1989, LANCET, V2, P1343; RATAJCZAK HV, 1988, J EXP MED, V168, P73, DOI 10.1084/jem.168.1.73; ROSEN PP, 1982, CANCER, V50, P171, DOI 10.1002/1097-0142(19820701)50:1<171::AID-CNCR2820500132>3.0.CO;2-M; SENIE R T, 1990, Breast Cancer Research and Treatment, V16, P146; SENIE RT, 1981, AM J PUBLIC HEALTH, V71, P583, DOI 10.2105/AJPH.71.6.583; SENIE RT, 1980, CANCER, V46, P1705, DOI 10.1002/1097-0142(19801001)46:7<1705::AID-CNCR2820460734>3.0.CO;2-Q; SENIE RT, 1985, BREAST CANCER RES TR, V5, P301, DOI 10.1007/BF01806025; STRATTON JA, 1984, J CLIN LAB IMMUNOL, V15, P127; SULKE AN, 1985, BRIT MED J, V290, P884, DOI 10.1136/bmj.290.6472.884; TRELOAR AE, 1967, INT J FERTIL, V12, P77; VIGNON F, 1983, J CLIN ENDOCR METAB, V56, P1124, DOI 10.1210/jcem-56-6-1124; VILLE Y, 1990, BREAST CANCER RES TR, V16, P119, DOI 10.1007/BF01809296; VOGEL PM, 1981, AM J PATHOL, V104, P23; Vollman RF., 1977, MENSTRUAL CYCLE; WHITE D, 1982, BRIT J CANCER, V46, P611, DOI 10.1038/bjc.1982.245; 1989, CLIN GYNECOLOGIC END, P3	34	118	118	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1991	115	5					337	342		10.7326/0003-4819-115-5-337	http://dx.doi.org/10.7326/0003-4819-115-5-337			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC065	1863022				2022-12-28	WOS:A1991GC06500001
J	BREO, DL				BREO, DL			WOLFE,SIDNEY - HEALING THE SYSTEM OR JUST RAISING HELL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		WOLFE, 1988, WORST PILLS BEST PIL	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1131	1133		10.1001/jama.266.8.1131	http://dx.doi.org/10.1001/jama.266.8.1131			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1865549				2022-12-28	WOS:A1991GB97500040
J	RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN				RISE, ML; FRANKEL, WN; COFFIN, JM; SEYFRIED, TN			GENES FOR EPILEPSY MAPPED IN THE MOUSE	SCIENCE			English	Article							EL MOUSE; QUANTITATIVE TRAITS; MENDELIAN FACTORS; LINKAGE MAP; MICE; PROVIRUSES; ANTICONVULSANTS; SUSCEPTIBILITY; SEIZURES; PROBES	The neurological mutant mouse strain El is a model for complex partial seizures in humans. The inheritance of epileptic seizures with seven conventional chromosomal markers and over 60 endogenous proviral markers was studied by means of backcrosses of El with two seizure-resistant strains, DBA/2J and ABP/LeJ. The major gene responsible for this epileptic phenotype (El-1) was localized to a region distal with respect to the centromere on chromosome 9. At least one other gene, El-2, linked to proviral markers on chromosome 2, also influences the seizure phenotype. In addition, a potential modifier of seizures was detected in the DBA/2J background. The location of El-1 on distal chromosome 9 may allow identification of an epilepsy candidate gene in humans on the basis of conserved synteny with human chromosome 3.	BOSTON COLL,DEPT BIOL,CHESTNUT HILL,MA 02167; TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,BOSTON,MA 02111	Boston College; Tufts University				Seyfried, Thomas/0000-0003-1491-3989	NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023355] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA44385] Funding Source: Medline; NINDS NIH HHS [NS 23355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON VE, 1986, ADV NEUROL, P59; BARANOV VS, 1987, CHROMOSOMA, V96, P60, DOI 10.1007/BF00285885; BAUMANN RJ, 1982, GENETIC BASIS EPILEP, P11; BRIGANDE J V, 1989, Epilepsia, V30, P652; DELGADOESCUETA AV, 1983, NEW ENGL J MED, V308, P1508, DOI 10.1056/NEJM198306233082506; EYFRIED TN, 1986, ADV NEUROL, P115; FELTON J, 1974, J BIOL CHEM, V249, P3267; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRANKEL WN, 1990, GENETICS, V124, P221; FRANKEL WN, 1989, J VIROL, V63, P1762; FRANKEL WN, 1991, MOUSE GENOME, V89, P266; FUETA Y, 1986, Journal of UOEH, V8, P417; FUKAHORI M, 1990, BRAIN RES, V529, P16, DOI 10.1016/0006-8993(90)90806-M; GLASER GH, 1977, PRACT MED, V10, P1; HAUSER WA, 1982, GENETIC BASIS EPILEP, P3; HONDA T, 1984, BRAIN DEV-JPN, V6, P22, DOI 10.1016/S0387-7604(84)80005-4; Imaizumi K., 1959, B EXP ANIM TOKYO, V8, P6; Kurokawa M, 1966, Prog Brain Res, V21, P112; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NEUMANN PE, 1990, BEHAV GENET, V20, P307, DOI 10.1007/BF01067798; NEUMANN PE, IN PRESS P NATL ACAD; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; RISE ML, UNPUB; SEARLE A G, 1987, Genomics, V1, P3, DOI 10.1016/0888-7543(87)90099-1; SEYFRIED TN, 1985, EPILEPSIA, V26, P143, DOI 10.1111/j.1528-1157.1985.tb05398.x; SEYFRIED TN, 1982, MOUSE BIOMEDICAL RES, P97; STOYE JP, 1988, J VIROL, V62, P168, DOI 10.1128/JVI.62.1.168-175.1988; SUGAYA E, 1986, EPILEPSIA, V27, P354, DOI 10.1111/j.1528-1157.1986.tb03553.x; SUZUKI J, 1976, EXPERIENTIA, V32, P336, DOI 10.1007/BF01940824; SUZUKI J, 1983, BRAIN RES, V266, P359, DOI 10.1016/0006-8993(83)90670-4	34	184	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					669	673		10.1126/science.1871601	http://dx.doi.org/10.1126/science.1871601			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1871601				2022-12-28	WOS:A1991GA30400040
J	BEATTIE, KL; FOWLER, RF				BEATTIE, KL; FOWLER, RF			SOLID-PHASE GENE ASSEMBLY	NATURE			English	Editorial Material							CHEMICAL SYNTHESIS; OLIGONUCLEOTIDES; DNA		HOUSTON ADV RES CTR,THE WOODLANDS,TX 77381		BEATTIE, KL (corresponding author), BAYLOR UNIV,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.							BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BEATTIE KL, 1988, BIOTECHNOL APPL BIOC, V10, P510; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; FRANK R, 1983, NUCLEIC ACIDS RES, V11, P4365, DOI 10.1093/nar/11.13.4365; HOSTOMSKY Z, 1987, NUCLEIC ACIDS RES, V15, P4849, DOI 10.1093/nar/15.12.4849; JAYARAMAN K, 1991, P NATL ACAD SCI USA, V88, P4084, DOI 10.1073/pnas.88.10.4084; KHORANA HG, 1979, SCIENCE, V203, P614, DOI 10.1126/science.366749; MATTHES HWD, 1984, EMBO J, V3, P801, DOI 10.1002/j.1460-2075.1984.tb01888.x; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P245, DOI 10.1016/S0040-4039(00)81376-3; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; RIORDAN ML, 1991, NATURE, V350, P442, DOI 10.1038/350442a0; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	15	23	31	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					548	549		10.1038/352548a0	http://dx.doi.org/10.1038/352548a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865911				2022-12-28	WOS:A1991GA22600071
J	[Anonymous]				[Anonymous]			ETHICAL PROBLEMS TO MERIT THE NAME	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					359	360						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861709				2022-12-28	WOS:A1991FZ34600001
J	MATSUMOTO, T; BEACH, D				MATSUMOTO, T; BEACH, D			PREMATURE INITIATION OF MITOSIS IN YEAST LACKING RCC1 OR AN INTERACTING GTPASE	CELL			English	Article							CDC2 PROTEIN-KINASE; FISSION YEAST; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; TYROSINE PHOSPHORYLATION; SEQUENCE-ANALYSIS; MITOTIC CONTROL; GENE	A fission yeast mutant is described in which the onset of mitosis is uncoupled from the completion of DNA replication. pim1 (premature initiation of mitosis) cells can undergo mitotic chromosome condensation and mitotic spindle formation without completion of S phase and without the cdc25 mitotic inducer. The M phase kinase is required for pim1-induced mitosis and becomes activated. pim1 encodes a homolog of the human RCC1 nuclear protein. pim1 mutants are fully rescued by overexpression of spi1, a newly identified essential gene whose predicted product shares 81% identity with human TC4. spi1 and TC4 define a new subclass within the "ras-like" GTPase superfamily that is structurally distinct from the ras, rho, or sec4 families. Diploid yeast that carry one wild-type and one disrupted copy of spi1 have multiple satellite nuclei, and mitotic haploidization occurs at very high frequency. spi1 appears to interact with pim1 in the maintenance of a coordinated cell cycle.			MATSUMOTO, T (corresponding author), COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724, USA.				NIGMS NIH HHS [GM34607] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1986, CELL, V44, P365, DOI 10.1016/0092-8674(86)90771-3; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN IM, 1988, J CELL SCI, V89, P343; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LITTLEFIELD JW, 1976, VARIATION SENESCENCE; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MITCHISON JMM, 1974, CELL CYCLE CONTROLS; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NIWA O, 1985, CURR GENET, V9, P463, DOI 10.1007/BF00434051; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; OHTSUBO M, 1991, EMBO J, V10, P1265, DOI 10.1002/j.1460-2075.1991.tb08068.x; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3722, DOI 10.1128/MCB.6.11.3722; SIKORSKI RS, 1989, GENETICS, V122, P19; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	56	212	222	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					347	360		10.1016/0092-8674(91)90624-8	http://dx.doi.org/10.1016/0092-8674(91)90624-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855255				2022-12-28	WOS:A1991FY71200015
J	ROLAND, M				ROLAND, M			FUNDHOLDING AND CASH LIMITS IN PRIMARY CARE - BLIGHT OR BLESSING .5.	BRITISH MEDICAL JOURNAL			English	Article											ROLAND, M (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CAMBRIDGE CB2 2QQ,ENGLAND.							FOSTER A, 1991, PRIMARY HLTH CARE MA, V1, P2; 1991, FHSAS TODAYS TOMORRO	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					171	172		10.1136/bmj.303.6795.171	http://dx.doi.org/10.1136/bmj.303.6795.171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878645	Green Published, Bronze			2022-12-28	WOS:A1991FX57800027
J	INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T				INOUE, I; NAGASE, H; KISHI, K; HIGUTI, T			ATP-SENSITIVE K+ CHANNEL IN THE MITOCHONDRIAL INNER MEMBRANE	NATURE			English	Article							OXIDATIVE-PHOSPHORYLATION; ENERGY TRANSDUCTION; CATIONIC CHANNEL; TRANSPORT; PROTEINS; IMPORT	MITOCHONDRIA take up and extrude various inorganic and organic ions, as well as larger substances such as proteins 1-4. The technique of patch clamping should provide real-time information on such transport and on energy transduction in oxidative phosphorylation. It has been applied to detect microscopic currents from mitochondrial membranes and conductances of ion channels in the 5-1,000 pS range in the outer and inner membranes 5-10. These pores are not, however, selective for particular ions. Here we use fused giant mitoplasts prepared from rat liver mitochondria to identify a small conductance channel highly selective for K+ in the inner mitochondrial membrane. This channel can be reversibly inactivated by ATP applied to the matrix side under inside-out patch configuration; it is also inhibited by 4-aminopyridine and by glybenclamide. The slope conductance of the unitary currents measured at negative membrane potentials was 9.7 +/- 1.0 pS (mean +/- s.d., n = 6) when the pipette solution contained 100 mM K+ and the bathing solution 33.3 mM K+. Our results indicate that mitochondria depolarize by generating a K+ conductance when ATP in the matrix is deficient.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN	Tokushima University	INOUE, I (corresponding author), UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN.							ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; CHAZOTTE B, 1985, BIOCHIM BIOPHYS ACTA, V818, P87, DOI 10.1016/0005-2736(85)90142-7; CROMPTON M, 1985, CURR TOP MEMBR TRANS, V25, P231; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HENRY JP, 1989, J MEMBRANE BIOL, V112, P139, DOI 10.1007/BF01871275; HIGUTI T, 1983, BIOCHIM BIOPHYS ACTA, V725, P1, DOI 10.1016/0005-2728(83)90217-7; HIGUTI T, 1985, P NATL ACAD SCI USA, V82, P1331, DOI 10.1073/pnas.82.5.1331; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LEHNINGER AL, 1964, MITOCHONDRION, P180; MEVES H, 1977, J PHYSIOL-LONDON, V268, P511, DOI 10.1113/jphysiol.1977.sp011869; MORAN O, 1990, J BIOL CHEM, V265, P980; Rottenberg H, 1979, Methods Enzymol, V55, P547; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; STURGESS NC, 1985, LANCET, V2, P474; THIEFFRY M, 1988, EMBO J, V7, P1449, DOI 10.1002/j.1460-2075.1988.tb02962.x	23	633	682	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1991	352	6332					244	247		10.1038/352244a0	http://dx.doi.org/10.1038/352244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX185	1857420				2022-12-28	WOS:A1991FX18500067
J	ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M				ERIKSON, J; RADIC, MZ; CAMPER, SA; HARDY, RR; CARMACK, C; WEIGERT, M			EXPRESSION OF ANTI-DNA IMMUNOGLOBULIN TRANSGENES IN NON-AUTOIMMUNE MICE	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; LYMPHOCYTES-B; ANTIBODIES; AUTOANTIBODIES; MOUSE; ACTIVATION; GENES; CELLS	SELF-REACTIVE B cells can be regulated by either deletion or inactivation 1. These manifestations of self-tolerance have been dramatically shown in transgenic mice in which the number of self-reactive cells has been artificially expanded 2,3. We have now extended these models to ask if B-cell tolerance as described for non-disease-associated antigens also operates for the targets of autoimmunity. The target we have chosen is DNA. Anti-DNA antibodies are diagnostic of certain autoimmune syndromes in humans and are a characteristic of the murine model of systemic autoimmunity, the MRI/Ipr mouse4. Antibodies to both single-stranded and double-stranded DNA have been implicated in disease 5,6. By generating anti-DNA transgenic mice, we have addressed the question of whether DNA-specific B cells are regulated in normal (non-autoimmune) mice. We indeed found that most transgenic B cells bind DNA, yet we failed to detect secreted anti-DNA. We suggest that as a consequence of their self-reactivity these B cells are developmentally arrested.	UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	ERIKSON, J (corresponding author), FOX CHASE CANC INST, INST CANC RES, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.			Camper, Sally/0000-0001-8556-3379; Radic, Marko/0000-0002-8004-282X				BASTEN A, 1989, PROGR IMMUNOLOGY, V7, P377; BENNETT RM, 1987, J EXP MED, V166, P850, DOI 10.1084/jem.166.4.850; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPER SA, 1987, BIOTECHNIQUES, V5, P638; CHACE JH, 1988, J IMMUNOL, V141, P3258; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; EATON RB, 1983, ARTHRITIS RHEUM, V26, P52, DOI 10.1002/art.1780260109; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1982, NATURE, V297, P589, DOI 10.1038/297589a0; HAYAKAWA K, 1988, J EXP MED, V168, P1825, DOI 10.1084/jem.168.5.1825; HOLMBERG D, 1986, IMMUNOL REV, V93, P147, DOI 10.1111/j.1600-065X.1986.tb01506.x; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; PANKEWYCZ OG, 1987, J IMMUNOL, V139, P3287; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; RADIC MZ, 1989, COLD SPRING HARB SYM, V54, P933; RADIC MZ, IN PRESS J IMMUN; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SOUROUJON M, 1988, J IMMUNOL, V140, P4173; STALL AM, 1984, J IMMUNOL, V132, P787; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; VANSNICK JL, 1982, J EXP MED, V155, P219, DOI 10.1084/jem.155.1.219; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YANCOPOULOS GD, 1988, J EXP MED, V168, P417, DOI 10.1084/jem.168.1.417	30	453	455	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 24	1991	349	6307					331	334		10.1038/349331a0	http://dx.doi.org/10.1038/349331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EU501	1898987	Green Published			2022-12-28	WOS:A1991EU50100053
J	MERRITT, DF				MERRITT, DF			HYPERPROLACTINEMIA AND DEPRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BROMOCRIPTINE; HOSTILITY; PROLACTIN; DISTRESS				MERRITT, DF (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							BUCKMAN MT, 1985, AM J PSYCHIAT, V142, P242; CARROLL BJ, 1978, PSYCHOPHARMACOLOGY G, P487; DELAFUENTE JR, 1981, AM J PSYCHIAT, V138, P1154; FAVA GA, 1981, PSYCHOTHER PSYCHOSOM, V36, P122, DOI 10.1159/000287535; GANGBAR R, 1983, AM J PSYCHIAT, V140, P790; KELLNER R, 1984, AM J PSYCHIAT, V141, P759; KOPPELMAN MCS, 1987, AM J PSYCHIAT, V144, P1037; MATTOX JH, 1986, J REPROD MED, V31, P694; MULLER EE, 1983, DRUGS, V25, P399; PSROFF L, 1989, CLIN GYNECOLOGIC END, P283	10	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					2004	2004		10.1001/jama.266.14.2004	http://dx.doi.org/10.1001/jama.266.14.2004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GH406	1895485				2022-12-28	WOS:A1991GH40600034
J	PARKER, RK; HOLTMANN, B; WHITE, PF				PARKER, RK; HOLTMANN, B; WHITE, PF			PATIENT-CONTROLLED ANALGESIA - DOES A CONCURRENT OPIOID INFUSION IMPROVE PAIN MANAGEMENT AFTER SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POST-OPERATIVE PAIN; POSTOPERATIVE PAIN; PLASMA-CONCENTRATIONS; BLOOD-CONCENTRATION; MORPHINE; RELIEF; PHARMACOKINETICS; METHADONE; FENTANYL; THERAPY	Objective. - To assess the influence of a continuous (basal) morphine infusion as part of a patient-controlled analgesia (PCA) system on the postoperative analgesic requirement and on recovery parameters following abdominal hysterectomy. Design. - Single-center, randomized, controlled protocol. Setting. - University medical center. Participants. - A total of 230 adult women were randomly assigned to receive no morphine infusion (control group) or a continuous 0.5-, 1.0-, or 2.0-mg/h morphine infusion. Each patient was able to self-administer supplemental intravenous bolus doses of morphine (1 to 2 mg) using a PCA infuser. Main Outcome Measures. - Use of the PCA device, opioid-related side effects, recovery times, and the patients' assessment of pain and sedation on linear visual analog scales were recorded during the 72-hour study period. Follow-up questionnaires were completed by the patients and their health care professionals to assess the overall adequacy of PCA therapy. Results. - Patients who received the 2-mg/h morphine infusions received significantly more opioid medication 9 to 72 hours after their operation than those who received no infusion (control group). The presence of a continuous morphine infusion of 0.5 to 2 mg/h did not significantly decrease the number of patient demands or supplemental bolus doses administered compared with the control group. Overall, 168 (84%) of the 199 patients who completed the 72-hour study were able to achieve adequate analgesia without requiring changes in the PCA regimen or experiencing major side effects. Recovery times and outcome variables were similar in all four groups. Conclusion. - The routine use of a continuous opioid infusion in combination with a standard PCA regimen does not improve pain management compared with PCA alone after abdominal hysterectomy.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,BOX 8054,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)								AUSTIN KL, 1980, PAIN, V8, P47, DOI 10.1016/0304-3959(80)90089-5; AUSTIN KL, 1980, ANESTHESIOLOGY, V53, P460, DOI 10.1097/00000542-198012000-00005; BOND A, 1974, BRIT J MED PSYCHOL, V47, P211, DOI 10.1111/j.2044-8341.1974.tb02285.x; CATLEY DM, 1985, ANESTHESIOLOGY, V63, P20, DOI 10.1097/00000542-198507000-00004; CHRUBASIK J, 1985, ANESTHESIOLOGY, V62, P263, DOI 10.1097/00000542-198503000-00009; CHRUBASIK J, 1988, ANESTHESIOLOGY, V68, P929, DOI 10.1097/00000542-198806000-00016; CHURCH JJ, 1979, BRIT MED J, V1, P977, DOI 10.1136/bmj.1.6169.977; DAHLSTROM B, 1982, CLIN PHARMACOKINET, V7, P266, DOI 10.2165/00003088-198207030-00006; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; GOUDIE TA, 1985, ANAESTHESIA, V40, P1086, DOI 10.1111/j.1365-2044.1985.tb10607.x; GOURLAY GK, 1984, ANESTHESIOLOGY, V61, P19, DOI 10.1097/00000542-198461010-00005; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; GOURLAY GK, 1982, ANESTHESIOLOGY, V57, P458, DOI 10.1097/00000542-198212000-00005; GRAVES DA, 1985, CLIN PHARMACY, V4, P41; HILL HF, 1990, PAIN, V40, P121, DOI 10.1016/0304-3959(90)90062-I; JONES RM, 1985, BRIT J ANAESTH, V57, P259, DOI 10.1093/bja/57.3.259; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LEHMANN KA, 1985, SCHMERZ PAIN DOLEUR, V3, P88; LEVINE J, 1984, ANN INTERN MED, V100, P269, DOI 10.7326/0003-4819-100-2-269; LOPER KA, 1990, ANESTH ANALG, V70, P72; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARLOWE S, 1989, PAIN, V37, P97, DOI 10.1016/0304-3959(89)90158-9; MARSHALL H, 1985, BMJ-BRIT MED J, V291, P19, DOI 10.1136/bmj.291.6487.19; Mather L. G., 1983, CLIN ANAESTHESIOL, V1, P17; NIMMO WS, 1985, BRIT J ANAESTH, V57, P250, DOI 10.1093/bja/57.3.250; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; RUTTER PC, 1980, BRIT MED J, V280, P12, DOI 10.1136/bmj.280.6206.12; SINATRA R, 1989, ANESTHESIOLOGY, V71, P502, DOI 10.1097/00000542-198910000-00005; STANSKI DR, 1987, ANAESTH INTENS CARE, V15, P23, DOI 10.1177/0310057X8701500105; STAPLETON JV, 1979, ANAESTH INTENS CARE, V7, P25, DOI 10.1177/0310057X7900700103; TAMSEN A, 1982, CLIN PHARMACOKINET, V7, P252, DOI 10.2165/00003088-198207030-00005; TAMSEN A, 1982, CLIN PHARMACOKINET, V7, P164, DOI 10.2165/00003088-198207020-00005; WHITE PF, 1988, JAMA-J AM MED ASSOC, V259, P243, DOI 10.1001/jama.259.2.243	34	109	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1991	266	14					1947	1952		10.1001/jama.266.14.1947	http://dx.doi.org/10.1001/jama.266.14.1947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH406	1895471				2022-12-28	WOS:A1991GH40600019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON ORGAN AND TISSUE-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, FED REG         0830	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1991	266	13					1751	1751						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG551	1890706				2022-12-28	WOS:A1991GG55100003
J	DAWSONHUGHES, B; DALLAL, GE; KRALL, EA; HARRIS, S; SOKOLL, LJ; FALCONER, G				DAWSONHUGHES, B; DALLAL, GE; KRALL, EA; HARRIS, S; SOKOLL, LJ; FALCONER, G			EFFECT OF VITAMIN-D SUPPLEMENTATION ON WINTERTIME AND OVERALL BONE LOSS IN HEALTHY POSTMENOPAUSAL WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						CALCIUM; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN-D; VITAMIN-D DEFICIENCY; PARATHYROID HORMONES	SEASONAL-VARIATION; NUTRITIONAL-STATUS; MINERAL CONTENT; PARATHYROID-HORMONE; ELDERLY POPULATION; PHYSICAL-ACTIVITY; CONTROLLED TRIAL; FOOD-INTAKE; CALCIUM; DENSITY	Objectives: To determine whether relative vitamin D deficiency during the winter months contributes to age-related bone loss and whether rates of change in hard- and soft-tissue mass vary during the year. Design: Double-blind, placebo-controlled, 1-year trial in 249 women in which equal numbers of women were randomized to either placebo or 400 IU of vitamin D daily. All women received 377 mg/d of supplemental calcium largely as calcium citrate malate. Patients: Healthy, ambulatory postmenopausal women with usual intakes of vitamin D of 100 IU/d. Measurements: Duplicate spine and whole-body scans were done by dual energy x-ray absorptiometry at 6-month intervals that were timed to periods when 25-hydroxyvitamin D levels were highest and lowest. Period 1 was June-July to December-January and period 2 was December-January to the next June-July. Serum parathyroid hormone and plasma 25-hydroxyvitamin D levels were measured during periods 1 and 2. Main Results: In the placebo group, spinal bone mineral density increased in period 1, decreased in period 2, and sustained no net change. Women treated with vitamin D had a similar spinal increase in period 1 (1.46% compared with 1.40% in placebo), less loss in period 2 (- 0.54% compared with - 1.22%, Cl for the difference, 0.05% to 1.31%, P = 0.032) and a significant overall benefit (0.85% compared with 0.15%, Cl for the difference, 0.03% to 1.37%, P = 0.04). In period 2, 25-hydroxyvitamin D levels were lower and parathyroid hormone levels were higher in the placebo than in the vitamin D group. Whole-body lean and fat tissue and bone mineral density varied during the year but did not change overall. Conclusions: At latitude 42 degrees, healthy postmenopausal women with vitamin D intakes of 100 IU daily can significantly reduce late wintertime bone loss and improve net bone density of the spine over one year by increasing their intake of vitamin D to 500 IU daily. A long-term benefit of preventing vitamin D insufficiency in the winter seems likely although it remains to be shown. Observed changes in bone as well as in fat and lean tissue appear to be related to season.			DAWSONHUGHES, B (corresponding author), TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,CALCIUM & BONE METAB LAB,BOSTON,MA 02111, USA.			Kaye, Elizabeth/0000-0001-7529-2501				ABRAHAM S, 1983, DHHS PHS831681 PUBL; ACHESON KJ, 1980, AM J CLIN NUTR, V33, P972, DOI 10.1093/ajcn/33.5.972; AITKEN JM, 1973, NATURE, V241, P59, DOI 10.1038/241059a0; BERGSTRALH EJ, 1990, J BONE MINER RES, V5, P371, DOI 10.1002/jbmr.5650050410; Cochran W.G, 1957, STAT METHODS, V6th ed; COHN SH, 1976, METABOLISM, V25, P85, DOI 10.1016/0026-0495(76)90163-3; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; DARK J, 1983, AM J PHYSIOL, V245, pR334, DOI 10.1152/ajpregu.1983.245.3.R334; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; Del Ponte A, 1984, Chronobiol Int, V1, P297; DELVIN EE, 1988, AM J CLIN NUTR, V48, P373, DOI 10.1093/ajcn/48.2.373; FROST HM, 1973, INT C SERIES, V270, P124; HEYMSFIELD SB, 1989, AM J CLIN NUTR, V49, P1283, DOI 10.1093/ajcn/49.6.1283; HYLDSTRUP L, 1986, BONE, V7, P167, DOI 10.1016/8756-3282(86)90013-X; JOHNSON J, 1991, CALCIFIED TISSUE INT, V49, P174, DOI 10.1007/BF02556113; Kaplan A., 1983, CLIN CHEM INTERPRETA, V2nd ed; KENNAWAY DJ, 1986, ACTA ENDOCRINOL-COP, V113, P450, DOI 10.1530/acta.0.1130450; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; KRISKA AM, 1988, AM J EPIDEMIOL, V127, P1053, DOI 10.1093/oxfordjournals.aje.a114881; KROLNER B, 1983, CLIN SCI, V64, P541, DOI 10.1042/cs0640541; KROLNER B, 1983, CALCIFIED TISSUE INT, V35, P145, DOI 10.1007/BF02405021; LAMBERG-ALLARDT C, 1984, ANN NUTR METAB, V28, P144, DOI 10.1159/000176796; LIPS P, 1983, J CLIN ENDOCR METAB, V57, P204, DOI 10.1210/jcem-57-1-204; LIPS P, 1987, AM J CLIN NUTR, V46, P1005, DOI 10.1093/ajcn/46.6.1005; LUKERT BP, 1987, CALCIFIED TISSUE INT, V40, P119, DOI 10.1007/BF02555695; MALM OLE J., 1958, SCAND JOUR CLIN AND LAB INVERT, V10, P1; MELLER Y, 1986, ISRAEL J MED SCI, V22, P8; NICOLAU G Y, 1984, Chronobiology International, V1, P301, DOI 10.3109/07420528409063911; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; OVERGAARD K, 1988, BONE, V9, P285, DOI 10.1016/8756-3282(88)90011-7; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; PREECE MA, 1974, CLIN CHIM ACTA, V54, P235, DOI 10.1016/0009-8981(74)90241-1; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SATO H, 1984, Annals of Physiological Anthropology, V3, P152; SMITH KT, 1987, CALCIFIED TISSUE INT, V41, P351, DOI 10.1007/BF02556676; SMITH RW, 1964, AM J CLIN NUTR, V14, P98, DOI 10.1093/ajcn/14.2.98; STAMP TCB, 1974, NATURE, V247, P563, DOI 10.1038/247563a0; TASHIRO Y, 1961, TAISHITSU IGAKU KENK, V12, P589; TOTHILL P, 1986, CLIN PHYS PHYSIOL M, V7, P361, DOI 10.1088/0143-0815/7/4/005; TOUITOU Y, 1983, J ENDOCRINOL, V96, P53, DOI 10.1677/joe.0.0960053; VIR SC, 1979, AM J CLIN NUTR, V32, P1934, DOI 10.1093/ajcn/32.9.1934; WADE GN, 1979, PHYSIOL BEHAV, V22, P583, DOI 10.1016/0031-9384(79)90028-3; 1989, RECOMMENDED DIETARY	43	397	405	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	OCT 1	1991	115	7					505	512		10.7326/0003-4819-115-7-505	http://dx.doi.org/10.7326/0003-4819-115-7-505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG283	1883119				2022-12-28	WOS:A1991GG28300001
J	PODOLSKY, DK				PODOLSKY, DK			INFLAMMATORY BOWEL-DISEASE .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LONG-TERM PROGNOSIS; CROHNS-DISEASE; ULCERATIVE-COLITIS; MONONUCLEAR-CELLS; INTESTINAL PERMEABILITY; LAMINA PROPRIA; INTERLEUKIN-2 RECEPTOR; ENHANCED PRODUCTION; CLINICAL-FEATURES; IMMUNOGLOBULIN-G		MASSACHUSETTS GEN HOSP, CTR STUDY INFLAMMATORY BOWEL DIS, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	PODOLSKY, DK (corresponding author), MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA.				NIDDK NIH HHS [P30 DK43351, DK34422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK034422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENSTEDT O, 1990, NEW ENGL J MED, V322, P1345, DOI 10.1056/NEJM199005103221903; ALLISON MC, 1990, GASTROENTEROLOGY, V99, P421, DOI 10.1016/0016-5085(90)91025-2; ASAKURA H, 1982, GASTROENTEROLOGY, V82, P413; BENNETT RA, 1991, GASTROENTEROLOGY, V100, P1638, DOI 10.1016/0016-5085(91)90663-6; BIEMOND I, 1986, GUT, V27, P934, DOI 10.1136/gut.27.8.934; BINDER V, 1985, GUT, V26, P146, DOI 10.1136/gut.26.2.146; BJARNASON I, 1989, GUT, V30, P22, DOI 10.1136/gut.30.Spec_No.22; BOOTH IW, 1984, GUT, V25, P188, DOI 10.1136/gut.25.2.188; BOYKO EJ, 1987, NEW ENGL J MED, V316, P707, DOI 10.1056/NEJM198703193161202; BRANDT LJ, 1982, AM J GASTROENTEROL, V77, P382; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562, DOI 10.1016/0016-5085(89)90406-X; BUTCHER PD, 1988, GUT, V29, P1222, DOI 10.1136/gut.29.9.1222; CALKINS BM, 1984, DIGEST DIS SCI, V29, P913, DOI 10.1007/BF01312480; CALKINS BM, 1989, DIGEST DIS SCI, V34, P1841, DOI 10.1007/BF01536701; CANTRELL M, 1990, J AUTOIMMUN, V3, P307, DOI 10.1016/0896-8411(90)90149-M; CASELLAS F, 1986, AM J GASTROENTEROL, V81, P767; CHIODINI RJ, 1984, DIGEST DIS SCI, V29, P1073, DOI 10.1007/BF01317078; CHO SN, 1986, GUT, V27, P1353, DOI 10.1136/gut.27.11.1353; COMINELLI F, 1990, J CLIN INVEST, V86, P972, DOI 10.1172/JCI114799; COTTONE M, 1985, GUT, V26, P952, DOI 10.1136/gut.26.9.952; CRABTREE JE, 1990, GUT, V31, P1033, DOI 10.1136/gut.31.9.1033; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; DALZEIL TK, 1913, BRIT MED J, V2, P1068; DELPRE G, 1989, AM J GASTROENTEROL, V84, P1038; DELPRE G, 1980, GASTROENTEROLOGY, V78, P1452; DONALDSON RM, 1985, NEW ENGL J MED, V312, P1616, DOI 10.1056/NEJM198506203122506; DUERR RH, 1991, GASTROENTEROLOGY, V100, P1385; DUERR RH, 1991, GASTROENTEROLOGY, V100, P1590, DOI 10.1016/0016-5085(91)90657-7; EDWARDS FC, 1964, GUT, V5, P1; EKBOM A, 1991, GASTROENTEROLOGY, V100, P350, DOI 10.1016/0016-5085(91)90202-V; ELLIOTT PR, 1982, LANCET, V1, P650; ELLIOTT PR, 1985, BRIT MED J, V291, P178, DOI 10.1136/bmj.291.6489.178; FABRICIUS PJ, 1985, GUT, V26, P461, DOI 10.1136/gut.26.5.461; FARMER RG, 1981, AM J GASTROENTEROL, V75, P97; GAZZARD B, 1984, GUT, V25, P325, DOI 10.1136/gut.25.4.325; GIARDIELLO FM, 1989, DIGEST DIS SCI, V34, P1730, DOI 10.1007/BF01540051; GIBSON PR, 1988, GUT, V29, P516, DOI 10.1136/gut.29.4.516; GOLLOP JH, 1988, GUT, V29, P49, DOI 10.1136/gut.29.1.49; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; HENRICKSEN C, 1985, GUT, V26, P158; HIBI T, 1990, GUT, V31, P1371, DOI 10.1136/gut.31.12.1371; JAMES SP, 1987, DIGEST DIS SCI, V32, P1297, DOI 10.1007/BF01296381; JARNEROT G, 1987, INFLAMMATORY BOWEL D; KATSCHINSKI B, 1988, GUT, V29, P1202, DOI 10.1136/gut.29.9.1202; KHOSLA R, 1984, GUT, V25, P52, DOI 10.1136/gut.25.1.52; KIRSNER JB, 1982, NEW ENGL J MED, V306, P837, DOI 10.1056/NEJM198204083061404; KIRSNER JB, 1982, NEW ENGL J MED, V306, P775, DOI 10.1056/NEJM198204013061304; KIRSNER JB, 1988, INFLAMMATORY BOWEL D; KUSUGAMI K, 1989, GASTROENTEROLOGY, V97, P1; LASHNER BA, 1990, DIGEST DIS SCI, V35, P827, DOI 10.1007/BF01536795; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; LOBOS EA, 1987, DIGEST DIS SCI, V32, P1380, DOI 10.1007/BF01296664; MACDERMOTT RP, 1988, ADV IMMUNOL, V42, P285, DOI 10.1016/S0065-2776(08)60848-2; MACDERMOTT RP, 1981, GASTROENTEROLOGY, V81, P844; MACDERMOTT RP, 1989, GASTROENTEROLOGY, V96, P764; MACDERMOTT RP, 1988, INT C SERIES, V775; MADARA JL, 1985, GASTROENTEROLOGY, V88, P13, DOI 10.1016/S0016-5085(85)80126-8; MAHIDA YR, 1990, CLIN EXP IMMUNOL, V82, P75; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MAHIDA YR, 1989, GUT, V30, P826, DOI 10.1136/gut.30.6.826; MAYBERRY JF, 1986, GUT, V27, P821, DOI 10.1136/gut.27.7.821; MAYBERRY JF, 1984, GUT, V25, P886, DOI 10.1136/gut.25.8.886; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; MENARD DB, 1976, NEW ENGL J MED, V295, P818, DOI 10.1056/NEJM197610072951506; MIELANTS H, 1985, J RHEUMATOL, V12, P294; MIELANTS H, 1987, J RHEUMATOL, V14, P466; MOGADAM M, 1981, AM J GASTROENTEROL, V75, P265; MORRIS T, 1984, GUT, V25, P846, DOI 10.1136/gut.25.8.846; NAST CC, 1988, DIGEST DIS SCI, V33, pS50, DOI 10.1007/BF01538131; NIELSEN OH, 1987, GUT, V28, P181, DOI 10.1136/gut.28.2.181; NUGENT FW, 1976, NEW ENGL J MED, V294, P262, DOI 10.1056/NEJM197601292940507; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; OLAISON G, 1988, GUT, V29, P196, DOI 10.1136/gut.29.2.196; PIRONI L, 1988, AM J GASTROENTEROL, V83, P1267; PODOLSKY DK, 1983, J CLIN INVEST, V72, P142, DOI 10.1172/JCI110952; PODOLSKY DK, 1988, GASTROENTEROLOGY, V95, P379, DOI 10.1016/0016-5085(88)90494-5; QIN OY, 1988, DIGEST DIS SCI, V33, P1528; RACHMILEWITZ D, 1990, DEV GASTROENTEROLOGY, V11; RAMPTON DS, 1983, GUT, V24, P187, DOI 10.1136/gut.24.3.187; ROBERTS PL, 1990, DIS COLON RECTUM, V33, P458, DOI 10.1007/BF02052138; ROCHE JK, 1985, J CLIN INVEST, V75, P522, DOI 10.1172/JCI111728; ROSE JDR, 1988, GUT, V29, P346, DOI 10.1136/gut.29.3.346; RUTGEERTS P, 1984, GUT, V25, P665, DOI 10.1136/gut.25.6.665; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P956, DOI 10.1016/0016-5085(90)90613-6; SARTOR RB, 1989, BAILLIERE CLIN RHEUM, V3, P223, DOI 10.1016/S0950-3579(89)80019-6; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; SCULLY C, 1982, GUT, V23, P198, DOI 10.1136/gut.23.3.198; SELBY WS, 1984, GUT, V25, P32, DOI 10.1136/gut.25.1.32; SHANAHAN F, 1988, DIGEST DIS SCI, V33, pS41, DOI 10.1007/BF01538130; SHAPIRO PA, 1981, AM J GASTROENTEROL, V76, P132; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; SIEBER G, 1984, GUT, V25, P1255, DOI 10.1136/gut.25.11.1255; SINGLETON JW, 1979, GASTROENTEROLOGY, V77, P827; SMITH MB, 1988, AM J GASTROENTEROL, V83, P407; SONNENBERG A, 1991, GASTROENTEROLOGY, V100, P143, DOI 10.1016/0016-5085(91)90594-B; SONNENBERG A, 1990, DIGEST DIS SCI, V35, P375, DOI 10.1007/BF01537417; SONNENBERG A, 1986, DIS COLON RECTUM, V29, P624, DOI 10.1007/BF02560320; SPILIADIS CA, 1987, DIS COLON RECTUM, V30, P334, DOI 10.1007/BF02555449; STAMPFL DA, 1991, DIGEST DIS SCI, V36, P705, DOI 10.1007/BF01311225; TAKAHASHI F, 1985, J CLIN INVEST, V76, P311, DOI 10.1172/JCI111963; THAYER WR, 1984, DIGEST DIS SCI, V29, P1080, DOI 10.1007/BF01317079; TYSK C, 1991, GASTROENTEROLOGY, V100, P419, DOI 10.1016/0016-5085(91)90211-3; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; VENDER RJ, 1982, J CLIN GASTROENTEROL, V4, P231, DOI 10.1097/00004836-198206000-00008; VISSER ND, 1990, GASTROENTEROLOGY, V99, P380, DOI 10.1016/0016-5085(90)91019-3; WAKEFIELD AJ, 1989, LANCET, V2, P1057; WAKEFIELD AJ, 1991, GASTROENTEROLOGY, V100, P1279; WRIGHT JP, 1987, DIGEST DIS SCI, V32, P164, DOI 10.1007/BF01297104; YARDLEY JH, 1990, HUM PATHOL, V21, P1089, DOI 10.1016/0046-8177(90)90143-S; ZIFRONI A, 1983, GUT, V24, P659, DOI 10.1136/gut.24.7.659; ZIMMERMAN J, 1985, J CLIN GASTROENTEROL, V7, P492, DOI 10.1097/00004836-198512000-00010	113	937	965	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					928	937		10.1056/NEJM199109263251306	http://dx.doi.org/10.1056/NEJM199109263251306			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1881418				2022-12-28	WOS:A1991GF85600006
J	MURPHY, PM; TIFFANY, HL				MURPHY, PM; TIFFANY, HL			CLONING OF COMPLEMENTARY-DNA ENCODING A FUNCTIONAL HUMAN INTERLEUKIN-8 RECEPTOR	SCIENCE			English	Article							PHAGOCYTIC CELL RECEPTORS; ACTIVATING FACTOR; XENOPUS OOCYTES; HUMAN-NEUTROPHILS; PROTEIN; GENES; CDNA; C5A	Interleukin-8 (IL-8) is an inflammatory cytokine that activates neutrophil chemotaxis, degranulation, and the respiratory burst. Neutrophils express receptors for IL-8 that are coupled to guanine nucleotide-binding proteins (G proteins); binding of IL-8 to its receptor induces the mobilization of intracellular calcium stores. A cDNA clone from HL-60 neutrophils, designated p2, has now been isolated that encodes a human IL-8 receptor. When p2 is expressed in oocytes from Xenopus laevis, the oocytes bind I-125-labeled IL-8 specifically and respond to IL-8 by mobilizing calcium stores with an EC50 of 20 nM. This IL-8 receptor has 77% amino acid identity with a second human neutrophil receptor isotype that binds IL-8 with higher affinity. It also exhibits 69% an-amino acid identity with a protein reported to be an N-formyl peptide receptor from rabbit neutrophils, but less than 30% identity with all other known G protein-coupled receptors, including the human N-formyl peptide receptor.			MURPHY, PM (corresponding author), NIAID,HOST DEF LAB,BETHESDA,MD 20892, USA.							BESEMER J, 1989, J BIOL CHEM, V264, P17409; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P389; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GROB PM, 1990, J BIOL CHEM, V265, P8311; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MALECH HL, 1985, J BIOL CHEM, V260, P2509; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MOSER B, 1991, J BIOL CHEM, V266, P10666; MURPHY PJ, UNPUB; MURPHY PM, 1990, J BIOL CHEM, V265, P11615; MURPHY PM, 1991, J BIOL CHEM, V266, P12560; MURPHY PM, 1990, J IMMUNOL, V145, P2227; OPPENHEIM JJ, 1990, PROG CLIN BIOL RES, V349, P405; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SULLIVAN R, 1987, BLOOD, V70, P1222; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WALZ A, 1989, J EXP MED, V170, P1745, DOI 10.1084/jem.170.5.1745; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YOKOYAMA S, 1989, MOL BIOL EVOL, V6, P342	27	846	910	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1280	1283		10.1126/science.1891716	http://dx.doi.org/10.1126/science.1891716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1891716	Green Submitted			2022-12-28	WOS:A1991GE68900041
J	HAGELBERG, E; GRAY, IC; JEFFREYS, AJ				HAGELBERG, E; GRAY, IC; JEFFREYS, AJ			IDENTIFICATION OF THE SKELETAL REMAINS OF A MURDER VICTIM BY DNA ANALYSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; DINUCLEOTIDE REPEAT; MINISATELLITES; POLYMORPHISMS; AMPLIFICATION	THERE is considerable anthropological and forensic interest in the possibility of DNA typing skeletal remains. Trace amounts of DNA can be recovered even from 5,500-year-old bones and multicopy human mitochondrial DNA sequences can frequently be amplified from such DNA using the polymerase chain reaction (PCR) 1,2. But given the sensitivity of PCR, it is very difficult to exclude contaminating material. We now report the successful identification of the 8-year-old skeletal remains of a murder victim, by comparative typing of nuclear microsatellite markers 3-5 in the remains and in the presumptive parents of the victim. This analysis establishes the authenticity of the bone DNA and the feasibility of bone DNA typing in forensic investigations.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	University of Leicester	HAGELBERG, E (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, MRC, MOLEC HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND.		Schneider, Peter M./A-6661-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAKRABORTY R, IN PRESS DNA FINGERP; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; HAGELBERG E, 1989, NATURE, V342, P485, DOI 10.1038/342485a0; HAGELBERG E, 1991, P ROY SOC B-BIOL SCI, V244, P45, DOI 10.1098/rspb.1991.0049; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; LITT M, 1989, AM J HUM GENET, V44, P397; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P2199; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	13	220	227	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1991	352	6334					427	429		10.1038/352427a0	http://dx.doi.org/10.1038/352427a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ346	1861721				2022-12-28	WOS:A1991FZ34600063
J	KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; ASHFORD, VA; XUONG, NH; TAYLOR, SS; SOWADSKI, JM				KNIGHTON, DR; ZHENG, JH; TENEYCK, LF; ASHFORD, VA; XUONG, NH; TAYLOR, SS; SOWADSKI, JM			CRYSTAL-STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE-MONOPHOSPHATE DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							MULTIWIRE AREA DETECTOR; AMINO-ACID-SEQUENCE; ATP-BINDING SITE; NUCLEOTIDE-BINDING; ADENYLATE KINASE; REFINEMENT; CRYSTALLOGRAPHY; RESOLUTION; MECHANISM; PROGRAM	The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 angstrom resolution to an R factor of 0.212. The magnesium adenosine triphosphate (MgATP) binding site was located by difference Fourier synthesis. The enzyme structure is bilobal with a deep cleft between the lobes. The cleft is filled by MgATP and a portion of the inhibitor peptide. The smaller lobe, consisting mostly of amino-terminal sequence, is associated with nucleotide binding, and its largely antiparallel beta-sheet architecture constitutes an unusual nucleotide binding motif. The larger lobe is dominated by helical structure with a single beta-sheet at the domain interface. This lobe is primarily involved in peptide binding and catalysis. Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases. Most of the invariant amino acids in this conserved catalytic core are clustered at the sites of nucleotide binding and catalysis.	UNIV CALIF SAN DIEGO, DEPT MED, 9500 GILMAN DR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SAN DIEGO SUPERCOMP CTR, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, DEPT PHYS, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [T32CA09523] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NIDDK NIH HHS [T32DK07233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; BEEBE SJ, 1986, ENZYME CONTROL PHO A, V17; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P3018, DOI 10.1021/bi00433a042; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; FIRST EA, 1989, BIOCHEMISTRY-US, V28, P3598, DOI 10.1021/bi00434a067; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; HO MF, 1988, J AM CHEM SOC, V110, P2680, DOI 10.1021/ja00216a068; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KNIGHTON DR, IN PRESS J MOL BIOL; KREBS EG, 1985, BIOCHEM SOC T, V13, P813, DOI 10.1042/bst0130813; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NELSON NC, 1983, J BIOL CHEM, V258, P981; PARELLO J, IN PRESS J MOL BIOL; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SIM GA, 1960, ACTA CRYSTALLOGR, V13, P511, DOI 10.1107/S0365110X60001266; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; SUTHERLAND EW, 1955, NATURE, V175, P169, DOI 10.1038/175169a0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1988, COLD SPRING HARB SYM, V53, P121, DOI 10.1101/SQB.1988.053.01.018; TAYLOR SS, 1990, CRC CRIT REV BIOCH, P1; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105; YONEMOTO W, UNPUB; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHENG J, IN PRESS METHODS ENZ; ZHENG JH, IN PRESS J MOL BIOL; ZOLLER MN, 1981, J BIOL CHEM, V256, P10387	60	1522	1639	4	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 26	1991	253	5018					407	414		10.1126/science.1862342	http://dx.doi.org/10.1126/science.1862342			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY288	1862342				2022-12-28	WOS:A1991FY28800030
J	LINN, S				LINN, S			HOW MANY POLS DOES IT TAKE TO REPLICATE NUCLEAR-DNA	CELL			English	Review							EUKARYOTIC DNA; SACCHAROMYCES-CEREVISIAE; POLYMERASE-DELTA; SIMIAN VIRUS-40; YEAST; PURIFICATION; PROTEINS; EXONUCLEASE; BINDING; ALPHA				LINN, S (corresponding author), UNIV CALIF BERKELEY,DEPT BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.							BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; KESTI T, 1991, J BIOL CHEM, V266, P6336; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; SKARNES W, 1986, J BIOL CHEM, V261, P6629; SPADARI S, 1989, MUTAT RES, V219, P147, DOI 10.1016/0921-8734(89)90009-X; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STRAUSS PR, 1990, EUKARYOTIC NUCLEUS M, V1; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WINTERSBERGER E, 1974, EUR J BIOCHEM, V50, P41, DOI 10.1111/j.1432-1033.1974.tb03871.x; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872	29	97	97	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					185	187		10.1016/0092-8674(91)90608-2	http://dx.doi.org/10.1016/0092-8674(91)90608-2			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855251				2022-12-28	WOS:A1991FY71200001
J	DEAL, JE; GROVES, RW; HARMER, AW; WELSH, KI; MACDONALD, DM; RIGDEN, SPA				DEAL, JE; GROVES, RW; HARMER, AW; WELSH, KI; MACDONALD, DM; RIGDEN, SPA			RENAL-DISEASE, EPIDERMAL NECROSIS, AND EPITHELIAL-CELL ANTIBODIES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To describe the association between epithelial cell IgM, which has previously been associated with an increased incidence of loss of renal graft in children, with a novel cutaneous eruption and unexplained native renal disease. Design - Observational study on children with epithelial cell antibody presenting with unexplained renal or skin disease. Setting - General paediatric department and regional paediatric nephrology unit. Patients - Six children (five girls, one boy), who presented to the unit in 1989-90. Results - Three children, two of whom had a history of a hyperpigmented rash, presented with hypertension, proteinuria, and impaired renal function. Renal biopsy specimens from two of these children showed severe arteriolar endothelial cell swelling with arteriolar occlusion. These children fully recovered after treatment with antihypertensive drugs. The third child developed end stage renal failure and required dialysis. Three other children presented with an unusual cutaneous eruption but no evidence of renal disease. Histology of the skin lesions showed acute epidermal necrosis and features consistent with a viral infection. Conclusions - The aetiology and pathogenesis of the epithelial cell antibody are unknown. These cases indicate that it may have a role in native kidney disease and focal epidermal necrosis. Clinical and histological features suggest that the antibody may be associated with a viral infection.	GUYS HOSP,DEPT DERMATOL,LONDON SE1 9RT,ENGLAND; GUYS HOSP,TISSUE TYPING LAB,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	DEAL, JE (corresponding author), GUYS HOSP,DEPT PAEDIAT NEPHROL,LONDON SE1 9RT,ENGLAND.							ACKERMAN AB, 1971, ARCH DERMATOL, V103, P180, DOI 10.1001/archderm.103.2.180; BEDI TR, 1976, BRIT J DERMATOL, V95, P243, DOI 10.1111/j.1365-2133.1976.tb07010.x; BEUTNER EH, 1987, IMMUNOPATHOLOGY SKIN, P177; HARMER AW, 1990, LANCET, V335, P1184, DOI 10.1016/0140-6736(90)92698-H; HARMER AW, 1990, TRANSPLANT INT, V3, P66, DOI 10.1007/BF00336205; LEVER WF, 1983, HISTOPATHOLOGY SKIN, P259; PUSEY CD, 1988, DISEASES KIDNEY, P1827	7	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1991	303	6795					161	163		10.1136/bmj.303.6795.161	http://dx.doi.org/10.1136/bmj.303.6795.161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FX578	1878640	Bronze, Green Published			2022-12-28	WOS:A1991FX57800022
J	HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P				HART, JT; THOMAS, C; GIBBONS, B; EDWARDS, C; HART, M; JONES, J; JONES, M; WALTON, P			25 YEARS OF CASE FINDING AND AUDIT IN A SOCIALLY DEPRIVED COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTICE; BLOOD-PRESSURE; DIETARY-SODIUM; INVERSE CARE; HEALTH CHECK; INEQUALITIES; HYPERTENSION; SATISFACTION; ATTENDERS	Objective - To evaluate audit and case finding (whole population care) in a community over 25 years. Design - Contemporary screening for and audits of care of chronic disease and risk factors; retrospective review of computerised practice records; and comparisons of mortality and social indices with neighbouring communities. Setting - One general practice in Glyncorrwg, West Glamorgan. Subjects - 1800 people registered with the practice in 1987 and 558 people who died from 1964 to 1987, whose records had been retained. Main outcome measures - Detection of high blood pressure, smoking, airways obstruction, obesity, diabetes, and alcohol problems in adults aged 20-79; prevalence of smoking in this population and in hypertensive and diabetic groups; age standardised mortality ratios in relation to indices of social deprivation. Results - In the population aged 20-79 (1207 patients) 249 (21%) had peak expiratory flow rate less than 50% of expected value or which improved by 15% or more with an inhaled beta-agonist, 207 (17%) had body mass index at or over 30 kg/m2, 118 (10%) had untreated mean arterial pressures greater than 159/104 mm Hg (three readings), 80 (7%) (65 (16%) men, 15 (4%) women) had recognised alcohol problems, and 35 (3%) had diabetes. The proportion of men aged 20-64 who said they smoked fell from 61% (290/476) in 1968-70 to 36% (162/456) in 1985 whereas that of women who smoked was unchanged (43%, 187/436 v 42%, 190/448 respectively). In 116 screened hypertensive patients group mean blood pressure fell from 186/110 mm Hg before treatment to 146/84 mm Hg at 1987 audit, as did the proportion of smokers (56% v 20%), but body mass index and total cholesterol concentration showed no significant change. In 34 diabetic patients mean blood pressure and the proportion of smokers fell (171/93 mm Hg v 155/81 mm Hg; 44% v 12%). The age standardised mortality ratio in 1981-6 was lower than in a neighbouring village without a developed case finding programme (actual to expected deaths < 65 = 21 to 22 in Glyncorrwg, 48 to 30 in control village). Conclusions - Whole population care through organised case finding and audit is feasible but only with a labour intensive approach combining accessibility, flexibility, and continuity, as well as a planned and structured approach, which requires substantial expansion of staff numbers and assiduous recording. It may reduce risks for at least some high risk groups. Despite their shortcomings the available data are consistent with the hypothesis that whole population care helps reduce mortality. Incentives in the new contract, which encourage the uncritical development of structured process, may diminish health outputs.	UNIV SWANSEA, DEPT GEOG, SWANSEA SA2 8PP, WALES; ABER BLAENGWYNFI HLTH CTR, BLAENGWYNFI, W GLAM, WALES; GLYNCORRWG HLTH CTR, GLYNCORRWYG, W GLAM, WALES	Swansea University	HART, JT (corresponding author), ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON W2 1PG, ENGLAND.							ALBASHIR MM, 1991, BRIT J GEN PRACT, V41, P6; AMIEL S, 1991, BRIT MED J, V302, P527, DOI 10.1136/bmj.302.6775.527; [Anonymous], 1970, JAMA, V213, P1143; BALLARD DJ, 1988, AM J PREV MED, V4, P133, DOI 10.1016/S0749-3797(18)31185-1; BOSANQUET N, 1988, BMJ-BRIT MED J, V296, P157; BUCHAN IC, 1973, SCOTTISH HLTH STUDIE, V27; CATFORD JC, 1984, BRIT MED J, V289, P1668, DOI 10.1136/bmj.289.6459.1668; Coope J, 1974, J R Coll Gen Pract, V24, P161; DAY JL, 1987, BRIT MED J, V294, P1590, DOI 10.1136/bmj.294.6587.1590; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAMILTON M, 1964, LANCET, V1, P235; Hart J T, 1974, J R Coll Physicians Lond, V8, P299; Hart J T, 1976, J R Coll Gen Pract, V26, P885; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; HART JT, 1970, LANCET, V2, P223; HART JT, 1990, BRIT J GEN PRACT, V40, P4; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HART JT, 1982, BRIT MED J, V284, P1686, DOI 10.1136/bmj.284.6330.1686; HART JT, 1987, HYPERTENSION COMMUNI; Hart JT, 1988, PREVENTION CORONARY; HARTLAGE JA, 1984, SOAP COSMET CHEM SPE, V60, P42; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; Kark SL, 1989, PRACTICE COMMUNITY O; KAUL SA, 1988, STUDY SMALL AREA STA; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; LITTLEPAGE BNC, 1988, STUDY SMALL AREA STA; MAIN J, 1990, RCGP CONNECTION  SEP, P4; MARMOT MG, 1984, LANCET, V1, P1003; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; PILL R, 1988, J ROY COLL GEN PRACT, V38, P57; PRINGLE M, 1989, BRIT MED J, V299, P470, DOI 10.1136/bmj.299.6697.470; RIDSDALE L, 1989, J ROY COLL GEN PRACT, V39, P488; RIDSDALE L, 1990, BRIT MED J, V301, P455, DOI 10.1136/bmj.301.6750.455; ROBSON J, 1989, BMJ-BRIT MED J, V298, P433, DOI 10.1136/bmj.298.6671.433; RUSSELL MAH, 1979, BRIT MED J, V2, P231, DOI 10.1136/bmj.2.6184.231; SAVAGE R, 1990, BRIT MED J, V301, P968, DOI 10.1136/bmj.301.6758.968; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; Stott N C, 1979, J R Coll Gen Pract, V29, P201; THOMAS K, 1989, J ROY COLL GEN PRACT, V39, P509; THOMPSON NF, 1990, BRIT J GEN PRACT, V40, P16; Townsend PP., 1988, HLTH DEPRIVATION INE; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WALLACE PG, 1987, J ROY COLL GEN PRACT, V37, P354; WALLER D, 1990, BRIT MED J, V300, P1115, DOI 10.1136/bmj.300.6732.1115; WATT GCM, 1983, LANCET, V1, P1245; WATT GCM, 1983, BMJ-BRIT MED J, V286, P432, DOI 10.1136/bmj.286.6363.432; WATT GCM, 1985, BMJ-BRIT MED J, V291, P1525, DOI 10.1136/bmj.291.6508.1525; 1980, INEQUALITIES HLTH; 1987, 7 HEARTB WAL; 1986, 24 ROYAL COLL GEN PR; 1985, 1 HEARTB WAL	54	60	59	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 22	1991	302	6791					1509	1513		10.1136/bmj.302.6791.1509	http://dx.doi.org/10.1136/bmj.302.6791.1509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT505	1855023	Green Published, Bronze			2022-12-28	WOS:A1991FT50500026
J	HALL, WH				HALL, WH			NIH TECHNOLOGY-ASSESSMENT CONFERENCE STATEMENT ON BOVINE SOMATOTROPIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HALL, WH (corresponding author), NIH,OFF MED APPLICAT RES,BLDG 1,ROOM 260,BETHESDA,MD 20892, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	1991	265	11					1423	1425		10.1001/jama.265.11.1423	http://dx.doi.org/10.1001/jama.265.11.1423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FB550	1867669				2022-12-28	WOS:A1991FB55000024
J	WARE, RE; HALL, SE; ROSSE, WF				WARE, RE; HALL, SE; ROSSE, WF			PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA WITH ONSET IN CHILDHOOD AND ADOLESCENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ERYTHROCYTE-MEMBRANE-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; APLASTIC-ANEMIA; REACTIVE LYSIS; RED-CELLS; COMPLEMENT; CD14; DEFICIENCY; INHIBITOR; RECEPTOR	Background. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematologic disorder characterized by hemoglobinuria, thrombosis, infection, and a tendency toward bone marrow aplasia. Onset usually occurs in adulthood. Few children and adolescents with PNH have been described, and data on diagnosis, clinical course, and survival in young patients are unavailable. Methods. We retrospectively reviewed clinical and laboratory data on all patients 21 years old or younger in whom PNH had been diagnosed at Duke University Medical Center from 1966 to 1991. Results. Medical records and clinical follow-up data were available for 26 young patients. Although 50 percent of adult patients present with hemoglobinuria, only four of our patients (15 percent) presented with this feature. In contrast, 15 of our patients (58 percent) had moderate or severe bone marrow failure at presentation, as compared with about 25 percent of adults in cases from the literature; all 26 patients eventually had evidence of bone marrow dysfunction. Eight patients (31 percent) have died, with a median survival of 13.5 years since their initial symptoms. Conclusions. Children and adolescents with PNH have a greater prevalence of bone marrow failure than do adults with this disorder, and their morbidity and mortality are high. Bone marrow transplantation should be considered for selected young patients with PNH.	DUKE UNIV,MED CTR,DEPT PEDIAT,DIV HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710	Duke University; Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031379] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-R37-DK-31379] Funding Source: Medline; PHS HHS [K11-H02015] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUDITORE JV, 1960, ARCH PATHOL, V69, P534; DACIE JV, 1961, BRIT J HAEMATOL, V7, P442, DOI 10.1111/j.1365-2141.1961.tb00354.x; DACIE JV, 1963, P ROY SOC MED, V56, P587, DOI 10.1177/003591576305600723; DEVINE DV, 1987, J CLIN INVEST, V79, P131, DOI 10.1172/JCI112773; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; DOERING TL, 1990, J BIOL CHEM, V265, P611; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Gull WW, 1866, GUYS HOSP REP, V12, P381; HARTMANN RC, 1977, ANNU REV MED, V28, P187, DOI 10.1146/annurev.me.28.020177.001155; HIRSCH VJ, 1981, ARCH INTERN MED, V141, P525, DOI 10.1001/archinte.141.4.525; HOLGUIN MH, 1989, J CLIN INVEST, V84, P1387, DOI 10.1172/JCI114311; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; KUNSTLING TR, 1969, BLOOD-J HEMATOL, V33, P607, DOI 10.1182/blood.V33.4.607.607; LEWIS SM, 1965, BRIT J HAEMATOL, V11, P549, DOI 10.1111/j.1365-2141.1965.tb00099.x; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MOORE JG, 1986, EXP HEMATOL, V14, P222; NICHOLSONWELLER A, 1982, J IMMUNOL, V129, P184; NICHOLSONWELLER A, 1983, P NATL ACAD SCI-BIOL, V80, P5066, DOI 10.1073/pnas.80.16.5066; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; PANGBURN MK, 1983, P NATL ACAD SCI-BIOL, V80, P5430, DOI 10.1073/pnas.80.17.5430; POLLI E, 1973, EMOGLOBINURIA PAROSS; ROSSE WF, 1985, CLIN HAEMATOL, V14, P105; ROSSE WF, 1966, J CLIN INVEST, V45, P736, DOI 10.1172/JCI105388; ROSSE WF, 1974, BRIT J HAEMATOL, V28, P181; ROSSE WF, 1978, CLIN HAEMATOL, V7, P541; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; ROSSE WF, 1990, BLOOD, V75, P1595; ROTOLI B, 1982, BLOOD, V60, P157; SCHONERMARK S, 1986, J IMMUNOL, V136, P1772; SELVARAJ P, 1988, NATURE, V333, P565, DOI 10.1038/333565a0; SELVARAJ P, 1987, J EXP MED, V166, P1011, DOI 10.1084/jem.166.4.1011; SIMMONS DL, 1989, BLOOD, V73, P284; SIRCHIA G, 1975, CLIN HAEMATOL, V4, P199; Strubing P., 1882, DMW DTSCH MED WOCHEN, V8, P1, DOI [DOI 10.1055/S-0029-1196307, 10.1055/s-0029-1196307]; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; VANDERSCHOOT CE, 1989, LEUCOCYTE TYPING, V4, P887; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZALMAN LS, 1986, P NATL ACAD SCI USA, V83, P6975, DOI 10.1073/pnas.83.18.6975	39	118	121	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					991	996		10.1056/NEJM199110033251403	http://dx.doi.org/10.1056/NEJM199110033251403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886636				2022-12-28	WOS:A1991GH44700003
J	CHAN, LS; SOONG, HK; FOSTER, CS; HAMMERBERG, C; COOPER, KD				CHAN, LS; SOONG, HK; FOSTER, CS; HAMMERBERG, C; COOPER, KD			OCULAR CICATRICIAL PEMPHIGOID OCCURRING AS A SEQUELA OF STEVENS-JOHNSON SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASEMENT-MEMBRANE ZONE; ERYTHEMA MULTIFORME; IMMUNE-COMPLEXES; IMMUNOFLUORESCENCE; ANTIBODIES; ANTIGENS; AUTOANTIBODIES; BINDING; SKIN	Ocular cicatricial pemphigoid is a chronic scarring inflammation of the ocular mucosae that can lead to blindness. Although cicatricial pemphigoid has been classified clinically, histopathologically, and immunopathologically, no definite initiating factor or precipitating factor has been identified. In this report, we describe five cases of ocular cicatricial pemphigoid that developed following an acute episode of severe ocular inflammatory injury secondary to Stevens-Johnson syndrome. The time lag between the onset of Stevens-Johnson syndrome and cicatricial pemphigoid ranged from a few months to 31 years. All five patients had linear immune deposits characteristic of cicatricial pemphigoid along the basement membrane zone of mucosal biopsy specimens as detected by either direct immunofluorescence microscopy or direct immunoperoxidase staining. In two patients whose serum was tested, a Western blot assay taken of keratinocyte antigens that had undergone electrophoresis reacted with the serum and identified a 120-kd epidermal antigen detected by the IgG class antibodies. All five patients were treated with systemic immunosuppressive therapy for cicatricial pemphigoid, and we obtained objective responses. Severe ocular mucosal injury such as that which occurs in Stevens-Johnson syndrome may be a precipitating factor in the development of ocular cicatricial pemphigoid.	UNIV MICHIGAN,SCH MED,DEPT OPHTHALMOL,ANN ARBOR,MI 48104; HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,BOSTON,MA 02115	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	CHAN, LS (corresponding author), UNIV MICHIGAN,MED CTR,SCH MED,DEPT DERMATOL,IMMUNODERMATOL UNIT,R5538 KRESGE 1,BOX 0530,ANN ARBOR,MI 48109, USA.			Soong, Hunson Kaz/0000-0002-2941-6910; Cooper, Kevin/0000-0002-1986-3602	NIAMS NIH HHS [T32 AR07197-11] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARSTIKAITIS MJ, 1973, ARCH OPHTHALMOL-CHIC, V90, P376, DOI 10.1001/archopht.1973.01000050378008; BEAN SF, 1974, ARCH DERMATOL, V110, P552, DOI 10.1001/archderm.110.4.552; BERNARD P, 1990, J INVEST DERMATOL, V94, P630, DOI 10.1111/1523-1747.ep12876206; BERNARD P, 1989, J INVEST DERMATOL, V92, P171, DOI 10.1111/1523-1747.ep12276689; BUSHKELL LL, 1980, J INVEST DERMATOL, V74, P372, DOI 10.1111/1523-1747.ep12543806; CHAN LS, 1990, ARCH DERMATOL, V126, P1466, DOI 10.1001/archderm.126.11.1466; DANTZIG P, 1973, ARCH DERMATOL, V108, P264; FINE JD, 1984, J INVEST DERMATOL, V82, P39, DOI 10.1111/1523-1747.ep12259075; FISHER GJ, 1988, J INVEST DERMATOL, V91, P142, DOI 10.1111/1523-1747.ep12464387; FLEMING MG, 1988, ARCH DERMATOL, V124, P1407, DOI 10.1001/archderm.124.9.1407; FOSTER CS, 1988, OPHTHALMOLOGY, V95, P453; FRANKLIN RM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1611, DOI 10.1001/archopht.1983.01040020613023; GRIFFITH MR, 1974, ARCH DERMATOL, V109, P195, DOI 10.1001/archderm.109.2.195; Hansen R C, 1984, Pediatr Dermatol, V1, P298, DOI 10.1111/j.1525-1470.1984.tb01133.x; HARDY KM, 1971, ARCH DERMATOL, V104, P467, DOI 10.1001/archderm.104.5.467; HOLUBAR K, 1973, ARCH DERMATOL, V108, P50, DOI 10.1001/archderm.108.1.50; HORIGUCHI Y, 1986, J INVEST DERMATOL, V87, P715, DOI 10.1111/1523-1747.ep12456694; HOWARD GM, 1963, AM J OPHTHALMOL, V55, P893, DOI 10.1016/0002-9394(63)90366-0; HUFF JC, 1980, J INVEST DERMATOL, V74, P375, DOI 10.1111/1523-1747.ep12543935; KAZMIEROWSKI JA, 1978, J INVEST DERMATOL, V71, P366, DOI 10.1111/1523-1747.ep12556746; KELLY SE, 1988, BRIT J DERMATOL, V118, P31, DOI 10.1111/j.1365-2133.1988.tb01747.x; LABIB RS, 1986, J IMMUNOL, V136, P1231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD JN, 1988, BRIT J DERMATOL, V118, P209, DOI 10.1111/j.1365-2133.1988.tb01776.x; Lever WF, 1965, PEMPHIGUS PEMPHIGOID; MCCUAIG CC, 1989, ARCH DERMATOL, V125, P944, DOI 10.1001/archderm.125.7.944; MONDINO BJ, 1981, OPHTHALMOLOGY, V88, P95; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; PATZ A, 1950, ARCH OPHTHALMOL-CHIC, V43, P244; ROGERS RS, 1977, J INVEST DERMATOL, V68, P39, DOI 10.1111/1523-1747.ep12485162; RUOCCO V, 1982, ARCH DERMATOL RES, V274, P123, DOI 10.1007/BF00510366; SACKS EH, 1989, OPHTHALMOLOGY, V96, P236; SARRET Y, 1989, AUTOIMMUNITY, V2, P145, DOI 10.3109/08916938909019951; SHKLAR G, 1971, ARCHIV OTOLARYNGOL, V93, P354; WUEPPER KD, 1980, J INVEST DERMATOL, V74, P368, DOI 10.1111/1523-1747.ep12543789	35	52	53	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1543	1546		10.1001/jama.266.11.1543	http://dx.doi.org/10.1001/jama.266.11.1543			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880886				2022-12-28	WOS:A1991GE45800035
J	LEE, PR; GINSBURG, PB				LEE, PR; GINSBURG, PB			THE TRIALS OF MEDICARE PHYSICIAN PAYMENT REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PHYSICIAN PAYMENT REVIEW COMMISS,2120 L ST NW,SUITE 510,WASHINGTON,DC 20037; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								Hsiao W C, 1979, Health Care Financ Rev, V1, P23; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; HSIAO WC, 1990, NATIONAL STUDY RESOU; Langwell K M, 1986, Med Care Rev, V43, P5, DOI 10.1177/107755878604300102; Wilensky G R, 1986, Med Care Rev, V43, P133, DOI 10.1177/107755878604300105; 1991, PHYSICIAN PAYMENT RE, V911; 1990, PHYSICIAN PAYMENT RE; 1991, FED REG         0605, V56, P25792; 1991, PHYSICIAN PAYMENT RE, V916	9	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1562	1565		10.1001/jama.266.11.1562	http://dx.doi.org/10.1001/jama.266.11.1562			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880890				2022-12-28	WOS:A1991GE45800039
J	BROWNE, PV; LAWLER, M; HUMPHRIES, P; MCCANN, SR				BROWNE, PV; LAWLER, M; HUMPHRIES, P; MCCANN, SR			DONOR-CELL LEUKEMIA AFTER BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; RECURRENCE		ST JAMES HOSP,DEPT HAEMATOL ONCOL,DUBLIN 8,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND	Trinity College Dublin; Trinity College Dublin			ODOnnell, Jim/C-2454-2009	Browne, Paul/0000-0001-5310-1487				BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BIONDI A, 1989, BONE MARROW TRANSPL, V4, P705; BOYD CN, 1982, LEUKEMIA RES, V6, P833, DOI 10.1016/0145-2126(82)90067-4; DEEG HJ, 1984, EXP HEMATOL, V12, P660; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; HAGEMEIJER A, 1982, CANCER GENET CYTOGEN, V5, P95, DOI 10.1016/0165-4608(82)90001-2; HUGHES RT, 1988, BRIT J HAEMATOL, V68, P391, DOI 10.1111/j.1365-2141.1988.tb04220.x; JACKSON DP, 1989, NUCLEIC ACIDS RES, V17, P10131; KLINGEMANN HG, 1986, BRIT J HAEMATOL, V63, P47, DOI 10.1111/j.1365-2141.1986.tb07493.x; LAWLER M, 1991, BLOOD, V77, P2504; LAWLER M, 1989, BRIT J HAEMATOL, V73, P205, DOI 10.1111/j.1365-2141.1989.tb00253.x; LAWLER M, 1990, J CELL BIOCH A S, V14, P329; MARMONT A, 1984, NEW ENGL J MED, V310, P903, DOI 10.1056/NEJM198404053101408; NIEDERWIESER DW, 1990, NEW ENGL J MED, V322, P1794, DOI 10.1056/NEJM199006213222507; STEIN J, 1989, BLOOD, V73, P2033; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; WEBER JL, 1989, AM J HUM GENET, V44, P388; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1985, BLOOD, V65, P1172	19	52	53	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					710	713		10.1056/NEJM199109053251007	http://dx.doi.org/10.1056/NEJM199109053251007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1870642				2022-12-28	WOS:A1991GD49700007
J	STRANDBERG, TE; SALOMAA, VV; NAUKKARINEN, VA; VANHANEN, HT; SARNA, SJ; MIETTINEN, TA				STRANDBERG, TE; SALOMAA, VV; NAUKKARINEN, VA; VANHANEN, HT; SARNA, SJ; MIETTINEN, TA			LONG-TERM MORTALITY AFTER 5-YEAR MULTIFACTORIAL PRIMARY PREVENTION OF CARDIOVASCULAR-DISEASES IN MIDDLE-AGED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; TRIAL; CHOLESTEROL; METABOLISM; PROJECT; THERAPY; STROKE; OSLO	Objective. - To investigate the long-term effects of multifactorial primary prevention of cardiovascular diseases (CVD). Design. - The 5-year randomized, controlled trial was performed between 1974 and 1980. The subjects and their risk factors were reevaluated in 1985. Posttrial mortality follow-up was continued up to December 31, 1989. Setting. - Institute of Occupational Health, Helsinki, Finland, and Second Department of Medicine, University of Helsinki. Participants. - In all, 3490 business executives born during 1919 through 1934 participated in health checkups in the late 1960s. In 1974, 1222 of these men who were clinically healthy, but with CVD risk factors, were entered into the primary prevention trial; 612 were randomized to an intervention and 610 to a control group. Interventions. - During the 5-year trial, the subjects of the intervention group visited the investigators every fourth month. They were treated with intensive dietetic-hygienic measures and frequently with hypolipidemic (mainly clofibrate and/or probucol) and antihypertensive (mainly beta-blockers and/or diuretics) drugs. The control group was not treated by the investigators. Main Outcome Measures. - Total mortality, cardiac mortality, mortality due to other causes. Results. - Total coronary heart disease risk was reduced by 46% in the intervention group as compared with the control group at end-trial. During 5 posttrial years, the risk factor and medication differences were largely leveled off between the groups. Between 1974 and 1989 the total number of deaths was 67 in the intervention group and 46 in the control group (relative risk [RR], 1.45; 95% confidence interval [Cl], 1.01 to 2.08; P=.048); there were 34 and 14 cardiac deaths (RR. 2.42; 95% Cl. 1.31 to 4.46. P =.001). two and four deaths due to other CVD (not significant), 13 and 21 deaths due to cancer (RR, 0.62; 95% Cl, 0.31 to 1.22; P = .15), and 13 and one deaths due to violence (RR, 13.0;95% Cl, 1.70 to 98.7; P = .002), respectively. Multiple logistic regression analysis of treatments in the intervention group did not explain the 15-year excess cardiac mortality. Conclusion. - These unexpected results may not question multifactorial prevention as such but do support the need for research on the selection and interaction(s) of methods used in the primary prevention of cardiovascular diseases.	JORVI HOSP,ESPOO,FINLAND; UNIV HELSINKI,DEPT PUBL HLTH,SF-00290 HELSINKI 29,FINLAND; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	University of Helsinki; Finland National Institute for Health & Welfare	STRANDBERG, TE (corresponding author), UNIV HELSINKI,DEPT MED 2,SF-00290 HELSINKI 29,FINLAND.			Sarna, Seppo/0000-0003-3458-1627; strandberg, timo/0000-0001-6299-925X				[Anonymous], 1984, LANCET, V2, P600; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cox D., 1966, RES PAPERS STAT FEST, P55; CRUICKSHANK JM, 1987, LANCET, V1, P581; DIXON WJ, 1988, BMDP STATISTICAL SOF; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HUANG TC, 1961, ANAL CHEM, V33, P1405, DOI 10.1021/ac60178a040; KEYS A, 1972, CIRCULATION, V45, P815, DOI 10.1161/01.CIR.45.4.815; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MIDDEKE M, 1990, ARTERIOSCLEROSIS, V10, P145, DOI 10.1161/01.ATV.10.1.145; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NAUKKARINEN V, 1989, CURR THER RES CLIN E, V45, P232; NAUKKARINEN V, 1981, THESIS U HELSINKI HE; NAUKKARINEN VA, 1989, ANN MED, V21, P441, DOI 10.3109/07853898909149236; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; ROSE G, 1983, LANCET, V1, P1062; SALOMAA V, 1988, THESIS U HELSINKI HE; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; STRANDBERG T E, 1989, European Heart Journal, V10, P217; STRUTHERS AD, 1985, HYPERTENSION, V7, P95; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; VANHANEN H, 1986, THESIS U HELSINKI HE; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065; 1975, JAMA-J AM MED ASSOC, V231, P360; 1989, CONFIDENCE INTERVAL; 1990, JAMA-J AM MED ASSOC, V263, P1795; 1971, BMJ, V4, P775; 1982, JAMA-J AM MED ASSOC, V248, P1465; 1971, BMJ, V4, P767; 1986, LANCET, V1, P869; 1984, JAMA-J AM MED ASSOC, V251, P351	39	176	178	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1225	1229		10.1001/jama.266.9.1225	http://dx.doi.org/10.1001/jama.266.9.1225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870247				2022-12-28	WOS:A1991GC85800030
J	BINDMAN, AB; GRUMBACH, K; KEANE, D; RAUCH, L; LUCE, JM				BINDMAN, AB; GRUMBACH, K; KEANE, D; RAUCH, L; LUCE, JM			CONSEQUENCES OF QUEUING FOR CARE AT A PUBLIC HOSPITAL EMERGENCY DEPARTMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSFERS; POPULATION; LEAVE; ILL	Objective.-To determine whether the length of a queue at a public hospital emergency department was associated with increased likelihood of patients' leaving without being seen by a physician and whether leaving adversely affected patients' health or affected their subsequent use of health care services. Design.-Observational cohort. Patients were surveyed during 1 week in July 1990 and received a follow-up survey 7 to 14 days later. The responses of patients who left without being seen by a physician were compared with those who were seen by a physician. Setting.-Emergency department at San Francisco (Calif) General Hospital. Patients.-All English-, Spanish-, and Cantonese-speaking adults waiting for emergency care were eligible. Of 882 eligible individuals, 700 agreed to participate; 85% of enrolled subjects saw a physician and 15% left without being seen. Demographic characteristics of patients who were and who were not seen were not significantly different. Main Outcome Measures.-Emergency department waiting time and changes in patients' self-reported health. Results.-Patients were more likely to leave as waiting times increased. At follow-up, patients who left without being seen were twice as likely as those who were seen to report that their pain or the seriousness of their problem was worse. Only 4% of patients who left required subsequent hospitalization, but 27% returned to an emergency department. Conclusion.-Many patients can appropriately decide whether their problem is truly urgent and make alternative plans in the face of long waits, but the health of some patients may be jeopardized by long queues for emergency care.	SAN FRANCISCO GEN HOSP,DEPT QUALITY ASSURANCE,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,JOINT MED PROGRAM,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	BINDMAN, AB (corresponding author), SAN FRANCISCO GEN HOSP,DEPT MED,DIV GEN INTERNAL MED,ROOM 5H22,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Grumbach, Kevin/L-9222-2016					ADAMS PF, 1989, VITAL HLTH STAT, V10, P173; AKIN BV, 1989, J GEN INTERN MED, V4, P216, DOI 10.1007/BF02599526; BUESCHING DP, 1985, ANN EMERG MED, V14, P672, DOI 10.1016/S0196-0644(85)80886-6; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; COREY CR, 1990, HEALTH SERV RES, V25, P129; DERLET RW, 1990, ANN EMERG MED, V19, P262, DOI 10.1016/S0196-0644(05)82041-4; DERSHEWITZ RA, 1986, ANN EMERG MED, V15, P717, DOI 10.1016/S0196-0644(86)80432-2; GIBSON G, 1978, JACEP-J AM COLL EMER, V7, P47, DOI 10.1016/S0361-1124(78)80035-5; GRUMBACH K, 1989, WESTERN J MED, V151, P210; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; KELLERMANN AL, 1988, AM J PUBLIC HEALTH, V78, P1287, DOI 10.2105/AJPH.78.10.1287; LINN LS, 1982, MED CARE, V20, P425, DOI 10.1097/00005650-198204000-00007; MANNING WG, 1982, EC ASPECTS HLTH, P143; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; SAINSBURY SJ, 1990, MIL MED, V155, P460; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; SHAW KN, 1990, ANN EMERG MED, V19, P59, DOI 10.1016/S0196-0644(05)82144-4; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; 1991, AM SAFETY NET HOSPIT, P26; [No title captured]	22	169	170	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1091	1096		10.1001/jama.266.8.1091	http://dx.doi.org/10.1001/jama.266.8.1091			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1865541				2022-12-28	WOS:A1991GB97500031
J	PAGE, DL; DUPONT, WD				PAGE, DL; DUPONT, WD			PROLIFERATIVE BREAST DISEASE - DIAGNOSIS AND IMPLICATIONS	SCIENCE			English	Article							TERM FOLLOW-UP; CANCER; LESIONS; WOMEN		VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV BIOSTAT,NASHVILLE,TN 37232	Vanderbilt University	PAGE, DL (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232, USA.		Dupont, William D./I-4430-2012	Bishop, Tim/0000-0002-8752-8785; albright, lisa/0000-0003-2602-3668				BIBBO M, 1988, ACTA CYTOL, V32, P193; CARTER CL, 1988, AM J EPIDEMIOL, V128, P467, DOI 10.1093/oxfordjournals.aje.a114995; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; PAGE DL, 1985, CANCER, V55, P2698, DOI 10.1002/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; TAVASSOLI FA, 1990, CANCER, V65, P518, DOI 10.1002/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O	7	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1991	253	5022					915	915		10.1126/science.1876848	http://dx.doi.org/10.1126/science.1876848			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC152	1876848				2022-12-28	WOS:A1991GC15200049
J	TUNIS, SR; BASS, EB; STEINBERG, EP				TUNIS, SR; BASS, EB; STEINBERG, EP			THE USE OF ANGIOPLASTY, BYPASS-SURGERY, AND AMPUTATION IN THE MANAGEMENT OF PERIPHERAL VASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANS-LUMINAL ANGIOPLASTY; LIMB-THREATENING ISCHEMIA; CORONARY HEART-DISEASE; INTERMITTENT CLAUDICATION; BALLOON DILATATION; SURGICAL PRACTICE; FRAMINGHAM; MORTALITY; IMPACT	Background. Percutaneous transluminal angioplasty has been adopted widely as a treatment for patients with peripheral vascular disease of the lower extremities. However, the effect of this procedure on the overall management of peripheral vascular disease and on the outcomes of patients has not been clearly delineated. In particular, it is not known whether angioplasty has replaced other treatments for peripheral vascular disease. Methods. To assess the extent to which angioplasty is used and the associated changes in the surgical management of peripheral vascular disease of the lower extremities, we used data on hospital discharges in Maryland to identify all angioplasty procedures, peripheral bypass operations, and lower-extremity amputations performed for peripheral vascular disease in Maryland hospitals between 1979 and 1989. Results. We estimate that from 1979 to 1989 the annual rate of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities, adjusted for age and sex, rose from 1 to 24 per 100,000 Maryland residents (P < 0.0001 by linear regression). Despite this increase in the use of angioplasty, the adjusted annual rate of peripheral bypass surgery also rose substantially, from 32 to 65 per 100,000 (P < 0.001), whereas the adjusted annual rate of lower-extremity amputation remained stable at about 30 per 100,000. Total charges for hospitalizations during which a peripheral revascularization procedure was performed increased from $14.7 million in 1979 (in 1989 dollars) to $30.5 million in 1989. Conclusions. In Maryland, the adoption of percutaneous transluminal angioplasty for peripheral vascular disease of the lower extremities has been associated with an increase in the use of peripheral bypass surgery and with no decline in lower-extremity amputations. These results could be due to increased diagnosis of peripheral vascular disease, expanded indications for procedural interventions; or an increased number of repeat procedures performed in patients with peripheral vascular disease of the lower extremities.	JOHNS HOPKINS PROGRAM MED TECHNOL & PRACTICE ASSES, 1830 E MONUMENT ST, RM 8068, BALTIMORE, MD 21205 USA	Johns Hopkins University				Bass, Eric/0000-0001-9106-527X	NHLBI NIH HHS [2 T32 HL07180] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAR R, 1989, J VASC SURG, V10, P57, DOI 10.1067/mva.1989.vs0100057; ANDERSON GM, 1988, AM J PUBLIC HEALTH, V78, P251, DOI 10.2105/AJPH.78.3.251; ANDERSON JB, 1986, BRIT J SURG, V73, P17, DOI 10.1002/bjs.1800730108; ASCER E, 1990, J VASC SURG, V11, P576, DOI 10.1067/mva.1990.18640; BECKER GJ, 1989, RADIOLOGY, V170, P921, DOI 10.1148/radiology.170.3.2521745; BILD DE, 1989, DIABETES CARE, V12, P24, DOI 10.2337/diacare.12.1.24; BLAIR JM, 1989, J VASC SURG, V9, P698, DOI 10.1067/mva.1989.vs0090698; CASARELLA WJ, 1986, CURR PROB CARDIOLOGY, V11, P138; CINTORA I, 1988, ANN SURG, V208, P625, DOI 10.1097/00000658-198811000-00014; CODD JE, 1979, AM J SURG, V138, P770, DOI 10.1016/0002-9610(79)90294-0; CUMBERLAND DC, 1988, CLIN RADIOL, V39, P573, DOI 10.1016/S0009-9260(88)80043-6; DAGOSTINO RB, 1989, INT J EPIDEMIOL, V18, pS67; DALEN JE, 1990, AM HEART J, V119, P502, DOI 10.1016/S0002-8703(05)80271-6; DAVIS PK, 1989, ANN THORAC SURG, V47, P493, DOI 10.1016/0003-4975(89)90422-0; DOUBILET P, 1984, NEW ENGL J MED, V310, P95, DOI 10.1056/NEJM198401123100206; EICKHOFF JH, 1980, ACTA CHIR SCAND, P181; ERNST CB, 1987, J VASC SURG, V6, P611, DOI 10.1067/mva.1987.avs0060611; FEINLEIB M, 1989, CIRCULATION, V79, P13; FRY SM, 1990, INVEST RADIOL, V25, P93, DOI 10.1097/00004424-199001000-00023; GALLINO A, 1984, CIRCULATION, V70, P619, DOI 10.1161/01.CIR.70.4.619; HOLLIER LH, 1989, J VASC SURG, V9, P627, DOI 10.1067/mva.1989.vs0090627; HOLLMAN J, 1988, INT J CARDIOL, V20, P193, DOI 10.1016/0167-5273(88)90263-X; JEANS WD, 1986, BRIT J RADIOL, V59, P453, DOI 10.1259/0007-1285-59-701-453; JEANS WD, 1990, RADIOLOGY, V177, P559, DOI 10.1148/radiology.177.2.2145608; JEANS WD, 1986, BRIT J RADIOL, V59, P457, DOI 10.1259/0007-1285-59-701-457; JOHNSTON KW, 1987, ANN SURG, V206, P403, DOI 10.1097/00000658-198710000-00002; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KANNEL WB, 1970, CIRCULATION, V41, P875, DOI 10.1161/01.CIR.41.5.875; MAINI BS, 1978, ARCH SURG-CHICAGO, V113, P1297; SAMSON RH, 1984, ANN SURG, V199, P234, DOI 10.1097/00000658-198402000-00017; SHEINER NM, 1985, CAN J SURG, V28, P193; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAYLOR LM, 1990, J VASC SURG, V11, P193, DOI 10.1067/mva.1990.17235; Veith F J, 1990, Ann Vasc Surg, V4, P85, DOI 10.1007/BF02042697; VEITH FJ, 1990, ANN SURG, V212, P402, DOI 10.1097/00000658-199010000-00003; VEITH FJ, 1990, ACTA CHIR SCAND, P139; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C; WIDLUS DM, 1989, JAMA-J AM MED ASSOC, V261, P3148, DOI 10.1001/jama.261.21.3148; Wilson S E, 1990, Ann Vasc Surg, V4, P351, DOI 10.1007/BF02000498; ZARINS CK, 1989, JAMA-J AM MED ASSOC, V261, P416, DOI 10.1001/jama.261.3.416; 1985, SAS USERS GUIDE STAT; 1988, HOSPITAL REPORT CLIN; 1990, CODING CLIN ICD9CM, P16; 1990, STATISTICAL ABSTRACT, P99	44	221	226	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					556	562		10.1056/NEJM199108223250806	http://dx.doi.org/10.1056/NEJM199108223250806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1857391				2022-12-28	WOS:A1991GB44700006
J	BRETT, AS				BRETT, AS			LIMITATIONS OF LISTING SPECIFIC MEDICAL INTERVENTIONS IN ADVANCE DIRECTIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Recent events, including the Cruzan decision and the passage of the Patient Self-Determination Act, have renewed interest in the strengths and limitations of various types of advance directives. In one well-known approach, the competent person indicates preferences for or against a series of specific medical interventions that might be considered if the person loses decision-making capacity However, such lists of interventions may shift attention away from overall treatment goals or may prescribe inappropriate medical care. Moreover, listing specific interventions in advance does not necessarily enhance self-determination or reduce uncertainty in decision making.	NEW ENGLAND DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	BRETT, AS (corresponding author), HARVARD UNIV, PROGRAM ETH & PROFESS, CAMBRIDGE, MA 02138 USA.							ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P98; CRANFORD RE, 1990, HASTINGS CENT REP, V20, P9, DOI 10.2307/3562524; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; Dresser R, 1989, ADV DIRECTIVES MED, P155; EMANUEL L, 1990, HARVARD MED SCH HLTH, V15, P4; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Lambert P, 1990, Law Med Health Care, V18, P202, DOI 10.1111/j.1748-720X.1990.tb00023.x; SACHS GA, 1990, JAMA-J AM MED ASSOC, V263, P1069, DOI 10.1001/jama.1990.03440080041019; 1987, GUIDELINES TERMINATI	15	112	112	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1991	266	6					825	828		10.1001/jama.266.6.825	http://dx.doi.org/10.1001/jama.266.6.825			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA073	1865521				2022-12-28	WOS:A1991GA07300035
J	GRALLA, JD				GRALLA, JD			TRANSCRIPTIONAL CONTROL - LESSONS FROM AN ESCHERICHIA-COLI PROMOTER DATA-BASE	CELL			English	Review							ESCHERICHIA-COLI; RNA-POLYMERASE; ACTIVATOR; ENHANCEMENT; GLNA		UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	GRALLA, JD (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.							BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; COLLADOVIDES J, 1991, IN PRESS MICROBIOL R, V55; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MAGASANIK B, 1989, New Biologist, V1, P247; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TSUNG K, 1990, P NATL ACAD SCI USA, V87, P5940, DOI 10.1073/pnas.87.15.5940; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K	18	87	91	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					415	418		10.1016/0092-8674(81)90001-5	http://dx.doi.org/10.1016/0092-8674(81)90001-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1868543				2022-12-28	WOS:A1991GA94100001
J	ATKINSON, NS; ROBERTSON, GA; GANETZKY, B				ATKINSON, NS; ROBERTSON, GA; GANETZKY, B			A COMPONENT OF CALCIUM-ACTIVATED POTASSIUM CHANNELS ENCODED BY THE DROSOPHILA-SLO LOCUS	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; SODIUM-CHANNEL; K+ CHANNELS; SUBSTRATE-SPECIFICITY; MOLECULAR ANALYSIS; SKELETAL-MUSCLE; ION CHANNELS; SHAKER LOCUS; CURRENTS; GENE	Calcium-activated potassium channels mediate many biologically important functions in electrically excitable cells. Despite recent progress in the molecular analysis of voltage-activated K+ channels, Ca2+-activated K+ channels have not been similarly characterized. The Drosophila slowpoke (slo) locus, mutations of which specifically abolish a Ca2+-activated K+ current in muscles and neurons, provides an opportunity for molecular characterization of these channels. Genomic and complementary DNA clones from the slo locus were isolated and sequenced. The polypeptide predicted by slo is similar to voltage-activated K+ channel polypeptides in discrete domains known to be essential for function. Thus, these results indicate that slo encodes a structural component of Ca2+-activated K+ channels.	UNIV WISCONSIN, GENET LAB, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison				Robertson, Gail/0000-0003-4694-5790	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07131] Funding Source: Medline; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATKINSON N S, 1989, Society for Neuroscience Abstracts, V15, P541; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRYSDALE R, 1991, GENETICS, V127, P497; ELKINS T, 1988, J NEUROSCI, V8, P428; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; ENGELS WR, 1986, FOCUS, V8, P6; GELBAND CH, 1990, P ROY SOC B-BIOL SCI, V242, P23, DOI 10.1098/rspb.1990.0098; GORCZYCA MG, 1991, J MEMBRANE BIOL, V121, P237, DOI 10.1007/BF01951557; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KOMATSU A, 1990, NEURON, V4, P313, DOI 10.1016/0896-6273(90)90105-O; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATORRE R, 1982, P NATL ACAD SCI-BIOL, V79, P805, DOI 10.1073/pnas.79.3.805; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LINDSLEY DL, 1968, PUBLICATION CARNEGIE, V627; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROBERTSON G A, 1990, Society for Neuroscience Abstracts, V16, P670; ROBERTSON GA, 1990, BIOPHYS J, V59, pA196; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUDY B, 1991, J MOL CELL NEUROSCI, V2, P89; SAITO M, 1991, J NEUROSCI, V11, P2135; SALKOFF L, 1983, NATURE, V302, P249, DOI 10.1038/302249a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TIMPE LC, 1988, NEURON, V1, P659, DOI 10.1016/0896-6273(88)90165-1; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	53	546	567	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 2	1991	253	5019					551	555		10.1126/science.1857984	http://dx.doi.org/10.1126/science.1857984			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1857984				2022-12-28	WOS:A1991FZ34700035
J	CHEN, WJ; ANDRES, DA; GOLDSTEIN, JL; RUSSELL, DW; BROWN, MS				CHEN, WJ; ANDRES, DA; GOLDSTEIN, JL; RUSSELL, DW; BROWN, MS			CDNA CLONING AND EXPRESSION OF THE PEPTIDE-BINDING BETA-SUBUNIT OF RAT P21RAS FARNESYLTRANSFERASE, THE COUNTERPART OF YEAST DPR1/RAM1	CELL			English	Article							DNA-POLYMERASE; GAMMA-SUBUNIT; PROTEINS; CYSTEINE; AMPLIFICATION; FARNESYL; MUTANTS; CONTAIN; PRIMER; CELLS	Protein farnesyltransferase is a heterodimeric enzyme that attaches a farnesyl group to cysteine in ras proteins and other membrane-associated proteins. The beta-subunit contains the recognition site for the peptide substrates, but is inactive in the absence of the alpha-subunit. A cloned cDNA for the rat beta-subunit predicts a protein of 437 amino acids whose mRNA is present in many tissues. Transfection of the beta-subunit cDNA produced farnesyltransferase activity in human kidney cells, but only when it was transfected together with a cDNA encoding part of the alpha-subunit. Each of the subunits appeared to be unstable in the transfected cells unless the other subunit was present. The rat beta-subunit shows 37% sequence identity with the protein encoded by the yeast DPR1/RAM1 gene, indicating that DPR1/RAM1 is the yeast counterpart of the peptide-binding subunit of the mammalian farnesyltransferase.			CHEN, WJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, IN PRESS P NATL ACAD; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; Maxam A M, 1980, Methods Enzymol, V65, P499; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; OHYA Y, 1991, IN PRESS J BIOL CHEM; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	39	193	202	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					327	334		10.1016/0092-8674(91)90622-6	http://dx.doi.org/10.1016/0092-8674(91)90622-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855253				2022-12-28	WOS:A1991FY71200013
J	DIXON, DA; KOWALCZYKOWSKI, SC				DIXON, DA; KOWALCZYKOWSKI, SC			HOMOLOGOUS PAIRING INVITRO STIMULATED BY THE RECOMBINATION HOTSPOT, CHI	CELL			English	Article							ESCHERICHIA-COLI RECA; HOT SPOT ACTIVITY; BACTERIOPHAGE-LAMBDA; GENERALIZED RECOMBINATION; STRAND EXCHANGE; RECBCD ENZYME; GENETIC-RECOMBINATION; BINDING-PROTEIN; PHAGE-LAMBDA; DNA	Genetic recombination in Escherichia coli is stimulated at DNA sequences known as Chi sites, 5'-GCTGGTGG-3'. We describe the in vitro formation of homologously paired joint molecules that is dependent upon this recombination hotspot. Chi-dependent joint molecule formation requires RecA, RecBCD, and SSB proteins and a Chi site in the donor linear dsDNA. The donor dsDNA is unwound by RecBCD enzyme, and the invasive strand is generated by nicking at Chi. This Chi-dependent invading strand must contain homology to the recipient supercoiled DNA substrate at its newly formed 3' end for efficient joint molecule formation. Action at Chi generates invasive ssDNA from the 5' but not the 3' side of Chi, suggesting that the nuclease activity of RecBCD enzyme is attenuated upon encountering a Chi site. These results support the view that RecBCD enzyme action can precede RecA protein action and reconcile the seemingly opposing degradative and recombination functions of RecBCD enzyme.			DIXON, DA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.				NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Berger S. L., 1987, GUIDE MOL CLONING TE; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, TRENDS BIOCHEM SCI, V12, P141, DOI 10.1016/0968-0004(87)90070-3; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LOVETT ST, 1988, GENETICS, V120, P37; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MESSING J, 1983, METHOD ENZYMOL, V101, P20; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; SMITH GR, 1990, NUCL ACIDS MOL BIOL, P78; SMITH JV, 1981, SCOT EDUC REV, V13, P25; STAHL FW, 1979, ANNU REV GENET, V13, P7, DOI 10.1146/annurev.ge.13.120179.000255; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1990, GENETICS, V126, P519; STAHL FW, 1975, MOL GEN GENET, V140, P29, DOI 10.1007/BF00268986; STAHL FW, 1980, GENETICS, V94, P235; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; WANG TCV, 1989, MOL GEN GENET, V216, P315, DOI 10.1007/BF00334370; WEST SC, 1988, TRENDS GENET, V4, P8, DOI 10.1016/0168-9525(88)90121-7; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573	57	150	151	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 26	1991	66	2					361	371		10.1016/0092-8674(91)90625-9	http://dx.doi.org/10.1016/0092-8674(91)90625-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1855256				2022-12-28	WOS:A1991FY71200016
J	ILIFFE, S; HAUG, U				ILIFFE, S; HAUG, U			OUT OF HOURS WORK IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									TAVISTOCK CLIN,LONDON NW3 5BA,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT PRIMARY HLTH CARE,LONDON WC1,ENGLAND	University of London; University College London			Iliffe, Steve/L-8379-2019	Iliffe, Stephen/0000-0003-2806-3997				Bennet G., 1987, WOUND DOCTOR HEALING; BETTLEHEIM B, 1987, GOOD ENOUGH PARENT; BOLAM M, 1988, BRIT MED J, V296, P829; CARTWRIGHT A, 1987, GENERAL PRACTICE REV; CLYNE M, 1973, 6 MINUTES PATIENT, P58; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Cunningham-Burley Sarah, 1990, READINGS MED SOCIOLO, P85; DIXON RA, 1988, BRIT MED J, V297, P1519, DOI 10.1136/bmj.297.6662.1519; FRY J, 1977, PRESENT STATE FUTURE; FURNIVALL J, 1991, MED MONITOR     0222, P37; GATHORNEHARDY J, 1984, DOCTORS OPEN LOOK DO; HAMILTON I, 1988, J ROY COLL GEN PRACT, V38, P171; HELMAN C G, 1978, Culture Medicine and Psychiatry, V2, P107, DOI 10.1007/BF00054580; HOBBS FDR, 1991, BRIT MED J, V302, P329, DOI 10.1136/bmj.302.6772.329; HOBDAY PJ, 1988, J ROY COLL GEN PRACT, V38, P35; HOLLAND S, 1989, CLIN PSYCHOL FORUM, V22, P35; HUYGEN F, 1991, FAMILY MED MED LIFE; JONES CS, 1989, BRIT MED J, V298, P859, DOI 10.1136/bmj.298.6677.859; LIVINGSTONE AE, 1989, BRIT MED J, V299, P368, DOI 10.1136/bmj.299.6695.368; MYERSON S, 1990, FAM PRACT, V7, P91, DOI 10.1093/fampra/7.2.91; MYERSON S, 1991, Medical Science Research, V19, P267; PRESCOTTCLARKE P, 1988, FOCUS HLTH CARE SURV, V1; SKINNER DV, 1990, BRIT MED J, V301, P1292, DOI 10.1136/bmj.301.6764.1292; SMITH R, 1991, SALARIED SERVICE GEN; USHERWOOD TP, 1991, BRIT J GEN PRACT, V41, P58; VIRJI A, 1990, BRIT MED J, V301, P22, DOI 10.1136/bmj.301.6742.22; WILKIN D, 1987, ANATOMY URBAN GENERA; WILSON S, 1985, BRIT J PSYCHIAT, V146, P277, DOI 10.1192/bjp.146.3.277; ZYLKE JW, 1990, JAMA-J AM MED ASSOC, V264, P1798; 1990, NEW CONTRACT GENERAL; 1991, GENERAL MED PRACTITI, V1	31	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1584	1586		10.1136/bmj.302.6792.1584	http://dx.doi.org/10.1136/bmj.302.6792.1584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855046	Green Published, Bronze			2022-12-28	WOS:A1991FU54900030
J	MUMFORD, E				MUMFORD, E			NEED FOR RELEVANCE IN MANAGEMENT-INFORMATION-SYSTEMS - WHAT THE NHS CAN LEARN FROM INDUSTRY	BRITISH MEDICAL JOURNAL			English	Article											MUMFORD, E (corresponding author), UNIV MANCHESTER,MANCHESTER BUSINESS SCH,MANCHESTER M15 6PB,ENGLAND.							Mumford E., 1989, XSELS PROGR CONTINUI; Mumford E., 1983, DESIGNING HUMAN SYST; QUAM L, 1989, BRIT MED J, V299, P448, DOI 10.1136/bmj.299.6696.448; Winograd T., 1986, UNDERSTANDING COMPUT; [No title captured]	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 29	1991	302	6792					1587	1590		10.1136/bmj.302.6792.1587	http://dx.doi.org/10.1136/bmj.302.6792.1587			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FU549	1855047	Green Published, Bronze			2022-12-28	WOS:A1991FU54900031
J	MANTLE, J; VERSI, E				MANTLE, J; VERSI, E			PHYSIOTHERAPY FOR STRESS URINARY-INCONTINENCE - A NATIONAL SURVEY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the physiotherapeutic treatment of urinary stress incontinence in England. Design-Postal questionnaire survey. Setting-All 192 English district health authorities. Subjects-One physiotherapist from each district who was primarily concerned with urinary incontinence. A consensus view was requested. Main outcome measures-Responses to questionnaire and analysis of a visual analogue scale to indicate effectiveness. Results-There was a 98% response rate. Treatment was often by senior physiotherapists (108 senior I grade or above) who, in 117 districts, claimed to have made a specialty of treating the condition. Gynaecologists and obstetricians were far more likely to refer patients than any other agency (147 respondents said that they were the commonest source of referral). One hundred and fifty four respondents stated that physiotherapy was usually used as the first line of treatment. Pelvic floor exercises and interferential treatment were most commonly used (by 178 and 144 respondents respectively) and thought to be the most effective, especially in combination, though various techniques were used in applying them. Positive motivation (108), recent onset of symptoms (55), and youth (40) were viewed optimistically, and obesity (60), previous surgery (59), prolapse (42), and a chronic cough (36) were considered to be bad prognostic features. The number of patients treated varied greatly (range 10-360) between districts and was poorly correlated with catchment size (correlation coefficient 0.3). Conclusions-As physiotherapists are treating considerable numbers of patients with stress incontinence research is urgently needed to produce efficacy data to enable rationalisation of resources to cater for the whole population.	ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND; POLYTECH E LONDON,DIV PHYSIOTHERAPY,LONDON E15 4LZ,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of East London								Bo K, 1989, NEUROLOGY URODYNAMIC, V8, P355; Harrison S M, 1973, Physiotherapy, V59, P363; KEGEL A H, 1948, Ann West Med Surg, V2, P213; KLARSKOV P, 1986, UROL INT, V41, P129, DOI 10.1159/000281181; PEATTIE AB, 1988, BRIT J OBSTET GYNAEC, V95, P1049, DOI 10.1111/j.1471-0528.1988.tb06512.x; STANTON SL, 1990, CLIN OBSTET GYNAECOL, P346; STODDART GD, 1983, PHYSIOTHERAPY, V69, P143; SWITZER D, 1988, IRISH MED J, V81, P30; Tapp AJ, 1989, NEUROUROL URODYNAM, V8, P356; TAPP AJS, 1988, NEUROLOGY URODYNAMIC, V7, P259; TEHON D, 1988, PHYS THER, V68, P652; VERSI E, 1989, BRIT J OBSTET GYNAEC, V96, P752, DOI 10.1111/j.1471-0528.1989.tb03306.x; WILSON PD, 1987, BRIT J OBSTET GYNAEC, V94, P575, DOI 10.1111/j.1471-0528.1987.tb03153.x; 1987, SERIES VS OFFICE POP, V14, P74	14	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1991	302	6779					753	755		10.1136/bmj.302.6779.753	http://dx.doi.org/10.1136/bmj.302.6779.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FF229	1888358	Bronze, Green Published			2022-12-28	WOS:A1991FF22900021
J	BELFORT, M				BELFORT, M			SELF-SPLICING INTRONS IN PROKARYOTES - MIGRANT FOSSILS	CELL			English	Review							GROUP-I INTRONS; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; RNA; SPECULATIONS; EVOLUTION; ORIGIN; DNA		SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany	BELFORT, M (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618				BELFORT M, 1990, ANNU REV GENET, V24, P363; BELLPEDERSEN D, 1990, NUCLEIC ACIDS RES, V18, P3763, DOI 10.1093/nar/18.13.3763; BERNSTEIN H, 1989, J BACTERIOL, V171, P2265, DOI 10.1128/jb.171.5.2265-2270.1989; CAMPBELL A, 1988, BACTERIOPHAGES, V1, P1; CAVALIERSMITH T, 1985, NATURE, V315, P283, DOI 10.1038/315283b0; CECH TR, 1985, INT REV CYTOL, V93, P3, DOI 10.1016/S0074-7696(08)61370-4; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	22	56	60	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 11	1991	64	1					9	11		10.1016/0092-8674(91)90201-9	http://dx.doi.org/10.1016/0092-8674(91)90201-9			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ET175	1898872				2022-12-28	WOS:A1991ET17500003
J	NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P				NARDELLI, J; GIBSON, TJ; VESQUE, C; CHARNAY, P			BASE SEQUENCE DISCRIMINATION BY ZINC-FINGER DNA-BINDING DOMAINS	NATURE			English	Article							TRANSCRIPTION FACTOR TFIIIA; REPRESSOR-OPERATOR INTERACTIONS; RNA-POLYMERASE; NUCLEIC-ACIDS; FACTOR-IIIA; PROTEINS; EXPRESSION; GENE; RECOGNITION; RESOLUTION	Zinc fingers 1,2 constitute important eukaryotic DNA-binding domains, being present in many transcription factors 3-5. The Cys2/His2 zinc-finger class has conserved motifs of 28-30 amino acids which are usually present as tandem repeats 1,2. The structure of a Cys2/His2 zinc finger has been determined by nuclear magnetic resonance 6, but details of its interaction with DNA were not established. Here we identify amino acids governing DNA-binding specificity using in vitro directed mutagenesis guided by similarities between the zinc fingers of transcription factors Sp1 (ref. 7) and Krox-20 (ref. 8). Krox-20 is a serum-inducible transcription activator 8,9 which is possibly involved in the regulation of hindbrain development 10; it contains three zinc fingers similar to those of Ap1 (refs 7, 8, 11) and binds to a 9-base-pair target sequence which is related to that of Sp1 (ref. 9). Our results show that each finger spans three nucleotides and indicate two positions in Krox-20 zinc fingers that are important for base-pair selectivity. Modelling with molecular graphics suggests that these residues could bind directly with the bases and that other amino acid-base contracts are also possible.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	NARDELLI, J (corresponding author), ECOLE POLYTECH,GENET MOLEC LAB,CNRS,D1302,46 RUE ULM,F-75230 PARIS 05,FRANCE.		Nardelli, Jeannette/N-5739-2017; Vesque, Christine/Q-8461-2019; Vesque, Christine/L-9839-2017	Vesque, Christine/0000-0001-7983-4953; Charnay, Patrick/0000-0002-3847-6042; Gibson, Toby James/0000-0003-0657-5166				AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BERG JA, 1990, REV BIOPHYS CHEM, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; BROWN RS, 1986, NATURE, V324, P215, DOI 10.1038/324215a0; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0	30	246	276	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 10	1991	349	6305					175	178		10.1038/349175a0	http://dx.doi.org/10.1038/349175a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ER418	1898772				2022-12-28	WOS:A1991ER41800065
J	SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S				SVENSSON, BG; NILSSON, A; HANSSON, M; RAPPE, C; AKESSON, B; SKERFVING, S			EXPOSURE TO DIOXINS AND DIBENZOFURANS THROUGH THE CONSUMPTION OF FISH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; POLYCHLORINATED-BIPHENYLS; ADIPOSE-TISSUE; VIETNAM VETERANS; MATCHED CONTROLS; BLOOD; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; MORTALITY; SAMPLES; PCDDS	Background. In some regions, including the Baltic Sea, fatty fish such as salmon and herring contain high levels of polychlorinated dibenzodioxins and dibenzofurans. We investigated human exposure to these potentially toxic substances in relation to the consumption of fish from the Baltic Sea. Methods. Plasma levels of 10 different dibenzofurans and 7 dioxins were analyzed in three groups of Swedish men: one group with a high intake of fish (fish eaten almost daily; n = 11), one with a moderate intake of fish (about once per week; n = 9), and one with no consumption of fish (usually because of allergy; n = 9). Results. Plasma levels of several of the compounds we measured were higher in the men with a high intake of fish than in those who consumed moderate amounts, and the levels were higher in those who ate moderate amounts of fish than in those who ate none. The median amounts of the most toxic dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin) were 8.0 pg per gram of plasma lipid (range, 2.0 to 13) in the high-intake group, 2.6 pg per gram (range, 1.2 to 4.2) in the moderate-intake group, and 1.8 pg per gram (range, 1.0 to 2.5) in the nonconsumers (P = 0.001 and 0.02, respectively). There were consistent and statistically significant associations between the reported amount of fish eaten and the plasma levels of several of the dibenzofurans and dioxins. Conclusions. Contaminated fish such as those from the Baltic Sea are an important source of exposure to polychlorinated dibenzofurans and dibenzodioxins in persons who eat fish regularly. However, the clinical consequences of such exposure remain uncertain.	UNIV LUND,DEPT MED & PHYSIOL CHEM,S-22101 LUND,SWEDEN; UMEA UNIV,INST ENVIRONM CHEM,S-90187 UMEA,SWEDEN	Lund University; Umea University	SVENSSON, BG (corresponding author), UNIV LUND HOSP,DEPT OCCUPAT & ENVIRONM MED,S-22185 LUND,SWEDEN.		Akesson, Bjorn/Q-9163-2017					ASPLUND L, 1990, CHEMOSPHERE, V20, P1481, DOI 10.1016/0045-6535(90)90301-9; BERGQVIST PA, 1989, CHEMOSPHERE, V19, P513, DOI 10.1016/0045-6535(89)90361-5; CHEN PHS, 1984, AM J IND MED, V5, P133; EKSTROM B, 1989, EUR J CLIN INVEST, V19, P259, DOI 10.1111/j.1365-2362.1989.tb00228.x; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; HAGBERG J, 1987, OKAD DIOXINHALT BLOD, P207; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KOLMODIN-HEDMAN B, 1973, Work-Environment-Health, V10, P100; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KUEHL DW, 1989, CHEMOSPHERE, V18, P1997, DOI 10.1016/0045-6535(89)90483-9; LINDSTROM G, 1988, THESIS U UMEA UMEA; MASUDA Y, 1984, AM J IND MED, V5, P31; NYGREN M, 1988, CHEMOSPHERE, V17, P1663, DOI 10.1016/0045-6535(88)90095-1; PAPKE O, 1989, CHEMOSPHERE, V19, P941, DOI 10.1016/0045-6535(89)90437-2; PATTERSON DG, 1986, JAMA-J AM MED ASSOC, V256, P2683, DOI 10.1001/jama.256.19.2683; PATTERSON DG, 1989, AM J IND MED, V16, P135, DOI 10.1002/ajim.4700160205; RAPPE C, 1990, CHEMOSPHERE, V20, P1649, DOI 10.1016/0045-6535(90)90325-N; RAPPE C, 1984, ENVIRON SCI TECHNOL, V18, pA78, DOI 10.1021/es00121a711; RAPPE C, 1989, CHEMOSPHERE, V18, P651, DOI 10.1016/0045-6535(89)90178-1; RAPPE C, 1987, ENVIRON SCI TECHNOL, V21, P964, DOI 10.1021/es50001a009; RAPPE C, 1982, CHLORINATED DIOXINS, P495; RONDAHL L, 1989, IVL PUBLICATION B, V951; SCHWARTZ PM, 1983, AM J PUBLIC HEALTH, V73, P293, DOI 10.2105/AJPH.73.3.293; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; SVENSSON BG, 1987, SCI TOTAL ENVIRON, V67, P101, DOI 10.1016/0048-9697(87)90204-X; YRJANHEIKKI E, IN PRESS WHO REG PUB; 1988, NORDISK DIOXINRISKBE, P7	28	139	145	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 3	1991	324	1					8	12		10.1056/NEJM199101033240102	http://dx.doi.org/10.1056/NEJM199101033240102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EQ503	1898530	Bronze			2022-12-28	WOS:A1991EQ50300002
J	WITKOWSKA, HE; LUBIN, BH; BEUZARD, Y; BARUCHEL, S; ESSELTINE, DW; VICHINSKY, EP; KLEMAN, KM; BARDAKDJIANMICHAU, J; PINKOSKI, L; CAHN, S; ROITMAN, E; GREEN, BN; FALICK, AM; SHACKLETON, CHL				WITKOWSKA, HE; LUBIN, BH; BEUZARD, Y; BARUCHEL, S; ESSELTINE, DW; VICHINSKY, EP; KLEMAN, KM; BARDAKDJIANMICHAU, J; PINKOSKI, L; CAHN, S; ROITMAN, E; GREEN, BN; FALICK, AM; SHACKLETON, CHL			SICKLE-CELL DISEASE IN A PATIENT WITH SICKLE-CELL TRAIT AND COMPOUND HETEROZYGOSITY FOR HEMOGLOBIN-S AND HEMOGLOBIN QUEBEC-CHORI	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DEOXYHEMOGLOBIN-S; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; POLYMERIZATION; SOLUBILITY; VARIANT		CHILDRENS HOSP OAKLAND,RES INST,CLIN MASS SPECTROMETRY FACIL,747 52ND ST,OAKLAND,CA 94609; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; MONTREAL CHILDRENS HOSP,MONTREAL H3H 1P3,QUEBEC,CANADA; ROBERT WOOD JOHNSON PHARMACEUT RES INST,DON MILLS,ONTARIO,CANADA; VG FISONS INSTRUMENTS,ALTRINCHAM,ENGLAND; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); McGill University; University of California System; University of California San Francisco			Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-20985] Funding Source: Medline; PHS HHS [01614, 03300] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADACHI K, 1987, J BIOL CHEM, V262, P10470; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADAMS JG, 1973, BLOOD, V42, P990; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; DAVIS AM, 1988, NEW ENGL J MED, V318, P787; FALICK AM, 1990, RAPID COMMUN MASS SP, V4, P396, DOI 10.1002/rcm.1290041010; FALICK AM, 1991, TECHNIQUES PROTEIN C, V2, P551; GALACTEROS F, 1980, BLOOD, V56, P1068; GALE RE, 1988, BRIT J HAEMATOL, V70, P251, DOI 10.1111/j.1365-2141.1988.tb02472.x; Imai K., 1982, ALLOSTERIC EFFECTS H; KARK JA, 1987, NEW ENGL J MED, V317, P781, DOI 10.1056/NEJM198709243171301; KIM HC, 1983, HEMATOLOGY, P1611; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; NUSSBAUM RL, 1984, SOUTHERN MED J, V77, P1049, DOI 10.1097/00007611-198408000-00031; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; RAHBAR S, 1986, HEMOGLOBIN, V10, P379, DOI 10.3109/03630268608996869; SCHWARTZ WE, 1980, ANAL BIOCHEM, V106, P43, DOI 10.1016/0003-2697(80)90116-5; SERJEANT GR, 1985, SICKLE CELL DISEASE, P329; SHACKLETON CHL, 1991, J CHROMATOGR-BIOMED, V562, P175, DOI 10.1016/0378-4347(91)80576-X; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2	24	48	49	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1991	325	16					1150	1154		10.1056/NEJM199110173251607	http://dx.doi.org/10.1056/NEJM199110173251607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GK538	1891024				2022-12-28	WOS:A1991GK53800007
J	MCCARTHY, DM				MCCARTHY, DM			SUCRALFATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHORT-TERM TREATMENT; DUODENAL-ULCER RECURRENCE; ENDOSCOPICALLY CONTROLLED TRIAL; ANTI-INFLAMMATORY DRUGS; DOUBLE-BLIND TRIAL; GASTRIC-ULCER; NOSOCOMIAL PNEUMONIA; MAINTENANCE THERAPY; PEPTIC-ULCER; BISMUTH SUBCITRATE		UNIV NEW MEXICO, SCH MED, ALBUQUERQUE, NM 87131 USA	University of New Mexico	MCCARTHY, DM (corresponding author), NEW MEXICO REG FED MED CTR, 111F, 2100 RIDGECREST DR SE, ALBUQUERQUE, NM 87108 USA.							ALBIN H, 1986, EUR J CLIN PHARMACOL, V30, P493, DOI 10.1007/BF00607967; ALGOZZINE GJ, 1983, NEW ENGL J MED, V309, P1387; ALLAIN P, 1990, BRIT J CLIN PHARMACO, V29, P391, DOI 10.1111/j.1365-2125.1990.tb03655.x; ANDERSON W, 1989, AM J GASTROENTEROL, V84, P205; BARRIER CH, 1989, ARTHRITIS RHEUM, V32, P926; BECK CL, 1987, CLIN PHARMACOL THER, V41, P168; BEHAR J, 1987, J CLIN GASTROENTEROL, V9, P23, DOI 10.1097/00004836-198709011-00006; BIGHLEY LD, 1979, PEPTIC ULCER DISEASE, P307; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BLUM AL, 1988, GASTROENTEROLOGY, V94, pA39; BOLIN TD, 1987, AM J MED, V83, P91, DOI 10.1016/0002-9343(87)90835-7; BOLIN TD, 1989, AM J MED, V86, P148, DOI 10.1016/0002-9343(89)90178-2; BOLIN TD, 1989, GASTROENTEROLOGY S, V6, P148; Bresci G, 1987, Minerva Dietol Gastroenterol, V33, P53; BYNUM TE, 1989, AM J MED, V86, P127; CALDWELL JR, 1987, AM J MED, V83, P74, DOI 10.1016/0002-9343(87)90832-1; CAMPISTOL JM, 1989, NEPHRON, V51, P103, DOI 10.1159/000185252; CANTRAL KA, 1988, CLIN PHARMACY, V7, P58; CASPARY WF, 1981, DUODENAL ULCER GASTR, P28; CHEN BW, 1981, J CLIN GASTROENTE S2, V2, P169; CHEN MC, 1989, J CLIN INVEST, V84, P1536, DOI 10.1172/JCI114330; CHIVERTON SG, 1988, GASTROENTEROLOGY S, V94, P69; CLASSEN M, 1983, SCAND J GASTROENTERO, V18, P61; COOK DJ, IN PRESS AM J MED; COOK DJ, 1990, CHEST S1S, V98; COSTE T, 1987, AM J MED, V83, P86, DOI 10.1016/0002-9343(87)90834-5; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DANGIO R, 1986, BRIT J CLIN PHARMACO, V21, P515, DOI 10.1111/j.1365-2125.1986.tb02834.x; DASCHNER F, 1987, Intensivmedizin, V24, P163; DCARLING L, 1988, SCAND J GASTROENTERO, V23, P1117; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; DUMOULIN GC, 1982, LANCET, V1, P242; ELSBORG L, 1984, HEPATO-GASTROENTEROL, V31, P269; EMMANUEL A, 1985, GASTROINTEST ENDOSC, V31, P404, DOI 10.1016/S0016-5107(85)72265-1; Falisevac V, 1985, Lijec Vjesn, V107, P23; FIORAVANTI A, 1989, Clinica Terapeutica, V130, P333; FISHER RS, 1981, J CLIN GASTROENTEROL, V3, P181; FLEISCHMANN R, 1984, VERH DTSCH GES INN M, V90, P1876; GACHOT B, 1988, NEW ENGL J MED, V318, P1466; GARRELS JC, 1990, ANTIMICROB AGENTS CH, V35, P931; GIESING DH, 1983, GASTROENTEROLOGY, V84, P1165; GLISE H, 1986, SCAND J GASTROENTERO, V21, P313, DOI 10.3109/00365528609003081; HALL TG, 1986, DRUG INTEL CLIN PHAR, V20, P607, DOI 10.1177/106002808602000726; HALLERBACK B, 1986, GUT, V27, P778, DOI 10.1136/gut.27.7.778; HARAM EM, 1987, SCAND J GASTROENTERO, V22, P615, DOI 10.3109/00365528708991908; HART RS, 1989, GASTROINTEST ENDOSC, V35, P474, DOI 10.1016/S0016-5107(89)72879-0; HASE T, 1975, AM J DIG DIS, V20, P443, DOI 10.1007/BF01070789; HENTSCHEL E, 1983, SCAND J GASTROENTERO, V18, P31; HERRERIASGUTIERREZ JM, 1989, AM J MED, V86, P94, DOI 10.1016/0002-9343(89)90166-6; HJORTRUP A, 1989, AM J MED, V86, P113, DOI 10.1016/0002-9343(89)90170-8; HOLLANDER D, 1986, SCAND J GASTROENTERO, V21, P151, DOI 10.3109/00365528609093831; HOLLANDER D, 1981, J CLIN GASTROENTEROL, V3, P153; HOLLANDER D, 1990, SCAND J GASTROENTERO, V25, P1, DOI 10.3109/00365529009091917; ISHIMORI A, 1981, DUODENAL ULCER GASTR, P93; ITOH M, 1989, Gastroenterology, V96, pA229; JENSEN DM, 1990, GASTROENTEROLOGY SA5, V98; KAHN RJ, 1982, CRIT CARE MED, V10, P229, DOI 10.1097/00003246-198203000-00109; KAMADA T, 1977, J TRAUMA, V17, P44, DOI 10.1097/00005373-197701000-00006; KARLSTADT RG, 1990, CLIN RES, V38, pA273; KINOSHITA H, 1982, RES COMMUN CHEM PATH, V35, P515; KONTUREK SJ, 1989, AM J MED, V86, P32, DOI 10.1016/0002-9343(89)90154-X; KONTUREK SJ, 1987, GUT, V28, P201, DOI 10.1136/gut.28.2.201; LACZ JP, 1982, GASTROENTEROLOGY, V82, P1108; LACZ JP, 1983, GASTROENTEROLOGY, V84, P402; LAHTINEN J, 1983, SCAND J GASTROENTERO, V18, P49; LAHTINEN J, 1982, FARMOS MED NEWS, V3, P14; LAM KT, 1985, J INT MED RES, V13, P338, DOI 10.1177/030006058501300607; LAM SK, 1985, AM J MED, V79, P24, DOI 10.1016/0002-9343(85)90568-6; LAM SK, 1989, AM J MED, V86, P122, DOI 10.1016/0002-9343(89)90172-1; LAM SK, 1987, GASTROENTEROLOGY, V92, P1193, DOI 10.1016/S0016-5085(87)91077-8; LEDERER ED, 1989, KIDNEY INT, V35, P378; LEUNG ACT, 1984, J INT BIOMED INF DAT, V5, P17; LEUNG ACT, 1983, BRIT MED J, V286, P1379, DOI 10.1136/bmj.286.6375.1379; LIBESKIND M, 1983, SCAND J GASTROENTERO, V18, P69; LIGUMSKY M, 1986, ISRAEL J MED SCI, V22, P801; LOMBARDO L, 1989, Z GASTROENTEROL, V27, P179; MACONOCHIE JG, 1987, CLIN PHARMACOL THER, V41, P205; MANNICHE C, 1987, GUT, V28, P226, DOI 10.1136/gut.28.2.226; MARKS IN, 1985, AM J MED, V79, P32, DOI 10.1016/0002-9343(85)90569-8; MARKS IN, 1980, S AFR MED J, V57, P567; MARKS IN, 1989, AM J MED, V86, P136, DOI 10.1016/0002-9343(89)90175-7; MARTIN F, 1989, AM J MED, V86, P104, DOI 10.1016/0002-9343(89)90168-X; MARTIN F, 1983, SCAND J GASTROENTERO, V18, P37; MARTIN F, 1982, GASTROENTEROLOGY, V82, P401; MASOERO G, 1986, J CLIN GASTROENTEROL, V8, P624, DOI 10.1097/00004836-198612000-00006; MCCARTHY DM, 1989, GASTROENTEROLOGY, V96, P662, DOI 10.1016/S0016-5085(89)80063-0; McCarthy DM, 1989, DRUG THER, V19, P59; MCCLOY RF, 1989, ADV DRUG THERAPY GAS, P121; MCHARDY GG, 1981, J CLIN GASTROENTEROL, V3, P147; MIYAKE T, 1980, DIGEST DIS SCI, V25, P1, DOI 10.1007/BF01312725; MORRIS GP, 1989, AM J MED, V86, P10, DOI 10.1016/0002-9343(89)90150-2; MOSHAL MG, 1980, S AFR MED J, V57, P742; MOSHAL MG, 1983, SCAND J GASTROENTERO, V18, P57; MULLERSMAN G, 1986, J PHARM SCI, V75, P995, DOI 10.1002/jps.2600751018; NAGASHIMA R, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1668; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P117; NAGASHIMA R, 1981, J CLIN GASTROENTEROL, V3, P103; NAGASHIMA R, 1985, PEPTIC ULCER DISEASE, V3, P181; NEXO E, 1987, SCAND J GASTROENTERO, V22, P45; NIELSEN MCL, 1988, J CLIN GASTROENTEROL, V10, P377, DOI 10.1097/00004836-198808000-00006; NIX DE, 1989, REV INFECT DIS, V11, pS1096; NIX DE, 1989, PHARMACOTHERAPY, V9, P377; Orlando R C, 1987, Scand J Gastroenterol Suppl, V140, P23; PAAKKONEN M, 1989, AM J MED, V86, P133, DOI 10.1016/0002-9343(89)90174-5; PAI S, 1987, J CLIN PHARMACOL, V27, P213, DOI 10.1002/j.1552-4604.1987.tb02187.x; PALMER RH, 1988, NEW ENGL J MED, V318, P1465; PARPIA SH, 1989, ANTIMICROB AGENTS CH, V33, P99, DOI 10.1128/AAC.33.1.99; PETERSON WL, 1989, GASTROENTEROLOGY, V97, P796, DOI 10.1016/0016-5085(89)90657-4; PFEIFFER P, 1990, ACTA ONCOL, V29, P171, DOI 10.3109/02841869009126540; POP P, 1983, SCAND J GASTROENTERO, V18, P43; PUBLIG W, 1989, Z GASTROENTEROL, V27, P188; QUADROS E, 1987, AM J MED, V83, P19, DOI 10.1016/0002-9343(87)90822-9; QUIGLEY MA, 1986, AM J GASTROENTEROL, V81, P724; REY JF, 1989, AM J MED, V86, P116, DOI 10.1016/0002-9343(89)90171-X; ROBERTSON JA, 1989, ANN INTERN MED, V111, P179, DOI 10.7326/0003-4819-111-2-179; RODGRIGO M, 1987, AM J MED S3B, V83, P99; ROWERS JRBJ, 1989, PHARM WEEKBLAD, V9, P16; ROXE DM, 1989, AM J KIDNEY DIS, V13, P194, DOI 10.1016/S0272-6386(89)80052-6; RYAN P, 1990, Critical Care Medicine, V18, pS253, DOI 10.1097/00003246-199012001-00148; RYAN R, 1986, FASEB J, V45, P205; SAMLOFF IM, 1985, AM J MED, V79, P15, DOI 10.1016/0002-9343(85)90566-2; SCHERLACHER A, 1989, Archives of Oto-Rhino-Laryngology, V246, P465; SCHWARTZ K, 1910, BEITRAGE KLINISCHEN, V67, P96; SHEADONOHUE T, 1986, GASTROENTEROLOGY, V91, P660, DOI 10.1016/0016-5085(86)90636-0; SHEPHERD HA, 1989, AM J MED, V86, P49, DOI 10.1016/0002-9343(89)90157-5; SHERMAN RA, 1983, AM J GASTROENTEROL, V78, P210; SHORROCK CJ, 1990, GUT, V31, P26, DOI 10.1136/gut.31.1.26; SINGAL AK, 1988, ENDOSCOPY, V20, P238, DOI 10.1055/s-2007-1018184; SISTO G, 1987, Gazzetta Medica Italiana Archivio per le Scienze Mediche, V146, P95; SLOMIANY BL, 1989, DIGESTION, V44, P222, DOI 10.1159/000199915; SMART HL, 1985, BRIT J CLIN PHARMACO, V20, P238, DOI 10.1111/j.1365-2125.1985.tb05067.x; STANNARD VA, 1988, BRIT MED J, V296, P155, DOI 10.1136/bmj.296.6616.155; SUNG JL, 1983, SCAND J GASTROENTERO, V18, P21; SZABO S, 1989, AM J MED, V86, P23, DOI 10.1016/0002-9343(89)90153-8; TABIBIAN N, 1989, GASTROINTEST ENDOSC, V35, P312, DOI 10.1016/S0016-5107(89)72799-1; TAKEMOTO T, 1989, GUT, V30, P1692, DOI 10.1136/gut.30.12.1692; Takemoto T, 1987, Scand J Gastroenterol Suppl, V140, P49; TARNAWSKI A, 1986, GASTROENTEROLOGY, V90, P893, DOI 10.1016/0016-5085(86)90865-6; THOMSEN L, 1989, SCAND J GASTROENTERO, V24, P781, DOI 10.3109/00365528909089214; TOMASSETTI P, 1983, CURR THER RES CLIN E, V34, P987; TOVEY FI, 1989, GUT, V30, P586, DOI 10.1136/gut.30.5.586; TRYBA M, 1985, AM J MED, V79, P55, DOI 10.1016/0002-9343(85)90574-1; TRYBA M, 1987, AM J MED, V83, P117, DOI 10.1016/0002-9343(87)90840-0; TRYBA M, 1987, AM J MED, V83, P125, DOI 10.1016/0002-9343(87)90841-2; TRYBA M, 1989, AM J MED, V86, P85, DOI 10.1016/0002-9343(89)90165-4; TRYBA M, 1990, SCAND J GASTROENTERO, V25, P22, DOI 10.3109/00365529009091920; TRYBA M, 1990, AM J MED S6A, V173, P22; TYTGAT GNJ, 1990, SCAND J GASTROENTERO, V25, P34, DOI 10.3109/00365529009091921; VANDEVENTER GM, 1985, AM J MED, V79, P39, DOI 10.1016/0002-9343(85)90571-6; VENABLES CW, 1986, GUT, V27, P233, DOI 10.1136/gut.27.3.233; WALLACE JL, 1988, CAN J PHYSIOL PHARM, V66, P666, DOI 10.1139/y88-105; WEISS W, 1983, DEUT MED WOCHENSCHR, V108, P1706, DOI 10.1055/s-2008-1069811; WITHERS DJ, 1989, LANCET, V2, P674; WONG C S, 1984, SMJ Singapore Medical Journal, V25, P314; WU WC, 1985, GASTROENTEROLOGY, V88, P1636; Yoshida Y, 1987, Nihon Shokakibyo Gakkai Zasshi, V84, P1025; YUK JH, 1989, JAMA-J AM MED ASSOC, V262, P901, DOI 10.1001/jama.1989.03430070049022; 1985, CARAFATE SUCRALFATE; 1988, GASTROENTEROLOGY, V94, P1107	159	149	153	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1991	325	14					1017	1025						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GH447	1886624				2022-12-28	WOS:A1991GH44700007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENTS PROPOSED FOR PANCREATIC-ENZYME PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V56, P32282	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1991	266	11					1482	1482						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE458	1880875				2022-12-28	WOS:A1991GE45800004
J	MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG				MEISTERERNST, M; ROY, AL; LIEU, HM; ROEDER, RG			ACTIVATION OF CLASS-II GENE-TRANSCRIPTION BY REGULATORY FACTORS IS POTENTIATED BY A NOVEL ACTIVITY	CELL			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; IMMEDIATE EARLY PROTEIN; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; UPSTREAM ELEMENT; FACTOR USF; INITIATION; INVITRO	A novel activity (USA) stimulated activator-dependent transcription in a reconstituted system in conjunction with natural TFIID, resulting in 10- to 50-fold levels of induction by regulatory factors. USA mediated a modest induction by USF in conjunction with either recombinant human TFIID, intact yeast TFIID, or the evolutionarily conserved C-terminal portion of yeast TFIID. Upon further purification, USA was resolved into two components that had opposite effects on core promoter activity and that in combination potentiated activator function. Gel mobility shift experiments indicated physical interactions between the inhibitory activity and TFIID, suggesting that the additional components (cofactors) associate with the preinitiation complex both to reduce promoter activity in the absence and to increase promoter activity in the presence of transcriptional activators.			MEISTERERNST, M (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BITTER GA, 1983, ANAL BIOCHEM, V128, P294, DOI 10.1016/0003-2697(83)90378-0; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1990, CELL, V61, P1172; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KIM WY, 1988, J BIOL CHEM, V263, P18880; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	58	280	285	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					981	993		10.1016/0092-8674(91)90443-3	http://dx.doi.org/10.1016/0092-8674(91)90443-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1889091				2022-12-28	WOS:A1991GE46000016
J	WRIGHT, JL				WRIGHT, JL			SOLILOQUY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 4	1991	266	9					1202	1202		10.1001/jama.266.9.1202	http://dx.doi.org/10.1001/jama.266.9.1202			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC858	1870238				2022-12-28	WOS:A1991GC85800012
J	ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE				ACSADI, G; DICKSON, G; LOVE, DR; JANI, A; WALSH, FS; GURUSINGHE, A; WOLFF, JA; DAVIES, KE			HUMAN DYSTROPHIN EXPRESSION IN MDX MICE AFTER INTRAMUSCULAR INJECTION OF DNA CONSTRUCTS	NATURE			English	Article							MUSCLE; MOUSE; INVIVO; TRANSFECTION; MYOPATHY; PROTEIN; REPEAT	DUCHENNE'S muscular dystrophy (DMD), which affects one in 3,500 males, causes progressive myopathy of skeletal and cardiac muscles and premature death 1. One approach to treatment would be to introduce the normal dystrophin gene into diseased muscle cells. When pure plasmid DNA is injected into rodent skeletal 2 or cardiac muscle 3-5, the cells express reporter genes. We now show that a 12-kilobase full-length human dystrophin complementary DNA gene and a 6.3-kilobase Becker-like gene 6 can be expressed in cultured cells and in vivo. When the human dystrophin expression plasmids are injected intramuscularly into dystrophin-deficient mdx mice, the human dystrophin proteins are present in the cytoplasm and sarcolemma of approximately 1% of the myofibres. Myofibres expressing human dystrophin contain an increased proportion of peripheral nuclei. The results indicate that transfer of the dystrophin gene into the myofibres of DMD patients could be beneficial, but a larger number of genetically modified myofibres will be necessary for clinical efficacy.	UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT PEDIAT,MADISON,WI 53706; UNIV WISCONSIN,WAISMAN CTR MENTAL RETARDAT & HUMAN DEV,DEPT MED GENET,MADISON,WI 53706; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON SE1 9RT,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC GENET GRP,OXFORD OX3 9DU,ENGLAND	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford				Love, Donald/0000-0003-4669-8769				ACSADI G, 1991, NEW BIOL, V3, P71; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DICKSON G, IN PRESS HUMAN GENET; ELLIS JM, 1990, LANCET, V336, P881, DOI 10.1016/0140-6736(90)92392-U; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORREST S M, 1988, Genomics, V2, P109, DOI 10.1016/0888-7543(88)90091-2; FRITZ JD, 1989, ANAL BIOCHEM, V180, P205, DOI 10.1016/0003-2697(89)90116-4; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MORGAN JE, 1990, J CELL BIOL, V111, P2437, DOI 10.1083/jcb.111.6.2437; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; TANABE Y, 1986, ACTA NEUROPATHOL, V69, P91, DOI 10.1007/BF00687043; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WANG AM, 1990, PCR PROTOCOLS GUIDE, P70; WESSEL HB, 1990, PEDIATR NEUROL, V6, P3, DOI 10.1016/0887-8994(90)90071-8; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, IN PRESS BIOTECHNIQU	30	391	498	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1991	352	6338					815	818		10.1038/352815a0	http://dx.doi.org/10.1038/352815a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1881437				2022-12-28	WOS:A1991GC96400064
J	LEE, JY; GOLDFARB, A				LEE, JY; GOLDFARB, A			LAC REPRESSOR ACTS BY MODIFYING THE INITIAL TRANSCRIBING COMPLEX SO THAT IT CANNOT LEAVE THE PROMOTER	CELL			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; RIBONUCLEIC-ACID POLYMERASE; TRANSCRIPTION INITIATION; TERNARY COMPLEXES; CHAIN ELONGATION; LACTOSE OPERON; SIGMA-SUBUNIT; INVITRO; PROTEIN	RNA polymerase engaged in the joint complex with the lac repressor at the lac UV5 promoter cannot escape into elongation but generates abortive RNA oligomers. The joint complex actively transcribes a few initial base pairs in a reaction unusually sensitive to a decrease in the substrate concentration. The joint complex, however, fails to traverse a point in the initial transcribed sequence that normally requires a high concentration of the elongating substrate. Thus, the repressor acts by augmenting a natural high "k(NTP)" site (pause site) embedded in the promoter. A lethal RNA polymerase mutation that mimics the effect of the repressor leads to an analogous block of promoter clearance and shortened abortive product pattern on several promoters, reflecting the widespread occurrence of high k(NTP) sites in promoters.			LEE, JY (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAHMBERLIN MJ, 1974, ANN REV BIOCH, V43, P721; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAN PT, 1989, J BIOL CHEM, V264, P21277; CHEN B, 1971, NATURE-NEW BIOL, V233, P67, DOI 10.1038/newbio233067a0; De Crombrugghe B, 1971, Nat New Biol, V231, P139; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GUIDIRONTANI C, 1985, J MOL BIOL, V186, P527, DOI 10.1016/0022-2836(85)90127-5; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MAJORS J, 1975, P NATL ACAD SCI USA, V72, P4394, DOI 10.1073/pnas.72.11.4394; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALIK S, 1984, J BIOL CHEM, V4259, P13292; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENENDEZ M, 1987, EMBO J, V6, P4227, DOI 10.1002/j.1460-2075.1987.tb02771.x; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Miller J. H., 1980, OPERON; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; RHODES G, 1974, J BIOL CHEM, V249, P6675; ROZOVSKAYA TA, 1982, FEBS LETT, V137, P100, DOI 10.1016/0014-5793(82)80323-2; SCHMIDT MC, 1984, BIOCHEMISTRY-US, V23, P197, DOI 10.1021/bi00297a004; SCHMITZ A, 1979, NUCLEIC ACIDS RES, V6, P111, DOI 10.1093/nar/6.1.111; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1242; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	37	67	68	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					793	798		10.1016/0092-8674(91)90122-F	http://dx.doi.org/10.1016/0092-8674(91)90122-F			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1878972				2022-12-28	WOS:A1991GC74500017
J	SONG, WC; BRASH, AR				SONG, WC; BRASH, AR			PURIFICATION OF AN ALLENE OXIDE SYNTHASE AND IDENTIFICATION OF THE ENZYME AS A CYTOCHROME-P-450	SCIENCE			English	Article							MICROSOMAL CYTOCHROME-P-450; HYDROPEROXIDE ISOMERASE; MARINE PROSTANOIDS; PLEXAURA-HOMOMALLA; LINOLENIC ACID; BIOSYNTHESIS; CYCLASE; CORAL; LIPOXYGENASE; METABOLISM	Fatty acid hydroperoxides (lipoxygenase products) are metabolized to allene oxides by a type of dehydrase that has been detected in plants, corals, and starfish oocytes. The allene oxides are unstable epoxide precursors of more complex products such as jasmonic acid, the plant growth hormone. Characterization of the dehydrase enzyme of flaxseed revealed that it is a 55-kilodalton hemoprotein. The spectral characteristics of this dehydrase revealed it to be a cytochrome P-450. It operates with the remarkable activity of greater-than-or-equal-to 1000 turnovers per second. The results establish a new catalytic activity for a cytochrome P-450 and illustrate the cooperation of different oxygenases in pathways of fatty acid metabolism.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035275] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35275] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAERTSCHI SW, 1988, BIOCHEMISTRY-US, V27, P18, DOI 10.1021/bi00401a004; BLACK SD, 1986, CYTOCHROME P 450 STR, pCH6; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, UNPUB; CAMP RL, 1968, J AM CHEM SOC, V90, P7349, DOI 10.1021/ja01028a032; CHAN TH, 1978, J ORG CHEM, V43, P2994, DOI 10.1021/jo00409a013; CHAN TH, 1980, TETRAHEDRON, V36, P2269, DOI 10.1016/0040-4020(80)80123-2; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; CRANDALL JK, 1968, J HETEROCYCLIC CHEM, V6, P777; CROMBIE L, 1988, J CHEM SOC CHEM COMM, P558, DOI 10.1039/c39880000558; GROSSMAN S, 1983, BIOCHIM BIOPHYS ACTA, V572, P65; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HIGASHI K, 1985, AGR BIOL CHEM TOKYO, V49, P2399, DOI 10.1080/00021369.1985.10867084; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JEFCOATE CR, 1969, BIOCHEMISTRY-US, V8, P3464, DOI 10.1021/bi00836a050; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; VICK BA, 1981, PLANT PHYSIOL, V67, P92, DOI 10.1104/pp.67.1.92; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; VICK BA, 1970, PLANT PHYSIOL, V46, P445; ZIMMERMAN DC, 1978, LIPIDS, V13, P313, DOI 10.1007/BF02533720; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6	28	232	241	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					781	784		10.1126/science.1876834	http://dx.doi.org/10.1126/science.1876834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1876834				2022-12-28	WOS:A1991GB29500035
J	STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM				STEDMAN, HH; SWEENEY, HL; SHRAGER, JB; MAGUIRE, HC; PANETTIERI, RA; PETROF, B; NARUSAWA, M; LEFEROVICH, JM; SLADKY, JT; KELLY, AM			THE MDX MOUSE DIAPHRAGM REPRODUCES THE DEGENERATIVE CHANGES OF DUCHENNE MUSCULAR-DYSTROPHY	NATURE			English	Article							SKELETAL-MUSCLE MYOPATHY; SATELLITE CELLS; RAT; PRODUCT; GROWTH; INVIVO; GENE	ALTHOUGH murine X-linked muscular dystrophy (mdx) and Duchenne muscular dystrophy (DMD) are genetically homologous and both characterized by a complete absence of dystrophin 1,2, the limb muscles of adult mdx mice suffer neither the detectable weakness nor the progressive degeneration that are features of DMD 3-8. Here we show that the mdx mouse diaphragm exhibits a pattern of degeneration, fibrosis and severe functional deficit comparable to that of DMD limb muscle, although adult mice show no overt respiratory impairment. Progressive functional changes include reductions in strength (to 13.5% of control by two years of age), elasticity, twitch speed and fibre length. The collagen density rises to at least seven times that of control diaphragm and ten times that of mdx hind-limb muscle. By 1.5 years of age, similar but less severe histological changes emerge in the accessory muscles of respiration. On the basis of these findings, we propose that dystrophin deficiency alters the threshold for work-induced injury. Our data provide a quantitative framework for studying the pathogenesis of dystrophy and extend the application of the mdx mouse as an animal model.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104	University of Pennsylvania	STEDMAN, HH (corresponding author), UNIV PENN,SCH MED,3800 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		panettieri, reynold/AAG-9485-2019; Sweeney, H Lee/F-1862-2010					ANDERSON JE, 1988, J MUSCLE RES CELL M, V9, P499, DOI 10.1007/BF01738755; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P299, DOI 10.1111/j.1365-2990.1988.tb00890.x; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DUSTERHOFT S, 1990, DIFFERENTIATION, V45, P185, DOI 10.1111/j.1432-0436.1990.tb00472.x; GRIFFITHS RI, 1987, J NEUROSCI METH, V21, P159, DOI 10.1016/0165-0270(87)90113-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KASPER CE, 1990, J APPL PHYSIOL, V68, P533, DOI 10.1152/jappl.1990.68.2.533; KELLY AM, 1978, DEV BIOL, V65, P1, DOI 10.1016/0012-1606(78)90174-4; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MANDEL JL, 1989, NATURE, V339, P584, DOI 10.1038/339584a0; MCCULLY KK, 1987, RESPIRATORY MUSCLES, P317; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NEWMAN S, 1984, J APPL PHYSIOL, V56, P753, DOI 10.1152/jappl.1984.56.3.753; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; SCHMALBRUCH H, 1977, ANAT REC, V189, P169, DOI 10.1002/ar.1091890204; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; SMITH PEM, 1987, NEW ENGL J MED, V316, P1197, DOI 10.1056/NEJM198705073161906; STAHL WR, 1967, J APPL PHYSIOL, V22, P453, DOI 10.1152/jappl.1967.22.3.453; SWITZER BR, 1971, ANAL BIOCHEM, V39, P487, DOI 10.1016/0003-2697(71)90438-6; SYME DA, 1990, J PHYSIOL-LONDON, V424, P301, DOI 10.1113/jphysiol.1990.sp018068; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	25	744	754	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					536	539		10.1038/352536a0	http://dx.doi.org/10.1038/352536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1865908				2022-12-28	WOS:A1991GA22600065
J	ROLLIN, H				ROLLIN, H			THE ROYAL-COLLEGE-OF-PSYCHIATRISTS, 150 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article											ROLLIN, H (corresponding author), ROYAL COLL PSYCHIAT,17 BELGRAVE SQ,LONDON SW1X 8PG,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1991	303	6796					238	239		10.1136/bmj.303.6796.238	http://dx.doi.org/10.1136/bmj.303.6796.238			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FZ563	1884063	Green Published, Bronze			2022-12-28	WOS:A1991FZ56300031
J	RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K				RORSMAN, P; BOKVIST, K; AMMALA, C; ARKHAMMAR, P; BERGGREN, PO; LARSSON, O; WAHLANDER, K			ACTIVATION BY ADRENALINE OF A LOW-CONDUCTANCE G- PROTEIN-DEPENDENT K+ CHANNEL IN MOUSE PANCREATIC B-CELLS	NATURE			English	Article							INSULIN-SECRETING CELLS; FREE CA-2+ CONCENTRATION; BETA-CELLS; SULFONYLUREAS; INHIBITION; GALANIN	INSULIN is produced and secreted by the B cells in the endocrine pancreas. In vivo, insulin secretion is under the control of a number of metabolic, neural and hormonal substances. It is now clear that stimulation of insulin release by fuel secretagogues, such as glucose, involves the closure of K+ channels that are sensitive ot the intracellular ATP concentration (K(ATP) channels)1. This leads to membrane depolarization and the generation of Ca2+-dependent action potentials2. The mechanisms whereby hormones and neurotransmitters such as adrenaline, galanin and somatostatin, which are released by intraislet nerve endings and the pancreatic D cells, produce inhibition of insulin secretion are not clear3. Here we show that adrenaline suppresses B-cell electrical activity (and thus insulin secretion) by a G protein-dependent mechanism, which culminates in the activation of a sulphonylurea-insensitive low-conductance K+ channel distinct from the K(ATP) channel.	KAROLINSKA INST,DEPT ENDOCRINOL,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,DEPT PHARMACOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska Institutet	RORSMAN, P (corresponding author), GOTHENBURG UNIV,DEPT MED PHYS,BOX 33031,S-40033 GOTHENBURG,SWEDEN.		Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767; Berggren, Per-Olof/0000-0001-8991-413X				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; DEWEILLE J, 1988, P NATL ACAD SCI USA, V85, P1312; DUNNE MJ, 1989, EMBO J, V8, P413, DOI 10.1002/j.1460-2075.1989.tb03392.x; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HILLE B, 1984, IONIC CHANNELS EXCIT, P211; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; NILSSON T, 1988, J BIOL CHEM, V263, P1855; SCHMIDANTOMARCHI H, 1987, J BIOL CHEM, V262, P15840; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506	13	122	126	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 3	1991	349	6304					77	79		10.1038/349077a0	http://dx.doi.org/10.1038/349077a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EQ601	1898674				2022-12-28	WOS:A1991EQ60100056
